# Storebø_2020_Psychological therapies for people with borderline personality disorder.

Cochrane
Library

Cochrane Database of Systematic Reviews

Psychological therapies for people with borderline personality
disorder (Review)

Storebø OJ, Stoffers-Winterling JM, Völlm BA, Kongerslev MT, Mattivi JT, Jørgensen MS, Faltinsen
E, Todorovac A, Sales CP, Callesen HE, Lieb K, Simonsen E

Storebø OJ, Stoffers-Winterling JM, Völlm BA, Kongerslev MT, Mattivi JT, Jørgensen MS, Faltinsen E, Todorovac A, Sales CP,
Callesen HE, Lieb K, Simonsen E. 
Psychological therapies for people with borderline personality disorder. 
Cochrane Database of Systematic Reviews 2020, Issue 5. Art. No.: CD012955. 
DOI: 10.1002/14651858.CD012955.pub2.

www.cochranelibrary.com

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1: Psychotherapy vs TAU, Outcome 1: Primary: BPD symptom severity (continuous)............................
Analysis 1.2. Comparison 1: Psychotherapy vs TAU, Outcome 2: Primary: BPD symptom severity (dichotomous), at above 12
months follow-up..................................................................................................................................................................................
Analysis 1.3. Comparison 1: Psychotherapy vs TAU, Outcome 3: Primary: self-harm (continuous).................................................
Analysis 1.4. Comparison 1: Psychotherapy vs TAU, Outcome 4: Primary: self-harm (dichotomous)..............................................
Analysis 1.5. Comparison 1: Psychotherapy vs TAU, Outcome 5: Primary: suicide-related outcomes (continuous).......................
Analysis 1.6. Comparison 1: Psychotherapy vs TAU, Outcome 6: Primary: suicide-related outcomes (dichotomous)....................
Analysis 1.7. Comparison 1: Psychotherapy vs TAU, Outcome 7: Primary: psychosocial functioning (continuous)........................
Analysis 1.8. Comparison 1: Psychotherapy vs TAU, Outcome 8: Secondary: anger (continuous)...................................................
Analysis 1.9. Comparison 1: Psychotherapy vs TAU, Outcome 9: Secondary: affective instability (continuous).............................
Analysis 1.10. Comparison 1: Psychotherapy vs TAU, Outcome 10: Secondary: chronic feelings of emptiness (continuous).........
Analysis 1.11. Comparison 1: Psychotherapy vs TAU, Outcome 11: Secondary: impulsivity (continuous)......................................
Analysis 1.12. Comparison 1: Psychotherapy vs TAU, Outcome 12: Secondary: impulsivity (dichotomous), at end of treatment....
Analysis 1.13. Comparison 1: Psychotherapy vs TAU, Outcome 13: Secondary: interpersonal problems (continuous)..................
Analysis 1.14. Comparison 1: Psychotherapy vs TAU, Outcome 14: Secondary: abandonment (continuous).................................
Analysis 1.15. Comparison 1: Psychotherapy vs TAU, Outcome 15: Secondary: identity disturbance (continuous).......................
Analysis  1.16.  Comparison  1:  Psychotherapy  vs  TAU,  Outcome  16:  Secondary:  dissociation  and  psychotic-like  symptoms
(continuous)...........................................................................................................................................................................................
Analysis 1.17. Comparison 1: Psychotherapy vs TAU, Outcome 17: Secondary: depression (continuous)......................................
Analysis 1.18. Comparison 1: Psychotherapy vs TAU, Outcome 18: Secondary: depression (dichotomous), at end of treatment....
Analysis 1.19. Comparison 1: Psychotherapy vs TAU, Outcome 19: Secondary: attrition (dichotomous)........................................
Analysis 1.20. Comparison 1: Psychotherapy vs TAU, Outcome 20: Secondary: non-serious adverse effects (dichotomous), at
end of treatment...................................................................................................................................................................................
Analysis 1.21. Comparison 1: Psychotherapy vs TAU, Outcome 21: Secondary: serious adverse effects (dichotomous), at end of
treatment...............................................................................................................................................................................................
Analysis 2.1. Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 1: Primary: BPD symptom severity
(continuous), at end of treatment.......................................................................................................................................................
Analysis 2.2. Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 2: Secondary: affective instability
(continuous), at end of treatment.......................................................................................................................................................
Analysis  2.3.  Comparison  2:  Acceptance  and  commitment  therapy  (ACT)  vs  TAU,  Outcome  3:  Secondary:  depression
(continuous), at end of treatment.......................................................................................................................................................
Analysis 2.4. Comparison 2: Acceptance and commitment therapy (ACT) vs TAU, Outcome 4: Secondary: attrition (dichotomous),
at end of treatment..............................................................................................................................................................................
Analysis  3.1.  Comparison  3:  Dialectical  behavior  therapy  (DBT)  vs  TAU,  Outcome  1:  Primary:  BPD  symptom  severity
(continuous), at end of treatment.......................................................................................................................................................
Analysis 3.2. Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 2: Primary, self-harm (continuous)..................

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
3
4
10
13
13
18
19
23
24
66
70
71
72
107
301
306
307

308
309
310
311
312
314
315
316
317
317
318
319
319
320

321
322
323
324

324

325

325

325

325

327

328

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  3.3.  Comparison  3:  Dialectical  behavior  therapy  (DBT)  vs  TAU,  Outcome  3:  Primary:  suicide-related  outcomes
(continuous), at end of treatment.......................................................................................................................................................
Analysis 3.4. Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 4: Primary: suicide-related outcomes, attempts
(dichotomous), at end of treatment....................................................................................................................................................
Analysis  3.5.  Comparison  3:  Dialectical  behavior  therapy  (DBT)  vs  TAU,  Outcome  5:  Primary:  psychosocial  functioning
(continuous), at end of treatment.......................................................................................................................................................
Analysis 3.6. Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 6: Secondary: anger (continuous)...................
Analysis 3.7. Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 7: Secondary: affective instability (continuous),
at end of treatment..............................................................................................................................................................................
Analysis 3.8. Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 8: Secondary: chronic feelings of emptiness
(continuous), at end of treatment.......................................................................................................................................................
Analysis 3.9. Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 9: Secondary: impulsivity (continuous)...........
Analysis  3.10.  Comparison  3:  Dialectical  behavior  therapy  (DBT)  vs  TAU,  Outcome  10:  Secondary:  interpersonal  problems
(continuous), at end of treatment.......................................................................................................................................................
Analysis 3.11. Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 11: Secondary: dissociation and psychotic-
like symptoms (continuous), at end of treatment..............................................................................................................................
Analysis 3.12. Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 12: Secondary: depression (continuous).......
Analysis 3.13. Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 13: Secondary: attrition (dichotomous)........
Analysis 3.14. Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 14: Secondary: adverse effects (dichotomous),
at end of treatment..............................................................................................................................................................................
Analysis  3.15.  Comparison  3:  Dialectical  behavior  therapy  (DBT)  vs  TAU,  Outcome  15:  Secondary:  serious  adverse  effects
(dichotomous), at end of treatment....................................................................................................................................................
Analysis  4.1.  Comparison  4:  Mentalisation  based  therapy  (MBT)  vs  TAU,  Outcome  1:  Primary:  BPD  symptom  severity
(continuous)...........................................................................................................................................................................................
Analysis 4.2. Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 2: Primary: self-harm (continuous), at end of
treatment...............................................................................................................................................................................................
Analysis 4.3. Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 3: Primary: self-harm (dichotomous).............
Analysis  4.4.  Comparison  4:  Mentalisation  based  therapy  (MBT)  vs  TAU,  Outcome  4:  Primary:  suicide-related  outcomes
(dichotomous).......................................................................................................................................................................................
Analysis  4.5.  Comparison  4:  Mentalisation  based  therapy  (MBT)  vs  TAU,  Outcome  5:  Primary:  psychosocial  functioning
(continuous)...........................................................................................................................................................................................
Analysis  4.6.  Comparison  4:  Mentalisation  based  therapy  (MBT)  vs  TAU,  Outcome  6:  Secondary:  interpersonal  problems
(continuous)...........................................................................................................................................................................................
Analysis 4.7. Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 7: Secondary: depression (continuous).........
Analysis 4.8. Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 8: Secondary: depression (dichotomous), at
end of treatment...................................................................................................................................................................................
Analysis 4.9. Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 9: Secondary: attrition (dichotomous), at end
of treatment..........................................................................................................................................................................................
Analysis  4.10.  Comparison  4:  Mentalisation  based  therapy  (MBT)  vs  TAU,  Outcome  10:  Secondary:  adverse  effects
(dichotomous), at end of treatment....................................................................................................................................................
Analysis 4.11. Comparison 4: Mentalisation based therapy (MBT) vs TAU, Outcome 11: Mentalisation-based treatment for eating
disorders (MBT-ED) versus specialist supportive clinical management (SSCM-ED) (generic inverse variance)...............................
Analysis  5.1.  Comparison  5:  Cognitive  behavioural  therapy  (CBT)  and  related  treatments  vs  TAU,  Outcome  1:  Primary:  BPD
symptom severity (continuous)...........................................................................................................................................................
Analysis  5.2.  Comparison  5:  Cognitive  behavioural  therapy  (CBT)  and  related  treatments  vs  TAU,  Outcome  2:  Primary:  BPD
symptom severity (dichotomous), at above 12 months follow-up....................................................................................................
Analysis 5.3. Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 3: Primary: self-harm
(continuous)...........................................................................................................................................................................................
Analysis 5.4. Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 4: Primary: self-harm
(dichotomous), at end of treatment....................................................................................................................................................
Analysis 5.5. Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 5: Primary: suicide-
related outcomes (continuous)............................................................................................................................................................
Analysis  5.6.  Comparison  5:  Cognitive  behavioural  therapy  (CBT)  and  related  treatments  vs  TAU,  Outcome  6:  Primary:
psychosocial functioning (continuous)...............................................................................................................................................
Analysis  5.7.  Comparison  5:  Cognitive  behavioural  therapy  (CBT)  and  related  treatments  vs  TAU,  Outcome  7:  Secondary:
interpersonal problems (continuous)..................................................................................................................................................

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

328

329

329

330
330

331

331
331

332

332
333
333

334

337

337

338
339

339

340

341
341

342

342

343

346

346

347

347

348

349

349

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  5.8.  Comparison  5:  Cognitive  behavioural  therapy  (CBT)  and  related  treatments  vs  TAU,  Outcome  8:  Secondary:
dissociation and psychotic-like symptoms (continuous)...................................................................................................................
Analysis  5.9.  Comparison  5:  Cognitive  behavioural  therapy  (CBT)  and  related  treatments  vs  TAU,  Outcome  9:  Secondary:
depression (continuous).......................................................................................................................................................................
Analysis 5.10. Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 10: Secondary:
attrition (dichotomous), at end of treatment.....................................................................................................................................
Analysis 5.11. Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs TAU, Outcome 11: Secondary:
adverse effects (dichotomous), at end of treatment..........................................................................................................................
Analysis 6.1. Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 1: Primary: BPD symptom severity (continuous)....
Analysis 6.2. Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 2: Primary: self-harm (continuous)......................
Analysis  6.3.  Comparison  6:  Psychodynamic  psychotherapy  vs  TAU,  Outcome  3:  Primary:  suicide-related  outcomes
(continuous)...........................................................................................................................................................................................
Analysis  6.4.  Comparison  6:  Psychodynamic  psychotherapy  vs  TAU,  Outcome  4:  Primary:  psychosocial  functioning
(continuous)...........................................................................................................................................................................................
Analysis 6.5. Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 5: Secondary: anger (continuous)........................
Analysis 6.6. Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 6: Secondary: affective instability (continuous).....
Analysis  6.7.  Comparison  6:  Psychodynamic  psychotherapy  vs  TAU,  Outcome  7:  Secondary:  chronic  feelings  of  emptiness
(continuous)...........................................................................................................................................................................................
Analysis 6.8. Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 8: Secondary: impulsivity (continuous)...............
Analysis  6.9.  Comparison  6:  Psychodynamic  psychotherapy  vs  TAU,  Outcome  9:  Secondary:  interpersonal  problems
(continuous)...........................................................................................................................................................................................
Analysis 6.10. Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 10: Secondary: abandonment (continuous).......
Analysis  6.11.  Comparison  6:  Psychodynamic  psychotherapy  vs  TAU,  Outcome  11:  Secondary:  identity  disturbance
(continuous)...........................................................................................................................................................................................
Analysis 6.12. Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 12: Secondary: dissociation and psychotic-like
symptoms (continuous)........................................................................................................................................................................
Analysis 6.13. Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 13: Secondary: depression (continuous)...........
Analysis 6.14. Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 14: Secondary: attrition (dichotomous), at end
of treatment..........................................................................................................................................................................................
Analysis 7.1. Comparison 7: Schema-focused therapy (SFT) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous),
at end of treatment..............................................................................................................................................................................
Analysis 7.2. Comparison 7: Schema-focused therapy (SFT) vs TAU, Outcome 2: Primary: psychosocial functioning (continuous),
at end of treatment..............................................................................................................................................................................
Analysis 7.3. Comparison 7: Schema-focused therapy (SFT) vs TAU, Outcome 3: Secondary: affective instability (continuous),
at end of treatment..............................................................................................................................................................................
Analysis 7.4. Comparison 7: Schema-focused therapy (SFT) vs TAU, Outcome 4: Secondary: impulsivity (continuous), at end of
treatment...............................................................................................................................................................................................
Analysis  7.5.  Comparison  7:  Schema-focused  therapy  (SFT)  vs  TAU,  Outcome  5:  Secondary:  interpersonal  problems
(continuous), at end of treatment.......................................................................................................................................................
Analysis  7.6.  Comparison  7:  Schema-focused  therapy  (SFT)  vs  TAU,  Outcome  6:  Secondary:  dissociation  and  psychotic-like
symptoms (continuous), at end of treatment.....................................................................................................................................
Analysis 7.7. Comparison 7: Schema-focused therapy (SFT) vs TAU, Outcome 7: Secondary: attrition (dichotomous), at end of
treatment...............................................................................................................................................................................................
Analysis 8.1. Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 1:
Primary: BPD symptom severity (continuous), at end of treatment.................................................................................................
Analysis 8.2. Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 2:
Primary: self-harm (dichtomous), at end of treatment......................................................................................................................
Analysis 8.3. Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 3:
Primary: psychosocial functioning (continuous)................................................................................................................................
Analysis 8.4. Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 4:
Secondary: affective instability (continuous), at end of treatment...................................................................................................
Analysis 8.5. Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 5:
Secondary: impulsivity (continuous), at end of treatment................................................................................................................
Analysis 8.6. Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 6:
Secondary: impulsivity (dichotomous), at end of treatment.............................................................................................................

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

350

351

351

352

355
355
356

356

357
357
358

358
359

359
360

360

361
361

362

362

363

363

363

363

364

365

365

366

366

366

367

iii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.7. Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 7:
Secondary: interpersonal problems (continuous), at end of treatment...........................................................................................
Analysis 8.8. Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 8:
Secondary: dissociation and psychotic-like symptoms (continuous), at end of treatment.............................................................
Analysis 8.9. Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 9:
Secondary: depression (continuous), at end of treatment................................................................................................................
Analysis 8.10. Comparison 8: Systems training for emotional predictability and problem solving (STEPPS) vs TAU, Outcome 10:
Secondary: attrition (dichotomous), at end of treatment.................................................................................................................
Analysis  9.1.  Comparison  9:  Cognitive  analytic  therapy  (CAT)  vs  TAU,  Outcome  1:  Primary:  suicide-related  outcomes
(continuous)...........................................................................................................................................................................................
Analysis  9.2.  Comparison  9:  Cognitive  analytic  therapy  (CAT)  vs  TAU,  Outcome  2:  Primary:  psychosocial  functioning
(continuous)...........................................................................................................................................................................................
Analysis 9.3. Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 3: Secondary: anger (continuous).......................
Analysis 9.4. Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 4: Secondary: dissociation and psychotic-like
symptoms (continuous)........................................................................................................................................................................
Analysis 9.5. Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 5: Secondary: depression (continuous)..............
Analysis 9.6. Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 6: Secondary: attrition (dichotomous), at end
of treatment..........................................................................................................................................................................................
Analysis  10.1.  Comparison  10:  Motivation  feedback  (MF)  vs  TAU,  Outcome  1:  Primary:  psychosocial  functioning,  at  end  of
treatment...............................................................................................................................................................................................
Analysis 11.1. Comparison 11: Psychoeducation vs TAU, Outcome 1: Secondary: depression (continuous), at end of treatment....
Analysis 11.2. Comparison 11: Psychoeducation vs TAU, Outcome 2: Secondary: attrition (dichotomous), at end of treatment....
Analysis 12.1. Comparison 12: Transference-focused psychotherapy (TFP) vs TAU, Outcome 1: Primary: BPD symptom severity
(continuous), at end of treatment.......................................................................................................................................................
Analysis  12.2.  Comparison  12:  Transference-focused  psychotherapy  (TFP)  vs  TAU,  Outcome  2:  Primary:  self-harm
(dichotomous), at end of treatment....................................................................................................................................................
Analysis  12.3.  Comparison  12:  Transference-focused  psychotherapy  (TFP)  vs  TAU,  Outcome  3:  Primary:  suicide-related
outcomes (dichotomous), at end of treatment..................................................................................................................................
Analysis  12.4.  Comparison  12:  Transference-focused  psychotherapy  (TFP)  vs  TAU,  Outcome  4:  Primary:  psychosocial
functioning (continuous), at end of treatment...................................................................................................................................
Analysis  12.5.  Comparison  12:  Transference-focused  psychotherapy  (TFP)  vs  TAU,  Outcome  5:  Secondary:  depression
(continuous), at end of treatment.......................................................................................................................................................
Analysis  12.6.  Comparison  12:  Transference-focused  psychotherapy  (TFP)  vs  TAU,  Outcome  6:  Secondary:  attrition
(dichotomous), at end of treatment....................................................................................................................................................
Analysis 13.1. Comparison 13: Once-only interventions (individual setting) vs TAU, Outcome 1: Primary: self-harm (continuous),
at end of treatment..............................................................................................................................................................................
Analysis  13.2.  Comparison  13:  Once-only  interventions  (individual  setting)  vs  TAU,  Outcome  2:  Primary:  psychosocial
functioning (continuous), at end of treatment...................................................................................................................................
Analysis  13.3.  Comparison  13:  Once-only  interventions  (individual  setting)  vs  TAU,  Outcome  3:  Secondary:  depression
(continuous), at end of treatment.......................................................................................................................................................
Analysis  13.4.  Comparison  13:  Once-only  interventions  (individual  setting)  vs  TAU,  Outcome  4:  Secondary:  attrition
(dichotomous), at end of treatment....................................................................................................................................................
Analysis 14.1. Comparison 14: Eclectic treatments vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of
treatment...............................................................................................................................................................................................
Analysis 14.2. Comparison 14: Eclectic treatments vs TAU, Outcome 2: Primary: self-harm (continuous), at end of treatment......
Analysis 14.3. Comparison 14: Eclectic treatments vs TAU, Outcome 3: Primary: suicide-related outcomes (continuous), at end
of treatment..........................................................................................................................................................................................
Analysis 14.4. Comparison 14: Eclectic treatments vs TAU, Outcome 4: Primary: psychosocial functioning (continuous).............
Analysis 14.5. Comparison 14: Eclectic treatments vs TAU, Outcome 5: Secondary: anger (continuous), at end of treatment.......
Analysis 14.6. Comparison 14: Eclectic treatments vs TAU, Outcome 6: Secondary: affective instability (continuous), at end of
treatment...............................................................................................................................................................................................
Analysis 14.7. Comparison 14: Eclectic treatments vs TAU, Outcome 7: Secondary: chronic feelings of emptiness (continuous),
at end of treatment..............................................................................................................................................................................
Analysis  14.8.  Comparison  14:  Eclectic  treatments  vs  TAU,  Outcome  8:  Secondary:  impulsivity  (continuous),  at  end  of
treatment...............................................................................................................................................................................................

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

367

367

368

368

369

370

370
371

371
371

372

372
373
373

374

374

374

374

375

375

376

376

376

378

378
378

379
379
379

380

380

iv

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.9. Comparison 14: Eclectic treatments vs TAU, Outcome 9: Secondary: interpersonal problems (continuous), at end
of treatment..........................................................................................................................................................................................
Analysis 14.10. Comparison 14: Eclectic treatments vs TAU, Outcome 10: Secondary: abandonment (continuous), at end of
treatment...............................................................................................................................................................................................
Analysis 14.11. Comparison 14: Eclectic treatments vs TAU, Outcome 11: Secondary: identity disturbance (continuous), at end
of treatment..........................................................................................................................................................................................
Analysis  14.12.  Comparison  14:  Eclectic  treatments  vs  TAU,  Outcome  12:  Secondary:  depression  (continuous),  at  end  of
treatment...............................................................................................................................................................................................
Analysis  14.13.  Comparison  14:  Eclectic  treatments  vs  TAU,  Outcome  13:  Secondary:  attrition  (dichotomuous),  at  end  of
treatment...............................................................................................................................................................................................
Analysis 14.14. Comparison 14: Eclectic treatments vs TAU, Outcome 14: Secondary: adverse effects (dichotomous), at end of
treatment...............................................................................................................................................................................................
Analysis  15.1.  Comparison  15:  Psychotherapy  vs  waiting  list  or  no  treatment,  Outcome  1:  Primary:  BPD  symptom  severity
(continuous), at end of treatment.......................................................................................................................................................
Analysis 15.2. Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 2: Primary: self-harm (continuous), at
end of treatment...................................................................................................................................................................................
Analysis 15.3. Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 3: Primary: suicide-related outcomes
(continuous), at end of treatment.......................................................................................................................................................
Analysis 15.4. Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 4: Primary: psychosocial functioning
(continuous)...........................................................................................................................................................................................
Analysis 15.5. Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 5: Secondary: anger (continuous), at
end of treatment...................................................................................................................................................................................
Analysis  15.6.  Comparison  15:  Psychotherapy  vs  waiting  list  or  no  treatment,  Outcome  6:  Secondary:  affective  instability
(continuous)...........................................................................................................................................................................................
Analysis  15.7.  Comparison  15:  Psychotherapy  vs  waiting  list  or  no  treatment,  Outcome  7:  Secondary:  chronic  feelings  of
emptiness (continuous), at end of treatment.....................................................................................................................................
Analysis 15.8. Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 8: Secondary: impulsivity (continuous)...
Analysis 15.9. Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 9: Secondary: interpersonal problems
(continuous)...........................................................................................................................................................................................
Analysis  15.10.  Comparison  15:  Psychotherapy  vs  waiting  list  or  no  treatment,  Outcome  10:  Secondary:  abandonment
(continuous), at end of treatment.......................................................................................................................................................
Analysis 15.11. Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 11: Secondary: identity disturbance
(continuous), at end of treatment.......................................................................................................................................................
Analysis  15.12.  Comparison  15:  Psychotherapy  vs  waiting  list  or  no  treatment,  Outcome  12:  Secondary:  dissociation  and
psychotic-like symptoms (continuous), at end of treatment.............................................................................................................
Analysis  15.13.  Comparison  15:  Psychotherapy  vs  waiting  list  or  no  treatment,  Outcome  13:  Secondary:  depression
(continuous), at end of treatment.......................................................................................................................................................
Analysis 15.14. Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome 14: Secondary: attrition (dichotomous),
at end of treatment..............................................................................................................................................................................
Analysis 16.1. Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 1: Primary: BPD
symptom severity (continuous), at end of treatment........................................................................................................................
Analysis 16.2. Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 2: Primary: self-harm
(continuous), at end of treatment.......................................................................................................................................................
Analysis 16.3. Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 3: Primary: suicide-
related outcomes (continuous), at end of treatment.........................................................................................................................
Analysis  16.4.  Comparison  16:  Dialectical  behavior  therapy  (DBT)  vs  waiting  list  or  no  treatment,  Outcome  4:  Primary:
psychosocial functioning (continuous), at end of treatment............................................................................................................
Analysis 16.5. Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 5: Secondary: anger
(continuous), at end of treatment.......................................................................................................................................................
Analysis  16.6.  Comparison  16:  Dialectical  behavior  therapy  (DBT)  vs  waiting  list  or  no  treatment,  Outcome  6:  Secondary:
affective instability (continuous), at end of treatment.......................................................................................................................
Analysis  16.7.  Comparison  16:  Dialectical  behavior  therapy  (DBT)  vs  waiting  list  or  no  treatment,  Outcome  7:  Secondary:
impulsivity (continuous), at end of treatment....................................................................................................................................
Analysis  16.8.  Comparison  16:  Dialectical  behavior  therapy  (DBT)  vs  waiting  list  or  no  treatment,  Outcome  8:  Secondary:
dissociation and psychotic-like symptoms (continuous), at end of treatment................................................................................

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

380

381

381

381

382

382

384

384

385

385

386

386

387

387
388

388

389

389

389

390

391

392

392

392

393

393

393

393

v

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  16.9.  Comparison  16:  Dialectical  behavior  therapy  (DBT)  vs  waiting  list  or  no  treatment,  Outcome  9:  Secondary:
depression (continuous), at end of treatment....................................................................................................................................
Analysis 16.10. Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 10: DBT-couple
therapy (CDBT) vs waiting list (generic inverse variance)..................................................................................................................
Analysis 17.1. Comparison 17: Schema-focused therapy (SFT) vs no treatment, Outcome 1: Primary: suicide-related outcomes
(continuous), at end of treatment.......................................................................................................................................................
Analysis 17.2. Comparison 17: Schema-focused therapy (SFT) vs no treatment, Outcome 2: Secondary: depression (continuous),
at end of treatment..............................................................................................................................................................................
Analysis 18.1. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 1: Primary: BPD symptom severity
(continuous), at end of treatment.......................................................................................................................................................
Analysis 18.2. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 2: Primary: self-harm (continuous),
at end of treatment..............................................................................................................................................................................
Analysis 18.3. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 3: Primary: psychosocial functioning
(continuous)...........................................................................................................................................................................................
Analysis 18.4. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 4: Secondary: anger (continuous), at
end of treatment...................................................................................................................................................................................
Analysis 18.5. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 5: Secondary: affective instability
(continuous)...........................................................................................................................................................................................
Analysis 18.6. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 6: Secondary: chronic feelings of
emptiness (continuous), at end of treatment.....................................................................................................................................
Analysis  18.7.  Comparison  18:  Interpersonal  psychotherapy  (IPT)  vs  waiting  list,  Outcome  7:  Secondary:  impulsivity
(continuous)...........................................................................................................................................................................................
Analysis 18.8. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 8: Secondary: interpersonal problems
(continuous)...........................................................................................................................................................................................
Analysis  18.9.  Comparison  18:  Interpersonal  psychotherapy  (IPT)  vs  waiting  list,  Outcome  9:  Secondary:  abandonment
(continuous), at end of treatment.......................................................................................................................................................
Analysis 18.10. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 10: Secondary: identity disturbance
(continuous), at end of treatment.......................................................................................................................................................
Analysis 18.11. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 11: Secondary: dissociation and
psychotic-like symptoms (continuous), at end of treatment.............................................................................................................
Analysis 18.12. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 12: Secondary outcome: depression
(continuous), at end of treatment.......................................................................................................................................................
Analysis 18.13. Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome 13: Secondary outcome: attrition
(dichotomous), at end of treatment....................................................................................................................................................
Analysis 19.1. Comparison 19: Once-only interventions (individual setting) vs waiting list, Outcome 1: Secondary: impulsivity
(continuous), at end of treatment.......................................................................................................................................................
Analysis 19.2. Comparison 19: Once-only interventions (individual setting) vs waiting list, Outcome 2: Secondary: interpersonal
problems (continuous), at end of treatment......................................................................................................................................
Analysis  19.3.  Comparison  19:  Once-only  interventions  (individual  setting)  vs  waiting  list,  Outcome  3:  Secondary:  attrition
(dichotomous), at end of treatment....................................................................................................................................................
Analysis  20.1.  Comparison  20:  Eclectic  treatments  vs  waiting  list,  Outcome  1:  Primary  outcome:  psychosocial  functioning
(continuous), at end of treatment.......................................................................................................................................................
Analysis  20.2.  Comparison  20:  Eclectic  treatments  vs  waiting  list,  Outcome  2:  Secondary  outcome:  interpersonal  problems
(continuous), at end of treatment.......................................................................................................................................................
Analysis  21.1.  Comparison  21:  Dialectical  behavior  therapy  (DBT)  and  related  treatments  vs  active  treatment,  Outcome  1:
Standard DBT (DBT) vs client-centred therapy (CCT) (continuous)...................................................................................................
Analysis 21.2. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 2: DBT
vs CCT, secondary: attrition (dichotomous), at end of treatment.....................................................................................................
Analysis  21.3.  Comparison  21:  Dialectical  behavior  therapy  (DBT)  and  related  treatments  vs  active  treatment,  Outcome  3:
Standard DBT (DBT) vs good psychiatric management (GPM) (continuous)....................................................................................
Analysis 21.4. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 4: DBT
vs GPM, secondary: attrition (dichotomous), at end of treatment....................................................................................................
Analysis  21.5.  Comparison  21:  Dialectical  behavior  therapy  (DBT)  and  related  treatments  vs  active  treatment,  Outcome  5:
Standard DBT (DBT) vs individual DBT therapy + activities group (DBT-I) (continuous)..................................................................
Analysis 21.6. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 6: DBT
vs DBT-I, secondary: attrition (dichotomous), at end of treatment...................................................................................................

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

394

395

397

397

399

399

400

400

401

401

402

403

403

403

404

404

404

405

405

405

406

406

412

413

413

414

414

415

vi

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis  21.7.  Comparison  21:  Dialectical  behavior  therapy  (DBT)  and  related  treatments  vs  active  treatment,  Outcome  7:
Standard DBT (DBT) vs skills training group + individual case management (DBT-S) (continuous)................................................
Analysis 21.8. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 8: DBT
vs DBT-S, secondary: attrition (dichotomous), at 6-12 months follow-up........................................................................................
Analysis  21.9.  Comparison  21:  Dialectical  behavior  therapy  (DBT)  and  related  treatments  vs  active  treatment,  Outcome  9:
Standard DBT (DBT) vs step-down DBT (DBT-SD) (continuous).........................................................................................................
Analysis 21.10. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 10:
DBT vs DBT-SD, secondary: attrition (dichotomous), at end of treatment.......................................................................................
Analysis 21.11. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 11:
Standard DBT (DBT) vs DBT Prolonged Exposure (PE) (continuous).................................................................................................
Analysis 21.12. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 12:
DBT vs DBT-PE, secondary: attrition (dichotomous), at 0-6 months follow-up................................................................................
Analysis 21.13. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 13:
DBT skills group + case management (DBT-S) vs DBT individual therapy + activity group (DBT-I) (continuous).............................
Analysis 21.14. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 14:
DBT-S vs DBT-I, secondary: attrition (dichotomous), at 6-12 months follow-up..............................................................................
Analysis 21.15. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 15:
DBT skills group (DBT-S) vs cognitive therapy group (CT-G) (continuous)........................................................................................
Analysis 21.16. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 16:
DBT-S vs CT-G, secondary: attrition (dichotomous), at end of treatment.........................................................................................
Analysis 21.17. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 17:
DBT skills group (DBT-S) vs schema-focused therapy group (SFT-G)................................................................................................
Analysis 21.18. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 18:
DBT mindfulness group (DBT-M) vs DBT interpersonal effectiveness group (DBT-IE) (continuous).................................................
Analysis 21.19. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 19:
DBT-M vs DBT-IE, secondary: attrition (dichotomous), at end of treatment.....................................................................................
Analysis 21.20. Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment, Outcome 20:
DBT  mindfulness  group  (DBT-M)  vs  loving-kindness  and  compassion  meditation  (LK/CM),  primary:  BPD  symptom  severity
(continuous), at end of treatment.......................................................................................................................................................
Analysis 22.1. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 1: CBT
vs trauma- and anxiety-related group psychoeducation (continuous).............................................................................................
Analysis 22.2. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 2: CBT
vs trauma- and anxiety-related group psychoeducation, secondary: attrition (dichotomous), at end of treatment.....................
Analysis 22.3. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 3: CBT
vs interpersonal psychotherapy (IPT) (continuous)............................................................................................................................
Analysis 22.4. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 4: CBT
vs IPT, secondary: attrition (dichotomous), at end of treatment.......................................................................................................
Analysis 22.5. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 5: CBT
vs Rogerian supportive therapy (continuous).....................................................................................................................................
Analysis 22.6. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 6: CBT
vs Rogerian supportive therapy, secondary: attrition (dichotomous), end of treatment.................................................................
Analysis 22.7. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 7:
MACT (Manual-assisted Cognitive Therapy) vs MACT + therapeutic assessment (MACT + TA) (continuous)....................................
Analysis 22.8. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 8:
MACT vs MACT + TA, secondary: attrition (dichotomous), at end of treatment................................................................................
Analysis 22.9. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 9:
Meta-Cognitive training for BPD (B-MCT) vs progressive muscle relaxation training (PMR)............................................................
Analysis 22.10. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 10:
B-MCT vs progressive muscle relaxation (PMR) training + TAU (dichotomous). Secondary: attrition (dichotomous), at end of
treatment...............................................................................................................................................................................................
Analysis 22.11. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 11:
MOTR (Motive-Oriented Therapeutic Relationship) vs Good Psychiatric Management (GPM) (continuous)...................................
Analysis 22.12. Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment, Outcome 12:
MOTR vs (GPM), secondary: attrition (dichotomous), at end of treatment.......................................................................................
Analysis  23.1.  Comparison  23:  Schema-focused  therapy  (SFT)  vs  active  treatment,  Outcome  1:  SFT  vs  TFP.  Primary:  BPD
symptom severity (continuous), at end of treatment........................................................................................................................

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

415

416

417

418

419

420

421

421

422

422

423

423

424

424

428

429

429

429

430

431

432

432

433

433

434

434

435

vii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 23.2. Comparison 23: Schema-focused therapy (SFT) vs active treatment, Outcome 2: SFT vs TFP. Secondary: attrition
(dichotomous), at 0-6 months follow-up............................................................................................................................................
Analysis 23.3. Comparison 23: Schema-focused therapy (SFT) vs active treatment, Outcome 3: SFT vs SFT + therapist availability
(TA). Primary: BPD symptom severity (continuous), at end of treatment.........................................................................................
Analysis 23.4. Comparison 23: Schema-focused therapy (SFT) vs active treatment, Outcome 4: SFT vs SFT + TA. Secondary:
attrition (dichotomous), 0-6 months follow-up..................................................................................................................................
Analysis  24.1.  Comparison  24:  Systems  training  for  emotional  predictability  and  problem  solving-based  psychoeducation
(STEPPS-PE) vs cognitive rehabilitation (CR), Outcome 1: STEPPS-PE vs CR...................................................................................
Analysis  24.2.  Comparison  24:  Systems  training  for  emotional  predictability  and  problem  solving-based  psychoeducation
(STEPPS-PE)  vs  cognitive  rehabilitation  (CR),  Outcome  2:  STEPPS-PE  vs  CR.  Secondary:  attrition  (dichotomous),  at  end  of
treatment...............................................................................................................................................................................................
Analysis  25.1.  Comparison  25:  Eclectic  treatments  vs  active  treatment,  Outcome  1:  Combined  inpatient  and  outpatient
psychotherapy versus outpatient psychotherapy..............................................................................................................................
Analysis  25.2.  Comparison  25:  Eclectic  treatments  vs  active  treatment,  Outcome  2:  Combined  inpatient  and  outpatient
psychotherapy versus outpatient psychotherapy. Secondary: attrition (dichotomous), at end of treatment................................
Analysis 25.3. Comparison 25: Eclectic treatments vs active treatment, Outcome 3: integrative BPD-oriented adolescent family
therapy (I-BAFT) vs individual drug counselling (IDC)........................................................................................................................
Analysis 26.1. Comparison 26: Subgroup analysis: therapeutic approaches, Outcome 1: BPD symptom severity.........................
Analysis 26.2. Comparison 26: Subgroup analysis: therapeutic approaches, Outcome 2: Psychosocial functioning.....................
Analysis 27.1. Comparison 27: Subgroup analysis: age, Outcome 1: BPD symptom severity..........................................................
Analysis 28.1. Comparison 28: Subgroup analysis: duration, Outcome 1: BPD symptom severity..................................................
Analysis 28.2. Comparison 28: Subgroup analysis: duration, Outcome 2: Psychosocial functioning..............................................
Analysis 29.1. Comparison 29: Subgroup analysis: mode of therapy, Outcome 1: BPD symptom severity.....................................
Analysis 29.2. Comparison 29: Subgroup analysis: mode of therapy, Outcome 2: Psychosocial functioning.................................
Analysis 30.1. Comparison 30: Subgroup analysis: setting, Outcome 1: BPD symptom severity.....................................................
Analysis 30.2. Comparison 30: Subgroup analysis: setting, Outcome 2: Psychosocial functioning.................................................
Analysis 31.1. Comparison 31: Subgroup analysis: types of raters, Outcome 1: BPD symptom severity.........................................
Analysis 31.2. Comparison 31: Subgroup analysis: types of raters, Outcome 2: Psychosocial functioning.....................................
Analysis 32.1. Comparison 32: Subgroup analysis: types of TAU, Outcome 1: BPD symptom severity............................................
Analysis 32.2. Comparison 32: Subgroup analysis: types of TAU, Outcome 2: Psychosocial functioning........................................
Analysis 33.1. Comparison 33: Subgroup analysis: type of comparison group, Outcome 1: BPD symptom severity......................
Analysis 33.2. Comparison 33: Subgroup analysis: type of comparison group, Outcome 2: Psychosocial functioning..................
Analysis 34.1. Comparison 34: Subgroup analysis: types of scales, Outcome 1: BPD symptom severity........................................
Analysis 34.2. Comparison 34: Subgroup analysis: types of scales, Outcome 2: Psychosocial functioning....................................
Analysis 35.1. Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 1: Primary: BPD symptom severity,
at end of treatment..............................................................................................................................................................................
Analysis 35.2. Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 2: Primary: self-harm...................
Analysis  35.3.  Comparison  35:  TSA  sensitivity  analyses:  psychotherapy  versus  TAU,  Outcome  3:  Primary:  suicide-related
outcomes...............................................................................................................................................................................................
Analysis  35.4.  Comparison  35:  TSA  sensitivity  analyses:  psychotherapy  versus  TAU,  Outcome  4:  Primary:  psychosocial
functioning, at end of treatment.........................................................................................................................................................
Analysis 35.5. Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 5: Secondary: depression............
ADDITIONAL TABLES....................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
Figure 5..................................................................................................................................................................................................
Figure 6..................................................................................................................................................................................................
Figure 7..................................................................................................................................................................................................
Figure 8..................................................................................................................................................................................................
Figure 9..................................................................................................................................................................................................
Figure 10................................................................................................................................................................................................
Figure 11................................................................................................................................................................................................
Figure 12................................................................................................................................................................................................
FEEDBACK.....................................................................................................................................................................................................

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

435

435

436

437

437

439

440

440

443
445
447
449
450
452
453
455
456
458
459
461
462
464
465
468
470
473

474
475

476

477
477
483
500
501
502
503
504
505
506
507
508
508

viii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

WHAT'S NEW.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
NOTES...........................................................................................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

509
509
509
510
510
510
512
512

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ix

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Psychological therapies for people with borderline personality disorder

Ole Jakob Storebø1,2,3a, Jutta M Stoffers-Winterling4b, Birgit A Völlm5, Mickey T Kongerslev6,7, Jessica T Mattivi4, Mie S Jørgensen6,
Erlend Faltinsen6, Adnan Todorovac6, Christian P Sales8,9, Henriette E Callesen1, Klaus Lieb10c, Erik Simonsen6d

1Psychiatric Research Unit, Psychiatry of Region Zealand, Slagelse, Denmark. 2Child and Adolescent Psychiatric Department,
Region Zealand, Roskilde, Denmark. 3Department of Psychology, University of Southern Denmark, Odense, Denmark. 4Department
of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany. 5Department of Forensic Psychiatry, Center
for Neurology, University Rostock, Rostock, Germany. 6Psychiatric Research Unit, Region Zealand Psychiatry, Slagelse, Denmark.
7Department of Psychology, Faculty of Health Science, University of Southern Denmark, Odense, Denmark. 8Duncan MacMillan House,
Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK. 9Institute of Mental Health, Department of Psychiatry & Applied
Psychology, Nottingham, UK. 10Leibniz Institute for Resilience Research (LIR), Mainz, Germany

aShared 1st authorship.. bShared 1st authorship.. cShared last authorship.. dShared last authorship.

Contact: Ole Jakob Storebø, ojst@regionsjaelland.dk.

Editorial group: Cochrane Developmental, Psychosocial and Learning Problems Group.
Publication status and date: Edited (no change to conclusions), published in Issue 11, 2020.

Citation: Storebø OJ, Stoffers-Winterling JM, Völlm BA, Kongerslev MT, Mattivi JT, Jørgensen MS, Faltinsen E, Todorovac A, Sales CP,
Callesen HE, Lieb K, Simonsen E. Psychological therapies for people with borderline personality disorder. Cochrane Database of
Systematic Reviews 2020, Issue 5. Art. No.: CD012955. DOI: 10.1002/14651858.CD012955.pub2.

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Over the decades, a variety of psychological interventions for borderline personality disorder (BPD) have been developed. This review
updates and replaces an earlier review (Stoffers-Winterling 2012).

Objectives

To assess the beneficial and harmful effects of psychological therapies for people with BPD.

Search methods

In March 2019, we searched CENTRAL, MEDLINE, Embase, 14 other databases and four trials registers. We contacted researchers working
in the field to ask for additional data from published and unpublished trials, and handsearched relevant journals. We did not restrict the
search by year of publication, language or type of publication.

Selection criteria

Randomised controlled trials comparing different psychotherapeutic interventions with treatment-as-usual (TAU; which included various
kinds of psychotherapy), waiting list, no treatment or active treatments in samples of all ages, in any setting, with a formal diagnosis of
BPD. The primary outcomes were BPD symptom severity, self-harm, suicide-related outcomes, and psychosocial functioning. There were
11 secondary outcomes, including individual BPD symptoms, as well as attrition and adverse effects.

Data collection and analysis

At least two review authors independently selected trials, extracted data, assessed risk of bias using Cochrane's 'Risk of bias' tool and
assessed the certainty of the evidence using the GRADE approach. We performed data analysis using Review Manager 5 and quantified the
statistical reliability of the data using Trial Sequential Analysis.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Main results

Cochrane Database of Systematic Reviews

We included 75 randomised controlled trials (4507 participants), predominantly involving females with mean ages ranging from 14.8 to 45.7
years. More than 16 different kinds of psychotherapy were included, mostly dialectical behaviour therapy (DBT) and mentalisation-based
treatment (MBT). The comparator interventions included treatment-as-usual (TAU), waiting list, and other active treatments. Treatment
duration ranged from one to 36 months.

Psychotherapy versus TAU

Psychotherapy reduced BPD symptom severity, compared to TAU; standardised mean difference (SMD) −0.52, 95% confidence interval (CI)
−0.70 to −0.33; 22 trials, 1244 participants; moderate-quality evidence. This corresponds to a mean difference (MD) of −3.6 (95% CI −4.4
to −2.08) on the Zanarini Rating Scale for BPD (range 0 to 36), a clinically relevant reduction in BPD symptom severity (minimal clinical
relevant difference (MIREDIF) on this scale is −3.0 points).

Psychotherapy may be more effective at reducing self-harm compared to TAU (SMD −0.32, 95% CI −0.49 to −0.14; 13 trials, 616 participants;
low-quality evidence), corresponding to a MD of −0.82 (95% CI −1.25 to 0.35) on the Deliberate Self-Harm Inventory Scale (range 0 to 34).
The MIREDIF of −1.25 points was not reached.

Suicide-related outcomes improved compared to TAU (SMD −0.34, 95% CI −0.57 to −0.11; 13 trials, 666 participants; low-quality evidence),
corresponding to a MD of −0.11 (95% CI −0.19 to −0.034) on the Suicidal Attempt Self Injury Interview. The MIREDIF of −0.17 points was
not reached.

Compared to TAU, psychotherapy may result in an improvement in psychosocial functioning (SMD −0.45, 95% CI −0.68 to −0.22; 22 trials,
1314 participants; low-quality evidence), corresponding to a MD of −2.8 (95% CI −4.25 to −1.38), on the Global Assessment of Functioning
Scale (range 0 to 100). The MIREDIF of −4.0 points was not reached.

Our  additional  Trial  Sequential  Analysis  on  all  primary  outcomes  reaching  significance  found  that  the  required  information  size  was
reached in all cases.

A subgroup analysis comparing the different types of psychotherapy compared to TAU showed no clear evidence of a difference for BPD
severity and psychosocial functioning.

Psychotherapy may reduce depressive symptoms compared to TAU but the evidence is very uncertain (SMD −0.39, 95% CI −0.61 to −0.17;
22 trials, 1568 participants; very low-quality evidence), corresponding to a MD of −2.45 points on the Hamilton Depression Scale (range 0
to 50). The MIREDIF of −3.0 points was not reached.

BPD-specific psychotherapy did not reduce attrition compared with TAU. Adverse effects were unclear due to too few data.

Psychotherapy versus waiting list or no treatment

Greater improvements in BPD symptom severity (SMD −0.49, 95% CI −0.93 to −0.05; 3 trials, 161 participants), psychosocial functioning
(SMD −0.56, 95% CI −1.01 to −0.11; 5 trials, 219 participants), and depression (SMD −1.28, 95% CI −2.21 to −0.34, 6 trials, 239 participants)
were observed in participants receiving psychotherapy versus waiting list or no treatment (all low-quality evidence). No evidence of a
difference was found for self-harm and suicide-related outcomes.

Individual treatment approaches

DBT and MBT have the highest numbers of primary trials, with DBT as subject of one-third of all included trials, followed by MBT with
seven RCTs.

Compared to TAU, DBT was more effective at reducing BPD severity (SMD −0.60, 95% CI −1.05 to −0.14; 3 trials, 149 participants), self-harm
(SMD −0.28, 95% CI −0.48 to −0.07; 7 trials, 376 participants) and improving psychosocial functioning (SMD −0.36, 95% CI −0.69 to −0.03;
6 trials, 225 participants). MBT appears to be more effective than TAU at reducing self-harm (RR 0.62, 95% CI 0.49 to 0.80; 3 trials, 252
participants), suicidality (RR 0.10, 95% CI 0.04, 0.30, 3 trials, 218 participants) and depression (SMD −0.58, 95% CI −1.22 to 0.05, 4 trials, 333
participants). All findings are based on low-quality evidence. For secondary outcomes see review text.

Authors' conclusions

Our assessments showed beneficial effects on all primary outcomes in favour of BPD-tailored psychotherapy compared with TAU. However,
only the outcome of BPD severity reached the MIREDIF-defined cut-off for a clinically meaningful improvement. Subgroup analyses found
no evidence of a difference in effect estimates between the different types of therapies (compared to TAU) .

The pooled analysis of psychotherapy versus waiting list or no treatment found significant improvement on BPD severity, psychosocial
functioning and depression at end of treatment, but these findings were based on low-quality evidence, and the true magnitude of these
effects is uncertain. No clear evidence of difference was found for self-harm and suicide-related outcomes.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

However, compared to TAU, we observed effects in favour of DBT for BPD severity, self-harm and psychosocial functioning and, for MBT, on
self-harm and suicidality at end of treatment, but these were all based on low-quality evidence. Therefore, we are unsure whether these
effects would alter with the addition of more data.

P L A I N   L A N G U A G E   S U M M A R Y

Psychological therapies for people with borderline personality disorder

Background

People affected by borderline personality disorder (BPD) often have difficulties with controlling their impulses and emotions. They may
have  a  poor  self-image,  experience  rapid  changes  in  mood,  harm  themselves  and  find  it  hard  to  engage  in  harmonious  interpersonal
relationships. Different types of psychological treatments ('talking treatments') have been developed to help people with BPD. The effects
of these treatments must be investigated to decide how well they work and if they can be harmful.

Objective

This review summarises what we currently know about the effect of psychotherapy in people with BPD.

Methods

We compared the effects of psychological treatments on people affected by BPD who did not receive treatment or who continued their
usual treatment, were on a waiting list or received active treatment.

Findings

We searched for relevant research articles, and found 75 trials (4507 participants, mostly female, mean age ranging from 14.8 to 45.7 years).
The trials examined a wide variety of psychological treatments (over 16 different types). They were mostly conducted in outpatient settings,
and lasted between one and 36 months. Dialectical behaviour Therapy (DBT) and Mentalisation-Based Treatment (MBT) were the therapies
most studied.

Psychotherapy compared with usual treatment

Psychotherapy reduced the severity of BPD symptoms and suicidality and may reduce self-harm and depression whilst also improving
psychological functioning compared to usual treatment. DBT may be better than usual treatment at reducing BPD severity, self-harm and
improving psychosocial functioning. Similarly, MBT appears to be more effective than usual treatment at reducing self-harm, suicidality
and depression. However, these findings were all based on low-quality evidence and therefore we are uncertain whether or not these
results would change if we added more trials. Most trials did not report adverse effects, and those that did, found no obvious unwanted
reactions following psychological treatment. The majority of trials (64 out of 75) were funded by grants from universities, authorities or
research foundations. Four trials reported that no funding was received. For the remaining trials (7), funding was not specified.

Psychotherapy versus waiting list or no treatment

Psychotherapy was more effective than waiting list at improving BPD symptoms, psychosocial functioning, and depression, but there was
no clear difference between psychotherapy, and waiting list for outcomes of self-harm, and suicide-related outcomes.

Conclusions

In  general,  psychotherapy  may  be  more  effective  than  usual  treatment  in  reducing  BPD  symptom  severity,  self-harm,  suicide-related
outcomes and depression, whilst also improving psychosocial functioning. However, only the decrease in BPD symptom severity was found
to be at a clinically important level. DBT appears to be better at reducing BPD severity, self-harm, and improving psychosocial functioning
compared to usual treatment and MBT appears more effective than usual treatment at reducing self-harm and suicidality. However, we
are still uncertain about these findings as the quality of the evidence is low.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
S U M M A R Y   O F   F I N D I N G S

Summary of findings 1.   Psychotherapy versus treatment-as-usual

Psychotherapy versus treatment-as-usual

Patient or population: borderline personality disorder

Settings: inpatient and outpatient

Intervention: psychotherapy

Comparison: treatment-as-usual (TAU)

Outcomes

Illustrative comparative risks* (95% CI)

Relative ef-
fect(95% CI)

Number of par-
ticipants

Quality of the
evidence

Comments

Assumed risk

Corresponding risk

TAU

Psychotherapy

(RCTs)

(GRADE)

-

-

-

BPD symptom severity

Measured by: clinicians and
self-rated

Timing of outcome assess-
ment: end of treatment

Self-harm (frequency)

Measured by: clinicians and
self-rated

Timing of outcome assess-
ment: end of treatment

Suicide-related outcomes
(suicidality)

Measured by: clinicians and
self-rated

Timing of outcome assess-
ment: end of treatment

The mean score in the
intervention groups was
0.52 SD lower (0.70 low-
er to 0.33 lower)

The mean score in the
intervention groups was
0.32 SD lower (0.49 low-
er to 0.14 lower)

The mean score in the
intervention groups was
0.34 SD lower (0.57 low-
er to 0.11 lower)

-

-

-

1244 

⊕⊕⊕⊝

(22 RCTs)

Moderatea

The SMD of −0.52 corresponds to
−3.6 on the Zanarini BPD scale. The
MIREDIF on this scale is 3.0 points

616

(13 RCTs)

⊕⊕⊝⊝
Lowa,b

666

(13 RCTs)

⊕⊕⊝⊝

Lowa,b

TSA adjusted Cl = −5.49 to −1.90 on
the Zanarini BPD scale

TSA RIS = 901

The SMD of −0. 32 corresponds to
−0.82 on the DSHI. The MIREDIF on
this scale is −1.25 points (½ SD)

TSA adjusted CI = −0.59 to −0.08 on
the DSHI

TSA RIS = 97

The SMD of −0. 34 corresponds to
−0.11 on the SASII. The MIREDIF on
this scale is −0.17 points (½ SD)

TSA adjusted CI = −0.18 to −0.04 on
the SASII

TSA RIS = 253

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

5

Psychosocial functioning

-

Measured by: clinicians and
self-rated

Timing of outcome assess-
ment: end of treatment

Depression

-

Measured by: clinicians and
self-rated

Timing of outcome assess-
ment: end of treatment

The mean score in the
intervention groups was
0.45 SD lower (0.68 low-
er to 0.22 lower)

The mean score in the
intervention groups was
0.39 SD lower (0.61 low-
er to 0.17 lower)

-

-

1314

(22 RCTs)

⊕⊕⊝⊝
Lowa,c

1568

(22 RCTs)

⊕⊝⊝⊝
Very lowa,b,c

The SMD of −0.45 corresponds to
−2.8 on the GAF. The MIREDIF on
this scale is −4.0 points

TSA adjusted CI = −3.97 to −1.94 on
the GAF

TSA RIS = 947

The SMD of -0.45 corresponds to
−2.45 on the Hamilton Depression
Scale. The MIREDIF on this scale is
3.0 points

TSA adjusted CI = −3.34 to −1.72 on
the Hamilton Depression Scale

TSA RIS = 2274

Attrition

328 per 1000

Timing of outcome assess-
ment: end of treatment

Adverse effects

74 per 1000

Timing of outcome assess-
ment: end of treatment

328 per 1000 (95% CI 56
fewer to 66 higher)

RR 1.00 (95%
CI 0.83 to 1.20)

6 per 1000 (95% CI 41
fewer to 65 higher)

RR 0.92 (95%
CI 0.45 to 1.88)

2225

(32 RCTs)

381

(2 RCTs)

⊕⊕⊝⊝
Lowa,b

⊕⊕⊝⊝
Lowa,b

-

-

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; DSHI: Deliberate Self-Harm Inventory; GAF: Global Assessment of Functioning scale; MIREDIF: Minimum relevant difference; RCTs: Randomised
controlled trials; RIS: Required information size; RR: Risk Ratio; SASII: Suicide Attempt Self-Injury Interview; SD: Standard deviation; SMD: Standardised mean difference;
TAU: treatment-as-usual; TSA: Trial Sequential Analysis

GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: we are very uncertain about the estimate

aWe downgraded the quality of this evidence by one level due to risk of bias (other bias).
bWe downgraded the quality of this evidence by one level due to imprecision.
cWe downgraded the quality of this evidence by one level due to high heterogeneity.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

6

Summary of findings 2.   Psychotherapy versus waiting list or no treatment

Psychotherapy versus waiting list or no treatment

Patient or population: borderline personality disorder

Settings: inpatient and outpatient

Intervention: psychotherapy

Comparison: waiting list or no treatment

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Waiting list or
no treatment

Psychotherapy

Relative effect
(95% CI)

Number of par-
ticipants

Quality of the
evidence

Comments

(RCTs)

(GRADE)

BPD symptom severity

Measured by: clinicians and self-rat-
ed

Timing of outcome assessment: end
of treatment

Self-harm

Measured by: clinicians and self-rat-
ed

Timing of outcome assessment: end
of treatment

Suicide-related outcomes

Measured by: self-rated

Timing of outcome assessment: end
of treatment

Psychosocial functioning

Measured by: clinicians and self-rat-
ed

-

-

-

-

The mean score in the interven-
tion groups was 0.49 SD lower
(0.93 lower to 0.05 lower)

The mean score in the interven-
tion groups was0.17 SD lower
(0.52 lower to 0.18 higher)

The mean score in the interven-
tion groups was 5.62 SD lower
(16.39 lower to 5.16 higher)

The mean score in the interven-
tion groups was 0.56 SD lower
(1.01 lower to 0.11 lower)

-

-

-

-

161

(3 RCTs)

⊕⊕⊝⊝
Lowa,b

An SMD of 0.49 rep-
resents a moderate
effect.

128

(2 RCTs)

⊕⊕⊝⊝
Lowa,b

An SMD of 0.17 rep-
resents a small ef-
fect.

108

⊕⊝⊝⊝

(2 RCTs)

Very lowa,b,c

An SMD of 5.62 rep-
resents a large ef-
fect.

219

(5 RCTs)

⊕⊕⊝⊝
Lowa,b

An SMD of 0.56 rep-
resents a moderate
effect.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
The mean score in the interven-
tion groups was 1.28 SD lower
(2.21 lower to 0.34 lower)

-

239

(6 RCTs)

⊕⊕⊝⊝
Lowa,b

An effect size of
1.28 represents a
large effect.

Timing of outcome assessment: end
of treatment

Depression

-

Measured by: clinicians and self-rat-
ed

Timing of outcome assessment: end
of treatment

Attrition

Timing of outcome assessment: end
of treatment

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

81 per 1000

147 per 1000 (95% CI 118 fewer
to 74 higher)

RR 0.55 (95%
CI 0.20 to 1.50)

144

(3 RCTs)

⊕⊝⊝⊝
Very lowa,b,c

-

Adverse effects (not measured

See comments

See comments

-

-

-

No studies were
found that as-
sessed this out-
come

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RCTs: Randomised controlled trials; RR: Risk ratio; SMD: Standardized mean difference

GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: we are very uncertain about the estimate

aWe downgraded the quality of this evidence by one level due to risk of bias.
bWe downgraded the quality of this evidence by one level due to imprecision (there was a wide CI).
cWe downgraded the quality of this evidence by one level due to inconsistency.

Summary of findings 3.   Dialectical behavioural therapy or mentalisation-based therapy versus treatment-as-usual

Dialectical behavioural therapy or mentalisation-based therapy versus treatment-as-usual

Patient or population: borderline personality disorder

Settings: inpatient and outpatient

Intervention: dialectical behavioural therapy (DBT) or mentalisation-based therapy (MBT)

7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Comparison: treatment-as-usual (TAU)

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

TAU

DBT or MBT

Relative effect
(95% CI)

Number of par-
ticipants

Quality of the
evidence

Comments

(RCTs)

(GRADE)

DBT

BPD severity

Measured by: clinicians

Timing of outcome assessment: end of
treatment

Self-harm

Measured by: clinicians

Timing of outcome assessment: end of
treatment

Psychosocial functioning

Measured by: clinicians and self-rated

Timing of outcome assessment: end of
treatment

-

-

-

The mean score in the interven-
tion groups was 0.60 SD lower
(1.05 lower to 0.14 lower)

The mean score in the interven-
tion groups was
0.28 SD lower (0.48 lower to 0.07
lower)

The mean score in the interven-
tion groups was 0.36 SD lower
(0.69 lower to 0.03 lower)

-

-

-

MBT

Self-harm

Measured by: clinicians

Timing of outcome assessment: end of
treatment

631 per 1000

240 per 1000 (95% CI 334 fewer
to 126 fewer)

RR 0.62 (95%
CI 0.49 to 0.80)

Suicide-related outcomes

298 per 1000

Measured by: clinicians

Timing of outcome assessment: end of
treatment

268 per 1000 (95% CI 286 fewer
to 209 fewer)

RR 0.10 (95%
CI 0.04 to 0.30)

149

(3 RCTs)

376

(7 RCTs)

225

(6 RCTs)

252

(3 RCTs)

218

(3 RCTs)

⊕⊕⊝⊝
Lowa,b

⊕⊕⊝⊝
Lowa,b

An SMD of 0.60
represents a
moderate ef-
fect.

An SMD of 0.28
represents a
small effect.

⊕⊕⊝⊝
Lowa,b,

An SMD of 0.36
represents a
small effect.

⊕⊕⊝⊝
Lowa,b

⊕⊕⊝⊝
Lowa,b

-

-

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; DBT: Dialectical behavioural therapy; MBT: Mentalisation-based therapy; RCTs: Randomised controlled trials; RR: Risk ratio; SMD: Standardized
mean difference; TAU: Treatment-as-usual

GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: we are very uncertain about the estimate

aWe downgraded the quality of this evidence by one level due to risk of bias.
bWe downgraded the quality of this evidence by one level due to imprecision (there was a wide CI).

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
e
o
p
l
e
w

i
t
h
b
o
r
d
e
r
l
i
n
e
p
e
r
s
o
n
a
l
i
t
y
d
i
s
o
r
d
e
r

(
R
e
v
i
e
w

)

9

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

Borderline personality disorder (BPD) is a condition first formally
described  in  the  20th  century  (Gunderson  2009).  Historically,  the
term  BPD  was  coined  by  Adolph  Stern  to  describe  a  condition
in  the  'borderland'  between  psychosis  and  neurosis  (Stern
1938).  Subsequent  psychoanalytic  contributions  (especially  that
of  Kernberg  1975)  have  reaffirmed  this  distinction,  emphasising
that  the  capacity  to  test  reality  remains  grossly  intact  but  is
subject to subtle distortions, especially under stress. The current
evidence  supports  a  biopsychological  model  of  the  aetiological
factors  in  BPD,  all  of  which  may  contribute.  It  is  assumed  that
there is an interaction between the experience of adverse effects
during  childhood  (like  neglect,  emotional  or  sexual  abuse),  and
genetic  or  biological  factors.  Relevant  biological  factors  include
neurobiological  structures,  such  as  reduced  aymgdala  volume,
increased  volume  of  the  pituitary  gland,  reduced  grey  matter
volume  in  the  anterior  cingulate  gyrus,  posterior  cingulate  gyrus
or hippocampus, and reduction in size of the right parietal cortex
(Leichsenring  2011;  Lieb  2004),  and  neurobiological  dysfunctions
(especially  of  the  serotonergic  system).  In  combination  with
(e.g.  neuroticisms),
psychosocial 
personality functioning (self and interpersonal) and proneness to
react  highly  emotionally  may  contribute  to  the  core  components
of BPD, like affective and behavioural dysregulation, and disturbed
relatedness (Leichsenring 2011; Lieb 2004).

factors,  personality 

traits 

According  to  current  diagnostic  criteria,  BPD  is  characterised  by
a  pervasive  pattern  of  instability  in  affect  regulation,  impulse
control, interpersonal relationships and self-image (APA 2013; WHO
1993). Clinical hallmarks include, amongst other things, emotional
dysregulation, impulsivity, anger, repeated self-injury and chronic
suicidal  tendencies,  together  with  inner  emptiness  and  fear  of
abandonment  (Dimaggio  2007;  Fonagy  2009;  Gunderson  2018;
Karterud 2019; Lieb 2004). Despite the difficulties and controversies
in  defining  and  delimiting  the  condition,  BPD  is  being  vigorously
researched  still,  not  only  in  adults  but  also  in  childhood  and
adolescence  (Chanen  2017),  and  is  the  only  specific  personality
disorder  to  be  carried  over  to  the  new,  eleventh  edition  of  the
International  Classification  of  Diseases  (ICD-11)  (Bach  2018;  WHO
2018). The importance of effective treatments for BPD stems from
the considerable psychological suffering of the persons concerned
(Stiglmayr  2005;  Zanarini  1998),  the  burden  incurred  on  their
families and significant others (Bailey 2014; Bateman 2019a), the
significant  impact  on  mental  health  services  (Cailhol  2015;  Hörz
2010; Soeteman 2008a; Tyrer 2015; Zanarini 2004; Zanarini 2012),
and  not  least  the  association  of  BPD  with  debilitating  functional
impairments  and  premature  death  (Fok  2012;  Gunderson  2011a;
Gunderson 2011b; Kjær 2018; Niesten 2016; Skodol 2002; Soeteman
2008b).

The  definition  of  BPD  in  the  Diagnostic  and  Statistical  Manual  of
Mental  Disorders  (DSM),  Fifth  Edition  (DSM-5;  APA  2013),  Fourth
Edition (DMS-IV; APA 1994) and Fourth Edition Text Revision (DSM-
IV-TR;  APA  2000)  comprises  nine  criteria  that  cover  the  features
mentioned  above.  At  least  five  criteria  should  be  met  for  a
definitive,  categorical  diagnosis  of  BPD  to  be  made,  and  four
criteria for a probable diagnosis (see Appendix 1). In the alternative
diagnostic classification system of the World Health Organization
(WHO), the ICD, which is currently in its tenth edition (ICD-10; WHO
1993), the relating condition is referred to as "Emotionally unstable

Cochrane Database of Systematic Reviews

personality  disorder  (F60.3)",  of  which  there  is  an  impulsive  type
(F60.30) and a borderline type (F60.31; see Appendix 2). The latter
essentially overlaps with the DSM-IV definition and DSM-5 criteria
(Ottosen 2002).

In  addition  to  categorical  classification  systems,  the  DSM-5  also
includes  an  alternative  model  for  personality  disorders  (Section
III: "Emerging Measures and Models"). This hybrid model is made
up of two dimensions: 1) the severity of impairment in personality
(self  and  interpersonal);  and  2)  the  domains  of  personality  traits
(i.e.  negative  affectivity,  detachment,  antagonism,  disinhibition,
psychoticism;  APA  2013,  Section  III).  The  ICD-11  (which  will  be  in
effect from 2022; WHO 2018) is also moving towards a dimensional
approach,  where  the  different  types  of  personality  disorders  are
being replaced with a model that focuses on the severity of core
personality  functioning  instead.  However,  a  specifier  relating  to
a  "Borderline  pattern"  will  be  retained.  Preliminary  studies  have
found  that  there  is  a  substantial  overlap  between  the  current
categorical  and  alternative  models  found  in  the  DSM-5  (Bach
2016;  Bach  2018;  Sellbom  2014),  as  well  as  overlap  between
the  dimensional  models  of  the  DSM-5  and  ICD-11  (Bach  2018).
Therefore,  sufficient  continuity  between  current  categorical  and
upcoming  dimensional  models  is  warranted.  The  findings  of  this
review will be applicable also to populations diagnosed with the
DSM-5 Section III Hybrid BPD type and ICD-11 Borderline pattern
qualifier.

The  prevalence  of  BPD  in  the  general  population  is  estimated
to  be  1.8  %  (95%  CI  1.2%  to  2.5%)  (Winsper  2020).  In  clinical
populations,  BPD  occurs  frequently  (Munk-Jørgensen  2010),  with
trials  reporting  a  prevalence  ranging  from  9.3%  to  46.3%  and  a
mean point prevalence across studies of 28.5% (Torgersen 2012).
BPD  usually  has  its  onset  in  childhood  and  adolescence,  and
younger people are affected as much as or even more often than
adults (Neacsiu 2017). BPD has been found to peak around 14 to
17  years  of  age  with  a  linearly  decline  into  adulthood;  however,
it  continues  throughout  the  lifespan  and  can  also  be  found  in
older  people  (Chanen  2007;  Newton-Howes  2015;  Sharp  2018;
Videler 2019). Though BPD is predominantly diagnosed in women
(75%;  APA  2000;  APA  2013),  it  is  estimated  to  be  almost  equally
frequent  in  men  in  epidemiological  studies  (Lenzenweger  2007;
Ten  Have  2016;  Torgersen  2001;  Torgersen  2012).  Moreover,  BPD
commonly co-occurs with mood disorders, substance use disorder,
eating disorders, post-traumatic stress disorder (PTSD), attention-
deficit hyperactivity disorder (ADHD), and other specific personality
disorders (Coid 2006; Lenzenweger 2007; Stepp 2012; Storebø 2014;
Tomko 2014). Suicidal behaviour is reported to occur in up to 84%
of people diagnosed with BPD (Goodman 2012; Soloff 2002), and
it  is  estimated  that  up  to  10%  of  those  affected  by  BPD  will  die
from suicide (Paris 2019). Comorbid mood disorders or substance
use  disorders  are  the  most  common  risk  factors  associated  with
successful suicide attempts (Black 2004; Doyle 2016; Yen 2004).

Although the short- to medium-term social functioning of people
with  BPD  is  poor,  diagnostic  remission  is  around  85%  within  10
years (Gunderson 2011b; Zanarini 2007). Here, however, remission
only  means  that  diagnostic  criteria  are  not  fulfilled;  it  does  not
indicate  the  absence  of  any  symptoms.  Indeed,  whereas  acute
symptoms — such as self-mutilation, help-seeking suicide threats
or attempts and impulsivity — decrease with time in most cases,
affective symptoms reflecting areas of chronic dysphoria, such as
chronic feelings of emptiness, intense anger or profound feelings

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

of  abandonment,  largely  remain  (Zanarini  2007).  Therefore,  the
majority  of  people  with  BPD  still  have  significant  levels  of
symptoms  and  experience  severe  and  persistent  impairment  in
social  functioning  over  time  (Kongerslev  2015;  Ng  2016).  Risk
factors  for  poor,  long-term  outcomes  are  comorbid  substance
use  disorders,  PTSD,  and  anxiety  cluster  disorders  (Zanarini
2005;  Zanarini  2007),  as  well  as  a  family  history  of  psychiatric
disorder (especially mood disorders and substance use disorders),
demographic  issues  such  as  older  age,  longer  treatment  history,
pathological  childhood  experiences,  temperament  issues  and
adult  psychosocial  functioning  (Chanen  2012;  De  Fruyt  2014;
Kongerslev 2015; Zanarini 2007).

People  with  BPD  have  severe  difficulties 
in  achieving  and
maintaining vocational and social functioning over time (Hastrup
2019a; Paris 2014; Zanarini 2010). Furthermore, treatment-seeking
people  with  personality  disorders,  such  as  BPD,  pose  a  high
economic  burden  on  society  (Hastrup  2019b;  Van  Asselt  2007).
Effective  treatments  could  potentially  decrease  the  high  costs
associated  with  the  condition  (Soeteman  2008a).  The  problem
of  deliberate  self-harm  is  also  a  particular  issue  within  this
group  (Ayodeji  2015;  Kongerslev  2015;  Linehan  1997;  Rossouw
2012b).  In  medical  settings,  people  diagnosed  with  BPD  often
present  after  self-harming  behaviour  or  in  suicidal  crisis  and  are
treated in emergency settings, often involving repeated psychiatric
hospitalisations (Cailhol 2015).

In summary, BPD is a condition that has been studied extensively.
It  has  a  major  impact  on  health  facilities  as  those  affected
often  present  in  crisis.  Recovery  from  symptoms  or  functional
impairment  (or  both)  was  previously  considered  likely  for  only  a
small  percentage  of  people  diagnosed  with  BPD.  However,  the
long-term course, in terms of symptomatic recovery, is favourable
(Gunderson  2011b;  Zanarini  2007;  Zanarini  2012).  Nonetheless,
people  diagnosed  with  BPD  continue  to  have  considerable
interpersonal  and  functional  problems,  and  sustainable  recovery
appears difficult to attain (Biskin 2015; Kongerslev 2015; Rossouw
2012b).

Description of the intervention

About  three-quarters  of  people  with  BPD  present  to  mental
healthcare  professionals  (Tomko  2014),  and  they  are  even  more
likely  to  do  so  than  people  with  mood,  anxiety,  or  other
personality disorders (Ansell 2007). Most will receive psychological
interventions,  because  drugs  are  not  effective  for  the  BPD  core
symptoms (Goodman 2010; Tomko 2014), and these psychosocial
interventions will often be provided for a relatively long periods of
time (e.g. for a period of one year or longer) (Ansell 2007; Zanarini
2015).

A broad range of psychotherapies exist for BPD. The therapy can be
delivered in individual or group formats, or a combination of these
two  treatment  modalities.  As  for  most  other  mental  disorders,
psychological interventions can be based on the traditional, major
psychotherapeutic schools such as psychodynamic psychotherapy,
cognitive  behaviour  therapy  (CBT)  or  client-centred/humanistic
therapy.  In  addition,  several  specific  treatment  approaches  have
been  developed  within  recent  decades  to  meet  the  particular
challenges  of  treating  BPD.  These  disorder-specific  approaches
are  usually  precisely  structured  and  manualised  (De  Groot  2008;
Levy 2006; Weinberg 2011). Strategies are provided for addressing
interpersonal  challenges,  such  as  emotional  dysregulation  and

Cochrane Database of Systematic Reviews

impulsivity,  which  are  core  problems  for  people  diagnosed  with
BPD  and  could  lead  to  difficulties  in  forming  a  therapeutic
alliance.  Most  BPD-specific  psychological  interventions  involve
multimodal therapy, treatment contracts, actively taking measures
to  minimise  premature  non-completion  of  treatment,  providing
a  crisis  intervention  protocol  and  encouraging  the  affected
one's  sense  of  agency  (Bateman  2018;  Clarkin  2012;  De  Groot
2008;  Kongerslev  2015;  Livesley  2012;  Weinberg  2011).  They  are
typically highly focused on affect and the therapeutic relationship,
with  a  relatively  active  therapist  implementing  interventions
within  a  supportive  and  validating  atmosphere  (Bateman  2018;
Clarkin  2012;  De  Groot  2008;  Kongerslev  2015;  Livesley  2012;
Weinberg  2011).  Eclectic  therapy  is  an  open,  integrative  form
of  psychotherapy,  which  adapts  to  the  unique  needs  of  each
specific  client,  depending  on  the  problem,  the  treatment  goals
and  the  person’s  expectations  and  motivation  (Sansone  2006).
Eclectic  therapies  integrate  elements  from  different  forms  of
psychotherapy.

Among  the  specific  psychological 
interventions  for  people
diagnosed with BPD, the most commonly used are: transference-
focused  therapy  (Clarkin  1999;  Yeomans  2015);  mentalisation-
based  treatment  (Bateman  2004;  Bateman  2006;  Bateman  2016);
dialectical  behaviour  therapy  (Linehan  1993a;  Linehan  2015b);
cognitive  analytic  therapy  (Chanen  2014;  Ryle  1997);  schema-
focused therapy (Arntz 2009; Young 2003); and the systems training
for emotional predictability and problem-solving (STEPPS) (Black
2009).  Most  of  these  treatments  are  designed  as  outpatient
treatments  of  six  to  24  months  duration,  with  once  or  twice
weekly  individual  sessions.  Some  also  include  additional  group
therapy sessions, inpatient or day-hospital therapeutic community
treatment and psychoeducation. Other potential therapies for BPD
include the likes of CBT (Beck 2003), acceptance and commitment
therapy  (ACT;  Gratz  2006),  interpersonal  psychotherapy  (IPT;
Markowitz  2006),  and  psychodynamic  psychotherapy 
(e.g.
psychoanalytic-interactional  therapy;  Streeck  2009).  Broadly
speaking, psychodynamic therapies aim to help people understand
and  reflect  on  their  inner  mental  processes  and  make  links
between  their  past  and  current  difficulties.  Treatments  based
on  CBT  place  emphasis  on  self-directed  learning  processes:
people are encouraged to identify their core beliefs; evaluate and
modify  their  behaviour  accordingly;  and  gain  new  experiences.
Psychotherapy  is  defined  as  the  "treatment  of  mental  illness
or  emotional  disturbances  primarily  by  verbal  or  nonverbal
communication" (quote; NLM 2009).

Dialectical  behavioural  therapy  (DBT;  Linehan  1993a)  is  a
highly  structured  and  complex  psychological  therapy  that  was
developed using some of the principles of CBT in combination with
mindfulness-based  and  Zen-Buddhistic  and  dialectical  thinking
strategies. It aims to change behaviour and enhance the ability to
tolerate difficult or painful feelings by focusing on improving skills
in  stress  tolerance,  emotion  regulation,  interpersonal  behaviour,
and mindfulness.

Mentalisation-based  therapy  (Bateman  2004;  Bateman  2016)  is
a  complex  psychodynamic  and  attachment-based  psychological
therapy programme that aims to increase the reflective functioning
or  mentalising  capacity  of  the  individual,  helping  the  person  to
understand  and  recognise  the  feelings  they  evoke  in  others  and
the feelings they experience themselves, as well as improving the
capacity for emotion regulation in interpersonal relations.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schema-focused  therapy  (SFT;  Young  2003)  draws  from  both
cognitive-behavioural  and  psychoanalytic  theories  and  helps
people with BPD to identify their self-defeating core themes arising
from  unmet  emotional  needs  in  childhood  and  presenting  as
maladaptive coping styles in adulthood. The goal of SFT is to aid
people affected by BPD in getting their needs met in adaptive ways.

Transference-focused psychotherapy (TFP; Clarkin 1999) strives
to  achieve 
integrated  representations  of  self  and  others,
modification  of  primitive  defence  operations,  and  resolution  of
identity  diffusion  by  analysis  of  the  transference  within  the
therapeutic  relationship.  Primitive  object  relations,  which  can
be  polarised  and  split,  may  be  transformed  to  advanced  or
mature  object  relations  characterised  by  more  integrated  object
relations.  TFP  relies  on  techniques  of  clarification,  confrontation
and  transference  interpretation  within  the  relationship  between
patient and therapist.

Cognitive analytic therapy (CAT; Ryle 1997) assumes that people
with BPD typically experience rapid switching from one self-state to
another in a dissociate manner. The aim is to work with the patient
cognitively,  to  identify  procedural  sequences,  chains  of  events,
emotions, thoughts and motivations, in order to understand how a
target problem (like self-harm) is established and maintained, and
to identify reciprocal roles (i.e. how early experiences are replayed
later in life).

Systems  training  for  emotional  predictability  and  problem-
group-based
solving 
psychoeducation  with  skills  training,  and  targets  biased  social
cognition driven by cognitive filters or schemas.

(STEPPS;  Black 

combines 

2009) 

Dynamic deconstructive psychotherapy (DDP) is a manualised,
12- to 18-month treatment for adults diagnosed with BPD and other
complex  co-occurring  disorders  such  as  substance  use  disorders,
additional personality disorders or eating disorders (Gregory 2008;
Gregory  2010).  The  DDP  model  of  BPD  pathology  draws  on  and
combines elements of translational neuroscience, object relations
theory,  and  the  philosophy  of  deconstruction.  The  aim  of  DDP
is  to  help  people  with  BPD  to  connect  with  and  verbalise  their
experience better, as well as to foster better interpersonal relations
and self-acceptance. DDP was used in a randomised controlled trial
(RCT) conducted by its developer (Gregory 2008).

Relaxation  techniques  and  patient  education  programmes
will  be  considered  their  own  intervention  class  (i.e.  not  CBT
or  psychoanalytically  based),  as  long  as  they  are  not  explicitly
grounded in or taken from a specific treatment approach (such as
psychoeducation according to the DBT approach, CBT, or the SFT
approach, etc.).

How the intervention might work

Evidence-based psychological therapies are based on assumptions
about  causality,  core  symptoms,  and  maintenance  of  the
disorder  (Kazdin  2004;  Livesley  2003;  Livesley  2004).  The  various
psychotherapeutic approaches to BPD claim different mechanisms
of  action  according  to  their  respective  models  of  causation
(Gunderson  2018;  Huprich  2015;  Livesley  2004;  Livesley  2016).
However,  they  also  contain  a  number  of  common  elements
that  can  account  for  why  a  number  of  seemingly  different
approaches appear to be effective in ameliorating BPD symptoms
(Bateman  2015;  Fonagy  2014;  Kongerslev  2015;  Weinberg  2011),

Cochrane Database of Systematic Reviews

including: a clear and highly structured treatment framework; an
explicit model of BPD symptomatology; a consistent focus on the
therapeutic relationship, affect regulation, tolerance of emotional
states,  and  biases  in  social  cognition;  a  high  priority  given  to
self-harm  and  suicidal  behaviour;  active  therapists  who  deliver
both  support  and  validation  as  well  as  explorative  and  change-
oriented interventions; mix of treatment formats (e.g. includes both
individual  and  group  therapy);  and  therapist  support  in  the  form
of  supervision  and  regular  meetings.  The  symptoms  of  BPD  are
addressed using the following therapeutic approaches. Following
Weinberg 2011:

1.

2.

3.

'emotional  dysregulation'  (e.g.  intense  anger  and  affective
instability)  is  addressed  through  attention  to  affect,  including
raising  awareness  of  emotional  states,  their  triggers,  and
enhancing tolerance and regulative strategies;
'behavioural  dysregulation'  (e.g.  impulsivity,  self-harm  and
suicidal  behaviours)  is  addressed  through  change-oriented
interventions,  including,  for  example,  challenging  negative
thoughts,  skills  training,  behavioural  experiments,  praise,  and
limit setting; and
'interpersonal  dysfunction'  (e.g.  unstable  relationships  and
stress-related paranoid ideation) is treated using interventions
that enhance the social-cognitive (or mentalising) capacities of
the  BPD  patient,  through  making  basic  and  often  negatively
biased  automatic  assumptions  explicit  and  more  realistic  or
adaptive,  and  through  paying  attention  to  the  establishment
and maintenance of a safe and sound working alliance within
the therapy sessions.

There is a risk that psychological therapies might not be helpful for
all people affected by BPD, either due to the interventions delivered
or through factors in the therapeutic relationship (Kongerslev 2015;
Lilienfeld  2007;  Parry  2016),  and  very  little  research  has  been
done on this in people with BPD. The effectiveness of the therapy
depends on the skills of the therapist to create the possibility for
change with each patient. There is, therefore, the added complexity
that  the  relationship  or  working  alliance  between  the  therapist
and  the  patient  itself  is  an  ‘active  ingredient’  of  the  therapy  and
that  the  quality  of  this  relationship  is  an  important  predictor  of
outcome (Horvath 2011; Norcross 2011). There is no guarantee that
the therapy will deliver what was specified in the manual or what
was investigated in a randomised clinical trial (Parry 2016).

Why it is important to do this review

People with BPD and their family and friends experience high levels
of  psychological  suffering.  BPD  is  associated  with  considerable
social  costs 
in  terms  of  service  use  (e.g.  presentation  to
emergency clinics due to self-harm or suicidal crises and repeated
hospitalisations) and poor psychosocial functioning (e.g. inability
to  complete  education  or  get/maintain  a  job).  Consequently,
identification  of  effective  psychological  therapies  for  BPD  is
important (Stoffers-Winterling 2012).

Our review aims to provide a systematic summary of the evidence
from  randomised  controlled  trials  (RCTs)  in  order  to  help  people
with  BPD,  their  family  and  friends,  mental  healthcare  workers,
and  policy  and  decision  managers  in  general,  to  make  informed
decisions about evidence-based treatment for BPD.

This  review  is  an  update  of  two  previous  Cochrane  Reviews  on
psychological  therapies  for  BPD  (Binks  2006;  Stoffers-Winterling

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

2012). In addition to updating the two former Cochrane Reviews,
our  study  also  seeks  to  address  some  of  the  methodological
limitations  of  both  past  and  current  reviews  (Bateman  2015;
Cristea 2017; Kliem 2010), by using updated methods, including a
more comprehensive search strategy. We also had a new protocol
published prior to conducting this review (Storebø 2018).

O B J E C T I V E S

To  assess  the  beneficial  and  harmful  effects  of  psychological
therapies for people with BPD.

M E T H O D S

We pooled the different types of TAU into one comparison in our
main analyses, and compared the effects between the two types of
TAU as well as the effect observed by comparison to TAU controls
to the effects of comparisons to waiting-list/no treatment controls
(see Subgroup analysis and investigation of heterogeneity).

We allowed concomitant treatments provided they were applied to
both treatment conditions.

We  accepted  trials  with  active  controls,  including  relaxation
techniques  such  as  autogenic  training  or  meditation  regimens,
or  patient  education  programmes  such  as  self-management  and
community-based education programmes.

Criteria for considering studies for this review

Types of outcome measures

Types of studies

Randomised controlled trials (RCTs).

Types of participants

Persons  of  all  ages,  in  any  setting,  with  a  formal,  categorical
diagnosis of BPD according to the Diagnostic and Statistical Manual
of Mental Disorders (DSM) Third Edition (DSM-III; APA 1980), Third
Edition Revised (DSM-III-R; APA 1987), Fourth Edition (DSM-IV; APA
1994), Fourth Edition Text Revision (DSM-IV-TR; APA 2000), and Fifth
Edition (DSM-5; APA 2013), and the International Classification of
Diseases  and  Related  Health  Problems  (ICD)  10th  version  (WHO
1993), with or without comorbid conditions.

To  meet  our  inclusion  criteria,  at  least  70%  of  participants  of
a  respective  trial  had  to  have  a  formal  diagnosis  of  BPD.  We
included  trials  involving  subsamples  of  people  with  BPD  when
data  on  those  with  BPD  were  provided  separately  (we  asked  for
separate data from trials including less than 70% BPD participants).
We  did  not  include  trials  that  focused  on  people  with  mental
impairment,  organic  brain  disorder,  dementia  or  other  severe
neurologic/neurodevelopmental diseases.

Types of interventions

Any  defined  psychological  intervention  regardless  of  theoretical
orientation  (e.g.  psychodynamic  therapy,  CBT,  systemic  therapy
or  eclectic  therapies  designed  for  BPD  treatment),  in  any  kind
of  treatment  setting  (e.g.  inpatient,  outpatient  or  day  clinic),
compared to:

1. control interventions, such as standard care, treatment-as-usual

(TAU), waiting list or no treatment; and

2. specific  psychotherapeutic 
defined and theory driven).

interventions  (that  were  well

We  divided  control  interventions  into  two  categories:  The  first
category  was  “waiting  list/no  treatment”:  participants  did  not
receive  any  treatment  or  support  from  the  study  centre  (like,
e.g.  clinical  management,  regular  medical  review,  or  support/
encouragement to find a therapist outside the study centre). The
second  category,  “TAU”  included  any  other  kinds  of  controls:
participants were either free to use any treatment except from the
respective experiential treatment (optional TAU), or they received
usual community treatment, or standardised usual care (obligatory
TAU).

Outcomes  were  either  self-rated  by  the  persons  with  BPD  or
observer-rated  by  clinicians,  with  clinician-rated  outcomes  being
preferred. We included only adequately validated measures (plus
spontaneous reporting of adverse effects).

We  analysed  all  outcomes  at  post-treatment  and  at  six  months
follow-up or longer.

Primary outcomes

1. BPD symptom severity, assessed by, for example, the Zanarini
Rating  Scale  for  Borderline  Personality  Disorder  (Zan-BPD;
Zanarini  2003a);  the  Borderline  Personality  Disorder  Severity
Index,  Fourth  version  (BPDSI-IV;  Arntz  2003)  or  the  Clinical
Global Impression Scale for people with Borderline Personality
Disorder (CGI-BPD; Perez 2007).

2. Self-harm,  in  terms  of  the  proportion  of  participants  with
self-harming  behaviour,  or  assessed  by,  for  example,  the
Deliberate  Self-harm  Inventory  (DSHI;  Gratz  2001)  or  the  Self-
harm behaviour Questionnaire (SHBQ; Guttierez 2001).

3. Suicide-related  outcomes,  assessed  by,  for  example,  the
Suicidal  Behaviours  Questionnaire  (SBQ;  Osman  2001)  or  the
Beck Scale for Suicidal Ideation (BSSI; Beck 1979), or in terms of
the proportion of participants with suicidal acts.

4. Psychosocial functioning, assessed by, for example, the Global
Assessment Scale (GAS; Endicott 1976), the Global Assessment
of Functioning Scale (GAF; APA 1987) or the Social Functioning
Questionnaire (SFQ; Tyrer 2005).

Secondary outcomes

1. Anger,  assessed  by,  for  example,  the  Hostility  subscale  of  the
Symptom Checklist - 90 - Revised (SCL-90-R; Derogatis 1994) or
the  State-Trait  Anger  Expression  Inventory  (STAXI;  Spielberger
1988).

2. Affective instability, assessed by, for example, the relevant item
or  subscale  on  the  Zan-BPD  (Zanarini  2003a),  CGI-BPD  (Perez
2007) or BPDSI-IV (Arntz 2003).

3. Chronic  feelings  of  emptiness,  assessed  by,  for  example,  the
relevant item or subscale on the Zan-BPD (Zanarini 2003a), CGI-
BPD (Perez 2007) or BPDSI-IV (Arntz 2003).

4. Impulsivity, assessed by, for example, the Barrett Impulsiveness
Scale  (BIS;  Barrett  1995),  or  the  Anger,  Irritability  and  Assault
Questionnaire (AIAQ; Coccaro 1991).

5. Interpersonal problems, assessed by, for example, the Inventory
of Interpersonal Problems (IIP; Horowitz 1988), or the relevant
item  or  subscale  on  the  Zan-BPD  (Zanarini  2003a),  CGI-BPD

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

(Perez  2007),  BPDSI-IV  (Arntz  2003),  or  SCL-90-R  (Derogatis
1994).

6. Abandonment,  assessed  by,  for  example,  the  relevant  item  or
subscale on the Zan-BPD (Zanarini 2003a), CGI-BPD (Perez 2007)
or BPDSI-IV (Arntz 2003).

7. Identity disturbance, assessed by, for example, the relevant item
or  subscale  on  the  Zan-BPD  (Zanarini  2003a),  CGI-BPD  (Perez
2007) or BPDSI-IV (Arntz 2003).

8. Dissociation  and  psychotic-like  symptoms,  assessed  by,  for
example,  the  Dissociative  Experience  Scale  (DES;  Bernstein
1986), or the Brief Psychiatric Rating Scale (BPRS; Overall 1962).
9. Depression,  assessed  by,  for  example,  the  Beck  Depression
Inventory  (BDI;  Beck  1961)  or  the  Montgomery  Åsberg
Depression Rating Scale (MADRS; Montgomery 1979).

10.Attrition,  in  terms  of  participants  lost  after  randomisation  in

each group.

11.Adverse  effects,  measured  by  the  use  of  standardised
psychometric rating scales, such as the Systematic Assessment
for  Treatment  Emergent  Events  (SAFTEE;  Levine  1986),  or  by
laboratory values or spontaneous reporting. We defined adverse
effects  as  unfavourable  outcomes  that  occurred  during  or
after  psychotherapy  but  that  were  not  necessarily  caused  by
it  (see  Chapter  19  in  the  Cochrane  Handbook  for  Systematic
Reviews of Interventions; Peryer 2019. We divided any reported
adverse  effects  into  severe  and  non-severe,  according  to  the
International  Committee  of  Harmonization  guidelines  (ICH
1996). We defined serious adverse effects as any event that led
to death, was life-threatening, required inpatient hospitalisation
or prolongation of existing hospitalisation, resulted in persistent
or  significant  disability,  or  any  important  medical  event  that
may  have  jeopardised  the  participant’s  health  or  required
intervention  to  prevent  one  of  the  aforementioned  outcomes
occurring.  We  considered  all  other  adverse  effects  to  be  non-
serious.

Search methods for identification of studies

Electronic searches

We  searched  the  electronic  databases  and  trials  registers  listed
below up to March 2019.

1. Cochrane  Central  Register  of  Controlled  trials  (CENTRAL;
2019,  Issue  3),  in  the  Cochrane  Library,  which  includes  the
Cochrane Developmental, Psychosocial and Learning Problems
Specialised Register (searched 20 March 2019).

2. MEDLINE Ovid (1948 to 20 March 2019).
3. Embase Ovid (1980 to 20 March 2019).
4. CINAHL  EBSCOhost  (Cumulative  Index  to  Nursing  and  Allied

Health Literature; 1980 to 20 March 2019).

5. PsycINFO Ovid (1806 to 20 March 2019).
6. ERIC EBSCOhost (Education Resources Information Center; 1966

to 20 March 2019).

7. BIOSIS Previews Web of Science Clarivate Analytics (1969 to 20

March 2019).

8. Web of Science Core Collection Clarivate Analytics (1900 to 20

March 2019).

9. Sociological Abstracts ProQuest (1952 to 20 March 2019).

10.LILACS 

(Latin  American  and  Caribbean  Health  Science
lilacs.bvsalud.org/en;  searched  20

Information  database; 
August 2019).

11.OpenGrey (www.opengrey.eu; searched 20 August 2019).
12.Library  Hub  Discover,previously  COPAC  (Library  Hub  Discover;

searched 20 August 2019).

13.ProQuest Dissertations and Theses A&I (1743 to 20 March 2019).
14.DART  Europe  E-Theses  Portal  (www.dart-europe.eu/basic-

search.php; searched 20 August 2019).

15.Networked Digital Library of Theses and Dissertations (NDLTD;

www.ndltd.org; searched 20 August 2019).

16.Australian  New  Zealand  Clinical  trials  Registry  (ANZCTR;
www.anzctr.org.au/BasicSearch.aspx;  searched  20  August
2019).

17.Clinicaltrials.gov (clinicaltrials.gov; searched 20 March 2019).
18.EU  Clinical  trials  Register  (www.clinicaltrialsregister.eu/ctr-

search/search; searched 20 August 2019).

19.ISRCTN Registry (www.isrctn.com; searched 20 August 2019).
20.Be 

(www.ukctg.nihr.ac.uk/

research 

Part 

of 

#popoverSearchDivId; searched 20 August 2019).

21.WHO  International  Clinical  trials  Registry  Platform  (ICTRP;

who.int/ictrp/en; searched 20 March 2019).

The search strategies for all databases can be found in Appendix 3.
We did not limit our searches by language, year of publication, or
type of publication. We sought translation of the relevant sections
of non-English language articles.

Searching other resources

journals, 

We  handsearched  relevant 
including:  Journal  of
Personality  Disorders;  American  Journal  of  Psychiatry;  JAMA
Psychiatry;  British  Journal  of  Psychiatry;  ACTA  Psychiatrica
Scandinavica;  Journal  of  the  American  Academy  of  Child  and
Adolescent Psychiatry; Personality Disorders: Theory, Research and
Treatment;  and  Journal  of  Clinical  Psychiatry.  Additionally,  we
emailed  researchers  working  in  the  field,  to  ask  for  unpublished
data.  We  also  checked  abstracts  of  key  conferences  for  BPD
(congresses of the European and the International Society for the
Study  of  Personality  Disorders;  ESSPD  and  ISSPD,  respectively)
and  asked  for  any  relevant  unpublished  data.  We  traced  cross-
references from relevant literature. On 13 December 2019, we ran
searches  to  make  sure  that  none  of  our  included  trials  had  been
retracted due to error or fraud. In the next update of this review,
we will handsearch additional journal titles for relevant trials, (see
Differences between protocol and review).

Data collection and analysis

We conducted this review in accordance with the guidelines set out
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins  2019),  and  performed  analyses  using  the  latest  version
of  Review  Manager  5  (RevMan  5),  Cochrane's  statistical  software
(Review Manager 2014).

We  report  only  the  methods  used  in  successive  sections  below.
Planned but unused methods can be found in the protocol, Storebø
2018, and additional Table 1.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Selection of studies

Twelve  review  authors  (OJS,  JMSW,  BAV,  JTM,  HEC,  AT,  CPS,
MTK,  SSN,  MLK,  MSJ,  EF)  worked  in  six  pairs  and  independently
screened  titles  and  abstracts  of  all  records  retrieved  by  the
searches.  For  any  record  that  could  have  been  an  eligible  RCT,
we  obtained  the  full-text  report  and  assessed  it  for  eligibility
against  the  inclusion  criteria  (see  Criteria  for  considering  studies
for  this  review).  During  all  stages  of  study  selection,  we  resolved
uncertainty or disagreement by consensus. When agreement could
not be reached, the review authors discussed disagreements and
consulted a third review author (KL, OJS, JMSW or ES).

We  list  apparently  relevant  RCTs  that  did  not  fulfil  the  inclusion
criteria, along with reasons for their exclusion, in the Characteristics
of  excluded  studies  tables.  We  used  Covidence  software  to  keep
track of appraised trials and decisions. To ensure transparency of
study selection, we provided flow charts according to the QUOROM
statement,  showing  how  many  records  have  been  excluded  for  a
certain reason (Moher 1999).

Data extraction and management

We developed data extraction forms to facilitate standardisation of
data extraction. The form was piloted by OJS, SSN, MTK.

Working in pairs, all review authors extracted data independently
using  the  data  collection  form  to  ensure  accuracy.  We  resolved
disagreements by discussion or by using an arbiter (ES), if required.

OJS, HEC, AT, EF, and JMSW entered data into RevMan 5 (Review
Manager 2014). After all data had been entered, another reviewer
(JMSW, OJS) re-checked the data for completeness and accuracy,
to  make  sure  the  data  were  complete,  correct  and  appropriately
categorised.  Any  entered  data  were  verified  against  the  original
publication, and we updated the list of outcomes (Appendix 4), if
necessary.

Assessment of risk of bias in included studies

Using Cochrane's tool for assessing risk of bias (Higgins 2011), all
review authors assessed the risk of bias in each included trial across
the  following  domains:  random  sequence  generation;  allocation
concealment;  blinding  of  outcome  assessment; 
incomplete
outcome  data,  selective  outcome  reporting;  and  other  potential
sources of bias. Data extractors independently assigned each trial
to one of three categories (low risk of bias, unclear (uncertain) risk
of bias or high risk of bias), according to guidelines provided in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011), using the criteria set out in Appendix 5. We called upon a third
review  author  (ES)  to  resolve  any  ongoing  disagreements,  when
needed.

Considering  bias  due  to  a  lack  of  blinding  is  undoubtedly  of
importance,  but  it  remains  unclear  how  best  to  deal  with  this
issue  in  research  practice  (Boutron  2008).  We  decided  not  to
judge the likelihood of detection bias due to inadequate blinding
of  participants  and  personnel,  as  it  is  almost  impossible  to
blind  therapists  and  people  receiving  treatment  in  psychological
therapy outcome research. However, we assessed the likelihood of
detection bias due to inadequate blinding of outcome assessors.

In accordance with Cochrane’s guidelines (Higgins 2011), we also
included other potential sources of bias as a final bias component.
Here,  we  included:  the  likelihood  of  performance  bias  due  to

Cochrane Database of Systematic Reviews

inadequate  treatment  adherence;  the  likelihood  of  bias  due  to
different  amounts  of  attention  given  to  the  treatment  groups
(attention  bias);  and  other  potential  sources  of  bias,  such  as
allegiance bias. We defined allegiance bias as a therapist’s personal
belief  both  in  the  superiority  and  the  efficacy  of  a  particular
treatment.  This  belief  can  be  based  on  an  education  in  that
particular treatment. This bias is especially strong if the inventor of
a treatment is investigating the effects of the particular treatment
he/she has invented.

We  considered  trials  with  one  or  more  unclear  or  high  risk  of
bias  domains  as  trials  at  high  risk  of  bias  overall,  due  to  the  risk
of overestimating beneficial effects and underestimating harmful
effects in RCTs with unclear or inadequate methodological quality
(Kjaergard 2001; Lundh 2012; Moher 1998; Savović 2012a; Savović
2012b; Schulz 1995; Wood 2008). We defined trials with a low risk of
bias in all domains to be at low risk of bias overall.

Measures of treatment effect

Continuous data

For continuous data, we compared the mean score between the two
groups to give a mean difference (MD) and presented this with 95%
confidence intervals (CIs). We used the overall MD, where possible,
to combine the same outcome measures from trials. If two or more
different instruments were used to measure the same construct, we
reported the effect sizes as standardised mean differences (SMD)
in  the  meta-analysis.  We  calculated  SMDs  on  the  basis  of  post-
treatment  results  and,  in  separate  analyses,  follow-up  data.  We
grouped follow-up data in six-month intervals (zero to six months,
six  to  12  months  and  12  months  and  over).  Where  the  direction
of a scale was opposite to most of the other scales, we multiplied
the corresponding mean values by −1 to ensure adjusted values. If
the trials did not report means and standard deviations (SDs) but
reported other values like t-tests and P values, we tried to transform
these into SDs.

To identify the minimum relevant clinical difference (MIREDIF), we
transformed the SMD to MD, using the scale with the best validity
and reliability for the given outcome. For the analyses of the four
primary outcomes in the comparison of psychotherapy versus TAU,
we transformed SMDs into MDs on the following scales, to assess
whether results exceeded the MIREDIF: ZAN-BPD Scale, Delibarate
Self-Harm Inventory (DSHI), Suicidal Attempt Self Injury Interview
(SASII), Global Assessment of Functioning (GAF), and the Hamilton
Depression  scale.  We  identified  a  MIREDIF  of  −3.0  points  on  the
ZAN-BPD, ranging from 0 to 36 points, based on a trial by Crawford
2018a;  a  MIREDIF  of  −1.25  points  on  the  DSHI,  ranging  from  0  to
34 points, which corresponds to ½ SD based on a trial by Farivar
2004; a MIREDIF of −0.17 points on the Suicidal Attempt Self Injury
Interview, ranging from 0 to 4 points, which corresponds to ½ SD
based on a trial by Farivar 2004; and a MIREDIF of −4.0 on the GAF
scale,  ranging  from  0  to  100,  based  on  a  trial  by  Amri  2014.  The
MIREDIF of the Hamilton Depression scale is 3.0 points (NICE CG90).
For other outcomes, we provided an interpretation of the effect size
using Cohen's D, considering 0.2 as a small effect, 0.5 as a medium
effect size, and 0.8 as a large effect size (Cohen 1988).

Dichotomous data

We summarised dichotomous data as risk ratios (RRs) with 95% CIs.
The  RR  is  the  ratio  of  the  risk  of  an  event  in  the  two  groups.  We

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

decided  to  use  the  RR  as  it  may  be  easier  to  interpret  than  odds
ratios (ORs).

Unit of analysis issues

Repeated observations

We calculated trial estimates on the basis of post-treatment group
results.  We  conducted  separate  analyses  for  data  from  different
points of measurement (i.e. post-treatment, follow-up data of 0- to
6-month, 6- to 12-month, and above 12-month intervals, where we
used the last measurement within these intervals). If a trial reported
data at both 7-month and 11-month follow-up periods, we included
both; however, we categorised cases like the 11-month follow-up
as above 12-month follow-up. We did not use interim observations
(Thalheimer 2002).

Adjustment for multiplicity

Multiplicity  reflects  the  concern  that  performing  multiple
comparisons  increases  the  risk  of  falsely  rejecting  the  null
hypothesis.  Multiplicity,  therefore,  may  affect  the  results  found
within a systematic review and, as a result, needs to be adjusted for.
We adjusted the P values and CIs of the primary outcomes and one
secondary outcome (depression) for multiplicity using the method
described by (Jakobsen 2014).

Dealing with missing data

We tried to obtain any missing data, including incomplete outcome
data, by contacting trial authors. We report this information in the
'Risk of bias' tables.

We evaluated the methods used to handle the missing data in the
publications and to what extent it was likely that the missing data
had influenced the results of outcomes of interest. We calculated
effect  sizes  on  the  basis  of  intention-to-treat  data,  if  that  was
possible.  If  only  available  case  analysis  data  were  reported,  we
calculated effect sizes on this basis.

We  consulted  a  statistician  if  data  were  not  reported  in  an
immediately  usable  way  and  if  data  required  processing  before
being  analysed.  We  assessed  results  derived  from  statistically
processed data in sensitivity analyses. See Sensitivity analysis.

Assessment of heterogeneity

We  assessed  trials  for  clinical  homogeneity  with  respect  to  type
of  therapy,  therapy  setting  and  control  group.  We  evaluated
methodological heterogeneity by comparing the designs of trials.
For any trials judged as homogeneous and adequate for pooling,
we investigated statistical heterogeneity by both visual inspection
of the graphs and the I2 statistic (Higgins 2003). We considered I2
values between 0% and 40% as indication of little heterogeneity,
between  30%  and  60%  as  indication  of  moderate  heterogeneity,
between 50% and 90% as indication of substantial heterogeneity,
and  between  75%  and  100%  as  indication  of  considerable
heterogeneity (Higgins 2019). Along with the size of the I2 scores,
we also took into account the P value, CI and the overall number
of included trials in the respective analysis when interpreting the
values (Deeks 2019).

Cochrane Database of Systematic Reviews

for  small-study  effects  for  the  primary  outcomes;  asymmetry  in
the funnel plot could be due to publication bias or could indicate
genuine  heterogeneity  between  small  and  large  trials  (Higgins
2019). It is important to assess the funnel axis in the funnel plot as
a significant Egger's test could also indicate publication bias or be
due to genuine small treatment effects. We did not visually inspect
the funnel plot if fewer than 10 trials were included in the meta-
analysis, in accordance with the recommendations of the Cochrane
Handbook  for  Systematic  Reviews  of  Interventions  (Higgins  2019;
Egger 1997; Sterne 2017).

Data synthesis

We  performed  the  statistical  analyses 
in  accordance  with
the  recommendations  in  the  latest  version  of  the  Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2019).

In  carrying  out  meta-analyses,  we  used  the  inverse-variance
method,  to  give  more  weight  to  more  precise  estimates  from
trials  with  less  variance  (mostly  larger  trials).  This  minimises  the
imprecision  of  the  pooled  effect  estimate,  and  is  a  common  and
simple approach to conducting meta-analyses (Higgins 2019). We
used  the  random-effects  model  for  our  meta-analyses,  since  we
expected  some  degree  of  clinical  heterogeneity  to  be  present  in
most  cases,  though  not  too  substantial  to  prevent  pooling  in
principle.  Where  only  one  trial  was  included  in  an  analysis,  we
used  the  fixed-effect  model,  and  where  different  models  led  to
different  results  (Sensitivity  analysis),  we  reported  the  results  of
both models.

For trials with a high level of statistical heterogeneity, and where the
amount of clinical heterogeneity made it inappropriate to use these
trials  in  meta-analyses,  we  provide  a  narrative  description  of  the
trial results. If data pooling seemed feasible, we pooled the primary
trials' effects and calculated their 95% CIs.

If  a  trial  reported  data  for  a  particular  outcome  using  two  or
more assessment instruments (e.g. several questionnaires for the
assessment  of  depression),  we  selected  the  one  used  most  often
in  the  whole  pool  of  included  trials  for  effect  size  calculation,  in
order to minimise heterogeneity of outcomes in form and content.
If  a  trial  reported  data  of  two  assessment  instruments  that  were
equally  frequently  used,  two  review  authors  discussed  the  issue
and chose the one that was, in its content, the most appropriate for
the assessment of people affected by BPD.

We  divided  the  doses  and  the  controls 
into  the  different
comparisons,  ensuring  that  the  treatment  comparisons  were
comparable and homogeneous.

We  have  two  main  overarching  comparisons. 
In  the  first
comparison, we pooled all of the different types of psychotherapy
together  and  compared  them  with  the  different  types  of  TAU
pooled  together.  In  the  second  comparison,  we  pooled  all  of
the  different  types  of  psychotherapy  and  compared  them  with
waiting list or no treatment. Within in each comparison, we broke
down  the  interventions  by  therapeutic  category  compared  with
different  types  of  TAU,  waiting  list,  no  treatment  or  with  another
psychotherapy (active control).

Assessment of reporting biases

Subgroup analysis and investigation of heterogeneity

We  drew  funnel  plots  (estimated  differences  in  treatment  effects
against their standard error) and performed Egger's statistical test

We  conducted  the  following  prespecified  subgroup  analyses  for
two  primary  outcomes  (BPD  symptom  severity  and  psychosocial

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

functioning),  where  data  were  sufficient,  in  order  to  make
hypotheses.

clinical  intervention  effect  was  approximately  ½  SD  on  the  used
scale, which can be used as a MIREDIF (Norman 2003).

1. Therapeutic  approaches:  specific  therapies  versus  each  other
(only  analyses  with  two  or  more  trials  were  included  in  this
subgroup)

2. Age: mean age of 15 to 18 years versus older than 18 years
3. Duration: less than six months versus six to 12 months versus

over 12 months

4. Mode of therapy: individual therapy versus group therapy and

with the combination of individual and group therapy

5. Setting:  inpatient  versus  outpatient  and  the  combination  of

inpatient and outpatient

In addition, we added the following four subgroup analyses post
hoc,  for  the  primary  outcomes  of  BPD  symptom  severity  and
psychosocial functioning.

1. Type of raters: self-rated versus clinician-rated
2. Types of TAU: obligatory TAU versus unspecified TAU
3. Type of comparison group: trials comparing psychotherapy plus
TAU versus trials comparing psychotherapy with waiting list or
no treatment

4. Types of scales: different measuring scales versus each other

Trial Sequential Analysis

Trial  Sequential  Analysis  (TSA)  is  a  methodology  that  combines
a  required  information  size  (RIS)  calculation  for  a  meta-analysis
with the threshold for statistical significance (Brok 2008; Brok 2009;
Thorlund 2009; Wetterslev 2008). TSA is a tool for quantifying the
statistical  reliability  of  the  data  in  a  cumulative  meta-analysis,
adjusting  P  values  for  sparse  data  and  for  repetitive  testing
on  accumulating  data  (Brok  2008;  Brok  2009;  Thorlund  2009;
Wetterslev 2008).

Comparable  to  the  a  priori  sample  size  estimation  in  a  single
randomised trial, a meta-analysis should include an RIS calculation
at least as large as the sample size of an adequately powered single
trial  to  reduce  the  risk  of  random  error.  TSA  calculates  the  RIS
in  a  meta-analysis  and  provides  an  alpha-spending  boundary  to
adjust the significance level for sparse data and repetitive testing
on accumulating data (CTU 2011; Wetterslev 2008); hence, the risk
of random error can be assessed. Multiple analyses of accumulating
data when new trials emerge leads to repeated significant testing
and  introduces  multiplicity.  Thus,  use  of  a  conventional  P  value
is prone to exacerbate the risk of random error (Berkey 1996; Lau
1995). Meta-analyses not reaching the RIS are analysed with trial
sequential  alpha-spending  monitoring  boundaries  analogous  to
interim  monitoring  boundaries  in  a  single  trial  (Wetterslev  2008).
This approach will be crucial in coming updates of the review.

If  a  TSA  does  not  reveal  significant  findings  (no  crossing  of  the
alpha-spending  boundary  and  no  crossing  of  the  conventional
boundary of  P = 0.05)  before the RIS has been reached, then the
conclusion should either be that more trials are needed to reject or
accept an intervention effect that was used for calculation of the
required sample size or — in case the cumulated Z-curve enters the
futility area — the anticipated effect can be rejected.

We used a MIREDIF from studies defining this or, where we could
not  find  this,  we  used  an  assumption  that  the  minimal  relevant

We  calculated  the  diversity-adjusted  required  information  size
(DARIS;  that  is  the  number  of  participants  required  to  detect
or  reject  a  specific  intervention  effect  in  a  meta-analysis),  and
performed a TSA for the primary outcomes at the end of treatment
for the main comparison versus TAU, based on the following a priori
assumptions:

1. the SD of the primary outcomes;
2. an anticipated MIREDIF defined in a trial reporting on this or we

used a ½ SD on the used scale;

3. a maximum type I error of 2.0% (due to four primary outcomes;

Jakobsen 2014);

4. a maximum type II error of 10% (minimum 90% power; Castellini

2018); and

5. the diversity observed in the meta-analysis.

We furthermore performed a TSA for the three secondary outcomes
(for  the  main  comparison  versus  TAU)  not  closely  connected  to
the BPD core symptoms (depression, attrition and adverse effects)
based on the following priori assumptions:

1. the SD of the primary outcomes;
2. an anticipated MIREDIF defined in a trial reporting on this or we

used a ½ SD on the used scale;

3. a maximum type I error of 0.8% (due to 11 secondary outcomes;

Jakobsen 2014);

4. a maximum type II error of 10% (minimum 90% power; Castellini

2018); and

5. the diversity observed in the meta-analysis.

We  only  performed  a  TSA  for  depression  as  this  was  the  only
significant finding.

Sensitivity analysis

We conducted sensitivity analyses to determine whether findings
were sensitive to:

1.

imprecision, as assessed by GRADE, by conducting TSA analyses
on all primary outcomes and for the three secondary outcomes
(for  the  main  comparison  versus  TAU)  not  closely  connected
to  the  BPD  core  symptoms  (depression,  attrition  and  adverse
effects) with significant findings.

2. random-effects or fixed-effect models.

Summary of findings and assessment of the certainty of the
evidence

We used the GRADE approach to construct 'Summary of findings'
tables in which to document the results of review outcomes. Two
reviewers  (HEC  and  JSW)  ,  working  independently,  assessed  the
quality of the evidence. Any conflicts were resolved by consulting
a  third  author  (OJS).  The  GRADE  approach  appraises  the  quality
of  a  body  of  evidence  based  on  the  extent  to  which  one  can  be
confident that an estimate of effect or association reflects the item
being assessed. Considerations are due to: within-trial risk of bias;
directness  of  the  evidence;  heterogeneity  of  the  data;  precision
of  effect  estimates;  and  risk  of  publication  bias  (Andrews  2013a;
Andrews 2013b; Balshem 2011; Brunetti 2013; Guyatt 2011a; Guyatt
2011b;  Guyatt  2011c;  Guyatt  2011d;  Guyatt  2011e;  Guyatt  2011f;

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Guyatt 2011g; Guyatt 2013a; Guyatt 2013b; Guyatt 2013c; Mustafa
2013). When possible, we reported the MD or the RR, and we used
TSA  to  rate  imprecision  (Jakobsen  2014).  TSA  can  be  used  as  a
secondary analysis in Cochrane Reviews, to provide an additional
interpretation of the data from a specific perspective, and can be
used for testing imprecision (Thomas 2019).

We  report  the  four  primary  outcomes  (BPD  severity,  self-harm,
suicide-related outcomes and psychosocial functioning) and three
secondary  outcomes  not  closely  connected  to  the  BPD  core
symptoms (depression, attrition and adverse effects) in 'Summary
of  findings'  tables  for  our  two  main  comparisons  (Atkins  2004):
psychotherapy versus treatment-as-usual (Summary of findings 1);
and psychotherapy versus waiting list or no treatment (Summary
of findings 2). We also created a third 'Summary of findings' table
in  which  we  report  data  from  the  DBT  and  MBT  treatments  with
the highest numbers of primary trials, with DBT being the subject
of  roughly  one-third  of  all  included  trials,  followed  by  MBT  with
seven RCTs. In this table, we report only the primary outcomes (see
Summary of findings 3).

Results of the search

All  electronic  databases  and  search  periods  are  listed  in  the
Methods section (see Electronic searches). There were no language,
date  or  document  format  restrictions.  This  current  review  is
part  of  a  series  of  reviews  on  interventions  for  BPD.  Therefore,
we  used  a  very  comprehensive  search  strategy,  covering  all
psychotherapeutic or pharmacological treatment (or both) of BPD.

Altogether, the searches generated 22,078 records, of which 3477
were  duplicates.  Following  screening  of  titles  and  abstracts,  400
citations  merited  closer  inspection.  An  assessment  of  full  texts
for  possible  inclusion  into  this  review  led  to  the  exclusion  of  118
reports. This left 282 reports included. Of these, 50 reports referred
to  33  different  ongoing  trials  (see  Ongoing  studies).  Another  12
reports related to 11 different trials that we were unable to classify
definitively as included or excluded at this point of time, despite
our best efforts to retrieve further information from the trial authors
(see  Studies  awaiting  classification).  This  finally  left  220  reports
relating  to  75  different  included  trials  (see  Included  studies,  and
Figure 1).

R E S U L T S

Description of studies

See Characteristics of included studies, Characteristics of excluded
studies,  Characteristics  of  studies  awaiting  classification  and
Characteristics of ongoing studies tables.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   Study flow diagram

Cochrane Database of Systematic Reviews

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Included studies

Below,  we  summarise  the  key  characteristics  of  the  included
trials.  For  information  about  which  trials  correspond  to  which
characteristics  for  certain  categories  below,  please  see  Table  2.
Further detail can also be found in the Characteristics of included
studies tables. 

Design

We included 75 randomised, parallel-arm trials.

Sample sizes

There  was  considerable  variation  in  sample  sizes  between  the
trials, as the total number of participants with BPD ranged from 16
(Gleeson 2012) to 190 participants (McMain 2009). Five trials had a
sample size of more than 100 participants (Table 2).

Setting

Sixty-three  trials  were  conducted  in  outpatient  settings,  five  in
inpatient  settings,  and  seven  in  both  inpatient  and  outpatient
settings (see Table 2).

Participants

The  75  trials  included  a  total  of  4507  participants  with  BPD;
the  mean  age  ranged  from  14.8  to  45.7  years.  Seventeen  trials
included  only  female  participants  and  two  trials  included  only
males  (see  Table  2).  All  remaining  trials  included  participants  of
both genders, predominantly females.

Diagnostic criteria

Participants  were  diagnosed  as  having  BPD  according  to  DSM-
III,  DSM-III-R,  DSM-IV,  DSM-IV-TR,  or  ICD-10  criteria  (see  Table
2).  The  diagnosis  was  confirmed  by  standardised  means  of
assessment.  The  most  frequently  used  assessment  instruments
were  the  Structured  Clinical  Interviews  for  DSM-III-R  or  DSM-IV
Axis  II  Personality  Disorders  (SCID-II)  (First  1997;  Spitzer  1989)
in  47  trials.  Eleven  trials  applied  the  Diagnostic  Interview  for
Borderline  Personality  Disorder  patients  (DIB;  Gunderson  1981)
or  the  Diagnostic  Interview  for  Borderline  Personality  Disorder
Patients  -  revised  (DIB-R;  Zanarini  1989).  Six  trials  made  use  of
the International Personality Disorder Examination (IPDE; Loranger
1995).  All  assessment  instruments  used  in  the  included  trials  are
listed in Table 2.

Participants exclusion criteria of primary studies

In  39  trials,  people  with  evident  mental  impairment,  organic
brain  disorder  and  neurological  conditions  were  not  eligible  for
participation.  In  addition,  with  the  exception  of  Bos  2010  and
Kredlow 2017a, schizophrenia, schizoaffective and other psychotic
disorders were reasons for exclusion in all trials. Participants with
substance  abuse  or  dependence  were  not  eligible  for  inclusion
in  43  trials.  Four  trials  included  participants  with  alcohol  or
substance  abuse/dependence  (Davidson  2014;  Gregory  2008b;
Robinson 2016; Santisteban 2015). Comorbid personality disorders
were  not  a  reason  for  exclusion  in  71  trials.  Nine  trials  excluded
participants  with  antisocial  features  or  full  antisocial  personality
disorders. See Table 2 for a list of the trials.

Cochrane Database of Systematic Reviews

Interventions

Durations of interventions

The duration of the trials ranged from one month (Jahangard 2012)
to 36 months (Giesen-Bloo 2006). Thirty-six trials had a duration of
less than six months. Thirty-two trials lasted between six months
and 12 months. See Table 2.

Formats of interventions

Most  of  the  trials  applied  individual  treatment,  with  a  total  of  33
trials  investigating  the  effects  of  individual  therapy.  Twenty-two
trials  investigated  the  effects  of  group  therapy  whereas  16  trials
assessed a combination of individual and group therapy (see Table
2).

Types of interventions

We included any defined, psychological intervention. The following
provides  a  brief  overview  and  description  of  the  interventions
individual  trials.  For  a  more  elaborate
investigated 
description, see the relevant references.

in  the 

Dialectical  behaviour  therapy  (DBT)  and  modified  DBT-related
treatments (DBT; Linehan 1993a; Linehan 1993b). Twenty-four trials
investigated the effect of DBT and DBT-related treatments (Bohus
2013; Bianchini 2019; Carter 2010;  Elices 2016; Feigenbaum 2012;
Feliu-Soler 2017; Gratz 2014; Harned 2014; Kamalabadi 2012; Koons
2001a; Kramer 2016; Lin 2019; Linehan 1991; Linehan 1994; Linehan
2006; Linehan 2015a; McMain 2009; McMain 2017; Mohamadizadeh
2017; Priebe 2012; Soler 2009; Stanley 2017; Turner 2000; Van den
Bosch 2005).

Cognitive  behavioural  therapy  (CBT)  and  CBT-  related  treatments.
Eleven  trials  investigated  the  effect  of  CBT  and  CBT-related
treatments (Bellino 2007; Cottraux 2009; Davidson 2006; Davidson
2014; Jahangard 2012; Kramer 2011; Kramer 2014; Kredlow 2017a;
Kredlow 2017b; McMurran 2016; Schilling 2018).

investigated  a  generic  form  of
Psychoeducation.  One  trial 
psychoeducation  in  which  the  first  step  (awareness  of  BPD)  of
the  STEPPS  programme  was  taught  (Pascual  2015),  and  one  trial
included a once-only workshop (Zanarini 2008).

Cognitive  analytic  therapy  (CAT)  and  CAT-related  treatments.  One
trial investigated the effect of CAT (Gleeson 2012).

psychotherapy 
investigated  by 

related
Psychodynamic 
trials:  psychic
treatments  were 
2013;
representation-focused  psychotherapy 
psychoanalytic-interactional 
in  Leichsenring  2016;
and  sequential  brief  Adlerian  psychodynamic  psychotherapy
in Amianto 2011.

in  Reneses 

therapy 

three 

and 

Dynamic deconstructive psychotherapy (DDP). One trial investigated
the effect of DDP (Gregory 2008b).

Schema-focused  therapy  (SFT)  and  SFT-related  treatments.  Four
trials  investigated  the  effect  of  SFT  and  SFT-related  treatment
(Farrell  2009;  Giesen-Bloo  2006;  Mohamadizadeh  2017;  Nadort
2009).

Acceptance  and  commitment  therapy  (ACT)  employs  mindfulness
and acceptance strategies. One trial investigated the effect of ACT
(Morton 2012).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mentalisation-based treatment (MBT) and MBT-related treatments.
Six trials investigated the effect of MBT and MBT-related treatments
(Bateman  1999;  Bateman  2009;  Jørgensen  2013;  Philips  2018;
Robinson 2016; Rossouw 2012b).

Interpersonal psychotherapy (IPT) and IPT-related treatments. Four
trials  investigated  the  effect  of  IPT  (Bellino  2006;  Bellino  2007;
Bellino 2010; Smith 2012).

Client-centred  therapy  (CCT)  and  related  treatments  aim  to
encourage  the  patient  to  find  solutions  to  their  own  problems
and  to  help  them  decide  how  they  need  to  change.  Two  trials
investigated the effect of CCT (Cottraux 2009; Turner 2000).

Manual-assisted cognitive treatment (MACT) is used to treat people
who are acutely self-harming. The treatment is structured around
a self-help book. Two trials investigated the effect of MACT (Morey
2010; Weinberg 2006).

Systems  training  for  emotional  predictability  and  problem-solving
for  borderline  personality  disorder  (STEPPS)  is  a  seminar-like,
group treatment programme that combines cognitive-behavioural
elements  and  skills  training.  Two  trials  investigated  the  effect  of
STEPPS (Blum 2008; Bos 2010).

therapy 

treatments 

included  art 

Eclectic 
(Haeyen  2018),
abandonment psychotherapy and intensive community treatment
(Andreoli  2016),  a  combination  of  individual  SFT  and  group
DBT  (Leppänen  2016),  combined 
inpatient  and  outpatient
integrative  BPD-oriented
(Antonsen  2017), 
psychotherapy 
adolescent  family  therapy  (Santisteban  2015),  joint  crises  plan
(Borschmann 2013), web-based psychoeducation (Zanarini 2018),
and motivation feedback (Jochems 2015). Eight trials investigated
eclectic treatments.

Concomitant treatment

Medication  use  was  not  allowed  in  three  trials  (Lin  2019;
Mohamadizadeh  2017;  Zanarini  2018  ).  The  majority  of  trials
allowed participants to continue their respective drug treatments
if initiated before the start of the trial (59 trials). Only four out of 75
RCTs gave the same medication to all participants (fluoxetine in the
first three trials, selective serotonin reuptake inhibitors not further
specified  in  the  latter)  (Bellino  2006;  Bellino  2007;  Bellino  2010;
Jahangard 2012). One trial, Stanley 2017, included four treatment
groups, which we integrated into two groups of DBT and supportive
treatment. Fifty percent of each of these two groups additionally
received  either  fluoxetine  or  placebo.  Concomitant  drug  use  was
not specified in nine trials (Bianchini 2019; Carter 2010; Davidson
2014; Haeyen 2018; Kamalabadi 2012; Leppänen 2016; Philips 2018;
Robinson 2016; Santisteban 2015). Two trials included medication-
free participants only (Lin 2019; Mohamadizadeh 2017; see Table 2).

Comparisons

The review includes 25 different comparisons.

Control interventions

The kinds of control interventions varied widely and included, for
example,  treatment-as-usual  (TAU),  waiting  list,  no  treatment  or
an active treatment. The composition of the control interventions
used  in  the  individual  trials  differed  as  to  whether  TAU  was
obligatory or optional.

Cochrane Database of Systematic Reviews

The majority of trials (42 trials) included a control intervention with
an obligatory TAU. Thirteen trials included a control intervention
with optional TAU. See Table 2.

Active treatment

Twenty-two trials included an active head-to-head comparison.

1. Antonsen 2017: inpatient plus outpatient psychotherapy versus

outpatient psychotherapy

2. Bellino 2007: cognitive therapy versus interpersonal therapy
3. Carmona  í  Farrés  2019:  dialectical  behaviour  therapy  (DBT)

mindfulness versus DBT interpersonal effectiveness

4. Cottraux 2009: cognitive therapy versus client-centred therapy

(CCT)

5. Elices  2016:  DBT  mindfulness  versus  DBT 

interpersonal

effectiveness

6. Feliu-Soler  2017:  DBT  mindfulness  versus  loving-kindness  and

compassion meditation

7. Giesen-Bloo  2006:  schema-focused  therapy 

(SFT)  versus

transference-focused therapy

8. Harned 2014: standard DBT versus DBT prolonged exposure (PE)
9. Kramer  2011  and  Kramer  2014:  motive-oriented  therapeutic
relationship  (MOTR)  versus  general  psychiatric  management
(GPM)

10.Kredlow  2017b:  cognitive  behavioural  therapy  (CBT)  versus

trauma-related plus anxiety-related psychoeducation

11.Lin 2019: DBT skills training versus cognitive therapy
12.Linehan  2015a:  standard  DBT  versus  DBT  skills  plus  case

management versus DBT individual therapy plus activity

13.McMain  2009:  DBT  versus  general  psychiatric  management

(GPM)

14.Mohamadizadeh 2017: DBT versus SFT
15.Morey  2010:  manual-assisted  cognitive  therapy  (MACT)  versus

MACT plus therapeutic assessment (TA)

16.Nadort  2009:  SFT  versus  SFT  plus  therapist  telephone  crisis

support outside office hours

17.Pascual  2015:  pseudoeducation 

versus  neurocognitive

rehabilitation group

18.Santisteban  2015:  BPD-oriented  adolescent  family  therapy

versus individual drug counselling
19.Schilling  2018:  meta-cognitive 

personality  disorder 
relaxation training (PMR)

for  borderline
(B-MCT)  versus  progressive  muscle

training 

20.Sinnaeve  2018:  standard  DBT  (outpatient)  versus  step-down

DBT (combined inpatient and outpatient DBT)

21.Turner 2000: DBT versus CCT
22.Kramer 2016: DBT informed and individual treatment versus TAU

Outcomes

When  several  measures  were  available  for  the  same  outcome,
we  chose  the  measure  that  was  used  most  often,  in  order  to
reduce heterogeneity of outcomes in form and content. Outcomes
could be either self-reported by people treated or observer-rated
by  clinicians,  with  clinician-rated  outcomes  being  preferred.  We
included  outcomes  reported  at  the  end  of  treatment  and  at  ≥
six  months  follow-up.  trials  used  a  variety  of  scales  to  assess
both  primary  and  secondary  outcomes.  The  table  of  outcomes
in Appendix 4 presents the list of scales used to assess the outcomes

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

in  the  individual  trials.  The  list  refers  to  the  measurement  scales
described in the original reports.

Adverse effects

Data  on  adverse  effects  were  available  from  five  trials  (Andreoli
2016;  Davidson  2014;  McMurran  2016;  Robinson  2016;  Stanley
2017). Two more trials reported to have recorded adverse effects,
but  we  could  not  use  the  data  for  effect  size  calculation,  either
because  the  final  results  were  not  reported  (Pascual  2015)  or
it  was  unclear  in  which  treatment  group  the  events  occurred
(Leichsenring  2016).  Adverse  effects  were  either  recorded  as  and
when  people  reported  them,  or  the  exact  method  of  assessment
was not specified.

We  categorised  adverse  effects  as  serious  (life-threatening,
resulting in death or requiring inpatient hospitalisation; available
from  Andreoli  2016;  Davidson  2014;  McMurran  2016;  Robinson
2016;  Stanley  2017)  or  non-serious  (any  other  adverse  effects;
available from McMurran 2016; Stanley 2017).

Funding source

(k  =  62)  were 

The  majority  of  trials 
funded  by  grants
from  universities,  authorities  or  research  foundations  (see  Table
2). Four trials reported that no funding was received (Bellino 2006;
Bellino  2007;  Bellino  2010;  Jahangard  2012).  The  nine  remaining
trials  did  not  specify  funding  (Andreoli  2016;  Bianchini  2019;
Carter  2010;  Kamalabadi  2012;  Koons  2001a;  Leppänen  2016;
Mohamadizadeh 2017; Morton 2012; Turner 2000).

Excluded studies

In  total,  we  excluded  105  trials  from  118  full-text  reports  (see
Characteristics  of  excluded  studies  tables).  Of  these,  70  trials
included  an  ineligible  patient  population,  28  assessed  ineligible
interventions, 1 included an ineligible comparator, 2 had unclear
numbers  of  participants  with  BPD  included  (we  were  unable  to
retrieve information), and 4 did not include any relevant outcomes
(see Figure 1).

Studies awaiting classification

We included 11 trials as awaiting classification, of which we were
unable  to  retrieve  four  trials,  two  of  the  trials  were  conference
abstracts,  two  of  the  trials  need  to  be  translated,  and  three
trials did not provide subsample data for people affected by BPD
(see  Characteristics  of  studies  awaiting  classification  tables  for
an  elaborated  description).  All  trials  investigated  different  types
of  psychotherapeutic  treatments  for  people  affected  by  BPD  or
individuals with PTSD or suicidal behaviour.

Cochrane Database of Systematic Reviews

Three  trials  involved  CBT  treatments  for  BPD  (Akbari  2009;
Dorrepaal  2012;  Johnson  2017)  and  five  trials  involved  DBT
treatments (Abdelkarim 2016; Cowperthwait 2017; McCauley 2018;
Ostermeier 2017; Santamarina 2017). One trial apiece investigated
ACT (Ducasse 2018), MBT (Einy 2018) and the STEPPS programme
(Isaia 2017).

Three  trials  involved  adolescents  (Cowperthwait  2017;  McCauley
2018; Santamarina 2017), whereas the rest involved adults.

Ongoing studies

We  included  33  ongoing  trials  assessing  different  types  of
psychological interventions for the treatment of BPD, for which the
outcome data are not yet available (see Characteristics of ongoing
studies tables).

The majority of trials investigated the effect of CBT, DBT or
related treatment for individuals with BPD displaying self-harm
or suicidal behaviour. More specifically, nine trials investigated
DBT (ACTRN12612001187831; ACTRN12616000236493;
NCT02134223; NCT02387736; NCT02517723; NCT02991586;
NCT03191565; NCT03297840; NCT03833453), five trials
investigated MBT (ACTRN12612000951853; NCT02068326;
NCT02771691; NCT03677037; NL2168/NTR2292), three trials
investigated cognitive behavioural treatments (DRKS00003605;
ISRCTN21802136; NCT01531634), three trials investigated SFT
(DRKS00011534; NL1144/NTR1186; NL2266/NTR2392), two
trials investigated STEPPS programmes (NCT03092271; NL3856/
NTR4016), two trials investigated self-help or psychoeducation
interventions (NCT03185026; NCT03376113), one investigated a
meditation-based treatment (NCT02125942), one investigated
internet-based treatment (NCT03418142), and one an emotional
regulation treatment (NCT03011190). Five trials investigated
other interventions like early interventions and general
care (ACTRN12610000100099; NCT00603421; NCT01823120;
NCT02685943; NCT02985047).

One  trial  investigated  adolescents  (NCT02771691)  whereas  the
other trials investigated adults.

Risk of bias in included studies

Figure  2  and  Figure  3  shows  the  review  authors´  judgements
concerning the risk of bias across the included trials and for each
individual trial, respectively. Further information for the individual
trials can be found in Characteristics of included studies tables.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.

Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias

Low risk of bias

Unclear risk of bias

High risk of bias

0%

25%

50%

75% 100%

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

s
e
m
o
c
t
u
o

l
l

A

:
)
s
a
i
b
n
o
i
t
c
e
t
e
d
(

t
n
e
m
s
s
e
s
s
a

e
m
o
c
t
u
o

f
o

g
n
i
d
n
i
l

B

s
e
m
o
c
t
u
o

l
l

A

:
)
s
a
i
b

n
o
i
t
i
r
t
t
a
(

a
t
a
d

e
m
o
c
t
u
o

e
t
e
l
p
m
o
c
n
I

)
s
a
i
b
n
o
i
t
c
e
l
e
s
(
n
o
i
t
a
r
e
n
e
g

e
c
n
e
u
q
e
s
m
o
d
n
a
R

)
s
a
i
b
n
o
i
t
c
e
l
e
s
(

t
n
e
m
l
a
e
c
n
o
c

n
o
i
t
a
c
o
l
l

A

)
s
a
i
b
g
n
i
t
r
o
p
e
r
(
g
n
i
t
r
o
p
e
r

e
v
i
t
c
e
l
e
S

s
a
i
b

r
e
h
t
O

Amianto 2011
Andreoli 2016
Antonsen 2017
Bateman 1999
Bateman 2009
Bellino 2006
Bellino 2007
Bellino 2010
Bianchini 2019
Blum 2008
Bohus 2013
Borschmann 2013
Bos 2010
Carmona í Farrés 2019
Carter 2010
Cottraux 2009
Davidson 2006
Davidson 2014
Doering 2010
Elices 2016
Farrell 2009
Feigenbaum 2012
Feliu-Soler 2017
Giesen-Bloo 2006
Gleeson 2012
Gratz 2006

-

?

+ + + + + -
-
+ + + -
-
-
? ? ? + -
? + + -
-
?
+ + + + + -
+ + + -
-
?
+ + + -
? +
-
+ ? + -
?
-
? ? + ? ?
-
-
-
+ ?
+ + + ? + -
+ + + + + -
+ + -
-
+ + + - + +
+ + + -
-
+ + + - + +
+ + + + + -
-
+ ? + ? ?
+ + + + + ?
+ - + - + ?
-
?
+ ?
? ?
+ + ?
-
? ? ? ? ?
+ + + + ? ?
+ - + -
?
-
+ ? + -

-
?

-
-

?

?

-

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   (Continued)

Cochrane Database of Systematic Reviews

Gleeson 2012
Gratz 2006
Gratz 2014
Gregory 2008b
Haeyen 2018
Harned 2014
Jahangard 2012
Jochems 2015
Jørgensen 2013
Kamalabadi 2012
Koons 2001a
Kramer 2011
Kramer 2014
Kramer 2016
Kredlow 2017a
Kredlow 2017b
Laurenssen 2018
Leichsenring 2016
Leppänen 2016
Lin 2019
Linehan 1991
Linehan 1994
Linehan 2006
Linehan 2015a
McMain 2009
McMain 2017
McMurran 2016
Mehlum 2014
Mohamadizadeh 2017
Morey 2010
Morton 2012
Nadort 2009
Pascual 2015
Philips 2018
Priebe 2012
Reneses 2013
Robinson 2016
Rossouw 2012b
Salzer 2014
Santisteban 2015
Schilling 2018
Schuppert 2012
Sinnaeve 2018
Smith 2012
Soler 2009
Stanley 2017
Turner 2000

-

-

-

-

-
+ - + -
?
-
+ ? + -
?
-
? ? + + ?
+ + + - + -
-
? ?
+ ? + + + -
+ + + + ? ?
+ + + ? + ?
-
-
? ?
?
-
? ? ? ? ?
? ? + -
? +
-
-
+ + + -
-
-
-
+ + ?
+ + + ? ? ?
-
+ + + + ?
-
+ + + + ?
-
-
+ + + -
-
-
+ + + ?
+ ? + -
-
?
+ ? ? + -
?
+ ? + ? ? ?
-
+ ? + -
?
-
+ + + + ?
-
-
+ ? + ?
+ + + ? + ?
+ + + + + ?
+ + - + + -
-
+ + + + ?
? ? ? ? ? ?
? ? ? ? ? +
+ -
-
? + ? ? + ?
-
+ ? + ? ?
-
-
+ + ?
+ + ? ? ? ?
-
+ ? ? ? ?
+ ? + ? + -
-
+ + + -
-
? ? + + ?
-
-
+ ?
? ?
-
? ? ? ? ?
-
-
+ + + ?
-
-
-
+ + -
-
-
-
?
? ?
+ ? + ? ? ?
? ? + ? + ?
? ? + ? ? ?

? ?

-

-

-

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 3.   (Continued)

Cochrane Database of Systematic Reviews

Stanley 2017
Turner 2000
Van den Bosch 2005
Weinberg 2006
Zanarini 2008
Zanarini 2018

? ? + ? + ?
? ? + ? ? ?
+ ? + ? ? ?
? ? + ? + ?
? ? ? ? ? ?
?
+ ?

- + -

Allocation

Sequence generation

There is evidence that poor reporting of randomisation increases
the  odds  of  presenting  significant  outcomes  (Chalmers  1983;
Schulz 1995). The trials provided further information on how the
randomisation sequence had been achieved, or that a stratification
was  used.  We  judged  56  trials,  where  a  randomisation  method
was  reported,  as  having  low  risk  of  bias  (Amianto  2011;  Andreoli
2016; Bateman 2009; Bellino 2006; Bellino 2007; Bellino 2010; Blum
2008; Bohus 2013; Borschmann 2013; Bos 2010; Carmona í Farrés
2019;  Carter  2010;  Cottraux  2009;  Davidson  2006;  Davidson  2014;
Doering 2010; Elices 2016; Farrell 2009; Feigenbaum 2012; Giesen-
Bloo  2006;  Gleeson  2012;  Gratz  2006;  Gregory  2008b;  Harned
2014; Jahangard 2012; Jochems 2015; Kramer 2011; Kramer 2014;
Kramer  2016;  Kredlow  2017a;  Kredlow  2017b;  Laurenssen  2018;
Leichsenring 2016; Leppänen 2016; Lin 2019; Linehan 1991; Linehan
1994;  Linehan  2006;  Linehan  2015a;  McMain  2009;  McMain  2017;
McMurran 2016; Mehlum 2014; Morton 2012; Pascual 2015; Philips
2018; Priebe 2012; Reneses 2013; Robinson 2016; Rossouw 2012b;
Santisteban  2015;  Schuppert  2012;  Sinnaeve  2018;  Soler  2009;
Van  den  Bosch  2005;  Zanarini  2018).  The  19  remaining  trials
did  not  describe  exactly  how  treatment  allocation  had  been
achieved, so we rated these trials at unclear risk of bias (Antonsen
2017; Bateman 1999; Bianchini 2019; Feliu-Soler 2017; Gratz 2014;
Haeyen  2018;  Jørgensen  2013;  Kamalabadi  2012;  Koons  2001a;
Mohamadizadeh  2017;  Morey  2010;  Nadort  2009;  Salzer  2014;
Schilling  2018;  Smith  2012;  Stanley  2017;  Turner  2000;  Weinberg
2006; Zanarini 2008)

Allocation concealment

Thirty-seven trials, reporting off-site randomisation or notification
of assignment by research coordinators not involved in delivering
the therapy, were rated as having a low risk of bias (Amianto 2011;
Andreoli 2016; Bateman 1999; Bateman 2009; Bellino 2006; Bellino
2007; Bohus 2013; Borschmann 2013; Bos 2010; Carmona í Farrés
2019;  Carter  2010;  Cottraux  2009;  Davidson  2006;  Doering  2010,
Feigenbaum  2012;  Giesen-Bloo  2006;  Gregory  2008b;  Jahangard
2012;  Jochems  2015;  Kramer  2011;  Kramer  2014;  Kramer  2016;
Kredlow  2017a;  Kredlow  2017b;  Laurenssen  2018;  Leichsenring
2016;  Linehan  2006;  McMain  2009;  McMain  2017;  McMurran  2016;
Mehlum  2014;  Nadort  2009;  Philips  2018;  Priebe  2012;  Rossouw
2012b; Schuppert 2012; Sinnaeve 2018). Thirty-five trials that did
not provide enough information to enable a judgement to be made
about  adequacy  of  allocation  concealment  were  rated  as  having
an  unclear  risk  of  bias  (Antonsen  2017;  Bellino  2010;  Bianchini
2019;  Blum  2008;  Davidson  2014;  Farrell  2009;  Feliu-Soler  2017;
Gratz 2006; Gratz 2014; Haeyen 2018; Harned 2014; Jørgensen 2013;
Kamalabadi 2012; Koons 2001a; Leppänen 2016; Lin 2019; Linehan
1991; Linehan 1994; Linehan 2015a; Mohamadizadeh 2017; Morey

2010;  Pascual  2015;  Reneses  2013;  Robinson  2016;  Salzer  2014;
Santisteban 2015; Schilling 2018; Smith 2012; Soler 2009; Stanley
2017;  Turner  2000;  Van  den  Bosch  2005;  Weinberg  2006;  Zanarini
2008;  Zanarini  2018).  We  rated  three  trials  as  being  at  high  risk
of  bias  due  to  explicit  inadequate  allocation  concealment  (Elices
2016;  Gleeson  2012;  Morton  2012).  One  example  can  be  found  in
Gleeson  2012,  where  the  following  was  stated:  "Outcome  ratings
were  made  by  the  trial  research  assistant  who  was  independent
of  the  treatment,  but  not  blind  to  treatment  allocation  because
of limited resources" (quote). This could potentially have induced
bias.

Blinding

The  majority  of  trials  (50  trials)  reported  that  outcome  assessors
were kept blind to treatment allocation and, for this reason, were
considered to be at low risk of bias (Amianto 2011; Andreoli 2016;
Bateman 1999; Bateman 2009; Bellino 2006; Bellino 2007; Bellino
2010;  Bianchini  2019;  Bohus  2013;  Borschmann  2013;  Carmona  í
Farrés 2019; Carter 2010; Cottraux 2009; Davidson 2006; Davidson
2014: Doering 2010; Elices 2016; Giesen-Bloo 2006; Gleeson 2012;
Gratz  2006;  Gratz  2014;  Gregory  2008b;  Harned  2014;  Jahangard
2012;  Jochems  2015;  Koons  2001a;  Kramer  2011;  Kramer  2016;
Kredlow  2017a;  Kredlow  2017b;  Laurenssen  2018;  Leichsenring
2016; Leppänen 2016; Linehan 1991; Linehan 1994; Linehan 2006;
Linehan 2015a; McMain 2009; McMain 2017; Mehlum 2014; Pascual
2015;  Robinson  2016;  Rossouw  2012b;  Salzer  2014;  Schuppert
2012;  Soler  2009;  Stanley  2017;  Turner  2000;  Van  den  Bosch
2005;  Weinberg  2006).  Fourteen  trials  did  not  have  an  adequate
description of the blinding of the outcome assessors and thus were
judged  to  be  at  unclear  risk  of  bias  (Antonsen  2017;  Feigenbaum
2012;  Feliu-Soler  2017;  Kamalabadi  2012;  Kramer  2014;  Lin  2019;
Mohamadizadeh  2017;  Morey  2010;  Nadort  2009;  Philips  2018;
Priebe 2012; Reneses 2013; Schilling 2018; Zanarini 2008). Eleven
trials reported inadequate blinding of outcome assessors and thus
were  considered  to  be  at  high  risk  of  bias  (Blum  2008;  Bos  2010;
Farrell 2009; Haeyen 2018; Jørgensen 2013; McMurran 2016; Morton
2012; Santisteban 2015; Sinnaeve 2018; Smith 2012; Zanarini 2018).

Incomplete outcome data

The  majority  of  trials  either  did  not  adequately  describe  the
possible reasons for missing data, and therefore were considered
to  be  at  unclear  risk  of  bias  (30  trials:  Bianchini  2019;  Blum
2008; Bohus 2013; Davidson 2014; Feliu-Soler 2017; Jochems 2015;
Kamalabadi 2012; Kramer 2016; Leichsenring 2016; Linehan 1991;
Linehan 2015a; McMain 2009; Mohamadizadeh 2017; Morey 2010;
Morton  2012;  Nadort  2009;  Pascual  2015;  Priebe  2012;  Reneses
2013; Robinson 2016; Santisteban 2015; Schilling 2018; Schuppert
2012; Smith 2012; Soler 2009; Stanley 2017; Turner 2000; Van den
Bosch  2005;  Weinberg  2006;  Zanarini  2008),  or  did  not  explicitly
address  obvious  missing  data  and  therefore  were  considered  to

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

be  at  high  risk  of  bias  (26  trials:  Andreoli  2016;  Bateman  1999;
Bellino  2006;  Bellino  2007;  Bellino  2010;  Bos  2010;  Carmona
í  Farrés  2019;  Carter  2010;  Cottraux  2009;  Elices  2016;  Farrell
2009; Feigenbaum 2012; Gleeson 2012; Gratz 2006; Gregory 2008b;
Haeyen 2018; Jørgensen 2013; Koons 2001a; Kramer 2011; Kramer
2014;  Laurenssen  2018;  Leppänen  2016;  Linehan  1994;  Philips
2018;  Rossouw  2012b;  Sinnaeve  2018).  Nineteen  trials  showed
no  indication  of  incomplete  outcome  reporting,  and  thus  were
considered  to  be  at  low  risk  of  bias  (Amianto  2011;  Antonsen
2017;  Bateman  2009;  Borschmann  2013;  Davidson  2006;  Doering
2010; Giesen-Bloo 2006; Gratz 2014; Harned 2014; Jahangard 2012;
Kredlow  2017a;  Kredlow  2017b;  Lin  2019;  Linehan  2006:  McMain
2017; McMurran 2016; Mehlum 2014; Salzer 2014; Zanarini 2018).

Selective reporting

The  majority  of  trials  (39  trials)  either  did  not  have  a  published
protocol  prior  to  initiating  the  trials  or  did  not  provide  sufficient
information in the report to judge the extent of reporting bias. We
considered these trials to be at unclear risk of bias (Bateman 1999;
Bellino 2006; Bellino 2007; Bellino 2010; Bianchini 2019; Bos 2010;
Carter 2010; Davidson 2014; Farrell 2009; Feigenbaum 2012; Feliu-
Soler  2017;  Giesen-Bloo  2006;  Gratz  2006;  Gratz  2014;  Jahangard
2012;  Jørgensen  2013;  Kamalabadi  2012;  Koons  2001a;  Kramer
2016;  Kredlow  2017a;  Kredlow  2017b;  Leppänen  2016;  Linehan
1991; Linehan 1994; Linehan 2006; Mehlum 2014; Mohamadizadeh
2017; Morey 2010; Morton 2012; Pascual 2015; Priebe 2012; Reneses
2013;  Salzer  2014;  Santisteban  2015;  Schilling  2018;  Soler  2009;
Turner  2000;  Van  den  Bosch  2005;  Zanarini  2008).  Seventeen
trials did not explicitly report data for prespecified outcomes even
though they initially had planned to report them. We considered
these  trials  to  be  at  high  risk  of  bias  (Andreoli  2016;  Antonsen
2017; Blum 2008; Gleeson 2012; Haeyen 2018; Kramer 2011; Kramer
2014; Laurenssen 2018; Leichsenring 2016; Lin 2019; Linehan 2015a;
Philips  2018;  Rossouw  2012b;  Schuppert  2012;  Sinnaeve  2018;
Smith 2012; Zanarini 2018). We rated 19 trials at low risk of bias due
to the fact that they had published a protocol or registered the trial
before conducting the trial, and reported all prespecified outcomes
(Amianto  2011;  Bateman  2009;  Bohus  2013;  Borschmann  2013;
Carmona  í  Farrés  2019;  Cottraux  2009;  Davidson  2006;  Doering
2010;  Elices  2016;  Gregory  2008b;  Harned  2014;  Jochems  2015;
McMain 2009; McMain 2017; McMurran 2016; Nadort 2009; Robinson
2016; Stanley 2017; Weinberg 2006).

Other potential sources of bias

Other  sources  of  bias  included  insufficient  treatment  adherence,
allegiance bias and attention bias. The total score for this outcome
was  based  on  the  highest  score  of  bias.  A  detailed  description  of
which domains are critical for the individual trials can be found in
the Characteristics of included studies tables.

Most  trials  (48  trials)  exhibited  high  risk  of  bias  in  one  or  more
of the assessed domains (Amianto 2011; Andreoli 2016; Antonsen
2017;  Bateman  1999;  Bateman  2009;  Bellino  2006;  Bellino  2010;
Bianchini  2019;  Blum  2008;  Borschmann  2013;  Bohus  2013;  Bos
2010;  Carter  2010;  Davidson  2006;  Davidson  2014;  Farrell  2009;
Feliu-Soler  2017;  Gratz  2006;  Gratz  2014;  Gregory  2008b;  Haeyen
2018;  Harned  2014;  Jørgensen  2013;  Kamalabadi  2012;  Kramer
2011;  Kramer  2014;  Kredlow  2017a;  Kredlow  2017b;  Laurenssen
2018;  Leichsenring  2016  Leppänen  2016;  Linehan  1994;  Linehan
2006; Linehan 2015a; McMurran 2016; Mehlum 2014; Morton 2012;
Pascual 2015; Philips 2018; Reneses 2013; Robinson 2016; Rossouw

Cochrane Database of Systematic Reviews

2012b;  Salzer  2014;  Santisteban  2015;  Schilling  2018;  Schuppert
2012;  Sinnaeve  2018;  Smith  2012).  Twenty-two  trials  had  at  least
one  domain  that  was  not  adequately  described  in  the  trials  and
therefore  were  considered  to  be  at  unclear  risk  of  bias  (Doering
2010;  Elices  2016;  Feigenbaum  2012;  Giesen-Bloo  2006;  Gleeson
2012;  Jahangard  2012;  Jochems  2015;  Kramer  2016;  Lin  2019;
Linehan 1991; McMain 2009; McMain 2017; Mohamadizadeh 2017;
Nadort 2009; Priebe 2012; Soler 2009; Stanley 2017; Turner 2000;
Van den Bosch 2005; Weinberg 2006; Zanarini 2008; Zanarini 2018).
Only five trials had an overall low risk of bias for all the domains
assessed as other potential sources of bias (Bellino 2007; Carmona
í Farrés 2019; Cottraux 2009; Koons 2001a; Morey 2010).

Effects of interventions

See: Summary of findings 1 Psychotherapy versus treatment-as-
usual;  Summary  of  findings  2  Psychotherapy  versus  waiting  list
or  no  treatment;  Summary  of  findings  3  Dialectical  behavioural
therapy or mentalisation-based therapy versus treatment-as-usual

We  present  the  results  for  each  of  the  primary  and  secondary
outcomes connected to the 25 comparisons below. Where a meta-
analysis  involved  two  or  more  different  instruments  to  measure
the  same  construct,  we  reported  effect  sizes  as  SMD,  otherwise
we reported the MD. To identify the MIREDIF, we transformed the
SMD  to  MD  for  the  scale  with  best  validity  and  reliability  for  that
outcome.  For  the  analyses  of  the  four  primary  outcomes  in  the
comparison of psychotherapy versus TAU, we transformed the SMD
into MD on the following scales, to assess whether results exceeded
the minimum clinically important difference: ZAN BPD Scale, DSHI,
Suicidal Attempt Self Injury Interview, GAF scale, and the Hamilton
Depression scale.

We contacted the authors of 44 trials with unclear or missing data
and requested the necessary information. Twenty-four trial authors
replied with answers (Amianto 2011; Bateman 1999; Bellino 2006;
Blum 2008; Borschmann 2013; Carmona í Farrés 2019; Carter 2010;
Doering 2010; Elices 2016; Farrell 2009; Gleeson 2012; Gratz 2006;
Kredlow  2017a;  Kredlow  2017b;  Leppänen  2016;  Mehlum  2014;
Morton  2012;  Priebe  2012;  Robinson  2016;  Salzer  2014;  Schilling
2018; Sinnaeve 2018; Smith 2012; Soler 2009).

We performed TSA on all primary outcomes and for the secondary
outcome depression.at end of treatment for the main comparison
versus  TSA  in  our  'Summary  of  findings'  tables,  adjusting  for
multiplicity and sparse data.

We  considered  all  trials  as  being  at  high  risk  of  bias  overall.
However,  we  used  all  eligible  trials  in  the  meta-analyses,  as
the  Cochrane  Handbook  for  Systematic  Reviews  of  Interventions
recommends  doing  so  when  all  trials  are  assigned  the  same  risk
of  bias.  We  took  account  of  our  'Risk  of  bias'  assessment  when
considering the quality of the evidence using the GRADE approach,
to  ensure  that  judgements  about  risk  of  bias  and  other  factors
affecting the quality of the evidence were taken into account when
interpreting the results of the review (Higgins 2011; Higgins 2019).

1. Psychotherapy versus treatment-as-usual (TAU)

Primary outcomes

1.1 BPD symptom severity (continuous)

Twenty-three  trials  reported  continuous  data  on  BPD  symptom
severity  (in  total  for  all  time  points)  (Amianto  2011;  Blum  2008;

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bateman  1999;  Bos  2010;  Doering  2010;  Farrell  2009;  Gratz  2006;
Gratz 2014; Gregory 2008b; Jørgensen 2013; Koons 2001a; Kredlow
2017a;  Laurenssen  2018;  Leichsenring  2016;  Leppänen  2016;
Morton  2012;  Philips  2018;  Priebe  2012;  Reneses  2013;  Robinson
2016; Rossouw 2012b; Schuppert 2012; Soler 2009).

Generally, psychotherapy improved BPD symptom severity at end
of  treatment  compared  with  TAU  (SMD  −0.52,  95%  CI  −0.70  to
−0.33;  22  trials,  1244  participants;  I2  =  57%;  P  <  0.001;  Analysis
1.1.1;  moderate-quality  evidence,  Summary  of  findings  1).  This
corresponds  to  a  MD  of  −3.6  (95%  CI  −4.4  to  -2.08)  on  the  ZAN-
BPD  scale,  which  ranges  from  0  to  36.  This  represents  a  clinical
relevant improvement in BPD symptoms. The MIREDIF on this scale
is −3.0 points (Crawford 2018a). The TSA analysis showed that the
RIS was reached (n = 907), and that there was no risk of type 1 error
(TSA  adjusted  confidence  interval  −5.49  to  −1.90)  (see  figure  4  in
Appendix 6).

Inspection of the funnel plot (see figure 5 in Appendix 6) suggested
potential bias (very small asymmetry), and we found evidence of
possible  significant  publication  bias:  Egger’s  regression  intercept
(bias)  2.234  (two  tailed,  P  =  0.043).  Analysis  1.1.1.  might  be
more  difficult  to  understand  as  we  found  asymmetry  in  the
funnel plot and also a significant Egger's test. All effect estimates
spread  unequivocally  at  the  left-hand  side  of  the  zero  line,
clearly favouring experimental treatments over controls. However,
identifying  smaller  sample  size  trials  with  insignificant  results
would  be  unlikely  to  change  our  pooled  estimate  substantially
because these smaller trials would only contribute lesser weights to
the pooled estimates. Hence, we concluded that our findings were
not essentially influenced by publication bias.

Generally, psychotherapy did not reduce BPD symptom severity at
zero to six months follow-up compared with TAU (SMD −0.59, 95%
CI −1.23 to 0.05; 2 trials, 41 participants; I2 = 0%; P = 0.17; Analysis
1.1.2).

Generally, psychotherapy did not reduce BPD symptom severity at
six to 12 months follow-up compared with TAU (SMD −0.04, 95% CI
−0.36 to 0.27; 2 trials, 157 participants; I2 = 0%; P = 0.79; Analysis
1.1.3).

Generally, psychotherapy did not reduce BPD symptom severity at
above 12 months follow-up compared with TAU (SMD −0.94, 95% CI
−2.58 to 0.70; 2 trials, 97 participants; I2 = 92%; P = 0.26; Analysis
1.1.4).

1.2 BPD symptom severity (dichotomous)

One  trial  reported  dichotomous  data  on  BPD  symptom  severity
(Davidson 2006).

Generally, psychotherapy did not reduce BPD symptom severity at
above 12 months follow-up compared with TAU (RR 0.91, 95% CI
0.56 to 1.48; 1 trial, 76 participants; P = 0.71; Analysis 1.2).

No data were available for end of treatment, zero to six months and
six to 12 months follow-up.

1.3 Self-harm (continuous)

Thirteen  trials  reported  continuous  data  on  self-harm  (Amianto
2011; Borschmann 2013; Carter 2010; Feigenbaum 2012; Gratz 2006;

Cochrane Database of Systematic Reviews

Gratz 2014; Koons 2001a; Linehan 1991; Linehan 2006; Philips 2018;
Priebe 2012; Van den Bosch 2005; Weinberg 2006).

Generally, psychotherapy improved self-harm at end of treatment
compared with TAU (SMD −0.32, 95% CI −0.49 to −0.14; 13 trials, 616
participants; I2 = 16%; P = 0.0004; low-quality evidence, Summary of
findings 1). This corresponds to a MD of −0.82 (95% CI −1.25 to 0.35),
on the DSHI, which ranges from 0 to 34. The MIREDIF on this scale is
−1.25 points, which corresponds to ½ SD (Farivar 2004). Clinically,
this  represents  no  clinically  important  reduction  in  self-harm  for
people with BPD. The TSA analysis showed that the RIS was reached
(n = 97). However, we cannot exclude the potential risk of type 1
error (TSA adjusted confidence interval −0.59 to −0.08) (see figure 6
in Appendix 6).

Inspection of the funnel plot (see figure 7 in Appendix 6) suggested
no  potential  bias  (asymmetry),  and  we  found  no  evidence  of
possible  significant  publication  bias:  Egger’s  regression  intercept
(bias) 1.524 (two tailed, P = 0.237).

Generally,  psychotherapy  did  not  reduce  self-harm  at  zero  to  six
months follow-up compared with TAU (SMD −0.52, 95% CI −1.28 to
0.23; 1 trial, 28 participants; P = 0.18; Analysis 1.3.2); MD −4.71, 95%
CI −11.60 to 2.18; 1 trial, 28 participants; P = 0.18; Analysis 1.3.2).

Generally,  psychotherapy  did  not  reduce  self-harm  at  six  to  12
months follow-up compared with TAU (SMD −0.18, 95% CI −0.48 to
0.12; 3 trials, 174 participants; I2 = 0%; P = 0.64; Analysis 1.3.3).

No data were available for 12 months and over follow-up.

1.4 Self-harm (dichotomous)

Six trials reported dichotomous data on self-harm (Bateman 1999;
Bateman 2009; Bos 2010; Davidson 2006; Doering 2010; Rossouw
2012b).

Generally,  psychotherapy  did  not  reduce  self-harm  at  end  of
treatment compared with TAU (RR 0.85, 95% CI 0.63 to 1.14; 6 trials,
513 participants; I2 = 73%; P = 0.28; Analysis 1.4.1).

Generally, psychotherapy reduced self-harm at zero to six months
follow-up compared with TAU (RR 0.14, 95% CI 0.04 to 0.56; 1 trial;
P = 0.005; Analysis 1.4.2).

Generally,  psychotherapy  reduced  self-harm  at  six  to  12  months
follow-up compared with TAU (RR 0.27, 95% CI 0.10 to 0.68; 1 trial;
P = 0.006; Analysis 1.4.3).

Generally,  psychotherapy  reduced  self-harm  at  above  12  months
follow-up compared with TAU (RR 0.33, 95% CI 0.15 to 0.76; 1 trial,
41 participants; P = 0.009; Analysis 1.4.4).

1.5 Suicide-related outcomes (continuous)

Thirteen  trials  reported  continuous  data  on  suicide-related
outcomes 
(Amianto  2011;  Andreoli  2016;  Davidson  2006;
Feigenbaum  2012;  Gleeson  2012;  Gregory  2008b;  Koons  2001a;
Leppänen 2016; Linehan 2006; Mehlum 2014; Reneses 2013; Soler
2009; Weinberg 2006).

Generally, psychotherapy reduced suicide-related outcomes at end
of  treatment  compared  with  TAU  (SMD  −0.34,  95%  CI  −0.57  to
−0.11; 13 trials, 666 participants; I2 = 43%; P = 0.004; Analysis 1.5.1;
low-quality  evidence,  Summary  of  findings  1).  The  improvement

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

corresponded  to  a  clinical  effect  MD  of  −0.11  (95%  CI  −0.19  to
−0.034), on the Suicidal Attempt Self Injury Interview. The MIREDIF
on  this  scale  is  −0.17  points,  which  corresponds  to  ½  SD  (Farivar
2004).  Clinically,  this  represents  no  reduction  in  suicide-related
outcomes for people with BPD. The TSA analysis showed that the
required  information  size  was  reached  (n  =  253).  However,  we
cannot exclude the potential risk of type 1 error, and that there was
no  risk  of  type  1  error  (TSA  adjusted  confidence  interval  −0.18  to
−0.04) (see figure 8 in Appendix 6).

Inspection of the funnel plot (see figure 9 in Appendix 6) suggested
potential bias (asymmetry), and we found no evidence of possible
significant  publication  bias:  Egger’s  regression  intercept  (bias)
0.405 (two tailed, P = 0.735).

Generally, psychotherapy did not reduce suicide-related outcomes
at zero to six months follow-up compared with TAU (SMD −0.43, 95%
CI −1.10 to 0.23; 2 trials, 36 participants; I2 = 0%; P = 0.20; Analysis
1.5.2).

Generally, psychotherapy reduced suicide-related outcomes at six
to  12  months  follow-up  compared  with  TAU  (SMD  −0.42,  95%  CI
−0.80 to −0.04; 2 trials, 109 participants; I2 = 0%; P = 0.03; Analysis
1.5.3).

Generally, psychotherapy did not reduce suicide-related outcomes
at above 12 months follow-up compared with TAU (SMD −0.31, 95%
CI −0.77 to 0.14; 1 trial, 76 participants; P = 0.18; MD −1.15, 95% CI
−2.86 to 0.56; 1 trial, 76 participants; P = 0.19; Analysis 1.5.4).

1.6 Suicide-related outcomes (dichotomous)

Five trials reported dichotomous data on suicide-related outcomes
(Bateman 1999; Bateman 2009; Doering 2010; Philips 2018; Stanley
2017).

Generally, psychotherapy reduced suicide-related outcomes at end
of treatment compared with TAU (RR 0.27, 95% CI 0.11 to 0.67; 5
trials, 396 participants; I2 = 45%; P = 0.005; Analysis 1.6.1).

Generally, psychotherapy did not reduce suicide-related outcomes
at zero to six months follow-up compared with TAU (RR 0.25, 95%
CI 0.06 to 1.05; 1 trial, 41 participants; P = 0.06; Analysis 1.6.2).

Generally,  psychotherapy  reduced  suicide-related  outcomes  at
above 12 months follow-up compared with TAU (RR 0.29, 95% CI
0.11 to 0.74; 1 trial, 41 participants; P = 0.01; Analysis 1.6.3).

No data were available for six to 12 months follow-up.

1.7 Psychosocial functioning

Twenty-two  trials  reported  continuous  data  on  psychosocial
functioning (Amianto 2011; Andreoli 2016; Bateman 1999; Bateman
2009; Blum 2008; Borschmann 2013; Carter 2010; Davidson 2006;
Doering 2010; Farrell 2009; Feigenbaum 2012; Gleeson 2012; Gratz
2014; Gregory 2008b; Jochems 2015; Jørgensen 2013; Kramer 2016;
Linehan  1994;  Mehlum  2014;  Reneses  2013;  Salzer  2014;  Soler
2009).

Generally,  psychotherapy  improved  psychosocial  functioning  at
end  of  treatment  compared  with  TAU  (SMD  −0.45,  95%  CI  −0.68
to  −0.22;  22  trials,  1314  participants;  I2  =  72%;  P  =  0.0001;
Analysis 1.7.1; low-quality evidence, Summary of findings 1). This
corresponds  to  a  MD  of  −2.8  (95%  CI  −4.25  to  −1.38),  on  the  GAF

Cochrane Database of Systematic Reviews

scale,  which  ranges  from  0  to  100.  The  MIREDIF  on  this  scale  is
−4.0 points (Amri 2014). This finding does not represent a clinically
important  improvement  in  psychosocial  functioning  for  people
with  BPD.  The  TSA  analysis  showed  that  the  RIS  was  reached  (n
=  947),  and  that  there  was  no  risk  of  type  1  error  (TSA  adjusted
confidence interval −3.97 to −1.94) (see figure 10 in Appendix 6).

Inspection  of  the  funnel  plot  in  (see  figure  11  in  Appendix  6)
suggested potential bias (asymmetry), and we found no evidence
of possible significant publication bias: Egger’s regression intercept
(bias) 1.50 (two tailed, P = 0.241).

Generally,  psychotherapy  did  not 
improve  psychosocial
functioning  at  zero  to  six  months  follow-up  compared  with  TAU
(SMD −1.23, 95% CI −2.74 to 0.29; 1 trial, 9 participants; P = 0.11; MD
−15.80, 95% CI −2.74 to 0.29; 1 trial, 9 participants; P = 0.11; Analysis
1.7.2).

Generally,  psychotherapy  did  not 
improve  psychosocial
functioning at six to 12 months follow-up compared with TAU (SMD
−0.09, 95% CI −0.40 to 0.23; 3 trials, 247 participants; I2 = 30%; P =
0.59; Analysis 1.7.3).

Generally,  psychotherapy  did  not 
improve  psychosocial
functioning at above 12 months follow-up compared with TAU (SMD
−0.27, 95% CI −0.60 to 0.05; 6 trials, 499 participants; I2 = 60%; P =
0.10; Analysis 1.7.4).

Secondary outcomes

1.8 Anger

Eight  trials  reported  continuous  data  on  anger  (Amianto  2011;
Feigenbaum  2012;  Gleeson  2012;  Koons  2001a;  Leppänen  2016;
Linehan 1994; Linehan 2006; Soler 2009)

Generally,  psychotherapy  reduced  anger  at  end  of  treatment
compared with TAU (SMD −0.38, 95% CI −0.64 to −0.12; 8 trials, 323
participants; I2 = 21%; P = 0.005; Analysis 1.8.1).

Generally, psychotherapy did not reduce anger at zero to six months
follow-up compared with TAU (SMD −1.20, 95% CI −2.82 to 0.41; 1
trial, 8 participants; P = 0.14; MD −4.50, 95% CI −9.01 to 0.01; 1 trial,
8 participants; P = 0.05; Analysis 1.8.2).

Generally, psychotherapy did not reduce anger at six to 12 months
follow-up compared with TAU (SMD −0.12, 95% CI −0.50 to 0.25; 2
trials, 111 participants; I2 = 0%; P = 0.52; Analysis 1.8.3).

Generally, psychotherapy did not reduce anger at above 12 months
follow-up  compared  with  TAU  (SMD  0.02,  95%  CI  −0.42  to  0.46;  1
trial, 80 participants; P = 0.93; MD 0.01, 95% CI −0.20 to 0.22; 1 trial,
80 participants; P = 0.93; Analysis 1.8.4).

1.9 Affective instability

Twelve  trials  reported  continuous  data  on  affective  instability
(Amianto 2011; Bianchini 2019; Blum 2008; Farrell 2009; Gratz 2006;
Gratz  2014;  Leppänen  2016;  Morton  2012;  Reneses  2013;  Salzer
2014; Schuppert 2012; Soler 2009).

Generally,  psychotherapy  improved  affective  instability  at  end  of
treatment compared with TAU (SMD −0.68, 95% CI −0.98 to −0.39;
12 trials, 620 participants; I2 = 65%; P < 0.001; (Analysis 1.9.1).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Generally, psychotherapy did not improve affective instability at six
to  12  months  follow-up  compared  with  TAU  (SMD  −0.52,  95%  CI
−1.21 to 0.18; 1 trial, 33 participants; P = 0.15; MD −0.70, 95% CI −1.59
to 0.19; 1 trial, 33 participants; P = 0.12; Analysis 1.9.2).

No data were available for zero to six months and above 12 months
follow-up.

1.10 Chronic feelings of emptiness

Four  trials  reported  continuous  data  on  chronic  feelings  of
emptiness  (Amianto  2011;  Leppänen  2016;  Reneses  2013;  Soler
2009).

Generally, psychotherapy improved chronic feelings of emptiness
at end of treatment compared with TAU (SMD −0.39, 95% CI −0.69 to
−0.10; 4 trials, 187 participants; I2 = 0%; P = 0.009; Analysis 1.10.1).

Generally,  psychotherapy  did  not  improve  chronic  feelings  of
emptiness at six to 12 months follow-up compared with TAU (SMD
−0.58,  95%  CI  −1.28  to  0.11;  1  trial,  37  participants;  P  =  0.10;  MD
−0.60, 95% CI −1.39 to 0.09; 1 trial, 33 participants; P = 0.09; Analysis
1.10.2).

No data were available for zero to six months and above 12 months
follow-up.

1.11 Impulsivity (continuous)

Generally, psychotherapy improved interpersonal problems at end
of treatment compared with TAU (SMD −0.42, 95% CI −0.68 to −0.16;
18 trials, 1159 participants; I2 = 77%; P = 0.002; Analysis 1.13.1).

Generally, psychotherapy did not improve interpersonal problems
at zero to six months follow-up compared with TAU (SMD −0.41, 95%
CI −1.01 to 0.20; 1 trial, 53 participants; P = 0.19; MD −0.30, 95% CI
−0.76 to 0.16; 1 trial, 53 participants; P = 0.20; Analysis 1.13.2).

Generally, psychotherapy did not improve interpersonal problems
at six to 12 months follow-up compared with TAU (SMD −0.17, 95%
CI −0.65 to 0.32; 1 trial, 132 participants; I2 = 39%; P = 0.50; Analysis
1.13.3).

Generally, psychotherapy did not improve interpersonal problems
at above 12 months follow-up compared with TAU (SMD 0.00, 95%
CI −0.54 to 0.54; 2 trials, 172 participants; I2 = 65%; P = 1.00; Analysis
1.13.4).

1.14 Abandonment

Two  trials  reported  continuous  data  on  abandonment  (Amianto
2011; Leppänen 2016).

Generally, psychotherapy did not improve abandonment at end of
treatment compared with TAU (SMD −0.22, 95% CI −0.66 to 0.21; 2
trials, 84 participants; I2 = 0%; P = 0.32; Analysis 1.14.1).

Ten  studiies  reported  continuous  data  on  impulsivity  (Amianto
2011;  Bianchini  2019;  Blum  2008;  Farrell  2009;  Gratz  2006;  Gratz
2014;  Leppänen  2016;  Reneses  2013;  Soler  2009;  Van  den  Bosch
2005).

Generally, psychotherapy did not improve abandonment at six to
12 months follow-up compared with TAU (SMD −0.39, 95% CI −1.08
to 0.30; 1 trial, 33 participants; P = 0.27; MD -−0.39, 95% CI −1.08 to
0.30; 1 trial, 33 participants; P = 0.25; Analysis 1.14.2).

Generally, psychotherapy improved impulsivity at end of treatment
compared with TAU (SMD −0.54, 95% CI −0.84 to −0.25; 10 trials, 491
participants; I2 = 58%; P = 0.0003; Analysis 1.11.1).

No data were available for zero to six months and above 12 months
follow-up.

1.15 Identity disturbance

Generally, psychotherapy did not improve impulsivity at six to 12
months follow-up compared with TAU (SMD 0.32, 95% CI −0.13 to
0.77; 2 trials, 77 participants; I2 = 0%; P = 0.16; Analysis 1.11.2).

No data were available for zero to six months and above 12 months
follow-up.

Four  trials  reported  continuous  data  on  identity  disturbance
(Amianto 2011; Leichsenring 2016; Leppänen 2016; Reneses 2013).

Generally, psychotherapy did not improve identity disturbance at
end of treatment compared with TAU (SMD −0.37, 95% CI −0.84 to
0.10; 4 trials, 250 participants; I2 = 65%; P = 0.12; Analysis 1.15.1).

1.12 Impulsivity (dichotomous)

One trial reported dichotomous data on impulsivity (Bos 2010).

Generally,  psychotherapy  did  not  improve  impulsivity  at  end  of
treatment compared with TAU (RR 0.93, 95% CI 0.66 to 1.29; 1 trial,
58 participants; P = 0.65; Analysis 1.12).

Generally, psychotherapy improved identity disturbance at six to 12
months follow-up compared with TAU (SMD −1.09, 95% CI −1.83 to
−0.35; 1 trial, 33 participants; P = 0.004; MD −1.40, 95% CI −2.25 to
−0.55; 1 trial, 33 participants; P = 0.001; Analysis 1.15.2).

No data were available for zero to six months and above 12 months
follow-up.

No data were available for zero to six months, six to 12 months, and
above 12 months follow-up.

1.16 Dissociation and psychotic-like symptoms

1.13 Interpersonal problems

Eighteen  trials  reported  continuous  data  on 
interpersonal
problems  (Amianto  2011;  Bateman  1999;  Bateman  2009;  Blum
2008;  Bos  2010;  Carter  2010;  Davidson  2006;  Farrell  2009;  Gratz
2014; Jørgensen 2013; Kramer 2016; Laurenssen 2018; Leichsenring
2016; Leppänen 2016; Philips 2018; Reneses 2013; Salzer 2014; Soler
2009).

Six trials reported continuous data on dissociation and psychotic-
like  symptoms  (Amianto  2011;  Blum  2008;  Farrell  2009;  Gleeson
2012; Gregory 2008b; Kredlow 2017a).

Generally, psychotherapy improved dissociation and psychotic-like
symptoms  at  end  of  treatment  compared  with  TAU  (SMD  −0.47,
95% CI −0.85 to −0.10; 6 trials, 244 participants; I2 = 38%; P = 0.01;
Analysis 1.16.1).

Generally, psychotherapy improved dissociation and psychotic-like
symptoms at zero to six months follow-up compared with TAU (SMD

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

0.97,  95%  CI  −1.69  to  −0.26;  2  trials,  35  participants;  I2  =  0%;  P  =
0.008; Analysis 1.16.2).

Generally,  psychotherapy  did  not 
improve  dissociation  and
psychotic-like symptoms at six to 12 months follow-up compared
with TAU (SMD −0.59, 95% CI −1.29 to 0.11; 1 trial, 33 participants;
P = 0.10; MD −0.70, 95% CI −1.59 to 0.09; 1 trial, 33 participants; P =
0.08; Analysis 1.16.3).

improve  dissociation  and
Generally,  psychotherapy  did  not 
psychotic-like symptoms at above 12 months follow-up compared
with TAU (SMD −0.01, 95% CI −0.81 to 0.79; 1 trial, 24 participants;
P = 0.98; MD -−0.20, 95% CI −20.07 to 19.67; 1 trial, 24 participants;
P = 0.98; Analysis 1.16.4).

1.17 Depression (continuous)

Twenty-two  trials  reported  continuous  data  on  depression
(Andreoli  2016;  Bateman  1999;  Bateman  2009;  Blum  2008;
Borschmann  2013;  Davidson  2006;  Davidson  2014;  Doering
2010;  Gleeson  2012;  Gratz  2006;  Gratz  2014;  Gregory  2008b;
Jahangard 2012; Jørgensen 2013; Kredlow 2017a; Laurenssen 2018;
Leichsenring 2016; Leppänen 2016; McMurran 2016; Morton 2012;
Reneses 2013; Zanarini 2018).

Generally, psychotherapy improved depression at end of treatment
compared to TAU (SMD −0.39, 95% CI −0.61 to −0.17; 22 trials, 1568
participants; I2 = 75%; P = 0.0006; Analysis 1.17.1; very low-quality
evidence, Summary of findings 1). This corresponds to −2.45 on the
Hamilton Depression Scale. The MIREDIF on this scale is 3.0 points
(NICE CG90). However, the TSA analysis showed that the RIS was
not reached (n = 2274), and that there was a potential risk of type
1 error (TSA adjusted confidence interval −3.34 to −1.72) (see figure
12 in Appendix 6).

Generally,  psychotherapy  improved  depression  at  zero  to  six
months follow-up compared with TAU (SMD −0.80, 95% CI −1.26 to
−0.34; 4 trials, 125 participants; I2 = 23%; P = 0.0006; Analysis 1.17.2).

Generally, psychotherapy did not improve depression at six to 12
months follow-up compared with TAU (SMD −0.40, 95% CI −0.95 to
0.16; 3 trials, 260 participants; I2 = 77%; P = 0.16; Analysis 1.17.3).

Generally, psychotherapy improved depression at above 12 months
follow-up compared with TAU (SMD −0.40, 95% CI -0.74 to −0.06; 5
trials, 311 participants; I2 = 47%; P = 0.02; Analysis 1.17.4).

1.18 Depression (dichotomous)

Cochrane Database of Systematic Reviews

Jørgensen  2013;  Koons  2001a;  Kramer  2016;  Laurenssen  2018;
Leichsenring  2016;  Leppänen  2016;  Linehan  1991;  Linehan  1994;
Linehan  2006;  Morton  2012;  Philips  2018;  Priebe  2012;  Reneses
2013; Robinson 2016; Rossouw 2012b; Stanley 2017; Van den Bosch
2005; Zanarini 2018).

Generally,  psychotherapy  did  not  reduce  attrition  at  end  of
treatment  compared  with  TAU  (RR  1.00,  95%  CI  0.83  to  1.20;  32
trials,  2225  participants;  I2  =  50%;  P  =  0.98;  Analysis  1.19.1;  low-
quality evidence, Summary of findings 1).

Generally,  psychotherapy  reduced  attrition  at  zero  to  six  months
follow-up compared with TAU (RR 0.58, 95% CI 0.34 to 1.00; 1 trial,
60 participants; P = 0.05; Analysis 19.2.2).

No data were available for six to 12 months and above 12 months
follow-up.

1.20 Non-serious adverse effects

Two  trials  reported  dichotomous  data  on  non-adverse  effects
(McMurran 2016; Stanley 2017).

There  was  no  clear  difference  in  the  number  of  serious  adverse
effects  between  psychotherapy  and  TAU  at  end  of  treatment  (RR
0.92, 95% CI 0.45 to 1.88; 2 trials, 381 participants, P = 0.81; Analysis
1.20.1; low-quality evidence, Summary of findings 1).

There  was  no  clear  difference  in  the  number  of  adverse  effects
between psychotherapy and TAU at zero to six months follow-up
(RR  1.40,  95%  CI  0.06  to  30.23;  1  trial,  20  participants;  P  =  0.83;
Analysis 1.20.2).

TAU  reduced  adverse  effects  compared  with  psychotherapy  at
above 12 months follow-up (RR 1.68, 95% CI 1.34 to 2.10; 1 trial, 183
participants; P < 0.001; Analysis 1.20.3).

No data were available for six to 12 months follow-up.

1.21 Serious adverse effects

Five  trials  reported  dichotomous  data  on  serious  adverse  effects
(Andreoli  2016;  Davidson  2014;  McMurran  2016;  Robinson  2016;
Stanley 2017).

There  was  no  clear  difference  in  the  number  of  serious  adverse
effects between psychotherapy and TAU at end of treatment ( RR
0.86, 95% CI 0.14 to 5.09; 4 trials, 571 participants, I2 = 46%, P = 0.86;
Analysis 1.21).

One  trial  reported  dichotomous  data  on  depression  (Rossouw
2012b).

No data were available for zero to six months, six to 12 months and
above 12 months.

Generally,  psychotherapy  did  not  improve  depression  at  end  of
treatment compared with TAU (RR 0.71, 95% CI 0.49 to 1.03; 1 trial,
80 participants; P = 0.08; Analysis 1.18).

2. Acceptance and commitment therapy (ACT) versus
treatment-as-usual (TAU)

2.1 Primary outcome: BPD symptom severity

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Morton 2012).

1.19 Attrition

Thirty-two trials reported dichotomous data on attrition (Amianto
2011;  Andreoli  2016;  Bateman  1999;  Bateman  2009;  Borschmann
2013; Bos 2010; Carter 2010; Davidson 2006; Doering 2010; Farrell
2009;  Feigenbaum  2012;  Gleeson  2012;  Gratz  2006;  Gratz  2014;

ACT reduced BPD symptom severity at end of treatment compared
with TAU (MD −14.66, 95% CI −21.85 to −7.47; 1 trial, 41 participants;
P < 0.001; Analysis 2.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

No  data  were  available  at  any  time  point  for  self-harm,  suicide-
related outcomes, and psychosocial functioning.

Secondary outcomes

2.2 Affective instability

One trial reported continuous data on affective instability (Morton
2012).

ACT reduced affective instability at end of treatment compared with
TAU (MD −27.00, 95% CI −38.86 to −15.14; 1 trial, 41 participants; P
< 0.001; Analysis 2.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

2.3 Depression

One trial reported continuous data on depression (Morton 2012).

ACT reduced depression at end of treatment compared with TAU
(MD −8.33, 95% CI −15.65 to −1.01; 1 trial, 41 participants; P = 0.03;
Analysis 2.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

2.4 Attrition

One trial reported dichotomous data on attrition (Morton 2012).

ACT  did  not  reduce  attrition  at  end  of  treatment  compared  with
TAU (RR 1.11, 95% CI 0.45 to 2.74; 1 trial, 41 participants; P = 0.82;
Analysis 2.4).

No data were available for zero to months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  chronic
feelings of emptiness, impulsivity, interpersonal problems, identity
disturbance,  dissociation  and  psychotic-like  symptoms  and
adverse effects.

3. Dialectical behaviour therapy (DBT) versus treatment-as-
usual (TAU)

Primary outcomes

3.1 BPD symptom severity

Three  trials  reported  continuous  data  on  BPD  symptom  severity
(Koons 2001a; Priebe 2012; Soler 2009).

DBT reduced BPD symptom severity at end of treatment compared
with  TAU  (SMD  −0.60,  95%  CI  −1.05  to  −0.14;  3  trials,  149
participants; I2 = 42%; P = 0.01; Analysis 3.1; low-quality evidence,
Summary of findings 3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

3.2 Self-harm

Seven  trials  reported  continuous  data  on  self-harm  (Carter  2010;
Feigenbaum  2012;  Koons  2001a;  Linehan  1991;  Linehan  2006;
Priebe 2012; Van den Bosch 2005).

Cochrane Database of Systematic Reviews

DBT  reduced  self-harm  at  end  of  treatment  compared  with  TAU
(SMD −0.28, 95% CI −0.48 to −0.07; 7 trials, 376 participants; I2 = 0%;
P = 0.008; Analysis 3.2.1; low-quality evidence, Summary of findings
3).

DBT  did  not  reduce  self-harm  at  six  to  12  months  follow-up
compared with TAU (SMD −0.26, 95% CI −0.59 to 0.07; 2 trials, 141
participants; I2 = 0%; P = 0.13; Analysis 3.2.2).

No data were available for zero to six months and above 12 months
follow-up.

3.3 Suicide-related outcomes

Five trials reported continuous data on suicide-related outcomes
(Feigenbaum 2012; Koons 2001a; Linehan 2006; Mehlum 2014; Soler
2009).

DBT did not reduce suicide-related outcomes at end of treatment
compared with TAU (SMD −0.23, 95% CI −0.68 to 0.23; 5 trials, 231
participants; I2 = 58%; P = 0.33; Analysis 3.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

3.4 Suicide-related outcomes, attempts

One trial reported dichotomous data on suicide-related outcomes
(Stanley 2017).

DBT did not reduce suicide-related outcomes at end of treatment
compared  with  TAU  (RR  0.51,  95%  CI  0.14  to  1.90;  1  trial,  75
participants; P = 0.32; Analysis 3.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

3.5 Psychosocial functioning

Six  trials  reported  continuous  data  on  psychosocial  functioning
(Carter  2010;  Feigenbaum  2012;  Kramer  2016;  Linehan  1994;
Mehlum 2014; Soler 2009).

DBT  improved  psychosocial  functioning  at  end  of  treatment
compared with TAU (SMD −0.36, 95% CI −0.69 to −0.03; 6 trials, 225
participants; I2 = 31%; P = 0.03; Analysis 3.5; low-quality evidence,
Summary of findings 3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Secondary outcomes

3.6 Anger

Five trials reported continuous data on anger (Feigenbaum 2012;
Koons 2001a; Linehan 1994; Linehan 2006; Soler 2009).

DBT reduced anger at end of treatment compared with TAU (SMD
−0.47, 95% CI −0.86 to −0.09; 5 trials, 230 participants; I2 = 46%; P =
0.02; Analysis 3.6.1).

DBT did not reduce anger at six to 12 months follow-up compared
with TAU (SMD −0.17, 95% CI −0.62 to 0.27; 1 trial, 78 participants;
P = 0.44; MD −0.10, 95% CI −0.36 to 0.16; 1 trial, 78 participants; P =
0.45; Analysis 3.6.2).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

DBT did not reduce anger at above 12 months follow-up compared
with TAU (SMD 0.02, 95% CI −0.42 to 0.46; 1 trial, 80 participants; P =
0.93; MD 0.01, 95% CI −0.20 to 0.22; 1 trial, 79 participants; P = 0.93;
Analysis 3.6.3).

3.11 Dissociation and psychotic-like symptoms

Four trials reported continuous data on dissociation and psychotic-
like symptoms (Feigenbaum 2012; Koons 2001a; Priebe 2012; Soler
2009).

No data were available for zero to six months follow-up.

3.7 Affective instability

Two  trials  reported  continuous  data  on  affective  instability
(Bianchini 2019; Soler 2009).

DBT  did  not  reduce  affective  instability  at  end  of  treatment
compared with TAU (SMD −0.57, 95% CI −1.64 to 0.51; 2 trials, 80
participants; I2 = 78%; P = 0.30; Analysis 3.7; random-effects model).

DBT  reduced  affective  instability  at  end  of  treatment  compared
with TAU (SMD -0.75, 95% CI−1.21 to −0.28; 2 trials, 80 participants;
I2 = 78%; P = 0.002; analysis not shown; fixed-effect model).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

3.8 Chronic feelings of emptiness

One trial reported continuous data on chronic feelings of emptiness
(Soler 2009).

DBT  did  not  reduce  chronic  feelings  of  emptiness  at  end  of
treatment compared with TAU (MD −0.67, 95% CI −1.45 to 0.11; 1
trial, 59 participants; P = 0.09; Analysis 3.8).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

3.9 Impulsivity

Three  trials  reported  continuous  data  on  impulsivity  (Bianchini
2019; Soler 2009; Van den Bosch 2005).

DBT reduced impulsivity at end of treatment compared with TAU
(SMD −0.35, 95% CI −0.71 to −0.00; 3 trials, 128 participants; I2 = 0%;
P = 0.05; Analysis 3.9.1).

DBT  did  not  reduce  impulsivity  at  six  to  12  months  follow-up
compared  with  TAU  (SMD  0.30,  95%  CI  −0.30  to  0.90;  1  trial,  44
participants;  P  =  0.33;  MD  0.23,  95%  CI  −0.24  to  0.70;  1  trial,  454
participants; P = 0.33; Van den Bosch 2005; Analysis 3.9.2).

DBT reduced dissociation and psychotic-like symptoms at end of
treatment compared with TAU (SMD −0.45, 95% CI −0.73 to −0.16; 4
trials, 194 participants; I2 = 0%; P = 0.002; Analysis 3.11).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

3.12 Depression

Five  trials  reported  continuous  data  on  depression  (Feigenbaum
2012; Koons 2001a; Linehan 2006; Mehlum 2014; Soler 2009).

DBT did not reduce depression at end of treatment compared with
TAU (SMD −0.47, 95% CI −0.98 to 0.03; 5 trials, 219 participants; I2 =
64%; P = 0.07; Analysis 3.12.1; random-effects model).

DBT reduced depression at end of treatment compared with TAU
(SMD −0.46, 95% CI −0.73 to −0.18; 5 trials, 219 participants; I2 = 64%;
P = 0.001; analysis not shown; fixed-effect model).

DBT  did  not  reduce  depression  at  six  to  12  months  follow-up
compared  with  TAU  (SMD  −0.23,  95%  CI  −0.67  to  0.21;  1  trial,  81
participants;  P  =  0.31;  MD  −1.80,  95%  CI  −5.40  to  1.80;  1  trial,  81
participants; P = 0.33; Analysis 3.12.2).

No data were available for zero to six months and above 12 months
follow-up.

3.13 Attrition

Eleven trials reported dichotomous data on attrition (Carter 2010;
Feigenbaum  2012;  Koons  2001a;  Kramer  2016;  Linehan  1991;
Linehan 1994; Linehan 2006; Priebe 2012; Soler 2009; Stanley 2017;
Van den Bosch 2005).

DBT did not reduce attrition at end of treatment compared with TAU
(RR 1.27, 95% CI 0.70 to 2.31; 10 trials, 217 participants; I2 = 81%; P
= 0.42; Analysis 3.13.1).

DBT  reduced  attrition  at  zero  to  six  months  follow-up  compared
with TAU (RR 0.58, 95% CI 0.34 to 1.00; 1 trial, 60 participants; P =
0.05; Analysis 3.13.2).

No data were available for zero to six months and above 12 months
follow-up.

No data were available for six to 12 months and above 12 months
follow-up.

3.10 Interpersonal problems

3.14 Adverse effects

Three  trials  reported  continuous  data  on  interpersonal  problems
(Carter 2010; Kramer 2016; Soler 2009).

One  trial  reported  dichotomous  data  on  adverse  effects  (Stanley
2017).

DBT  did  not  reduce  interpersonal  problems  at  end  of  treatment
compared with TAU (SMD −0.12, 95% CI −0.45 to 0.20; 3 trials, 148
participants; I2 = 0%; P = 0.45; Analysis 3.10).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

There  were  no  adverse  effects  at  end  of  treatment  in  any  of  the
groups (effect not estimable; 1 trial, 75 participants; Analysis 3.14).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

3.15 Serious adverse effects

One  trial  reported  dichotomous  data  on  serious  adverse  effects
(Stanley 2017).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

There  was  no  clear  difference  in  the  number  of  serious  adverse
effects at end of treatment (RR 0.51, 95% CI 0.05 to 5.42; 1 trial, 75
participants; P = 0.58; Analysis 3.15).

MBT  reduced  self-harm  at  above  12  months  follow-up  compared
with TAU (RR 0.33, 95% CI 0.15 to 0.76; 1 trial, 41 participants; P =
0.009; Analysis 4.3.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  abandonment  and
identity disturbance.

4. Mentalisation-based therapy (MBT) versus treatment-as-
usual (TAU)

Primary outcomes

4.1 BPD symptom severity

Six  trials  reported  continuous  data  on  BPD  symptom  severity
(Bateman  1999;  Jørgensen  2013;  Laurenssen  2018;  Philips  2018;
Robinson 2016; Rossouw 2012b).

MBT  did  not  reduce  BPD  symptom  severity  at  end  of  treatment
compared with TAU (SMD −0.13, 95% CI −0.38 to 0.11; 5 trials, 267
participants; I2 = 0%; P = 0.28; Analysis 4.1.1).

MBT did not reduce BPD symptom severity at zero to six months
follow-up compared with TAU (SMD −0.40, 95% CI −1.49 to 0.68; 1
trial, 15 participants; P = 0.47; MD −2.90, 95% CI −10.87 to 5.07; 1
trial, 15 participants; P = 0.48; Analysis 4.1.2).

Above  12  months  follow-up:  MBT  did  not  reduce  BPD  symptom
severity  at  above  12  months  follow-up  compared  with  TAU  (SMD
−0.94, 95% CI −2.58 to 0.70; 2 trials, 97 participants; I2 = 92%; P =
0.26; Analysis 4.1.3; random-effects model).

Above 12 months follow-up: MBT reduced BPD symptom severity at
above 12 months follow-up compared with TAU (SMD −0.76, 95% CI
−1.22 to −0.30; 2 trials, 97 participants; I2 = 92%; P = 0.001; analysis
not shown; fixed-effect model).

No data were available for six to 12 months follow-up.

4.2 Self-harm (continuous)

One trial reported continuous data on self-harm (Philips 2018).

4.4 Suicide-related outcomes

Three  trials  reported  dichotomous  data  on  suicide-related
outcomes (Bateman 1999; Bateman 2009; Philips 2018).

MBT  reduced  suicide-related  outcomes  at  end  of  treatment
compared  with  TAU  (RR  0.10,  95%  CI  0.04  to  0.30;  3  trials,  218
participants; I2 = 0%; P < 0.001; Analysis 4.4.1; low-quality evidence,
Summary of findings 3).

MBT did not reduce suicide-related outcomes at zero to six months
follow-up compared with TAU (RR 0.25, 95% CI 0.06 to 1.05; 1 trial,
41 participants; P = 0.06; Analysis 4.4.2).

MBT reduced suicide-related outcomes at above 12 months follow-
up  compared  with  TAU  (RR  0.29,  95%  CI  0.11  to  0.74;  1  trial,  41
participants; P < 0.001; Analysis 4.4.3).

No data were available for six to 12 months follow-up.

4.5 Psychosocial functioning

Three trials reported continuous data on psychosocial functioning
(Bateman 1999; Bateman 2009; Jørgensen 2013).

MBT did not improve psychosocial functioning at end of treatment
compared  with  TAU  (SMD  −0.54,  95%  CI  −1.24  to  0.16;  3  trials,
239 participants; I2 = 83%; P = 0.13; Analysis 4.5.1; random-effects
model).

MBT  improved  psychosocial  functioning  at  end  of  treatment
compared with TAU (SMD −0.53, 95% CI −0.79 to −0.27; 3 trials, 239
participants; I2 = 83%; P < 0.0001; analysis not shown; fixed-effect
model).

MBT did not improve psychosocial functioning at above 12 months
follow-up compared with TAU (SMD −0.41, 95% CI −0.97 to 0.15; 2
trials, 104 participants; I2 = 47%; P = 0.1507; Analysis 4.5.2).

No data were available for zero to six months and six to 12 months
follow-up.

MBT did not reduce self-harm at end of treatment compared with
TAU (MD 0.10, 95% CI −4.02 to 4.22; 1 trial, 24 participants; P = 0.96;
Analysis 4.2.1).

Secondary outcomes

4.6 Interpersonal problems

4.3 Self-harm (dichotomous)

Three  trials  reported  dichotomous  data  on  self-harm  (Bateman
1999; Bateman 2009; Rossouw 2012b).

MBT  reduced  self-harm  at  end  of  treatment  compared  with  TAU
(RR 0.62, 95% CI 0.49 to 0.80; 3 trials, 252 participants; I2 = 7%; P =
0.0002; Analysis 4.3.1; low-quality evidence, Summary of findings
3).

MBT reduced self-harm at zero to six months follow-up compared
with TAU (RR 0.14, 95% CI 0.04 to 0.56; 1 trial, 41 participants; P =
0.005; Analysis 4.3.2).

MBT  reduced  self-harm  at  six  to  12  months  follow-up  compared
with TAU (RR 0.27, 95% CI 0.10 to 0.68; 1 trial, 41 participants; P =
0.006; Analysis 4.3.3).

Five  trials  reported  continuous  data  on  interpersonal  problems
(Bateman 1999; Bateman 2009; Jørgensen 2013; Jørgensen 2013;
Philips 2018).

MBT  reduced 
interpersonal  problems  at  end  of  treatment
compared with TAU (SMD −0.68, 95% CI −1.33 to −0.02; 5 trials, 357
participants; I2 = 87%; P = 0.04; Analysis 4.6.1).

MBT did not reduce interpersonal problems at zero to six months
follow-up compared with TAU (SMD −0.41, 95% CI −1.01 to 0.20; 1
trial, 53 participants; P = 0.19; MD −0.30, 95% CI −0.76 to 0.16; 1 trial,
53 participants; P = 0.20; Analysis 4.6.2).

MBT  did  not  reduce  interpersonal  problems  at  above  12  months
follow-up compared with TAU (SMD −0.28, 95% CI −0.71 to 0.14; 2
trials, 96 participants; I2 = 0%; P = 0.19; Analysis 4.6.3).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

No data were available for six to 12 months follow-up.

4.7 Depression (continuous)

Four trials reported continuous data on depression (Bateman 1999;
Bateman 2009; Jørgensen 2013; Laurenssen 2018).

MBT did not reduce depression at end of treatment compared with
TAU (SMD −0.58, 95% CI −1.22 to 0.05; 4 trials, 333 participants; I2 =
86%; P = 0.07; Analysis 4.7.1; random-effects model).

MBT reduced depression at end of treatment compared with TAU
(SMD −0.38, 95% CI − 0.60 to −0.16; 4 trials, 333 participants; I2 =
86%; P = 0.0009; analysis not shown; fixed-effect model).

MBT  did  not  reduce  depression  at  zero  to  six  months  follow-up
compared  with  TAU  (SMD  −0.81,  95%  CI  −1.69  to  0.07;  2  trials,
91 participants; I2 = 72%; P = 0.07; Analysis 4.7.2; random-effects
model).

MBT reduced depression at zero to six months follow-up compared
with TAU (SMD −0.76, 95% CI −1.22 to − 0.30; 2 trials, 91 participants;
I2 = 72%; P = 0.001; analysis not shown; fixed-effect model).

MBT reduced depression at six to 12 months follow-up compared
with TAU (SMD −1.17, 95% CI −1.88 to −0.45; 1 trial, 37 participants;
P = 0.001; MD −8.20, 95% CI -12.96 to −3.44; 1 trial, 37 participants;
P = 0.0007; Analysis 4.7.3).

MBT  did  not  reduce  depression  at  above  12  months  follow-up
compared  with  TAU  (SMD  −0.72,  95%  CI  −1.55  to  0.10;  2  trials,
90 participants; I2 = 68%; P = 0.08; Analysis 4.7.4; random-effects
model).

MBT reduced depression at above 12 months follow-up compared
with TAU (SMD −0.68, 95% CI −1.14 to − 0.22; 2 trials, 90 participants;
I2 = 68%; P = 0.004; analysis not shown; fixed-effect model).

4.8 Depression (dichotomous)

One  trial  reported  dichotomous  data  on  depression  (Rossouw
2012b).

MBT did not reduce depression at end of treatment compared with
TAU (RR 0.71, 95% CI 0.49 to 1.03; 1 trial, 80 participants; P = 0.08;
Analysis 4.8.1).

No data were available for zero to six months, six to 12 months, and
above 12 months follow-up.

4.9 Attrition

Seven  trials  reported  dichotomous  data  on  attrition  (Bateman
1999;  Bateman  2009;  Jørgensen  2013;  Laurenssen  2018;  Philips
2018; Robinson 2016; Rossouw 2012b).

MBT  did  not  reduce  attrition  at  end  of  treatment  compared  with
TAU (RR 0.99, 95% CI 0.79 to 1.25; 7 trials, 552 participants; I2 = 0%;
P = 0.96; Analysis 4.9.1).

No data were available for zero to six months, six to 12 months, and
above 12 months follow-up.

4.10 Adverse effects

One  trial  reported  dichotomous  data  on  serious  adverse  effects
(Robinson 2016).

Cochrane Database of Systematic Reviews

There was no clear difference in terms of severe adverse effects at
end  of  treatment  (RR  3.00,  95%  CI  0.13  to  71.15;  1  trial,  P  =  0.50;
Analysis 4.10).

No data were available for zero to six months, six to 12 months, and
above 12 months follow-up.

*  No  data  were  available  on  any  time  point  for  anger,
affective  instability,  chronic  feelings  of  emptiness,  impulsivity,
abandonment,  identity  disturbance,  dissociation  and  psychotic-
like symptoms.

4.11 Mentalisation-based treatment for eating disorders (MBT-
ED) versus specialist supportive clinical management (SSCM-ED)
(generic inverse variance)

Primary outcome: psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Robinson 2016).

MBT-ED  did  not  improve  psychosocial  functioning  at  end  of
treatment compared with SSCM-ED (MD −0.07, 95% CI −0.86 to 0.72;
1 trial, 23 participants; P = 0.86; Analysis 4.11.1).

MBT-ED  did  not  improve  psychosocial  functioning  at  zero  to  six
months follow-up compared with SSCM-ED (MD −0.44, 95% CI −1.52
to 0.64; 1 trial, 15 participants; P = 0.42 Analysis 4.11.2).

No data were available for six to 12 months and above 12 months
follow-up.

No data were available on any time point for BPD symptom severity,
self-harm and suicide-related outcomes.

Secondary outcomes

Interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(Robinson 2016).

MBT-ED did not reduce interpersonal problems at end of treatment
compared with SSCM-ED (MD −0.10, 95% CI −0.89 to 0.69; 1 trial, 23
participants; P = 0.80; Analysis 4.11.3).

MBT-ED  did  not  reduce  interpersonal  problems  at  zero  to  six
months follow-up compared with SSCM-ED (MD −0.06, 95% CI −1.15
to 1.03; 1 trial, 15 participants; P = 0.91; Analysis 4.11.4).

No data were available for six to 12 months and above 12 months
follow-up.

Depression

One trial reported continuous data on depression (Robinson 2016).

MBT-ED did not reduce depression at end of treatment compared
with SSCM-ED (MD 0.19, 95% CI −0.60 to 0.98; 1 trial, 23 participants;
P = 0.64; Analysis 4.11.5).

MBT-ED did not reduce depression at zero to six months follow-up
compared with SSCM-ED (MD 0.51, 95% CI −0.62 to 1.64; 1 trial, 15
participants; P = 0.38; Analysis 4.11.6).

No data were available for six to 12 months and above 12 months
follow-up.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

for  anger,
No  data  were  available  on  any 
affective  instability,  chronic  feelings  of  emptiness,  impulsivity,
abandonment,  identity  disturbance,  dissociation  and  psychotic-
like symptoms, attrition and adverse effects.

time  point 

5. Cognitive behaviour therapy (CBT) versus treatment-as-
usual (TAU)

Primary outcomes

5.1 BPD symptom severity (continuous)

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Kredlow 2017a).

CBT reduced BPD symptom severity at end of treatment compared
with TAU (MD −3.08, 95% CI −4.99 to −1.17; 1 trial, 26 participants; P
= 0.002; Analysis 5.1.1) (random-effects model analysis).

CBT did not reduce suicide-related outcomes at end of treatment
compared with TAU (SMD −0.47, 95% CI −1.02 to 0.08; 2 trials, 104
participants; P = 0.09; Analysis 5.5.1; random-effects model).

CBT  reduced  suicide-related  outcomes  at  end  of  treatment
compared  with  TAU  (SMD  −0.42,  95%  −0.81,  −0.02;  2  trials,  104
participants; P = 0.04; analysis not shown; fixed-effect model).

CBT did not reduce suicide-related outcomes at zero to six months
follow-up compared with TAU (SMD −0.45, 95% CI −1.20 to 0.31; 1
trial, 28 participants; P = 0.25; MD −7.73, 95% CI −20.00 to 4.54; 1
trial, 28 participants; P = 0.22; Analysis 5.5.2).

CBT did not reduce suicide-related outcomes at six to 12 months
follow-up compared with TAU (SMD −0.44, 95% CI −0.89 to 0.02; 1
trial, 76 participants; P = 0.06; MD −1.16, 95% CI −2.47 to 0.15; 1 trial,
76 participants; P = 0.08; Analysis 5.5.3).

CBT  did  not  reduce  BPD  symptom  severity  at  zero  to  six  months
follow-up  compared  with  TAU  (MD  −2.02,  95%  CI  −4.23  to  0.19;  1
trial,  26  participants;  P  =  0.07;  Analysis  5.1.2)  (fixed-effect  model
analysis).

CBT did not reduce suicide-related outcomes at above 12 months
follow-up compared with TAU (SMD −0.31, 95% CI −0.77 to 0.14; 1
trial, 76 participants; P = 0.18; MD −1.15, 95% CI −2.86 to 0.07; 1 trial,
76 participants; P = 0.19; Analysis 5.5.4).

No data were available for six to 12 months and above 12 months
follow-up.

5.2 BPD symptom severity (dichotomous)

One  trial  reported  dichotomous  data  on  BPD  symptom  severity
(Davidson 2006).

CBT  did  not  reduce  BPD  symptom  severity  at  above  12  months
follow-up compared with TAU (RR 0.91, 95% CI 0.56 to 1.48; 1 trial,
76 participants; P = 0.71; Analysis 5.2).

No data were available for end of treatment, zero to six months and
six to 12 months follow-up.

5.3 Self-harm (continuous)

One trial reported continuous data on self-harm (Weinberg 2006).

CBT  reduced  self-harm  at  end  of  treatment  compared  with  TAU
(MD −3.03, 95% CI −5.68 to −0.38; 1 trial, 28 participants; P = 0.03;
Analysis 5.3.1).

CBT  did  not  reduce  self-harm  at  zero  to  six  months  follow-up
compared  with  TAU  (MD  −4.71,  95%  CI  −11.60  to  2.18;  1  trial,  28
participants; P = 0.18; Analysis 5.3.2).

No data were available for six to 12 months and above 12 months
follow-up.

5.4 Self-harm (dichotomous)

One trial reported dichotomous data on self-harm (Davidson 2006).

CBT did not reduce self-harm at end of treatment compared with
TAU (RR 1.17, 95% CI 0.86 to 1.60; 1 trial, 99 participants; P = 0.32;
Analysis 5.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

5.6 Psychosocial functioning

Two  trials  reported  continuous  data  on  psychosocial  functioning
(Davidson 2006; McMurran 2016).

CBT did not improve psychosocial functioning at end of treatment
compared  with  TAU  (SMD  0.00,  95%  CI  −0.39  to  0.39;  1  trial,  99
participants;  P  =  1.00;  MD  0.00,  95%  CI  −1.78  to  1.78;  1  trial,  99
participants; P = 1.00; Analysis 5.6.1).

CBT did not improve psychosocial functioning at six to 12 months
follow-up  compared  with  TAU  (SMD  0.13,  95%  CI  −0.28  to  0.55;  1
trial, 90 participants; P = 0.52; MD 0.70, 95% CI −1.43 to 2.83; 1 trial,
90 participants; P = 0.52; Analysis 5.6.2).

CBT did not improve psychosocial functioning at above 12 months
follow-up  compared  with  TAU  (SMD  0.04,  95%  CI  −0.36  to  0.43;  2
trials, 209 participants; I2 = 51%; P = 0.86; Analysis 5.6.3.

No data were available for zero to six months follow-up.

Secondary outcomes

5.7 Interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(Davidson 2006).

CBT  did  not  reduce  interpersonal  problems  at  end  of  treatment
compared  with  TAU  (MD  5.40,  95%  CI  −3.70  to  14.50;  1  trial,  99
participants; P = 0.24; Analysis 5.7.1).

CBT  did  not  reduce  interpersonal  problems  at  six  to  12  months
follow-up compared with TAU (MD 0.30, 95% CI −9.17 to 9.77; 1 trial,
99 participants; P = 0.95; Analysis 5.7.2).

TAU reduced interpersonal problems at above 12 months follow-
up compared with CBT (MD 11.70, 95% CI 0.72 to 22.68; 1 trial, 76
participants; P = 0.04; Analysis 5.7.3).

5.5 Suicide-related outcomes

No data were available for zero to six months follow-up.

Two trials reported continuous data on suicide-related outcomes
(Davidson 2006; Weinberg 2006).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

5.8 Dissociation and psychotic-like symptoms

One trial reported continuous data on dissociation and psychotic-
like symptoms (Kredlow 2017a).

CBT  did  not  reduce  dissociation  and  psychotic-like  symptoms  at
end of treatment compared with TAU (MD −2.30, 95% CI −8.84 to
4.24; 1 trial, 26 participants; P = 0.49; Analysis 5.8.1).

CBT reduced dissociation and psychotic-like symptoms at zero to
six months follow-up compared with TAU (MD −13.40, 95% CI −24.49
to −2.31; 1 trial, 26 participants; P = 0.02; Analysis 5.8.2).

No data were available for six to 12 months and above 12 months
follow-up.

5.9 Depression

Five trials reported continuous data on depression (Davidson 2006;
Davidson 2014; Jahangard 2012; Kredlow 2017a; McMurran 2016).

CBT did not reduce depression at end of treatment compared with
TAU (SMD −0.21, 95% CI −0.77 to 0.35; 5 trials, 314 participants; I2 =
77%; P = 0.47; Analysis 5.9.1).

CBT reduced depression at zero to six months follow-up compared
with TAU (SMD −0.96, 95% CI −1.78 to −0.14; 1 trial, 26 participants;
P = 0.02; MD −12.70, 95% CI −22.62 to −2.78; 1 trial, 26 participants;
P = 0.01; Analysis 5.9.2).

CBT  did  not  reduce  depression  at  six  to  12  months  follow-up
compared  with  TAU  (SMD  −0.29,  95%  CI  −0.69  to  0.11;  1  trial,  99
participants; P = 0.15; MD −4.60, 95% CI −10.82 to 1.62; 1 trial, 99
participants; P = 0.15; Analysis 5.9.3).

CBT  did  not  reduce  depression  at  above  12  months  follow-up
compared with TAU (SMD −0.15, 95% CI −0.43 to 0.13; 2 trials, 197
participants; I2 = 0%; P = 0.30; Analysis 5.9.4).

6. Psychodynamic psychotherapy versus treatment-as-usual
(TAU)

Primary outcomes

6.1 BPD symptom severity

Four  trials  reported  continuous  data  on  BPD  symptom  severity
(Amianto 2011; Gregory 2008b; Leichsenring 2016; Reneses 2013).

Psychodynamic  psychotherapy  did  not  reduce  BPD  symptom
severity at end of treatment compared with TAU (SMD −0.29, 95%
CI −0.66 to 0.09; 4 trials, 222 participants; I2 = 38%; P = 0.13; Analysis
6.1.1).

Psychodynamic  psychotherapy  did  not  reduce  BPD  symptom
severity  at  six  to  12  months  follow-up  compared  with  TAU  (SMD
−0.31,  95%  CI  −1.00  to  0.38;  1  trial,  33  participants;  P  =  0.38;  MD
−0.30, 95% CI −0.95 to 0.35; 1 trial, 33 participants; P = 0.37; Analysis
6.1.2).

No data were available for zero to six months and above 12 months
follow-up.

6.2 Self-harm

Two trials reported continuous data on self-harm (Amianto 2011;
Gregory 2008b).

Psychodynamic psychotherapy did not reduce self-harm at end of
treatment compared with TAU (MD 0.12, 95% CI −0.56 to 0.80; 1 trial,
33 participants; P = 0.73; Analysis 6.2.1).

Psychodynamic psychotherapy did not reduce self-harm at six to
12 months follow-up compared with TAU (MD 0.14, 95% CI −0.55 to
0.82; 1 trial, 33 participants; P = 0.69; Analysis 6.2.2).

No data were available for zero to six months and above 12 months
follow-up.

5.10 Attrition

6.3 Suicide-related outcomes

One trial reported dichotomous data on attrition (Davidson 2006).

CBT  did  not  reduce  attrition  at  end  of  treatment  compared  with
TAU (RR 0.48, 95% CI 0.09 to 2.52; 1 trial, 106 participants; P = 0.39;
Analysis 5.10).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

5.11 Adverse effects

Two trials reported dichotomous data on non-serious and serious
adverse effects (Davidson 2014 McMurran 2016).

There was no clear difference in the number of non-serious adverse
effects at end of treatment (RR 0.92, 95% CI 0.45 to 1.88; 1 trial, 306
participants; P = 0.81; Analysis 5.11.1).

There  was  no  clear  difference  in  the  number  of  serious  adverse
effects at end of treatment (RR 2.65, 95% CI 0.31 to 22.93; 2 trials,
326 participants; I2= 0%, P = 0.56; Analysis 5.11.2).

No  data  were  available  on  any 
for  anger,
affective  instability,  chronic  feelings  of  emptiness,  impulsivity,
abandonment and identity disturbance.

time  point 

Three trials reported continuous data on suicide-related outcomes
(Amianto 2011; Gregory 2008b; Reneses 2013).

Psychodynamic  psychotherapy  did  not  reduce  suicide-related
outcomes at end of treatment compared with TAU (SMD −0.22, 95%
CI −0.62 to 0.17; 3 trials, 101 participants; I2 = 27%; P = 0.27; Analysis
6.3.1).

Psychodynamic  psychotherapy  did  not  reduce  suicide-related
outcomes at six to 12 months follow-up compared with TAU (SMD
−0.38,  95%  CI  −1.07  to  0.31;  1  trial,  33  participants;  P  =  0.28;  MD
−0.30, 95% CI −0.82 to 0.2; 1 trial, 33 participants; P = 0.26; Analysis
6.3.2).

No data were available for zero to six months and above 12 months
follow-up.

6.4 Psychosocial functioning

Four trials reported continuous data on psychosocial functioning
(Amianto 2011; Gregory 2008b; Reneses 2013; Salzer 2014).

Psychodynamic  psychotherapy  did  not  improve  psychosocial
functioning  at  end  of  treatment  compared  with  TAU  (SMD  −0.69,

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

95% CI −1.98 to 0.59; 4 trials, 140 participants; I2 = 92%; P = 0.29;
Analysis 6.4.1; random-effects model).

CI −0.96 to −0.04; 2 trials, 77 participants; I2 = 24%; P = 0.03; analysis
not shown; fixed-effect model).

Psychodynamic psychotherapy improved psychosocial functioning
at end of treatment compared with TAU (SMD −0.38, 95% CI −0.75
to −0.02; 4 trials, 140 participants; I2 = 92%; P = 0.04; analysis not
shown; fixed-effect model).

Psychodynamic  psychotherapy  did  not  improve  psychosocial
functioning at six to 12 months follow-up compared with TAU (SMD
0.05, 95% CI −0.64 to 0.73; 1 trial, 33 participants; P = 0.89; MD 0.60,
95% CI −8.07 to 9.27; 1 trial, 33 participants; P = 0.89; Analysis 6.4.2).

Psychodynamic  psychotherapy  did  not  improve  psychosocial
functioning  at  above  12  months  follow-up  compared  with  TAU
(SMD −0.40, 95% CI −1.39 to 0.60; 1 trial, 16 participants; P = 0.44;
MD −3.70, 95% CI −12.37 to 4.97; 1 trial, 16 participants; P = 0.40;
Analysis 6.4.3).

No data were available for zero to six months.

Secondary outcomes

6.5 Anger

One trial reported continuous data on anger (Amianto 2011).

Psychodynamic  psychotherapy  did  not  reduce  anger  at  end  of
treatment compared with TAU (MD 0.00, 95% CI −0.86 to 0.86; 1 trial,
33 participants; P = 1.00; Analysis 6.5.1).

Psychodynamic  psychotherapy  did  not  reduce  anger  at  six  to  12
months  follow-up  compared  with  TAU  (MD  0.00,  95%  CI  −0.89  to
0.89; 1 trial, 33 participants; P = 1.00; Analysis 6.5.2).

No data were available for zero to six months and above 12 months
follow-up.

6.6 Affective instability

Three  trials  reported  continuous  data  on  affective  instability
(Amianto 2011; Reneses 2013; Salzer 2014).

Psychodynamic psychotherapy reduced affective instability at end
of treatment compared with TAU (SMD −0.50, 95% CI −0.87 to −0.13;
3 trials, 116 participants; I2 = 0%; P = 0.009; Analysis 6.6.1).

Psychodynamic psychotherapy did not reduce affective instability
at six to 12 months follow-up compared with TAU (SMD −0.52, 95%
CI −1.21 to 0.18; 1 trial, 33 participants; P = 0.15; MD −0.70, 95% CI
−1.59 to 0.19; 1 trial, 33 participants; P = 0.12; Analysis 6.6.2).

No data were available for zero to six months and above 12 months
follow-up.

6.7 Chronic feelings of emptiness

Two  trials  reported  continuous  data  on  chronic  feelings  of
emptiness (Amianto 2011; Reneses 2013).

Psychodynamic psychotherapy did not reduce chronic feelings of
emptiness at end of treatment compared with TAU (SMD −0.49, 95%
CI −1.02 to 0.04; 2 trials, 77 participants; I2 = 24%; P = 0.07; Analysis
6.7.1; random-effects model).

feelings  of
Psychodynamic  psychotherapy  reduced  chronic 
emptiness at end of treatment compared with TAU (SMD −0.50, 95%

Psychodynamic psychotherapy did not reduce chronic feelings of
emptiness at six to 12 months follow-up compared with TAU (SMD
−0.58,  95%  CI  −1.28  to  0.11;  1  trial,  33  participants;  P  =  0.10;  MD
−0.60, 95% CI −1.29 to 0.09; 1 trial, 33 participants; P = 0.09; Analysis
6.7.2).

No data were available for six to 12 months and above 12 months
follow-up.

6.8 Impulsivity

Two trials reported continuous data on impulsivity (Amianto 2011;
Reneses 2013).

Psychodynamic psychotherapy did not reduce impulsivity at end of
treatment compared with TAU (SMD −0.39, 95% CI −0.85 to 0.07; 2
trials, 77 participants; I2 = 0%; P = 0.09; Analysis 6.8.1).

Psychodynamic psychotherapy did not reduce impulsivity at six to
12 months follow-up compared with TAU (SMD 0.35, 95% CI −0.34 to
1.04; 1 trial, 33 participants; P = 0.32; MD 0.20, 95% CI −0.18 to 0.58;
1 trial, 33 participants; P = 0.30; Analysis 6.8.2).

No data were available for zero to six months and above 12 months
follow-up.

6.9 Interpersonal problems

Four  trials  reported  continuous  data  on  interpersonal  problems
(Amianto 2011; Leichsenring 2016; Reneses 2013; Salzer 2014).

Psychodynamic  psychotherapy  did  not  reduce 
interpersonal
problems at end of treatment compared with TAU (SMD −0.21, 95%
CI −0.71 to 0.29; 4 trials, 238 participants; I2 = 68%; P = 0.41; Analysis
6.9.1).

Psychodynamic  psychotherapy  did  not  reduce 
interpersonal
problems at six to 12 months follow-up compared with TAU (SMD
−0.51,  95%  CI  −1.20  to  0.19;  1  trial,  33  participants;  P  =  0.15;  MD
−0.60, 95% CI −1.38 to 0.18; 1 trial, 33 participants; P = 0.13; Analysis
6.9.2).

No data were available for zero to six months and above 12 months
follow-up.

6.10 Abandonment

One  trial  reported  continuous  data  on  abandonment  (Amianto
2011).

Psychodynamic  psychotherapy  did  not  reduce  abandonment  at
end of treatment compared with TAU (MD −0.20, 95% CI −0.95 to
0.55; 1 trial, 33 participants; P = 0.60; Analysis 6.10.1).

Psychodynamic psychotherapy did not reduce abandonment at six
to 12 months follow-up compared with TAU (MD −0.40, 95% CI −1.08
to 0.28; 1 trial, 33 participants; P = 0.25; Analysis 6.10.2).

No data were available for zero to six months and above 12 months
follow-up.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

6.11 Identity disturbance

Three  trials  reported  continuous  data  on  identity  disturbance
(Amianto 2011; Leichsenring 2016; Reneses 2013).

Psychodynamic psychotherapy did not reduce identity disturbance
at end of treatment compared with TAU (SMD −0.38, 95% CI −1.02
to 0.27; 3 trials, 199 participants; I2 = 75%; P = 0.25; Analysis 6.11.1).

Psychodynamic psychotherapy reduced identity disturbance at six
to  12  months  follow-up  compared  with  TAU  (SMD  −1.09,  95%  CI
−1.83 to −0.35; 1 trial, 33 participants; P = 0.004; MD −1.40, 95% CI
−2.25 to −0.55; 1 trial, 33 participants; P = 0.001; Analysis 6.11.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for adverse effects.

7. Schema-focused therapy (SFT) versus treatment-as-usual
(TAU)

Primary outcomes

7.1 BPD symptom severity

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Farrell 2009).

No data were available for zero to six months and above 12 months
follow-up.

6.12 Dissociation and psychotic-like symptoms

Two trials reported continuous data on dissociation and psychotic-
like symptoms (Amianto 2011; Gregory 2008b).

SFT reduced BPD symptom severity at end of treatment compared
with TAU (MD −13.94, 95% CI −19.66 to −8.22; 1 trial, 28 participants;
P < 0.001; Analysis 7.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Psychodynamic  psychotherapy  did  not  reduce  dissociation  and
psychotic-like symptoms at end of treatment compared with TAU
(SMD −0.18, 95% CI −0.96 to 0.60; 2 trials, 57 participants; I2 = 53%;
P = 0.66; Analysis 6.12.1).

Psychodynamic  psychotherapy  did  not  reduce  dissociation  and
psychotic-like symptoms at six to 12 months follow-up compared
with TAU (SMD −0.59, 95% CI −1.29 to 0.11; 1 trial, 33 participants;
P = 0.10; MD −0.70, 95% CI −1.49 to 0.09; 1 trial, 33 participants; P =
0.08; Analysis 6.12.2).

Psychodynamic  psychotherapy  did  not  reduce  dissociation  and
psychotic-like symptoms at above 12 months follow-up compared
with TAU (SMD −0.01, 95% CI −0.81 to 0.79; 1 trial, 24 participants;
P = 0.98; MD −0.20, 95% CI −20.07 to 19.67; 1 trial, 24 participants;
P = 0.98; Analysis 6.12.3).

No data were available for zero to six months follow-up.

6.13 Depression

Three  trials  reported  continuous  data  on  depression  (Amianto
2011; Leichsenring 2016; Reneses 2013).

Psychodynamic psychotherapy did not reduce depression at end of
treatment compared with TAU (SMD −0.17, 95% CI −0.81 to 0.47; 3
trials, 190 participants; I2 = 73%; P = 0.61; Analysis 6.13.1).

Psychodynamic psychotherapy did not reduce depression at above
12 months follow-up compared with TAU (SMD −0.68, 95% CI −1.51
to 0.15; 1 trial, 24 participants; P = 0.11; MD −7.80, 95% CI −16.71 to
1.11; 1 trial, 24 participants; P = 0.09; Analysis 6.13.2).

No data were available for zero to six months and six to 12 months
follow-up.

6.14 Attrition

Three trials reported dichotomous data on attrition (Amianto 2011;
Leichsenring 2016; Reneses 2013).

Psychodynamic  psychotherapy  did  not  reduce  attrition  at  end  of
treatment compared with TAU (RR 0.90, 95% CI 0.56 to 1.47; 3 trials,
210 participants; I2 = 0%; P = 0.68; Analysis 6.14).

7.2 Psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Farrell 2009).

SFT  improved  psychosocial  functioning  at  end  of  treatment
compared with TAU (MD −10.42, 95% CI −16.17 to −4.67; 1 trial, 28
participants; P < 0.001; Analysis 7.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for self-harm and suicide-
related outcomes.

Secondary outcomes

7.3 Affective instability

One trial reported continuous data on affective instability (Farrell
2009).

SFT reduced affective instability at end of treatment compared with
TAU (MD −3.95, 95% CI −5.75 to −2.15; 1 trial, 28 participants; P <
0.001; Analysis 7.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

7.4 Impulsivity

One trial reported continuous data on impulsivity (Farrell 2009).

SFT  reduced  impulsivity  at  end  of  treatment  compared  with  TAU
(MD −4.02, 95% CI −5.68 to −2.36; 1 trial, 28 participants; P < 0.001;
Analysis 7.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

7.5 Interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(Farrell 2009).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

SFT reduced interpersonal problems at end of treatment compared
with TAU (MD −7.12, 95% CI −9.65 to −4.59; 1 trial, 28 participants;
P < 0.001; Analysis 7.5).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

7.6 Dissociation and psychotic-like symptoms

One trial reported continuous data on dissociation and psychotic-
like symptoms (Farrell 2009).

SFT  reduced  dissociation  and  psychotic-like  symptoms  at  end  of
treatment compared with TAU (MD −2.56, 95% CI −3.86 to −1.26; 1
trial, 28 participants; P < 0.001; Analysis 7.6).

8.3 Psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Blum 2008).

STEPPS  improved  psychosocial  functioning  at  end  of  treatment
compared with TAU (MD −7.00, 95% CI −11.43 to −2.57; 1 trial, 124
participants; P = 0.002; Analysis 8.3.1).

STEPPS  did  not  improve  psychosocial  functioning  at  six  to  12
months follow-up compared with TAU (MD −5.90, 95% CI −12.49 to
0.69; 1 trial, 124 participants; P = 0.08; Analysis 8.3.2).

No data were available for zero to six months and above 12 months
follow-up.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up..

No  data  were  available  on  any  time  point  for  suicide-related
outcomes.

7.7 Attrition

Secondary outcomes

One trial reported dichotomous data on attrition (Farrell 2009).

8.4 Affective instability

SFT  did  not  reduce  attrition  at  end  of  treatment  compared  with
TAU (RR 0.11, 95% CI 0.01 to 1.91; 1 trial, 32 participants; P = 0.13;
Analysis 7.7).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

*  No  data  were  available  on  any  time  point  for  anger,
chronic feelings of emptiness, abandonment, identity disturbance,
depression, and adverse effects

8. Systems training for emotional predictability and problem
solving (STEPPS) versus treatment-as-usual (TAU)

Primary outcomes

8.1 BPD symptom severity

Three  trials  reported  continuous  data  on  BPD  symptom  severity
(Blum 2008; Bos 2010; Schuppert 2012).

STEPPS  reduced  BPD  symptom  severity  at  end  of  treatment
compared with TAU (SMD −0.39, 95% CI −0.63 to −0.15; 3 trials, 273
participants; I2 = 0%; P = 0.001; Analysis 8.1.1).

STEPPS did not reduce BPD symptom severity at six to 12 months
follow-up  compared  with  TAU  (SMD  0.03,  95%  CI  −0.33  to  0.38;  1
trial, 124 participants; P = 0.88; MD 0.60, 95% CI −7.45 to 8.65; 1 trial,
124 participants; P = 0.88; Analysis 8.1.2).

Two trials reported continuous data on affective instability (Blum
2008; Schuppert 2012).

STEPPS  did  not  reduce  affective  instability  at  end  of  treatment
compared with TAU (SMD −0.25, 95% CI −0.52 to 0.02; 2 trials, 221
participants; P = 0.06; Analysis 8.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

8.5 Impulsivity (continuous)

One trial reported continuous data on impulsivity (Blum 2008).

STEPPS did not reduce impulsivity at end of treatment compared
with TAU (MD −0.40, 95% CI −1.23 to 0.43; 1 trial, 124 participants;
P = 0.35; Analysis 8.5).

8.6 Impulsivity (dichotomous)

One trial reported dichotomous data on impulsivity (Bos 2010).

STEPPS did not reduce impulsivity at end of treatment compared
with TAU (RR 0.93, 95% CI 0.66 to 1.29; 1 trial, 58 participants; P =
0.65; Analysis 8.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

8.7 Interpersonal problems

No data were available for zero to six months and above 12 months
follow-up.

Two  trials  reported  continuous  data  on  interpersonal  problems
(Blum 2008; Bos 2010).

8.2 Self-harm

One trial reported dichotomous data on self-harm (Bos 2010).

STEPPS  did  not  reduce  self-harm  at  end  of  treatment  compared
with TAU (RR 1.32, 95% CI 0.78 to 2.22; 1 trial, 58 participants; P =
0.30; Analysis 8.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

STEPPS  reduced  interpersonal  problems  at  end  of  treatment
compared with TAU (SMD −0.38, 95% CI −0.67 to −0.08; 2 trials, 177
participants; I2 = 0%; P = 0.01; Analysis 8.7).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

8.8 Dissociation and psychotic-like symptoms

One trial reported continuous data on dissociation and psychotic-
like symptoms (Blum 2008).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

STEPPS reduced dissociation and psychotic-like symptoms at end
of treatment compared with TAU (MD −1.00, 95% CI −1.83 to −0.17;
1 trial, 124 participants; P = 0.02; Analysis 8.8).

CAT  improved  psychosocial  functioning  at  zero  to  six  months
follow-up compared with TAU (MD −15.80, 95% CI −29.36 to −2.24; 1
trial, 9 participants; P = 0.02; Analysis 9.2.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available for six to 12 months and above 12 months
follow-up.

8.9 Depression

One trial reported continuous data on depression (Blum 2008).

STEPPS did not reduce depression at end of treatment compared
with TAU (MD −3.80, 95% CI −9.34 to 1.74; 1 trial, 124 participants;
P = 0.18; Analysis 8.9.1).

STEPPS  did  not  reduce  depression  at  six  to  12  months  follow-up
compared  with  TAU  (MD  −0.60,  95%  CI  −8.42  to  9.62;  1  trial,  124
participants; P = 0.90; Analysis 8.9.2).

No data were available for zero to six months and above 12 months
follow-up.

8.10 Attrition

One trial reported dichotomous data on attrition (Bos 2010).

STEPPS did not reduce attrition at end of treatment compared with
TAU (RR 1.47, 95% CI 0.59 to 3.65; 1 trial, 79 participants; P = 0.41;
Analysis 8.10).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for anger, chronic feelings
of  emptiness,  abandonment,  identity  disturbance,  and  adverse
effects.

9. Cognitive analytic therapy (CAT) versus treatment-as-usual
(TAU)

Primary outcomes

9.1 Suicide-related outcomes

No data were available on any time point for BPD symptom severity,
and self-harm.

Secondary outcomes

9.3 Anger

One trial reported continuous data on anger (Gleeson 2012).

CAT did not reduce anger at end of treatment compared with TAU
(MD  −1.90,  95%  CI  −7.97  to  4.17;  1  trial,  9  participants;  P  =  0.54;
Analysis 9.3.1).

CAT did not reduce anger at zero to six months follow-up compared
with TAU (MD −4.50, 95% CI −9.01 to 0.01; 1 trial, 8 participants; P =
0.05; Analysis 9.3.2).

No data were available for six to 12 months and above 12 months
follow-up.

9.4 Dissociation and psychotic-like symptoms

One trial reported continuous data on dissociation and psychotic-
like symptoms (Gleeson 2012).

CAT  did  not  reduce  dissociation  and  psychotic-like  symptoms  at
end of treatment compared with TAU (MD −6.10, 95% CI −15.01 to
2.81; 1 trial, 9 participants; P = 0.18; Analysis 9.4.1).

CAT  did  not  reduce  dissociation  and  psychotic-like  symptoms  at
zero to six months follow-up compared with TAU (MD −11.70, 95%
CI −24.02 to 0.62; 1 trial, 8 participants; P = 0.06; Analysis 9.4.2).

No data were available for six to 12 months and above 12 months
follow-up.

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Gleeson 2012).

9.5 Depression

One trial reported continuous data on depression (Gleeson 2012).

CAT did not reduce suicide-related outcomes at end of treatment
compared  with  TAU  (MD  −1.40,  95%  CI  −4.21  to  1.41;  1  trial,  9
participants; P = 0.33; Analysis 9.1.1).

CAT did not reduce depression at end of treatment compared with
TAU (MD −9.70, 95% CI −20.10 to 0.70; 1 trial, 9 participants; P = 0.07;
Analysis 9.5.1).

CAT did not reduce suicide-related outcomes at zero to six months
follow-up  compared  with  TAU  (MD  −0.50,  95%  CI  −2.05  to  1.05;  1
trial, 8 participants; P = 0.53; Analysis 9.1.2).

CAT  did  not  reduce  depression  at  zero  to  six  months  follow-up
compared  with  TAU  (MD  −3.70,  95%  CI  −11.99  to  4.59;  1  trial,  8
participants; P = 0.38; Analysis 9.5.2).

No data were available for six to 12 months and above 12 months
follow-up.

No data were available for six to 12 months and above 12 months
follow-up.

9.2 Psychosocial functioning

9.6 Attrition

One  trial  reported  continuous  data  on  psychosocial  functioning
(Gleeson 2012).

CAT  improved  psychosocial  functioning  at  end  of  treatment
compared with TAU (MD −16.40, 95% CI −31.20 to −1.60; 1 trial, 9
participants; P = 0.03; Analysis 9.2.1).

One trial reported dichotomous data on attrition (Gleeson 2012).

CAT  did  not  reduce  attrition  at  end  of  treatment  compared  with
TAU (RR 1.33, 95% CI 0.43 to 4.13; 1 trial, 16 participants; P = 0.62;
Analysis 9.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No data were available on any time point for affective instability,
chronic feelings of emptiness, impulsivity, interpersonal problems,
abandonment, identity disturbance, and adverse effects.

12. Transference-focused psychotherapy (TFP) versus
treatment-as-usual (TAU)

Primary outcomes

10. Motivation feedback (MF) versus treatment-as-usual (TAU)

12.1 BPD symptom severity

10.1 Primary outcome: psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Jochems 2015).

MF did not improve psychosocial functioning at end of treatment
compared  with  TAU  (MD  −0.42,  95%  CI  −4.23  to  3.39;  1  trial,  43
participants; P = 0.83; Analysis 10.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for BPD symptom severity,
self-harm, and suicide-related outcomes.

Secondary outcomes

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, attrition and adverse effects

11. Psychoeducation versus treatment-as-usual (TAU)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcomes

11.1 Depression

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Doering 2010).

TFP reduced BPD symptom severity at end of treatment compared
with TAU (MD −0.84, 95% CI −1.42 to −0.26; 1 trial, 104 participants;
P = 0.004; Analysis 12.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

12.2 Self-harm

One trial reported dichotomous data on self-harm (Doering 2010).

TFP did not reduce self-harm at end of treatment compared with
TAU (RR 1.09, 95% CI 0.84 to 1.40; 1 trial, 104 participants; P = 0.52;
Analysis 12.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

12.3 Suicide-related outcomes

One trial reported dichotomous data on suicide-related outcomes
(Doering 2010).

TFP did not reduce suicide-related outcomes at end of treatment
compared  with  TAU  (RR  0.65,  95%  CI  0.27  to  1.54;  1  trial,  104
participants; P = 0.33; Analysis 12.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

One trial reported continuous data on depression (Zanarini 2018).

12.4 Psychosocial functioning

Psychoeducation  did  not  reduce  depression  at  end  of  treatment
compared  with  TAU  (MD  −7.03,  95%  CI  −14.35  to  0.29;  1  trial,  77
participants; P = 0.06; Analysis 11.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

11.2 Attrition

One trial reported continuous data on attrition (Zanarini 2018).

Psychoeducation  did  not  reduce  attrition  at  end  of  treatment
compared  with  TAU  (RR  0.49,  95%  CI  0.04  to  5.60;  1  trial,  80
participants; P = 0.56; Analysis 11.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, and adverse effects

One  trial  reported  continuous  data  on  psychosocial  functioning
(Doering 2010).

TFP did not improve psychosocial functioning at end of treatment
compared  with  TAU  (MD  −2.56,  95%  CI  −5.43  to  0.31;  1  trial,  104
participants; P = 0.08; Analysis 12.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Secondary outcomes

12.5 Depression

One trial reported continuous data on depression (Doering 2010).

TFP did not reduce depression at end of treatment compared with
TAU (MD 1.65, 95% CI −3.44 to 6.74; 1 trial, 104 participants; P = 0.52;
Analysis 12.5).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

12.6 Attrition

One trial reported dichotomous data on attrition (Doering 2010).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

TFP reduced attrition at end of treatment compared with TAU (RR
0.57, 95% CI 0.39 to 0.85; 1 trial, 104 participants; P = 0.005; Analysis
12.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, and adverse effects.

13. Once-only interventions (individual setting) versus
treatment-as-usual (TAU)

Primary outcomes

13.1 Self-harm

One  trial  reported  continuous  data  on  self-harm  (Borschmann
2013).

Once-only  interventions  did  not  reduce  self-harm  at  end  of
treatment compared with TAU (MD 0.60, 95% CI −33.88 to 35.08; 1
trial, 72 participants; P = 0.97; Analysis 13.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

13.2 Psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Borschmann 2013).

Once-only interventions did not improve psychosocial functioning
at end of treatment compared with TAU (MD 0.25, 95% CI −3.66 to
4.16; 1 trial, 72 participants; P = 0.90; Analysis 13.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for BPD symptom severity,
and suicide-related outcomes.

Secondary outcomes

13.3 Depression

One  trial  reported  continuous  data  on  depression  (Borschmann
2013).

Once-only  interventions  did  not  improve  depression  at  end  of
treatment compared with TAU (MD 0.27, 95% CI −1.72 to 2.26; 1 trial,
72 participants; P = 0.79; Analysis 13.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

13.4 Attrition

One  trial  reported  dichotomous  data  on  attrition  (Borschmann
2013).

Once-only  interventions  did  not  reduce  attrition  at  end  of
treatment compared with TAU (RR 1.37, 95% CI 0.53 to 3.52; 1 trial,
88 participants; P = 0.51; Analysis 13.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Cochrane Database of Systematic Reviews

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, and adverse effects.

14. Eclectic treatments versus treatment-as-usual (TAU)

Primary outcomes

14.1 BPD symptom severity

Three  trials  reported  continuous  data  on  BPD  symptom  severity
(Gratz 2006; Gratz 2014; Leppänen 2016).

Eclectic  treatments  reduced  BPD  symptom  severity  at  end  of
treatment compared with TAU (SMD −0.90, 95% CI −1.57 to −0.23; 3
trials, 134 participants; I2 = 67%; P = 0.008; Analysis 14.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

14.2 Self-harm

Two trials reported continuous data on self-harm (Gratz 2006; Gratz
2014).

Eclectic  treatments  reduced  self-harm  at  end  of  treatment
compared with TAU (SMD −0.84, 95% CI −1.29 to −0.39; 2 trials, 83
participants; I2 = 0%; P = 0.0003; Analysis 14.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

14.3 Suicide-related outcomes

Two trials reported continuous data on suicide-related outcomes
(Andreoli 2016; Leppänen 2016).

Eclectic treatments did not reduce suicide-related outcomes at end
of treatment compared with TAU (SMD −0.55, 95% CI −1.29 to 0.19;
2 trials, 221 participants; I2 = 78%; P = 0.14; Analysis 14.3; random-
effects model).

Eclectic  treatments  reduced  suicide-related  outcomes  at  end  of
treatment compared with TAU (SMD −0.65, 95% CI −0.98 to − 0.32;
2 trials, 221 participants; I2 = 78%; P = 0.0001; analysis not shown;
fixed-effect model).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

14.4 Psychosocial functioning

Two  trials  reported  continuous  data  on  psychosocial  functioning
(Andreoli 2016; Gratz 2014).

Eclectic  treatments  improved  psychosocial  functioning  at  end  of
treatment compared with TAU (SMD −0.57, 95% CI −1.10 to −0.04; 2
trials, 231 participants; I2 = 63%; P = 0.03; Analysis 14.4.1).

Eclectic treatments improved psychosocial functioning at above 12
months follow-up compared with TAU (SMD −0.64, 95% CI −1.04 to
−0.24; 1 trial, 170 participants; P = 0.002; MD −7.50, 95% CI −12.30 to
−2.70; 1 trial, 170 participants; P = 0.002; Analysis 14.4.2).

No data were available for zero to months and six to 12 months.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Secondary outcomes

14.5 Anger

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

One trial reported continuous data on anger (Leppänen 2016).

14.11 Identity disturbance

Eclectic  treatments  did  not  reduce  anger  at  end  of  treatment
compared  with  TAU  (MD  −0.47,  95%  CI  −1.26  to  0.32;  1  trial,  51
participants; P = 0.24; Analysis 14.5).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

14.6 Affective instability

One  trial  reported  continuous  data  on  identity  disturbance
(Leppänen 2016).

Eclectic treatments did not reduce identity disturbance at end of
treatment compared with TAU (MD −0.85, 95% CI −1.92 to 0.22; 1
trial, 51 participants; P = 0.12; Analysis 14.11).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Three trials reported continuous data on affective instability (Gratz
2006; Gratz 2014; Leppänen 2016).

14.14 Depression

Eclectic treatments reduced affective instability at end of treatment
compared with TAU (SMD −0.95, 95% CI −1.74 to −0.15; 3 trials, 134
participants; I2 = 76%; P = 0.02; Analysis 14.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

14.7 Chronic feelings of emptiness

Four trials reported continuous data on depression (Andreoli 2016;
Gratz 2006; Gratz 2014; Leppänen 2016).

Eclectic  treatments  reduced  depression  at  end  of  treatment
compared with TAU (SMD −0.82, 95% CI −1.38 to −0.26; 4 trials, 304
participants; I2 = 73%; P = 0.004; Analysis 14.12).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

One trial reported continuous data on chronic feelings of emptiness
(Leppänen 2016).

14.13 Attrition

Eclectic treatments did not reduce chronic feelings of emptiness at
end of treatment compared with TAU (MD −0.59, 95% CI −2.44 to
1.26; 1 trial, 51 participants; P = 0.53; Analysis 14.7).

No data were available for zero to months, six to 12 months and
above 12 months follow-up.

14.8 Impulsivity

Four trials reported dichotomous data on attrition (Andreoli 2016;
Gratz 2006; Gratz 2014; Leppänen 2016).

Eclectic  treatments  did  not  reduce  attrition  at  end  of  treatment
compared  with  TAU  (RR  1.10,  95%  CI  0.91  to  1.33;  4  trials,  326
participants; I2 = 25%; P = 0.31; Analysis 14.13).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Three trials reported continuous data on impulsivity (Gratz 2006;
Gratz 2014; Leppänen 2016).

14.14 Adverse effects

Eclectic  treatments  reduced  impulsivity  at  end  of  treatment
compared with TAU (SMD −0.76, 95% CI −1.30 to −0.22; 3 trials, 134
participants; I2 = 52%; P = 0.006; Analysis 14.8).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

14.9 Interpersonal problems

Two  trials  reported  continuous  data  on  interpersonal  problems
(Gratz 2014; Leppänen 2016).

Eclectic  treatments  reduced  interpersonal  problems  at  end  of
treatment compared with TAU (SMD −0.62, 95% CI −1.09 to −0.15; 2
trials, 112 participants; I2 = 32%; P = 0.01; Analysis 14.9).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

14.10 Abandonment

One  trial  reported  continuous  data  on  abandonment  (Leppänen
2016).

Eclectic  treatments  did  not  reduce  abandonment  at  end  of
treatment compared with TAU (MD −0.46, 95% CI −1.39 to 0.47; 1
trial, 51 participants; P = 0.33; Analysis 14.10).

One trial reported dichotomous data on adverse effects (Andreoli
2016).

Eclectic  treatments  did  not  reduce  adverse  effects  at  end  of
treatment compared with TAU (RR 0.66, 95% CI 0.03 to 15.81; 1 trial,
170 participants; P = 0.80; Analysis 14.14).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  dissociation  and
psychotic-like symptoms.

15. Psychotherapy versus waiting list or no treatment

Primary outcomes

15.1 BPD symptom severity

Three  trials  reported  continuous  data  on  BPD  symptom  severity
(Bellino 2010; Bohus 2013; McMain 2017).

Psychotherapy reduced BPD symptom severity at end of treatment
compared  with  waiting  list  (SMD  −0.49,  95%  CI  −0.93  to  −0.5;  3
trials, 161 participants; I2 = 44%; P = 0.03; Analysis 15.1; low-quality
evidence, Summary of findings 2).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

15.2 Self-harm

Two  trials  reported  continuous  data  on  self-harm  (Bellino  2010;
McMain 2017).

Psychotherapy  did  not  reduce  self-harm  at  end  of  treatment
compared  with  waiting  list  (SMD  −0.17,  95%  CI  −0.52  to  0.18;  2
trials, 128 participants; I2 = 0%; P = 0.34; Analysis 15.2; low-quality
evidence, Summary of findings 2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

15.3 Suicide-related outcomes

Two trials reported continuous data on suicide-related outcomes
(McMain 2017; Mohamadizadeh 2017).

Psychotherapy did not reduce suicide-related outcomes at end of
treatment compared with waiting list or no treatment (SMD −5.62,
95% CI −16.39 to 5.16; 2 trials, 108 participants; I2 = 97%; P = 0.31;
Analysis 15.3; very low-quality evidence, Summary of findings 2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

15.4 Psychosocial functioning

Five  trials  reported  continuous  data  on  psychosocial  functioning
(Bellino  2006;  Bellino  2007;  Bohus  2013;  Haeyen  2018;  McMain
2017).

Psychotherapy  improved  psychosocial  functioning  at  end  of
treatment compared with waiting list (SMD −0.56, 95% CI −1.01 to
−0.11; 5 trials, 219 participants; I2 = 59%; P = 0.01; Analysis 15.4.1;
low-quality evidence, Summary of findings 2).

Psychotherapy  improved  psychosocial  functioning  at  zero  to  six
months follow-up compared with waiting list (SMD −0.89, 95% CI
−1.65 to −0.13; 1 trial, 30 participants; P = 0.02; MD −12.39, 95% CI
−22.00 to −2.78; 1 trial, 30 participants; P = 0.01; Analysis 15.4.2).

Psychotherapy  improved  psychosocial  functioning  at  six  to  12
months follow-up compared with waiting list (SMD −1.04, 95% CI
−1.81 to −0.27; 1 trial, 30 participants; P = 0.008: MD −13.59, 95% CI
−22.65 to −4.53; 1 trial, 30 participants; P = 0.003; Analysis 15.4.3).

Psychotherapy did not improve psychosocial functioning at above
12 months follow-up compared with waiting list (SMD −0.38, 95%
CI −1.14 to 0.37; 1 trial, 28 participants; P = 0.32; MD −14.68, 95% CI
−46.63 to 17.27; 1 trial, 28 participants; P = 0.37; Analysis 15.4.4).

Secondary outcomes

15.5 Anger

Two trials reported continuous data on anger (Bellino 2010; McMain
2017).

Psychotherapy did not reduce anger at end of treatment compared
with  waiting  list  (SMD  −0.58,  95%  CI  −1.70  to  0.55;  2  trials,  128
participants;  I2  =  89%;  P  =  0.32;  Analysis  15.5,  random-effects
model).

Cochrane Database of Systematic Reviews

Psychotherapy reduced anger at end of treatment compared with
waiting  list  (SMD  −0.70,  95%  CI  −1.06  to  −0.33;  2  trials,  128
participants; I2 = 89%; P = 0.0002; analysis not shown; fixed-effect
model).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

15.6 Affective instability

Two trials reported continuous data on affective instability (Bellino
2010; McMain 2017).

Psychotherapy  reduced  affective  instability  at  end  of  treatment
compared  with  waiting  list  (SMD  −0.99,  95%  CI  −1.36  to  −0.62;  2
trials, 128 participants; I2 = 0%; P < 0.001; Analysis 15.6.1).

Psychotherapy  did  not  reduce  affective  instability  at  zero  to  six
months follow-up compared with waiting list (SMD −0.47, 95% CI
−1.20 to 0.26; 1 trial, 30 participants; P = 0.21; MD −0.46, 95% CI −1.15
to 0.23; 1 trial, 30 participants; P = 0.19; Analysis 15.6.2).

Psychotherapy  did  not  reduce  affective  instability  at  six  to  12
months follow-up compared with waiting list (SMD −0.38, 95% CI
−1.10 to 0.34; 1 trial, 30 participants; P = 0.30; MD −0.39, 95% CI −1.12
to 0.34; 1 trial, 30 participants; P = 0.29; Analysis 15.6.3).

Psychotherapy  did  not  reduce  affective  instability  at  above  12
months follow-up compared with waiting list (SMD −0.28, 95% CI
−1.01 to 0.44; 1 trial, 30 participants; P = 0.44; MD −0.34, 95% CI −1.17
to 0.49; 1 trial, 30 participants; P = 0.42; Analysis 15.6.4).

15.7 Chronic feelings of emptiness

One trial reported continuous data on chronic feelings of emptiness
(Bellino 2010).

Psychotherapy did not reduce chronic feelings of emptiness at end
of treatment compared with waiting list (MD 0.04, 95% CI −0.21 to
0.29; 1 trial, 44 participants; P = 0.75; Analysis 15.7).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

15.8 Impulsivity

Three trials reported continuous data on impulsivity (Bellino 2010;
McMain 2017; Zanarini 2008).

Psychotherapy reduced impulsivity at end of treatment compared
with  waiting  list  (SMD  −0.52,  95%  CI  −0.82  to  -0.22;  3  trials,  178
participants; I2 = 0%; P = 0.0007; Analysis 15.8.1).

Psychotherapy reduced impulsivity at zero to six months follow-up
compared with waiting list (SMD −0.90, 95% CI −1.66 to −0.14; 1 trial,
30 participants; P = 0.02; MD −1.10, 95% CI −1.95 to −0.25; 1 trial, 30
participants; P = 0.01; Analysis 15.8.2).

Psychotherapy reduced impulsivity at six to 12 months follow-up
compared with waiting list (SMD −0.79, 95% CI −1.54 to −0.04; 1 trial,
30 participants; P = 0.04; MD −1.10, 95% CI −2.06 to −0.14; 1 trial, 30
participants; P = 0.02; Analysis 15.8.3).

Psychotherapy reduced impulsivity at above 12 months follow-up
compared with waiting list (SMD −0.75, 95% CI −1.50 to −0.01; 1 trial,

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

30 participants; P = 0.05; MD −1.09, 95% CI −2.09 to -0.09; 1 trial, 30
participants; P = 0.03; Analysis 15.8.4).

15.9 Interpersonal problems

Three  trials  reported  continuous  data  on  interpersonal  problems
(Bellino 2010; Haeyen 2018; Zanarini 2008).

Psychotherapy  reduced 
interpersonal  problems  at  end  of
treatment compared with waiting list (SMD −0.85, 95% CI −1.23 to
−0.47; 3 trials, 120 participants; I2 = 0%; P < 0.001; Analysis 15.9.1).

Psychotherapy  reduced  interpersonal  problems  at  zero  to  six
months follow-up compared with waiting list (SMD −1.40, 95% CI
−2.21 to −0.59; 1 trial, 30 participants; P = 0.0007; MD −2.00, 95% CI
−2.98 to −1.02; 1 trial, 30 participants; P < 0.001; Analysis 15.9.2).

Psychotherapy reduced interpersonal problems at six to 12 months
follow-up compared with waiting list (SMD −0.90, 95% CI −1.66 to
−0.14; 1 trial, 30 participants; P = 0.02; MD −1.56, 95% CI −2.74 to
−0.38; 1 trial, 30 participants; P = 0.009; Analysis 15.9.3).

Psychotherapy  reduced  interpersonal  problems  at  above  12
months follow-up compared with waiting list (SMD −0.86, 95% CI
−1.62 to −0.11; 1 trial, 30 participants; P = 0.02; MD −1.48, 95% CI
−2.63 to −0.33; 1 trial, 30 participants; P = 0.01; Analysis 15.9.4).

15.10 Abandonment

Psychotherapy reduced depression at end of treatment compared
with waiting list or no treatment (SMD −1.28, 95% CI −2.21 to −0.34;
6 trials, 239 participants; I2 = 89%; P = 0.007; Analysis 15.13; low-
quality evidence, Summary of findings 2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

15.14 Attrition

Three trials reported dichotomous data on attrition (Bellino 2006;
Bellino 2010; Zanarini 2008).

Psychotherapy  did  not  reduce  attrition  at  end  of  treatment
compared  with  waiting  list  (RR  0.55,  95%  CI  0.20  to  1.50;  3  trials,
144 participants; I2 = 0%; P = 0.24; Analysis 15.14; very low-quality
evidence, Summary of findings 2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for adverse effects.

16. Dialectical behaviour therapy (DBT) versus waiting list or
no treatment

Primary outcomes

16.1 BPD symptom severity

One trial reported continuous data on abandonment (Bellino 2010).

Psychotherapy did not reduce abandonment at end of treatment
compared with waiting list (MD 0.01, 95% CI −0.90 to 0.92; 1 trial, 44
participants; P = 0.98; Analysis 15.10).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

15.11 Identity disturbance

One trial reported continuous data on identity disturbance (Bellino
2010).

Two  trials  reported  continuous  data  on  BPD  symptom  severity
(Bohus 2013; McMain 2017).

DBT reduced BPD symptom severity at end of treatment compared
with  waiting  list  (SMD  −0.71,  95%  CI  −1.08  to  −0.33;  2  trials,  117
participants; I2 = 0%; P = 0.0002; Analysis 16.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

16.2 Self-harm

One trial reported continuous data on self-harm (McMain 2017).

Psychotherapy  did  not  reduce  identity  disturbance  at  end  of
treatment  compared  with  waiting  list  (MD  −0.03,  95%  CI  −0.56  to
0.50; 1 trial, 44 participants; P = 0.91; Analysis 15.11).

DBT did not reduce self-harm at end of treatment compared with
waiting list (MD −1.45, 95% CI −3.76 to 0.86; 1 trial, 84 participants;
P = 0.22; Analysis 16.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

15.12 Dissociation and psychotic-like

16.3 Suicide-related outcomes

Two trials reported continuous data on dissociation and psychotic-
like symptoms (Bellino 2010; Bohus 2013).

Two trials reported continuous data on suicide-related outcomes
(McMain 2017; Mohamadizadeh 2017).

Psychotherapy  did  not  reduce  dissociation  and  psychotic-like
symptoms  at  end  of  treatment  compared  with  waiting  list  (SMD
−0.13, 95% CI −0.65 to 0.39; 2 trials, 77 participants; I2 = 24%; P =
0.62; Analysis 15.12).

Psychotherapy did not reduce suicide-related outcomes at end of
treatment compared with waiting list or no treatment (SMD −5.62,
95% CI −16.39 to 5.16; 2 trials, 108 participants; I2 = 97%; P = 0.30;
Analysis 16.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

15.13 Depression

16.4 Psychosocial functioning

Six  trials  reported  continuous  data  on  depression  (Bellino  2006;
Bellino  2007;  Bohus  2013;  McMain  2017;  Mohamadizadeh  2017;
Smith 2012).

Two  trials  reported  continuous  data  on  psychosocial  functioning
(Bohus 2013; McMain 2017).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

DBT  reduced  psychosocial  functioning  at  end  of  treatment
compared  with  waiting  list  (SMD  −0.73,  95%  CI  −1.11  to  −0.36;  2
trials, 117 participants; I2 = 0%; P = 0.0001; Analysis 16.4).

No  data  were  available  on  any  time  point  for  chronic  feelings
of  emptiness,  interpersonal  problems,  abandonment,  identity
disturbance, attrition and adverse effects.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

16.10. DBT couple therapy (CDBT) versus waiting list (generic
inverse variance)

Secondary outcomes

16.5 Anger

One trial reported continuous data on anger (McMain 2017).

DBT reduced anger at end of treatment compared with waiting list
(MD −11.45, 95% CI −15.73 to −7.17; 1 trial, 84 participants; P < 0.001;
Analysis 16.5).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

16.6 Affective instability

One trial reported continuous data on affective instability (McMain
2017).

DBT  reduced  affective  instability  at  end  of  treatment  compared
with  waiting  list  (MD  −20.15,  95%  CI  −28.49  to  −11.81;  1  trial,  84
participants; P < 0.001; Analysis 16.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

16.7 Impulsivity

One trial reported continuous data on impulsivity (McMain 2017).

DBT did not reduce impulsivity at end of treatment compared with
waiting list (MD −3.41, 95% CI −7.32 to 0.50; 1 trial, 84 participants;
P = 0.09; Analysis 16.7).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

16.8 Dissociation and psychotic-like symptoms

Primary outcomes

BPD symptom severity

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Kamalabadi 2012).

End of treatment: CDBT reduced BPD symptom severity at end of
treatment compared with waiting list (MD −27.15, 95% CI −31.59 to
−22.71; 1 trial, 30 participants; P < 0.001; Analysis 16.10.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Suicide-related outcomes

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Kamalabadi 2012).

CDBT  reduced  suicide-related  outcomes  at  end  of  treatment
compared with waiting list (MD −0.94, 95% CI −1.24 to −0.64; 1 trial,
30 participants; P < 0.001; Analysis 16.10.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Kamalabadi 2012).

CDBT  improved  psychosocial  functioning  at  end  of  treatment
compared with waiting list (MD −10.70, 95% CI −12.31 to −9.09; 1
trial, 30 participants; P < 0.001; Analysis 16.10.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

One trial reported continuous data on dissociation and psychotic-
like symptoms (Bohus 2013).

No data were available on any time point for self-harm.

DBT  did  not  reduce  dissociation  and  psychotic-like  symptoms  at
end  of  treatment  compared  with  waiting  list  (MD  −6.45,  95%  CI
−16.51 to 3.61; 1 trial, 33 participants; P = 0.21; Analysis 16.8).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

16.9 Depression

Three trials reported continuous data on depression (Bohus 2013;
McMain 2017; Mohamadizadeh 2017).

DBT  reduced  depression  at  end  of  treatment  compared  with
waiting  list  or  no  treatment  (SMD  −3.20,  95%  CI  −5.57  to  −0.83;  3
trials, 141 participants; P = 0.008; Analysis 16.9).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Secondary outcomes

Anger

One trial reported continuous data on anger (Kamalabadi 2012).

CDBT reduced anger at end of treatment compared with waiting list
(MD −1.42, 95% CI −1.72 to −1.12; 1 trial, 30 participants; P < 0.001;
Analysis 16.10.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Affective instability

One  trial  reported  continuous  data  on  affective 
(Kamalabadi 2012).

instability

CDBT  reduced  affective  instability  at  end  of  treatment  compared
with  waiting  list  (MD  −4.01,  95%  CI  −5.44  to  −2.58;  1  trial,  30
participants; P < 0.001; Analysis 16.10.5).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Chronic feelings of emptiness

One trial reported continuous data on chronic feelings of emptiness
(Kamalabadi 2012).

CDBT  reduced  chronic  feelings  of  emptiness  at  end  of  treatment
compared with waiting list (MD −3.54, 95% CI −4.81 to −2.27; 1 trial,
30 participants; P < 0.001; Analysis 16.10.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Impulsivity

One  trial  reported  continuous  data  on  impulsivity  (Kamalabadi
2012).

CDBT  reduced  impulsivity  at  end  of  treatment  compared  with
waiting list (MD −0.51, 95% CI −0.72 to −0.30; 1 trial, 30 participants;
P < 0.001; Analysis 16.10.7).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(Kamalabadi 2012).

CDBT  reduced  interpersonal  problems  at  end  of  treatment
compared with waiting list (MD −1.98, 95% CI −2.47 to −1.49; 1 trial,
30 participants;, P < 0.001; Analysis 16.10.8).

CDBT  reduced  dissociation  or  psychotic-like  symptoms  at  end  of
treatment  compared  with  waiting  list  (MD  −1.92,  95%  CI  −2.46  to
−1.38; 1 trial, 30 participants; P < 0.001; Analysis 16.10.11).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Depression

One  trial  reported  continuous  data  on  depression  (Kamalabadi
2012).

CDBT  reduced  depression  at  end  of  treatment  compared  with
waiting list (MD −10.43, 95% CI −11.86 to −9.00; 1 trial, number of
participants = 30, P < 0.001; Analysis 16.10.12).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for attrition and adverse
effects.

17. Schema-focused therapy (SFT) versus no treatment

17.1 Primary outcome: suicide-related outcomes

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Mohamadizadeh 2017).

SFT  reduced  suicide-related  outcomes  at  end  of  treatment
compared with no treatment (MD −16.67, 95% CI −17.70 to −15.64;
1 trial, 24 participants; P < 0.001; Analysis 17.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for BPD symptom severity,
self-harm, and psychosocial functioning.

Abandonment

17.2 Secondary outcome: depression

One trial reported continuous data on abandonment (Kamalabadi
2012).

One trial reported continuous data on depression (Mohamadizadeh
2017).

CDBT reduced abandonment at end of treatment compared with
waiting list (MD −0.86, 95% CI −1.09 to -0.63; 1 trial, 30 participants;
P < 0.001; Analysis 16.10.9).

SFT  reduced  depression  at  end  of  treatment  compared  with
no  treatment  (MD  −33.92,  95%  CI  −35.40  to  −32.44;  1  trial,  24
participants; P < 0.001; Analysis 17.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Identity disturbance

One  trial  reported  continuous  data  on  identity  disturbance
(Kamalabadi 2012).

CDBT reduced identity disturbance at end of treatment compared
with  waiting  list  (MD  −2.44,  95%  CI  −2.77  to  −2.11;  1  trial,  30
participants; P < 0.001; Analysis 16.10.10).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Dissociation and psychotic-like symptoms

One trial reported continuous data on dissociation and psychotic-
like symptoms (Kamalabadi 2012).

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, attrition and adverse effects.

18. Interpersonal psychotherapy (IPT) versus waiting list

Primary outcomes

18.1 BPD symptom severity

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Bellino 2010).

IPT  did  not  reduce  BPD  symptom  severity  at  end  of  treatment
compared with waiting list (MD −0.19, 95% CI −3.71 to 3.33; 1 trial,
44 participants; P = 0.92; Analysis 18.1).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

18.2 Self-harm

One trial reported continuous data on self-harm (Bellino 2010).

IPT  did  not  reduce  self-harm  at  end  of  treatment  compared  with
waiting list (MD 0.03, 95% CI −1.09 to 1.15; 1 trial, 44 participants; P
= 0.96; Analysis 18.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

18.3 Psychosocial functioning

Two  trials  reported  continuous  data  on  psychosocial  functioning
(Bellino 2006; Bellino 2010).

IPT did not improve psychosocial functioning at end of treatment
compared with waiting list (SMD −0.03, 95% CI −0.48 to 0.42; 2 trials,
76 participants; I2 = 0%; P = 0.91; Analysis 18.3.1).

IPT improved psychosocial functioning at zero to six months follow-
up compared with waiting list (SMD −0.89, 95% CI −1.65 to −0.13; 1
trial, 30 participants; P = 0.02; MD −12.39, 95% CI −22.00 to −2.78; 1
trial, 30 participants; P = 0.01; Analysis 18.3.2).

IPT improved psychosocial functioning at six to 12 months follow-
up compared with waiting list (SMD −1.04, 95% CI −1.81 to −0.27; 1
trial, 30 participants; P = 0.008; MD −13.59, 95% CI −22.65 to −4.53;
1 trial, 30 participants; P = 0.003; Analysis 18.3.3).

IPT did not improve psychosocial functioning at above 12 months
follow-up compared with waiting list (SMD −0.38, 95% CI −1.14 to
0.37; 1 trial, 30 participants; P = 0.32; MD −14.68, 95% CI −46.63 to
17.27; 1 trial, 30 participants; P = 0.37; Analysis 18.3.4).

No  data  were  available  on  any  time  point  for  suicide-related
outcomes.

Secondary outcomes

18.4 Anger

One trial reported continuous data on anger (Bellino 2010).

IPT did not reduce anger at end of treatment compared with waiting
list (MD 0.01, 95% CI −0.40 to 0.42; 1 trial, 44 participants; P = 0.96;
Analysis 18.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

18.5 Affective instability

One trial reported continuous data on affective instability (Bellino
2010).

IPT reduced affective instability at end of treatment compared with
waiting list (MD −1.02, 95% CI −1.66 to −0.38; 1 trial, 44 participants;
P = 0.002; Analysis 18.5.1).

IPT did not reduce affective instability at zero to six months follow-
up  compared  with  waiting  list  (MD  −0.46,  95%  CI  −1.15  to  0.23;  1
trial, 30 participants; P = 0.19; Analysis 18.5.2).

Cochrane Database of Systematic Reviews

IPT did not reduce affective instability at six to 12 months follow-up
compared with waiting list (MD −0.39, 95% CI −1.12 to 0.34; 1 trial,
30 participants; P = 0.29; Analysis 18.5.3).

IPT did not reduce affective instability at above 12 months follow-
up  compared  with  waiting  list  (MD  −0.34,  95%  CI  −1.17  to  0.49;  1
trial, 30 participants; P = 0.42; Analysis 18.5.4).

18.6 Chronic feelings of emptiness

One trial reported continuous data on chronic feelings of emptiness
(Bellino 2010).

IPT did not reduce chronic feelings of emptiness at end of treatment
compared with waiting list (MD 0.04, 95% CI −0.21 to 0.29; 1 trial, 44
participants; P = 0.75; Analysis 18.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

18.7 Impulsivity

One trial reported continuous data on impulsivity (Bellino 2010).

IPT reduced impulsivity at end of treatment compared with waiting
list  (MD  −1.03,  95%  CI  −1.69  to  −0.37;  1  trial,  44  participants;  P  =
0.002; Analysis 18.7.1).

IPT reduced impulsivity at zero to six months follow-up compared
with  waiting  list  (MD  −1.10,  95%  CI  −1.95  to  −0.25;  1  trial,  30
participants; P = 0.01; Analysis 18.7.2).

IPT reduced impulsivity at six to 12 months compared with waiting
list (MD −1.10, 95% CI −2.06 to −0.14; 1 trial, 30 participants; P = 0.02;
Analysis 18.7.3).

IPT reduced impulsivity at above 12 months follow-up compared
with  waiting  list  (MD  −1.09,  95%  CI  −2.09  to  −0.09;  1  trial,  30
participants; P = 0.03; Analysis 18.7.4).

18.8 Interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(Bellino 2010).

IPT reduced interpersonal problems at end of treatment compared
with  waiting  list  (MD  −1.14,  95%  CI  −1.94  to  −0.34;  1  trial,  44
participants; P = 0.005; Analysis 18.8.1).

IPT reduced interpersonal problems at zero to six months follow-up
compared with waiting list (MD −2.00, 95% CI −2.98 to −1.02; 1 trial,
30 participants; P < 0.001; Analysis 18.8.2).

IPT reduced interpersonal problems at six to 12 months follow-up
compared with waiting list (MD −1.56, 95% CI −2.74 to −0.38; 1 trial,
30 participants; P = 0.009; Analysis 18.8.3).

IPT  reduced  interpersonal  problems  above  12  months  follow-up
compared with waiting list (MD −1.48, 95% CI −2.63 to −0.33; 1 trial,
30 participants; P = 0.01; Analysis 18.8.4).

18.9 Abandonment

One trial reported continuous data on abandonment (Bellino 2010).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

IPT  did  not  reduce  abandonment  at  end  of  treatment  compared
with  waiting  list  (MD  0.01,  95%  CI  −0.90  to  0.92;  1  trial,  44
participants; P = 0.98; Analysis 18.9).

Secondary outcomes

19.1 Impulsivity

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

18.10 Identity disturbance

One trial reported continuous data on identity disturbance (Bellino
2010).

IPT  did  not  reduce  identity  disturbance  at  end  of  treatment
compared with waiting list (MD −0.03, 95% CI −0.56 to 0.50; 1 trial,
44 participants; P = 0.91; Analysis 18.10).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

18.11 Dissociation and psychotic-like symptoms

One trial reported continuous data on dissociation and psychotic-
like symptoms (Bellino 2010).

IPT did not reduce dissociation and psychotic-like symptoms at end
of treatment compared with waiting list (MD 0.23, 95% CI −1.06 to
1.52; 1 trial, 44 participants; P = 0.73; Analysis 18.11).

One trial reported continuous data on impulsivity (Zanarini 2008).

Once-only  interventions  did  not  reduce  impulsivity  at  end  of
treatment  compared  with  waiting  list  (MD  −0.48,  95%  CI  −1.07  to
0.11; 1 trial, 50 participants; P = 0.11; Analysis 19.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

19.2 Interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(Zanarini 2008).

Once-only interventions reduced interpersonal problems at end of
treatment  compared  with  waiting  list  (MD  −0.88,  95%  CI  −1.59  to
−0.17; 1 trial, 50 participants; P = 0.02; Analysis 19.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

19.3 Attrition

One trial reported dichotomous data on attrition (Zanarini 2008).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

There  was  no  attrition  at  end  of  treatment  in  any  of  the  groups
(effect not estimable; one trial, 50 participants; Analysis 19.3).

18.12 Depression

Three trials reported continuous data on depression (Bellino 2006;
Bellino 2010; Smith 2012).

No  data  were  available  on  any  time  point  for  anger,  affective
instability,  chronic  feelings  of  emptiness,  abandonment,  identity
disturbance, dissociation and psychotic-like symptoms, depression
and adverse effects.

IPT did not reduce depression at end of treatment compared with
waiting list (SMD −0.52, 95% CI −1.11 to 0.06; 3 trials, 98 participants;
P = 0.08; Analysis 18.12; random-effects model).

20. Eclectic treatments versus waiting list

20.1 Primary outcome: psychosocial functioning

IPT reduced depression at end of treatment compared with waiting
list (SMD −0.46, 95% CI − 0.88 to −0.05; 3 trials, 98 participants; P =
0.03; analysis not shown; fixed-effect model).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

One  trial  reported  continuous  data  on  psychosocial  functioning
(Haeyen 2018).

Eclectic  treatments  improved  psychosocial  functioning  at  end  of
treatment compared with waiting list (MD −18.64, 95% CI −30.06 to
−7.22; 1 trial, 16 participants; P = 0.001; Analysis 20.1).

18.13 Attrition

Two  trials  reported  dichotomous  data  on  attrition  (Bellino  2006;
Bellino 2010).

IPT  did  not  reduce  attrition  at  end  of  treatment  compared  with
waiting list (RR 0.55, 95% CI 0.20 to 1.50; 2 trials, 94 participants; P
= 0.24; Analysis 18.13).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for adverse effects.

19. Once-only interventions (individual setting) versus waiting
list

Primary outcomes

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for BPD symptom severity,
self-harm, and suicide-related outcomes.

20.2 Secondary outcome: interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(Haeyen 2018).

Eclectic  treatments  reduced  interpersonal  problems  at  end  of
treatment  compared  with  waiting  list  (MD  −4.89,  95%  CI  −8.49  to
−1.29; 1 trial, 16 participants; P = 0.008; Analysis 20.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for BPD symptom severity,
self-harm, suicide-related outcomes and psychosocial functioning.

No  data  were  available  on  any 
for  anger,
affective  instability,  chronic  feelings  of  emptiness,  impulsivity,

time  point 

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

abandonment,  identity  disturbance,  dissociation  and  psychotic-
like symptoms, depression, attrition and adverse effects.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

21. Dialectical behaviour therapy (DBT) and related
treatments versus active treatment

21.1 Standard DBT (DBT) versus client-centred therapy (CCT)
(continuous)

Primary outcomes

Self-harm

One trial reported continuous data on self-harm (Turner 2000).

Depression

One trial reported continuous data on depression (Turner 2000).

DBT reduced depression at end of treatment compared with CCT
(MD −9.16, 95% CI −14.79 to −3.53; 1 trial, 24 participants; P = 0.001;
Analysis 21.1.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

DBT  reduced  self-harm  at  end  of  treatment  compared  with  CCT
(MD −2.75, 95% CI −4.42 to −1.08; 1 trial, 24 participants; P = 0.001;
Analysis 21.1.1).

No  data  were  available  on  any  time  point 
for  affective
instability, chronic feelings of emptiness, interpersonal problems,
abandonment, identity disturbance, attrition, and adverse effects.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

21.2 DBT versus CCT (dichotomous)

Primary outcomes

Suicide-related outcomes

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Turner 2000).

DBT  reduced  suicide-related  outcomes  at  end  of  treatment
compared with CCT (MD −7.75, 95% CI −14.66 to −0.84; 1 trial, 24
participants; P = 0.03; Analysis 21.1.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Turner 2000).

DBT  did  not  reduce  attrition  at  end  of  treatment  compared  with
CCT (RR 0.50, 95% CI 0.16 to 1.55; 1 trial, 24 participants; P = 0.23;
Analysis 21.2).

No data were available on any time point for BPD symptom severity
and psychosocial functioning.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Secondary outcomes

Anger

One trial reported continuous data on anger (Turner 2000).

DBT  reduced  anger  at  end  of  treatment  compared  with  CCT  (MD
−1.00,  95%  CI  −1.98  to  −0.02;  1  trial,  24  participants;  P  =  0.05,
Analysis 21.1.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Impulsivity

One trial reported continuous data on impulsivity (Turner 2000).

DBT reduced impulsivity at end of treatment compared with CCT
(MD −1.50, 95% CI −2.60 to −0.40; 1 trial, 24 participants; P = 0.008;
Analysis 21.1.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms. depression, and adverse effects.

21.3 Standard DBT (DBT) versus good psychiatric management
(GPM) (continuous)

Primary outcomes

BPD symptom severity

One  trial  reported  continuous  data  on  BPD  symptom  severity
(McMain 2009).

DBT  did  not  reduce  BPD  symptom  severity  at  end  of  treatment
compared  with  GPM  (MD  −0.23,  95%  CI  −1.97  to  1.51;  1  trial,  180
participants; P = 0.80; Analysis 21.3.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Self-harm

Dissociation and psychotic-like symptoms

One trial reported continuous data on self-harm (McMain 2009).

One trial reported continuous data on dissociation and psychotic-
like symptoms (Turner 2000).

DBT reduced dissociation and psychotic-like symptoms at end of
treatment compared with CCT (MD −7.16, 95% CI −12.15 to −2.17; 1
trial, 24 participants; P = 0.005; Analysis 21.1.5).

DBT did not reduce self-harm at end of treatment compared with
GPM (MD −8.58, 95% CI −19.38 to 2.22; 1 trial, 180 participants; P =
0.12; Analysis 21.3.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No  data  were  available  on  any  time  point  for  suicide-related
outcomes and psychosocial functioning.

21.5 Standard DBT (DBT) versus individual DBT therapy +
activities group (DBT-I) (continuous)

Secondary outcomes

Anger

Primary outcomes

Self-harm

One trial reported continuous data on anger (McMain 2009).

One trial reported continuous data on self-harm (Linehan 2015a).

DBT did not reduce anger at end of treatment compared with GPM
(MD −0.15, 95% CI −1.65 to 1.35; 1 trial, 180 participants; P = 0.85;
Analysis 21.3.3).

DBT did not reduce self-harm at end of treatment compared with
DBT-I (MD −10.40, 95% CI −22.99 to 2.19; 1 trial, 66 participants; P =
0.11; Analysis 21.5.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(McMain 2009).

DBT  did  not  reduce  interpersonal  problems  at  end  of  treatment
compared with GPM (MD −1.34, 95% CI −15.36 to 12.68; 1 trial, 180
participants; P = 0.85; Analysis 21.3.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Depression

One trial reported continuous data on depression (McMain 2009).

DBT did not reduce depression at end of treatment compared with
GPM (MD −2.65, 95% CI −7.18 to 1.88; 1 trial, 180 participants; P =
0.25; Analysis 21.3.5).

DBT did not reduce self-harm at six to 12 months compared with
DBT-I (MD −8.10, 95% CI −19.59 to 3.39; 1 trial, 66 participants; P =
0.17; Analysis 21.5.2).

No data were available for zero to six months and above 12 months
follow-up.

Suicide-related outcomes

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Linehan 2015a).

DBT did not reduce suicide-related outcomes at end of treatment
compared  with  DBT-I  (MD  0.50,  95%  CI  −1.37  to  2.37;  1  trial,  66
participants; P = 0.60; Analysis 21.5.3).

DBT reduced suicide-related outcomes at six to 12 months follow-
up compared with DBT-I (MD −1.60, 95% CI −2.79 to −0.41; 1 trial, 66
participants; P = 0.009; Analysis 21.5.4).

No data were available for zero to six months and above 12 months
follow-up.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for BPD symptom severity
and psychosocial functioning.

No data were available on any time point for affective instability,
chronic feelings of emptiness, impulsivity, abandonment, identity
disturbance,  dissociation  and  psychotic-like  symptoms,  attrition,
and adverse effects.

21.4 DBT versus GPM (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (McMain 2009).

DBT  did  not  reduce  attrition  at  end  of  treatment  compared  with
GPM (RR 1.03, 95% CI 0.71 to 1.49; 1 trial, 180 participants; P = 0.88;
Analysis 21.4).

Secondary outcomes: depression

One trial reported continuous data on depression (Linehan 2015a).

DBT reduced depression at end of treatment compared with DBT-I
(MD −5.90, 95% CI −9.74 to −2.06; 1 trial, 66 participants; P = 0.003,
Analysis 21.5.5).

DBT  did  not  reduce  depression  at  six  to  12  months  follow-up
compared  with  DBT-I  (MD  1.30,  95%  CI  −3.10  to  5.70;  1  trial,  66
participants; P = 0.56; Analysis 21.5.6).

No data were available for zero to six months and above 12 months
follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, attrition, and adverse effects.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

21.6 DBT versus GPM (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Linehan 2015a).

DBT  did  not  reduce  attrition  at  end  of  treatment  compared  with
DBT-I (RR 0.50, 95% CI 0.25 to 1.01; 1 trial, 66 participants; P = 0.05;
Analysis 21.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

21.7 Standard DBT (DBT) versus skills training group + individual
case management (DBT-S) (continuous)

Primary outcomes

Self-harm

One trial reported continuous data on self-harm (Linehan 2015a).

DBT did not reduce self-harm at end of treatment compared with
DBT-S (MD 0.30, 95% CI −8.42 to 9.02; 1 trial, 66 participants, P = 0.95;
Analysis 21.7.1).

DBT  did  not  reduce  self-harm  at  six  to  12  months  follow-up
compared  with  DBT-S  (MD  −1.50,  95%  CI  −9.04  to  6.04,  1  trial,  66
participants; P = 0.70; Analysis 21.7.2).

No data were available for zero to six months and above 12 months
follow-up.

Suicide-related outcomes

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Linehan 2015a).

DBT did not reduce suicide-related outcomes at end of treatment
compared  with  DBT-S  (MD  0.80,  95%  CI  −1.06  to  2.66;  1  trial,  66
participants; P = 0.40; Analysis 21.7.3).

DBT reduced suicide-related outcomes at six to 12 months follow-
up compared with DBT-S (MD 0.50, 95% CI −0.02 to 1.02; 1 trial, 66
participants; P = 0.06; Analysis 21.7.4).

No data were available for zero to six months and above 12 months
follow-up.

Cochrane Database of Systematic Reviews

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, attrition, and adverse effects.

21.8 DBT versus DBT-S (dichotomous)

Primary outcomes

No data were available on any time point for BPD symptom severity,
self-harm, suicide-related outcomes and psychosocial functioning.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Linehan 2015a).

DBT did not reduce attrition at six to 12 months follow-up compared
with DBT-S (RR 0.62, 95% CI 0.29 to 1.29; 1 trial, 66 participants; P =
0.20; Analysis 21.8).

No data were available for end of treatment, zero to six months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

21.9 Standard DBT (DBT) versus step-down DBT (DBT-SD)
(continuous)

Primary outcomes

BPD symptom severity

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Sinnaeve 2018).

DBT did not reduce BPD severity at end of treatment compared with
DBT-SD (MD −2.83, 95% CI −11.21 to 5.55; 1 trial, 38 participants; P
= 0.51; Analysis 21.9.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Self-harm

One trial reported continuous data on self-harm (Sinnaeve 2018).

DBT did not reduce self-harm at end of treatment compared with
DBT-SD (MD 4.10, 95% CI −4.07 to 12.27; 1 trial, 38 participants; P =
0.33; Analysis 21.9.2).

No data were available on any time point for BPD symptom severity
and psychosocial functioning.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Secondary outcomes: depression

Suicide-related outcomes

One trial reported continuous data on depression (Linehan 2015a).

DBT did not reduce depression at end of treatment compared with
DBT-S (MD 1.90, 95% CI −1.60 to 5.40; 1 trial, 66 participants; P = 0.29;
Analysis 21.7.5).

DBT  did  not  reduce  depression  at  six  to  12  months  follow-up
compared  with  DBT-S  (MD  3.30,  95%  CI  −0.90  to  7.50;  1  trial,  66
participants; P = 0.12; Analysis 21.7.6).

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Sinnaeve 2018).

DBT did not reduce suicide-related outcomes at end of treatment
compared with DBT-SD (MD 0.30, 95% CI −0.73 to 1.33; 1 trial, 38
participants; P = 0.57; Analysis 21.9.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available for zero to six months, and above 12 months
follow-up.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No  data  were  available  on  any  time  point  for  psychosocial
functioning.

Secondary outcomes

Anger

One trial reported continuous data on anger (Sinnaeve 2018).

DBT did not reduce anger symptoms at end of treatment compared
with DBT-SD (MD −0.53, 95% CI −1.48 to 0.43; 1 trial, 41 participants;
P = 0.28; Analysis 21.9.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Affective instability

One  trial  reported  continuous  data  on  affective 
(Sinnaeve 2018).

instability

DBT  did  not  reduce  affective  instability  at  end  of  treatment
compared with DBT-SD (MD −0.71, 95% CI −2.51 to 1.09; 1 trial, 41
participants; P = 0.44; Analysis 21.9.5).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Chronic feelings of emptiness

DBT  reduced  abandonment  at  end  of  treatment  compared  with
DBT-SD (MD −1.11, 95% CI −2.14 to −0.08; 1 trial, 41 participants; P
= 0.03; Analysis 21.9.9).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Dissociation and psychotic-like symptoms

One trial reported continuous data on dissociation and psychotic-
like symptoms (Sinnaeve 2018).

DBT  did  not  reduce  dissociation  and  psychotic-like  symptoms  at
end of treatment compared with DBT-SD (MD −0.44, 95% CI −1.56 to
0.68; 1 trial, 41 participants; P = 0.44; Analysis 21.9.10).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for identity disturbance,
depression, attrition, and adverse effects.

21.10 DBT versus DBT-SD (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

One trial reported continuous data on chronic feelings of emptiness
(Sinnaeve 2018).

Secondary outcome: attrition

DBT  did  not  reduce  chronic  feelings  of  emptiness  at  end  of
treatment compared with DBT-SD (MD 0.18, 95% CI −1.68 to 2.04; 1
trial, 41 participants; P = 0.85; Analysis 21.9.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Impulsivity

One trial reported continuous data on impulsivity (Sinnaeve 2018).

DBT did not reduce impulsivity at end of treatment compared with
DBT-SD (MD 0.24, 95% CI −0.26 to 0.75; 1 trial, 41 participants; P =
0.34; Analysis 21.9.7).

One  trial  reported  dichotomous  data  on  attrition  (Sinnaeve
2018).0.37 [0.17, 0.78]

DBT reduced attrition at end of treatment compared with DBT-SD
(RR  0.37,  95%  CI  0.17  to  0.78;  1  trial,  84  participants;  P  =  0.009;
Analysis 21.10).

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

21.11 Standard DBT (DBT) versus DBT prolonged exposure (DBT-
PE) (continuous)

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Primary outcomes

Self-harm

Interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(Sinnaeve 2018).

DBT reduced interpersonal at end of treatment problems compared
with  DBT-SD  (MD  −1.31,  95%  CI  −2.05  to  −0.57;  1  trial,  41
participants; P = 0.005; Analysis 21.9.8).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Abandonment

One  trial  reported  continuous  data  on  abandonment  (Sinnaeve
2018).

One trial reported continuous data on self-harm (Harned 2014).

DBT did not reduce self-harm at end of treatment compared with
DBT-PE (MD 0.10, 95% CI −1.86 to 2.06; 1 trial, 18 participants; P =
0.92; Analysis 21.11.1).

DBT  did  not  reduce  self-harm  at  zero  to  six  months  follow-up
compared with DBT-PE (MD −0.30, 95% CI −1.09 to 0.49; 1 trial, 18
participants; P = 0.46; Analysis 21.11.2).

No data were available for six to 12 months and above 12 months
follow-up.

Suicide-related outcomes

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Harned 2014).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

There were no suicide attempts in DBT-PE group at end of treatment
(effect not estimable; 1 trial, 18 participants; Analysis 21.11.3).

There were no suicide attempts in DBT group at zero to six months
follow-up  (effect  not  estimable;  1  trial,  18  participants;  Analysis
21.11.4).

No data were available for six to 12 months and above 12 months
follow-up.

Psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Harned 2014).

DBT did not improve psychosocial functioning at end of treatment
compared with DBT-PE (MD 5.27, 95% CI −2.06 to 12.60; 1 trial, 18
participants; P = 0.16, Analysis 21.11.5).

DBT did not improve psychosocial functioning at zero to six months
follow-up compared with DBT-PE (MD 2.00, 95% CI −6.27 to 10.27; 1
trial, 18 participants; P = 0.64; Analysis 21.11.6).

DBT did not reduce depression at end of treatment compared with
DBT-PE (MD 3.70, 95% CI −3.19 to 10.59; 1 trial, 18 participants; P =
0.29; Analysis 21.11.11).

DBT  did  not  reduce  depression  at  zero  to  six  months  follow-up
compared  to  DBT-PE  (MD  4.30,  95%  CI  −1.08  to  9.68;  1  trial,  18
participants; P = 0.12; Analysis 21.11.12).

No data were available for six to 12 months and above 12 months
follow-up.

No  data  were  available  on  any 
for  anger,
affective  instability,  chronic  feelings  of  emptiness,  impulsivity,
abandonment, identity disturbance, attrition, and adverse effects.

time  point 

21.12 Standard DBT (DBT) versus DBT prolonged exposure (DBT-
PE) (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

No data were available for six to 12 months and above 12 months
follow-up.

Secondary outcome: attrition

No data were available on any time point for BPD symptom severity.

Secondary outcomes

Interpersonal problems

One trial reported dichotomous data on attrition Harned 2014).

DBT  did  not  reduce  attrition  at  zero  to  six  months  follow-up
compared  with  DBT-PE  (RR  0.88,  95%  CI  0.27  to  2.88;  1  trial,  28
participants; P = 0.84; Analysis 21.12).

One  trial  reported  continuous  data  on  interpersonal  problems
(Harned 2014).

No data were available for end of treatment, six to 12 months and
above 12 months follow-up.

DBT  did  not  reduce  interpersonal  problems  at  end  of  treatment
compared  with  DBT-PE  (MD  0.14,  95%  CI  −0.42  to  0.70;  1  trial,  18
participants; P = 0.62; Analysis 21.11.7).

DBT did not reduce interpersonal problems at zero to six months
follow-up compared with DBT-PE (MD 0.19, 95% CI −0.48 to 0.86; 1
trial, 18 participants; P = 0.58; Analysis 21.11.8).

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression,and adverse effects.

21.13 DBT skills group plus case management (DBT-S) versus
DBT individual therapy plus activity group (DBT-I) (continuous)

No data were available for six to 12 months and above 12 months
follow-up.

Primary outcomes

Self-harm

Dissociation and psychotic-like symptoms

One trial reported continuous data on self-harm (Linehan 2015a).

One trial reported continuous data on dissociation and psychotic-
like symptoms (Harned 2014).

DBT  did  not  reduce  dissociation  and  psychotic-like  symptoms  at
end of treatment compared with DBT-PE (MD 4.60, 95% CI −9.24 to
18.44; 1 trial, 18 participants; P = 0.51; Analysis 21.11.9).

DBT  did  not  reduce  dissociation  and  psychotic-like  symptoms  at
zero to six months follow-up compared with DBT-PE (MD 6.00, 95%
CI −9.46 to 21.46; 1 trial, 18 participants; P = 0.45; Analysis 21.11.10).

DBT-S did not reduce self harm at end of treatment compared with
DBT-I (MD −10.70, 95% CI −22.47 to 1.07; 1 trial, 66 participants; P =
0.07; Analysis 21.13.1).

DBT-S  did  not  reduce  self  harm  at  six  to  12  months  follow-up
compared with DBT-I (MD −6.60, 95% CI −19.72 to 6.52; 1 trial, 66
participants; P = 0.32; Analysis 21.13.2).

No data were available for six to 12 months and above 12 months
follow-up.

No data were available for six to 12 months and above 12 months
follow-up.

Suicide-related outcomes

Depression

One trial reported continuous data on depression (Harned 2014).

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Linehan 2015a).

DBT-S did not reduce suicide-related outcomes at end of treatment
compared  with  DBT-I  (MD  −0.30,  95%  CI  −1.72  to  1.12;  1  trial,  66
participants: P = 0.68; Analysis 21.13.3).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

DBT-S reduced suicide-related outcomes at six to 12 months follow-
up compared with DBT-I (MD −2.10, 95% CI −3.21 to −0.99; 1 trial, 66
participants; P = 0.0002; Analysis 21.13.4).

DBT-S reduced BPD symptom severity at zero to six months follow-
up compared with CT-G (MD −0.96, 95% CI −1.15 to −0.77; 1 trial, 82
participants = 82; P < 0.001; Analysis 21.15.2).

No data were available for six to 12 months and above 12 months
follow-up.

No data were available for six to 12 months and above 12 months
follow-up.

No data were available on any time point for BPD symptom severity
and psychosocial functioning.

Secondary outcomes: depression

One trial reported continuous data on depression (Linehan 2015a).

DBT-S reduced depression at end of treatment compared with DBT-
I (MD −7.80, 95% CI −11.27 to −4.33; 1 trial, 66 participants; P < 0.001;
Analysis 21.13.5).

DBT-S  did  not  reduce  depression  at  six  to  12  months  follow-up
compared  with  DBT-I  (MD  −2.00,  95%  CI  −6.44  to  2.44;  1  trial,  66
participants; P = 0.38; Analysis 21.13.6).

No data were available for six to 12 months and above 12 months
follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, attrition, and adverse effects.

21.14 DBT-S versus DBT-I (dichotomous)

Primary outcomes

Suicide-related outcomes

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Lin 2019).

DBT-S did not reduce suicide-related outcomes at end of treatment
compared  with  CT-G  (MD  0.46,  95%  CI  −2.47  to  3.39;  1  trial,  82
participants; P = 0.76; Analysis 21.15.3).

DBT-S  reduced  suicide-related  outcomes  at  zero  to  six  months
follow-up compared with CT-G (MD −2.69, 95% CI −4.89 to −0.49; 1
trial, 82 participants; P = 0.02; Analysis 21.15.4).

No data were available for six to 12 months and above 12 months
follow-up.

No  data  were  available  on  any  time  point  for  self-harm  and
psychosocial functioning.

Secondary outcomes: depression

One trial reported continuous data on depression (Lin 2019).

DBT-S  did  not  reduce  depression  at  end  of  treatment  compared
with CT-G (MD −2.12, 95% CI −5.25 to 1.01; 1 trial, 82 participants; P
= 0.18, Analysis 21.15.5).

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

DBT-S  did  not  reduce  depression  at  zero  to  six  months  follow-up
compared  with  CT-G  (MD  −1.60,  95%  CI  −5.07  to  1.87;  1  trial,  82
participants, P = 0.37 Analysis 21.15.6).

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Linehan 2015a).

DBT-S  did  not  reduce  attrition  at  six  to  12  months  follow-up
compared  with  DBT-I  (RR  0.81,  95%  CI  0.61  to  1.09;  1  trial,  66
participants; P = 0.17; Analysis 21.14).

No data were available for end of treatment, zero to six months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

No data were available for six to 12 months and above 12 months
follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, attrition, and adverse effects.

21.16 DBT-S versus CT-G (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

21.15 DBT skills group (DBT-S) versus cognitive therapy group
(CT-G) (continuous)

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Lin 2019).

Primary outcomes

BPD symptom severity

One trial reported continuous data on BPD symptom severity (Lin
2019).

DBT-S did not reduce BPD symptom severity at end of treatment
compared  with  CT-G  (MD  0.26,  95%  CI  −0.13  to  0.65;  1  trial,  82
participants; P = 0.19; Analysis 21.15.1).

DBT-S did not reduce attrition at end of treatment compared with
CT-G (RR 0.71, 95% CI 0.27 to 1.88; 1 trial, 82 participants; P = 0.49;
Analysis 21.16).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

21.17 DBT skills group (DBT-S) versus schema-focused therapy
group (SFT-G) (continuous)

Primary outcomes: suicide-related outcomes

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Mohamadizadeh 2017).

DBT-S did not reduce suicide-related outcomes at end of treatment
compared  with  SFT-G  (MD  0.92,  95%  CI  −0.36  to  2.20;  1  trial,  24
participants; P = 0.16; Analysis 21.17.1).

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, interpersonal problems,
abandonment,  identity  disturbance,  dissociation  and  psychotic-
like symptoms, depression, attrition, and adverse effects.

21.19 DBT-M versus DBT-IE (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcome: attrition

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Two  trials  reported  dichotomous  data  on  attrition  (Carmona  í
Farrés 2019; Elices 2016).

No data were available on any time point for BPD symptom severity,
self-harm, and psychosocial functioning.

Secondary outcomes: depression

One trial reported continuous data on depression (Mohamadizadeh
2017).

SFT-G reduced depression at end of treatment compared with DBT-
S (MD 4.33, 95% CI 2.57 to 6.09; 1 trial, 24 participants; P < 0.001;
Analysis 21.17.2).

DBT-IE reduced attrition at end of treatment compared with DBT-M
(RR 1.86, 95% CI 1.07 to 3.23; 2 trials, 134 participants; I2 = 0%; P =
0.03; Analysis 21.19).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

21.20 DBT mindfulness group (DBT-M) versus loving-kindness
and compassion mediation (LKM/CM)

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, attrition and adverse effects.

21.18 DBT mindfulness group (DBT-M) versus DBT interpersonal
effectiveness group (DBT-IE) (continuous)

Primary outcomes: BPD symptom severity

Two  trials  reported  continuous  data  on  BPD  symptom  severity
(Carmona í Farrés 2019; Elices 2016).

DBT-M did not reduce BPD symptom severity at end of treatment
compared with DBT-IE (SMD −0.45, 95% CI −1.47 to 0.58, 2 trials, 113
participants; I2 = 86%; P = 0.39; Analysis 21.18.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  self-harm,  suicide-
related outcomes and psychosocial functioning.

Secondary outcomes: impulsivity

Primary outcomes: BPD symptom severity

One trial reported continuous data on BPD symptom severity (Feliu-
Soler 2017).

DBT-M did not reduce BPD symptom severity at end of treatment
compared with LKM/CM (MD 0.04, 95% CI −0.66 to 0.74; 1 trial, 32
participants; P = 0.91; Analysis 21.20).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  self-harm,  suicide-
related outcomes and psychosocial functioning.

Secondary outcomes

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, attrition and adverse effects.

22. Cognitive behavioural therapy (CBT) and related
treatments versus active treatment

Two  trials  reported  continuous  data  on  impulsivity  (Carmona  í
Farrés 2019; Elices 2016).

22.1 CBT versus brief trauma and anxiety-related group
psychoeducation (continuous)

DBT-M  did  not  reduce  impulsivity  at  end  of  treatment  compared
with  DBT-IE  (SMD  −0.36,  95%  CI  −0.77  to  0.06;  2  trials,  91
participants; I2 = 0%; P = 0.09; Analysis 21.18.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Primary outcomes

BPD symptom severity

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Kredlow 2017b).

CBT  did  not  reduce  BPD  symptom  severity  at  end  of
treatment compared with brief trauma and anxiety-related group

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

psychoeducation  (MD  −0.26,  95%  CI  −1.46  to  0.94;  1  trial,  50
participants; P = 0.67; Analysis 22.1.1).

22.2 CBT versus brief trauma and anxiety-related group
psychoeducation (dichotomous)

CBT  did  not  reduce  BPD  symptom  severity  at  zero  to  six  months
follow-up compared with brief trauma and anxiety-related group
psychoeducation  (MD  −0.39,  95%  CI  −1.60  to  0.82;  1  trial,  50
participants; P = 0.53; Analysis 22.1.2).

CBT  did  not  reduce  BPD  symptom  severity  at  six  to  12  months
follow-up  compared  to  brief  trauma  and  anxiety-related  group
psychoeducation (MD 0.57, 95% CI −0.48 to 1.62; 1 trial, number of
50 participants; P = 0.29; Analysis 22.1.3).

No data were available for above 12 months follow-up.

Psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Kredlow 2017b).

improve  psychosocial  functioning  at  end  of
CBT  did  not 
treatment compared with brief trauma and anxiety-related group
psychoeducation  (MD  −0.64,  95%  CI  −5.76  to  4.48;  1  trial,  50
participants; P = 0.81; Analysis 22.1.4).

CBT did not improve psychosocial functioning at zero to six months
follow-up compared with brief trauma and anxiety-related group
psychoeducation  (MD  −1.23,  95%  CI  −6.94  to  4.48;  1  trial,  50
participants; P = 0.67; Analysis 22.1.5).

CBT did not improve psychosocial functioning at six to 12 months
follow-up compared with brief trauma and anxiety-related group
psychoeducation  (MD  0.61,  95%  CI  −5.00  to  6.22;  1  trial,  50
participants; P = 0.83; Analysis 22.1.6).

No data were available for above 12 months follow-up.

No data were available on any time point for self-harm and suicide-
related outcomes.

Secondary outcomes: depression

One trial reported continuous data on depression (Kredlow 2017b).

CBT did not reduce depression at end of treatment compared with
brief trauma and anxiety-related group psychoeducation (MD 0.76,
95%  CI  −8.20  to  9.72,  1  trial;  50  participants;  P  =  0.87;  Analysis
22.1.7).

CBT  did  not  reduce  depression  at  zero  to  six  months  follow-
up  compared  with  brief  trauma  and  anxiety-related  group
psychoeducation  (MD  3.13,  95%  CI  −4.05  to  10.31;  1  trial,  50
participants; P = 0.39; Analysis 22.1.8).

CBT  did  not  reduce  depression  at  six  to  12  months  follow-
up  compared  with  brief  trauma  and  anxiety-related  group
psychoeducation  (MD  0.77,  95%  CI  −7.08  to  8.62;  1  trial;  50
participants; P = 0.85; Analysis 22.1.9).

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, attrition, and adverse effects.

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Kredlow 2017b).

CBT  did  not  reduce  attrition  at  end  of  treatment  compared  with
brief trauma and anxiety-related group psychoeducation (RR 1.99,
95% CI 0.58 to 6.82, 1 trial, 50 participants, P = 0.27; Analysis 22.2).

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

22.3 CBT versus interpersonal therapy (IPT) (continuous)

Primary outcome: psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Bellino 2007).

CBT did not improve psychosocial functioning at end of treatment
compared  with  IPT  (MD  −5.30,  95%  CI  −12.36  to  1.76;  1  trial,  26
participants; P = 0.14; Analysis 22.3.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No data were available on any time point for BPD symptom severity,
self-harm, and suicide-related outcomes.

Secondary outcomes: depression

One trial reported continuous data on depression (Bellino 2007).

CBT did not reduce depression at end of treatment compared to IPT
(MD  −0.40,  95%  CI  −4.72  to  3.92;  1  trial,  26  participants;  P  =  0.86;
Analysis 22.3.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, attrition and adverse effects.

22.4 CBT versus interpersonal therapy (IPT) (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Bellino 2007).

CBT  did  not  reduce  attrition  at  end  of  treatment  compared  with
IPT (RR 2.00, 95% CI 0.42 to 9.42; 1 trial; 32 participants; P = 0.38;
Analysis 22.4).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

CBT did not reduce impulsivity at end of treatment compared with
Rogerian support therapy (MD −1.01, 95% CI −3.85 to 1.83; 1 trial, 38
participants; P = 0.49; Analysis 22.5.7).

CBT did not reduce impulsivity at six to 12 months compared with
Rogerian support therapy (MD -2.18, 95% CI -5.91 to 1.55; 1 trial, 21
participants; P = 0.25; Analysis 22.5.8).

22.5 CBT versus Rogerian supportive therapy (continuous)

Primary outcomes

Self-harm

No data were available for zero to six months and above 12 months
follow-up.

Depression

One trial reported continuous data on self-harm (Cottraux 2009).

One trial reported continuous data on depression (Cottraux 2009).

CBT did not reduce self-harm at end of treatment compared with
Rogerian support therapy (MD 0.74, 95% CI −0.03 to 1.51; 1 trial, 38
participants; P = 0.06; Analysis 22.5.1).

CBT did not reduce depression at end of treatment compared with
Rogerian support therapy (MD 1.04, 95% CI −5.59 to 7.67; 1 trial, 38
participants; P = 0.76; Analysis 22.5.9).

CBT did not reduce self-harm at six to 12 months compared with
Rogerian support therapy (MD -0.63, 95% CI −1.75 to 0.49; 1 trial, 21
participants; P = 0.27; Analysis 22.5.2).

CBT  did  reduce  depression  at  six  to  12  months  compared  with
Rogerian support therapy (MD -5.15, 95% CI -9.38 to -0.92; 1 trial, 21
participants; P = 0.02; Analysis 22.5.10).

No data were available for zero to six months and above 12 months
follow-up.

No data were available for zero to six months and above 12 months
follow-up.

Suicide-related outcomes

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Cottraux 2009).

CBT did not reduce suicide-related outcomes at end of treatment
compared with Rogerian support therapy (MD 0.69, 95% CI −2.60 to
3.9; 1 trial, 38 participants; P = 0.68; Analysis 22.5.3).

CBT did not reduce suicide-related outcomes at six to 12 months
compared with Rogerian support therapy (MD -2.43, 95% CI -6.14 to
1.28; 1 trial, 21 participants; P = 0.20; Analysis 22.5.4).

No data were available for zero to six months and above 12 months
follow-up.

Psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Cottraux 2009).

CBT did not improve psychosocial functioning at end of treatment
compared with Rogerian support therapy (MD −0.43, 95% CI −1.31
to 0.45; 1 trial, 38 participants; P = 0.34; Analysis 22.5.5).

CBT did not improve psychosocial functioning at six to 12 months
compared with Rogerian support therapy (MD -0.98, 95% CI -2.02 to
0.06; 1 trial, 21 participants; P = 0.07; Analysis 22.5.6).

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, interpersonal problems,
abandonment,  identity  disturbance,  dissociation  and  psychotic-
like symptoms, attrition, and adverse effects.

22.6 CBT versus Rogerian supportive therapy (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Cottraux 2009).

CBT  did  not  reduce  attrition  at  end  of  treatment  compared  with
Rogerian support therapy (RR 0.90, 95% CI 0.51 to 1.60; 1 trial, 38
participants; P = 0.72; Analysis 22.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

No data were available for zero to six months and above 12 months
follow-up.

22.7 MACT (manual-assisted cognitive therapy) versus MACT +
therapeutic assessment (TA) (continuous)

No data were available on any time point for BPD symptom severity.

Primary outcomes

BPD symptom severity

Secondary outcomes

Impulsivity

One trial reported continuous data on Impulsivity (Cottraux 2009).

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Morey 2010).

MACT  did  not  reduce  BPD  symptom  severity  at  end  of  treatment
compared with MACT + TA (MD −3.75, 95% CI −14.17 to 6.67; 1 trial,
16 participants; P = 0.48; Analysis 22.7.1).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

and  psychotic-like  symptoms,  depression,  attrition,  and  adverse
effects.

Self-harm

22.8 MACT versus MACT + TA (dichotomous)

One trial reported continuous data on self-harm (Morey 2010).

Primary outcomes

MACT did not reduce self-harm at end of treatment compared with
MACT + TA (MD 1.75, 95% CI −18.71 to 22.21; 1 trial, 16 participants;
P = 0.87; Analysis 22.7.2).

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Suicide-related outcomes

One  trial  reported  continuous  data  on  suicide-related  outcomes
(Morey 2010).

MACT did not reduce suicide-related outcomes at end of treatment
compared with MACT + TA (MD −0.63, 95% CI −17.71 to 16.45; 1 trial,
16 participants; P = 0.94; Analysis 22.7.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  psychosocial
functioning.

Secondary outcomes

Affective instability

One trial reported continuous data on affective instability (Morey
2010).

MACT  did  not  reduce  affective  instability  at  end  of  treatment
compared with MACT + TA (MD −5.25, 95% CI −12.10 to 1.60; 1 trial,
16 participants; P = 0.13; Analysis 22.7.4).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(Morey 2010).

MACT  did  not  interpersonal  problems  at  end  of  treatment
compared with MACT + TA (MD −0.50, 95% CI −11.24 to 10.24; 1 trial,
16 participants; P = 0.93; Analysis 22.7.5).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Identity disturbance

One trial reported continuous data on identity disturbance (Morey
2010).

MACT  did  not  reduce  identity  disturbance  at  end  of  treatment
compared with MACT + TA (MD −4.88, 95% CI −14.98 to 5.22; 1 trial,
16 participants; P = 0.34; Analysis 22.7.6).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  chronic
feelings  of  emptiness,  impulsivity,  abandonment,  dissociation

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Morey 2010).

MACT did not reduce attrition at end of treatment compared with
MACT + TA (RR 0.80, 95% CI 0.33 to 1.92; 1 trial, 16 participants; P =
0.62; Analysis 22.8).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

22.9 Meta-cognitive training for BPD (B-MCT) versus progressive
muscle relaxation (PMR) (continuous)

Primary outcome: BPD symptom severity

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Schilling 2018).

B-MCT did not reduce BPD symptom severity at end of treatment
compared  PMR  (MD  −1.80,  95%  CI  −4.97  to  1.37;  1  trial,  49
participants; P = 0.27; Analysis 22.9.1).

PMR reduced BPD symptom severity at zero to six months follow-
up  compared  B-MCT  (MD  −3.60,  95%  CI  −7.16  to  −0.04;  1  trial,  39
participants; P = 0.05; Analysis 22.9.2).

No data were available for six to 12 months and above 12 months
follow-up.

No  data  were  available  on  any  time  point  for  self-harm,  suicide-
related outcomes and psychosocial functioning.

Secondary outcomes: depression

One trial reported continuous data on depression (Schilling 2018).

B-MCT  did  not  reduce  depression  at  end  of  treatment  compared
with PMR (MD −3.20, 95% CI −9.91 to 3.51; 1 trial, 54 participants; P
= 0.35; Analysis 22.9.3).

B-MCT  reduced  depression  at  zero  to  six  months  follow-up
compared  with  PMR  (MD  8.50,  95%  CI  2.03  to  14.97;  1  trial,  47
participants, P = 0.01 Analysis 22.9.4).

No data were available for six to 12 months and above 12 months
follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, attrition and adverse effects.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

22.10 B-MCT versus PMR (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Schilling 2018).

B-MCT did not reduce attrition at end of treatment compared with
PMR (RR 0.95, 95% CI 0.45 to 2.00; 1 trial, 74 participants; P = 0.89;
Analysis 22.10).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

22.11 Motive-oriented therapeutic relationship (MOTR) versus
good psychiatric management (GPM)

Primary outcomes

BPD symptom severity

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Kramer 2014).

MOTR did not reduce BPD symptom severity at end of treatment
compared  with  GPM  (MD  0.07,  95%  CI  −0.38  to  0.52;  1  trial,  74
participants = 74; P = 0.76; Analysis 22.11.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Psychosocial functioning

Two  trials  reported  continuous  data  on  psychosocial  functioning
(Kramer 2011; Kramer 2014).

MOTR  group 
improved  psychosocial  functioning  at  end  of
treatment compared with GPM (SMD −0.45, 95% CI −0.85 to −0.05: 2
trials, 99 participants; I2 = 0%; P = 0.03; Analysis 22.11.2).

Cochrane Database of Systematic Reviews

for  anger,
No  data  were  available  on  any 
affective  instability,  chronic  feelings  of  emptiness,  impulsivity,
abandonment,  identity  disturbance,  dissociation  and  psychotic-
like symptoms, depression, attrition, and adverse effects.

time  point 

22.12 MOTR versus GPM (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcome: attrition

Two  trials  reported  dichotomous  data  on  attrition  (Kramer  2011;
Kramer 2014).

MOTR group did not reduce attrition at end of treatment compared
with GPM (RR 0.61, 95% CI 0.26 to 1.41: 2 trials, 110 participants; I2
= 34%; P = 0.25; Analysis 22.12).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

23. Schema-focused therapy (SFT) versus active treatment

23.1 SFT versus transference-focused psychotherapy (TFP)
(continuous)

Primary outcome: BPD symptom severity

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Giesen-Bloo 2006).

SFT reduced BPD symptom severity at end of treatment compared
with TFP (MD −4.95, 95% CI −9.59 to −0.31; 1 trial, 86 participants; P
= 0.04; Analysis 23.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  self-harm,  suicide-
related outcomes, and psychosocial functioning.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Secondary outcomes

No data were available on any time point for self-harm and suicide-
related outcomes.

Secondary outcomes: interpersonal problems

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, attrition and adverse effects.

Two  trials  reported  continuous  data  on  interpersonal  problems
(Kramer 2011; Kramer 2014).

23.2 SFT versus TFP (dichotomous)

Primary outcomes

MOTR group improved interpersonal problems at end of treatment
compared with GPM (SMD −0.56, 95% CI −0.97 to −0.16: 2 trials, 99
participants; I2 = 0%; P = 0.006; Analysis 22.11.3).

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

Secondary outcome: attrition

One  trial  reported  dichotomous  data  on  attrition  (Giesen-Bloo
2006).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

SFT  reduced  attrition  at  zero  to  six  months  follow-up  compared
with TFP (RR 0.52, 95% CI 0.30 to 0.92; 1 trial, 88 participants; P =
0.02; Analysis 23.2).

24. Systems training for emotional predictability and problem
solving (STEPPS)-based psychoeducation (STEPPS-PE) versus
cognitive rehabilitation (CR)

No data were available for end of treatment, six to 12 months and
above 12 months follow-up.

24.1 STEPPS-PE versus CR (continuous)

Primary outcome: BPD symptom severity

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

23.3 SFT versus SFT + therapist availability (continuous)

Primary outcome: BPD symptom severity

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Nadort 2009).

SFT did not reduce BPD severity at end of treatment compared with
TFP (MD −0.30, 95% CI −5.51 to 4.91; 1 trial, 61 participants; P = 0.91;
Analysis 23.3).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  self-harm,  suicide-
related outcomes and psychosocial functioning.

Secondary outcomes

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, attrition and adverse effects.

23.4 SFT versus SFT + therapist availability (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Nadort 2009).

SFT  did  not  reduce  attrition  at  zero  to  six  months  follow-up
compared  with  TFP  (RR  0.91,  95%  CI  0.35  to  2.41;  1  trial,  62
participants; P = 0.86; Analysis 23.4).

No data were available for end of treatment, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

One  trial  reported  continuous  data  on  BPD  symptom  severity
(Pascual 2015).

STEPPS-PE  reduced  BPD  symptom  severity  at  end  of  treatment
compared with cognitive rehabilitation (MD −3.67, 95% CI −6.52 to
−0.82; 1 trial, 46 participants; P = 0.01; Analysis 24.1.1).

Cognitive rehabilitation reduced BPD symptom severity at zero to
six months follow-up compared with STEPPS-PE (MD 4.68, 95% CI
1.42 to 7.94; 1 trial, 42 participants; P = 0.005; Analysis 24.1.2).

No data were available for six to 12 months and above 12 months
follow-up.

No  data  were  available  on  any  time  point  for  self-harm,  suicide-
related outcomes and psychosocial functioning.

Secondary outcomes

Impulsivity

One trial reported continuous data on impulsivity (Pascual 2015).

Cognitive  rehabilitation  reduced  impulsivity  at  end  of  treatment
compared with STEPPS-PE (MD 1.99, 95% CI 0.06 to 3.92; 1 trial, 46
participants; P = 0.04; Analysis 24.1.3).

Cognitive rehabilitation reduced impulsivity at zero to six months
follow-up compared with STEPPS-PE (MD 9.92, 95% CI 7.38 to 12.46;
1 trial, 42 participants; P < 0.001; Analysis 24.1.4).

No data were available for six to 12 months and above 12 months
follow-up.

Depression

One trial reported continuous data on depression (Pascual 2015).

STEPPS-PE reduced depression at end of treatment compared with
cognitive rehabilitation (MD −2.58, 95% CI −3.62 to −1.54; 1 trial, 48
participants; P < 0.001; Analysis 24.1.5).

STEPPS-PE  reduced  depression  at  zero  to  six  months  follow-up
compared to cognitive rehabilitation (MD −10.11, 95% CI −11.35 to
−8.87; 1 trial, 42 participants; P < 0.001; Analysis 24.1.6).

No data were available for six to 12 months and above 12 months
follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, interpersonal problems,
abandonment,  identity  disturbance,  dissociation  and  psychotic-
like symptoms, attrition and adverse effects.

24.2 STEPPS-PE versus CR (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Pascual 2015).

STEPPS-PE did not reduce attrition at end of treatment compared
with cognitive rehabilitation (RR 0.76, 95% CI 0.39 to 1.47; 1 trial, 70
participants; P = 0.41; Analysis 24.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, interpersonal problems,
abandonment,  identity  disturbance,  dissociation  and  psychotic-
like symptoms, and adverse effects.

25. Eclectic treatments versus active treatment

25.1 Combined inpatient and outpatient psychotherapy versus
outpatient psychotherapy (continuous)

Primary outcome: psychosocial functioning

One  trial  reported  continuous  data  on  psychosocial  functioning
(Antonsen 2017).

improve
Inpatient  and  outpatient  psychotherapy  did  not 
psychosocial  functioning  at  end  of  treatment  compared  with
psychotherapy  alone  (MD  6.50,  95%  CI  −0.06  to  13.06;  1  trial,  52
participants; P = 0.05; Analysis 25.1.1).

improve
Inpatient  and  outpatient  psychotherapy  did  not 
psychosocial functioning at above 12 months follow-up compared
with psychotherapy alone (MD −5.70, 95% CI −13.33 to 1.93; 1 trial,
52 participants; P = 0.14, Analysis 25.1.2).

No data were available for zero to six months and six to 12 months
follow-up.

No data were available on any time point for BPD symptom severity,
self-harm, and suicide-related outcomes.

Secondary outcomes

Interpersonal problems

One  trial  reported  continuous  data  on  interpersonal  problems
(Antonsen 2017).

Inpatient  and  outpatient  psychotherapy  did  not 
reduce
interpersonal problems at end of treatment (three years) compared
with psychotherapy alone (MD 0.05, 95% CI −0.24 to 0.34; 1 trial, 52
participants; P = 0.74; Analysis 25.1.3).

in  the 

Participants 
inpatient  and  outpatient  psychotherapy
reported fewer interpersonal problems at above 12 months follow-
up compared with psychotherapy alone (MD −0.42, 95% CI −0.77 to
−0.0; 1 trial, 52 participants; P = 0.02; Analysis 25.1.4).

No data were available for zero to six months and six to 12 months
follow-up.

Identity disturbance

One  trial  reported  continuous  data  on  identity  disturbance
(Antonsen 2017).

Inpatient  and  outpatient  psychotherapy  did  not  reduce  identity
disturbance  at  end  of  treatment  (three  years)  compared  with

Cochrane Database of Systematic Reviews

psychotherapy  alone  (MD  −0.25,  95%  CI  −0.59  to  0.09;  1  trial,  52
participants; P = 0.15; Analysis 25.1.5).

Inpatient  and  outpatient  psychotherapy  reported  less  identity
disturbance  at  above  12  months  follow-up  compared  with
psychotherapy alone (MD −0.47, 95% CI −0.78 to −0.16; 1 trial, 52
participants; P = 0.003; Analysis 25.1.6).

No data were available for zero to six months and six to 12 months
follow-up.

Depression

One trial reported continuous data on depression (Antonsen 2017).

Inpatient and outpatient psychotherapy did not reduce depression
at  end  of  treatment  (three  years)  compared  with  psychotherapy
alone (MD −0.40, 95% CI −6.25 to 5.45; 1 trial, 52 participants; P =
0.8; Analysis 25.1.7).

Inpatient and outpatient psychotherapy did not reduce depression
at above 12 months follow-up compared to psychotherapy alone
(MD −4.70, 95% CI −11.02 to 1.62; 1 trial, 52 participants; P = 0.14;
Analysis 25.1.8).

No data were available for zero to six months and six to 12 months
follow-up.

No  data  were  available  on  any 
for  anger,
affective  instability,  chronic  feelings  of  emptiness,  impulsivity,
abandonment, dissociation and psychotic-like symptoms, attrition
and adverse effects.

time  point 

25.2 Combined inpatient and outpatient psychotherapy versus
outpatient psychotherapy (dichotomous)

Primary outcomes

No  data  were  available  on  any  time  point  for  BPD  symptom
severity,  self-harm,  suicide-related  outcomes,  and  psychosocial
functioning.

Secondary outcome: attrition

One trial reported dichotomous data on attrition (Antonsen 2017).

Inpatient  and  outpatient  psychotherapy  did  not  reduce  attrition
at  end  of  treatment  (three  years)  compared  with  psychotherapy
alone (RR 0.62, 95% CI 0.26 to 1.49; 1 trial, 52 participants; P = 0.28;
Analysis 25.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

25.3 Integrative BPD-oriented adolescent family therapy (I-
BAFT) versus individual drug counselling (IDC)

Primary outcome: BPD symptom severity

One  trial  reported  dichotomous  data  on  BPD  symptom  severity
(Santisteban 2015).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Integrative  BPD  did  not  reduce  BPD  severity  at  end  of  treatment
compared  with  control  (RR  0.91,  95%  CI  0.50  to  1.64;  1  trial,  40
participants; P = 0.75; Analysis 25.3.1).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  self-harm,  suicide-
related outcomes and psychosocial functioning.

MBT SMD = −0.54 (95% CI −1.24 to 0.16; 3 trials, 239 participants;
I2 = 83%; P = 0.13; Analysis 26.2.2); psychodynamic psychotherapy
SMD  =  −0.69  (95%  CI  −1.98  to  0.59;  4  trials,  140  participants;  I2  =
92%; P = 0.29; Analysis 26.2.3); and eclectic treatments SMD = −0.57
(95% CI −1.10 to −0.04; 2 trials, 231 participants; I2 = 63%; P = 0.03;
Analysis 26.2.11). For illustrative purposes, we present the results
of other therapeutic approaches from single trials in Analysis 26.2.5
to Analysis 26.2.11.

Secondary outcome: attrition

27. Age: BPD symptom severity

One  trial  reported  dichotomous  data  on  attrition  (Santisteban
2015).

Integrative  BPD  did  not  reduce  attrition  at  end  of  treatment
compared  with  control  (RR  0.50,  95%  CI  0.18  to  1.40;  1  trial,  40
participants; P = 0.19; Analysis 25.3.2).

No data were available for zero to six months, six to 12 months and
above 12 months follow-up.

No  data  were  available  on  any  time  point  for  anger,  affective
instability, chronic feelings of emptiness, impulsivity, interpersonal
problems,  abandonment,  identity  disturbance,  dissociation  and
psychotic-like symptoms, depression, and adverse effects.

Subgroup analyses

Where  data  permitted,  we  conducted  our  planned  subgroup
analyses,  in  addition  to  two  post  hoc  subgroup  analyses,  for  the
primary  outcomes  of  BPD  symptom  severity  and  psychosocial
functioning.  For  the  'types  of  comparisons'  subgroup,  we  also
conducted  analyses  for  self-harm  and  suicide-related  outcomes.
Only  subgroups  with  two  or  more  trials  were  included  in  the
subgroup analyses.

26. Therapeutic approaches

26.1 BPD symptom severity

We compared the effects of DBT versus MBT versus psychodynamic
psychotherapy  versus  STEPPS  versus  eclectic  treatments  for  the
outcome  of  BPD  symptom  severity.  We  found  no  evidence  of
significant  differences  between  the  subgroups  (test  for  subgroup
differences:  Chi2  =  6.88,  df  =  4  (P  =  0.14),  I2  =  41.8%):  DBT  SMD  =
−0.60 (95% CI −1.05 to −0.14; 3 trials, 149 participants; I2 = 42%; P =
0.01; Analysis 26.1.1); MBT SMD = −0.13 (95% CI −0.38 to 0.11; 5 trials,
267 participants; I2 = 0%; P = 0.28; Analysis 26.1.2); psychodynamic
psychotherapy  SMD  =  −0.29  (95%  CI  −0.66  to  0.09;  4  trials,  222
participants;  I2  =  38%;  P  =  0.13;  Analysis  26.1.3);  STEPPS  SMD  =
−0.39 (95% CI −0.63 to −0.15; 3 trials, 273 participants; I2 = 0%; P =
0.001; Analysis 26.1.4); and eclectic treatments SMD = −0.90 (95%
CI  −1.57  to  −0.23;  2  trials,  134  participants;  I2  =  67%;  P  =  0.008;
Analysis 26.1.5). For illustrative purposes, we present the results of
other therapeutic approaches from single trials in Analysis 26.1.6 to
Analysis 26.1.10.

26.2 Psychosocial functioning

We compared the effects of DBT versus MBT versus psychodynamic
psychotherapy  versus  eclectic  treatments  for  the  outcome  of
psychosocial  functioning.  We  found  no  evidence  of  significant
differences between the subgroups (test for subgroup differences:
Chi2 = 0.67, df = 3 (P = 0.88), I2 = 0%): DBT SMD = −0.36 (95% CI −0.69
to −0.03; 6 trials, 225 participants; I2 = 31%; P = 0.03; Analysis 26.2.1);

We compared the effects for the subgroup of 15 to 18 years of age
versus  above  18  years  of  age  for  the  outcome  of  BPD  symptom
severity.  There  were  significant  differences  between  subgroups
(test  for  subgroup  differences:  Chi2  =  5.03,  df  =  1  (P  =  0.02),  I2  =
80.1%): 15 to 18 years of age SMD = −0.14 (95% CI −0.46 to 0.17; 2
trials, 156 participants; I2 = 0%; P = 0.38; Analysis 27.1.1); and above
18 years of age SMD = −0.57 (95% CI −0.76 to -0.37; 20 trials, 1088
participants; I2 = 57%; P < 0.001; Analysis 27.1.2).

28. Duration

28.1 BPD symptom severity

We compared the effects of less than six months versus six to 12
months versus above 12 months duration for the outcome of BPD
symptom severity. We found no evidence of significant differences
between the subgroups (test for subgroup differences: Chi2 = 3.86,
df = 2 (P = 0.15), I2 = 48.2%): less than six months SMD = −0.76 (95% CI
−1.10 to −0.42; 8 trials, 525 participants; I2 = 69%; P < 0.001; Analysis
28.1.1);  six  to  12  months  SMD  =  −0.36  (95%  CI  −0.60  to  −0.12;  11
trials,  606  participants;  I2  =  50%;  P  =  0.003;  Analysis  28.1.2);  and
above 12 months SMD = −0.37 (95% CI −0.75 to 0.01; 3 trials, 113
participants; I2 = 0%; P = 0.06; Analysis 28.1.3).

28.2 Psychosocial functioning

We  compared  the  effects  of  less  than  six  months  versus  six  to
12  months  versus  above  12  months  durations  for  the  outcome
of psychosocial functioning. There were no significant differences
between subgroups (test for subgroup differences: Chi2 = 2.24, df =
2 (P = 0.33), I2 = 10.9%): less than six months SMD = −0.31 (95% CI
−0.73 to 0.11; 6 trials, 468 participants; I2 = 73%; P = 0.14; Analysis
28.2.1);  six  to  12  months  SMD  =  −0.25  (95%  CI  −0.49  to  −0.01;  10
trials,  535  participants;  I2  =  45%;  P  =  0.04;  Analysis  28.2.2);  and
above 12 months SMD = −0.86 (95% CI −1.62 to −0.10; 4 trials, 263
participants; I2 = 86%; P = 0.03; Analysis 28.2.3).

29. Mode of therapy

29.1 BPD symptom severity

We compared the effects of individual therapy versus group therapy
versus  mixed  therapy  for  the  outcome  of  BPD  symptom  severity.
There  were  significant  differences  between  subgroups  (test  for
subgroup differences: Chi2 = 13.23, df = 2 (P = 0.001), I2 = 84.9%):
individual therapy SMD = −0.39 (95% CI −0.63 to −0.16; 8 trials, 520
participants; I2 = 39%; P = 0.001; Analysis 29.1.1); group therapy SMD
= −0.89 (95% CI −1.21 to −0.57; 8 trials, 438 participants; I2 = 57%;
P < 0.001; Analysis 29.1.2); and mixed therapy SMD = −0.15 (95% CI
−0.38 to 0.09; 6 trials, 286 participants; I2 = 0%; P = 0.22; Analysis
29.1.3).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

29.2 Psychosocial functioning

We compared the effects of individual therapy versus group therapy
versus mixed therapy for the outcome of psychosocial functioning.
There were no significant differences between subgroups (test for
subgroup  differences:  Chi2  =  0.89,  df  =  2  (P  =  0.64),  I2  =  0%):
individual therapy = SMD −0.31 (95% CI −0.75 to 0.12; 8 trials, 570
participants; I2 = 80%; P = 0.16; Analysis 29.2.1); group therapy SMD
= −0.44 (95% CI −0.65 to −0.23; 7 trials, 366 participants; I2 = 0%; P
< 0.001; Analysis 29.2.2); and mixed therapy SMD = −0.63 (95% CI
−1.14 to −0.13; 7 trials, 378 participants; I2 = 80%; P = 0.01; Analysis
29.2.3).

30. Setting

30.1 BPD symptom severity

We  compared  the  effects  of  inpatient  versus  outpatient  settings
for the outcome of BPD symptom severity. There were significant
differences between subgroups (test for subgroup differences: Chi2
= 9.18, df = 1 (P = 0.002), I2 = 89.1%): inpatient SMD = −0.07 (95% CI
−0.34 to 0.20; 2 trials, 217 participants; I2 = 0%; P = 0.61; Analysis
30.1.1); and outpatient SMD = −0.58 (95% CI −0.77 to −0.39; 20 trials,
1027 participants; I2 = 51%; P < 0.001; Analysis 30.1.2).

30.2 Psychosocial functioning

We  compared  the  effects  of  inpatient  versus  outpatient  versus
combined  inpatient  and  outpatient  settings  for  the  outcome
of  psychosocial  functioning.  There  were  significant  differences
between subgroups (test for subgroup differences: Chi2 = 15.99, df
= 2 (P = 0.0003), I2 = 87.5%): inpatient SMD = −0.85 (95% CI −1.24 to
−0.46; 2 trials, 179 participants; I2 = 0%; P < 0.001; Analysis 30.2.1);
outpatient  SMD  =  −0.31  (95%  CI  −0.54  to  −0.08;  18  trials,  1057
participants;  I2  =  67%;  P  =  0.008;  Analysis  30.2.2);  and  combined
inpatient and outpatient SMD = −1.34 (95% CI −1.84 to −0.84; two
trials, 78 participants; I2 = 0%; P < 0.001; Analysis 30.2.3).

31. Type of raters

31.1 BPD symptom severity

We  compared  the  effects  of  self-rated  versus  clinician-rated  for
the outcome of BPD symptom severity. There were no significant
differences between subgroups (test for subgroup differences: Chi2
= 1.79, df = 1 (P = 0.18), I2 = 44.2%): self-rated SMD = −0.74 (95% CI
−1.19 to −0.29; 8 trials, 408 participants; I2 = 77%; P = 0.001; Analysis
31.1.1); and clinician-rated SMD = −0.42 (95% CI −0.58 to −0.25; 14
trials, 836 participants; I2 = 24%; P < 0.001; Analysis 31.1.2).

31.2 Psychosocial functioning

We compared the effects of self-rated versus clinician-rated for the
outcome  of  psychosocial  functioning.  There  were  no  significant
differences between subgroups (test for subgroup differences: Chi2
= 2.86, df = 1 (P = 0.09), I2 = 65.1%): self-rated SMD = −0.29 (95% CI
−0.60 to 0.03; 12 trials, 728 participants; I2 = 76%; P = 0.07; Analysis
31.2.1); and clinician-rated SMD = −0.66 (95% CI −0.96 to −0.37; 10
trials, 586 participants; I2 = 54%; P < 0.001; Analysis 31.2.2).

32. Types of TAU

32.1 BPD symptom severity

We compared the effects of obligatory TAU versus optional TAU for
the outcome of BPD symptom severity. There were no significant

Cochrane Database of Systematic Reviews

differences between subgroups (test for subgroup differences: Chi2
= 0.25, df = 1 (P = 0.61), I2 = 0%): obligatory TAU SMD = −0.50 (95%
CI −0.70 to −0.30; 19 trials, 1071 participants; I2 = 60%; P < 0.001;
Analysis 32.1.1); and unspecified TAU SMD = −0.63 (95% CI −1.09 to
-0.17; 3 trials, 173 participants; I2 = 36%; P = 0.007; Analysis 32.1.2).

32.2 Psychosocial functioning

We compared the effects of obligatory TAU versus optional TAU for
the outcome of psychosocial functioning. There were no significant
differences between subgroups (test for subgroup differences: Chi2
= 3.18, df = 1 (P = 0.07), I2 = 68.6%): obligatory TAU SMD = −0.32 (95%
CI −0.56 to −0.09; 17 trials, 1002 participants; I2 = 65%; P = 0.007;
Analysis 32.2.1); and unspecified TAU SMD = −0.96 (95% CI −1.62 to
−0.30; 5 trials, 312 participants; I2 = 84%; P = 0.004; Analysis 32.2.2).

33. Types of comparison group

33.1 BPD symptom severity

We  compared  the  effects  of  trials  with  TAU  versus  trials  with
waiting list for the outcome of BPD symptom severity. There were
no  significant  differences  between  subgroups  (test  for  subgroup
differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 = 0%): trials with TAU
SMD = −0.52 (95% CI −0.70 to −0.33; 22 trials, 1244 participants; I2
= 57%; P < 0.001; Analysis 33.1.1); and trials with waiting list (SMD
−0.49, 95% CI −0.93 to −0.05; 3 trials, 161 participants; I2 = 44%; P =
0.03; Analysis 33.1.2).

33.2 Psychosocial functioning

We  compared  the  effects  of  trials  with  TAU  versus  trials  with
waiting list for the outcome of psychosocial functioning. There were
no  significant  differences  between  subgroups  (test  for  subgroup
differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 = 0%): trials with TAU SMD
= −0.45 (95% CI −0.68 to −0.22; 22 trials, 1314 participants; I2 = 72%;
P = 0.0001; Analysis 33.2.1); and trials with waiting list SMD = −0.56
(95% CI −1.01 to −0.11; 5 trials, 219 participants; I2 = 59%; P = 0.01;
Analysis 33.2.2).

34. Types of scales

34.1 BPD symptom severity

We  compared  the  effects  of  ZAN-BPD  versus  SCID  versus  BEST
versus  BPDSI  on  the  outcome  of  BPD  symptom  severity.  There
were significant differences between subgroups (test for subgroup
differences: Chi2 = 15.40, df = 3 (P = 0.002), I2 = 80.5%): ZAN-BPD SMD
= −0.45 (95% CI −0.69 to −0.20; 4 trials, 261 participants; I2 = 0%; P =
0.0004; Analysis 34.1.1); SCID SMD = −0.58 (95% CI −1.16 to −0.00; 3
trials, 112 participants; I2 = 47%; P = 0.05; Analysis 34.1.2); BEST SMD
= −1.10 (95% CI −1.47 to −0.72; 4 trials, 147 participants; I2 = 10%;
P < 0.001; Analysis 34.1.3); and BPDSI SMD = −0.21 (95% CI −0.45 to
0.04; 4 trials, 267 participants; I2 = 0%; P = 0.10; Analysis 34.1.4. For
illustrative purposes, the results of other scales from single trials
are report in Analysis 34.1.5 to Analysis 34.1.11.

34.2 Psychosocial functioning

We compared the effects of the GAF versus GAS versus SAS on the
outcome  of  psychosocial  functioning.  There  were  no  significant
differences between subgroups (test for subgroup differences: Chi2
= 1.39, df = 2 (P = 0.50), I2 = 0%): GAF SMD = −0.73 (95% CI −1.41 to
−0.05; 4 trials, 204 participants; I2 = 78%; P = 0.04; Analysis 34.2.1);
GAS SMD = −0.71 (95% CI −0.96 to −0.46; 4 trials, 330 participants; I2 =

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

0%; P < 0.001; Analysis 34.2.2); and SAS SMD = −0.23 (95% CI −0.99 to
0.53; 4 trials, 283 participants; I2 = 88%; P = 0.55; Analysis 34.2.3). For
illustrative purposes, the results of other scales from single trials
are reported in Analysis 34.2.4. to Analysis 34.2.13

Sensitivity analysis

We  conducted  a  TSA  as  an  sensitivity  analysis  on  the  significant
findings  for  all  primary  outcomes  and  the  secondary  outcome
of  depression  at  end  of  treatment.  The  RIS  was  reached  for
BPD  symptom  severity,  self-harm,  suicide-related  outcomes  and
psychosocial  functioning.  However,  due  to  inconsistency  for  self-
harm  and  suicide-related  outcomes,  we  could  only  exclude  the
risk  of  a  false  positive  finding  (type  1  error)  for  BPD  symptom
severity and psychosocial functioning. The RIS was not reached for
depression.

We  used  both  the  fixed-effect  and  random-effects  models  in  all
meta-analyses.  However,  when  there  were  two  or  more  trials
included  in  an  analysis,  we  chose  to  report  the  results  of  the
random-effects model, which gives greater weight to smaller trials;
where only one trial was included in an analysis, we reported the
results of the fixed-effect model. Statistical significance changed in
13 analyses and in those cases we reported the results of both the
random-effects and fixed-effect models (see Analysis 3.7, Analysis
3.12,  Analysis  4.1.3,  Analysis  4.5.1,  Analysis  4.7.1,  Analysis  4.7.2,
Analysis 4.7.4, Analysis 5.5.1, Analysis 6.4.1, Analysis 6.7.1, Analysis
14.3, Analysis 15.5, Analysis 18.12).

D I S C U S S I O N

Summary of main results

We considered 400 full-text reports and, of these, we included 75
trials that randomised a total of 4507 participants. The age ranged
from 14.8 to 45.7 mean years, and the majority of included persons
were female. The length of the trials ranged from one to 36 months,
with most of them performed in outpatient settings. We judged all
included trials to be at high risk of bias.

DBT  and  related  treatments  were  the  most  intensively  studied,
with  more  than  one-third  of  all  included  trials  comparing  DBT
to  TAU,  a  waiting  list  or  an  alternate  active  treatment  (26  RCTs).
Fifteen RCTs investigated the effects of CBT and related treatments,
seven of which assessed MBT or eclectic treatments, five evaluated
BPD-specific psychodynamic therapies, four investigated SFT and
related  treatments,  and  three  assessed  STEPPS  and  IPT,  two
investigated TFP, PE or MOTR, and one evaluated CAT, ACT, JCP or
motivation feedback, respectively.

In  the  following  section,  we  summarise  the  main  findings  for
the  pooled  analyses  of  psychotherapy  versus  TAU  or  waiting
list  for  our  primary  outcomes  (BPD  symptom  severity,  self-harm,
suicide-related  outcomes  and  psychosocial  functioning),  and  for
those  secondary  outcomes  that  are  not  a  part  of  the  symptom
characteristics  of  BPD  (depression,  attrition  and  adverse  effects).
We report end-of-treatment data. We advise the interested reader
to explore the Effects of interventions section for a more elaborated
description  of  the  effect  of  psychotherapy  on  the  remaining
secondary  outcomes,  and  follow-up  data.  There,  they  will  also
find  a  complete  overview  of  the  effects  of  specific  kinds  of
psychotherapy (such as DBT, MBT, CBT, etc.).

Cochrane Database of Systematic Reviews

Psychotherapy versus TAU

Comparing  the  effects  of  psychotherapy  with  TAU,  we  observed
significant effects for all primary outcomes at the end of treatment
(Summary of findings 1).

Psychotherapy significantly reduced BPD symptom severity (SMD
−0.52, 95% CI −0.70 to −0.33; 22 trials, 1244 participants) compared
with TAU. This corresponds to a MD of −3.6 (95% CI −4.4 to −2.08)
on the ZAN-BPD scale, which ranges from 0 to 36. This represents a
clinically relevant improvement in BPD symptoms. The MIREDIF on
this scale is −3.0 points (Crawford 2018a).

Psychotherapy  also  showed  a  significant  reduction 
in  self-
harm  when  measured  as  a  continuous  outcome  (SMD  −0.32,
95%  CI  −0.49  to  −0.14;  13  trials,  616  participants),  but  not
a  dichotomous  outcome.  The  significant  effect  of  continuous
outcomes corresponds to a MD of −0.816 (95% CI −1.25 to 0.35) on
the DSHI, which ranges from 0 to 34. The MIREDIF on this scale is
−1.25 points, which corresponds to ½ SD (Farivar 2004). Clinically,
this finding does not represent an important reduction in self-harm
for people with BPD.

Additionally, suicide-related outcomes were significantly reduced
in  both  continuous  (SMD  −0.34,  95%  CI  −0.57  to  −0.11;  13  trials,
616 participants) and dichotomous outcomes (RR 0.27, 95% CI 0.11
to 0.67; 5 trials, 396 participants). The improvement corresponded
to a MD of −0.11 (95% CI −0.19 to −0.034) on the Suicidal Attempt
Self  Injury  Interview.  The  MIREDIF  on  this  scale  is  −0.17  points,
which corresponds to ½ SD (Farivar 2004). These findings suggest
that suicide-related outcomes improved following treatment, but
these improvements did not quite reach a clinically relevant level.
However,  when  it  comes  to  suicide  or  suicide  attempts,  any
reduction is of importance.

improved 

functioning 

significantly 

Psychosocial 
following
psychotherapy  compared  with  TAU  (SMD  −0.45,  95%  CI  −0.68  to
−0.22; 22 trials, 1314 participants). This corresponds to a MD of −2.8
(95% CI −4.25 to −1.38) on the GAF Scale, which ranges from 0 to
100. The MIREDIF on this scale is −4.0 points (Amri 2014); therefore,
the improvement did not reach clinical relevance.

Regarding  our  secondary  outcomes,  we  observed  a  significant
reduction  in  depression  for  participants  receiving  psychotherapy
compared  to  TAU  (SMD  −0.39,  95%  CI  −0.61  to  −0.17;  22  trials,
1570  participants).  This  corresponds  to  −2.45  on  the  Hamilton
Depression  Scale,  and  does  not  quite  reach  the  MIREDIF  on  this
scale, which is 3.0 points (NICE CG90) .

Sufficient data were not available for effect size calculation for the
outcome of adverse effects.

Our  additional  TSA  on  all  significant  findings  of  the  primary
outcomes found that the RIS was reached for all primary outcomes
but  not  for  the  secondary  outcome  of  depression.  However,  only
for BPD symptoms severity and psychosocial functioning could we
reject the possibility of type 1 error.

Only 15 trials reported on the effect following end of treatment at
zero  to  six  months,  six  to  12  months  and  >  12  months  (Amianto
2011;  Andreoli  2016;  Bateman  1999;  Blum  2008;  Davidson  2006;
Gleeson  2012;  Gregory  2008b;  Jørgensen  2013;  Kredlow  2017a;
Linehan 2006; McMurran 2016; Robinson 2016; Soler 2009; Van den
Bosch 2005; Weinberg 2006). There was no effect on BPD severity

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

at  follow-up  when  assessed  as  a  continuous  measure;  however,
an  improvement  was  observed  at  >  12  months  follow-up  in  the
number  of  people  presenting  with  severe  BPD.  In  addition,  the
number  of  persons  with  self-harm  was  reduced  at  the  zero  to
six  months,  six  to  12  months  and  >  12  months  follow-up  time
points. Suicide-related behaviour was reduced at six to 12 months
follow-up, and a reduction in the number of persons with suicidal
behaviour  was  seen  at  >  12  months  follow-up.  There  was  an
improvement  in  psychosocial  functioning  at  zero  to  six  months
follow-up; however, this was not sustained at six to 12 months or at
> 12 months follow-up time points.

Regarding the secondary outcomes, there was an improvement in
depression at zero to six months and > 12 months follow-up, as well
as a reduction in adverse effects at > 12 months follow-up only. No
improvement in anger, affective instability, impulsivity, emptiness,
interpersonal problems or abandonment was observed at follow-
up.

Psychotherapy versus waiting list or no treatment

Comparing  the  effects  of  psychotherapy  with  waiting  list,  we
observed  effects  in  favour  of  psychotherapy  for  the  primary
outcomes of BPD severity (SMD −0.49, 95% CI −0.93 to −0.05; 3 trials,
161 participants) and psychosocial functioning (SMD −0.56, 95% CI
−1.01 to −0.11; 5 trials, 219 participants. No clear differences were
found for self-harm and suicide-related outcomes. See Summary of
findings 2.

We  moreover  observed  a  significant  reduction  in  depression  for
participants  receiving  psychotherapy  compared  to  waiting  list  or
no  treatment  (SMD  −1.28,  95%  CI  −2.21  to  −0.34;  6  trials,  239
participants).  No  reductions  were  detected  in  attrition,  and  once
again, sufficient data were not available for effect size calculation
for the outcome of adverse effects.

Only  one  trial,  Bellino  2010,  reported  on  the  effect  following
end  of  treatment  (zero  to  six  months,  six  to  12  months  and  >
12  months  follow-up  periods).  Follow-up  data  were  reported  on
psychosocial functioning, in which an improvement was observed
at zero to six months and six to 12 months post-treatment. There
was  no  significant  improvement  observed  at  >  12  months  post-
treatment.  Regarding  the  secondary  outcomes,  improvements  in
both impulsivity and interpersonal problems were observed at zero
to six months, six to 12 months and > 12 months post-treatment.
No improvement was observed in affective instability at any of the
follow-up time points.

Individual treatment approaches

Among distinct BPD-specific therapies, most findings were based
on single trials. DBT and MBT had the highest numbers of primary
trials,  with  DBT  accounting  for  roughly  one-third  of  all  included
trials, followed by MBT with seven RCTs.

Compared  to  TAU,  we  observed  significant  effects  of  DBT  for  the
primary  outcomes  of  BPD  severity  (SMD  −0.60,  95%  CI  −1.05  to
−0.14; 3 trials, 149 participants), self-harm (SMD −0.28, 95% CI −0.48
to  −0.07;  7  trials,  376  participants)  and  psychosocial  functioning
(SMD −0.36, 95% CI −0.69 to −0.03; 6 trials, 225 participants). MBT
was found to have significant effects on self-harm (RR 0.62, 95% CI
0.49 to 0.80; 3 trials, 252 participants) and suicidality (RR 0.10, 95%
CI 0.04, 0.30, 3 trials, 218 participants). See Summary of findings 3.

Cochrane Database of Systematic Reviews

Subgroup analysis and investigation of heterogeneity

We  had  intended  to  conduct  several  subgroup  analyses,  but  not
all  were  possible  due  to  a  lack  of  data.  See  Table  1  for  more
information.

In  one  subgroup  analysis,  we  tested  for  differences  between
psychotherapeutic  approaches  appearing  in  two  or  more  trials.
We  found  no  significant  subgroup  differences  between  the
different  therapeutic  approaches  for  BPD  symptom  severity  and
psychosocial functioning.

To test the statistical heterogeneity in our analyses of BPD symptom
severity  and  psychosocial  functioning,  we  added  a  post  hoc
subgroup  analysis  exploring  the  different  measurement  scales
versus each other. We found significant differences between ZAN-
BPD, SCID, BEST and BPDSI, with BEST providing the highest effect
estimate.  By  differentiating  between  scales,  we  found  that  the
heterogeneity between trials was I2 = 0% with ZAN-BPD; I2 = 47%
with SCID; I2 = 10% with BEST; and I2 = 0% with BPDSI. The results
suggest  that  much  of  the  statistical  heterogeneity  found  in  the
analysis  of  psychotherapy  versus  TAU  for  BPD  symptom  severity
was due to the various scales used in trials. We found no significant
differences  between  GAF,  GAS  and  SAS,  and  no  reductions  in
heterogeneity.

We  found  significant  subgroup  differences  for  BPD  symptom
severity  for  age,  where  the  effects  of  psychotherapy  were  higher
for  the  subgroup  'older  than  18  years  of  age';  'mode  of  therapy',
with  group  therapy  being  more  effective  than  individual  or
mixed  therapy;  and  setting,  with  outpatient  groups  being  more
effective than inpatient groups. Additionally, we found significant
differences  for  psychosocial  functioning  for  setting,  with  the
combination  of  inpatient  and  outpatient  groups  and  inpatient
groups alone showing to be more effective than outpatient groups.
We  found  no  subgroup  differences  for  BPD  symptom  severity  for
duration  and  type  of  raters,  or  for  psychosocial  functioning  for
duration, mode of therapy and types of raters.

trials of psychotherapy versus TAU did not indicate any significant
subgroup differences for BPD symptom severity and psychosocial
functioning compared with trials of psychotherapy versus waiting
list or no treatment. Likewise, we found no subgroup differences
for  the  different  types  of  TAU.  Therefore,  effect  estimates  do  not
seem to differ between comparisons with control groups consisting
of any kind of unspecified intervention, such as TAU, standard care
or regular appointments, and comparisons with waiting list or no
treatment,  the  participants  of  which  were  not  paid  any  special
attention at all.

Previous review

In  contrast  to  the  previous  versions  of  this  review  (Binks  2006;
Stoffers-Winterling 2012), we broadened the scope to include the
treatment of adolescents also. We were able to include only three
RCTs  that  focused  solely  on  adolescents:  the  Mehlum  2014  trial
on  DBT-A;  the  Rossouw  2012b  trial  on  MBT-A;  and  the  Schuppert
2012 trial on ERT, an adaptation of STEPPS for adolescents. Another
pilot RCT on HYPE + CAT + SFET included participants from ages 15
to 25 years old, with a mean age of 18.4 years (SD = 2.9) (Gleeson
2012).  Subgroup  analyses  revealed  that  adolescents  benefited
less  from  psychotherapy  than  those  older  than  18  years  of  age.
However, the power was much too low to detect any true effects,
with  sample  sizes  ranging  from  10  participants  (subsample  of

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

participants with five or more DSM-IV BPD criteria in the Mehlum
2014 trial) to 97 participants (in Schuppert 2012). Notably, we only
included  trial  samples  or  subsamples  in  which  at  least  70%  of
participants had full BPD (i.e. fulfilled a minimum of five DSM BPD
criteria). Oftentimes, however, adolescents may only fulfil criteria
at  a  subthreshold  level  while  both  their  personality  and  BPD  are
still developing. Nevertheless, they might profit from BPD-specific
treatments in terms of preventing the development of full threshold
BPD later in life.

Overall completeness and applicability of evidence

In most cases, we were able to calculate the effect sizes from the
data  reported  in  the  included  trials.  If  information  was  missing,
we contacted and requested the missing information from the trial
authors. Therefore, there is no evident bias within this review as a
consequence of inadequate inclusion of existing data.

We rated all trials at high risk of bias, with the most prevalent risk
of bias being categorised as 'other risk of bias'; that is insufficient
treatment  adherence,  allegiance  bias  or  attention  bias,  which
might lead to biased data.

Participants

The majority of trials included mainly females, with only two trials
solely  including  males  (Bianchini  2019;  Kamalabadi  2012).  This
configuration  may  reflect  the  reality  of  clinical  settings,  where
approximately  75%  of  all  BPD  diagnoses  are  assigned  to  women
(APA  2000).  There  are,  however,  contradictory  findings  pointing
towards  balanced  proportions  or  an  even  higher  prevalence  in
men  (Sansone  2011).  Men  with  BPD  may  display  a  different
clinical  picture  than  women,  especially  with  antisocial  features
being  more  prevalent  in  men  than  in  women  with  BPD  (Sansone
2011). Clinically, this may mediate different treatment approaches
or  special  requirements,  which  may  not  be  reflected  in  most
of  the  RCT  evidence,  which  stems  from  either  all  female  or
predominantly female samples (see the Characteristics of included
studies  tables).  In  addition,  in  several  of  the  included  trials,  full
antisocial personality disorders or antisocial features were reasons
for exclusion. As such, the extent to which the findings in this review
are applicable to men with BPD may be limited. Level of functioning
at  baseline  was  not  available  in  several  of  the  included  trials.
However,  trials  that  reported  level  of  functioning  using  objective
measures, such as GAS, GAF, CGI or SFQ, showed that the degree
of illness ranged from moderate to severe. Regarding comorbidity,
most  trials  excluded  participants  with  severe  mental  disorders,
organic  brain  disorders  and  mental  impairments.  In  sum,  the
findings of this review may apply mainly to females with a moderate
to  severe  level  of  illness,  and  without  severe  comorbid  mental
disorders.  We  do  not  know  how  the  lack  of  this  information  has
affected our findings, only that we cannot generalise the findings
to  men,  to  females  with  low  levels  of  illness  or  to  those  with
severe comorbid mental disorders. On the other hand, several trials
concentrated on people with BPD plus distinct comorbidities (i.e.
PTSD,  depression,  eating  disorders  or  substance  use  disorders).
Moreover,  subgroups  analyses  revealed  a  significant  difference,
where the effect of psychotherapy on BPD symptom severity and
psychosocial functioning seemed lower for adolescents. However,
only three trials on adolescents were included in the review, and
readers should exercise caution when drawing conclusions.

Cochrane Database of Systematic Reviews

Some  argue  that  BPD  treatment  should  start  before  the
condition has developed fully, and stress the importance of early
assessment and treatment (Chanen 2013; Sharp 2015). Therefore,
psychological interventions may also be relevant for patients who
have yet to fully fulfil the DSM-5 criteria. Nevertheless, with respect
to the patient sample in this review, we only included adolescent
samples  if  at  least  70%  of  them  fulfilled  (a  minimum  five)  DSM-5
criteria  for  a  diagnosis  of  BPD.  We  decided  to  do  so  in  order  to
assure  a  minimum  level  of  clinical  homogeneity  throughout  the
overall pool of trials.

Interventions

The  major  psychotherapeutic  treatments  used  in  the  treatment
of  BPD  (DBT,  MBT,  SFT,  TFP)  have  been  tested  in  the  RCTs
included in this review. However, the number of available trials per
intervention vary broadly, with the majority of trials investigating
DBT;  a  very  limited  number  of  trials  assessed  SFT  and  TFP
especially,  which  may  not  reflect  their  prevalence  in  clinical
practice.  The  vast  majority  of  primary  trials  were  conducted  in
outpatient settings. However, psychotherapy may also be provided
on  inpatient  wards  (depending  on  the  respective  health  system),
but only limited evidence was available for this setting. Subgroups
analyses  showed  no  evidence  of  significant  differences  between
psychotherapeutic approaches, indicating that all individual types
of  psychotherapy  are  effective  in  treating  people  with  BPD.
Most  trials  allowed  concurrent  psychotherapy  and  psychotropic
treatments.  As  such,  it  cannot  be  ruled  out  that  the  concurrent
treatment  may  have  confounded  the  corresponding  findings.
However, we only included trials if possible concurrent treatments
were the same for all trial groups.

Some  interesting  findings  revealed  that  group  therapy  might  be
more  effective  than  individual  or  mixed  therapy  for  reducing
BPD  symptom  severity.  However,  there  was  no  evidence  of
subgroup  differences  for  psychosocial  functioning.  Additionally,
outpatient care seemed to be more effective than inpatient care in
reducing BPD symptom severity, but not in improving psychosocial
functioning,  where  a  combination  of  inpatient  and  outpatient
treatment was more effective. The duration of treatment does not
seem  to  be  a  factor  in  the  improvement  of  BPD  symptoms  and
psychosocial functioning.

Comparisons

is  a  common 

including  TAU,  which 

in  the  control  groups  were 

largely
The  treatments  used 
heterogeneous, 
label
for  controls.  TAU  itself  may  differ  between  different  treatment
formats,  let  alone  between  different  health  systems.  In  some
trials,  participants  receiving  TAU  were  free  to  use  any  kind  of
care, whereas other participants in receipt of TAU were required to
receive a minimum standard of care whilst taking part in the trial
(see Types of interventions). Consequently, the components of TAU
will most certainly vary between countries, as the standard of care
is known to differ depending on the national healthcare system.

The use of a control group in randomised trials provides a point of
reference from which the effect of a given intervention is measured
against.  As  such,  a  'clean'  control  group  is  essential  when  we
want  to  obtain  insight  into  the  magnitude  of  treatment  effects
and  potential  adverse  effects.  In  psychiatric  research,  there  is
a  lack  of  consensus  on  what  constitutes  an  appropriate  control
intervention  (Finch  2019).  In  accordance,  we  found  that  control
groups across trials were heterogeneous and included, for example,

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

TAU,  standard  care  or  waiting  list.  In  72%  of  the  included  trials,
either  psychotherapeutic  treatment  was  a  part  of  the  control
intervention  or  concomitant  psychotherapy  was  allowed  while
participating in the trial (for more information see Characteristics
of included studies tables). As such, a majority of trials compared
psychotherapeutic  therapy  against  another  intervention  that
included  psychotherapeutic  elements.  The  willingness  to  let
people  affected  by  BPD  continue  with  different  variations  of
psychotherapeutic therapy while included in a control group may
indicate a general concern of otherwise withholding them from an
important  treatment.  Yet  a  drawback  of  this  approach  is  that  it
could potentially mask the difference in treatment effects between
the control and intervention groups. Concurrently, we found that
effects  sizes  were  small,  heterogeneous  and  largely  insignificant
for  the  majority  of  comparisons.  There  is  a  substantial  need  for
larger, well-performed randomised trials that include standardised
control groups before we can make firmer conclusions about the
effects of psychological therapies in BPD.

Outcomes

The  individual  trials  included  a  great  variety  of  outcomes,  with
only minor consensus on what constituted core outcomes for BPD
and  how  these  ideally  should  be  assessed.  We  identified  high
heterogeneity  and  significant  differences  between  scales  for  BPD
symptom severity, which might indicate that different scales may
give different effect estimates. We found no significant differences
between  scales  for  psychosocial  functioning,  and  there  were  no
significant differences for self-rated and clinician-rated outcomes.
In addition, core symptoms, such as fewer interpersonal conflicts
or crises that both caregivers and people with BPD may consider
essential  when  searching  for  helpful  treatments,  are  sometimes
neglected.  The  outcome  of  attrition  must  be  interpreted  with
caution,  as  the  likelihood  of  leaving  a  trial  may  depend  on  the
specific  type  of  control  group  used.  For  example,  participants
assigned to waiting lists may be more likely to leave a trial early than
participants assigned to TAU or participants who are provided with
regular  appointments.  Geographical  conditions  and  accessibility
of study centres can also play an important role, as rural regions
with  long  distances  to  study  centres  may  lead  to  higher  dropout
rates than urban settings (Blum 2008 trial completer analysis: high
dropouts).

Most trials did not consider adverse effects but did consider suicidal
or  self-harming  behaviour.  These  outcomes  were  categorised
as  primary  outcomes  in  this  review  (see  Appendix  4)  and  are
usually  classified  as  severe  adverse  effects.  Future  randomised
trials  should  not  only  concentrate  on  these  outcomes,  but  also
transparently report non-serious adverse effects that occur during
BPD  treatment.  Adverse  effects  of  importance  would  include
increased  impulsive  behaviour  or  substance  use.  Such  outcomes
may  occur  if  psychotherapy  induces  excessive  emotional  arousal
with which the affected person is not (yet) able to cope (Berk 2009).

For more information, see the Characteristics of included studies
tables, where we describe the characteristics of each included trial
in greater detail.

Quality of the evidence

Cochrane Database of Systematic Reviews

We  assessed  the  risk  of  bias  in  all  trials  in  accordance  with
the  Cochrane  Handbook  for  Systematic  Reviews  of  Interventions
(Higgins  2019).  The  majority  of  the  trials  were prone  to  selection
bias,  as  well  as  attrition  and  reporting  bias.  High  risk  of  bias  in
randomised clinical trials has been shown to overestimate benefits
and  underestimate  harms  (Kjaergard  2001;  Lundh  2012;  Moher
1998; Savović 2012a; Savović 2012b; Schulz 1995; Wood 2008). The
results  are  based  on  75  trials  that  involved  a  limited  number  of
people (n = 4507). Most trials included small sample sizes, with the
number of participants ranging from 7 to 151 in the individual trials.
Heterogeneity in the reporting of outcomes and the interventions
investigated in the individual trials hindered the pooling of effect
estimates. Except for DBT, ERGT, MBT and MOTR, the review findings
are based largely on single trial effects that could not be pooled. The
small samples and inability to pool results led to imprecise effect
estimates.

The  highest  risk  of  bias  we  observed  in  the  individual  trials  was
for  the  category  of  'other  bias',  covering  attention,  affiliation  or
adherence bias. We rated approximately two-thirds of trials (49 out
of 75) as having a high risk of bias, and another 21 RCTs as having
an  unclear  risk  of  bias,  leaving  only  five  (i.e.  6.7%)  RCTs  at  low
risk  of  bias.  We  rated  two-thirds  of  trials  as  having  either  a  high
or  an  unclear  risk  of  bias  in  terms  of  both  incomplete  outcome
data and selective reporting (only 19 trials out of 75 had a low risk
of bias in these categories). We rated half or more of the trials as
having applied appropriate means of random sequence generation,
allocation concealment, and blinding of outcome assessment.

From the analyses regarding psychotherapy and DBT versus waiting
list or no treatment for suicide-related outcomes and depression,
we  found  one  trial  to  be  an  outlier  (Mohamadizadeh  2017).  The
trial  was  rated  at  high  risk  of  bias  due  to  unclear  risks  of  bias  in
all  domains.  To  ensure  transparency,  we  did  not  exclude  it  from
the analyses. However, sensitivity analyses showed that the trial's
inclusion did not change any conclusions on the aforementioned
outcomes.

Notably,  there  were  only  two  RCTs  out  of  75  that  included
medication-free  patients  only.  The  majority  of  trials  allowed
participants  to  continue  their  respective  drug  treatments.  There
were no reports of different medication rates between the groups
at  baseline  from  any  trial.  Apart  from  those  trials  that  included
medication  as  a  compulsory  part  of  their  respective  treatment
regimens  for  both  groups  (Bellino  2006;  Bellino  2007;  Bellino
2010;  Jahangard  2012),  24  trials  reported  on  actual  medication
use  during  the  trial  observation  period:  17  found  no  difference
in  medication  use  between  the  groups  (Antonsen  2017;  Blum
2008;  Bohus  2013;  Bos  2010;  Doering  2010;  Elices  2016;  Gleeson
2012;  Leichsenring  2016;  Lin  2019;  Linehan  2015a;  McMain  2009;
McMain  2017;  Mohamadizadeh  2017;  Reneses  2013;  Schuppert
2012;  Sinnaeve  2018;  Van  den  Bosch  2005);  six  reported  a  higher
use of medications in their control groups (Bateman 1999; Bateman
2009;  Gregory  2008;  Linehan  1994;  Linehan  2006;  Turner  2000);
and    only  one  found  a  higher  rate  in  the  active  treatment
group  (Andreoli  2016).  Therefore,  medication  use  as  a  possible
confounding variable can be ruled out whenever beneficial effects
for the experimental group were observed.

We  rated  the  quality  of  evidence  using  the  GRADE  approach,
based on the following considerations; risk of bias, inconsistency,
indirectness, imprecision and publication bias.

Potential biases in the review process

This  review  was  designed  to  minimise  the  risk  of  potential
biases. We developed a protocol, Storebø 2018, for this review in

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

accordance with the Cochrane Handbook for Systematic Reviews of
Interventions  (Higgins  2019).  We  conducted  extensive  searches  of
relevant  databases,  with  no  restrictions  in  language,  publication
year,  publication  type  or  publication  status.  Two  independent
review authors selected appropriate trials, extracted data, assessed
the  risk  of  bias  and  graded  the  quality  of  the  evidence.
Disagreements were resolved through discussion. We conducted a
TSA, to estimate the RIS needed to either detect or reject a certain
intervention effect.

With  regard  to  our  inclusion  criteria  (Criteria  for  considering
studies  for  this  review),  we  tried  to  retain  a  homogeneous  pool
of  primary  trials.  However,  there  were  some  inconsistencies
between  trials,  particularly  pertaining  to  psychiatric  comorbidity
of  trial  participants.  For  example,  although  the  presence  of  a
substance-related disorder was a common exclusion criterion (see
Types  of  participants),  two  trials  required  participants  to  have
such  a  disorder  (Gregory  2008b;  Santisteban  2015),  and  another
trial  included  a  mixed  sample  of  participants  with  and  without
substance abuse problems (Van den Bosch 2005). In addition, the
severity of illness varied between trials, ranging from severe to mild.

We  also  went  to  great  effort  to  try  and  obtain  unpublished  data
pertaining to BPD subsamples where the full sample included fewer
than 70% of participants with full BPD. We were able to obtain such
subsample data from some trials, but in other cases, trial authors
did not respond. We do not know why they did not respond, but
it is possible that the subsample data we received are biased in a
positive way (i.e. being associated with desired findings).

Agreements and disagreements with other studies or
reviews

This updated review has a new conclusion compared to the review
published  in  2012  (Stoffers-Winterling  2012).  The  2012  review
concluded  that  there  were  indications  of  beneficial  effects  for
psychological  therapies  for  BPD  core  pathology  and  associated
general  psychopathology.  The  overall  findings  supported  a
substantial role for psychotherapy in the treatment of people with
BPD. However, the authors also reported that the treatments did
not have a very robust evidence base, as there were some concerns
regarding  the  quality  of  individual  trials,  and  therefore  indicated
a  need  for  replication  trials  (Stoffers-Winterling  2012).  Following
the  update  of  this  review,  we  are  now  able  to  state,  for  the  first
time,  that  BPD-specific  psychotherapy  seem  to  be  better  than
usual  or  control  treatments  for  reducing  BPD  severity  in  persons
affected by BPD, with effect sizes of clinical relevance. This change
in conclusion may result from the following: in 2012, only 28 trials
were  available  for  inclusion,  and  any  comparisons  were  done  on
treatment approach levels. This means that the review authors did
not  pool  any  kind  of  BPD-specific  treatment,  only  DBT,  MBT  and
so  on.  This  new  review  has  used  updated  methods,  including  a
broader search strategy, and thus a new protocol was published in
2018 (Storebø 2018). What is more, this version is the first to include
the required information sizes, for at least some comparisons, on
the  level  of  BPD-specific  approaches  in  general  (see  Summary  of
findings  1),  allowing  for  drawing  conclusions  on  a  much  more
reliable basis.

Our  review  is  in  partial  agreement  with  the  review  by  Cristea
and  colleagues  who  found  that  psychotherapy,  especially  DBT
and  psychodynamic  approaches,  are  effective  for  borderline
symptoms  and  related  problems  (Cristea  2017).  Similarly,  we

Cochrane Database of Systematic Reviews

found  that  psychotherapy  appears  to  be  more  effective  than
usual treatment at improving BPD symptoms; however, we found
no  clear  differences  between  the  various  treatments.  We  agree
that  DBT  treatments  in  particular,  seem  to  have  a  more  robust
evidence base, due to more clinical trials having been conducted.
This  discrepancy  in  conclusions  may  be  due  to  differences  in
methodological  approach.  The  study  by  Cristea  and  colleagues
searched  for  data  in  only  four  databases  and  included  only  one
publication per trial. They also did not use subsamples of persons
with BPD and did not perform an assessment of the overall quality
of the evidence. Taken together these limitations suggest that their
conclusions may be too optimistic (Faltinsen 2017).

Matthijs  Oud  and  colleagues  published  a  review  in  2018  (Oud
2018), which investigated the effects of specialised psychotherapy
for  BPD.  In  contrast  to  our  review,  they  focused  on  four  BPD-
specific  treatments  (DBT,  MBT,  SFT,  and  TFP)  and  only  included
adult  samples,  resulting  in  the  inclusion  of  20  trials.  In  line
with  the  findings  of  this  review,  they  reported  moderate-quality
evidence  that  psychotherapy  is  effective  in  reducing  overall  BPD
severity  (SMD  of  −0.59  compared  to  our  SMD  of  −0.52).  We  took
a  broader  approach  and  included  all  types  of  psychotherapy
conducted  in  participants  of  all  ages,  which  resulted  in  a  more
complete picture of the area with a larger evidence base (Oud and
colleagues included only 321 participants in their analysis of BPD
severity compared to 1244 participants in our analysis of the same
outcome).

A U T H O R S '   C O N C L U S I O N S

Implications for practice

The  interventions  included  in  this  review  represent  a  broad
spectrum  of  therapies,  covering  cognitive-behavioural  therapy
(CBT),  dialectical  behavioural  therapy  (DBT),  DBT  skills  group,
eclectic  therapy,  psychodynamic  therapy,  systems  training
for  emotional  predictability  and  problem-solving  (STEPPS),
schema-focused  therapy  (SFT),  interpersonal  psychotherapy  and
mentalisation-based therapy.

Analyses showed beneficial effects of psychotherapy compared to
TAU  for  all  primary  outcomes.  However,  only  the  improvement
in  BPD  severity  reached  the  level  of  a  clinically  important
improvement  compared  to  the  MIREDIF;  we  considered  this  to
be  moderate-quality  evidence,  meaning  that  additional  research
could impact our confidence in the effect estimate and may change
the  estimate.  All  trials  had  a  high  risk  of  bias  and,  for  most
outcomes,  we  considered  the  data  to  be  of  low  quality  due  to
imprecision, small sample sizes and inconsistency.

We  found  no  unequivocal,  high-quality  evidence  to  support  one
BPD-specific  therapy  over  another  in  the  treatment  of  BPD;  our
subgroup  analyses  showed  no  differences  in  effect  estimates
between  the  different  types  of  therapies.  However,  compared  to
TAU, we observed significant effects in favour of DBT for the primary
outcomes of BPD severity, self-harm and psychosocial functioning,
and  in  favour  of  MBT  for  self-harm,  suicidality  and  depression.
We  rated  the  quality  of  the  evidence  for  these  outcomes  as  low,
meaning that the true magnitude of these effects is uncertain.

In  relation  to  implications  for  practice,  low-certainty  evidence
shows  that  that  BPD-tailored  therapies  (like  DBT,  MBT,  CBT,  SFT,
TFP  and  ACT)  may  be  more  effective  than  usual  treatments.  We

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

must await ongoing and new trials that can compare more validly
the  different  treatment  effects  for  the  various  types  of  treatment
for  BPD,  including  head-to-head  comparisons.  Current  evidence
indicates that psychotherapy, especially BPD-tailored approaches,
have  beneficial  effects  on  a  variety  of  outcomes.  However,  only
the decrease in BPD symptom severity was found to be clinically
important.  In  order  to  help  people  affected  by  BPD  decide  on
treatment according to their preferences and values, they should
be  informed  about  the  variety  of  treatments  available,  working
models, treatment durations and related information.

Though a subgroup analysis indicated that adolescents may benefit
less from psychotherapy compared to adults regarding overall BPD
severity, this finding is based on low-quality evidence only and very
few observations (only two RCTs of adolescents included; Analysis
27.1.1),  so  the  true  effect  remains  uncertain.  In  practice,  many
adolescents often present with BPD symptoms on a subthreshold
level,  not  yet  reaching  the  full  diagnostic  threshold  for  BPD.
Subthreshold  BPD  symptoms  (even  with  only  one  BPD  feature
present) have been shown to be clinically important and correlated
with  the  presence  of  mental  state  disorders,  reduced  social
functioning  and  suicidal  behaviour  (Thomson  2019).  Therefore,
RCTs  on  early  intervention  for  BPD  in  adolescence  often  include
participants  with  subthreshold  BPD.  We  have  not  included  such
participants in this review despite accumulating research findings
that  support  the  conduct  of  early  interventions  (Chanen  2016;
Chanen 2018).

Implications for research

In  order  to  thoroughly  investigate  the  efficacy  of  the  treatments
described  in  this  review,  there  is  a  need  for  further  high-quality
RCTs with larger patient groups. Here, it is essential that individual
researchers  are  not  involved  in  the  delivery  or  the  development
of  the  treatment  being  investigated.  Additionally,  to  assess  the
efficacy  of  psychotherapeutic  treatments  in  BPD,  there  is  a  need
for  a  greater  consensus  on  what  constitutes  the  core  outcomes
of  BPD.  Here,  the  selection  of  outcomes  should  be  based  on
what  people  with  BPD  and  their  caregivers  consider  to  be
of  value.  Besides  the  core  symptoms  of  BPD,  which  are  still
included  in  the  DSM-5  (APA  2013)  and  will  be  retained  in  ICD-11
(WHO  2018),  the  dimensional  outcome  domains  of  personality
disorders  should  also  be  considered,  as  this  would  foster  the
applicability  of  BPD  research  to  non-BPD  personality  disorders.
Furthermore,  assessment  of  outcomes  should  be  based  on
validated, universal scales that enable a comparison of treatment
effects  between  trials.  Fortunately,  BPD-specific  measures  have
been  developed  and  used  more  often  during  the  past  decade.
Yet for some important BPD-specific outcomes (like 'avoidance of
abandonment',  'feeling  of  emptiness'),  assessment  still  relies  on
single items of questionnaires (like the Zan-BPD (Zanarini 2003a) or
BPDSI-IV (Arntz 2003)). The development of validated assessments
tools would be helpful.

Future trials should include standardised control interventions that
are carefully considered and reported fully in order to get a clear

Cochrane Database of Systematic Reviews

picture  of  what  the  psychological  therapies  are  being  compared
to. More research is needed, when it comes to understanding the
effects  of  interventions  in  certain  groups  of  people,  especially
adolescents and the elderly, but also in men who are still under-
represented in BPD research. Long-term trials should be conducted
in order to understand which treatment effects are maintained and
which diminish over time.

Our  findings  that  different  BPD-specific  treatments  are  helpful
is  certainly  in  line  with  all-day  experiences  of  clinicians.  There
are  some  interventions  beyond  the  prominent  paradigms  for
which  we  found  encouraging  results  and  that  deserve  further
attention.  These  especially  include  add-on  therapies  such  as
STEPPS  and  ERGT.  Though  the  different  treatment  approaches
are  theoretically  divergent  and  postulate  different  mechanisms
of  change  (Gunderson  2018),  analyses  of  the  technical  aspects
reveal  many  commonalities  in  terms  of  structure,  focus  and
interventions,  including  general  factors  across  therapies  such
as  a  structured  treatment  framework,  consistent  focus  on  the
therapeutic  relationship,  active  therapists  and  therapist  support
(Bateman  2015;  De  Groot  2008;  Kongerslev  2015;  Weinberg
2011).  However,  more  research  is  needed  to  understand  the
shared mechanisms of these specialist treatments, and how they
contribute  to  change  in  BPD  symptomatology  (Karterud  2020).
Future  RCTs  should  consider  incorporating  measurements  of
diverse  mechanisms  of  change  that  are  known  to  be  generally
effective  across  therapies  and  diagnoses  (e.g.  focusing  on  the
working  alliance).  This  would  allow  for  investigating  the  role  of
general mechanisms of change across different treatments in terms
of outcome (Chatoor 2001; Kazdin 2009).

A C K N O W L E D G E M E N T S

We  thank  the  Cochrane  Developmental,  Psychosocial  and
Learning  Problems  (CDPLP)  Editorial  Team,  especially  Joanne
Duffield  (Managing  Editor),  Margaret  Anderson  (Information
Specialist), and Geraldine Macdonald (Co-ordinating Editor).

We  are  grateful  to  the  German  Cochrane  Centre  for  supporting
this work, especially Gerd Antes, Director of the German Cochrane
Centre,  who  initially  made  contact  with  CDPLP.  We  thank  Maja
Kielsholm and Signe Nielsen for their help on the review.

We are grateful to the following peer reviewers for their time and
comments:  Anees  Bahji,  Queen’s  University,  Canada;  Fiona  Ng,
University of Nottingham, UK; and Abhijna Vithal Yergolkar, India.
We also thank the following reviewers for their contributions to an
earlier version of this review: Gerta Rücker, Antje Timmer and Nick
Huband.

The  previous  version  of  this  review  was  supported  by  the
Nottinghamshire  Healthcare  NHS  Trust,  UK;  NHS  Cochrane
Collaboration  Programme  Grant  Scheme,  UK;  German  Federal
Ministry of Education and Research, Germany (grant no. 01KG0609);
and a stipend to JSW by the Ministry of Science, Research and Arts
of the federal state of Baden-Württemberg, Germany.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Amianto 2011 {published data only}

*  Amianto F, Ferrero A, Pierò A, Cairo E, Rocca G, Simonelli B, et
al. Supervised team management, with or without structured
psychotherapy, in heavy users of a mental health service
with borderline personality disorder: a two-year follow-up
preliminary randomized study. BMC Psychiatry 2011;11:181.
[DOI: 10.1186/1471-244X-11-181] [PMC3260092 ] [PMID:
22103890]

NCT01356069. Efficacy of time-limited psychodynamic
psychotherapy and informed clinical management in BPD high
MHS users (HUMSH) [Sequential brief Adlerian psychodynamic
psychotherapy in heavy users of a mental health service
with borderline personality disorder: a two years follow-up
preliminary randomized study]. clinicaltrials.gov/ct2/show/
NCT01356069 (first received 16 May 2011).

Andreoli 2016 {published data only}

Andreoli A, Burnand Y, Cochennec MF, Marie D, Di Clemente T,
Ohlendorf P. Psychoanalytic psychotherapy and venlafaxine
among acutely suicidal borderline patients: a randomized
clinical study. European Psychiatry 2009;24(Suppl 1):S93. [DOI:
10.1016/S0924-9338(09)70326-8] [S18-03]

*  Andreoli A, Burnand Y, Cochennec MF, Ohlendorf P,
Frambati L, Gaudry-Maire D, et al. Disappointed love and
suicide: a randomized controlled trial of "abandonment
psychotherapy" among borderline patients. Journal of
Personality Disorders 2016;30(2):271-87. [DOI: 10.1521/
pedi_2015_29_196] [PMID: 26111250]

Andreoli A, Burnand Y, Frambati L, Manning D, Frances A.
Abandonment psychotherapy and psychosocial functioning
among suicidal patients with borderline personality disorder:
a 3-year naturalistic follow-up. Journal of Personality
Disorders 2019 Feb 20 [Epub ahead of print]. [DOI: 10.1521/
pedi_2019_33_423] [PMID: 30785852]

Andreoli A. Re: your study in BPD - Cochrane Collaboration
review [personal communication]. Email to: J Stoffers-
Winterling 5 June 2018.

Antonsen 2017 {published data only}

Antonsen BT, Johansen MS, Rø FG, Kvarstein EH, Wilberg T.
Is reflective functioning associated with clinical symptoms
and long-term course in patients with personality disorders?
Comprehensive Psychiatry 2016;64:46-58. [DOI: 10.1016/
j.comppsych.2015.05.016] [PMID: 26104432]

Antonsen BT, Klungsøyr O, Kamps A, Hummelen B,
Johansen MS, Pedersen G, et al. Step-down versus outpatient
psychotherapeutic treatment for personality disorders: 6-year
follow-up of the Ullevål personality project. BMC Psychiatry
2014;14:119. [DOI: 10.1186/1471-244X-14-119] [PMC4000615]
[PMID: 24758722]

*  Antonsen BT, Kvarstein EH, Urnes Ø, Hummelen B,
Karterud S, Wilberg T. Favourable outcome of long-term
combined psychotherapy for patients with borderline

personality disorder: six-year follow-up of a randomized
study. Psychotherapy Research 2017;27(1):51-63. [DOI:
10.1080/10503307.2015.1072283] [PMID: 26261865]

Arnevik E, Wilberg T, Urnes Ø, Johansen M, Monsen JT,
Karterud S. Psychotherapy for personality disorders: short-
term day hospital psychotherapy versus outpatient individual
therapy - a randomized controlled study. European Psychiatry
2009;24(2):71-8. [DOI: 10.1016/j.eurpsy.2008.09.004] [PMID:
19097870]

Gullestad FS, Johansen MS, Høglend P, Karterud S,
Wilberg T. Mentalization as a moderator of treatment effects:
findings from a randomized clinical trial for personality
disorders. Psychotherapy Research 2013;23(6):674-89. [DOI:
10.1080/10503307.2012.684103] [PMID: 22612470]

Gullestad FS. Re: questions regarding your trial on day hospital
step-down program [personal communication]. Email to: E
Faltinsen 4 December 2017.

Kvarstein EH, Arnevik E, Halsteinli V, Rø FG, Karterud S,
Wilberg T. Health service costs and clinical gains of
psychotherapy for personality disorders: a randomized
controlled trial of day-hospital-based step-down treatment
versus outpatient treatment at a specialist practice. BMC
Psychiatry 2013;13:315. [DOI: 10.1186/1471-244X-13-315]
[PMC4222503] [PMID: 24268099]

Bateman 1999 {published data only}

Bateman A, Fonagy P. 8-year follow-up of patients treated for
borderline personality disorder: mentalization-based treatment
versus treatment as usual. American Journal of Psychiatry
2008;165(5):631-8. [DOI: 10.1176/appi.ajp.2007.07040636]
[PMID: 18347003]

*  Bateman A, Fonagy P. Effectiveness of partial hospitalization
in the treatment of borderline personality disorder: a
randomized controlled trial. American Journal of Psychiatry
1999;156(10):1563-9. [DOI: 10.1176/ajp.156.10.1563] [PMID:
10518167]

Bateman A, Fonagy P. Health care utilization costs for borderline
personality disorder patients treated with psychoanalytically
oriented partial hospitalization versus general psychiatric care.
American Journal of Psychiatry 2003;160(1):169-71. [10.1176/
appi.ajp.160.1.169] [12505818]

Bateman A, Fonagy P. Treatment of borderline personality
disorder with psychoanalytically oriented partial
hospitalization: an 18-month follow-up. American Journal of
Psychiatry 2001;158(1):36-42. [DOI: 10.1176/appi.ajp.158.1.36]
[PMID: 11136631]

Bateman A. Important: question regarding your BPD trial
for systematic review in Cochrane Collaboration [personal
communication]. Email to: K Lieb, J Stoffers 14 December 2010.

Bateman A. Intensive outpatient and partial hospital care for
BPD. In: 157th annual meeting of the American Psychiatric
Association. Psychotherapy and pharmacology: dissolving

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

the mind-brain barrier; 2004 May 1-6; New York (NY). Arlington
(VA): American Psychiatric Association, 2004:102. [Symposium
100B] [www.psychiatry.org/File%20Library/Psychiatrists/
Directories/Library-and-Archive/conference_publications/
am_program_2004.pdf]

personality disorder [Effectiveness of intensive out-patient
psychotherapy for treatment of borderline personality disorder:
a pragmatic randomised single blind controlled study].
www.isrctn.com/ISRCTN27660668 (first received 12 October
2008).

Bateman AW, Fonagy P. Drs Bateman and Fonagy reply [to Stern
R. Partial hospitalization for borderline personality disorder.
American Journal of Psychiatry 2001;158(11):1932-3. DOI:
10.1176/appi.ajp.158.11.1932]. American Journal of Psychiatry
2001;158(11):1932-3. [DOI: 10.1176/appi.ajp.158.11.1932-a]

Evans C. Treatment benefits of psychoanalytically oriented
partial hospitalisation were maintained over 18 months in
borderline personality disorder. Evidence-Based Mental Health
2001;4(3):73. [DOI: 10.1136/ebmh.4.3.73]

Fonagy P, Bateman AW. Mentalizing and borderline personality
disorder. Journal of Mental Health 2007;16(1):83-101. [DOI:
10.1080/09638230601182045]

Stern R. Partial hospitalization for borderline personality
disorder. American Journal of Psychiatry 2001;158(11):1932-3.
[DOI: 10.1176/appi.ajp.158.11.1932] [PMID: 11691712]

Bateman 2009 {published data only}ISRCTN27660668

Bateman A, Fonagy P. Impact of clinical severity on outcomes
of mentalisation-based treatment for borderline personality
disorder. British Journal of Psychiatry 2013;203(3):221-7. [DOI:
10.1192/bjp.bp.112.121129] [PMID: 23887998]

*  Bateman A, Fonagy P. Randomized controlled trial of
outpatient mentalization-based treatment versus structured
clinical management for borderline personality disorder.
American Journal of Psychiatry 2009;166(12):1355-64. [DOI:
10.1176/appi.ajp.2009.09040539] [PMID: 19833787]

Bateman A, Fonagy P. Randomized controlled trial of
outpatient mentalization-based treatment versus structured
clinical management for borderline personality disorder.
Supplementary data. ajp.psychiatryonline.org/doi/
suppl/10.1176/appi.ajp.2009.09040539/suppl_ file/ajp_ 166_ 12_
 1355_ 01.pdf (accessed 27 February 2020).

Bateman A, O'Connell J, Lorenzini N, Gardner T, Fonagy P. A
randomised controlled trial of mentalization-based treatment
versus structured clinical management for patients with
comorbid borderline personality disorder and antisocial
personality disorder. BMC Psychiatry 2016;16:304. [DOI:
10.1186/s12888-016-1000-9] [PMC5006360] [PMID: 27577562]

Bateman A. Important question regarding your BPD trial
for systematic review in Cochrane Collaboration [personal
communication]. Email to: K Lieb 14 December 2010.

Bateman AW. Mentalization, borderline personality
disorder and what works for whom? Presentation at the
11th International Congress of the International Society
for the Study of Personality Disorders; 2009 Aug 21-23.
www.borderlinepersonalitydisorder.com/Conferences/ISSPD/
isspd_ 09_ Bateman (accessed 21 April 2010).

ISRCTN27660668. Randomised controlled trial of manualised
out-patient individual and group therapy for borderline

Bellino 2006 {published data only}

Bellino S, Paradiso E, Zizza M, Di Lorenzo R, Bogetto F.
Combined therapy with interpersonal psychotherapy of major
depressed patients with borderline personality disorder: a
comparison with pharmacotherapy [Terapia combinata con
psicoterapia interpersonale di pazienti depressi maggiori
con disturbo borderline di personalità: confronto con la
farmacoterapia]. Journal of Psychopathology 2005;11(1):34-42.
[bit.ly/2rZUh5h]

*  Bellino S, Zizza M, Rinaldi C, Bogetto F. Combined
treatment of major depression in patients with borderline
personality disorder: a comparison with pharmacotherapy.
Canadian Journal of Psychiatry 2006;51(7):453-60. [DOI:
10.1177/070674370605100707] [PMID: 16838827]

Bellino 2007 {published data only}

*  Bellino S, Zizza M, Rinaldi C, Bogetto F. Combined
therapy of major depression with concomitant borderline
personality disorder: comparison of interpersonal and
cognitive psychotherapy. Canadian Journal of Psychiatry
2007;52(11):718-25. [DOI: 10.1177/070674370705201106] [PMID:
18399039]

Bellino 2010 {published data only}

Bellino S, Bozzatello P, Bogetto F. Combined treatment
of borderline personality disorder with interpersonal
psychotherapy and pharmacotherapy: predictors of response.
Psychiatry Research 2015;226(1):284-8. [DOI: 10.1016/
j.psychres.2014.12.064] [isiarticles.com/bundles/Article/pre/
pdf/34125.pdf]

*  Bellino S, Rinaldi C, Bogetto F. Adaptation of interpersonal
psychotherapy to borderline personality disorder: a
comparison of combined therapy and single pharmacotherapy.
Canadian Journal of Psychiatry 2010;55(2):74-81. [DOI:
10.1177/070674371005500203] [PMID: 20181302]

Bellino S. Question regarding your BPD trials for inclusion in
Cochrane Collaboration review [personal communication].
Email to: J Stoffers-Winterling 19 December 2010.

Bellino S. Re: question regarding your BPD trials [personal
communication]. Email to: J Stoffers 16 December 2010.

Bozzatello P, Bellino S. Combined therapy with interpersonal
psychotherapy adapted for borderline personality disorder:
a two-years follow-up. Psychiatry Research 2016;240:151-6.
[DOI: 10.1016/j.psychres.2016.04.014] [www.sciencedirect.com/
science/article/pii/S0165178115302389]

Zizza M, Fenocchio M, Rinaldi C, Bellino S. Combined treatment
of borderline personality disorder: a trial of modified
interpersonal therapy. World Psychiatry 2009;8(Suppl 1):234.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bianchini 2019 {published data only}

*  Bianchini V, Cofini V, Curto M, Lagrotteria B, Manzi A, Navari S,
et al. Dialectical behavior therapy (DBT) for forensic psychiatric
patients: an Italian pilot study. Criminal Behavior and Mental
Health 2019;29(9):122-30. [DOI: 10.1002/cbm.2102] [PMID:
30648303]

Blum 2008 {published data only}

Black D. Question regarding your BPD trial [personal
communication]. Email to: J Stoffers 04 January 2011.

Black DW, Allen J, McCormick B, Blum N. Treatment received
by persons with BPD participating in a randomized clinical
trial of the systems training for emotional predictability and
problem solving programme. Personality and Mental Health
2011;5(3):159-68. [DOI: 10.1002/pmh.167]

Black DW, Allen J, St John D, Pfohl B, McCormick B,
Blum N. Predictors of response to systems training for
emotional predictability and problem solving (STEPPS) for
borderline personality disorder: an exploratory study. Acta
Psychiatrica Scandinavica 2009;120(1):53-61. [DOI: 10.1111/
j.1600-0447.2008.01340.x] [PMC3665337] [PMID: 19183126]

Black DW, Blum N, Pfohl B, St John D. The STEPPS
group treatment program for outpatients with
borderline personality disorder. Journal of Contemporary
Psychotherapy 2004;34(3):193-210. [DOI: 10.1023/
B:JOCP.0000036630.25741.83]

Black DW, Pfohl BM. Randomized clinical trial of STEPPS versus
treatment as usual. In: 158th annual meeting of the American
Psychiatric Association. Psychosomatic medicine: integrating
psychiatry & medicine; 2005 May 21-26; Atlanta (GA). Arlington
(VA): American Psychiatric Association, 2005:104. [No. 1B]
[www.psychiatry.org/File%20Library/Psychiatrists/Directories/
Library-and-Archive/syllabus/am_syllabus_2005.pdf]

Black DW, Simsek-Duran F, Blum N, McCormick B, Allen J.
Do people with borderline personality disorder complicated
by antisocial personality disorder benefit from the STEPPS
treatment program? Personality and Mental Health
2016;10(3):205-15. [DOI: 10.1002/pmh.1326] [PMC4911327]
[PMID: 26671625]

Black DW. RE: [external] questions regarding your trial on the
STEPPS program for BPD [personal communication]. Email to:
EG Faltinsen 27 November 2017.

Blum N, Allen J, McCormick B, Black DW. Ms Blum and
colleagues reply [to Schulte-Herbrüggen O, Koerting J, Roepke
S. Effectiveness of adjunctive STEPPS group treatment
in borderline personality disorder patients. American
Journal of Psychiatry 2008;165(10):1354-5. DOI: 10.1176/
appi.ajp.2008.08030390]. American Journal of Psychiatry
2008;165(10):1354-5. [DOI: 10.1176/appi.ajp.2008.08030390r]

Blum N, Franklin J, Hansel R, McCormick B, St John D, Pfohl B,
et al. Relationship of age to symptom severity, psychiatric
comorbidity and health care utilization in persons with
borderline personality disorder. Personality and Mental Health
2008;2(1):25-43. [DOI: 10.1002/pmh.26]

Cochrane Database of Systematic Reviews

Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, et
al. Erratum. American Journal of Psychiatry 2008;165(6):777.
Erratum for: American Journal of Psychiatry 2008;165(4):468-78.
[psycnet.apa.org/record/2008-07854-033]

*  Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, et
al. Systems training for emotional predictability and problem
solving (STEPPS) for outpatients with borderline personality
disorder: a randomized controlled trial and 1-year follow-
up. American Journal of Psychiatry 2008;165(4):468-78. [DOI:
10.1176/appi.ajp.2007.07071079] [PMC3608469] [PMID:
18281407]

Davidson KM. Borderline personality disorder: STEPPS
improves symptoms. Evidence-Based Mental Health
2008;11(4):120. [DOI: 10.1136/ebmh.11.4.120] [PMID: 18952969]

NCT00055315. Treatment for borderline personality disorder
[A cognitive group treatment for borderline outpatients].
clinicaltrials.gov/ct2/show/NCT00055315 (first received 25
February 2003).

Bohus 2013 {unpublished data only}

*  Bohus M, Dyer AS, Priebe K, Krüger A, Kleindienst N,
Schmahl C, et al. Dialectical behaviour therapy for post-
traumatic stress disorder after childhood sexual abuse in
patients with and without borderline personality disorder: a
randomised controlled trial. Psychotherapy and Psychosomatics
2013;82(4):221-33. [DOI: 10.1159/000348451] [PMID: 23712109]

Brand S. AW: questions regarding your trial on emotional
intelligence training for BPD [personal communication]. Email
to: EG Faltinsen 28 November 2017.

DBT Working Group at the Central Institute for Mental Health,
Mannheim, Germany. Requested supplementary data (as
supplied 1 October 2010). Data on file.

NCT00481000. Dialectical cognitive traumatherapy (DCT)
on patients with severe PTSD following sexual abuse (PASA)
[Dialectical cognitive traumatherapy (DCT) on patients with
severe posttraumatic stress disorder following sexual abuse
- a randomised controlled trial]. clinicaltrials.gov/ct2/show/
NCT00481000 (first received 31 May 2007).

Steil R, Dyer A, Priebe K, Kleindienst N, Bohus M. Dialectical
behavior therapy for posttraumatic stress disorder related to
childhood sexual abuse: a pilot study of an intensive treatment
program. Journal of Traumatic Stress 2011;24(1):102-6. [DOI:
10.1002/jts.20617] [PMID: 21351167]

Borschmann 2013 {published data only}ISRCTN12440268

*  Borschmann R, Barrett B, Hellier JM, Byford S, Henderson C,
Rose D, et al. Joint crisis plans for people with borderline
personality disorder: feasibility and outcomes in a randomised
controlled trial. British Journal of Psychiatry 2013;202(5):357-64.
[DOI: 10.1192/bjp.bp.112.117762] [PMID: 23637110]

Borschmann R. Joint crisis plans for BPD - question
on publication in British Journal of Psychiatry [pers
communication]. Email to: J Stoffers-Winterling 22 August 2017.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Borschmann R. RE: joint crisis plans for BPD - question
on publication in British Journal of Psychiatry [personal
communication]. Email to: J Stoffers-Winterling 22 August 2017.

Borschmann R. The development and testing of joint
crisis plans for people with borderline personality
disorder: a feasibility study. ethos.bl.uk/OrderDetails.do?
uin=uk.bl.ethos.628499 (accessed 27 January 2019).

Hellier J. RE: regarding your study on on MBT for eating
disorders [personal communication]. Email to: E Faltinsen 27
March 2018.

Hellier J. RE: regarding your study on on MBT for eating
disorders [personal communication]. Email to: E Faltinsen 3
January 2018.

Hellier J. SV: regarding your study on MBT for eating disorders
[personal communication]. Email to: EG Faltinsen, P Robinson
27 March 2018.

ISRCTN12440268. JOSHUA: a pilot randomised controlled trial
of joint crisis plans for people who self harm. www.isrctn.com/
ISRCTN12440268 (first received 17 September 2009).

Bos 2010 {published data only}

*  Bos EH, Van Wel E, Appelo MT, Verbraak MJP. A randomized
controlled trial of a Dutch version of systems training for
emotional predictability and problem solving for borderline
personality disorder. Journal of Nervous and Mental Disease
2010;198(4):299-304. [DOI: 10.1097/NMD.0b013e3181d619cf]
[PMID: 20386260]

Van Wel EB, Bos EH, Appelo MT, Berendsen EM, Willgeroth FC,
Verbraak MJPM. The efficacy of the systems training for
emotional predictability and problem solving (STEPPS) in the
treatment of borderline personality disorder. A randomized
controlled trial [De effectiviteit van de vaardigheidstraining
emotieregulatiestoornis (VERS) in de behandeling van de
borderlinepersoonlijkheidsstoornis: een gerandomiseerd
onderzoek]. Tijdschrift voor Psychiatrie 2009;51(5):291-301.
[PMID: 19434566]

Carmona í Farrés 2019 {published data only}

*  Carmona i Farrés C, Elices M, Soler J, Domínguez-Clavé E,
Pomarol-Clotet E, Salvador R, et al. Effects of mindfulness
training on borderline personality disorder: impulsivity versus
emotional dysregulation. Mindfulness 2019;10:1243-54. [DOI:
10.1007/s12671-018-1071-4]

NCT03363230. Effects of mindfulness training on emotion
regulation and impulsivity. www.clinicaltrials.gov/ct2/show/
NCT03363230 (first received 30 November 2017).

Carter 2010 {published data only}

Carter G. Question regarding your BPD trial [personal
communication]. Email to: J Stoffers 21 December 2010.

*  Carter GL, Willcox CH, Lewin TJ, Conrad AM, Bendit N.
Hunter DBT project: randomized controlled trial of dialectical
behaviour therapy in women with borderline personality
disorder. Australian and New Zealand Journal of Psychiatry

Cochrane Database of Systematic Reviews

2010;44(2):162-73. [DOI: 10.3109/00048670903393621] [PMID:
20113305]

Cottraux 2009 {published data only}

*  Cottraux J, Note ID, Boutitie F, Milliery M, Genouihlac V,
Yao SN, et al. Cognitive therapy versus Rogerian supportive
therapy in borderline personality disorder. Two-year follow-up
of a controlled pilot study. Psychotherapy and Psychosomatics
2009;78(5):307-16. [DOI: 10.1159/000229769] [PMID: 19628959]

NCT00131781. Cognitive therapy versus supportive therapy
in borderline personality disorder. www.clinicaltrials.gov/ct2/
show/NCT00131781 (first received 18 August 2005).

Davidson 2006 {published data only}ISRCTN86177428

Davidson K, Livingstone S, McArthur K, Dickson L, Gumley A.
An integrative complexity analysis of cognitive behaviour
therapy sessions for borderline personality disorder.
Psychology and Psychotherapy 2007;80(Pt 4):513-23. [DOI:
10.1348/147608307X191535] [PMID: 17535542]

*  Davidson K, Norrie J, Tyrer P, Gumley A, Tata P, Murray H, et al.
The effectiveness of cognitive behavior therapy for borderline
personality disorder: results from the borderline personality
disorder study of cognitive therapy (BOSCOT) trial. Journal
of Personality Disorders 2006;20(5):450-65. [DOI: 10.1521/
pedi.2006.20.5.450] [PMC1852259] [PMID: 17032158]

Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, Palmer S,
et al. A randomized controlled trial of cognitive behavior
therapy for borderline personality disorder: rationale for trial,
method, and description of sample. Journal of Personality
Disorders 2006;20(5):431-49. [DOI: 10.1521/pedi.2006.20.5.431]
[PMC1847748] [PMID: 17032157]

Davidson KM, Tyrer P, Norrie J, Palmer SJ, Tyrer H. Cognitive
therapy v usual treatment for borderline personality disorder:
prospective 6-year follow-up. British Journal of Psychiatry
2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID:
21119151]

ISRCTN86177428. Borderline personality disorder study
of cognitive therapy trial [A randomised controlled trial of
cognitive therapy plus treatment as usual versus treatment
as usual in the treatment of borderline personality disorder].
www.isrctn.com/ISRCTN86177428 (first received 22 July 2005).

NCT00538135. BOSCOT: a randomised controlled trial of
cognitive behavioural therapy in borderline personality
disorder [BOSCOT: a randomised control trial of cognitive
behavioural therapy plus treatment as usual versus treatment
as usual in the treatment of borderline personality disorder].
www.clinicaltrials.gov/ct2/show/NCT00538135 (first received 29
September 2007).

Norrie J, Davidson K, Tata P, Gumley A. Influence of therapist
competence and quantity of cognitive behavioural therapy
on suicidal behaviour and inpatient hospitalisation in a
randomised controlled trial in borderline personality disorder:
further analyses of treatment effects in the BOSCOT study.
Psychology and Psychotherapy 2013;86(3):280-93. [DOI: 10.1111/
papt.12004] [PMC4491320] [PMID: 23420622]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Palmer S, Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, et
al. The cost-effectiveness of cognitive behavior therapy for
borderline personality disorder: results from the BOSCOT
trial. Journal of Personality Disorders 2006;20(5):466-81. [DOI:
10.1521/pedi.2006.20.5.466] [PMC1852260] [PMID: 17032159]

Davidson 2014 {published data only}

*  Davidson KM, Brown TM, James V, Kirk J, Richardson J.
Manual-assisted cognitive therapy for self-harm in personality
disorder and substance misuse: a feasibility trial. Psychiatric
Bulletin 2014;38(3):108-11. [DOI: 10.1192/pb.bp.113.043109]
[PMC4115373] [PMID: 25237519]

Davidson KM. Re: question regarding your trial on manual-
assisted cognitive therapy [personal communication]. Email to:
EG Faltinsen 28 November 2017.

Doering 2010 {published data only}

Buchheim A, Hörz-Sagstetter S, Doering S, Rentrop M,
Schuster P, Buchheim P, et al. Change of unresolved attachment
in borderline personality disorders: RCT study of transference-
focused psychotherapy. Psychotherapy and Psychosomatics
2017;86(5):314-6. [DOI: 10.1159/000460257] [PMID: 28903103]

Diamond D, Levy KN, Clarkin JF, Fischer-Kern M, Cain NM,
Doering S, et al. Attachment and mentalization in female
patients with comorbid narcissistic and borderline personality
disorder. Personality Disorders 2014;5(4):428-33. [DOI: 10.1037/
per0000065] [PMID: 25314231]

Diamond D, Yeomans FE, Stern B, Levy KN, Hörz S, Doering S,
et al. Transference-focused psychotherapy for patients
with comorbid narcissistic and borderline personality
disorder. Psychoanalytic Inquiry 2013;33(6):527-51. [DOI:
10.1080/07351690.2013.815087]

*  Doering S, Hörz S, Rentrop M, Fischer-Kern M, Schuster P,
Benecke C, et al. Transference-focused psychotherapy v
treatment by community psychotherapists for borderline
personality disorder: randomised controlled trial. British
Journal of Psychiatry 2010;196(5):389-95. [DOI: 10.1192/
bjp.bp.109.070177] [PMID: 20435966]

Doering S. Author's reply [to Kleindienst N, Krumm B, Bohus
M. Is transference-focused psychotherapy really efficacious for
borderline personality disorder? British Journal of Psychiatry
2011;198(2):156-7. DOI: 10.1192/bjp.198.2.156b]. British Journal
of Psychiatry 2011;198(2):156-7. [DOI: 10.1192/bjp.198.2.157]

Doering S. Question regarding your BPD trial for systematic
review in Cochrane Collaboration [personal communication].
Email to: K Lieb, J Stoffers 10 December 2010.

Fischer-Kern M, Doering S, Taubner S, Hörz S, Zimmermann J,
Rentrop M, et al. Transference-focused psychotherapy for
borderline personality disorder: change in reflective function.
British Journal of Psychiatry 2015;207(2):173-4. [DOI: 10.1192/
bjp.bp.113.143842] [PMID: 25999334]

Kleindienst N, Krumm B, Bohus M. Is transference-focused
psychotherapy really efficacious for borderline personality
disorder? British Journal of Psychiatry 2011;198(2):156-7. [DOI:
10.1192/bjp.198.2.156b] [PMID: 21282787]

Cochrane Database of Systematic Reviews

Levy KN, Meehan KB, Yeomans FE. Transference-focused
psychotherapy reduces treatment drop-out and suicide
attempters compared with community psychotherapist
treatment in borderline personality disorder. Evidence-based
Mental Health 2010;13(4):119. [DOI: 10.1136/ebmh.13.4.119]
[PMID: 21036981]

NCT00714311. Efficacy of transference-focused psychotherapy
for borderline personality disorder [A randomized-controlled
trial of transference-focused psychotherapy vs treatment
by experienced community psychotherapists for borderline
personality disorder]. www.clinicaltrials.gov/ct2/show/
NCT00714311 (first received 9 July 2008).

Rentrop M, Martius P, Bäuml J, Buchheim P, Döering S,
Hörz S. Patients with borderline personality disorder not
participating in an RCT: are they different? Psychopathology
2010;43(6):369-72. [DOI: 10.1159/000320351] [PMID: 20798576]

Elices 2016 {published data only}

*  Elices M, Pascual JC, Portella MJ, Feliu-Soler A, Martín-
Blanco A, Carmona C, et al. Impact of mindfulness training on
borderline personality disorder: a randomized trial. Mindfulness
2016;7:584-95. [DOI: 10.1007/s12671-016-0492-1]

NCT02397031. Mindfulness and interpersonal effectiveness
skills in borderline personality disorder [Randomized, active-
controlled, clinical trial comparing effects of mindfulness and
interpersonal effectiveness skills in borderline personality
disorder]. www.clinicaltrials.gov/ct2/show/NCT02397031 (first
received 12 March 2015).

Soler J, Elices M, Pascual JC, Martín-Blanco A, Feliu-Soler A,
Carmona C, et al. Effects of mindfulness training on different
components of impulsivity in borderline personality disorder:
results from a pilot randomized study. Borderline Personality
Disorder and Emotion Dysregulation 2016;3:1. [DOI: 10.1186/
s40479-015-0035-8] [PMC4709962] [PMID: 26759718]

Farrell 2009 {published data only}

*  Farrell JM, Shaw IA, Webber MA. A schema-focused
approach to group psychotherapy for outpatients with
borderline personality disorder: a randomized controlled
trial. Journal of Behavior Therapy and Experimental Psychiatry
2009;40(2):317-28 Corrigendum to: Journal of Behavior Therapy
and Experimental Psychiatry 2018; 60: 111. [DOI: 10.1016/
j.jbtep.2009.01.002] [PMID: 19176222]

Farrell JM. Question regarding your BPD trials [personal
communication]. Email to: K Lieb, J Stoffers 9 December 2010.

Feigenbaum 2012 {published data only}

Feigenbaum JD, Fonagy P, Pilling S, Jones A, Wildgoose A,
Bebbington PE. A real-world study of the effectiveness
of DBT in the UK National Health Service. British Journal
of Clinical Psychology 2012;51(2):121-41. [DOI: 10.1111/
j.2044-8260.2011.02017.x] [PMID: 22574799]

Feliu-Soler 2017 {published data only}

Feliu-Soler A, Pascual JC, Elices M, Martín-Blanco A, Carmona C,
Cebolla A, et al. Fostering self-compassion and loving-
kindness in patients with borderline personality disorder: a

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

randomized pilot study. Clinical Psychology & Psychotherapy
2017;24(1):278-86. [DOI: 10.1002/cpp.2000] [PMID: 26818533]

Gleeson JFM. RE: separate data [personal communication].
Email to: M Kielsholm 28 October 2016.

Giesen-Bloo 2006 {published and unpublished data}

Gratz 2006 {published data only}

Arntz A, Stupar-Rutenfrans S, Bloo J, Van Dyck R, Spinhoven P.
Prediction of treatment discontinuation and recovery from
borderline personality disorder: results from an RCT comparing
schema therapy and transference-focused psychotherapy.
Behaviour Research and Therapy 2015;74:60-71. [DOI: 10.1016/
j.brat.2015.09.002] [PMID: 26432172]

Giesen-Bloo J, Arntz A. Questions concerning the randomized
trial of schema-focused therapy vs transference-focused
psychotherapy—reply. Archives of General Psychiatry
2007;64(5):610-1. [DOI: 10.1001/archpsyc.64.5.610]

Giesen-Bloo J, Van Dyck R, Spinhoven P, Van Tilburg W,
Dirksen C, Van Asselt T, et al. Errors in table and figure in:
outpatient psychotherapy for borderline personality disorder:
randomized trial of schema-focused therapy vs transference-
focused psychotherapy. Archives of General Psychiatry
2006;63(9):1008. Erratum for: Archives of General Psychiatry
2006;63(6):649-58. [DOI: 10.1001/archpsyc.63.9.1008]

*  Giesen-Bloo J, Van Dyck R, Spinhoven P, Van Tilburg W,
Dirksen C, Van Asselt T, et al. Outpatient psychotherapy for
borderline personality disorder: randomized trial of schema-
focused therapy vs transference-focused psychotherapy.
Archives of General Psychiatry 2006;63(6):649-58. [DOI: 10.1001/
archpsyc.63.6.649] [PMID: 16754838]

Spinhoven P, Giesen-Bloo J, Van Dyck R, Kooiman K, Arntz A.
The therapeutic alliance in schema-focused therapy and
transference-focused psychotherapy for borderline personality
disorder. Journal of Consulting and Clinical Psychology
2007;75(1):104-15. [DOI: 10.1037/0022-006X.75.1.104] [PMID:
17295569]

Van Asselt ADI, Dirksen CD, Arntz A, Giesen-Bloo JH, Van
Dyck R, Spinhoven P, et al. Out-patient psychotherapy for
borderline personality disorder: cost-effectiveness of schema-
focused therapy v transference-focused psychotherapy.
British Journal of Psychiatry 2008;192(6):450-7. [DOI: 10.1192/
bjp.bp.106.033597] [PMID: 18515897]

Van Asselt ADI, Dirksen CD, Arntz A, Severens JL. Difficulties
in calculating productivity costs: work disability associated
with borderline personality disorder. Value in Health
2008;11(4):637-44. [DOI: 10.1111/j.1524-4733.2007.00288.x]

Yeomans F. Questions concerning the randomized
trial of schema-focused therapy vs transference-
focused psychotherapy. Archives of General Psychiatry
2007;64(5):609-10. [DOI: 10.1001/archpsyc.64.5.609-c] [PMID:
17485613]

Gleeson 2012 {published data only}

*  Gleeson JF, Chanen A, Cotton SM, Pearce T, Newman B,
McCutcheon L. Treating co-occurring first-episode psychosis
and borderline personality: a pilot randomized controlled trial.
Early Intervention in Psychiatry 2012;6(1):21-9. [DOI: 10.1111/
j.1751-7893.2011.00306.x] [PMID: 22379625]

Gratz KL. Important: question regarding your BPD trial for
systematic review in Cochrane Collaboration [personal
communication]. Email to: J Stoffers-Winterling 11 December
2010.

*  Gratz KL, Gunderson JG. Preliminary data on an acceptance-
based emotion regulation group intervention for deliberate
self-harm among women with borderline personality
disorder. Behavior Therapy 2006;37(1):25-35. [DOI: 10.1016/
j.beth.2005.03.002] [PMID: 16942958]

Gratz 2014 {published data only}

Gratz KL, Bardeen JR, Levy R, Dixon-Gordon KL, Tull MT.
Mechanisms of change in an emotion regulation group therapy
for deliberate self-harm among women with borderline
personality disorder. Behaviour Research and Therapy
2015;65:29-35. [DOI: 10.1016/j.brat.2014.12.005] [PMC4306622]
[PMID: 25557395]

Gratz KL, Dixon-Gordon KL, Tull MT. Predictors of treatment
response to an adjunctive emotion regulation group therapy for
deliberate self-harm among women with borderline personality
disorder. Personality Disorders 2014;5(1):97-107. [DOI: 10.1037/
per0000062] [PMC4059504] [PMID: 2458806]

*  Gratz KL, Tull MT, Levy R. Randomized controlled trial
and uncontrolled 9-month follow-up of an adjunctive
emotion regulation group therapy for deliberate self-
harm among women with borderline personality disorder.
Psychological Medicine 2014;44(10):2099-112. [DOI: 10.1017/
S0033291713002134] [PMID: 23985088]

Gratz KL. Question regarding your BPD trials [personal
communication]. Email to: J Stoffers 11 December 2010.

Gregory 2008b {published data only}

Gregory RJ, Chlebowski S, Kang D, Remen A, Soderberg M.
Psychodynamic therapy for borderline personality disorder and
co-occurring alcohol use disorders: a newly designed ongoing
study. Journal of the American Psychoanalytic Association
2006;54(4):1331-4. [DOI: 10.1177/00030651060540040107]
[PMID: 17354507]

*  Gregory RJ, Chlebowski S, Kang D, Remen AL, Soderberg MG,
Stepkovitch J, et al. A controlled trial of psychodynamic
psychotherapy for co-occurring borderline personality disorder
and alcohol use disorder. Psychotherapy 2008;45(1):28-41. [DOI:
10.1037/0033-3204.45.1.28] [PMID: 22122363]

Gregory RJ, DeLucia-Deranja E, Mogle JA. Dynamic
deconstructive psychotherapy versus optimized community
care for borderline personality disorder co-occuring with
alcohol use disorders: a 30-month follow-up. Journal of
Nervous and Mental Disease 2010;198(4):292-8. [DOI: 10.1097/
NMD.0b013e3181d6172d] [PMID: 20386259]

Gregory RJ, Remen AL, Soderberg M, Ploutz-Snyder RJ.
A controlled trial of psychodynamic psychotherapy for
co-occurring borderline personality disorder and alcohol

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

use disorder: six-month outcome. Journal of the American
Psychoanalytic Association 2009;57(1):199-205. [DOI:
10.1177/00030651090570011006] [PMID: 19270255]

NCT00145678. Psychodynamic therapy for co-occurring
borderline personality disorder and alcohol use disorder
[Psychodynamic therapy for patients With borderline
personality disorder and alcohol abuse]. www.clinicaltrials.gov/
show/NCT00145678 (first received 1 September 2005).

Haeyen 2018 {published data only}

Haeyen S, Van Hooren S, Hutschemaekers G. Efficacy of art
therapy in individuals with personality disorders cluster B/C: a
randomised controlled trial. International Journal of Psychology
July 2016;51:60. [DOI: 10.1521/pedi_2017_31_312] [PMID:
28926306]

*  Haeyen S, Van Hooren S, Van der Veld W, Hutschemaekers G.
Efficacy of art therapy in individuals with personality disorders
cluster B/C: a randomised controlled trial. Journal of Personality
Disorders 2018;32(4):527-42. [DOI: 10.1521/pedi_2017_31_312]
[PMID: 28926306]

Haeyen S. Re: Cochrane Collaboration review of
psychotherapies for BPD - your RCT of art therapy [personal
communication]. Email to: J Stoffers-Winterling 18 August 2018.

Harned 2014 {published data only}

Harned M. Re: SV: question regarding your trial on brief therapy
for attempted suicide [personal communication]. Email to: EG
Faltinsen 11 December 2018.

*  Harned MS, Korslund KE, Linehan MM. A pilot randomized
controlled trial of dialectical behavior therapy with and
without the dialectical behavior therapy prolonged exposure
protocol for suicidal and self-injuring women with borderline
personality disorder and PTSD. Behaviour Research and Therapy
2014;55:7-17. [DOI: 10.1016/j.brat.2014.01.008] [PMC3987949]
[PMID: 24562087]

Harned MS, Wilks CR, Schmidt SC, Coyle TN. Improving
functional outcomes in women with borderline personality
disorder and PTSD by changing PTSD severity and post-
traumatic cognitions. Behaviour Research and Therapy
2018;103:53-61. [DOI: 10.1016/j.brat.2018.02.002] [PMC5837954]
[PMID: 29448136]

Harned MS. RE: questions regarding your trial on brief therapy
for attempted suicide [personal communication]. Email to: E
Faltinsen 29 November 2017.

Jahangard 2012 {published data only}

Brand S. AW: questions regarding your trial on emotional
intelligence training for BPD [personal communication]. Email
to: EG Faltinsen 28 November 2017.

Brand S. Questions regarding your trial on emotional
intelligence training for BPD [personal communication]. Email
to: EG Faltinsen 28 November 2017.

*  Jahangard L, Haghighi M, Bajoghli H, Ahmadpanah M,
Ghaleiha A, Zarrabian MK, et al. Training emotional
intelligence improves both emotional intelligence and

Cochrane Database of Systematic Reviews

depressive symptoms in inpatients with borderline
personality disorder and depression. International Journal
of Psychiatry in Clinical Practice 2012;16(3):197-204. [DOI:
10.3109/13651501.2012.687454] [PMID: 22873719]

Jochems 2015 {published data only}

*  Jochems EC, Van der Feltz-Cornelis CM, Van Dam A,
Duivenvoorden HJ, Mulder CL. The effects of motivation
feedback in patients with severe mental illness: a cluster
randomized controlled trial. Neuropsychiatric Disease and
Treatment 2015;11:3049-64. [DOI: 10.2147/NDT.S95190]
[PMC4686323] [PMID: 26715847]

Jochems EC. Cochrane Collaboration review on
psychotherapies for borderline PD [personal communication].
Email to: EG Faltinsen 2 July 2018.

Jochems EC. Re: Cochrane Collaboration review on
psychotherapies for borderline PD [personal communication].
Email to: J Stoffers-Winterling 02 July 2018.

Jørgensen 2013 {published data only}

Jørgensen CR, Bøye R, Andersen D, Døssing Blaabjerg AH,
Freund C, Jordet H, et al. Eighteen months post-treatment
naturalistic follow-up study of mentalization-based therapy
and supportive group treatment of borderline personality
disorder: clinical outcomes and functioning. Nordic Psychology
2014;66(4):254-73. [DOI: 10.1080/19012276.2014.963649]

*  Jørgensen CR, Freund C, Bøye R, Jordet H, Andersen D,
Kjølbye M. Outcome of mentalization-based and supportive
psychotherapy in patients with borderline personality
disorder: a randomized trial. Acta Psychiatrica Scandinavica
2013;127(4):305-17. [DOI: 10.1111/j.1600-0447.2012.01923.x]
[PMID: 22897123]

Jorgensen CR. SV: questions on your trial regarding MBT for BPD
patients [personal communication]. Email to: EG Faltinsen 28
November 2017.

Kamalabadi 2012 {published data only}

Kamalabadi MJ, Ahmadi SA, Etemadi O, Fatehizadeh M,
Bahrami F, Firoozabadi A. A study of the effect of couple
dialectical behavioral therapy on symptoms and quality of
marital relationships and mental health of Iranian borderline
personality couples: a controlled trial. Interdisciplinary Journal
of Contemporary Research in Business 2012;3(9):1480-7.
[psycnet.apa.org/record/2012-22425-047]

Koons 2001a {published data only}

Koons CR, Robins CJ, Tweed JL, Lynch TR, Gonzalez AM,
Morse JQ, et al. Efficacy of dialectical behavior therapy
in women veterans with borderline personality disorder.
Behavior Therapy 2001;32(2):371-90. [DOI: 10.1016/
S0005-7894(01)80009-5]

Kramer 2011 {published data only}

*  Kramer U, Berger T, Kolly S, Marquet P, Preisig M, De Roten Y,
et al. Effects of motive-oriented therapeutic relationship in
early-phase treatment of borderline personality disorder:
a pilot study of a randomized trial. Journal of Nervous

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

and Mental Disease 2011;199(4):244-50. [DOI: 10.1097/
NMD.0b013e3182125d19] [PMID: 21451348]

Kramer U, Caspar F, Drapeau M. Change in biased thinking in
a 10-session treatment for borderline personality disorder:
further evidence of the motive-oriented therapeutic
relationship. Psychotherapy Research 2013;23(6):633-45. [DOI:
10.1080/10503307.2013.791404] [PMID: 23631622]

Kramer 2014 {published data only}

Berthoud L, Kramer U, Caspar F, Pascual-Leone A. Emotional
processing in a ten-session general psychiatric treatment for
borderline personality disorder: a case study. Personality and
Mental Health 2015;9(1):73-8. [DOI: 10.1002/pmh.1287] [PMID:
25711648]

Berthoud L, Pascual-Leone A, Caspar F, Tissot H, Keller S,
Rohde KB, et al. Leaving distress behind: a randomized
controlled study on change in emotional processing in
borderline personality disorder. Psychiatry 2017;80(2):139-54.
[DOI: 10.1080/00332747.2016.1220230] [PMID: 28767333]

Keller S, Stelmaszczyk K, Kolly S, De Roten Y, Despland JN,
Caspar F, et al. Change in biased thinking in a treatment
based on the motive-oriented therapeutic relationship for
borderline personality disorder. Journal of Personality Disorders
2018;32(Suppl):75-92. [DOI: 10.1521/pedi.2018.32.supp.75]
[PMID: 29388899]

Kramer U, Flückiger C, Kolly S, Caspar F, Marquet P,
Despland JN, et al. Unpacking the effects of therapist
responsiveness in borderline personality disorder: motive-
oriented therapeutic relationship, patient in-session
experience, and the therapeutic alliance. Psychotherapy and
Psychosomatics 2014;83(6):386-7. [DOI: 10.1159/000365400]
[PMID: 25324025]

Kramer U, Keller S, Caspar F, De Roten Y, Despland JN, Kolly S.
Early change in coping strategies in responsive treatments for
borderline personality disorder: a mediation analysis. Journal
of Consulting and Clinical Psychology 2017;85(5):530-5. [DOI:
10.1037/ccp0000196] [PMID: 28425747]

*  Kramer U, Kolly S, Berthoud L, Keller S, Preisig M, Caspar F, et
al. Effects of motive-oriented therapeutic relationship in a ten-
session general psychiatric treatment of borderline personality
disorder: a randomized controlled trial. Psychotherapy and
Psychosomatics 2014;83(3):176-86. [DOI: 10.1159/000358528]
[PMID: 24752034]

Kramer U, Stulz N, Berthoud L, Caspar F, Marquet P, Kolly S,
et al. The shorter the better? A follow-up analysis of 10-
session psychiatric treatment including the motive-
oriented therapeutic relationship for borderline personality
disorder. Psychotherapy Research 2017;27(3):362-70. [DOI:
10.1080/10503307.2015.1110635] [PMID: 26684670]

NCT01896024. Effects of motive-oriented therapeutic
relationship in the early-phase treatment of borderline
personality disorder (MOTR). www.clinicaltrials.gov/ct2/show/
NCT01896024 (first received 5 July 2013).

Cochrane Database of Systematic Reviews

Kramer 2016 {published data only}

*  Kramer U, Pascual-Leone A, Berthoud L, De Roten Y,
Marquet P, Kolly S, et al. Assertive anger mediates effects of
dialectical behaviour-informed skills training for borderline
personality disorder: a randomized controlled trial. Clinical
Psychology & Psychotherapy 2016;23(3):189-202. [DOI: 10.1002/
cpp.1956] [PMID: 25864773]

Kramer U. The role of coping change in borderline personality
disorder: a process-outcome analysis on dialectical-
behaviour skills training. Clinical Psychology & Psychotherapy
2017;24(2):302-11. [DOI: 10.1002/cpp.2017] [PMID: 27098296]

Kredlow 2017a {published data only}

*  Kredlow MA, Szuhany KL, Lo S, Xie H, Gottlieb JD,
Rosenberg SD, et al. Cognitive behavioral therapy for
posttraumatic stress disorder in individuals with severe
mental illness and borderline personality disorder. Psychiatry
Research 2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045]
[PMC5325773] [PMID: 28086181]

Mueser K. Re: question regarding your trial on CBT for BPD
patients [personal communication]. Email to: EG Faltinsen 28
November 2017.

Kredlow 2017b {published data only}

*  Kredlow MA, Szuhany KL, Lo S, Xie H, Gottlieb JD,
Rosenberg SD, et al. Cognitive behavioral therapy for
posttraumatic stress disorder in individuals with severe
mental illness and borderline personality disorder. Psychiatry
Research 2017;249:86-93. [DOI: 10.1016/j.psychres.2016.12.045]
[PMC5325773] [PMID: 28086181]

Mueser KT, Gottlieb JD, Xie H, Lu W, Yanos PT, Rosenberg SD,
et al. Evaluation of cognitive restructuring for post-traumatic
stress disorder in people with severe mental illness.. British
Journal of Psychiatry 2015;206(6):501-8. [DOI: 10.1192/
bjp.bp.114.147926] [PMC4450219] [PMID: 25858178]

Mueser KT, Rosenberg SD, Xie H, Jankowski MK, Bolton EE,
Lu W, et al. A randomized controlled trial of cognitive-
behavioral treatment for posttraumatic stress disorder in severe
mental illness. Journal of Consulting and Clinical Psychology
2008;76(2):259-71. [DOI: 10.1037/0022-006X.76.2.259]
[PMC3916092] [PMID: 18377122]

Mueser KT. Re: question regarding your trial on CBT for PTSD
participants [personal communication]. Email to: E Faltinsen 28
November 2018.

Laurenssen 2018 {published data only}

Laurenssen EM, Westra D, Kikkert MJ, Noom MJ, Eeren HV,
Van Broekhuyzen AJ, et al. Day hospital mentalization-based
treatment (MBT-DH) versus treatment as usual in the treatment
of severe borderline personality disorder: protocol of a
randomized controlled trial. BMC Psychiatry 2014;14:149. [DOI:
10.1186/1471-244X-14-149] [PMC4045960] [PMID: 24886402]

*  Laurenssen EMP, Luyten P, Kikkert MJ, Westra D, Peen J,
Soons MBJ, et al. Day hospital mentalization-based
treatment v specialist treatment as usual in patients with
borderline personality disorder: randomized controlled trial.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Psychological Medicine 2018;48(15):2522-9. [DOI: 10.1017/
S0033291718000132] [PMID: 29478425]

NL2058 (NTR2175). Mentalisation-based treatment versus care-
as-usual in the treatment of severe borderline personality
disorders. www.trialregister.nl/trial/2058 (first received 21
January 2010).

Leichsenring 2016 {published data only}

Leichsenring F, Masuhr O, Jaeger U, Rabung S, Dally A,
Dümpelmann M, et al. Psychoanalytic-interactional therapy
versus psychodynamic therapy by experts for personality
disorders: a randomized controlled efficacy-effectiveness
study in cluster B personality disorders. Psychotherapy and
Psychosomatics 2016;85(2):71-80. [DOI: 10.1159/000441731]
[PMID: 26808580]

Leppänen 2016 {published data only}

*  Leppänen V, Hakko H, Sintonen H, Lindeman S. Comparing
effectiveness of treatments for borderline personality disorder
in communal mental health care: the Oulu BPD study.
Community Mental Health Journal 2016;52(2):216-27. [DOI:
10.1007/s10597-015-9866-4] [PMID: 25824852]

Leppänen V. Re: questions regarding the Oulu BPD study
[personal communication]. Email to: E Faltinsen 20 December
2017.

Leppänen V. Re: SV: question regarding the Oulu BPD study
[personal communication]. Email to: EG Faltinsen 22 December
2017.

Lin 2019 {published data only}

Lin T-J, Ko H-C, Wu JY-W, Oei TP, Lane H-Y, Chen C-H. The
effectiveness of dialectical behavior therapy skills training
group vs cognitive therapy group on reducing depression
and suicide attempts for borderline personality disorder in
Taiwan. Archives of Suicide Research 2019;23(1):82-99. [DOI:
10.1080/13811118.2018.1436104] [PMID: 29528807]

Linehan 1991 {published data only}

Hoffman RE. Impact of treatment accessibility on
clinical course of parasuicidal patients. Archives of
General Psychiatry 1993;50(2):157-8. [DOI: 10.1001/
archpsyc.1993.01820140083010] [PMID: 8427557]

Lindenboim N. To Know Me is to Keep Me: Self-Verification,
Validation, and Therapy Dropout in the Treatment of Borderline
Personality Disorder [PhD thesis]. Washington (DC): University
of Washington, 2009.

*  Linehan MM, Armstrong HE, Suarez A, Allmon D,
Heard HL. Cognitive-behavioral treatment of chronically
parasuicidal borderline patients. Archives of General
Psychiatry 1991;48(12):1060-4. [DOI: 10.1001/
archpsyc.1991.01810360024003] [PMID: 1845222]

Linehan MM, Heard HL. Impact of treatment accessibility
on clinical course of parasuicidal patients — reply. Archives
of General Psychiatry 1993;50(2):157-8. [DOI: 10.1001/
archpsyc.1993.01820140083011]

Cochrane Database of Systematic Reviews

Linehan 1994 {published data only}

Heard HL. Cost-Effectiveness of Dialectical Behavior Therapy in
the Treatment of Borderline Personality Disorder [PhD thesis].
Washington (DC): University of Washington, 2000.

Lindenboim N. To Know Me is to Keep Me: Self-Verification,
Validation, and Therapy Dropout in the Treatment of Borderline
Personality Disorder [PhD thesis]. Washington (DC): University
of Washington, 2009.

Linehan MM, Heard HL, Armstrong HE. Naturalistic follow-up of
a behavioral treatment for chronically parasuicidal borderline
patients. Archives of General Psychiatry 1993;50(12):971-4. [DOI:
10.1001/archpsyc.1993.01820240055007] [PMID: 8250683]

*  Linehan MM, Tutek DA, Heard HL, Armstrong HE. Interpersonal
outcome of cognitive behavioral treatment for chronically
suicidal borderline patients. American Journal of Psychiatry
1994;151(12):1771-6. [DOI: 10.1176/ajp.151.12.1771] [PMID:
7977884]

Linehan 2006 {published data only}

Bedics JD, Atkins DC, Comtois KA, Linehan MM. Treatment
differences in the therapeutic relationship and introject during
a 2-year randomized controlled trial of dialectical behavior
therapy versus nonbehavioral psychotherapy experts for
borderline personality disorder. Journal of Consulting and
Clinical Psychology 2012;80(1):66-77. [DOI: 10.1037/a0026113]
[PMC3265694] [PMID: 22061867]

Bedics JD, Atkins DC, Comtois KA, Linehan MM. Weekly therapist
ratings of the therapeutic relationship and patient introject
furing the course of dialectical behavioral therapy for the
treatment of borderline personality disorder. Psychotherapy
2012;49(2):231-40. [DOI: 10.1037/a0028254] [PMID: 22642526]

Bedics JD, Atkins DC, Harned MS, Linehan MM. The
therapeutic alliance as a predictor of outcome in dialectical
behavior therapy versus nonbehavioral psychotherapy by
experts for borderline personality disorder. Psychotherapy
2015;52(1):67-77. [DOI: 10.1037/a0038457] [PMID: 25751116]

Brown MZ, Linehan MM, Comtois KA, Murray A, Chapman AL.
Shame as a prospective predictor of self-inflicted injury in
borderline personality disorder: a multi-modal analysis.
Behaviour Research and Therapy 2009;47(10):815-22. [DOI:
10.1016/j.brat.2009.06.008] [PMC2761705] [PMID: 19596223 ]

Coyle TN, Shaver JA, Linehan MM. On the potential for
iatrogenic effects of psychiatric crisis services: the example of
dialectical behavior therapy for adult women with borderline
personality disorder. Journal of Consulting and Clinical
Psychology 2018;86(2):116-24. [DOI: 10.1037/ccp0000275]
[PMID: 29369662]

Harned MS, Chapman AL, Dexter-Mazza ET, Murray A,
Comtois KA, Linehan MM. Treating co-occurring Axis I disorders
in recurrently suicidal women with borderline personality
disorder: a 2-year randomized trial of dialectical behavior
therapy versus community treatment by experts. Journal of
Consulting and Clinical Psychology 2008;76(6):1068-75. [DOI:
10.1037/a0014044] [PMID: 19045974]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Harned MS, Chapman AL, Dexter-Mazza ET, Murray A,
Comtois KA, Linehan MM. Treating co-occurring Axis I disorders
in recurrently suicidal women with borderline personality
disorder: a 2-year randomized trial of dialectical behavior
therapy versus community treatment by experts. Personality
Disorders: Theory, Research, and Treatment 2009;S(1):35-45.
[DOI: 10.1037/1949-2715.S.1.35]

Harned MS, Jackson SC, Comtois KA, Linehan MM. Dialectical
behavior therapy as a precursor to PTSD treatment for suicidal
and/or self-injuring women with bordreline personality
disorder. Journal of Traumatic Stress 2010;23(4):421-9. [DOI:
10.1002/jts.20553] [PMID: 20648564]

Lindenboim N, Comtois KA, Linehan MM. Skills practice in
dialectical behavior therapy for suicidal women meeting criteria
for borderline personality disorder. Cognitive and Behavioral
Practice 2007;14(2):147-56. [DOI: 10.1016/j.cbpra.2006.10.004]

*  Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ,
Heard HL, et al. Two-year randomized controlled trial and
follow-up of dialectical behavior therapy vs therapy by experts
for suicidal behaviors and borderline personality disorder.
Archives of General Psychiatry 2006;63(7):757-66. [DOI: 10.1001/
archpsyc.63.7.757] [PMID: 16818865]

Linehan MM. Error in table in: two-year randomized controlled
trial and follow-up of dialectical behavior therapy vs therapy
by experts for suicidal behaviors and borderline personality
disorder. Archives of General Psychiatry 2007;64(12):1401.
Erratum for: Archives of General Psychiatry 2007;64(12):1401.

McMain S. Dialectic behaviour therapy reduces suicide attempts
compared with non-behavioural psychotherapy in women with
borderline personality disorder. Evidence-Based Mental Health
2007;10(1):18. [DOI: 10.1136/ebmh.10.1.18] [PMID: 17255387]

Neacsiu AD, Lungu A, Harned MS, Rizvi SL, Linehan MM. Impact
of dialectical behavior therapy versus community treatment by
experts on emotional experience, expression, and acceptance
in borderline personality disorder. Behaviour Research and
Therapy 2014;53:47-54. [DOI: 10.1016/j.brat.2013.12.004]
[PMC3955205] [PMID: 24418652]

Neacsiu AD, Rizvi SL, Linehan MM. Dialectical behavior
therapy skills use as a mediator and outcome of treatment
for borderline personality disorder. Behaviour Research and
Therapy 2010;48(9):832-9. [DOI: 10.1016/j.brat.2010.05.017]
[PMC2914145] [PMID: 20579633]

Secrist CD. The Role of Executive Functioning in the Treatment
of Borderline Personality Disorder [PhD thesis]. Washington
(DC): University of Washington, 2014.

Linehan 2015a {published data only}

*  Linehan MM, Korslund KE, Harned MS, Gallop RJ, Lungu A,
Neacsiu AD, et al. Dialectical behavior therapy for high suicide
risk in individuals with borderline personality disorder: a
randomized clinical trial and component analysis. JAMA
Psychiatry 2015;72(5):475-82 Erratum for: JAMA Psychiatry
2015; 72(9): 951. [DOI: 10.1001/jamapsychiatry.2014.3039]
[PMID: 25806661]

Cochrane Database of Systematic Reviews

NCT00183651. Treatment of suicidal women with borderline
personality disorder [Assessment and treatment of parasuicidal
patients]. www.clinicaltrials.gov/ct2/show/NCT00183651 (first
received 13 September 2005).

McMain 2009 {published data only}ISRCTN02634417

Case BG. Letter to the editor on 'McMain SF, Links PS, Gnam
WH, Guimond T, Cardish RJ, Korman L, et al. A randomized
trial of dialectical behavior therapy versus general psychiatric
management for borderline personality disorder. American
Journal of Psychiatry 2009;166(12):1365-74. DOI: 10.1176/
appi.ajp.2009.09010039'. American Journal of Psychiatry
2010;167(4):475. [DOI: 10.1176/appi.ajp.2009.09101532] [PMID:
20360332 ]

ISRCTN02634417. Hope for chronically suicidal patient:
evaluating the clinical and health services impact of dialectical
behaviour therapy (DBT) in individuals with borderline
personality disorder [Evaluating the clinical and health services
impact of dialectical behaviour therapy (DBT) in individuals
with borderline personality disorder: a randomised controlled
trial]. www.isrctn.com/ISRCTN02634417 (first received 16
November 2005). [DOI: 10.1186/ISRCTN02634417]

McMain SF, Fitzpatrick S, Boritz T, Barnhart R, Links P,
Streiner DL. Outcome trajectories and prognostic factors
for suicide and self-harm behaviors in patients with
borderline personaliy disorder following one year of
outpatient psychotherapy. Journal of Personality Disorders
2018;32(4):497-512. [DOI: 10.1521/pedi_2017_31_309] [PMID:
28910214]

*  McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ,
Korman L, et al. A randomized trial of dialectical behavior
therapy versus general psychiatric management for borderline
personality disorder. American Journal of Psychiatry
2009;166(12):1365-74. [DOI: 10.1176/appi.ajp.2009.09010039]
[PMID: 19755574]

McMain SF. Dr McMain replies to letter to the editor on 'McMain
SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman
L, et al. A randomized trial of dialectical behavior therapy
versus general psychiatric management for borderline
personality disorder. American Journal of Psychiatry
2009;166(12):1365-74. DOI: 10.1176/appi.ajp.2009.09010039'.
American Journal of Psychiatry 2010;167(4):475-6. [DOI: 10.1176/
appi.ajp.2009.09101532r)]

NCT00154154. Hope for the chronically suicidal patient
[Hope for the chronically suicidal patient: evaluating the
clinical and health services impact of dialectical behaviour
therapy in individuals with borderline personality disorder].
www.clinicaltrials.gov/ct2/show/NCT00154154 (first received 7
September 2005).

McMain 2017 {published data only}

McMain SF, Guimond T, Barnhart R, Habinski L, Streiner DL. A
randomized trial of brief dialectical behaviour therapy skills
training in suicidal patients suffering from borderline disorder.
Acta Psychiatrica Scandinavica 2017;135(2):138-48. [DOI:
10.1111/acps.12664] [PMID: 27858962]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

McMurran 2016 {published data only}

*  McMurran M, Crawford MJ, Reilly J, Delport J, McCrone P,
Whitham D, et al. Psychoeducation with problem-solving
(PEPS) therapy for adults with personality disorder: a
pragmatic randomised controlled trial to determine the
clinical effectiveness and cost-effectiveness of a manualised
intervention to improve social functioning. Health Technology
Assessment 2016;20(52):1-282. [DOI: 10.3310/hta20520]

McMurran M. RE: Cochrane Collaboration review - PEPS study
[personal communication]. Email to: J Stoffers-Winterling 5 July
2018.

McMurran M. Request for data on BPD subjects in the
PEPS rcp-study for use a new Cochrane review [personal
communication]. Email to: M Kongerslev 7 March 2017.

therapy (DBT) and schema therapy (ST) on reducing
mood activity and suicidal thoughts in patients with
borderline personality disorder. Acta Medica Mediterranea
2017;33:1025-31. [DOI: 10.19193/0393-6384_2017_6_162]
[www.actamedicamediterranea.com/archive/2017/medica-6/
comparing-of-the-effect-of-dialectical-behavior-therapy-
dbt-and-schema-therapy-st-on-reducing-mood-activity-and-
suicidal-thoughts-in-patients-with-borderline-personality-
disorder/pdf]

Morey 2010 {published data only}

Morey LC, Lowmaster SE, Hopwood CJ. A pilot study of
manual-assisted cognitive therapy with a therapeutic
assessment augmentation for borderline personality disorder.
Psychiatry Research 2010;178(3):531-5. [DOI: 10.1016/
j.psychres.2010.04.055] [PMID: 20537722]

Mehlum 2014 {published data only}

Morton 2012 {published data only}

Haga E, Aas E, Grøholt B, Tørmoen AJ, Mehlum L. Cost-
effectiveness of dialectical behaviour therapy vs enhanced
usual care in the treatment of adolescents with self-harm. Child
and Adolescent Psychiatry and Mental Health 2018;12:22. [DOI:
10.1186/s13034-018-0227-2] [PMC5928596] [PMID: 29743941]

*  Morton J, Snowdon S, Gopold M, Guymer E. Acceptance
and commitment therapy group treatment for symptoms of
borderline personality disorder: a public sector pilot study.
Cognitive and Behavioral Practice 2012;19(4):527-44. [DOI:
10.1016/j.cbpra.2012.03.005]

Mehlum L, Ramberg M, Tørmoen AJ, Haga E, Diep LM,
Stanley BH, et al. Dialectical behavior therapy compared with
enhanced usual care for adolescents with repeated suicidal
and self-harming behavior: outcomes over a one-year follow-
up. Journal of the American Academy of Child and Adolescent
Psychiatry 2016;55(4):295-300. [DOI: 10.1016/j.jaac.2016.01.005]
[PMID: 27015720]

*  Mehlum L, Tørmoen AJ, Ramberg M, Haga E, Diep LM,
Laberg S, et al. Dialectical behavior therapy for adolescents
with repeated suicidal and self-harming behavior: a
randomized trial. Journal of the American Academy of Child
and Adolescent Psychiatry 2014;53(10):1082-91. [DOI: 10.1016/
j.jaac.2014.07.003] [PMID: 25245352]

Mehlum L. Re: regarding your study of DBT for your with
suicidal behavior [personal communication] [Re: angående din
studie om DBT for ungdom med selvmordsatferd [personlig
kommunikation]]. Email to: E Faltinsen 5 December 2017.

NCT00675129. Treatment for adolescents with deliberate
self harm [A randomized controlled trial for repetitive
deliberate self-harm and suicidal behaviours among Norwegian
adolescents: a comparison between dialectical behaviour
therapy adapted for adolescents (DBT-A) and enhanced usual
care (EUC)]. www.clinicaltrials.gov/ct2/show/NCT00675129 (first
received 6 May 2008).

Ramleth RK, Groholt B, Diep LM, Walby FA, Mehlum L. The
impact of borderline personality disorder and sub-threshold
borderline personality disorder on the course of self-reported
and clinician-rated depression in self-harming adolescents.
Borderline Personality Disorder and Emotion Dysregulation
2017;4:22. [DOI: 10.1186/s40479-017-0073-5] [PMC5663078]
[PMID: 29093819]

Mohamadizadeh 2017 {published data only}

Mohamadizadeh L, Makvandi B, Pasha R, Bakhtiarpour S,
Hafezi F. Comparing of the effect of dialectical behavior

Morton J. Re: SV: regarding your study on acceptance and
commitment therapy for BPD [personal communication]. Email
to: EG Faltinsen 22 December 2017.

Nadort 2009 {published data only}

*  Nadort M, Arntz A, Smit JH, Giesen-Bloo J, Eikelenboom J,
Spinhoven P, et al. Implementation of outpatient schema
therapy for borderline personality disorder with versus
without crisis support by the therapist outside office
hours: a randomized trial. Behaviour Research and Therapy
2009;47(11):961-73. [DOI: 10.1016/j.brat.2009.07.013] [PMID:
19698939]

Nadort M, Arntz A, Smit JH, Giesen-Bloo J, Eikelenboom M,
Spinhoven P, et al. Implementation of outpatient schema
therapy for borderline personality disorder: study design.
BMC Psychiatry 2009;9:64. [DOI: 10.1186/1471-244X-9-64]
[PMC2762959] [PMID: 19807925]

NL1680 (NTR1781). Implementation of out-patient schema-
focused therapy for borderline personality disorder in regular
mental healthcare. www.trialregister.nl/trial/1680 (first received
29 April 2009).

Pascual 2015 {published data only}

NCT02033044. Cognitive rehabilitation versus psychoeducation
in psychosocial functioning of borderline personality
disorder [Randomized controlled trial comparing the effects
on psychosocial functioning of cognitive rehabilitation
versus psychoeducation in borderline personality disorder].
www.clinicaltrials.gov/ct2/show/NCT02033044 (first received 23
December 2013).

*  Pascual JC, Palomares N, Ibáñez Á, Portella MJ, Arza R,
Reyes R, et al. Efficacy of cognitive rehabilitation on
psychosocial functioning in borderline personality disorder: a
randomized controlled trial. BMC Psychiatry 2015;15:255. [DOI:
10.1186/s12888-015-0640-5] [PMC4617906] [PMID: 26487284]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Philips 2018 {published data only}

Rossouw 2012b {published data only}ISRCTN95266816

Philips B, Wenneberg P, Konradsson P, Franck J. Mentalization-
based treatment for concurrent borderline personality disorder
and substance use disorder: a randomized controlled feasibility
study. European Addiction Research 2018;24(1):1-8. [DOI:
10.1159/000485564] [PMC5969093] [PMID: 294028]

Priebe 2012 {published data only}

Barnicot K. Re: Regarding your study on DBT for self-harming
patients [personal communication]. Email to: EG Faltinsen 28
February 2018.

*  Priebe S, Bhatti N, Barnicot K, Bremner S, Gaglia A,
Katsakou C, et al. Effectiveness and cost-effectiveness of
dialectical behaviour therapy for self-harming patients with
personality disorder: a pragmatic randomised controlled trial.
Psychotherapy and Psychosomatics 2012;81(6):356-65. [DOI:
10.1159/000338897] [PMID: 22964561]

Priebe S. Supplemental information [personal communication].
Email to: M Kielsholm 20 May 2016.

Reneses 2013 {published data only}

Reneses B, Figuera D, Salcedo G, Trujillo M, López-Ibor JJ,
Galián M, et al. A controlled randomized study on the efficacy
of short-term dinamic psychotherapy in borderline personality
disorders (BPD). Preliminary results. European Psychiatry
2011;26(Suppl 1):1040. [DOI: 10.1016/S0924-9338(11)72745-6]
[P02-444]

*  Reneses B, Galián M, Serrano R, Figuera D, Fernandez Del
Moral A, López-Ibor JJ, et al. A new time limited psychotherapy
for BPD: preliminary results of a randomized and controlled
trial. Actas Espanolas de Psiquiatria 2013;41(3):139-48. [PMID:
23803797]

Robinson 2016 {published data only}ISRCTN51304415

ISRCTN51304415. Nice OUtcomes for Referrals with Impulsivity,
Self Harm and Eating Disorders: the NOURISHED study [A
randomised controlled trial of mentalisation based therapy
against specialist supportive clinical management in patients
with both eating disorders and symptoms of borderline
personality disorder]. www.isrctn.com/ISRCTN51304415 (first
received 31 January 2011).

Robinson P, Barrett B, Bateman A, Hakeem A, Hellier J,
Lemonsky F, et al. Study protocol for a randomized controlled
trial of mentalization based therapy against specialist
supportive clinical management in patients with both eating
disorders and symptoms of borderline personality disorder.
BMC Psychiatry 2014;14:51. [DOI: 10.1186/1471-244X-14-51]
[PMC3996076] [PMID: 24555511]

*  Robinson P, Hellier J, Barrett B, Barzdaitiene D, Bateman A,
Bogaardt A, et al. The NOURISHED randomised controlled trial
comparing mentalisation-based treatment for eating disorders
(MBT-ED) with specialist supportive clinical management
(SSCM-ED) for patients with eating disorders and symptoms
of borderline personality disorder. Trials 2016;17(1):549. [DOI:
10.1186/s13063-016-1606-8] [PMC5114835] [PMID: 27855714]

ISRCTN95266816. The emergence of personality disorder traits
in adolescents who deliberately self harm and the potential for
using a mentalisation based treatment approach as an early
intervention for such individuals: a randomised controlled trial.
www.isrctn.com/ISRCTN95266816 (first received 29 October
2007).

Rossouw T. Mentalisation based treatment for
adolescents with self harm: an RCT. European Child
& Adolescent Psychiatry 2015;24(1 Suppl):S113. [DOI:
10.1007%2Fs00787-015-0714-4.pdf] [W1-02-02]

Rossouw T. Self harm in adolescence, is MBT the answer?:
an RCT. Adolescent Psychiatry 2012;2(1):102. [DOI:
10.2174/2210676611202010077]

*  Rossouw TI, Fonagy P. Mentalization-based treatment for self-
harm in adolescents: a randomized controlled trial. Journal
of the American Academy of Child and Adolescent Psychiatry
2012;51(12):1304-13.e3. [DOI: 10.1016/j.jaac.2012.09.018]
[PMID: 23200287]

Salzer 2014 {published data only}

*  Salzer S, Cropp C, Jaeger U, Masuhr O, Streeck-Fischer A.
Psychodynamic therapy for adolescents suffering from co-
morbid disorders of conduct and emotions in an in-patient
setting: a randomized controlled trial. Psychological Medicine
2014;44(10):2213-22. [DOI: 10.1017/S003329171300278X] [PMID:
24229481]

Salzer S, Streeck-Fischer A. The psychoanalytic-interactional
method (PiM) for adolescents with borderline personality
disorder [Die psychoanalytisch-interaktionelle methode
(PiM) für adoleszente mit borderline-persönlichkeitsstörung].
Personlichkeitsstorungen Theorie und Therapie 2015;19(1):67-76.
[elibrary.klett-cotta.de/article/99.120110/ptt-19-1-67]

Salzer S. AW: Re: Cochrane Review on psychotherapies for BPD
- RCT testing PiM vs WL [personal communication] [AW:Re:
Cochrane Review zur Psychotherapie bei BPS - RCT zu PiM vs WL
[persönliche kommunikation]]. Email to: J Stoffers-Winterling
15 July 2018.

Santisteban 2015 {published data only}

Santisteban DA, Mena MP, Muir J, McCabe BE, Abalo C,
Cummings AM. The efficacy of two adolescent substance
abuse treatments and the impact of comorbid depression:
results of a small randomized controlled trial. Psychiatric
Rehabilitation Journal 2015;38(1):55-64. [DOI: 10.1037/
prj0000106] [PMC5021542] [PMID: 25799306]

Schilling 2018 {published data only}

Schilling L, Moritz S, Köther U, Nagel M. Preliminary results
on acceptance, feasibility, and subjective efficacy of the add-
on group intervention metacognitive training for borderline
patients. Journal of Cognitive Psychotherapy 2015;29(2):153-64.
[DOI: 10.1891/0889-8391.29.2.153]

*  Schilling L, Moritz S, Kriston L, Krieger M, Nagel M. Efficacy
of metacognitive training for patients with borderline
personality disorder: preliminary results. Psychiatry Research

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

2018;262:459-64. [DOI: 10.1016/j.psychres.2017.09.024] [PMID:
28927866]

Schilling L. Re Schilling 2015/2018 - Cochrane Review of
psychotherapies for BPD [personal communication] [Re
Schilling 2015/2018 - Cochrane Review zur Psychotherapie
bei BPS [persönliche Kommunikation]]. Email to: J Stoffers-
Winterling 22 January 2019.

Schuppert 2012 {published data only}ISRCTN9758910

ISRCTN97589104. Evaluation of a group training for adolescents
(emotion regulation training) with emotion regulation problems
- a randomised controlled clinical trial. www.isrctn.com/
ISRCTN97589104 (first received 23 August 2007).

*  Schuppert HM, Timmerman ME, Bloo J, Van Gemert TG,
Wiersema HM, Minderaa RB, et al. Emotion regulation training
for adolescents with borderline personality disorder traits: a
randomized controlled trial. Journal of the American Academy
of Child & Adolescent Psychiatry 2012;51(12):1314-23. [DOI:
10.1016/j.jaac.2012.09.002] [PMID: 23200288]

Sinnaeve 2018 {published data only}

NCT01904227. Intensified, inpatient adaptation of dialectical
behavior therapy (DBT) (REDBT) [A randomized controlled
study of the efficacy of an intensified, inpatient adaptation
of dialectical behavior therapy (DBT) for a population of
borderline patients (young adults/adults: 18-40), compared
with standard outpatient DBT]. www.clinicaltrials.gov/ct2/
show/NCT01904227 (first received 11 July 2013).

Sinnaeve R, Van den Bosch LM, Van Steenbergen-
Weijenburg KM. Change in interpersonal functioning during
psychological interventions for borderline personality disorder
— a systematic review of measures and efficacy. Personality and
Mental Health 2015;9(3):173-94. [DOI: 10.1002/pmh.1296] [PMID:
26058794]

*  Sinnaeve R, Van den Bosch LMC, Hakkaart-van Roijen L,
Vansteelandt K. Effectiveness of step-down versus outpatient
dialectical behaviour therapy for patients with severe levels
of borderline personality disorder: a pragmatic randomized
controlled trial. Borderline Personality Disorder and Emotion
Dysregulation 2018;5:12. [DOI: 10.1186/s40479-018-0089-5]
[PMC6040072] [PMID: 30002832]

Sinnaeve R. Cochrane Collaboration review [personal
communication]. Email to: J Stoffers-Winterling 11 June 2018.

Sinnaeve R. Re: BPDSI subscale data Sinnaeve et al (2018)
[personal communication]. Email to: A Tadorovac 15 November
2018.

Sinnaeve R. RE: BPDSI subscale data Sinnaeve et al (2018)
[personal communication] [RE: BPDSI subschale data Sinnaeve
et al (2018) [personlig kommunikation]]. Email to: A Todorovac
15 November 2018.

Sinnaeve R. RE: BPDSI subscale data Sinnaeve et al (2018)
[personal communication] [RE: BPDSI subschale data Sinnaeve
et al (2018) [personlig kommunikation]]. Email to: A Todorovac
9 October 2018.

Cochrane Database of Systematic Reviews

Van den Bosch LM, Sinnaeve R, Hakkaart-van Roijen L, Van
Furth EF. Efficacy and cost-effectiveness of an experimental
short-term inpatient dialectical behavior therapy (DBT)
program: study protocol for a randomized controlled trial. Trials
2014;15:152. [DOI: 10.1186/1745-6215-15-152] [PMC4017823]
[PMID: 24885551]

Van Roijen LH, Sinnaeve R, Bouwmans C, Van Den Bosch L.
Cost-effectiveness and cost-utility of shortterm inpatient
dialectical behavior therapy for chronically parasuicidal BPD
(young) adults. Journal of Mental Health Policy and Economics
2015;18(Suppl 1):S19-20. [www.icmpe.org/test1/journal/issues/
v18s1toc.html]

Smith 2012 {published data only}

*  Smith PN, Gamble SA, Cort NA, Ward EA, He H, Talbot NL.
Attachment and alliance in the treatment of depressed, sexually
abused women. Depression and Anxiety 2012;29(2):123-30. [DOI:
10.1002/da.20913] [PMC3325338] [PMID: 22065593]

Smith PN. Re: Cochrane Collaboration review of
psychotherapies for BPD [personal communication]. Email to: J
Stoffers-Winterling 05 July 2018.

Soler 2009 {published data only}

*  Soler J, Pascual JC, Tiana T, Cebrià A, Barrachina J,
Campins MJ, et al. Dialectical behaviour therapy skills training
compared to standard group therapy in borderline personality
disorder: a 3-month randomised controlled clinical trial.
Behaviour Research and Therapy 2009;47(5):353-8. [DOI:
10.1016/j.brat.2009.01.013] [PMID: 19246029]

Soler J. Question regarding your BPD trials [personal
communication]. Email to: J Stoffers 15 December 2010.

Stanley 2017 {published data only}

Fertuck EA, Keilp J, Song I, Morris MC, Wilson ST, Brodsky BS, et
al. Higher executive control and visual memory performance
predict treatment completion in borderline personality
disorder. Psychotherapy and Psychosomatics 2012;81(1):38-43.
[DOI: 10.1159/000329700] [PMC3242704] [PMID: 22116411]

*  NCT00533117. Treating suicidal behavior and self-
mutilation in people with borderline personality disorder.
www.clinicaltrials.gov/ct2/show/NCT00533117 (first received 19
September 2007).

Turner 2000 {published data only}

Turner RM. Naturalistic evaluation of dialectical behavior
therapy-oriented treatment for borderline personality disorder.
Cognitive and Behavioral Practice 2000;7(4):413-9. [DOI:
10.1016/S1077-7229(00)80052-8]

Van den Bosch 2005 {published data only}

*  Van den Bosch LM, Koeter MW, Stijnen T, Verheul R, Van den
Brink W. Sustained efficacy of dialectical behaviour therapy
for borderline personality disorder. Behaviour Research and
Therapy 2005;43(9):1231-41. [DOI: 10.1016/j.brat.2004.09.008]
[PMID: 16005708]

Van den Bosch LM, Verheul R, Schippers GM, Van den Brink W.
Dialectical behavior therapy of borderline patients with and

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

without substance use problems. Implementation and long-
term effects. Addictive Behaviors 2002;27(6):911-23. [DOI:
10.1016/s0306-4603(02)00293-9] [PMID: 12369475]

Van den Bosch LMC. Efficacy of dialectical behaviour therapy
in the treatment of female borderline patients with and
without substance abuse problems: results of a Dutch study
[Dialectische gedragstherapie bij Nederlandse vrouwen
met een borderline persoonlijkheidsstoornis, met en
zonder verslavingsproblemen]. Tijdschrift voor Psychiatrie
2005;47(3):127-37. [www.tijdschriftvoorpsychiatrie.nl/assets/
articles/articles_ 1335pdf.pdf]

Verheul R, Van den Bosch LM, Koeter MW, De Ridder MA,
Stijnen T, Van den Brink W. Dialectical behaviour therapy
for women with borderline personality disorder: 12-month,
randomised clinical trial in The Netherlands. British Journal of
Psychiatry 2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID:
12562741]

Weinberg 2006 {published data only}

*  Weinberg I, Gunderson JG, Hennen J, Cutter CJ Jr. Manual
assisted cognitive treatment for deliberate self-harm in
borderline personality disorder patients. Journal of Personality
Disorders 2006;20(5):482-92. [DOI: 10.1521/pedi.2006.20.5.482]
[PMID: 17032160]

Wilberg T. SV: separate data [personal communication] [SV:
separat data [personlig kommunikation]]. Email to: M Kielsholm
25 May 2016.

Zanarini 2008 {published data only}

*  Zanarini MC, Frankenburg FR. A preliminary, randomized trial
of psychoeducation for women with borderline personality
disorder. Journal of Personality Disorders 2008;22(3):284-90.
[DOI: 10.1521/pedi.2008.22.3.284] [PMID: 18540800]

Zanarini MC, Frankenburg FR. A randomized trial of
psychoeducation for patients with BPD. In: 157th
annual meeting of the American Psychiatric Association.
Psychotherapy and psychopharmacology: dissolving the mind-
brain barrier; 2004 May 1-6; New York (NY). Arlington (VA):
American Psychiatric Association, 2004:102. [Symposium
100E] [www.psychiatry.org/File%20Library/Psychiatrists/
Directories/Library-and-Archive/conference_publications/
am_program_2004.pdf]

Cochrane Database of Systematic Reviews

Open 2016;6(9):e012043. [DOI: http://dx.doi.org/10.1136/
bmjopen-2016-012043]

Andover 2017 {published data only}

Andover MS, Schatten HT, Morris BW, Holman CS, Miller IW. An
intervention for nonsuicidal self-injury in young adults: a pilot
randomized controlled trial. Journal of Consulting and Clinical
Psychology 2017;85(6):620-31. [DOI: 10.1037/ccp0000206]
[PMC5760269] [PMID: 2841448]

Andreasson 2016 {published data only}

Andreasson K, Krogh J, Wenneberg C, Jessen HKL, Krakauer K,
Gluud C, et al. Effectiveness of dialectical behavior therapy
versus collaborative assessment and management of suicidality
treatment for reduction of self-harm in adults with borderline
personality traits and disorder — a randomized observer-
blinded clinical trial. Depression & Anxiety 2016;33(6):520-30.
[DOI: 10.1002/da.22472] [PMID: 26854478]

Apsche 2006 {published data only}

Apsche JA, Bass CK. A treatment study of mode deactivation
therapy in an out patient community setting. International
Journal of Behavioral Consultation and Therapy 2006;2(1):85-93.
[DOI: 10.1037/h0100769]

Asarnow 2017 {published data only}

Asarnow JR, Hughes JL, Babeva KN, Sugar CA. Cognitive-
behavioral family treatment for suicide attempt prevention: a
randomized controlled trial. Journal of the American Academy
of Child and Adolescent Psychiatry 2017;56(6):506-14. [DOI:
10.1016/j.jaac.2017.03.015] [PMC5474088] [PMID: 28545756]

Bamelis 2012a {published data only}

Bamelis LL, Evers SM, Arntz A. Design of a multicentered
randomized controlled trial on the clinical and cost
effectiveness of schema therapy for personality disorders.
BMC Public Health 2012;12:75. [DOI: 10.1186/1471-2458-12-75]
[PMC3305366 ] [PMID: 22272740]

Bateman 2019b {published data only}

Bateman A, Fonagy P. A randomized controlled trial of a
mentalization-based intervention (MBT-FACTS) for families
of people with borderline personality disorder. Personality
Disorders: Theory, Research, & Treatment 2019;10(1):70-9. [DOI:
10.1037/per0000298] [PMID: 29999394]

Zanarini 2018 {published data only}

Bertsch 2013 {published data only}

*  Zanarini MC, Conkey LC, Temes CM, Fitzmaurice GM.
Randomized controlled trial of web-based psychoeducation for
women with borderline personality disorder. Journal of Clinical
Psychiatry 2018;79(3):16m11153. [DOI: 10.4088/JCP.16m11153]
[PMC5764827] [PMID: 28703950]

Bertsch K, Gamer M, Schmidt B, Schmidinger I, Walther S,
Kästel T, et al. Oxytocin and reduction of social threat
hypersensitivity in women with borderline personality disorder.
American Journal of Psychiatry 2013;170(10):1169-77. Erratum
in: American Journal of Psychiatry 2013;170(10):1218a. [DOI:
10.1176/appi.ajp.2013.13020263] [PMID: 23982273]

References to studies excluded from this review

Bira 2014 {published data only}

Ahmed 2016 {published data only}ISRCTN76914248

Ahmed N, John A, Islam S, Jones R, Anderson P, Davies C,
et al. Investigating the feasibility of an enhanced contact
intervention in self-harm and suicidal behaviour: a protocol
for a randomised controlled trial delivering a Social support
and Wellbeing Intervention following Self Harm (SWISH). BMJ

Bira LM. Brief Psychological Intervention for Acute
Posttraumatic stress: Individual and Trauma Factors Affecting
Recovery in Low-SES Minorities [PhD thesis]. Miami (FL):
University of Miami, 2014.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Brent 2018 {published data only}

Coccaro 1997 {published data only}

Brent DA, Kennard BD. Impact of a brief inpatient intervention
and suicide safety planning app to decrease suicidal behavior
after hospital discharge. Journal of the American Academy of
Child & Adolescent Psychiatry 2018;57(10 Suppl):S33. [DOI:
10.1016/j.jaac.2018.07.142] [Abstract #22.4]

Brune 2012 {published data only}

*  Brüne M, Ebert A, Kolb M, Tas C, Edel MA, Roser P. Oxytocin
influences avoidant reactions to social threat in adults with
borderline personality disorder. Human Psychopharmacology
2013;28(6):552-61. [DOI: 10.1002/hup.2343] [PMID: 23950057]

Brüne M, Ebert A. Does oxytocin have a role in
borderline personality disorder? International Journal of
Neuropsychopharmacology 2012;15(Suppl 1):20. [DOI: 10.1017/
S1461145712000508] [Abstract # S-15-004]

Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive
behavior in personality-disordered subjects. Archives of
General Psychiatry 1997;54(12):1081-8. [DOI: 10.1001/
archpsyc.1997.01830240035005] [9400343]

Cornelius 1993 {published data only}

*  Cornelius JR, Soloff PH, George A, Ulrich RF, Perel JM.
Haloperidol vs phenelzine in continuation therapy of borderline
disorder. Psychopharmacology Bulletin 1993;29(2):333-7. [PMID:
8290683]

Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Continuation
pharmacotherapy of borderline personality disorder with
haloperidol and phenelzine. American Journal of Psychiatry
1993;150(12):1843-8. [DOI: 10.1176/ajp.150.12.1843] [PMID:
8238640]

Buric 2019 {published data only}

Cottrell 2018 {published data only}ISRCTN59793150

Buric I, Farias M, Van Mulukom V, Jong J, Kurtev S, Mee C, et
al. The neural, genetic and behavioural effects of intensive
meditation and yoga on prisoners with personality disorders.
Brain, Behavior, and Immunity 2019;76 Suppl:e17. [DOI:
10.1016/j.bbi.2018.11.224] [Abstract #3099]

Cailhol 2014 {published data only}

Cailhol L, Roussignol B, Klein R, Bousquet B, Simonetta-
Moreau M, Schmitt L, et al. Borderline personality disorder and
rTMS: a pilot trial. Psychiatry Research 2014;216(1):155-7. [DOI:
10.1016/j.psychres.2014.01.030] [PMID: 24503285]

Carta 2014 {published data only}

Carta MG, Maggiani F, Pilutzu L, Moro MF, Mura G, Sancassiani F,
et al. Sailing can improve quality of life of people with
severe mental disorders: results of a cross over randomized
controlled trial. Clinical Practice and Epidemiology in Mental
Health 2014;10:80-6. [DOI: 10.2174/1745017901410010080]
[PMC4150378] [PMID: 25191521]

Carter 2013 {published data only}

Carter JD, McIntosh VV, Jordan J, Porter RJ, Frampton CM,
Joyce PR. Psychotherapy for depression: a randomized clinical
trial comparing schema therapy and cognitive behavior
therapy. Journal of Affective Disorders 2013;151(2):500-5. [DOI:
10.1016/j.jad.2013.06.034] [PMID: 23870427]

Chanen 2008 {published data only}

Chanen AM, Jackson HJ, McCutcheon LK, Jovev M, Dudgeon P,
Yuen HP, et al. Early intervention for adolescents with
borderline personality disorder using cognitive analytic
therapy: randomised controlled trial. British Journal of
Psychiatry 2008;193(6):477-84. [PMID: 19043151]

Charney 2015 {published data only}

Charney DA, Heath LM, Zikos E, Palacios-Boix J, Gill KJ.
Poorer drinking outcomes with citalopram treatment for
alcohol dependence: a randomized, double-blind, placebo-
controlled trial. Alcoholism: Clinical and Experimental Research
2015;39(9):1756-65. [DOI: 10.1111/acer.12802] [PMID: 26208048]

Cottrell DJ, Wright-Hughes A, Collinson M, Boston P, Eisler I,
Fortune S, et al. A pragmatic randomised controlled trial
and economic evaluation of family therapy versus treatment
as usual for young people seen after second or subsequent
episodes of self-harm: the self-harm intervention - family
therapy (SHIFT) trial. Health Technology Assessment
2018;22(12):1-222. [DOI: 10.3310/hta22120] [PMC5867393 ]
[PMID: 29532784]

*  Cottrell DJ, Wright-Hughes A, Collinson M, Boston P, Eisler I,
Fortune S, et al. Effectiveness of systemic family therapy
versus treatment as usual for young people after self-harm:
a pragmatic, phase 3, multicentre, randomised controlled
trial. Lancet Psychiatry 2018;5(3):203-16. [DOI: 10.1016/
S2215-0366%2818%2930058-0] [PMC5835764 ] [PMID:
29449180]

Crawford 2018b {published data only}ISRCTN14994755

Crawford MJ, Thana L, Parker J, Turner O, Xing KP, McMurran M,
et al. Psychological support for personality (PSP) versus
treatment as usual: study protocol for a feasibility randomized
controlled trial of a low intensity intervention for people with
personality disorder. Trials 2018;19(1):547. [DOI: 10.1186/
s13063-018-2920-0] [PMC6180621] [PMID: 30305148]

Cullen 2012a {published data only}

Cullen AE, Clarke AY, Kuipers E, Hodgins S, Dean K, Fahy T.
A multi-site randomized controlled trial of a cognitive skills
programme for male mentally disordered offenders: social-
cognitive outcomes. Psychological Medicine 2012;42(3):557-69.
[DOI: 10.1017/s0033291711001553] [PMID: 21846425]

*  Cullen AE, Clarke AY, Kuipers E, Hodgins S, Dean K, Fahy T. A
multisite randomized trial of a cognitive skills program for male
mentally disordered offenders: violence and antisocial behavior
outcomes. Journal of Consulting and Clinical Psychology
2012;80(6):1114-20. [DOI: 10.1037/a0030291] [PMID: 23025249]

De Beurs 2013 {published data only}

De Beurs DP, De Groot MH, Bosmans JE, De Keijser J,
Mokkenstorm J, Verwey B, et al. Reducing patients' suicide
ideation through training mental health teams in the
application of the Dutch multidisciplinary practice guideline on

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

assessment and treatment of suicidal behavior: study protocol
of a randomized controlled trial. Trials 2013;14:372. [DOI:
10.1186/1745-6215-14-372] [PMC3826515] [PMID: 24195781]

DeSaeger 2014 {published data only}

De Saeger H, Kamphuis JH, Finn SE, Smith JD, Verheul R,
Van Busschbach JJ, et al. Therapeutic assessment promotes
treatment readiness but does not affect symptom change in
patients with personality disorders: findings from a randomized
clinical trial. Psychological Assessment 2014;26(2):474-83.
Erratum in: Psychological Assessment 2014;26(2):483. [DOI:
10.1037/a0035667] [PMID: 24467336]

Dunlop 2012 {published data only}

Dunlop BW, Binder EB, Cubells JF, Goodman MM, Kelley ME,
Kinkead B, et al. Predictors of remission in depression to
individual and combined treatments (PReDICT): study protocol
for a randomized controlled trial. Trials 2012;13:106. [DOI: 106
10.1186/1745-6215-13-106] [PMC3539869 ] [PMID: 22776534]

on repeat self-harm in patients admitted for suicide attempt:
findings from ACTION-J study. Journal of Affective Disorders
2018;225:460-5. [DOI: 10.1016/j.jad.2017.08.071] [PMID:
28863298]

Ghahramanlou Holloway 2012 {published data only}

Ghahramanlou-Holloway M, Bhar SS, Brown GK, Olsen C,
Beck AT. Changes in problem-solving appraisal after cognitive
therapy for the prevention of suicide. Psychological Medicine
2012;42(6):1185-93. [DOI: 10.1017/S0033291711002169] [PMID:
22008384]

Ginty 2016 {published data only}

Ginty AT, Muldoon MF, Kuan DCH, Schirda B, Kamarck TW,
Jennings JR, et al. Omega-3 supplementation and the
neural correlates of mood and impulsivity: a double-blind,
randomized, placebo-controlled trial in midlife adults.
Psychosomatic Medicine 2016;78(3):A41. [DOI: 10.1097/
PSY.0000000000000343]

Ehlers 2013 {published data only}

Gold 2013 {published data only}

Ehlers A, Grey N, Wild J, Stott R, Liness S, Deale A, et al.
Implementation of cognitive therapy for PTSD in routine clinical
care: effectiveness and moderators of outcome in a consecutive
sample. Behaviour Research and Therapy 2013;51(11):742-52.
[DOI: 10.1016/j.brat.2013.08.006] [PMC3897916] [PMID:
24076408]

Ekeblad 2016 {published data only}

Ekeblad A, Falkenström F, Andersson G, Vestberg R,
Holmqvist R. Randomized trial of interpersonal psychotherapy
and cognitive behavioral therapy for major depressive disorder
in a community-based psychiatric outpatient clinic. Depression
& Anxiety 2016;33(12):1090-8. [DOI: 10.1002/da.22495] [PMID:
27029912]

EUCTR 2010-020956-69 {published data only}

EUCTR 2010-020956-69. Effekte von oxytocin bei patientinnen
und patienten mit borderline-persönlichkeitsstörung.
www.clinicaltrialsregister.eu/ctr-search/trial/2010-020956-69/
DE (first received 20 October 2010).

EUCTR 2015-000749-21 {published data only}

EUCTR 2015-000749-21. Botulinumtoxin A for emotional
stabilization in borderline personality disorder [Botulinumtoxin
A zur emotionalen stabilisierung bei der borderline-
persönlichkeitsstörung]. www.clinicaltrialsregister.eu/ctr-
search/trial/2015-000749-21/DE (first received 30 December
2015).

Fleischer 2015 {published data only}

Fleischer J, Wingenfeld K, Kuehl LK, Hinkelmann K, Roepke S,
Otte C. Does fludrocortisone influence autobiographical
memory retrieval? A study in patients with major
depression, patients with borderline personality disorder
and healthy controls. Stress 2015;18(6):718-22. [DOI:
10.3109/10253890.2015.1087504] [PMID: 26457343]

Furuno 2018 {published data only}

Furuno T, Nakagawa M, Hino K, Yamada T, Kawashima Y,
Matsuoka Y, et al. Effectiveness of assertive case management

Gold C, Mössler K, Grocke D, Heldal TO, Tjemsland L, Aarre T, et
al. Individual music therapy for mental health care clients with
low therapy motivation: multicentre randomised controlled
trial. Psychotherapy and Psychosomatics 2013;82(5):319-31.
[DOI: 10.1159/000348452] [PMID: 23942318]

Green 2011 {published data only}

Green JM, Wood AJ, Kerfoot MJ, Trainor G, Roberts C,
Rothwell J, et al. Group therapy for adolescents with repeated
self harm: randomised controlled trial with economic
evaluation. BMJ 2011;342:d682. [DOI: 10.1136/bmj.d682]
[PMC3069684] [PMID: 21459975]

Grimholt 2015 {published data only}

Grimholt TK, Jacobsen D, Haavet O, Sandvik L, Jorgensen T,
Norheim AB, et al. Effect of systematic follow-up by general
practitioners after deliberate self-poisoning: a randomised
controlled trial. PLOS One 2015;10(12):e0143934. [DOI: 10.1371/
journal.pone.0143934] [PMC4667913 ] [PMID: 26629812]

Ha 2016 {published data only}

Ha C. The Effects of Intranasal Oxytocin on Social Cognitive
Functioning in Adolescents with Borderline Personality Disorder
Compared to a Sample of Non-Clinical Adolescents [PhD thesis].
Houston (TX): University of Houston, 2016.

Haddock 2016 {published data only}

Haddock G, Davies L, Evans E, Emsley R, Gooding P, Heaney L, et
al. Investigating the feasibility and acceptability of a cognitive
behavioural suicide prevention therapy for people in acute
psychiatric wards (the 'INSITE' trial): study protocol for a
randomised controlled trial. Trials 2016;17:79. [DOI: 10.1186/
s13063-016-1192-9]

Hassanzadeh 2010 {published data only}

Hassanzadeh M, Khajeddin N, Nojomi M, Fleischmann A,
Eshrati T. Brief intervention and contact after deliberate
self-harm: an Iranian randomized controlled trial. Iranian
Journal of Psychiatry and Behavioral Sciences 2010;4(2):5-12.
[ijpsychiatrybs.com/en/articles/2900.html]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hatcher 2015 {published data only}

Hooley 2018 {published data only}ISRCTN12276176

Hatcher S, Coupe N, Wikiriwhi K, Durie SM, Pillai A. Te Ira
Tangata: a Zelen randomised controlled trial of a culturally
informed treatment compared to treatment as usual in Māori
who present to hospital after self-harm. Social Psychiatry &
Psychiatric Epidemiology 2016;51(6):885-94. [DOI: 10.1007/
s00127-016-1194-7] [PMID: 26956679]

Hatcher S, Sharon C, House A, Collings S, Parag V, Collins N.
The ACCESS study: a Zelen randomised controlled
trial of a treatment package including problem solving
therapy compared to treatment as usual in people who
present to hospital after self-harm: study protocol for
a randomised controlled trial. Trials 2011;12:135. [DOI:
10.1186/1745-6215-12-135] [PMC3117717 ] [PMID: 21615951]

*  Hatcher S, Sharon C, House A, Collins N, Collings S, Pillai A.
The ACCESS study: Zelen randomised controlled trial of a
package of care for people presenting to hospital after self-
harm. British Journal of Psychiatry 2015;206(3):229-36. [DOI:
10.1192/bjp.bp.113.135780] [PMID: 25614531]

Hazell 2009 {published data only}

Hazell PL, Martin G, McGill K, Kay T, Wood A, Trainor G,
et al. Group therapy for repeated deliberate self-harm in
adolescents: failure of replication of a randomized trial. Journal
of the American Academy of Child and Adolescent Psychiatry
2009;48(6):662-70. [DOI: 10.1097/CHI.0b013e3181aOacec]
[PMID: 19454922]

Hesse 2010 {published data only}

Hesse M. Psychoeducation for personality disorders as an add-
on to substance abuse treatment versus attention placebo: a
controlled trial. Drugs and Alcohol Today 2010;10(1):25-32. [DOI:
10.5042/daat.2010.0125]

Hewage 2018 {published data only}

Hewage K, Steel Z, Mohsin M, Tay AK, De Oliveira JC, Da
Piedade M, et al. A wait-list controlled study of a trauma-
focused cognitive behavioral treatment for intermittent
explosive disorder in Timor-Leste. American Journal of
Orthopsychiatry 2018;88(3):282-94. [DOI: 10.1037/ort0000280]
[PMID: 28749158]

Hirayasu 2009 {published data only}

Hirayasu Y, Kawanishi C, Yonemoto N, Ishizuka N, Okubo Y,
Sakai A, et al. A randomized controlled multicenter trial of
post-suicide attempt case management for the prevention
of further attempts in Japan (ACTION-J). BMC Public Health
2009;9:364. [DOI: 10.1186/1471-2458-9-364] [PMC2760885]
[PMID: 19781096]

Holder 2017 {published data only}

Holder N, Holliday R, Pai A, Surís A. Role of borderline
personality disorder in the treatment of military sexual
trauma-related posttraumatic stress disorder with cognitive
processing therapy. Behavioral Medicine 2017;43(3):184-90.
[DOI: 10.1080/08964289.2016.1276430] [PMID: 28767012]

Hooley JM, Fox KR, Wang SB, Kwashie AND. Novel online daily
diary interventions for nonsuicidal self-injury: a randomized
controlled trial. BMC Psychiatry 2018;18:264. [DOI: 10.1186/
s12888-018-1840-6] [PMC6106828] [PMID: 30134866]

Husain 2011 {published data only}

Husain N, Fayyaz H, Chaudhry N, Afsar S, Husain M, Rahman R.
Culturally adapted manual assisted problem solving training (C-
MAPS) for prevention of self harm: an RCT from a low income
country. Journal of Psychosomatic Research 2011;70(6):595.
[DOI: 10.1016/j.jpsychores.2011.03.006]

Husain 2014 {published data only}

*  Husain N, Afsar S, Ara J, Fayyaz H, Rahman RU, Tomenson B,
et al. Brief psychological intervention after self-harm:
randomised controlled trial from Pakistan. British
Journal of Psychiatry 2014;204(6):462-70. [DOI: 10.1192/
bjp.bp.113.138370] [PMID: 24676964]

NCT01308151. Culturally adapted manual assisted cognitive
behavioral therapy for prevention of self harm: a randomized
control trial [Culturally adapted cognitive behavioral therapy
for prevention of self harm]. www.ichgcp.net/clinical-trials-
registry/NCT01308151 (first received 2 March 2011).

Johansson 2010 {published data only}

Johansson P, Høglend P, Ulberg R, Amlo S, Marble A, Bøgwald
K-P, et al. The mediating role of insight for long-term
improvements in psychodynamic therapy. Journal of Consulting
and Clinical Psychology 2010;78(3):438-48. [DOI: 10.1037/
a0019245] [PMID: 20515219]

Kawanishi 2014 {published data only}

Kawanishi C, Aruga T, Ishizuka N, Yonemoto N, Otsuka K,
Kamijo Y, et al. Assertive case management versus enhanced
usual care for people with mental health problems who had
attempted suicide and were admitted to hospital emergency
departments in Japan (ACTION-J): a multicentre, randomised
controlled trial. Lancet Psychiatry 2014;1(3):193-201. [DOI:
10.1016/S2215-0366(14)70259-7] [PMID: 26360731]

Keefe 2016 {published data only}

Keefe JR, Webb CA, DeRubeis RJ. In cognitive therapy for
depression, early focus on maladaptive beliefs may be
especially efficacious for patients with personality disorders.
Journal of Consulting and Clinical Psychology 2016;84(4):353-64.
[DOI: 10.1037/ccp0000071] [PMC4936187] [PMID: 26727410]

Keefe 2018 {published data only}

Keefe JR, Milrod BL, Gallop R, Barber JP, Chambless DL. What
is the effect on comorbid personality disorder of brief panic-
focused psychotherapy in patients with panic disorder?
Depression & Anxiety 2018;35(3):239-47. [DOI: 10.1002/da.22708]
[PMC5842115] [PMID: 29212135]

Kellett 2014 {published data only}

Kellett S, Wilbram M, Davis C, Hardy G. Team consultancy using
cognitive analytic therapy: a controlled study in assertive
outreach. Journal of Psychiatric and Mental Health Nursing
2014;21(8):687-97. [DOI: 10.1111/jpm.12123]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Keng 2018 {published data only}

Keng SL, Tan HH. Effects of brief mindfulness and loving-
kindness meditation inductions on emotional and behavioral
responses to social rejection among individuals with high
borderline personality traits. Behaviour Research and Therapy
2018;100:44-53. [DOI: 10.1016/j.brat.2017.11.005] [PMID:
29179024]

Kennard 2018 {published data only}

Kennard BD, Goldstein T, Foxwell AA, McMakin DL, Wolfe K,
Biernesser C, et al. As safe as possible (ASAP): a brief app-
supported inpatient intervention to prevent postdischarge
suicidal behavior in hospitalized, suicidal adolescents. American
Journal of Psychiatry 2018;175(9):864-72. [DOI: 10.1176/
appi.ajp.2018.17101151] [PMC6169524] [PMID: 30021457]

Koenigsberg 2003 {published data only}

Koenigsberg HW, Reynolds D, Goodman M, New AS,
Mitropoulou V, Trestman RL, et al. Risperidone in the treatment
of schizotypal personality disorder. Journal of Clinical Psychiatry
2003;64(6):628-34. [DOI: 10.4088/jcp.v64n0602] [PMID:
12823075]

Krause Utz 2016 {published data only}

Krause-Utz AD, Walther J-C, Schweizer S, Lis S, Schmahl C,
Bohus M. Cognitive control of disturbing social information
and heart rate variablility in borderline personality disorder:
a randomized-controlled trial on the effects of an emotional
working memory training. Biological Psychiatry 2016;79(9
Suppl):415S. [DOI: 10.1016/j.biopsych.2016.03.1410] [Abstract
#1187]

Krause Utz 2017 {published data only}

Krause-Utz A, Walther J-C, Schweizer S, Lis S, Dalgleish T,
Schmahl C, et al. The effectiveness of an emotional working
memory training in borderline personality disorder. Biological
Psychiatry 2017;81(10 Suppl):S164-5. [DOI: 10.1016/
j.biopsych.2017.02.421] [Abstract #404]

Linehan 1999 {published data only}

Linehan MM, Schmidt H 3rd, Dimeff LA, Craft JC, Kanter J,
Comtois KA. Dialectical behavior therapy for patients with
borderline personality disorder and drug-dependence.
American Journal on Addictions 1999;8(4):279-92. [DOI:
10.1080/105504999305686] [PMID: 10598211]

Linehan 2002 {published data only}

Linehan MM, Dimeff LA, Reynolds SK, Comtois KA, Welch SS,
Heagerty P, et al. Dialectical behavior therapy versus
comprehensive validation therapy plus 12-step for the
treatment of opioid dependent women meeting criteria for
borderline personality disorder. Drug and Alcohol Dependence
2002;67(1):13-26. [DOI: 10.1016/s0376-8716(02)00011-x] [PMID:
12062776]

Cochrane Database of Systematic Reviews

Lorentzen S, Ruud T, Fjeldstad A, Høglend PA. Personality
disorder moderates outcome in short- and long-term group
analytic psychotherapy: a randomized clinical trial. British
Journal of Clinical Psychology 2015;54(2):129-46. [DOI: 10.1111/
bjc.12065] [PMID: 25178520]

Maffei 2018 {published data only}

Maffei C, Cavicchioli M, Movalli M, Cavallaro R, Fossati A.
Dialectical behavior therapy skills training in alcohol
dependence treatment: findings based on an open
trial. Substance Use & Misuse 2018;53(14):2368-85. [DOI:
10.1080/10826084.2018.1480035] [PMID: 29958050]

Mahlke 2015 {published data only}

Mahlke CI, Bock T. Peer to peer-support in severe mental
disorders: affective disorders, psychosis and personality
disorder — a randomized controlled trial. European Psychiatry
2015;30 Suppl 1:28-31. [DOI: 10.1016/S0924-9338(15)30135-8]
[Article: 0165]

Marasinghe 2012 {published data only}

Marasinghe RB, Edirippulige S, Kavanagh D, Smith A, Jiffry MT.
Effect of mobile phone-based psychotherapy in suicide
prevention: a randomized controlled trial in Sri Lanka. Journal
of Telemedicine and Telecare 2012;18(3):151-5. [DOI: 10.1258/
jtt.2012.SFT107] [PMID: 22362830]

Marchesi 2006 {published data only}

Marchesi C, De Panfilis C, Cantoni A, Fontò S, Giannelli MR,
Maggini C. Personality disorders and response to medication
treatment in panic disorder: a 1-year naturalistic study. Progress
in Neuro-Psychopharmacology and Biological Psychiatry
2006;30(7):1240-5. [DOI: 10.1016/j.pnpbp.2006.03.010] [PMID:
16678956]

McAuliffe 2014 {published data only}

McAuliffe C, McLeavey BC, Fitzgerald T, Corcoran P, Carroll B,
Ryan L, at al. Group problem-solving skills training for self-
harm: randomised controlled trial. British Journal of Psychiatry
2014;204(5):383-90. [DOI: 10.1192/bjp.bp.111.101816] [PMID:
24434070]

Merolla 2017 {published data only}

Merolla AB. A Study of the Relationship between Borderline-
Dysregulated Personality and Treatment-Resistant Depression
in the Course of the TADS Randomised Controlled Trial [D Clin
Psy thesis]. Cholchester (Es): University of Essex, 2017.

Moran 2010 {published data only}

Moran P, Borschmann R, Flach C, Barrett B, Byford S, Hogg J,
et al. The effectiveness of joint crisis plans for people with
borderline personality disorder: protocol for an exploratory
randomised controlled trial. Trials 2010;11:18. [DOI:
10.1186/1745-6215-11-18] [PMC2837648] [PMID: 20178572]

Lorentzen 2013 {published data only}

Munroe-Blum 1995 {published data only}

*  Lorentzen S, Ruud T, Fjeldstad A, Høglend P. Comparison
of short- and long-term dynamic group psychotherapy:
randomised clinical trial. British Journal of Psychiatry
2013;203(3):280-7. [DOI: 10.1192/bjp.bp.112.113688] [PMID:
24029539]

Munroe-Blum H, Marziali E. A controlled trial of short-term
group treatment for borderline personality disorder. Journal
of Personality Disorders 1995;9(3):190-8. [DOI: 10.1521/
pedi.1995.9.3.190]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT01311193 {published data only}

NCT01311193. Circadian sleep-wake cycles and light therapy in
borderline personality disorder [Circadian sleep-wake cycles,
well-being and light therapy in borderline personality disorder].
www.clinicaltrials.gov/ct2/show/NCT01311193 (first received 3
March 2011).

NCT02728778 {published data only}

NCT02728778. Botulinum toxin A for emotional stabilization in
borderline personality disorder (BPD) (BTX-BPD) [Botulinum
toxin A for emotional stabilization in borderline personality
disorder (BPD)]. clinicaltrials.gov/ct2/show/NCT02728778 (first
received 31 March 2016).

NCT03498937 {published data only}

NCT03498937. Effects of tDCS on impulsiveness among people
suffering from borderline personality disorder (TIMBER) [Effet
de la tDCS sur i'impulsivité chez les personnes souffrant d'un
trouble borderline: TIMBER]. www.clinicaltrials.gov/ct2/show/
NCT03498937 (first received 9 April 2018).

Nickel 2007a {published data only}

Nickel MK. Topiramate treatment of aggression in male
borderline patients. Australian and New Zealand Journal of
Psychiatry 2007;41(5):461-2. [DOI: 10.1080/00048670701261251]

Nickel 2007b {published data only}

Nickel MK. Aripiprazole treatment of patients with
borderline personality disorder. Journal of Clinical Psychiatry
2007;68(11):1815-6. [DOI: 10.4088/jcp.v68n1124f] [PMID:
18052583]

Nickel 2008 {published data only}

Nickel MK, Loew TH. Treatment of aggression with topiramate in
male borderline patients, part II: 18-month follow-up. European
Psychiatry 2008;23(2):115-7. [DOI: 10.1016/j.eurpsy.2007.09.004]

NL1680/NTR1781 {published data only}

NL1680 (NTR1781). Implementation of out-patient schema-
focused therapy for borderline personality disorder in regular
mental healthcare. www.trialregister.nl/trial/1680 (first received
29 April 2009).

NL5802/NTR5957 {published data only}

NL5802 (NTR5957). Mentalization-based treatment with
and without competitive memory training for patients with
borderline personality disorder: randomized controlled trial.
www.trialregister.nl/trial/5802 (first received 3 July 2016).

O'Connor 2017 {published data only}ISRCTN99488269

O'Connor RC, Ferguson E, Scott F, Smyth R, McDaid D, Park AL,
et al. A brief psychological intervention to reduce repetition of
self-harm in patients admitted to hospital following a suicide
attempt: a randomised controlled trial. Lancet Psychiatry
2017;4(6):451-60. [DOI: 10.1016/S2215-0366(17)30129-3]
[PMC5447136] [PMID: 28434871]

Oquendo 2012 {published data only}

*  Oquendo MA, Galfalvy HC, Currier D, Grunebaum MF,
Sher L, Sullivan GM, et al. Treatment of suicide attempters
with bipolar disorder: a randomized clinical trial comparing

Cochrane Database of Systematic Reviews

lithium and valproate in the prevention of suicidal behavior.
American Journal of Psychiatry 2011;168(10):1050-6. Erratum in:
American Journal of Psychiatry 2012;169(2):223. [DOI: 10.1176/
appi.ajp.2011.11010163] [PMC3767999] [PMID: 21768611]

Oquendo MA. First RCT comparing lithium and divalproex
in the prevention of suicidal behavior in bipolar suicide
attempters. Bipolar Disorders 2009;11(Suppl 1):5-6. [DOI:
10.1111/j.1399-5618.2009.00692.x]

Ougrin 2011 {published data only}ISRCTN81605131

Ougrin D, Boege I, Stahl D, Banarsee R, Taylor E. Randomised
controlled trial of therapeutic assessment versus usual
assessment in adolescents with self-harm: 2-year follow-
up. Archives of Disease in Childhood 2013;98(10):772-6. [DOI:
10.1136/archdischild-2012-303200]

*  Ougrin D, Zundel T, Ng A, Banarsee R, Bottle A, Taylor E. Trial
of therapeutic assessment in London: randomised controlled
trial of therapeutic assessment versus standard psychosocial
assessment in adolescents presenting with self-harm. Archives
of Disease in Childhood 2011;96(2):148-53. [DOI: 10.1136/
adc.2010.188755]

Ower 2014 {published data only}

Ower N. Effects of Oxytocin on Social Cognition and Empathy
in Women with Borderline Personality Disorder/Effekte von
Oxytocin auf die Soziale Kognition und Empathie bei Frauen
mit Borderline-Pers ̈onlichkeitsst ̈orung [PhD thesis]. Freiburg im
Breisgau (BW): Albert-Ludwigs-Universität Freiburg, 2014.

Roberts 2018 {published data only}

Roberts ID, Krajbich I, Cheavens JS, Campo JV, Way BM.
Acetaminophen reduces distrust in individuals with borderline
personality disorder features. Clinical Psychological Science
2018;6(1):145-54. [DOI: 10.1177/2167702617731374]

Rombold 2014 {published data only}

Rombold F, Lauterbach E, Felber W, Mueller-Oerlinghausen B,
Ahrens B, Bronisch T, et al. Adjunctive lithium treatment in the
prevention of suicidal behavior in patients with depression
and comorbid personality disorders. International Journal
of Psychiatry in Clinical Practice 2014;18(4):300-3. [DOI:
10.3109/13651501.2014.940052] [PMID: 24994476]

Rosa 2009 {published data only}

Rosa AR, Cruz N, Comes M, Vieta E. Impulsivity in bipolar
disorder: a randomized clinical trial of adjunctive
oxcarbazepine. European Neuropsychopharmacology 2009;19
Suppl 1:S75-6. [DOI: 10.1016/S0924-977X(09)70086-0] [Abstract
#P.3.16]

Roussignol 2010 {published data only}

Roussignol B.  ́Etude de L'effet de la Stimulation Magn ́etique
Transcr ̂anienne R ́ep ́etitive Chez des Patients Pr ́esentant un
Trouble de la Personnalit ́e borderline [Thèse d'exercice] / [Effect
of Repetitive Transcranial Magnetic Stimulation in Patients with
Borderline Personality Disorder] [Exercise thesis]. Toulouse (FR):
M ́edecine Sp ́ecialis ́ee Clinique, 2010.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Santamarina Pérez 2017 {published data only}

Santamarina Pérez P, Romero Cela S, Méndez Blanco I, Font
Martínez E, Picado Rossi M, Martínez Mallén E, et al. Efficacy
of dialectical behavior therapy compared to supportive
therapy in adolescents with suicidal behavior. European
Neuropsychopharmacology 2017;27 Suppl 4:S853-4. [DOI:
10.1016/S0924-977X(17)31533-X] [Abstract #P.2.f.013]

Schuiringa 2017 {published data only}

Schuiringa H, Van Nieuwenhuijzen M, Orobio de Castro B,
Lochman JE, Matthys W. Effectiveness of an intervention for
children with externalizing behavior and mild to borderline
intellectual disabilities: a randomized trial. Cognitive
Therapy and Research 2017;41(2):237-51. [DOI: 10.1007/
s10608-016-9815-8] [PMC5346153] [PMID: 28344370]

Schuppert 2009 {published data only}

Schuppert HM, Giesen-Bloo J, Van Gemert TG, Wiersema HM,
Minderaa RD, Emmelkamp PMG, at al. Effectiveness of an
emotion regulation group training for adolescents — a
randomized controlled pilot study. Clinical Psychology &
Psychotherapy 2009;16(6):467-78. [DOI: 10.1002/cpp.637] [PMID:
19630069]

Sharp 2015 {published data only}

Sharp C, Venta A, Ha C, Newlin E. Oxytocin and trust
in adolescents with borderline personality disorder.
Biological Psychiatry 2015;77(9 Suppl):30S. [DOI: 10.1016/
j.biopsych.2015.03.006] [Abstract #78]

Thunnissen 2009 {published data only}

Thunnissen M, Duivenvoorden H, Van Busschbach J, Hakkaart-
van Roijen L, Van Tilburg W, Verheul R, et al. A randomized
clinical trial on the effectiveness of a re-integration training
after short-term inpatient psychotherapy [De effectiviteit van
re-integratietraining versus boostersessies na kortdurende
klinische psychotherapie: een gerandomiseerd klinisch
onderzoek]. Tijdschrift voor Psychiatrie 2009;51(2):75-86. [PMID:
19194849]

Cochrane Database of Systematic Reviews

behaviour therapy versus treatment as usual in recurrent
deliberate self-harm: the POPMACT study. Psychological
Medicine 2003;33(6):969-76. [DOI: 10.1017/S0033291703008171]
[PMID: 12946081]

Van Beek 2009 {published data only}ISRCTN56421759

Van Beek W, Kerkhof A, Beekman A. Future oriented group
training for suicidal patients: a randomized clinical trial.
BMC Psychiatry 2009;9:65. [DOI: 10.1186/1471-244X-9-65]
[PMC2767345 ] [PMID: 19811638]

Van Dijk 2019 {published data only}

Van Dijk SD, Veenstra MS, Bouman R, Peekel J, Veenstra DH,
Van Dalen PJ, et al. Group schema-focused therapy enriched
with psychomotor therapy versus treatment as usual for
older adults with cluster B and/or C personality disorders: a
randomized trial. BMC Psychiatry 2019;19:26. [DOI: 10.1186/
s12888-018-2004-4] [PMC6334382 ] [PMID: 30646879]

Van Spijker 2010 {published data only}

Van Spijker BA, Van Straten A, Kerkhof AJ. The effectiveness
of a web-based self-help intervention to reduce suicidal
thoughts: a randomized controlled trial. Trials 2010;11:25. [DOI:
10.1186/1745-6215-11-25] [PMC2841163 ] [PMID: 20214777]

Vidal 2013 {published data only}

Vidal R, Bosch R, Nogueira M, Gómez-Barros N, Valero S,
Palomar G, et al. Psychoeducation for adults with attention
deficit hyperactivity disorder vs cognitive behavioral group
therapy: a randomized controlled pilot study. Journal of Nervous
and Mental Disease 2013;201(10):894-900. [DOI: 10.1097/
NMD.0b013e3182a5c2c5] [PMID: 24080677]

Vijayakumar 2011 {published data only}

Vijayakumar L, Umamaheswari C, Shujaath Ali ZS, Devaraj P,
Kesavan K. Intervention for suicide attempters: a randomized
controlled study. Indian Journal of Psychiatry 2011;53(3):244-8.
[DOI: 10.4103/0019-5545.86817] [PMC3221182] [PMID:
22135444]

TufekciogIu 2015 {published data only}

Waltz 2009 {published data only}

TufekciogIu S. Pre-Treatment Axis II Diagnosis and
Psychotherapy Process in Two Time-Limited Therapies [PhD
thesis]. New York (NY): Adelphi University, The Institute of
Advanced Psychological Studies, 2015.

*  Tufekcioglu S, Muran JC, Safran JD, Winston A. Personality
disorder and early therapeutic alliance in two time-limited
therapies. Psychotherapy Research 2013;23(6):646-57. [DOI:
10.1080/10503307.2013.843803] [PMID: 24156505]

Tyrer 2003a {published data only}

Tyrer P, Jones V, Thompson S, Catalan J, Schmidt U, Davidson K,
et al. Service variation in baseline variables and prediction
of risk in a randomised controlled trial of psychological
treatment in repeated parasuicide: the POPMACT study.
International Journal of Social Psychiatry 2003;49(1):58-69. [DOI:
10.1177/0020764003049001148] [PMID: 12793516]

*  Tyrer P, Thompson S, Schmidt U, Jones V, Knapp M,
Davidson K, et al. Randomized controlled trial of brief cognitive

Waltz J, Dimeff LA, Koerner K, Linehan MM, Taylor L, Miller C.
Feasibility of using video to teach a dialectical behavior therapy
skill to clients with borderline personality disorder. Cognitive
and Behavioral Practice 2009;16(2):214-22. [DOI: 10.1016/
j.cbpra.2008.08.004]

Watzke 2012 {published data only}

Watzke B, Ruddel H, Jürgensen R, Koch U, Kriston L, Grothgar B,
et al. Longer term outcome of cognitive-behavioural and
psychodynamic psychotherapy in routine mental health care:
randomised controlled trial. Behaviour Research and Therapy
2012;50(9):580-7. [DOI: 10.1016/j.brat.2012.04.005] [PMID:
22750189]

Weertman 2007 {published data only}

Weertman A, Arntz A. Effectiveness of treatment of childhood
memories in cognitive therapy for personality disorders: a
controlled study contrasting methods focusing on the present
and methods focusing on childhood memories. Behaviour

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Research and Therapy 2007;45(9):2133-43. [DOI: 10.1016/
j.brat.2007.02.013] [PMID: 17462588]

Wilks 2018 {published data only}

Wilks CR, Lungu A, Ang SY, Matsumiya B, Yin Q, Linehan MM. A
randomized controlled trial of an Internet delivered dialectical
behavior therapy skills training for suicidal and heavy episodic
drinkers. Journal of Affective Disorders 2018;232:219-28. [DOI:
10.1016/j.jad.2018.02.053] [PMC5859943 ] [PMID: 29499504]

Wingenfeld 2013 {published data only}

Wingenfeld K, Driessen M, Terfehr K, Schlosser N, Fernando S,
Otte C, et al. Effects of cortisol on memory in women
with borderline personality disorder: role of co-morbid
post-traumatic stress disorder and major depression.
Psychological Medicine 2013;43(3):495-505. [DOI: 10.1017/
S0033291712001961] [PMID: 23171911]

Wingenfeld 2014 {published data only}

*  Wingenfeld K, Kuehl LK, Janke K, Hinkelmann K, Dziobek I,
Fleischer J, et al. Enhanced emotional empathy after
mineralocorticoid receptor stimulation in women with
borderline personality disorder and healthy women.
Neuropsychopharmacology 2014;39(8):1799-804. [DOI: 10.1038/
npp.2014.36] [PMC4059897] [PMID: 24535100]

Wingenfeld K, Kuehl LK, Janke K, Hinkelmann K, Eckert FC,
Roepke S, et al. Effects of mineralocorticoid receptor
stimulation via fludrocortisone on memory in women with
borderline personality disorder. Neurobiology of Learning and
Memory 2015;120:94-100. [DOI: 10.1016/j.nlm.2015.02.013]
[PMID: 25732250]

Wölwer 2001 {published data only}

Wölwer W, Burtscheidt W, Redner C, Schwarz R, Gaebel W.
Out-patient behaviour therapy in alcoholism: impact of
personality disorders and cognitive impairments. Acta
Psychiatrica Scandinavica 2001;103(1):30-7. [DOI: 10.1034/
j.1600-0447.2001.00149.x] [PMID: 11202126]

References to studies awaiting assessment

Abdelkarim 2016 {published data only}

Abdelkarim A, Nagui Rizk D, Esmaiel M, Helal H. Social media
group parallel to dialectical behavior therapy skills training
group, the pros and cons. European Psychiatry 2016;33
Suppl:S556. [DOI: 10.1016/j.eurpsy.2016.01.2054]

Akbari 2009 {published data only}

Akbari J, Aghamohammadian HR, Ghanbari BA. Effectiveness
of CBT, pharmacotherapy and combined approach in
improvement of symptoms depression anger in borderline
personality disorder. Journal of Psychology 2009;13(3):342-59.

Cowperthwait 2017 {published data only}

Cowperthwait CM. Outpatient Dialectical Behavior Therapy
for Adolescents: Treatment Outcomes and Comparison
of Treatment Effects in Two Skills Training Group Formats
[PhD thesis]. Atlanta (GA): Emroy University, 2016. [EMORY
UNIVERSITY: etd.library.emory.edu/concern/etds/0p0967135?
locale=es]

Cochrane Database of Systematic Reviews

Dorrepaal 2012 {published data only}

Dorrepaal E, Thomaes K, Smit JH, Van Balkom AJ, Veltman DJ,
Hoogendoorn AW, et al. Stabilizing group treatment for complex
posttraumatic stress disorder related to child abuse based on
psychoeducation and cognitive behavioural therapy: a multisite
randomized controlled trial. Psychotherapy and Psychosomatics
2012;81(4):217-25. [DOI: 10.1159/000335044] [PMID: 22585094]

Ducasse 2018 {published data only}

Ducasse D, Jaussent I, Arpon-Brand V, Vienot M, Laglaoui C,
 Béziat S, et al. Acceptance and commitment therapy for the
management of suicidal patients: a randomized controlled trial.
Psychotherapy and Psychosomatics 2018;87(4):211-22. [DOI:
10.1159/000488715] [PMID: 29874680]

Einy 2018 {published data only}

Einy S, Narimani M, Atadokht A, Basharpoor S, Fariba SM.
Effectiveness of mentalization based therapy and cognitive-
analytical therapy on improved object relationship of people
with borderline personality disorder: a comparison. Payesh
2018;17(3):275-87. [SCIENTIFIC INFORMATION DATABASE:
www.sid.ir/en/journal/ViewPaper.aspx?ID=576872]

Isaia 2017 {published data only}

Isaia NC. Effective Therapeutic Components in Systems Training
for Emotional Predictability and Problem Solving (STEPPS)
for Borderline Personality Disorder [PhD thesis]. Guildford
(UK): University of Surrey, 2017. [SURREY RESEARCH INSIGHT:
epubs.surrey.ac.uk/842255/]

Johnson 2017 {published data only}

Johnson R. Cognitive Analytic Therapy (CAT) for Borderline
Personality Disorder : Is CAT effective, and what influences
the delivery of this therapy? [DClinPsy thesis]. Sheffield (UK):
University of Sheffield, 2017. [WHITE ROSE ETHESES ONLINE:
etheses.whiterose.ac.uk/18158/]

McCauley 2018 {published data only}

McCauley E, Berk MS, Asarnow JR, Adrian M, Cohen J,
Korslund K, et al. Efficacy of dialectical behavior therapy for
adolescents at high risk for suicide: a randomized clinical
trial. JAMA Psychiatry 2018;75(8):777-85. [DOI: 10.1001/
jamapsychiatry.2018.1109] [PMCID: PMC6584278] [PMID:
29926087]

NCT01528020. Collaborative adolescent research on emotions
and suicide (CARES) [Treatment of suicidal and self-injurious
adolescents with emotional dysregulation]. clinicaltrials.gov/
ct2/show/NCT01528020 (first received 2 February 2012).

Ostermeier 2017 {published data only}

Ostermeier R. Adapting Dialectic Behavioral Therapy Skills
Group Based on the Severity Level of Borderline Personality
Disorder [PsyD thesis). Eagan (MN): Minnesota School of
Professional Psychology, 2014.

Santamarina 2017 {published data only}

Santamarina P, Blanco IM, Picado M, Font E, Moreno E,
Martínez E, et al. Dialectical behavior therapy versus supportive
therapy for adolescents with suicidal behavior: a randomized
controlled trial. Journal of the American Academy of Child and

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Adolescent Psychiatry 2017;56(10 Suppl):S226-7. [DOI: 10.1016/
j.jaac.2017.09.213] [POSTER NUMBER: 3.65]

References to ongoing studies

ACTRN12610000100099 {published data only}

ACTRN12610000100099. A randomised controlled trial of
three forms of psychosocial early intervention for borderline
personality disorder in youth [MOBY: a randomised controlled
trial of specialised early intervention with individual Cognitive
Analytic Therapy, specialised early intervention without
individual psychotherapy, and standard youth mental health
care for first-presentation borderline personality disorder in
youth]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?
ACTRN=12610000100099 (first received 21 December 2009).

Chanen A, Jackson H, Cotton S, Gleeson J, Davey C, Betts J,
et al. Comparing three forms of early intervention for youth
with borderline personality disorder (the MOBY study). Early
Intervention in Psychiatry 2018;12(Supp 1):201. [POSTER
NUMBER: C30]

*  Chanen A, Jackson H, Cotton SM, Gleeson J, Davey CG, Betts J,
et al. Comparing three forms of early intervention for youth
with borderline personality disorder (the MOBY study): study
protocol for a randomised controlled trial. Trials 2015;16:476.
[DOI: 10.1186/s13063-015-1001-x] [PMCID: PMC4618920] [PMID:
26489661]

ACTRN12612000951853 {published data only}

ACTRN12612000951853. A clinical trial of mentalization
based therapy treatment for borderline personality disorder
[Outcome effects of a mentalization based treatment service
(Mindsight) for people with borderline personality disorder
in urban Christchurch: a clinical trial and evaluative study].
www.anzctr.org.au/Trial/Registration/TrialReview.aspx?
id=362981 (first received 4 September 2012).

ACTRN12612001187831 {published data only}

ACTRN12612001187831. Exploring dialectical behaviour
therapy vs conversational model in the treatment of borderline
personality disorder: a randomised clinical trial [Randomised
clinical trial of dialectical behaviour therapy compared to
conversational model in the treatment of borderline personality
disorder in reducing parasuicidal behaviour and depression].
www.anzctr.org.au/Trial/Registration/TrialReview.aspx?
id=363251 (first received 8 November 2012).

ACTRN12616000236493 {published data only}

ACTRN12616000236493. Effectiveness of dialectical
behaviour therapy (DBT) group skills training for borderline
personality disorder (BPD) in community mental health.
www.anzctr.org.au/Trial/Registration/TrialReview.aspx?
id=370119 (first received 15 February 2016).

DRKS00003605 {published data only}

DRKS00003605. Short term therapy in adolescents with
self-destructive and risk-taking behaviours. www.drks.de/
drks_ web/navigate.do?navigationId=trial.HTML&TRIAL_
 ID=DRKS00003605 (first received 10 July 2012).

Cochrane Database of Systematic Reviews

*  Fischer G, Brunner R, Parzer P, Resch F, Kaess M. Short-
term psychotherapeutic treatment in adolescents engaging
in non-suicidal self-injury: a randomized controlled trial.
Trials 2013;14:294. [DOI: 10.1186/1745-6215-14-294] [PMCID::
PMC3848593] [PMID: 24034810]

DRKS00011534 {published data only}

DRKS00011534. PRO*BPD: effectiveness of outpatient
treatment programmes for borderline personality
disorder: a comparison of schema therapy and dialectical
behaviour therapy. www.drks.de/drks_ web/navigate.do?
navigationId=trial.HTML&TRIAL_ ID=DRKS00011534 (first
received 11 January 2017).

*  Fassbinder E, Assmann N, Schaich A, Heinecke K, Wagner T,
Sipos V, et al. PRO*BPD: effectiveness of outpatient treatment
programs for borderline personality disorder: a comparison
of schema therapy and dialectical behavior therapy: study
protocol for a randomized trial. BMC Psychiatry 2018;18(1):341.
[DOI: 10.1186/s12888-018-1905-6] [PMCID: PMC6194626] [PMID:
30340474]

ISRCTN21802136 {published data only}ISRCTN21802136

ISRCTN21802136. Coping with unusual experiences for 12-18
(CUES+) [Coping with unusual experiences for 12-18 year
olds (CUES+): a transdiagnostic randomised controlled trial
of the effectiveness of cognitive therapy in reducing distress
associated with unusual experiences in adolescent mental
health services]. www.isrctn.com/ISRCTN21802136 (first
received 8 January 2015).

*  Jolley S, Browning S, Corrigall R, Laurens KR, Hirsch C,
Bracegirdle K, et al. Coping with unusual experiences for 12-18
year olds (CUES+): a transdiagnostic randomised controlled trial
of the effectiveness of cognitive therapy in reducing distress
associated with unusual experiences in adolescent mental
health services: study protocol for a randomised controlled
trial. Trials 2017;18(1):586. [DOI: 10.1186/s13063-017-2326-4]
[PMCID: PMC5716372] [PMID: 29202862]

NCT00603421 {published data only}

NCT00603421. Effectiveness of a 24 hour phone line on the rate
of suicide attempts in borderline patients. clinicaltrials.gov/ct2/
show/NCT00603421 (first received 16 January 2008).

NCT01531634 {published data only}

NCT01531634. Promoting recovery processes in women with
borderline personality disorder using a dynamic cognitive
intervention. clinicaltrials.gov/ct2/show/NCT01531634 (first
received 3 February 2012).

NCT01823120 {published data only}

Agyapong V, Behre T, Juhas M, Greenshaw A. Preventing self-
harm and reducing suicidal ideation through an expedited
regular supportive psychotherapy and assertive case
management-protocol for a three-arm partial randomised
controlled trial. European Psychiatry 2016;33 Suppl:S440. [DOI:
10.1016/j.eurpsy.2016.01.1599]

*  NCT01823120. Text message intervention to reduce repeat
self-harm [Text message intervention to reduce repeat self-
harm in patients presenting to the emergency department].

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

clinicaltrials.gov/ct2/show/NCT01823120 (first received 26
March 2013).

NCT02068326 {published data only}

*  Beck E, Bo S, Gondan M, Poulsen S, Pedersen L, Pedersen J,
et al. Mentalization-based treatment in groups for adolescents
with borderline personality disorder (BPD) or subthreshold
BPD versus treatment as usual (M-GAB): study protocol for
a randomized controlled trial. Trials 2016;17(1):314. [DOI:
10.1186/s13063-016-1431-0] [PMCID: PMC4942923] [PMID:
27405522]

NCT02068326. MBT in groups for adolescents with BPD
or subthreshold BPD versus TAU - the M-GAB randomized
controlled trial (M-GAB) [Mentalization-based treatment in
groups for adolescents with borderline personality disorder
(BPD) or subthreshold BPD versus treatment as usual - the M-
GAB randomized controlled trial]. clinicaltrials.gov/ct2/show/
NCT02068326 (first received 19 February 2014).

NCT02125942 {published data only}

NCT02125942. Central meditation and imagery therapy for
augmentation of borderline personality disorder treatment
[Pilot study of central meditation and imagery therapy for
borderline personality disorder]. clinicaltrials.gov/ct2/show/
NCT02125942 (first received 26 April 2014).

NCT02126787 {published data only}

NCT02126787. Short-term, intensive psychodynamic group
therapy versus cognitive-behavioral group therapy in the day
treatment [Short-term, intensive psychodynamic group therapy
versus cognitive-behavioral group therapy in the day treatment
of anxiety disorders and comorbid depressive or personality
disorders]. clinicaltrials.gov/ct2/show/NCT02126787 (first
received 9 April 2014).

*  Suszek H, Holas P, Wyrzykowski T, Lorentzen S, Kokoszka A.
Short-term intensive psychodynamic group therapy versus
cognitive-behavioral group therapy in day treatment of
anxiety disorders and comorbid depressive or personality
disorders: study protocol for a randomized controlled trial.
Trials 2015;16:319. [DOI: 10.1186/s13063-015-0827-6] [PMCID:
PMC4517633] [PMID: 26220089]

NCT02134223 {published data only}

NCT02134223. Methylation status of BDNF gene after dialectical
behavior therapy in BPD [Changes in methylation status of
BDNF gene after receiving dialectical behavior therapy in
patients with borderline personality disorder]. clinicaltrials.gov/
ct2/show/NCT02134223 (first received 6 May 2014).

NCT02387736 {published data only}

*  McMain SF, Chapman AL, Kuo JR, Guimond T, Streiner DL,
Dixon-Gordon KL, et al. The effectiveness of 6 versus 12
months of dialectical behaviour therapy for borderline
personality disorder: the feasibility of a shorter treatment and
evaluating responses (FASTER) trial protocol. BMC Psychiatry
2018;18(1):230. [DOI: 10.1186/s12888-018-1802-z] [PMCID:
PMC6050694] [PMID: 30016935]

NCT02387736. DBT for chronically self-harming Individuals
with BPD: evaluating the clinical & cost effectiveness of a 6

Cochrane Database of Systematic Reviews

mo. treatment (FASTER-DBT) [Dialectical behaviour therapy
for chronically self-harming individuals with BPD: evaluating
the clinical and cost effectiveness of a 6-month treatment].
clinicaltrials.gov/ct2/show/NCT02387736 (first received 20
February 2015).

NCT02517723 {published data only}

NCT02517723. Narrative exposure therapy in women with
borderline personality disorder and posttraumatic stress
disorder [A randomized controlled clinical trial (RCCT) to test
the effectiveness of narrative exposure therapy (NET) versus
dialectical-behavioral therapy in reducing trauma related
symptoms in women suffering from borderline personality
disorder (BPD) and posttraumatic stress disorder (PTSD)].
clinicaltrials.gov/ct2/show/NCT02517723 (first received 6
January 2014).

*  Steuwe C, Rullkötter N, Ertl V, Berg M, Neuner F, Beblo T, et
al. Effectiveness and feasibility of narrative exposure therapy
(NET) in patients with borderline personality disorder and
posttraumatic stress disorder – a pilot study. BMC Psychiatry
2016;16:254. [DOI: 10.1186/s12888-016-0969-4] [PMCID:
PMC4955150] [PMID: 27439618]

NCT02685943 {published data only}

NCT02685943. A randomized trial for suicidal patients
[Collaborative assessment and management of suicidality
(CAMS) in comparison to treatment as usual (TAU) for suicidal
patients: a randomized controlled trial]. clinicaltrials.gov/ct2/
show/NCT02685943 (first received 8 February 2016).

*  Ryberg W, Fossse R, Zahl PH, Borson I,  Møller P,  Landrø NI,
 et al. Collaborative assessment and management of suicidality
(CAMS) compared to treatment as usual (TAU) for suicidal
patients: study protocol for a randomized controlled trial. Trials
2016;17(1):481. [DOI: 10.1186/s13063-016-1602-z] [PMCID:
PMC5048411] [PMID: 27716298]

NCT02771691 {published data only}

NCT02771691. Mentalization-based group therapy for
adolescents [Efficacy of mentalization-based group therapy
for adolescents: a pilot randomised controlled trial].
clinicaltrials.gov/show/nct02771691 (first received 25 April
2016).

NCT02985047 {published data only}

*  Liljedahl SI, Helleman M, Daukantaité D, Westrin A, Westling S.
A standardized crisis management model for self-harming and
suicidal individuals with three or more diagnostic criteria of
borderline personality disorder: the Brief Admission Skane
randomized controlled trial protocol (BASRCT). BMC Psychiatry
2017;17(1):220. [DOI: 10.1186/s12888-017-1371-6] [PMCID:
PMC5472925] [PMID: 28619050]

NCT02985047. Brief Admission Skane: replacing general
admission for individuals with self-harm and acute risk of
suicide (BAS) [Brief Admission Skane: can brief admission
replace general admission for individuals with self-harm and
acute risk of suicide]. clinicaltrials.gov/ct2/show/NCT02985047
(first received 25 November 2016).

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT02991586 {published data only}

NCT02991586. Effectiveness study of a dialectical behavioral
treatment for families of adolescents with emotional instability
(FAL). clinicaltrials.gov/show/nct02991586 (first received 10
June 2016).

NCT03011190 {published data only}

*  Hurtado-Santiago S, Guzmán-Parra J,  Bersabé RM, Mayoral F.
Effectiveness of iconic therapy for the reduction of borderline
personality disorder symptoms among suicidal youth: study
protocol for a randomised controlled trial. BMC Psychiatry
2018;18(1):277. [DOI: 10.1186/s12888-018-1857-x] [PMCID:
PMC6122595] [PMID: 30176878]

NCT03011190. Effectiveness of the iconic therapy for borderline
personality disorder symptoms [Effectiveness of the iconic
therapy in youth with suicidal ideation/self-injuring behavior
and borderline personality traits: study protocol for a
randomized controlled trial]. clinicaltrials.gov/ct2/show/
NCT03011190 (first received 28 December 2016).

NCT03092271 {published data only}

NCT03092271. Randomized trial of stepped care for suicide
prevention in teens and young adults (Step2Health)
[Randomized trial of stepped care for suicide prevention
in teens and young adults]. clinicaltrials.gov/ct2/show/
NCT03092271 (first received 21 March 2017).

NCT03185026 {published data only}

NCT03185026. Psychoeducation for suicidal behavior
(PEPSUI) [Effectiveness of the first French psychoeducational
program for suicidal behavior: a randomized controlled trial].
clinicaltrials.gov/ct2/show/NCT03185026 (first received 11 May
2017).

NCT03191565 {published data only}

NCT03191565. Using smartphones for self-monitoring of skill-
use in dialectical behavior therapy (mDIARY) [The mDIARY
study: using smartphones for daily self-monitoring of skill use
and outcome in dialectical behavior therapy with borderline
personality disorder: a combined RCT and time series study].
clinicaltrials.gov/ct2/show/NCT03191565 (first received 24
March 2017).

NCT03297840 {published data only}

NCT03297840. Change in mindfulness in borderline personality
disorder [Change in mindfulness in borderline personality
disorder after dialectic-behavioural therapy (DBT): a pre-post-
comparison]. clinicaltrials.gov/ct2/show/NCT03297840 (first
received 9 May 2017).

NCT03376113 {published data only}

NCT03376113. The effect of a brief psychological intervention
on reducing self-harm repetition: feasibility study.
clinicaltrials.gov/ct2/show/NCT03376113 (first received 2
November 2017).

NCT03418142 {published data only}

*  Klein JP, Hauer A, Berger T, Fassbinder E, Schweiger U,
Jacob G. Protocol for the REVISIT-BPD trial, a randomized
controlled trial testing the effectiveness of an internet-based

Cochrane Database of Systematic Reviews

self-management intervention in the treatment of borderline
personality disorder (BPD). Frontiers in Psychiatry 2018;9:439.
[DOI: 10.3389/fpsyt.2018.00439] [PMCID: PMC6160537] [PMID:
3029802]

NCT03418142. Evaluating an internet-based self-management
intervention for borderline (REVISIT) [Research evaluating the
effectiveness of adding an internet-based self-management
intervention to usual care in the treatment of borderline
personality disorder - REVISIT BPD]. clinicaltrials.gov/ct2/show/
NCT03418142 (first received 23 January 2018).

NCT03677037 {published data only}

NCT03677037. The short-term MBT project (MBT-RCT)
[Short-term versus long-term mentalization-based
therapy for outpatients with subthreshold or diagnosed
borderline personality disorder: a randomized clinical trial].
clinicaltrials.gov/ct2/show/NCT03677037 (first received 14
September 2018).

NCT03833453 {published data only}

NCT03833453. Effectiveness of PTSD-treatment compared to
integrated PTSD-PD-treatment in adult patients with comorbid
PTSD and BPD [Prediction and outcome study in PTSD and
(borderline) personality disorders]. clinicaltrials.gov/ct2/show/
NCT03833453 (first received 24 January 2019).

NL1144/NTR1186 {published data only}

NL1144/NTR1186. SFT for forensic PD patients [Efficacy of
schema-focused therapy versus usual treatment in forensic
patients with personality disorders: a three-year randomized
clinical trial]. www.trialregister.nl/trial/1144 (first received 16
January 2008).

NL2168/NTR2292 {published data only}

*  Laurenssen EM, Smits ML, Bales DL, Feenstra DJ, Eeren HV,
Noom MJ, et al. Day hospital mentalization-based treatment
versus intensive outpatient mentalization-based treatment for
patients with severe borderline personality disorder: protocol
of a multicentre randomized clinical trial. BMC Psychiatry
2014;14:301. [DOI: 10.1186/s12888-014-0301-0] [PMCID:
PMC4240895] [PMID: 25403144]

NL2168/NTR2292. Dosage-trial mentalisation-based treatment
(MBT): intensive outpatient MBT versus day hospital MBT
[Intensive outpatient mentalisation-based treatment versus
day hospital mentalisation-based treatment: a randomised
controlled trial]. www.trialregister.nl/trial/2168 (first received 16
April 2010).

NL2266/NTR2392 {published data only}

NL2266/NTR2392. Group schema therapy for borderline
personality disorder [Multi-site RCT of group schema therapy
for borderline personality disorder]. www.trialregister.nl/
trial/2266 (first received 25 June 2010).

*  Wetzelaer P, Farrell J, Evers SM, Jacob GA, Lee CW, Brand O, et
al. Design of an international multicentre RCT on group schema
therapy for borderline personality disorder. BMC Psychiatry
2014;14:319. [DOI: 10.1186/s12888-014-0319-3]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NL3856/NTR4016 {published data only}

APA 1994

NL3856/NTR4016. The addition of STEPPS in the treatment
of patients with bipolar disorder and comorbid borderline
personality features: a randomized controlled trial [Toetsing
van een geïntegreerd behandelprotocol voor patiënten
met een bipolaire stoornis en een comorbide borderline
persoonlijkheidskenmerken. Een randomized clinical trial].
www.trialregister.nl/trial/3856 (first received 28 May 2013).

*  Riemann G, Weisscher N, Goossens PJJ, Draijer N,
Apenhorst-Hol M, Kupka RW. The addition of STEPPS
in the treatment of patients with bipolar disorder and
comorbid borderline personality features: a protocol for a
randomized controlled trial. BMC Psychiatry 2014;14:172.
[DOI: 10.1186/1471-244X-14-172] [PMCID: PMC4065586] [PMID:
24912456]

Additional references

Amri 2014

Amri A, Millier M, Toumi M. Minimum clinically important
difference in the global assessment functioning in patients with
schizophrenia. Value in Health 2014;17(7):A765-6. [DOI: 10.1016/
j.jval.2014.08.285] [Abstract #PMH2] [PMID: 27202809]

Andrews 2013a

Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-
Ytter Y, et al. GRADE guidelines: 14. Going from evidence
to recommendations: the significance and presentation
of recommendations. Journal of Clinical Epidemiology
2013;66(7):719–25. [DOI: 10.1016/j.jclinepi.2012.03.013] [PMID:
23312392]

Andrews 2013b

Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ,
Coello PA, et al. GRADE guidelines: 15. Going from evidence
to recommendation - determinants of a recommendation’s
direction and strength. Journal of Clinical Epidemiology
2013;66(7):726–35. [DOI: 10.1016/j.jclinepi.2013.02.003] [PMID:
23570745]

Ansell 2007

Ansell EB, Sanislow CA, McGlashan TH, Grilo CM. Psychosocial
impairment and treatment utilization by patients with
borderline personality disorder, other personality disorders,
mood and anxiety disorders, and a healthy comparison group.
Comprehensive Psychiatry 2007;48(4):329-36. [DOI: 10.1016/
j.comppsych.2007.02.001] [PMID: 17560953]

APA 1980

American Psychiatric Asssociation. Diagnostic and Statistical
Manual of Mental Disorders (DSM-III). 3rd edition. Washington
(DC): American Psychiatric Association, 1980. [ISBN
978-0-89042-0416]

APA 1987

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-III-R). 3rd edition.
Washington (DC): American Psychiatric Association, 1987. [ISBN
978-0-89042-0195]

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV). 4th edition. Washington
(DC): American Psychiatric Association, 1994. [ISBN
978-0-89042-0610]

APA 2000

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV-TR), 4th edition, text
revision. Washington (DC): American Psychiatric Association,
2000. [ISBN 978-0-89042-0256]

APA 2013

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-5). 5th edition. Washington
(DC): American Psychiatric Association, 2013. [ISBN
978-0-89042-554-1]

Arntz 2003

Arntz A, Van den Hoorn M, Cornelis J, Verheul R, Van den
Bosch W, De Bie AJ. Reliability and validity of the borderline
personality disorder severity index. Journal of Personality
Disorders 2003;17(1):45-59. [PMID: 12659546]

Arntz 2009

Arntz A, Van Genderen H. Schema Therapy for Borderline
Personality Disorder. Chichester (UK): Wiley-Blackwell, 2009.
[ISBN 978-0-470-51080-3]

Atkins 2004

Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al.
Grading quality of evidence and strength of recommendations.
BMJ 2004;328(7454):1490-9. [DOI: doi.org/10.1136/
bmj.328.7454.1490] [PMC428525] [PMID: 15205295]

Ayodeji 2015

Ayodeji E, Green J, Roberts C, Trainor G, Rothwell J,
Woodham A, et al. The influence of personality disorder on
outcome in adolescent self-harm. British Journal of Psychiatry
2015;207(4):313-9. [DOI: 10.1192/bjp.bp.113.138941] [PMID:
26250743]

Bach 2016

Bach B, Sellbom M. Continuity between DSM-5 categorial
criteria and traits criteria for borderline personality disorder.
Canadian Journal of Psychiatry 2016;61(8):489-94. [DOI:
10.1177/0706743716640756] [PMC4959646] [PMID: 27310232]

Bach 2018

Bach B, First MB . Application of the ICD-11 classification of
personality disorders. BMC Psychiatry 2018;18:351. [DOI:
10.1186/s12888-018-1908-3] [PMCID: PMC6206910] [PMID:
30373564]

Bailey 2014

Bailey RC, Grenyer BF. Supporting a person with personality
disorder: a study of carer burden and well-being. Journal
of Personality Disorders 2014;28(6):796-809. [DOI: 10.1521/
pedi_2014_28_136] [PMID: 24689763]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Balshem 2011

Beck 2003

Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R,
Brozek J, et al. GRADE guidelines: 3. Rating the quality of
evidence. Journal of Clinical Epidemiology 2011;64(4):401–6.
[DOI: 10.1016/j.jclinepi.2010.07.015] [PMID: 21208779]

Barrett 1995

Barrett ES, Stanford MS. Impulsiveness. In: Costello CG,
editors(s). Personality Characteristics of the Personality
Disordered. New York (NY): Wiley, 1995:91-118. [ISBN
978-0-471-01529-1]

Bateman 2003

Bateman A, Fonagy P. Health care utilization costs for borderline
personality disorder patients treated with psychoanalytically
oriented partial hospitalization versus general psychiatric care.
American Journal of Psychiatry 2003;160(1):169-71.

Bateman 2004

Bateman A, Fonagy P. Psychotherapy for Borderline Personality
Disorder: Mentalisation Based Treatment. Oxford (UK): Oxford
University Press, 2004. [ISBN 978-0-19-852766-4]

Bateman 2006

Bateman A, Fonagy P. Mentalization-Based Treatment for
Borderline Personality Disorders: A Practical Guide. Oxford (UK):
Oxford University Press, 2006. [ISBN 978-0-19-857090-5]

Bateman 2015

Bateman AW, Gunderson J, Mulder R. Treatment of personality
disorder. Lancet 2015;385(9969):735-43. [DOI: 10.1016/
S0140-6736(14)61394-5]

Beck AT, Freeman A. Cognitive Therapy of Personality Disorder.
New York (NY): Guilford Press, 2003.

Berk 2009

Berk M, Parker G. The elephant on the couch: side-effects of
psychotherapy. Australian & New Zealand Journal of Psychiatry
2009;43(9):787-94. [DOI: doi.org/10.1080/00048670903107559]
[PMID: 19670051]

Berkey 1996

Berkey CS, Mosteller F, Lau J, Antman EM. Uncertainty of the
time of first significance in random effects cumulative meta-
analysis. Controlled Clinical Trials 1996;17(5):357-71. [PMID:
8932970]

Bernstein 1986

Bernstein EM, Putnam FW. Development, reliability, and validity
of a dissociation scale. Journal of Nervous and Mental Disease
1986;174(12):727-35. [PMID: 3783140]

Biskin 2015

Biskin RS. The lifetime course of borderline personality
disorder. Canadian Journal of Psychiatry 2015;60(7):303-8. [DOI:
10.1177/070674371506000702] [PMC4500179] [PMID: 26175388]

Black 2004

Black DW, Blum N, Pfohl B, Hale N. Suicidal behavior in
borderline personality disorder: prevalence, risk factors,
prediction, and prevention. Journal of Personality Disorders
2004;18(3):226-39. [DOI: 10.1521/pedi.18.3.226.35445] [PMID:
15237043]

Bateman 2016

Black 2009

Bateman A, Fonagy P. Mentalization-Based Treatment for
Personality Disorders: A Practical Guide. Oxford (UK): Oxford
University Press, 2016. [ISBN 019968037X]

Black DW, Blum N, St John D. STEPPS: a practical, evidence-
based way to treat borderline personality disorder. Current
Psychiatry 2009;8:31-7.

Bateman 2018

Bohus 2004

Bateman A, Campbell C, Luyten P, Fonagy P. A mentalization-
based approach to common factors in the treatment of
borderline personality disorder. Current Opinion in Psychology
2018;21:44-49. [DOI: doi:10.1016/j.copsyc.2017.09.005]

Bateman 2019a

Bateman A, Fonagy P. A randomized controlled trial of a
mentalization-based intervention (MBT-FACTS) for families
of people with borderline personality disorder. Personality
Disorders 2019;10(1):70-9. [DOI: 10.1037/per0000298] [PMID:
29999394]

Beck 1961

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An
inventory for measuring depression. Archives of General
Psychiatry 1961;4:561-71. [PMID: 13688369]

Beck 1979

Beck AT, Kovacs M, Weissman A. Assessment of suicidal
intention: the Scale for Suicide Ideation. Journal of Consulting
and Clinical Psychology 1979;47(2):343-52. [PMID: 469082]

Bohus M, Haaf B, Simms T, Limberger MF, Schmal C, Unckel C,
et al. Effectiveness of inpatient dialectical behavioral therapy
for borderline personality disorder: a controlled trial. Behaviour
Research and Therapy 2004;42(5):487-99. [DOI: 10.1016/
S0005-7967(03)00174-8] [PMID: 15033496]

Boutron 2008

Boutron I, Moher D, Altman DG, Schulz K, Ravaud P, CONSORT
Group. Extending the CONSORT statement to randomised trials
of nonpharmacologic treatment: explanation and elaboration.
Annals of Internal Medicine 2008;148(4):295-309. [PMID:
18283207]

Brok 2008

Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential
analysis reveals insufficient information size and potentially
false positive results in many meta-analyses. Journal of
Clinical Epidemiology 2008;61(8):763-9. [DOI: 10.1016/
j.jclinepi.2007.10.007] [PMID: 18411040]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Brok 2009

Chanen 2017

Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive
meta-analysis may be inconclusive -- trial sequential analysis
adjustment of random error risk due to repetitive testing
of accumulating data in apparently conclusive neonatal
meta-analyses. International Journal of Epidemiology
2009;38(1):287-98. [DOI: 10.1093/ije/dyn188] [PMID: 18824466]

Chanen A, Sharp C, Hoffman P, Global Alliance for the
Prevention and Early Intervention for Borderline Personality
Disorder. Prevention and early intervention for borderline
personality disorder: a novel public health priority. World
Psychiatry 2017;16(2):215-6. [DOI: 10.1002/wps.20429] [PMCID:
PMC5428197] [PMID: 28498598]

Brunetti 2013

Chanen 2018

Brunetti M, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J, et al.
GRADE guidelines: 10. Considering resource use and rating the
quality of economic evidence. Journal of Clinical Epidemiology
2013;66(2):140–50. [DOI: 10.1016/j.jclinepi.2012.04.012] [PMID:
22863410]

Cailhol 2015

Cailhol L, Thalamas C, Garrido C, Birmes P, Lapeyre-Mestre M.
Mental health service utilization among borderline personality
disorder patients inpatient [Utilisation des services de soin par
les patients hospitalisés, présentant un trouble de personnalité
borderline en Midi-Pyrénées]. L'Encéphale 2015;41(2):115-22.
[DOI: 10.1016/j.encep.2014.10.008] [PMID: 25526809]

Chalmers 1983

Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment
assignment in controlled clinical trials. New England
Journal of Medicine 1983;309(22):1358-61. [DOI: 10.1056/
NEJM198312013092204] [PMID: 6633598]

Chanen 2007

Chanen AM, McCutcheon LK, Jovev M, Jackson HJ, McGorry PD.
Prevention and early intervention for borderline personality
disorder. Medical Journal of Australia 2007;187(7):S18-21. [DOI:
10.5694/j.1326-5377.2007.tb01330.x]

Chanen 2012

Chanen AM, Kaess M. Developmental pathways to
borderline personality disorder. Current Psychiatry Reports
2012;14(1):45-53. [DOI: 10.1007/s11920-011-0242-y] [PMID:
22009682]

Chanen AM, Thompson KN. Early intervention for personality
disorder. Current Opinion in Psychology 2018;21:132-5. [DOI:
https://doi.org/10.1016/j.copsyc.2018.02.012]

Chatoor 2001

Chatoor I, Krupnick J. The role of non-speciifc factors in
treatment outcome of psychotherapy studies. European
Child & Adolescent Psychiatry 2001;10:19-25. [DOI: 10.1007/
s007870170004]

Clarkin 1999

Clarkin JF, Yeomans FE, Kernberg OF. Psychotherapy for
Borderline Personality. New York (NY): John Wiley & Sons, Inc.,
1999.

Clarkin 2012

Clarkin JF. An integrated approach to psychotherapy techniques
for patients with personality disorder. Journal of Personality
Disorders 2012;26(1):43-62. [DOI: 10.1521/pedi.2012.26.1.43]
[PMID: 22369166]

Coccaro 1991

Coccaro EF, Harvey PD, Kupsaw-Lawrence E, Herbert JL,
Bernstein DP. Development of neuropharmacologically-
based behavioral assessments of impulsive aggressive
behavior. Journal of Neuropsychiatry and Clinical Neurosciences
1991;3(2):S44-S51. [PMID: 1821222]

Cohen 1988

Cohen J. Statistical Power Analysis for the Behavioral Sciences.
2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, 1988.

Chanen 2013

Coid 2006

Chanen AM, McCutcheon L. Prevention and early intervention
for borderline personality disorder: current status and
recent evidence. British Journal of Psychiatry 2013;202(54
Suppl):S24-9. [DOI: 10.1192/bjp.bp.112.119180] [PMID:
23288497]

Chanen 2014

Chanen AM, McCutcheon L, Kerr IB. HYPE: a cognitive analytic
therapy-based prevention and early intervention programme
for borderline personality disorder. In: Sharp C, Tackett JL,
editors(s). Handbook of Borderline Personality Disorder in
Children and Adolescents. New York (NY): Springer, 2014:361-83.
[ISBN 978-1-4939-0590-4]

Chanen 2016

Chanen AM, Berk M, Thompson K. Integrating early intervention
for borderline personality disorder and mood disorders.
Harvard Review of Psychiatry 2016;24(5):330–41. [DOI: https://
doi.org/10.1097/HRP.0000000000000105]

Coid J, Yang M, Tyrer P, Roberts A, Ullrich S. Prevalence
and correlates of personality disorder in Great Britain.
British Journal of Psychiatry 2006;188:423-31. [DOI: 10.1192/
bjp.188.5.423] [PMID: 16648528]

Conte 1980

Conte HR, Plutchik R, Karasu TB, Jerret I. A self-report
borderline scale. Discriminative validity and preliminary norms.
Journal of Nervous and Mental Disease 1980;168(7):428-35. [DOI:
10.1097/00005053-198007000-00007] [PMID: 7400793]

Crawford 2018a

Crawford MJ,  Sanatinia R,  Barrett B, Cunningham G, Dale O,
 Ganguli P, et al. The clinical effectiveness and cost-effectiveness
of lamotrigine in borderline personality disorder: a randomized
placebo-controlled trial. American Journal of Psychiatry
2018;175(8):756-64. [DOI: 10.1176/appi.ajp.2018.17091006]
[PMID: 29621901]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cristea 2017

Donner 2002

Cristea IA, Gentili C, Cotet CD, Palomba D, Barbui C, Cuijpers P.
Efficacy of psychotherapies for borderline personality disorder:
a systematic review and meta-analysis. JAMA Psychiatry
2017;74(4):319-28. [DOI: doi:10.1001/jamapsychiatry.2016.4287]
[PMID: 28249086]

CTU 2011

Copenhagen Trial Unit. TSA - Trial Sequential Analysis.
www.ctu.dk/tsa (accessed 12 December 2016).

Curtin 2002

Curtin F, Elbourne D, Altman DG. Meta-analysis combining
parallel and cross-over clinical trials. III: the issue of carry-
over. Statistics in Medicine 2002;21(15):2161-73. [DOI: 10.1002/
sim.1207] [PMID: 12210631]

Davidson 2010

Donner A, Klar N. Issues in the meta-analysis of cluster-
randomized trials. Statistics in Medicine 2002;21(9):2971-80.
[DOI: 10.1002/sim.1301] [PMID: 12325113]

Doyle 2016

Doyle M, While D, Mok PL, Windfuhr K, Ashcroft, DM,
Kontopantelis E, et al. Suicide risk in primary care patients
diagnosed with a personality disorder: a nested case control
study. BMC Family Practice 2016;17:106. [DOI: 10.1186/
s12875-016-0479-y] [PMC4974738] [PMID: 27495284]

Endicott 1976

Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment
scale. A procedure for measuring overall severity of psychiatric
disturbance. Archives of General Psychiatry 1976;33(6):766-71.
[PMID: 938196]

Davidson KM, Tyrer P, Norrie J, Palmer SJ, Tyrer H. Cognitive
therapy v usual treatment for borderline personality disorder:
prospective 6-year follow-up. British Journal of Psychiatry
2010;197(6):456-62. [DOI: 10.1192/bjp.bp.109.074286] [PMID:
21119151]

Faltinsen 2017

Faltinsen EG, Kongerslev M, Storebø OJ. Reviews and meta-
analyses of psychotherapy efficacy for borderline personality
disorder. JAMA Psychiatry 2017;74(8):853–4. [DOI: doi:10.1001/
jamapsychiatry.2017.1397] [PMID: 28636688]

Deeks 2019

Farivar 2004

Deeks JJ, Higgins JPT, Altman DG editor(s). Chapter 10:
Analysing data and undertaking meta-analyses. In: Higgins
JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch
VA (editors). Cochrane Handbook for Systematic Reviews of
Interventions version 6.0 (updated July 2019). Cochrane 2019.
Available from www.training.cochrane.org/handbook.

De Fruyt 2014

De Fruyt F, De Clercq B. Antecedents of personality disorder
in childhood and adolescence: towards an integrative
developmental model. Annual Review of Clinical Psychology
2014;10:449-76. [DOI: 10.1146/annurev-clinpsy-032813-15364]
[PMID: 24471374]

De Groot 2008

De Groot ER, Verheul R, Trijsburg RW. An integrative perspective
on psychotherapeutic treatments for borderline personality
disorders. Journal of Personality Disorders 2008;22(4):332-52.
[DOI: 10.1521/pedi.2008.22.4.332] [PMID: 18684048]

Derogatis 1994

Derogatis LR, Lazarus L. SCL-90-R, Brief Symptom Inventory,
and matching clinical rating scales. In: Maruish ME, editors(s).
The Use of Psychological Testing for Treatment Planning and
Outcomes Assessment. Hillsdale (NJ): Lawrence Erlbaum
Associates, Inc., 1994:217-48.

Dimaggio 2007

Dimaggio G, Semerari A, Carcione A, Nicolò G, Procacci M.
Psychotherapy of Personality Disorders: Metacognition, States
of Mind and Interpersonal Cycles. London (UK): Routledge,
2007.

Farivar SS, Liu H,  Hays RD. Half standard deviation estimate
of the minimally important difference in HRQOL scores?
Expert Review of Pharmacoeconomics & Outcomes Research
2004;4(5):515-23. [DOI: 10.1586/14737167.4.5.515] [PMID:
19807545]

Finch 2019

Finch EF, Iliakis EA, Masland SR, Choi-Kain LW. A meta-
analysis of treatment as usual for borderline personality
disorder. Personality Disorders 2019;10(6):491-9. [DOI: 10.1037/
per0000353] [PMID: 31414854]

First 1997

First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS.
Structured Clinical Interview for DSM-IV Axis II Personality
Disorders (SCID-II). Washington (DC): American Psychiatric
Press, 1997.

Fok 2012

Fok ML, Hayes RD, Chang CK, Stewart R, Callard FJ, Moran P.
Life expectancy at birth and all-cause mortality among people
with personality disorder. Journal of Psychosomatic Research
2012;73(2):104-7. [DOI: 10.1016/j.jpsychores.2012.05.001]
[PMID: 22789412]

Fonagy 2009

Fonagy P, Luyten P. A developmental, mentalization-based
approach to the understanding and treatment of borderline
personality disorder. Development and Psychopathology
2009;21(4):1355-81. [DOI: 10.1017/S0954579409990198] [PMID:
19825272]

Fonagy 2014

Fonagy P, Allison E. The role of mentalizing and epistemic
trust in the therapeutic relationship. Psychotherapy
2014;51(3):372-80. [DOI: 10.1037/a0036505] [PMID: 24773092]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Goodman 2010

Goodman M, Patil U, Steffel L, Avedon J, Sasso S, Triebwasser J,
et al. Treatment utilization by gender in patients with
borderline personality disorder. Journal of Psychiatric Practice
2010;16(3):155-63. [DOI: 10.1097/01.pra.0000375711.47337.27]
[PMID: 20485103]

Goodman 2012

Goodman M, Roiff T, Oakes AH, Paris J. Suicidal risk and
management in borderline personality disorder. Current
Psychiatry Reports 2012;14(1):79-85. [DOI: doi.org/10.1007/
s11920-011-0249-4] [PMID: 22113831]

Gratz 2001

Gratz KL. Measurement of deliberate self-harm: preliminary
data on the Deliberate Self-Harm Inventory. Journal of
Psychopathology and Behavioral Assessment 2001;23(4):253-63.
[DOI: 10.1023/A:1012779403943.pdf]

Gratz 2004

Gratz KL, Roemer L. Multidimensional assessment of emotion
regulation and dysregulation: development, factor structure,
and initial validation of the Difficulties in Emotion Regulation
Scale. Journal of Psychopathology and Behavioral Assessment
2004;26:41-54. [DOI: 10.1023/B:JOBA.0000007455.08539.94]

Gregory 2008

Gregory RJ, Remen AL. A manual-based psychodynamic
therapy for treatment-resistant borderline personality
disorder. Psychotherapy: Theory, Research, Practice, Training
2008;45:15-27.

Gregory 2010

Gregory RJ, DeLucia-Deranja E, Mogle JA. Dynamic
deconstructive psychotherapy versus optimized community
care for borderline personality disorder co-occurring with
alcohol use disorders: a 30-month follow-up.. Journal
of Nervous and Mental Disease 2010;198(4):292-8. [DOI:
doi:10.1097/NMD.0b013e3181d6172d]

Gunderson 1981

Gunderson JG, Kolb JE, Austin V. The diagnostic interview
for borderline patients. American Journal of Psychiatry
1981;138(7):896-903. [DOI: 10.1176/ajp.138.7.896] [PMID:
7258348]

Gunderson 2009

Gunderson JG. Borderline personality disorder: ontogeny of a
diagnosis. American Journal of Psychiatry 2009;166(5):530-9.
[DOI: 10.1176/appi.ajp.2009.08121825] [NIHMS313194]
[PMC3145201]

Gunderson 2011a

Gunderson JG. Borderline personality disorder. New
England Journal of Medicine 2011;364(21):2037-42. [DOI:
doi.org/10.1056/NEJMcp1007358]

Gunderson 2011b

Gunderson JG, Stout RL, McGlashan TH, Shea MT, Morey LC,
Grilo CM, et al. Ten-year course of borderline personality
disorder: psychopathology and function from the Collaborative

Cochrane Database of Systematic Reviews

Longitudinal Personality Disorders study. Archives of
General Psychiatry 2011;68(8):827-37. [DOI: doi.org/10.1001/
archgenpsychiatry.2011.37] [PMC3158489] [PMID: 21464343]

Gunderson 2018

Gunderson JG, Fruzzetti A, Unruh B, Choi-Kain L. Competing
theories of borderline personality disorder. Journal of
Personality Disorders 2018;32(2):148-67. [DOI: 10.1521/
pedi.2018.32.2.148] [PMID: 29561723]

Guttierez 2001

Guttierez PM, Osman A, Barrios FX, Kopper BA. Development
and initial validation of the Self-Harm Behavior Questionnaire.
Journal of Personality Assessment 2001;77(3):475-90. [DOI:
10.1207/S15327752JPA7703_08] [PMID: 11781034]

Guyatt 2011a

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et
al. GRADE guidelines: 1. Introduction - GRADE evidence
profiles and summary of findings tables. Journal of
Clinical Epidemiology 2011;64(4):383–94. [DOI: 10.1016/
j.jclinepi.2010.04.026] [PMID: 21195583]

Guyatt 2011b

Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et
al. GRADE guidelines: 2. Framing the question and deciding
on important outcomes. Journal of Clinical Epidemiology
2011;64(4):395–400. [DOI: 10.1016/j.jclinepi.2010.09.012] [PMID:
21194891]

Guyatt 2011c

Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P,
et al. GRADE guidelines: 4. Rating the quality of evidence -
study limitations (risk of bias). Journal of Clinical Epidemiology
2011;64(4):407–15. [DOI: 10.1016/j.jclinepi.2010.07.017] [PMID:
21247734]

Guyatt 2011d

Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J,
et al. GRADE guidelines: 5. Rating the quality of evidence
- publication bias. Journal of Clinical Epidemiology
2011;64(12):1277–82. [DOI: 10.1016/j.jclinepi.2011.01.011]
[PMID: 21802904]

Guyatt 2011e

Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P,
Rind D, et al. GRADE guidelines 6. Rating the quality of
evidence - imprecision. Journal of Clinical Epidemiology
2011;64(12):1283–93. [DOI: 10.1016/j.jclinepi.2011.01.012]
[PMID: 21839614]

Guyatt 2011f

Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J,
Helfand M, et al. GRADE guidelines: 7. Rating the quality of
evidence - inconsistency. Journal of Clinical Epidemiology
2011;64(12):1294–302. [DOI: 10.1016/j.jclinepi.2011.03.017]
[PMID: 21803546]

Guyatt 2011g

Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J,
Helfand M, et al. GRADE guidelines: 8. Rating the quality of

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

evidence - indirectness. Journal of Clinical Epidemiology
2011;64(12):1303–10. [DOI: 10.1016/j.jclinepi.2011.04.014]
[PMID: 21802903]

Guyatt 2013a

Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-
Coello P, et al. GRADE guidelines: 11. Making an overall rating of
confidence in effect estimates for a single outcome and for all
outcomes. Journal of Clinical Epidemiology 2013;66(2):151–7.
[DOI: 10.1016/j.jclinepi.2012.01.006] [PMID: 22542023]

Horowitz 1988

Horowitz LM, Rosenberg SE, Baer BA, Ureño G, Villaseñor VS.
Inventory of interpersonal problems: psychometric properties
and clinical applications. Journal of Consulting and Clinical
Psychology 1988;56(6):885-92. [PMID: 3204198]

Horvath 2011

Horvath AO, Del Re AC, Flückiger C, Symonds D. Alliance in
individual psychotherapy. Psychotherapy 2011;48(1):9-16. [DOI:
10.1037/a0022186] [PMID: 21401269]

Guyatt 2013b

Hörz 2010

Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R,
et al. GRADE guidelines: 12. Preparing summary of findings
tables - binary outcomes. Journal of Clinical Epidemiology
2013;66(2):158–72. [DOI: 10.1016/j.jclinepi.2012.01.012] [PMID:
22609141]

Hörz S, Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G.
Ten-year use of mental health services by patients with
borderline personality disorder and with other axis II
disorders. Psychiatric Services 2010;61(6):612-6. [DOI: 10.1176/
ps.2010.61.6.612] [PMC3889171] [PMID: 20513685]

Guyatt 2013c

Huprich 2015

Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D,
Furukawa TA, et al. GRADE guidelines: 13. Preparing summary
of findings tables and evidence profiles - continuous outcomes.
Journal of Clinical Epidemiology 2013;66(2):173–83. [DOI:
10.1016/j.jclinepi.2012.08.001] [PMID: 23116689]

Hastrup 2019a

Hastrup LH, Kongerslev MT, Simonsen E. Low vocational
outcome among people diagnosed with borderline personality
disorder during first admission to mental health services in
Denmark: a nationwide 9-year register-based study. Journal
of Personality Disorders 2019;33(3):326-40. [DOI: 10.1521/
pedi_2018_32_344] [PMID: 29505387]

Huprich SK. Personality Disorders: Toward Theoretical and
Empirical Integration in Diagnosis and Assessment. Washington
(DC): American Psychological Association, 2015. [ISBN
978-1-4228-1846-2]

ICH 1996

International Council for Harmonisation Expert Working
Group. International conference on harmonisation of technical
requirements for registration of pharmaceuticals for human
use. ICH harmonised tripartite guideline. Guideline for good
clinical practice E6(R1). www.ich.org/fileadmin/Public_
 Web_ Site/ICH_ Products/Guidelines/Efficacy/E6/E6_ R1_
 Guideline.pdf (accessed 6 May 2011).

Hastrup 2019b

Jakobsen 2014

Hastrup LH, Jennum P, Ibsen R, Kjellberg J, Simonsen E.
Societal costs of borderline personality disorders: a matched-
controlled nationwide study of patients and spouses. Acta
Psychiatrica Scandinavica 2019;140(5):458-67. [DOI: 10.1111/
acps.13094] [PMID: 31483859]

Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C.
Thresholds for statistical and clinical significance in systematic
reviews with meta-analytic methods. BMC Medical Research
Methodology 2014;14:120. [DOI: 10.1186/1471-2288-14-120]
[PMCID: PMC4251848] [PMID: 25416419]

Higgins 2003

Karterud 2019

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
[DOI: https://doi.org/10.1136/bmj.327.7414.557] [PMC192859]
[PMID: 12958120]

Karterud SW, Kongerslev MT. A temperament-attachment-
mentalization-based (TAM) theory of personality and its
disorders. Frontiers in Psychology 2019;10:518. [DOI: 10.3389/
fpsyg.2019.00518] [PMCID: PMC6439347] [PMID: 30967807]

Higgins 2011

Karterud 2020

Higgins JPT, Deeks JJ, Altman DG, editor(s), Cochrane Statistical
Methods Group. Chapter 16: Special topics in statistics. In:
Higgins JPT, Green S, editor(s). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.

Higgins 2019

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
et al (editors). Cochrane Handbook for Systematic Reviews of
Interventions. 2nd edition. Chichester (UK): John Wiley & Sons,
2019. [Available from: www.training.cochrane.org/handbook]

Karterud S, Kongerslev MT. Psychotherapy of personality
disorders needs an integrative theory of personality. Journal
of Psychotherapy Integration 2020 Mar 2 [Epub ahead of print].
[DOI: 10.1037/int0000196]

Kazdin 2004

Kazdin AE. Psychotherapy for children and adolescents. In:
Lambert MJ, editors(s). Bergin and Garfield's Handbook of
Psychotherapy and Behavior Change. 5th edition. New York
(NY): John Wiley & Sons, Inc., 2004:543-89. [ISBN 0-471-37755-4]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kazdin 2009

Kazdin AE. Understanding how and why psychotherapy leads
to change. Psychotherapy Research 2009;19(4-5):418-28. [DOI:
10.1080/10503300802448899]

Kernberg 1975

Kernberg OF. Borderline Conditions and Pathological
Narcissism. New York (NY): Aronson, 1975.

Kjær 2018

Kjær JNR, Biskin R, Vestergaard C, Munk-Jørgensen P. All-
cause mortality of hospital-treated borderline personality
disorder: a nationwide cohort study. Journal of Personality
Disorders 2018;11:1-13. [DOI: 10.1521/pedi_2018_32_403]
[PMID: 30307824]

Kjaergard 2001

Kjaergard LL, Villumsen J, Gluud C. Reported methodologic
quality and discrepancies between large and small
randomized trials in meta-analyses. Annals of Internal Medicine
2001;135(11):982-9. [PMID: 11730399]

Kliem 2010

Kliem S, Kröger C, Kosfelder J. Dialectical behavior therapy for
borderline personality disorder: a meta-analysis using mixed-
effects modeling. Journal of Consulting and Clinical Psychology
2010;78(6):936-51. [DOI: 10.1037/a0021015] [PMID: 21114345]

Kongerslev 2015

Kongerslev MT, Chanen AM, Simonsen E. Personality disorder
in childhood and adolescence comes of age: a review of
the current evidence and prospects for future research.
Scandinavian Journal of Child and Adolescent Psychiatry and
Psychology 2015;3(1):31-48. [DOI: 10.21307/sjcapp-2015-004]

Lau 1995

Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis
of clinical trials builds evidence for exemplary medical care.
Journal of Clinical Epidemiology 1995;48(1):45-57. [PMID:
7853047]

Leichsenring 2011

Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline
personality disorder.. Lancet 2011;377(9759):74-84.

Lenzenweger 2007

Lenzenweger MF, Willett JB. Predicting individual change
in personality disorder features by simultaneous individual
change in personality dimensions linked to neurobehavioral
systems: the longitudinal study of personality disorders.
Journal of Abnormal Psychology 2007;116(4):684–700. [DOI:
10.1037/0021-843X.116.4.684] [PMID: 18020716]

Levine 1986

Levine J, Schooler NR. SAFTEE: a technique for the systematic
assessment of side effects in clinical trials. Psychopharmacology
Bulletin 1986;22(2):343-81. [PMID: 3774930]

Levy 2006

Levy KN, Clarkin JF, Yeomans FE. The mechanisms of change
In the treatment of borderline personality disorder with

Cochrane Database of Systematic Reviews

transference focused psychotherapy. Journal of Clinical
Psychology 2006;62(4):481-501. [DOI: https://doi.org/10.1002/
jclp.20239.]

Lieb 2004

Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M.
Borderline personality disorder. Lancet 2004;364(9432):453-61.
[DOI: dx.doi.org/10.1016/S0140-6736(04)16770-6] [PMID:
15288745]

Lilienfeld 2007

Lilienfeld SO. Psychological treatments that cause harm.
Perspectives on Psychology Science 2007;2(1):53-70. [DOI: doi:
10.1111/j.1745-6916.2007.00029.x] [PMID: 26151919]

Linehan 1993a

Linehan MM. Cognitive-Behavioral Treatment of Borderline
Personality Disorder. New York (NY): Guilford Press, 1993. [ISBN
0-89862-183-6]

Linehan 1993b

Linehan MM. Skills Training Manual for Treating Borderline
Personality Disorder. New York (NY): Guilford Press, 1993.

Linehan 1997

Linehan MM. Behavioral treatments of suicidal behaviors.
Definitional obfuscation and treatment outcomes. Annals of the
New York Academy of Sciences 1997;836:302-28. [DOI: 10.1111/
j.1749-6632.1997.tb52367.x] [PMID: 9616806]

Linehan 2015b

Linehan MM. DBT® Skills Training Manual. 2nd edition. New York
(NY): Guilford Press, 2015. [ISBN 978-1-4625-1699-5]

Links 2015

Links PS, Ross J, Gunderson JG. Promoting good psychiatric
management for patients with borderline personality disorder.
Journal of Clinical Psychology 2015;71(8):753-63. [DOI: 10.1002/
jclp.22203] [PMID: 26197971]

Livesley 2003

Livesley WJ. Practical Management of Personality Disorder. New
York (NY): Guilford Press, 2003. [ISBN 1-57230-889-3]

Livesley 2004

Livesley WJ. Changing ideas about the treatment of borderline
personality disorder. Journal of Contemporary Psychotherapy
2004;34(3):185-92. [DOI: 10.1023/B:JOCP.0000036697.03467.27]

Livesley 2012

Livesley WJ. Moving beyond specialized therapies for borderline
personality disorder: the importance of integrated domain-
focused treatment. Psychodynamic Psychiatry 2012;40(1):47-74.
[DOI: 10.1521/pdps.2012.40.1.4] [PMID: 23006029]

Livesley 2016

Livesley WJ, Dimaggio G, Clarkin JF, editor(s). Integrated
Treatment for Personality Disorder: A Modular Approach. New
York (NY): Guilford Press, 2016. [ISBN 978-1-4625-2288-0]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Loranger 1988

Neacsiu 2017

Loranger AW. Personality Disorder Examination (PDE) Manual.
Yonkers (NY): DV Communications, 1988.

Loranger 1995

Loranger AW, Janca A, Sartorius N, editor(s). Assessment and
Diagnosis of Personality Disorders. The ICD-10 International
Personality Disorder Examination (IPDE). Cambridge (Camb):
Cambridge University Press, 1995. [WHO IRIS: apps.who.int/iris/
handle/10665/41912]

Lundh 2012

Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry
sponsorship and research outcome. Cochrane Database of
Systematic Reviews 2012, Issue 12. Art. No: MR000033. [DOI:
10.1002/14651858.MR000033.pub2]

Markowitz 2006

Markowitz JC, Skodol AE, Bleiberg K. Interpersonal
psychotherapy for borderline personality disorder: possible
mechanisms of change. Journal of Clinical Psychology
2006;62(4):431-44. [DOI: 10.1002/jclp.20242] [PMID: 16470711]

Moher 1998

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.
Does quality of reports of randomised trials affect estimates
of intervention efficacy reported in meta-analysis? Lancet
1998;352(9128):609-13. [DOI: 10.1016/S0140-6736(98)01085-X]
[PMID: 9746022]

Moher 1999

Neacsiu AD, Eberle JW, Keng SL, Fang CM, Rosenthal Z.
Understanding borderline personality disorder across
sociocultural groups: findings, issues, and future directions.
Current Psychiatry Reviews 2017;13(3):188-223. [DOI:
10.2174/1573400513666170612122034]

Newton-Howes 2015

Newton-Howes G, Clark LA, Chanen A. Personality disorder
across the life course. Lancet 2015;385(9969):727-34. [DOI:
10.1016/S0140-6736(14)61283-6] [PMID: 25706218]

Ng 2016

Ng FY, Bourke ME, Grenyer BFS. Recovery from borderline
personality disorder: a systematic review of the perspectives
of consumers, clinicians, family and carers. PLOS One
2016;11(8):e0160515. [DOI: 10.1371/journal.pone.0160515]
[PMC4978398] [PMID: 27504634]

NICE CG90

National Institute for Health and Care Excellence. Depression in
adults: recognition and management. Cinical guideline (CG90).
www.nice.org.uk/guidance/cg90 (accessed prior to 16 March
2020).

Niesten 2016

Niesten IJ, Karan E, Frankenburg FR, Fitzmaurice GM,
Zanarini MC. Description and prediction of the income status
of borderline patients over 10 years of prospective follow-up.
Personality and Mental Health 2016;10(4):285-92. [DOI: 10.1002/
pmh.1331] [PMID: 26864557]

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF.
Improving the quality of reports of meta-analyses of
randomised controlled trials: the QUOROM statement. Quality
of reporting of meta-analyses. Lancet 1999;354(9193):1896-900.
[PMID: 10584742]

NLM 2009

US National Library of Medicine. Medical Subject Headings
(MeSH Browser). meshb.nlm.nih.gov/search (accessed 31 March
2009).

Montgomery 1979

Norcross 2011

Montgomery SA, Asberg M. A new depression scale designed
to be sensitive to change. British Journal of Psychiatry
1979;134:382-9. [PMID: 444788]

Norcross JC, editor(s). Psychotherapy Relationships That Work:
Evidence-Based Responsiveness. 2nd edition. New York (NY):
Oxford University Press, Inc., 2011. [ISBN 978-0-19-973720-8]

Morey 2007

Osman 2001

Morey LC. Personality Assessment Inventory (PAI): Professional
Manual. 2nd edition. Lutz (FL): Psychological Assessment
Resources, 2007.

Munk-Jørgensen 2010

Munk-Jørgensen P, Najarraq Lund M, Bertelsen A. Use of ICD-10
diagnoses in Danish psychiatric hospital-based services in
2001-2007. World Psychiatry 2010;9(3):183-4. [ PMC2948730]
[PMID: 20975866]

Mustafa 2013

Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G,
et al. The GRADE approach is reproducible in assessing the
quality of evidence of quantitative evidence syntheses. Journal
of Clinical Epidemiology 2013;66(7):736-42. [DOI: 10.1016/
j.jclinepi.2013.02.004] [PMID: 23623694]

Osman A, Bagge CL, Gutierrez PM, Konick LC, Kopper BA,
Barrios FX. The Suicidal Behaviors Questionnaire-
Revised (SBQ-R): validation with clinical and
nonclinical samples. Assessment 2001;8(4):443-54. [DOI:
dx.doi.org/10.1177/107319110100800409] [PMID: 11785588]

Ottosen 2002

Ottosson H, Ekselius L, Grann M, Kullgren G. Cross-system
concordance of personality disorder diagnoses of DSM-IV and
diagnostic criteria for research of ICD-10. Journal of Personality
Disorders 2002;16(3):283-92. [DOI: 10.1521/pedi.16.3.283.22537]
[PMID: 12136684]

Oud 2018

Oud M, Arntz A, Hermens MLM, Verhoef R, Kendall T. Specialized
psychotherapies for adults with borderline personality
disorder: a systematic review and meta-analysis. Australian &
New Zealand Journal of Psychiatry 2018;52(10):949-61. [DOI:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

10.1177/0004867418791257] [PMCID: PMC6151959] [PMID:
30091375]

Overall 1962

Overall JE, Gorham DR. The Brief Psychiatric Rating Scale.
Psychological Reports 1962;10(3):799-812. [DOI: 10.2466/
pr0.1962.10.3.799]

Paris 2014

Paris J. The relevance of social capital for the treatment
of personality disorders. Personality and Mental Health
2014;8(1):24-9. [DOI: 10.1002/pmh.1238]

Paris 2019

Paris J. Suicidality in borderline personality disorder. Medicina
2019;55(6):E223. [DOI: 10.3390/medicina55060223] [PMCID:
PMC6632023] [PMID: 31142033]

Sansone 2006

Sansone R, Levitt J. Personality Disorders and Eating
Disorders. New York: Routledge, 2006. [DOI: https://
doi.org/10.4324/9780203957097]

Sansone 2011

Sansone RA, Sansone LA. Gender patterns in borderline
personality disorder. Innovations in Clinical Neuroscience
2011;8(5):16-20. [PMCID:: PMC3115767] [PMID: 21686143]

Savović 2012a

Savović J, Jones H, Altman D, Harris R, Jüni P, Pildal J, et
al. Influence of reported study design characteristics on
intervention effect estimates from randomised controlled
trials: combined analysis of meta-epidemiological studies.
Health Technology Assessment 2012;16(35):1-82. [DOI: 10.3310/
hta16350] [PMID: 22989478]

Parry 2016

Savović 2012b

Parry GD, Crawford MJ, Duggan C. Iatrogenic harm from
psychological therapies - time to move on. British Journal of
Psychiatry 2016;208(3):210-2. [DOI: 10.1192/bjp.bp.115.163618]
[PMID: 26932481]

Perez 2007

Perez V, Barrachina J, Soler J, Pascual JC, Campins MJ,
Puigdemont D, et al. The clinical global impression scale for
borderline personality disorder patients (CGI-BPD): a scale
sensible to detect changes [Impresión clinica global para
pacientes con trastorno límite de la personalidad (ICG-TLP):
una escala sensible al cambio]. Actas Espanolas de Psiquiatria
2007;35(4):229-35. [PMID: 17592784]

Peryer 2019

Peryer G, Golder S, Junqueira D, Vohra S, Loke YK. Chapter
19: Adverse effects. In: Higgins JPT, Thomas J, Chandler J,
Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane
Handbook for Systematic Reviews of Interventions version
6.0 (updated July 2019), Cochrane 2019. Available from
www.training.cochrane.org/handbook.

Pfohl 1997

Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM-
IV Personality (SIPD-IV). Washington (DC): American Psychiatric
Press, 1997.

Reiss 2014

Reiss N, Lieb K, Arntz A, Shaw IA, Farrell J. Responding to the
treatment challenge of patients with severe BPD: results of
three pilot studies of inpatient schema therapy. Behavioural
and Cognitive Psychotherapy 2014;42(3):355-67. [DOI: 10.1017/
S1352465813000027] [PMID: 23458343]

Review Manager 2014 [Computer program]

Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic
Cochrane Centre, The Cochrane Collaboration, 2014.

Ryle 1997

Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J,
et al. Influence of reported study design characteristics on
intervention effect estimates from randomized, controlled
trials. Annals of Internal Medicine 2012;157(6):429-38. [DOI:
10.7326/0003-4819-157-6-201209180-00537] [PMID: 22945832]

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence
of bias. Dimensions of methodological quality associated
with estimates of treatment effects in controlled trials. JAMA
1995;273(5):408-12. [PMID: 7823387]

Sellbom 2014

Sellbom M, Sansone RA, Songer DA, Anderson JL. Convergence
between DSM-5 Section II and Section III diagnostic criteria
for borderline personality disorder. Australian & New
Zealand Journal of Psychiatry 2014;48(4):325-32. [DOI:
10.1177/0004867413511997] [PMID: 24253360]

Sharp 2018

Sharp C, Wall K. Personality pathology grows up: adolescence
as a sensitive period. Current Opinion in Psychology
2018;21:111-6. [DOI: 10.1016/j.copsyc.2017.11.010] [PMID:
29227834]

Skodol 2002

Skodol AE, Gunderson JG, McGlashan TH, Dyck IR, Stout RL,
Bender DS, et al. Functional impairment in patients with
schizotypal, borderline, avoidant, or obsessive-compulsive
personality disorder. American Journal of Psychiatry
2002;159(2):276-83. [DOI: 10.1176/appi.ajp.159.2.276] [PMID:
11823271]

Soeteman 2008a

Soeteman DI, Hakkaart-van Roijen L, Verheul R, Busschbach JJV.
The economic burden of personality disorders in mental health
care. Journal of Clinical Psychiatry 2008;69(2):259–65. [PMID:
18363454]

Ryle A. Cognitive Analytic Therapy and Borderline Personality
Disorder: The Model and the Method. Chichester (UK): John
Wiley & Sons, Inc., 1997. [ISBN-13: 978-0471976189]

Soeteman 2008b

Soeteman DI, Verheul R, Busschbach JJV. The burden of
disease in personality disorders: diagnosis-specific quality of

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

life. Journal of Personality Disorders 2008;22(3):259-68. [DOI:
doi.org/10.1521/pedi.2008.22.3.259] [PMID: 18540798]

Soloff 2002

Soloff PH, Lynch KG, Kelly TM. Childhood abuse as a risk factor
for suicidal behavior in borderline personality disorder. Journal
of Personality Disorders 2002;16(3):201-14. [PMID: 12136678]

Ten Have 2016

Ten Have M, Verheul R, Kaasenbrood A, Van Dorsselaer S,
Tuithof M, Kleinjan M, et al. Prevalence rates of borderline
personality disorder symptoms: a study based on the
Netherlands Mental Health Survey and Incidence Study-2. BMC
Psychiatry 2016;16:249. [DOI: doi.org/10.1186/s12888-016-0939-
x] [PMC4949762] [PMID: 27435813]

Spielberger 1988

Thalheimer 2002

Spielberger CD. Manual for the State-Trait Anger Expression
Inventory. Odessa (FL): Psychological Assessment Resources,
1988.

Spitzer 1989

Spitzer RL, William JBW, Gibbon M, First MB. Structured Clinical
Interview for DSM-III-R Personality Disorders (SCID-II). New
York (NY): Biometrics Research Department, New York State
Psychiatric Institute, 1989.

Stepp 2012

Stepp SD. Development of borderline personality disorder in
adolescence and young adulthood: introduction to the special
section. Journal of Abnormal Child Psychology 2012;40(1):1-5.
[DOI: 10.1007/s10802-011-9594-3] [ PMC3865353] [PMID:
22116635]

Stern 1938

Stern A. Psychoanalytic investigation of and therapy in the
borderline group of neuroses. Psychoanalytic Quarterly
1938;7:467-89.

Sterne 2017

Sterne JAC, Egger M, Moher D, Boutron I, editor(s). Chapter
10: Addressing reporting biases. In: Higgins JPT, Churchill
R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions version 5.2.0
(updated June 2017). Cochrane, 2017. Available from
www.training.cochrane.org/handbook.

Stiglmayr 2005

Stiglmayr CE, Grathwol T, Linehan MM, Ihorst G, Fahrenberg J,
Bohus M. Aversive tension in patients with borderline
personality disorder: a computer-based controlled field
study. Acta Psychiatrica Scandinavica 2005;111(5):372-9. [DOI:
10.1111/j.1600-0447.2004.00466.x] [PMID: 15819731]

Storebø 2014

Storebø OJ, Simonsen E. Is ADHD an early stage in
the development of borderline personality disorder?
Nordic Journal of Psychiatry 2014;68(5):289-95. [DOI:
10.3109/08039488.2013.841992] [PMID: 24117059]

Streeck 2009

Streeck U, Leichsenring F. Handbuch Psychoanalytisch-
Interaktionelle Therapie. Zur Behandlung von
Patienten mit Strukturellen Störungen und Schweren
Persönlichkeitsstörungen. Göttingen (NI): Vandenhoeck &
Ruprecht, 2009.

Thalheimer W, Cook S. How to calculate effect sizes
from published research: a simplified methodology.
www.bwgriffin.com/gsu/courses/edur9131/content/Effect_
 Sizes_ pdf5.pdf (accessed 9 August 2019).

Thomas 2019

Thomas J, Askie LM, Berlin JA, Elliott JH, Ghersi D, Simmonds M,
et al. Chapter 22: Prospective approaches to accumulating
evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston
M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook
for Systematic Reviews of Interventions version 6.0
(updated July 2019). Cochrane, 2019. Available from
www.training.cochrane.org/handbook.

Thomson 2019

Thompson KN, Jackson H, Cavelti M, Betts J, McCutcheon L,
Jovev M, et al. The clinical significance of subthreshold
borderline personality disorder features in outpatient youth.
Journal of Personality Disorders 2019;33(1):71-81. [DOI: 10.1521/
pedi_2018_32_330] [PMID: 30036169]

Thorlund 2009

Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP,
Thabane L, et al. Can trial sequential monitoring boundaries
reduce spurious inferences from meta-analysis? International
Journal of Epidemiology 2009;38(1):276-86. [DOI: 10.1093/ije/
dyn179] [PMID: 18824467]

Tomko 2014

Tomko RL, Trull TJ, Wood PK, Sher KJ. Characteristics of
borderline personality disorder in a community sample:
comorbidity, treatment utilization, and general functioning.
Journal of Personality Disorders 2014;28(5):734-50. [DOI:
doi.org/10.1521/pedi_2012_26_093] [PMC3864176] [PMID:
25248122]

Torgersen 2001

Torgersen S, Kringlen E, Cramer V. The prevalence of personality
disorders in a community sample. Archives of General Psychiatry
2001;58(6):590–6. [PMID: 11386989]

Torgersen 2012

Torgersen S. Epidemiology. In: Widiger TA, editors(s). The
Oxford Handbook of Personality Disorders. New York (NY):
Oxford University Press, 2012:186-205. [DOI: 10.1093/
oxfordhb/9780199735013.013.0009] [ISBN 978-0-19-973501-3]

Tyrer 2005

Tyrer P, Nur U, Crawford M, Karlsen S, McLean C, Rao B, et
al. The Social Functioning Questionnaire: a rapid and robust
measure of perceived functioning. International Journal of
Social Psychiatry 2005;51(3):265-75. [PMID: 16252794]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tyrer 2015

Wood 2008

Tyrer P, Reed GM, Crawford MJ. Classification, assessment,
prevalence, and effect of personality disorders. Lancet
2015;385(9969):717-26. [DOI: 10.1016/S0140-6736(14)61995-4]

Van Asselt 2007

Van Asselt AD, Dirksen CD, Arntz A, Severens JL. The cost of
borderline personality disorder: societal cost of illness in BPD-
patients. European Psychiatry 2007;22(6):354-61. [DOI: 10.1016/
j.eurpsy.2007.04.001] [PMID: 17544636]

Verheul 2003

Verheul R, Van den Bosch LM, Koeter MW, De Ridder MA,
Stijnen T, Van den Brink W. Dialectical behaviour therapy
for women with borderline personality disorder: 12-month,
randomised clinical trial in The Netherlands. British Journal of
Psychiatry 2003;182:135-40. [DOI: 10.1192/bjp.182.2.135] [PMID:
12562741]

Videler 2019

Videler AC, Hutsebaut J, Schulkens JEM, Sobczak S, Van
Alphen SPJ. A life span perspective on borderline personality
disorder. Current Psychiatry Reports 2019;21(7):51. [10.1007/
s11920-019-1040-1] [31161404] [PMC6546651]

Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et
al. Empirical evidence of bias in treatment effect estimates in
controlled trials with different interventions and outcomes:
meta-epidemiological study. BMJ 2008;336(7644):601-5. [DOI:
10.1136/bmj.39465.451748.AD] [PMC2267990] [PMID: 18316340]

Yen 2004

Yen S, Shea MT, Sanislow CA, Grilo CM, Skodol AE,
Gunderson JG, et al. Borderline personality disorder criteria
associated with prospectively observed suicidal behavior.
American Journal of Psychiatry 2004;161(7):1296-8. [DOI:
doi.org/10.1176/appi.ajp.161.7.1296] [PMID: 15229066]

Yeomans 2015

Yeomans FE, Clarkin JF, Kernberg OF. Transference-Focused
Psychotherapy for Borderline Personality Disorder: A Clinical
Guide. Arlington (VA): American Psychiatric Publishing, 2015.
[ISBN 978-1-58562-437-9]

Young 2003

Young JE, Klosko JS, Weishaar ME. Schema Therapy: A
Practitioner's Guide. New York (NY): Guilford Press, 2003.

Zanarini 1987

Vrouva 2010

Vrouva I, Fonagy P, Fearon PRM, Roussow T. The risk-taking
and self-harm inventory for adolescents: development
and psychometric evaluation. Psychological Assessment
2010;22(4):852-65. [DOI: 10.1037/a0020583] [PMID: 20919771]

Zanarini MC, Frankenburg FR, Chauncey DL, Gunderson JG.
The Diagnostic Interview for Personality Disorders: interrater
and test-retest reliability. Comprehensive Psychiatry
1987;28(6):467-80. [DOI: 10.1016/0010-440x(87)90012-5] [PMID:
3691072]

Weinberg 2011

Zanarini 1989

Weinberg I, Ronningstam E, Goldblatt MJ, Schechter M,
Maltsberger JT. Common factors in empirically supported
treatments of borderline personality disorder. Current
Psychiatry Reports 2011;13(1):60-8. [DOI: 10.1007/
s11920-010-0167-x] [PMID: 21057901]

Wetterslev 2008

Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential
analysis may establish when firm evidence is reached in
cumulative meta-analysis. Journal of Clinical Epidemiology
2008;61(1):64-75. [DOI: 10.1016/j.jclinepi.2007.03.013] [PMID:
18083463]

WHO 1993

World Health Organization. The ICD-10 Classification of Mental
and Behavioural Disorders: Diagnostic Criteria for Research.
Geneva (CH): World Health Organization, 1993.

WHO 2018

World Health Organization. ICD-11 for mortality and morbidity
statistics. icd.who.int/browse11/l-m/en (accessed 06 December
2019).

Winsper 2020

Zanarini MC, Gunderson JG, Frankenburg FR, Chauncey DL. The
revised Diagnostic Interview for Borderlines: discriminating
BPD from other Axis II disorders. Journal of Personality Disorders
1989;3(1):10-8. [DOI: 10.1521/pedi.1989.3.1.10]

Zanarini 1996

Zanarini MC, Frankenburg FR, Sickel AE, Young L. Diagnostic
interview for DSM-IV personality disorders (unpublished
measure). Boston (MA): McLean Hospital, 1996.

Zanarini 1998

Zanarini MC, Frankenburg FR, DeLuca CJ, Hennen J, Khera GS,
Gunderson JG. The pain of being borderline: dysphoric states
specific to borderline personality disorder. Harvard Review of
Psychiatry 1998;6(4):201-7. [DOI: 10.3109/10673229809000330]
[PMID: 10370445]

Zanarini 2003a

Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL,
Frankenburg FR, Hennen J. Zanarini Rating Scale for Borderline
Personality Disorder (Zan-BPD): a continuous measure of DSM-
IV borderline psychopathology. Journal of Personality Disorders
2003;17(3):233-42. [DOI: 10.1521/pedi.17.3.233.22147] [PMID:
12839102]

Winsper C, Bilgin A, Thompson A, Marwaha S, Chanen AM,
Singh S, et al. The prevalence of personality disorders in the
community: a global systematic review and meta-analysis..
British Journal of Psychiatry 2020;216(2):69-78. [DOI: 10.1192/
bjp.2019.166]

Zanarini 2003b

Zanarini MC. The Childhood Interview for DSM-IV Borderline
Personality Disorder (CI-BPD). Belmont (MA): McLean Hospital
and Harvard Medical School, 2003.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Zanarini 2004

Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health
service utilization by borderline personality disorder patients
and Axis II comparison subjects followed prospectively for 6
years. Journal of Clinical Psychiatry 2004;65(1):28-36. [PMID:
14744165]

Zanarini 2005

Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR.
The McLean Study of Adult Development (MSAD): overview
and implications of the first six years of prospective follow-
up. Journal of Personality Disorders 2005;19(5):505-23. [DOI:
10.1521/pedi.2005.19.5.505] [PMID: 16274279]

2012;169(5):476-83. [DOI: 10.1176/appi.ajp.2011.11101550]
[PMC3509999] [PMID: 22737693]

Zanarini 2015

Zanarini MC, Frankenburg FR, Reich DB, Conkey LC,
Fitzmaurice GM. Rates of psychiatric treatment reported
by patients with borderline personality disorder and other
personality disorders over 16 years of prospective follow-
up. Psychiatric Services 2015;66(1):15-20. [DOI: 10.1176/
appi.ps.201400055] [NIHMS597508] [PMC4283568] [PMID:
25270039]

References to other published versions of this review

Zanarini 2007

Binks 2006

Binks C, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C.
Psychological therapies for people with borderline personality
disorder. Cochrane Database of Systematic Reviews 2006, Issue
1. Art. No: CD005652. [DOI: 10.1002/14651858.CD005652]

Stoffers-Winterling 2012

Stoffers-Winterling JM, Völlm BA, Rücker G, Timmer A,
Huband N, Lieb K. Psychological therapies for people with
borderline personality disorder. Cochrane Database of
Systematic Reviews 2012, Issue 8. Art. No: CD005652. [DOI:
10.1002/14651858.CD005652.pub2]

Storebø 2018

Storebø OJ, Stoffers-Winterling JM, Völlm BA, Kongerslev MT,
Mattivi JT, Kielsholm ML, et al. Psychological therapies for
people with borderline personality disorder. Cochrane Database
of Systematic Reviews 2018, Issue 2. Art. No: CD012955. [DOI:
10.1002/14651858.CD012955]

* Indicates the major publication for the study

Zanarini MC, Frankenburg FR, Reich DB, Silk KR, Hudson JI,
McSweeney LB. The subsyndromal phenomenology of
borderline personality disorder: a 10-year follow-up study.
American Journal of Psychiatry 2007;164(6):929-35. [DOI:
10.1176/ajp.2007.164.6.929] [PMID: 17541053]

Zanarini 2010

Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G. The
10-year course of psychosocial functioning among patients
with borderline personality disorder and axis II comparison
subjects. Acta Psychiatrica Scandinavica 2010;122(2):103-9.
[DOI: doi:10.1111/j.1600-0447.2010.01543.x] [PMC3876887]
[PMID: 20199493]

Zanarini 2012

Zanarini MC, Frankenburg FR, Reich B, Fitzmaurice G.
Attainment and stability of sustained symptomatic
remission and recovery among patients with borderline
personality disorder and axis II comparison subjects: a 16-year
prospective follow-up study. American Journal of Psychiatry

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Amianto 2011 

Study characteristics

Methods

12-month trial with 2 arms

1. Supervised team management (STM)
2. STM + sequential brief Adlerian psychodynamic psychotherapy (SB-APP)

Duration of trial: 10-12 months intervention, 1 year follow-up
Country: Italy

Setting: outpatient, the Mental Health Center of Chivasso, Turin

Participants

Method of recruitment of participants: screened through clinical notes of outpatient mental health
service. Patients who had been treated and clinically managed at least 1 year were eligible.

Overall sample size: 35

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition, Text Revision (DSM-IV-TR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Amianto 2011  (Continued)

Cochrane Database of Systematic Reviews

Means of assessment: Structured Clinical Interview for DSM (SCID)
Mean age: 39.5 years (standard deviation = 9.4; range = 24-57)
Sex: not stated
Comorbidity: of all the included participants, only 13 participants (37.1%) did not show a comorbid Ax-
is I diagnosis.

Inclusion criteria

1. Borderline Personality Disorder diagnosis according to Diagnostic and Statistical Manual of Mental

Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria

2. Aged between 20-50 years
3. Heavy use of mental health services throughout the prior year
4. Absence of an acute comorbid Axis I disorder requiring hospitalisation
5. No current substance dependence disorder
6. No mental retardation
7. No previous psychotherapy interventions
8. Valid informed consent

Exclusion criteria

1. Acute Axis I disorder requiring hospitalisation
2. Mental retardation
3. Substance dependence

Interventions

Experimental group
Treatment name: supervised team management (STM) + sequential brief Adlerian psychodynamic
psychotherapy (SB-APP)
Number randomised to group: 18
Duration: 12 months

Control/comparison group
Comparison name: STM only
Number randomised to group: 17
Duration: 12 months

Both groups

Concomitant psychotherapy: supervised team management (STM) includes unstructured psycholog-
ical support focused on socio-relational impairment as well as rehabilitative interventions and mental
health services training.
Concomitant pharmacotherapy: supervised team management (STM) includes medications that were
administered according to American Psychiatric Association (APA) guidelines for borderline personali-
ty disorder. Three classes of drugs were used: antidepressants, mood stabilisers and atypical antipsy-
chotics. Drug treatment was prescribed during the first or second visit and modified if necessary during
follow-up.

Proportions of participants taking standing medication during trial observation period: No further
information on pharmacotherapy

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Clinical Global Impression Scale (CGI)
2. Self-harm, assessed by the number of self-harm incidents reported
3. Suicide-related outcomes, assessed by the the Clinical Global Impression - Modified (CGI-BPD) item

on suicidality and self-damaging acts

4. Psychosocial functioning, assessed by the Glocal Assessment of Functioning

Secondary

1. Anger, assessed by the CGI-BPD item on anger

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Amianto 2011  (Continued)

Cochrane Database of Systematic Reviews

2. Affective instability, assessed by the CGI-BPD item on affective instability
3. Chronic feeling of emptiness, assessed by CGI-BPD item on a feeling of chronic emptiness
4. Impulsivity, assessed by the CGI-BPD item on impulsivity
5. Interpersonal problems, assessed by the CGI-BPD item on disturbed relationships
6. Abandonment, assessed by the CGI-BPD item on fear of abandonment
7. Identity disturbance, assessed by the CGI-BPD item on identity distortion
8. Dissociation and psychotic-like symptoms, assessed by the CGI-BPD item on dissociative symptoms
9. Attrition, in terms of patients lost after randomisation in each group

Notes

Risk of bias

Bias

Sample size calculation: not stated
Ethics approval: yes

Comments from review authors:

1. Small sample size with no power calculation

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Low risk

Low risk

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Quote: "Patients, after providing their informed consent, were randomly as-
signed to SB-APP in addition to Supervised Team Management (STM; number
of participants = 18) or to STM alone (number of participants = 17) groups. The
random allocation was generated using a random number table and was car-
ried out by one author (BR), who was not involved in patients’ clinical manage-
ment". (p 3).

Quote: "[Randomisation] was carried out by one author (BR), who was not
involved in patients’ clinical management. Patients were enrolled by a psy-
chiatrist of the MHS who communicated the generalities of the participants
who signed the informed consent to BR and received from BR the group as-
signment. The treatment allocation was assured by both psychiatrist and psy-
chotherapist....Treatments of each branch were conducted simultaneously
and both started the week after the enrollment in the study" (p 4).

Comment: The raters were blind with regard to the group assignment of pa-
tients.

Comment: Intention-to-treat (ITT) analysis was used, dropout rates were low
and balanced across groups.

Low risk

Comment: ITT, low dropout that was balanced in each group

Other bias

High risk

Treatment adherence: Adherence to Sequential Brief Adlerian Psychodynam-
ic Psychotherapy (SB-APP) technique was monitored. However, no results of
adherence scores were published.

Allegiance bias: SB-APP was developed by some of the authors.

Attention bias: “The number of sessions performed by the two groups in the
first year (T0-T12) was planned to be comparable, reducing the bias about the
number of sessions”.

Vested interest: No funding was received by any author to perform the
present research which was introduced within the ordinary activities of the
Chivasso MHS therapeutic team.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Andreoli 2016 

Study characteristics

Methods

3-month duration trial with 3 arms

1. Abandonment psychotherapy (AP-P)
2. Abandonment psychotherapy delivered by nurses (AP-N)
3. Intensive community treatment-as-usual (TAU, control)

Duration of trial: 3 months
Country: Switzerland

Setting: community and hospital

Participants

Method of recruitment of participants: consecutive patients entering the emergency room of the
Geneva (Switzerland) Cantonal University Hospital were screened for deliberate self-harm by spe-
cialised emergency room nurses.

Overall sample size: 107

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition, (DSM-IV)
Means of assessment: International Personality Disorder Examination (IPDE; Loranger 1995)
Mean age: 31.9 years (standard deviation = 10.1)
Sex: 84.1% female

Comorbidity: major depressive disorder (MDD), substance abuse (10.6%), alcohol dependence (4.1%),
alcohol abuse (21.8%)

Inclusion criteria

1. 18-60 years old
2. Met Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, (DSM-IV) criteria for major de-

pressive disorder (MDD) and borderline personality disorder

Exclusion criteria

1. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, (DSM-IV) psychotic disorder, bipo-

lar I disorder, severe substance dependence, mental retardation

2. Inability to speak French
3. Any medical condition precluding antidepressant medication or likely to significantly influence psy-

chiatric outcome

Interventions

Experimental group 1
Treatment name: abandonment psychotherapy (AP-P)
Number randomised to group: 70
Duration: 3 months

Experimental group 2
Treatment name: abandonment psychotherapy delivered by nurses (AP-N)
Number randomised to group: 70
Duration: 3 months

Both experimental groups

Concomitant psychotherapy: When therapists were not available, participants could call the 24-hour
emergency room hotline and receive emergency care from the psychiatric staff of the general hospital.
Concomitant pharmacotherapy: Abandonment psychotherapy was applied in combination with an
antidepressant medication protocol. Antidepressant medication was prescribed in a standard clini-
cal management format by a psychiatrist who was blind to treatment choice. Most patients (n = 125,
89.3%) were prescribed venlafaxine, with an initial 0.5 mg/kg dosage and an optimal 2 to 3 mg/kg

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Andreoli 2016  (Continued)

Cochrane Database of Systematic Reviews

dosage. Repeated drug plasma level monitoring was performed at 2 weeks, 1 month, and 2 months to
control for compliance. Venlafaxine was chosen because locally it was the medication most frequently
prescribed among these patients. Additional mild neuroleptic medication (quetiapine 25 to 75 mg/day)
was occasionally prescribed for brief periods, mostly limited to the first weeks of treatment. Not speci-
fied which exact proportions of participants received medication in each group

Control/comparison group
Comparison name: intensive community treatment-as-usual
Number randomised to group: 30
Duration: 3 months

Concomitant psychotherapy: Treatment-as-usual included as many nurse visits as required for two
weeks and biweekly thereafter, weekly clinical review and medication adjustment from a psychiatrist,
group therapy, social worker support, and as much day care, night hospitalisation and family interven-
tion as needed to deal with suicidal relapse, emergency response.
Concomitant pharmacotherapy: weekly clinical review and medication adjustment

Proportions of participants taking standing medication during trial observation period: "The rate
of subjects who were prescribed an antidepressant medication was lower in the TAU group compared
to the AP groups (AP-P: 68, 97.1%; AP-N: 68, 97.1%, TAU: 23, 76.7%; Fisher’s exact test: p < .003), but
the mean number of days spent in antidepressant treatment (AP-P: 89.6, SD 32.9; AP-N: 81.8, SD 36.7;
TAU: 70.7, SD 55.9) and the number of participants who completed antidepressant treatment (AP-P: 47,
67.1%; AP-N: 48, 68.6%; TAU: 17, 56.7%) did not differ in the treatment cells. Among patients assigned
to AP, the number of days spent in antidepressant medication and venlafaxine plasma levels did not
differ as a function of type of therapist delivering AP" (Andreoli 2016, p. 280).

“The analyses were repeated using […] presence of antidepressant medication, number of days spent
in antidepressant medication, […] as covariates […]: the results were not materially altered.” (Andreoli
2016, p. 283)

"...when we statistically controlled for the presence of additional antidepressant medication, the ob-
served between-group differences held.” (Andreoli 2016, p.285)

Outcomes

Primary

1. Suicide-related outcomes, defined as number of suicidal ideations
2. Mental health status, assessed by the Global Assessment Scale

Secondary

1. Depression, assessed by the Hamilton Depression Rating Scale - 17 items
2. Attrition, in terms of patients lost after randomisation in each group
3. Adverse effects

Notes

Sample size calculation: yes

Ethics approval: yes

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Comment: Eligible participants were randomly allocated to treatment by a re-
searcher not involved in the treatment procedures. This was done using a pre-
generated block randomisation scheme developed and held by a statistician,
who prepared two series of sealed envelopes.

Allocation concealment
(selection bias)

Low risk

Comment: Treatment allocation was masked to clinicians through sealed en-
velopes in charge of the treatments.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Andreoli 2016  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Cochrane Database of Systematic Reviews

Comment: Subjects were assessed at intake and at 3-month follow-up by
well- trained psychologists with clinical experience who were blind to treat-
ment assignment.

Comment: Intention-to-treat analysis was used and there were relatively low
numbers of dropouts.
However, the attrition rate was higher in TAU (16.7% who did not come to
treatment and 20% who terminated their treatment early) compared to inter-
vention (AP-P: 5.7% and AP-N: 2.9% who did not come to treatment and AP-
P: 5.7% and AP-N: 2.9% who terminated their treatment early). Thus, attrition
rates were not balanced between intervention groups and control group.

Selective reporting (re-
porting bias)

High risk

Comment: The authors provided no data on the Hamilton Depression Rating
Scale 17 items (HDRS-17: Hamilton, 1960), even though it was stated as an out-
come.

Other bias

High risk

Treatment adherence: No data were provided on the Hamilton Depression
Rating Scale 17 items (HDRS-17: Hamilton, 1960), even though it was stated as
an outcome.

Allegience bias: It was unclear who developed the manual for abandonment
psychotherapy. It was however mentioned that the developers of the manual
were involved in supervision p. 275.

Attention bias: TAU patients seem to have received more attention given the
inpatient treatment. With regards to medication, the intervention groups had
received more antidepressants.

Vested interest: Unclear who developed manual for abandonment psy-
chotherapy, but there were no clear indications of vested interest.

Antonsen 2017 

Study characteristics

Methods

Approximately 18-week trial with 2 arms

1. Short-term day hospital psychotherapy
2. Outpatient individual psychotherapy

Duration of trial: 18 weeks
Country: Norway

Setting: inpatient and outpatient

Participants

Method of recruitment of participants: Participants were referred to the respective departments as
stated in the individual trials.

Overall sample size: 52

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM, version 2 (SCID-II)

Mean age: 29 years (standard deviation = 6.7)

Sex: 85% female

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Antonsen 2017  (Continued)

Cochrane Database of Systematic Reviews

Comorbidity: The distribution of personality disorder (PD) diagnoses was as follows: borderline per-
sonality disorder (46%); avoidant personality disorder (40-41%); personality disorder not otherwise
specified (21%); paranoid personality disorder (15%-14%); obsessive compulsive personality disorder
(9%); dependent personality disorder (7%); narcissistic personality disorder (2%); and schizoid person-
ality disorder (1%). The patients had a mean of 3.4 symptom disorders: 74% with major depression;
37% with dysthymia; 8% with bipolar II disorder; 46% with panic disorder; 47% with social phobia; 12%
with obsessive compulsive disorder; 48% with general anxiety disorder; 27% with substance misuse
disorders; and 14% with eating disorder

Inclusion criteria

1. Patients with personality disorders

Exclusion criteria

1. Schizotypal personality disorder
2. Antisocial personality disorder
3. Ongoing alcohol or drug dependence
4. Psychotic disorders
5. Bipolar I disorder
6. Untreated attention deficit hyperactivity disorder (ADHD) (adult type)
7. Pervasive developmental disorder (e.g. Asperger’s syndrome)
8. Organic syndromes
9. Being homeless

Interventions

Experimental group 
Treatment name: combination program (CP) of short-term day hospital psychotherapy (DHP) fol-
lowed by outpatient combined individual and group psychotherapy
Number randomised to group: 27
Duration: 18 weeks

Control/comparison group 
Comparison name: outpatient individual psychotherapy (OIP)
Number randomised to group: 25
Duration: 18 weeks

Both groups

Concomitant psychotherapy:

The outpatient treatment consisted of weekly group therapy (1.5 hours) for a maximum of 4 years,
combined with weekly individual therapy for a maximum of 2.5 years.

Concomitant pharmacotherapy:

All patients received optional psychopharmacological consultations with a psychiatrist as part of the
follow-up evaluations.

Proportions of participants taking standing medication during trial observation period:

"Patients in the CP tended to use less psychotropic medications over time compared with the OIP, but
the difference was not statistically significant (p = .09)." (Antonsen 2017; p. 57)

Outcomes

Primary

1. Mental health status (psychosocial functioning), assessed using the Global Assessment of Functioning

Scale

Secondary

1. Interpersonal problems, assessed with the Circumplex of Interpersonal Problems (self-reported)
2. Depression, assessed by the Beck Depression Inventory

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Antonsen 2017  (Continued)

3. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes (in prior studies)

Ethics approval: yes

Comments from review authors:

1. We  emailed  the  authors  in  2016  and  asked  for  subsample  data  on  borderline  personality  disorder
(BPD). We received information that they did not have these data; however, they sent us information
about an article with follow-up data on borderline personality disorder (BPD)-only patients.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Quote: “Patients meeting the entry criteria [...] were consecutively randomly
allocated to either day hospital psychotherapy (DHP) [i.e., CP] or outpatient in-
dividual psychotherapy (OIP)” (p 72).

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Comment: no clear details were provided by the authors.

Unclear risk

Comment: no clear details were provided by the authors.

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Comment: attrition rates were 14% and 8% attrition rates in the groups. This
difference was not statistically significant. ITT analysis was used. The reasons
for missing data were similar between groups.

Selective reporting (re-
porting bias)

High risk

Comment: Self-esteem, self-destructive behavior, personality pathology,
healthcare utilisation, affect consciousness, and reflective functioning includ-
ed in trial registration and not in Arnevik 2009.

Other bias

High risk

Treatment adherence: day hospital psychotherapy (DHP) “However, there
was no formal training for the therapists, nor did the guidelines serve as a
standard for treatment adherence.” (p 72) OIP: “The researchers gave no in-
structions to the OIP therapists regarding the duration and intensity of psy-
chotherapy, nor did they interfere with any treatment decisions in the OIP con-
ditions.” (p 72)

Allegiance bias: no obvious risk of bias

Attention bias: Similar total length. Frequency of therapy from once a month
to three times a week in OIP. Frequency of therapy in groups were different
(not reported in Arnevik, 2009). There was an obvious difference in the amount
of therapy received. CP patients received 18 weeks’ intensive day hospital
treatment followed by conjoint treatment, while in OIP, most patients attend-
ed therapy once a week. The mean number of participants who received thera-
py sessions at 18 months in OIP was 40. (Arnevik 2010, p 199)

Bateman 1999 

Study characteristics

Methods

Randomised controlled trial with 2 arms for 18 months

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bateman 1999  (Continued)

Cochrane Database of Systematic Reviews

1. Partial hospitalised group receiving mentalisation-based therapy
2. Standard psychiatric care

Duration of trial: up to 18 months

Country: UK

Setting: partially hospitalised/outpatient

Participants

Method of recruitment: Patients referred

Overall sample size: 38

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
3rd revision (DSM-III-R)

Means of assessment: both Structured Clinical Interview for DSM-IV personality disorders (SCID) and
Revised Diagnostic Interview for Borderlines (DIB-R)

Mean age: 31.8 years

Sex: 57.9% female

Comorbidity: In terms of axis I diagnosis, 70% and 62% had major depression in the intervention and
control group, respectively.

Inclusion criteria:

1. Patients diagnosed with borderline personality disorder

Exclusion criteria

1. Schizophrenia
2. Bipolar disorder
3. Substance misuse
4. Mental impairment
5. Evidence of organic brain disorder

Interventions

Experimental group

Treatment name: mentalisation-based treatment (MBT)

Number randomised to group: 19

Duration: up to 18 months

Control/comparison group

Comparison name: standard treatment in the general psychiatric services

Number randomised to group: 19

Duration: up to 18 months

Both groups

Concomitant psychotherapy: none

Concomitant pharmacotherapy: antidepressant and antipsychotic drugs prescribed, as appropriate,
polypharmacy was discouraged

Proportions of participants taking standing medication during trial observation period:

"The initial types and doses of medication were the same for both groups." (Bateman 1999, p. 1565)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bateman 1999  (Continued)

Cochrane Database of Systematic Reviews

Exact medication use during treatment unclear: higher medication costs in control group (z-3.9, P <
0.001) (Bateman 2003, Tab. 1, p. 170) indicates more frequent use of medications in the control group.

Outcomes

Primary

1. Number of patients with self-harming behaviour in the last 6-month period
2. Number of patients with suicide attempts in the last 6-month period

Both outcomes assessed with the Suicide and Self-Harm Inventory, a semi-structured interview.

Secondary

1. Interpersonal problems, assessed with the Inventory of Interpersonal Problems
2. Depression, assessed with the Beck Depression Inventory

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors:

1. Per protocol (22 randomised to each group, only 19 per group analysed since treated per protocol)
2. Information about randomisation and allocation procedure, as well as blinding, was received by email

from Dr Bateman.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Comments: Did not use a minimisation method. This method is used to min-
imise the imbalance between the number of patients in each treatment group.
This method maintains a better balance than traditional blocked randomisa-
tion, and its advantage increases with the number of stratification factors. It is
reported that random assignment was used but it is unclear how the random
assignment was performed.

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Comment: Allocation was completed centrally at the university.

Low risk

Comment: Outcome assessors were blind to intervention group.

High risk

Comment: Analyses were based on completers only.

Selective reporting (re-
porting bias)

Unclear risk

Comment: There was no clear indication of selective reporting, but there was
insufficient information to permit judgement of 'high' or 'low'.

Other bias

High risk

Attention bias: more attention paid to experimental group participants

Allegiance bias: there was no indication given for an allegiance effect. Howev-
er, as both authors are the founders of MBT, the treatment actually used in the
experimental group, an allegiance effect seems not improbable.

Adherence bias: "All sessions were audiotaped. Adherence to the treatment
manuals was determined by randomly selected audiotapes of individual and
group sessions drawn from two distinct 6-months periods of each case using

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bateman 1999  (Continued)

Cochrane Database of Systematic Reviews

a modified version of the recommended adherence rating scale." (Bateman
2009, online data supplement, p 1)

Bateman 2009 

Study characteristics

Methods

Randomised controlled trial with 2 arms for 18 months

1. Mentalisation based treatment
2. Structured clinical management

Duration of trial: 18 months

Country: UK

Setting: outpatient

Participants

Methods of recruitment of patients: consecutive referrals

Overall sample size: 168

Diagnosis of Borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV)

Means of assessment: Structured and Clinical Interview for DSM axis II disorders

Mean age: 31.3 years (standard deviation = 7.6)

Sex: 79.9% females

Comorbidity: comorbid antisocial personality disorder

Inclusion criteria

1. Diagnosis of borderline personality disorder
2. Suicide attempt or episode of life-threatening self-harm within last 6 months
3. Age 18–65 years

Exclusion criteria

1. Psychotic disorder
2. Bipolar I disorder
3. Opiate dependence requiring specialist treatment
4. Mental impairment
5. Evidence of organic brain disorder
6. Being in long-term psychotherapeutic treatment

Interventions

Experimental group

Treatment name: mentalisation-based therapy

Number randomised to group: 71

Duration: 18 months

Control/comparison group

Comparison name: structured clinical management

Number randomised to group: 63

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bateman 2009  (Continued)

Duration: 18 months

Both groups

Cochrane Database of Systematic Reviews

Concomitant psychotherapy: patients already in long-term psychotherapeutic treatment were not el-
igible.

Concomitant pharmacotherapy: patients were prescribed medication according to the American Psy-
chological Association (APA) guidelines; all patients were offered medication reviews every 3 months.

Proportions of participants taking standing medication during trial observation period: MBT
group: 29.6%, control group 57.1%; group effect over time: IRR 0.77, P < 0.001 (less medication use in
MBT group)

Outcomes

Primary:

1. Suicidal ideation, assessed by the number of patients with suicide attempt in the previous 6-month

period

2. Self-harming behaviour, assessed by the number of patients with self-harming behaviour in the pre-

vious 6-month period

3. Mental health status, assessed with the Global Assessment of Functioning

Secondary:

1. Interpersonal problems, assessed with the Inventory of Interpersonal Problems–circumflex version
2. Depression, assessed with the Becks Depression Inventory

Notes

Sample size calculation: yes

Ethic approval: The study was approved by Barnet Enfield and Haringey Local Research and Ethics
Committee and conducted at the Halliwick Personality Disorder service and in a community outpatient
facility.

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "randomization using a stochastic minimization program (MINIM) bal-
ancing for age (blocked as 18-25, 26-30, > 30 years), gender, and presence of
antisocial personality disorder." (Bateman 2009, p 1357)

Allocation concealment
(selection bias)

Low risk

Quote: "Treatment allocation was made offsite [...] A study psychiatrist in-
formed patients of their assignment." (Bateman 2009, p. 1357)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Quote: "Assessors were blind to treatment group." (Bateman 2009, p 1358)

Low risk

Comment: ITT analyses were used by the authors.

Selective reporting (re-
porting bias)

Low risk

Comment: A study protocol is available (ISRCTN27660668); there was no indi-
cation of selective reporting.

Other bias

High risk

Adherence bias: "All sessions were audiotaped. Adherence to the MBT-OP and
SCM-OP manuals was determined by randomly selected audiotapes of individ-
ual and group sessions drawn from two distinct 6-months periods of each case

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bateman 2009  (Continued)

Cochrane Database of Systematic Reviews

using a modified version of the recommended adherence rating scale." (Bate-
man 2009, online data supplement, p 1)

Allegiance bias: There was no indication given for an allegiance effect. How-
ever, as both authors are the founders of MBT, the treatment actually used in
the experimental group, an allegiance effect seems not improbable.

Attention bias: Equal amounts of attention paid to both groups

Bellino 2006 

Study characteristics

Methods

Randomised controlled trial with 2 treatment arms

1. Fluoxetine + interpersonal therapy
2. Fluoxetine + clinical management

Duration of trial: 24 weeks

Country: Italy

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Overall sample size: 39

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition, Text-Revision (DSM-IV-TR)

Means of assessment: Structured Clinical Interview for Personality Disorders

Mean age: 26.4 years (standard deviation = 3.7)

Sex: 60% female

Comorbidity: comorbid diagnosis of mild to moderate major depressive episode required for inclusion

Inclusion criteria

1. Patients with a diagnosis of borderline personality disorder

Exclusion criteria

1. Lifetime diagnosis of delirium
2. Dementia
3. Amnestic or other cognitive disorders
4. Schizophrenia or other psychotic disorders
5. Patients whose major depressive episode was an expression of bipolar disorder
6. Current diagnosis of substance abuse disorder
7. Treatment with psychotropic drugs or psychotherapy during the 2 months prior to the study
8. Female patients not using an adequate method of birth control

Interventions

Experimental group

Treatment name: fluoxetine + interpersonal therapy (IPT)

Number randomised to group: 19

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellino 2006  (Continued)

Cochrane Database of Systematic Reviews

Duration: 24 weeks (1 weekly session)

Control/comparison group

Comparison name: fluoxetine + clinical management (CM)

Number randomised to group: 20

Duration: 24 weeks (CM; 6 appointments, first two fortnightly, monthly afterwards)

Both groups

Concomitant psychotherapy: patients who received psychotherapy during the 2 months prior to the
study were not eligible.

Concomitant pharmacotherapy: all study participants received 20 to 40 mg fluoxetine daily; patients
with psychotropic treatment during the 2 months prior to the study were not eligible for inclusion.

Proportions of participants taking standing medication during trial observation period: 100% of
each group were taking fluoxetine (see above)

Outcomes

Primary

1. Mental health status, assessed with the the Clinical Global Impressions scale

Secondary

1. Depression, assessed with the Hamilton Depression scale

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors:

1. Information about randomisation and allocation procedure, as well as about treatment adherence,

was received by email from Dr Bellino.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Comment: The authors used a computer random number generator (Bellino
2006) [pers comm].

Allocation concealment
(selection bias)

Low risk

Comment: Allocation was by central allocation (Bellino 2010c [pers comm].

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Quote: "assessments were performed by an investigator who was blind to the
treatment methods" (Bellino 2006, p. 455).

Comment: the authors conducted a completer analysis. Quote: "Owing to
noncompliance, 7 patients discontinued treatment during the first 3 weeks,. Of
these individuals, 4 were in the medication-only group, and 3 were in the com-
bined therapy group. We performed analyses on the 32 patients [...] who com-
pleted the 24 weeks of treatment." (Bellino 2006, p. 455)

Selective reporting (re-
porting bias)

Unclear risk

Comment: No clear indication for selective reporting, but Insufficient informa-
tion to permit a judgement of 'high' or 'low'

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellino 2006  (Continued)

Other bias

High risk

Cochrane Database of Systematic Reviews

Adherence bias: "[...] psychotherapist [....] had 5 years of experience practis-
ing IPT" (Bellino 2006, p. 455). No specific measures to monitor treatment ad-
herence (Bellino 2010a [pers comm])

Allegiance bias: The authors seemed not to be associated with IPT.

Attention bias: More attention paid to EG participants

Bellino 2007 

Study characteristics

Methods

Randomised controlled trial with 2 treatment arms

1. Fluoxetine + interpersonal therapy
2. Fluoxetine + cognitive therapy

Duration of trial: 24 weeks

Country: Italy

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Sample size: 32

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV)

Means of assessment: Structured Clinical Interview for Personality Disorders (SCID)

Mean age: 30.55 years (standard deviation = 5.75)

Sex: 63.2% females

Comorbidity: comorbid diagnosis of mild to moderate major depressive episode required for inclusion

Inclusion criteria

1. Patients diagnosed with borderline personality disorder

Exclusion criteria

1. Lifetime diagnosis of delirium
2. Dementia
3. Amnestic or other cognitive disorders
4. Schizophrenia
5. Other psychotic disorders
6. Patients whose major depressive episode was an expression of bipolar disorder
7. Current diagnosis of substance abuse disorder
8. Treatment with psychotropic drugs or psychotherapy during 2 months prior to study
9. Female patients of child-bearing age not using adequate method of birth control

Interventions

Experimental group

Treatment name: fluoxetine + interpersonal therapy (IPT)

Number randomised to group: 16

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellino 2007  (Continued)

Cochrane Database of Systematic Reviews

Duration: 24 weeks (1 weekly session)

Control/comparison group

Comparison name: fluoxetine + cognitive therapy

Number randomised to group: 16

Duration: 24 weeks (1 weekly session)

Both groups

Concomitant psychotherapy: patients who received psychotherapy during the 2 months prior to the
study were not eligible.

Concomitant pharmacotherapy: all study participants received 20 to 40 mg fluoxetine daily, with
7 appointments, the first 2 fortnightly and the last 5 monthly; patients with additional current psy-
chotropic treatment were not eligible for inclusion.

Proportions of participants taking standing medication during trial observation period: 100% of
each group were taking fluoxetine (see above).

Outcomes

Primary

1. Mental health status, assessed with the Clinical Global Impression scale

Secondary

1. Depression, assessed with the Hamillton Depression scale

Notes

Sample size calculation: not stated

Ethics approval: had ethics board approval and followed Declaration of Helsinki guidelines

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Patients [...] were randomized using the web program Research Ran-
domizer v3.0 (Urbaniak & Plous, Social Psychology Network, 2007)" (Bellino
2007, p. 720).

Allocation concealment
(selection bias)

Low risk

Comment: Allocation was conducted centrally (Bellino 2010 [pers comm]).

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Comment: "A psychiatrist provided pharmacotherapy. He was blind to which
type of psychotherapy the patients were receiving [...] The assessments were
performed by an investigator who was blind to the treatment methods." (Belli-
no 2007, p. 720)

Comment: the authors conducted a completer analysis. Quote: "Initially,
there were 32 patients enrolled in the study. [...] Owing to noncompliance, 6
patients discontinued treatment during the first 3 weeks. Of these subjects,
2 were in the IPT group, and 4 were in the CT group. We performed statistical
analyses of outcome measures on the 26 patients [...] who completed the 24
weeks of treatment." (Bellino 2007, p. 720)

Selective reporting (re-
porting bias)

Unclear risk

Comment: no indication for selective reporting, but Insufficient information to
permit judgement of 'Yes' or 'No'

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellino 2007  (Continued)

Other bias

Low risk

Cochrane Database of Systematic Reviews

Adherence bias:"Both psychotherapists received supervision during the treat-
ment to assess their adherence to the psychotherapy manuals." (Bellino 2007,
p. 720)

Allegiance bias: The authors seemed neither to be associated to IPT nor CT.

Attention bias: Equal amounts of attention paid to both groups

Bellino 2010 

Study characteristics

Methods

Parallel-arm, randomised controlled trial with 2 treatment arms

1. Combined therapy + fluoxetine
2. Fluoxetine

Duration of trial: 32 weeks

Country: Italy

Setting: outpatient

Participants

Methods of recruitment of participants: participants recruited from patients attending the Service
for Personality Disorders of the Unit of Psychiatry 1, Department of Neurosciences, University of Turin,
Italy

Sample size: 55

Diagnosis of borderline personality disorder diagnosis: Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV)

Means of assessment: Structured Clinical Interview for Personality Disorders (SCID)

Mean age: combined therapy + fluoxetine = 26.23 years (standard deviation = 6.4), fluoxetine = 25.86
years (standard deviation = 7.2)

Sex: 67.3% female

Comorbidity: participants had no comorbid axis-I or II comorbidities

Inclusion criteria

1. Patients with borderline personality disorder

Exclusion criteria

1. Concomitant diagnoses of Axis I or Axis II disorders
2. Schizophrenia or other psychotic disorders
3. Bipolar disorder
4. Lifetime diagnosis of delirium
5. Dementia
6. Amnestic disorder
7. Other cognitive disorders
8. Not using adequate methods of birth control if in childbearing age
9. Receiving psychotropic drugs during last 2 months
10.Psychotherapy in last 6 months

Interventions

Experimental group

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

123

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellino 2010  (Continued)

Cochrane Database of Systematic Reviews

Treatment name: combined therapy of fluoxetine (20 to 40 mg/d) plus weekly individual Interpersonal
therapy adapted to borderline personality disorder (IPT-BPD)

Number randomised to group: 27

Duration: 32 weeks

Control/comparison group

Comparison name: single pharmacotherapy treatment with fluoxetine plus TAU (treatment approach
of patients attending the Service for Personality Disorders. A visit lasting 15 to 20 minutes was provided
every 2 weeks, dealing with clinical issues)

Number randomised to group: 28

Duration: 32 weeks ((20 to 40 mg/d) + clinical management (medical appointments lasting 15 to 20
minutes every 2 weeks, dealing with clinical issues)

Both groups

Concomitant psychotherapy: eligible patients were not in psychotherapeutic treatment during the
last 6 months prior to study entry.

Concomitant pharmacotherapy: eligible patients were not receiving psychotropic drugs during the
last two months prior to study entry.

Proportions of participants taking standing medication during trial observation period: 100% of
each group were taking fluoxetine (see above).

Outcomes

Primary

1. Borderline Personality Disorder severity, assessed with the Borderline Personality Disorder Severity

Index (BPDSI-IV) - total score

2. Self-harming behaviour, assessed with the BPDSI-IV - parasuicidal behaviour subscale
3. Mental health status, assessed with the Clinical Global Impression scale

Secondary

1. Anger, assessed with the BPDSI-IV - anger subscale
2. Affective instability, assessed with the BPDSI-IV - affective instability subscale
3. Chronic feelings of emptiness, assessed with the BPDSI-IV - emptiness subscale
4. Impulsivity, assessed with the BPDSI-IV - impulsivity subscale
5. Interpersonal problems, assessed with the BPDSI-IV - interpersonal relationships subscale
6. Avoidance of abandonment, assessed with the BPDSI-IV - abandonment subscale
7. Identity disturbance, assessed with the BPDSI-IV - identity disturbance subscale
8. Dissociation/stress-related paranoid ideation, assessed with the BPDSI-IV - paranoid ideation sub-

scale

9. Depression, assessed with the Hamillton Depression scale

Notes

Sample size calculation: not stated

Ethics approval: followed the Declaration of Helsinki guidelines and received approval from ethics
board

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bellino 2010  (Continued)

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Randomization was performed using the web program Research Ran-
domizer version 3.0 (Urbaniak and Plous, [...])." (Bellino 2010, p. 75)

Allocation concealment
(selection bias)

Unclear risk

Comment: no further details

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Quote: "Assessments were performed by an investigator who was blind to the
treatment methods." (Bellino 2010, p. 76)

Comment: the authors conducted a completer analysis (IPT-BPD + fluoxetine
group: 5 participants lost, CM + fluoxetine group: 6 participants lost).

Selective reporting (re-
porting bias)

Unclear risk

Comment: no clear indication of selective reporting, but Insufficient informa-
tion to permit judgement of 'high' or 'low'

Other bias

High risk

Performance bias

Quote: "Patients in the IPT-BPD group were treated by a psychotherapist [...]
who had at least 5 years of experience practising IPT" (Bellino 2010, p 76). No
further information, adherence seems not to have been monitored.

Allegiance bias

Comment: The working group seems to be experienced in but not associated
with IPT (cf. Bellino 2006; Bellino 2007).

Attention bias: More attention paid to EG participants

Bianchini 2019 

Study characteristics

Methods

12-month trial with 2 arms:

1. Standard dialectical behavior therapy (DBT) + treatment-as-usual (TAU) within the forensic hospital

Duration of trial: 12 months

Country: Italy

Setting: hospital (forensic)

Participants

Method of recruitment of participants: participants recruited from men consecutively detained as
patients in three high intensity therapeutic facilities

Sample size: 21

Diagnosis of borderline personality disorder: measured by the Personality Assessment Inventory
(Morey 2007)

Means of assessment: diagnosis confirmed in a clinical interview by a psychiatrist

Mean age: 41.79 years (standard deviation = 8.14)

Sex: 100% males

Comorbidity: not stated

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bianchini 2019  (Continued)

Inclusion criteria

1. Criteria for borderline personality disorder
2. History of violence

Exclusion criteria

1. Cognitive deficit (intelligence quotient (IQ) < 70)
2. Comorbid neurological diseases

Interventions

Experimental group

Treatment name: DBT + treatment-as-usual

Number randomised to group: 10

Duration: 12 months (once-weekly individual therapy (60 minutes), once-weekly group sessions (120
minutes))

Concomitant psychotherapy: treatment-as-usual included social skills, and cognitive remediation

Concomitant pharmacotherapy: treatment-as-usual included pharmacotherapy

Control/comparison group

Comparison name: treatment-as-usual (pharmacotherapy, social skills, cognitive remediation)

Number randomised to group: 11

Duration: 12 months

Concomitant psychotherapy: not stated

Concomitant pharmacotherapy: not stated

Outcomes

Secondary

1. Affective instability, assessed by the Difficulties in Emotion Regulation Scale, total score
2. Impulsivity, assessed by the Barrett Impulsiveness Scale, total score

Notes

Sample size calculation: no

Ethics approval: The study was approved by the Local Ethic Committee.

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Quote: “Each pair was randomised into either a group receiving 12 months of
DBT along with other therapies available in the high security hospital (phar-
macotherapy, social skills, and cognitive remediation) or a group receiving the
other usual therapies alone” (pg. 124).

No further details provided

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)

Unclear risk

Comment: the authors did not specify the process of allocation.

Low risk

Comment: outcomes were self-reported.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bianchini 2019  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Cochrane Database of Systematic Reviews

Comment: Dropouts were not explicitly specified. However, the authors
stated that “All participants completed at least 90% of the DBT sessions of-
fered.” (p.127) Also “Once patients have been admitted […], they are required
to complete any treatment programme offered; if a person does not, s/he may
be referred back to the magistrate, who must consider if the individual is in
breach of his/her order.” (p. 123) No details about the proportion of TAU com-
pleters, but, since all participants were convicted inpatients of a secure hospi-
tal, “completion” of TAU treatment was very likely.

“All participants were reassessed after completion of the DBT programme or,
for the control group, after the same time had elapsed”. (p.125)

Selective reporting (re-
porting bias)

Unclear risk

Comment: no protocol was available.

Other bias

High risk

Adherence bias: therapeutic adherence not assessed

Attention bias: DBT (once weekly individual plus group therapy) offered addi-
tionally to TAU, hence more attention spent to DBT group

Allegiance bias: there was no indication of allegiance bias.

Blum 2008 

Study characteristics

Methods

Randomised controlled trial with 2 treatment arms

1. Systems Training for Emotional Predictability and Problem Solving
2. Treatment-as-usual

Duration of trial: 20 weeks

Country: USA

Setting: outpatient

Participants

Methods of recruitment: participants recruited from the University of Iowa inpatient and outpatient
psychiatric service

Sample size: 124

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV)

Means of assessment: Structured Interview for DSMIV Personality (SIDP-IV)

Mean age: 31.5 years (standard deviation = 9.5)

Sex: 83.1% female

Comorbidity: not stated

Inclusion criteria

1. Patients with borderline personality disorder

Exclusion criteria

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Blum 2008  (Continued)

1. Not speaking English
2. Psychotic or primary neurological disorder
3. Cognitively impaired patients
4. Current substance abuse or dependence
5. Participated in STEPPS treatment previously

Interventions

Experimental group

Cochrane Database of Systematic Reviews

Treatment name: systems training for emotional predictability and problem solving (STEPPS)

Number randomised to group: 93

Duration: 20 weeks (20 × 2-hour weekly group therapy sessions + homework assignments + 1 session
for family members or significant others; no individual therapy)

Control/comparison group

Comparison name: treatment-as-usual (TAU)

Number randomised to group: 72

Duration: 20 weeks

Both groups

Concomitant psychotherapy: participants were encouraged to continue with ongoing concomitant
treatments. 59% of all participants had an additional individual therapy.

Concomitant pharmacotherapy: 90% of participants reported at least one psychotropic medication
at baseline; on average.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod:

Exact numbers unclear

"Psychotropic usage significantly decreased during the 20-week treatment period for both groups
(from 2.9 to 1.3 medications per subject), but there was no group difference in level of change (Mann-.2
Whitney test: = 0.1, df = 1, p = 0.782). Thus, medication usage did not confound study results.” (Blum
2008; p. 474)

Outcomes

Primary

1. Borderline  personality  disorder  severity,  assessed  with  the  Borderline  Evaluation  of  Severity  Over

Time scale (BEST)

2. Mental health status, assessed with the Clinical Global Impression scale (CGI-S)

Secondary

1. Degres of Impulsivity assessed with the Barratt Impulsiveness Scale
2. Depression, assessed with the Becks Depression Inventory (BDI)
3. Affective instability, assessed with the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-

BPD) - affective subscale

4. Interpersonal problems, assessed with the Zanarini Rating Scale for Borderline Personality Disorder

- Disturbed Relationships subscale

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Blum 2008  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

1. Information about ethical approval and power calculation was received by email from Dr Black.

Authors' judgement

Support for judgement

Low risk

Quote: "Subjects were assigned by coin toss". (Blum 2008, p. 469)

Unclear risk

Comment: No indication of bias

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Quote: "While we intended to conduct blind assessments, we found it near-
ly impossible to maintain blindness. The convergence of both rater- and pa-
tient-administered scales suggests that this may not have been an important
deficiency." (Blum 2008, p. 477)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Selective reporting (re-
porting bias)

High risk

Other bias

High risk

Comment: analysis was conducted on those participants that actually start-
ed to receive the allocated intervention, regardless of completion or noncom-
pletion. However, 40 participants that had been randomly allocated did not re-
ceive the allocated intervention and were not included in analyses.

Quote: "Subjects with at least one post-baseline assessment were included in
the analyses." (Blum 2008, p. 470)

Comment: a study protocol was available, but there was no information about
primary or secondary outcomes. The authors reported a broad range of out-
comes, so there was no indication for selective reporting given. However,
there was insufficient information to permit judgment of 'Yes' or 'No'.

Adherence bias: "Adherence to the manual was rated on a 5-point scale [...]
A score of 4 (good) or higher was considered acceptable. Two Ph.D.-level psy-
chologists who were not involved with the randomized controlled trial but
familiar with STEPPS rated 43 randomly selected video-taped sessions. The
mean adherence score was 4.4 (SD = 0.8)." (Blum 2008, p. 470)

Allegiance bias: some authors are founders of STEPPS, the treatment actual-
ly used in the experimental group, therefore an allegiance effect seemed possi-
ble.

Attention bias: more attention was paid to STEPPS group participants.

Bohus 2013 

Study characteristics

Methods

Randomised controlled trial with 2 treatment arms

1. Dialectical behavioral therapy
2. Waiting list

Duration of trial: 3 months of inpatient treatment (i.e. 13 weekly sessions in each condition) + 1 boost-
er session 6 weeks after dismissal

Country: Germany

Setting: inpatient

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bohus 2013  (Continued)

Participants

Methods of recruitment of patients: referred by local psychiatrist

Sample size: 74

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV)

Means of assessment: International Personality Disorder Examination (IPDE)

Mean age: 32.9 years (range = 19-52 years)

Sex: 100% female

Inclusion criteria

1. Treatment-resistant post-traumatic stress disorder
2. Women

Exclusion criteria

1. Lifetime diagnosis of schizophrenic disorder
2. Severe other mental disorder(s) requiring immediate treatment in a different setting (e.g. eating dis-

order or acute delirium after withdrawal)

3. Suicide attempt with clear suicidal intention during last 4 months
4. Severe self-injuring behaviour during last 4 months

Interventions

Experimental group

Treatment name: dialectical behavioral therapy for patients with post-traumatic stress disorder after
childhood sexual abuse (DBT-PTSD); depressive episodes were treated with selective serotonin reup-
take inhibitor antidepressive agents (100-150 mg/d of sertraline); difficulties of sleeping were treated
with sleep-inducing antidepressants (50-100 mg/d of trimipramine); no benzodiazepines, no neurolep-
tics

Number randomised to group: 36

Duration: 3 months, 13 psychotherapy sessions of 120 minutes each

Control/comparison group

Comparison name: Waiting list

Number randomised to group: 38

Duration: 3 months (continuation of already ongoing treatments for 6 months, inpatient DBT-PTSD
treatment afterwards; points of measurement: baseline, 3 months, 4.5 months and 6 months after
study inclusion)

Both groups

Concomitant psychotherapy: participants in the experimental group did not receive any other indi-
vidual or group psychotherapy; participants in the waiting-list condition continued their usual treat-
ments (if any)

Concomitant pharmacotherapy: psychiatrists in both treatment arms were free to follow their clinical
experience

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: 82.9% of DBT-PTSD group, 87.1% of control group (P = 0.74)

Outcomes

Primary

1. Borderline personality disorder severity, assessed with the Borderline Symptom List (BSL)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bohus 2013  (Continued)

Secondary

Cochrane Database of Systematic Reviews

1. Dissociation, assessed with the Dissociative Experience Scale (DES)
2. Depression, assessed with the Becks Depression Inventory II (BDI-II)

Notes

Sample size calculation: yes

Ethics approval: yes

Comments from review authors: Originally, female participants with a diagnosis of post-traumatic
stress disorder (PTSD) and at least 4 criteria of DSM-IV-BPD were eligible. We refer to the subsample da-
ta of those participants fulfilling 5 or more criteria.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Randomisation was carried out using the procedure proposed by
Efron". (p. 224) (the bootstrapping method)

Allocation concealment
(selection bias)

Low risk

Quote: "Care was taken that the randomization was concealed to both the pa-
tient and to all persons involved in the study until the written informed con-
sent has been given by the patient." (p. 224)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: "Interviewers were blinded. [...] the diagnostician who was assessing
the patient at follow-up was masked to the assignment." (p. 224)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: No further details provided about attrition rates

Selective reporting (re-
porting bias)

Low risk

Comment: a study protocol was available (NCT00481000 ), no indication for
selective reporting

Other bias

High risk

Attention bias: more attention paid to active group

Borschmann 2013 

Study characteristics

Methods

6-month trial with 2 arms

1. Joint crisis plan plus treatment-as-usual (JCP)
2. Treatment-as-usual (TAU)

Duration of trial: 6 months
Duration of participation: 6 months
Country: UK

Setting: outpatient

Participants

Method of recruitment of participants: patients under ongoing care of community mental health
teams
Sample size: 88

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition, Text Revision (DSM-IV-TR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Borschmann 2013  (Continued)

Means of assessment: Structured Clinical Interview for Personality Disorders (SCID-II)

Mean age: 35.8 years (standard deviation = 11.6)

Sex: 19.3% male

Comorbidity: alcohol use disorders (according to AUDIT test score), depression (according to Hamilton
Anxiety and Depression Scale - depression subscale score)

Inclusion criteria

1. Aged 18 years or older
2. Borderline personality disorder according to Diagnostic and Statistical Manual of Mental Disorders,

4th Edition, Text Revision (DSM-IV-TR)

3. Had self-harmed in the previous 12 months (defined as at least one act with a non-fatal outcome in
which the individual had initiated a behaviour (such as self-cutting), or ingested a toxic substance or
object, with the intention of causing harm to themselves)
4. Under the ongoing care of a community mental health team
5. Able to provide written informed consent

Exclusion criteria

1. Currently inpatient
2. Primary diagnosis of a psychotic illness
3. Unable to read or write in English
4. Unable to provide written informed consent

Interventions

Experimental group
Treatment name: joint crisis plan + treatment-as-usual (JCP)
Number randomised to group: 46
Duration: 6 months

Control/comparison group
Comparison name: treatment-as-usual (TAU)
Number randomised to group: 42
Duration: 6 months

Both groups
Concomitant psychotherapy: as provided usually by community mental health team
Concomitant pharmacotherapy: yes, as part of standard care, if needed

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Frequency of self-harm, assessed by a quote: "Self-harm data were obtained from an established self-

report questionnaire" (by Hawton 2002)

2. Mental health status (social functioning), assessed by the Work and Social Adjustment Scale (WSAS)

Secondary

1. Depression,  assessed  by  the  depression  subscale  of  the  Hamillton  Anxiety  and  Depression

Scale(HADS-D)

2. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes, but with remarks that this was the pilot study
Ethics approval: approved by the South London Research Ethics Committee (reference number: 09/
H0803/113)

Comments from review authors:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Borschmann 2013  (Continued)

Cochrane Database of Systematic Reviews

1. It seems all outcomes listed in the protocol were reported. However, an additional outcome mea-
sure not listed in the protocol has been used as well; the Warwick-Edinburgh Mental Well-Being Scale
(WEMBS), and Hamillton Anxiety and Depression Scale data were assessed not only at the time of
baseline but also at follow-up.

2. Information about treatment adherence was received by email from Dr Borschmann.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Low risk

Quote: “Randomisation was conducted at the level of the individual and was
stratified by alcohol use […] and depression […]. Randomisation was man-
aged electronically by the Clinical Trials Unit at the Kings’s College London In-
stitute of Psychiatry, UK.” (p. 358)

Quote: “Randomisation was managed electronically by the Clinical Trials Unit
at the Kings’s College London Institute of Psychiatry, UK.” (p 358)

Quote: “Follow-up data were collected by a research worker who was masked
to treatment allocation and all data analyses were conducted by a statistician
who was also masked to treatment allocation. The extent to which masking
was achieved in the collection of outcome data was assessed at the end of the
trial". (p. 358)
“…all data analyses were conducted masked to treatment allocation and fol-
low-up data were collected by a researcher masked to treatment allocation
and this masking was maintained in 62 of 73 cases (85%).” (p. 362)

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Quote: “All analyses were based on the Intention-to-treat sample using a sta-
tistical analysis plan finalised by the trial statistician (J.M.H.) and approved by
the principal investigator (P.M.) in advance of conducting any analyses.“ (p.
359) Dropout rates were similar across both groups.

Selective reporting (re-
porting bias)

Low risk

Comment: Additional use of outcomes not specified in the protocol (esp.
HADS), but no indication of bias

Other bias

High risk

Treatment adherence: “Progress of the trial, [and] adherence to protocol […]
were overseen by a trial steering committee.” (Borschmann 2013, p 358)

“Adherence to the protocol was high, as a total of 41 out of 46 participants in
the JCP + TAU group (89.1%) attended their JCP planning meeting and conse-
quently received the active intervention. […] Data gathered at follow-up indi-
cated that JCPs were used both during and between crises and were viewed
favourably by the majority of participants. More than 90 percent of partici-
pants were still in possession of their JCP at follow-up (two participants stat-
ed that they had lost their plans) and approximately three-quarters stated that
they had used their JCP during a crisis". (Borschmann 2014, p 170)

“All JCP meeting were facilitated by the same person (i.e. me), so fideli-
ty between facilitators was not an issue. We did not record any meetings
though – adherence was only measured by the same checklist being com-
pleted (by me) during each meeting to ensure uniformity between partici-
pants.” (Borschmann 2013 [pers comm]

Allegiance bias: Though developers/advocates of JCP were involved (espe-
cially Kim Sutherby, George Szmukler), there was no indication of bias, as no
significant effects were found.

Attention bias: Both groups received TAU, but the JCP group received an ad-
ditional meeting with carers and healthcare professionals to elaborate their
joint crisis plan.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Borschmann 2013  (Continued)

Vested interest: no indication of bias

Bos 2010 

Study characteristics

Methods

Multicentre, parallel-arm trial with 2 treatment arms

1. Systems Training for Emotional Predictability and Problem Solving
2. Treatment-as-usual

Duration of trial: 4.5 months

Country: The Netherlands

Setting: outpatient

Participants

Methods of recruitment of participants: patients recruited from nonacademic outpatient clinics of 2
mental health care institutes in The Netherlands (Lentis, Groningen; Dimence, Deventer)

Sample size: 79

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II), Personality
Disorders Questionnaire (PDQ-IV)

Mean age: 32.4 years

Sex: 86.1% female

Comorbidity: not stated

Inclusion criteria: none reported

Exclusion criteria

1. Insufficient command of Dutch language
2. Intellectual disability
3. In coercive treatment
4. Acute endangering self or others

Interventions

Experimental group

Treatment name: systems training for emotional predictability and problem solving (STEPPS) pro-
gram + limited individual therapy (STEPPS + LIT; STEPPS)

Randomised to group: 42

Duration: 4.5 months (18 weekly sessions)

Control/comparison group

Comparison name: treatment-as-usual (TAU)

Randomised to group: 37

Duration: 4.5 months (offered every 1 to 4 weeks)

Both groups

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bos 2010  (Continued)

Cochrane Database of Systematic Reviews

Concomitant psychotherapy: STEPPS-related treatments like dialectical behavior therapy (DBT) or
family groups or family members of the patients were not allowed; all participants were allowed to
have contacts with social worker or another healthcare professional.

Concomitant pharmacotherapy: All participants were allowed to have (medication) contacts with a
psychiatrist.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod:

Exact proportions unclear. “We further investigated whether the results were confounded by the use
of psychotropic medication. Medication use did not differ between the two conditions. Adding medica-
tion use at the different time points (yes/no) to the models did not weaken the results; on the contrary,
estimated differences became larger and p values smaller. Thus, the results were not likely confounded
by medication
use.“ (Bos 2010, p. 178)

Outcomes

Primary

1. Borderline  personality  disorder  severity,  assessed  with  the  Borderline  Personality  Disorder  check-

list-40 total score (BPD-40)

2. Self-harming behaviour, assessed by number of patients scoring above the cut-off on the Borderline

Personality Disorder Severity Index-IV (BPDSI-IV) - parasuicide subscale

Secondary

1. Interpersonal problems, assess with the World Health Organization Quality of Life Assessment-Bref

(WHOQOL BREF) - social relationships subscale

2. Impulsivity, assessed by the number of patients scoring above the cut-off on the Borderline Person-

ality Disorder Severity Index-IV (BPDSI-IV)

Notes

Sample size calculation: yes

Ethics approval: The study protocol was approved by the Medical Ethical Committee for Dutch Mental
Health Institutes.

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Comment: Allocation was determined by drawing of lots (equal numbers for
both groups at each study site) some weeks before start of the STEPPS group
after inclusion of all participants.

Allocation concealment
(selection bias)

Low risk

Comment: Randomisation was carried out by a research assistant.

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Quote: "Interviews were conducted by research assistants who were not blind
to treatment group assignment." ( p. 300)

Comment: Non-blindness of interviewers may have affected interviewer-as-
sessed outcomes, i.e. BPDSI-IV impulsivity and parasuicide scores. All other
outcomes were self-rated by participants.

Quote: "All available data of patients who received the intervention accord-
ing to protocol were used in the analyses. Intention-to-treat analyses, in which
also patients are included who did not receive the intervention as intend-
ed, were performed as well. The per protocol and intention-to-treat analyses
yielded similar results. We present only the per-protocol analyses, as we are

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bos 2010  (Continued)

Cochrane Database of Systematic Reviews

Selective reporting (re-
porting bias)

Unclear risk

Comment: No indication for selective reporting, but Insufficient information
to permit judgement of 'Yes' or 'No'

primarily interested in “method effectiveness” (as opposed to “use effective-
ness"). (p. 300)

Other bias

High risk

Adherence bias: "STEPPS therapists met twice a year under the supervision of
expert trainers to evaluate the procedure and to preserve uniformity. Individ-
ual therapists in the STEPPS condition received a 1-day training and monthly
phone supervision. After each session, individual therapists in both conditions
completed a self-report questionnaire by which the content and frequency of
the therapy contacts could be checked." (p. 300)

Allegiance bias: "[...] this RCT on STEPPS is the first done by others than its
developers." (p. 303)

Attention bias: more attention was paid to STEPPS participants.

Carmona í Farrés 2019 

Study characteristics

Methods

Randomised controlled with 2 arms

1. Dialectical behavioral therapy - mindfulness
2. Dialectical behavioral therapy - interpersonal effectiveness

Duration of trial: 10 weeks

Country: Spain

Setting: outpatient

Participants

Method of recruitment of participants: Patients for this single-centre randomised trial were recruited
from the outpatient facility of the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain).

Overall sample size: 70

Diagnosis of borderline personality disorder: Structured clinical interview for DSM IV axis II personal-
ity disorders (SCID II)

Means of assessment: Diagnostic interview for borderline (DIB-R)

Mean age: 31.9 years

Sex: 90% female

Comorbidity: no comorbidity

Inclusion criteria

1. Borderline personality disorder diagnosis based on 2 semi-structured interviews
2. Aged 18–50 years
3. Not receiving any other type of psychotherapy at the time of study enrollment
4. No previous training in mindfulness, other meditation-contemplative practices (e.g. compassion or

loving-kindness practices), or any other mind-body practice

5. No comorbidities with any of the following conditions: schizophrenia, drug-induced psychosis, organ-
ic brain syndrome, substance dependence, bipolar disorder, mental retardation, or major depressive
episode in course

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carmona í Farrés 2019  (Continued)

Exclusion criteria

Cochrane Database of Systematic Reviews

1. Comorbidities with any of the following conditions: schizophrenia, drug-induced psychosis, organic
brain syndrome, substance dependence, bipolar disorder, mental retardation, or major depressive
episode in course

Interventions

Experimental group

Treatment name: dialectical behavioral therapy (DBT) - mindfulness

Number randomised to group: 35

Duration: 10 weeks

Control/comparison group

Comparison name: dialectical behavioral therapy (DBT) - interpersonal effectiveness

Number randomised to group: 35

Duration: 10 weeks

Both groups

Concomitant psychotherapy: not allowed to receive any other type of psychotherapy

Concomitant pharmacotherapy: Patients were allowed to continue taking any medications pre-
scribed prior to study inclusion, provided that no modifications of the medication type or dose were
made during the intervention period.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Borderline Symptom List-23 (BSL)

Secondary

1. Impulsivity, assessed by the Barrett Impulsiveness Scale-11 (BIS)
2. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: no

Ethics approval: yes

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "An independent statistician randomized the participants using a
computer-generated sequence (blocks of four participants without stratifica-
tion)." (Carmona í Farrés 2019 [pers comm])

Allocation concealment
(selection bias)

Low risk

Quote: "An independent statistician randomized the participants using a com-
puter-generated sequence (blocks of four participants without stratification),
allocation was concealed". (Carmona í Farrés 2019 [pers comm])

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: "the evaluators of the patients were blinded to the participants' treat-
ment arm throughout the study." (Carmona í Farrés 2019 [pers comm])

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carmona í Farrés 2019  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Cochrane Database of Systematic Reviews

Quote: "Analyses were conducted on the per-protocol sample, comprising
participants who completed at least 80% of the intervention and for whom
all data points (pre- and post-intervention) were available." (Carmona í Far-
rés 2019, p. 5) "Analyses of primary outcomes [i.e., DERS, BIS-11] were also
conducted in the intention-to-treat (ITT) sample, including all enrolled par-
ticipants, regardless of whether they completed the intervention or not. Miss-
ing data were treated with the last observation carried forward method (Lit-
tle and Rubin 1987). Further analyses [i.e., BSL-23] were run only for subjects
considered completers." Reported data (means, SDs) which were used for ef-
fect size calculation in this review were based on completers. "Of the 70 partic-
ipants who participated in the study, a total of 18 dropped out: 13 in the DBT-M
group (37.14%) and 7 (20%) from the DBT-IE group. There were no differences
between completers and non-completers in baseline demographic character-
istics." (Carmona í Farrés 2019, p. 6)

Selective reporting (re-
porting bias)

Low risk

Comment: Reported outcomes matched study protocol.

Other bias

Low risk

Allegiance bias: No obvious allegiance bias

Adherence bias: "In relation to treatment adherence, the group sessions were
witnessed by video camera, after the session a feedback to the therapists were
provided, but there is no available to Spanish any validated DBT adherence
tool measurement." (Soler 2019a [pers comm]). Adequate measures taken to
ensure treatment adherence.

Attention bias: Equal amounts of attention spent on both groups. Both the
DBT-M and DBT-IE interventions were delivered in a group format consisting of
9–12 participants. The treatment sessions were 2.5 h in length and held once
weekly over a 10-week period.

Carter 2010 

Study characteristics

Methods

Parallel-arm, randomised controlled trial with 2 treatment arms

1. Dialectical behavioral therapy (DBT)
2. Treatment as usual + waiting list (TAU + WL)

Duration of trial: 6 months (all participants were offered 12 months of DBT, but the comparison be-
tween groups was restricted to the first 6 months of DBT vs TAU + WL).

Country: Australia

Setting: outpatient

Participants

Methods of recruitment of participants: Participants were referred from treating general practition-
ers, treating psychiatrists or public mental health services (any units of Hunter Mental Health Services).

Sample size: 73

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV)

Means of assessment: clinical interview, ICD-10 International Personality Disorder Examination (IPDE)

Mean age: 42.5 years (standard deviation = 6.1)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

138

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carter 2010  (Continued)

Sex: 100% female

Cochrane Database of Systematic Reviews

Comorbidity: participants showed substantial psychopathology with high rates of BPD criteria, Inter-
national Personality Disorder Examination (IPDE) scores and Axis 1 comorbidity.

Inclusion criteria: not stated

Exclusion criteria

1. Schizophrenia
2. Bipolar affective disorder
3. Psychotic depression
4. Florid antisocial behaviour
5. Developmental disability
6. Disabling organic condition; "The psychiatrist assessor had the option of determining if any potential
subjects were unsuitable for inclusion in therapy or unmotivated to participate, although there were
no specific criteria for this exclusion." (quote, p 164)

Interventions

Experimental group

Treatment name: DBT

Number randomised to group: 38

Duration: 6 months (weekly individual therapy, weekly group-based skills training, telephone access
to an individual therapist, therapist supervision)

Control/comparison group

Comparison name: TAU + waiting list

Number randomised to group: 35

Duration: 6 months (participants were offered DBT treatment after a 6-month waiting period)

Both groups

Concomitant psychotherapy: participants were asked to discontinue psychological therapy of any
sort for at least the 12-month duration of dialectical behavior therapy (DBT)

Concomitant pharmacotherapy: not specified

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Self-harm, assessed as the number of patients with self-harming behaviour
2. Mental health status, assessed with Brief Disability Questionnaire - subscale, days out of role

Secondary

1. Interpersonal  problems,  assessed  with  the  World  Health  Organization  Quality  of  Life  Instruments

(WHOQOL-BREF) - social relationships subscale

Notes

Sample size calculation: yes

Ethics approval: not stated

Comments from review authors:

1. We received information about the trial from the first author via email.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carter 2010  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Comment: the authors used a computerised random number generator to
generate allocations - placed into sealed opaque envelopes (in blocks of 8).
Envelope drawn after baseline assessments complete". (Carter 2010 [pers
comm])

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Low risk

Quote: "Randomization was carried out by the research staff. [...] participants
were allocated by selecton of sealed opaque envelopes." (p. 164)

Quote: "Outcomes were determined [...] by assessors blinded to allocation.
[...] All reasonable attempts were made to maintain blindness to allocation
status for these raters, but this could not achieve perfect blindness." (pp. 164)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Comment: the authors conducted per protocol analyses (DBT group: 20 com-
pleters of treatment and self-reports out of 38 allocated to this group; TAU
group: 31 completers of waiting list and self-reports out of 35 allocated)

Selective reporting (re-
porting bias)

Unclear risk

Comment: there was no indication for selective reporting, but Insufficient in-
formation to permit judgement of 'high' or 'low'.

Other bias

High risk

Performance bias: "The intervention condition was based on the comprehen-
sive DBT model, a team-based approach including [...] therapist supervision
groups." (p. 163). "[...] possible inferiority of training of DBT therapists to that
of those in other studies or inferior adherence to the DBT methods despite ad-
equate training" (p. 170). There was no mention of any objective means of as-
sessment.

Allegiance bias: no indication of allegiance bias

Attention bias: more attention paid to DBT group participants

Cottraux 2009 

Study characteristics

Methods

Randomised controlled trial with 2 treatment arms

1. Cognitive therapy (CT)
2. Rogerian supportive therapy (RST)

Duration of trial: 1 year

Country: France

Setting: outpatient

Participants

Methods of recruitment of participants: borderline personality disorder outpatients recruited and
treated at 2 university hospital centres: Lyon (Anxiety Disorder Unit) and Marseille (Behaviour Therapy
Unit)

Sample size: 65

Diagnosis of borderline personality disorder diagnosis: Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cottraux 2009  (Continued)

Cochrane Database of Systematic Reviews

Means of assessment: structured interview screening form, Revised Diagnostic Interview for Border-
lines (DIB-R)

Mean age: CT = 34.3 years (standard deviation = 10.2), RST = 32.6 years (standard deviation = 8.3)

Sex: 76.9% female

Comorbidity: "The MINI investigation found a high DSM-IV axis-1 comorbidity throughout the entire
sample: 40% of the patients had a social phobia, 26% a panic disorder, 15% agoraphobia, 18% a cur-
rent PTSD, 15% presented hypomania, 38% bulimia, 23% a somatisation disorder, 26% excessive alco-
hol consumption, 32% took street drugs irregularly, 53% presented a generalised anxiety disorder, 55%
a current major depressive disorder and 46% were at risk of suicide. Frequencies of the diagnoses were
comparable in the 2 groups [...].
There was no between-group difference in psychometric assessment for the 62 patients evaluated be-
fore therapy ( table 2 )." (Cottraux 2009, p. 311)

Inclusion criteria

1. Patients meeting the diagnosis of borderline personality disorder

Exclusion criteria

1. Age under 18 or over 60 years
2. Psychotic disorders with current delusions
3. Significant drug or alcohol addiction
4. Antisocial behaviours
5. Living too far from the study centres

Interventions

Experimental group

Treatment name: cognitive therapy

Number randomised to group: 33

Duration: 6 months (1-hour sessions 24 sessions)

Control/comparison group

Comparison name: Rogerian supportive therapy

Number randomised to group: 32

Duration: 6 months (1-hour sessions 24 sessions)

Both groups

Concomitant psychotherapy: eligible patients were not to be following psychotherapy at the time of
the study

Concomitant pharmacotherapy: participants could keep their medication as long as they accepted to
have it monitored by the principal investigator

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear; current psychotropic medication at baseline: CT N = 24 (72.7%), RT N = 26 (81.3%); P =
0.55

Outcomes

Primary

1. Self-harming  behaviour,  assessed  with:  "a  checklist  constructed  to  rate  self-harming  behav-

iours" (quote) - (SHBCL)

2. Mental health status, assessed with the ClinIcal Global Impression - Severity (CGI-S) scale
3. Suicidality, assessed with the Beck Hopelessness Scale (BHS)

Secondary

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cottraux 2009  (Continued)

Cochrane Database of Systematic Reviews

1. Impulsivity, assessed with the Eysenck Impulsivity Venturesomeness Empathy Questionnaire (IVE-I)
2. Depression, assessed with the Becks depression inventory (BDI)

Notes

Sample size calculation: not stated

Ethics approval: The ethics committee, CCPPRB Lyon B, approved the protocol for the entire country.

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "The randomisation process used blocks of 4 patients for each centre,
and was organised by the Lyon University Hospital's Biostatistics Departmen-
t." (p. 309)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Quote: "The allocation was confidential and delivered via phone call [of the
Biostastics Department] to the secretary of each centre." ( p. 309)

Quote: "Psychologists who had not taken part in the treatments performed
the assessment. They had no information on either the randomisation or the
treatment and did not attend the team meetings about the patients." (p. 310)

"[...] evaluators may have received inadvertent or indirect information from
the patients about the treatment underway. The evaluators' blindness was not
tested." (p. 313)

Comment: the authors per protocol analyses: treatment completers only
(20/33 people randomised to CT, 18/32 people randomised to RST)

Selective reporting (re-
porting bias)

Low risk

Comment: Study protocol available (NCT00131781). There was no indication
of selective reporting.

Other bias

Low risk

Performance bias: "At the end of each session, the therapists were to com-
plete a checklist of the techniques they used, which was revised and discussed
with the prinicipal investigator [...] weekly supervision session." (p. 309)

Allegiance bias: there was no indication of an allegiance effect. None of the
authors was among the developers of any of the treatments under investiga-
tion.

Attention bias: equal amounts of attention paid to both groups

Davidson 2006 

Study characteristics

Methods

Multicentre, parallel-arm RCT, with 2 treatment arms

1. Cognitive behavioral therapy and treatment-as-usual
2. Treatment-as-usual (TAU)

Duration of trial: 1 year

Country: UK

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Davidson 2006  (Continued)

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Sample size: 106

Cochrane Database of Systematic Reviews

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DMS-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Personality Disorders (SCID)

Mean age: 31.9 years (standard deviation = 9.1)

Sex: 84% female

Comorbidity: "We did not rule out comorbid problems such as depression or alcohol and drug abuse
that are common in Borderline personality disorder." (quote, p 8)

Inclusion criteria

1. Patients with borderline personality disorder

Exclusion criteria

1. Patients currently receiving inpatient treatment for a mental state disorder
2. Currently receiving a systematic psychological therapy of specialist service
3. Insufficient knowledge of English
4. Evidence of organic illness
5. Mental impairment
6. Alcohol or drug dependence
7. Schizophrenia or bipolar affective disorder
8. Drug or alcohol abusing patients were eligible for inclusion

Interventions

Experimental group

Treatment name: cognitive behaviour therapy + treatment-as-usual (CBT + TAU)

Number randomised to group: 54

Duration: 1 year (mean = 27 sessions)

Control/comparison group

Comparison name: treatment-as-usual (TAU)

Number randomised to group: 52

Duration: 1 year

Both groups

Concomitant psychotherapy: patients currently receiving inpatient treatment for a mental state dis-
order or a systematic psychological therapy or specialist service were excluded. All other kinds of treat-
ments a patient would have received if the trial had not been in place (e.g. general practitioner care,
contact with community mental health teams) were allowed. 90% of participants were in contact with
mental health services.

Concomitant pharmacotherapy: allowed as part of TAU which allowed "all other kinds of treatments
a patients would have received if the trial had not been in place".

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: There were no details on how many of the study participants actually received psychotropic med-
ical treatment.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Davidson 2006  (Continued)

Cochrane Database of Systematic Reviews

“Although no information on comorbidity or the use of prescription drugs was collated, there are
no major imbalances in resource utilisation to suggest that comorbidity or drug prescribing differed
either across the original randomised groups or in the subset of the 76 patients who were followed
up.“ (Davidson 2010, p. 461)

Outcomes

Primary

1. Suicidality, assessed by the mean number of patients with suicidal act in the previous 12 months
2. Parasuicidality, assessed by the number of patients with self-harming behaviour in the previous 12-

month period

Secondary

1. Interpersonal  problems,  assessed  with  the  Inventory  of  Interpersonal  Problems-Short  Circumplex

(IIP-SC)

2. Depression, assessed with the Becks Depression Inventory II (BDI-II)

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "The randomization schedules were generated by the study center at
[...] Glasgow University, and kept securely and confidentially by the trial coor-
dinator at the Study Coordinating Centre." (p. 437)

Allocation concealment
(selection bias)

Low risk

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Quote: "The randomization schedules were [...] kept securely and confiden-
tially by the trial coordinator [...] The trial coordinator informed the referring
agent of the result of randomization immediately and in writing, and then con-
tacted the CBT therapist/s in each area with the patients details so that CBT
therapy could be initiated." (p. 437)

106 patients enrolled and randomised

Quote: "The research assistants on each site carry out all assessments and are
blind to treatment group allocation. In addition, research assistants request
that patients do not mention any details of any psychological treatment they
may be receiving. [...] The research assistants responsible for the recording of
outcomes were unaware of the treatment allocated or received." (p. 439)

Quote: "The analyses were according to the intention-to-treat principle." (p.
454)

Selective reporting (re-
porting bias)

Low risk

Comment: study protocol available (ISRCTN86177428). No indication of selec-
tive reporting

Other bias

High risk

Performance bias: "All therapists received training in the protocol at the be-
ginning of the trial and regular meetings of all therapists were held to ensure
consistency of approach across the sites. In addition, all therapists received
weekly supervision from CBT experts at each site." (p. 452)

Allegiance bias: there was no indication of an allegiance effect. However, as
one of the authors is the main author of the CT manual according to which the
active group was treated, an allegiance effect seems not improbable.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Davidson 2006  (Continued)

Cochrane Database of Systematic Reviews

Attention bias: more attention paid to CT group participants

Davidson 2014 

Study characteristics

Methods

6-session trial with 2 arms

1. Manual-assisted cognitive therapy (MACT)
2. Treatment-as-usual (TAU)

Duration of trial: 6-session trial, unknown length

Country: Scotland

Setting: outpatient

Participants

Method of recruitment of participants: referral to hospital liaison psychiatry team
Sample size: 20

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV axis II disorders

Mean age: not stated
Sex: not stated

Comorbidity: 4 people had simple personality disorder and 16 had diffuse personality disorder (per-
sonality disorder in more than one cluster). The most common diagnoses were borderline personality
disorder (n = 17) followed by avoidant (n = 13) and paranoid personality disorder (n = 8).

Inclusion criteria

1. Aged 18-65 years
2. Presence of personality disorder
3. 3 or more on Standardised Assessment of Personality: Abbreviated Scale (SAPAS)
4. With or without substance misuse

Exclusion criteria

1. If participants did not consent

Interventions

Experimental group
Treatment name: manual-assisted cognitive therapy (MACT)
Number randomised to group: 14
Duration: 6 sessions

Control/comparison group
Comparison name: TAU
Number randomised to group: 6
Duration: 6 sessions

Both groups
Concomitant psychotherapy: seems as if both treatments included inpatient care, if required
Concomitant pharmacotherapy: not stated

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Davidson 2014  (Continued)

Cochrane Database of Systematic Reviews

1. Self-harm, assessed by the Acts of Deliberate Self-Harm Inventory (Acts DSH)
2. Suicide-related outcomes, assessed by the Beck Scale for Suicidal Ideation (BSS)

Secondary

1. Depression, assessed by the Hospital Anxiety and Depression Scale(HADS)
2. Attrition, in terms of patients lost after randomisation in each group
3. Adverse effects, as measured by spontaneous reporting

Notes

Risk of bias

Bias

Sample size calculation: not stated 
Ethics approval: yes

Comments from review authors: none

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “Patients were randomised to MACT or TAU using a random numbers
table with an allocation ratio of 2:1 in favour of MACT”. (p.109)

Allocation concealment
(selection bias)

Unclear risk

Comment: We do not know who conducted the randomisation, or if the par-
ticipants were informed of allocation prior to baseline assessment. Baseline
assessment was conducted by a blinded assessor.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: “The research assistant, who assessed patients at baseline and
outcome, remained masked to treatment allocation throughout the
study.” (p.109)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: the authors used intention-to-treat analysis – it did not mea-
sure outcome data on all participants (due to attrition), but included all ran-
domised participants in the analysis, evidently. No info on imputation method.
3/14 (21.4%) lost in MACT, 2/6 (33%) in TAU – fairly balanced in numbers. On-
ly one reason given for missing outcome data (suicide). We do not know if rea-
sons differed between the groups.

Selective reporting (re-
porting bias)

Unclear risk

Comment: there was no protocol available for this study.

Other bias

High risk

Adherence bias: "Therapy was delivered to individuals in the community by
two therapists, a doctoral-level clinical psychologist and a psychiatrist, both
trained and supervised on a weekly basis in MACT by one of the authors of the
manual (K.D.).” (p. 109)

Allegiance bias: Main author K.D. is the author of the intervention-manual.

Attention bias: MACT had 6 sessions. There was no mention of how extensive
the TAU treatment was, compared to MACT.

Doering 2010 

Study characteristics

Methods

Randomised controlled trial with 2 treatment arms

1. Transference-focused psychotherapy (TFP)
2. Community Treatment by experienced community psychotherapist (CTBE)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Doering 2010  (Continued)

Duration of trial: 12 months

Country: Germany, Austria

Setting: outpatient

Cochrane Database of Systematic Reviews

Participants

Methods of recruitment of participants: participants recruited at the outpatient units of the Depart-
ments of Psychiatry and Psychotherapy, Technical University of Munich, Germany, and the Psycho-
analysis and Psychotherapy Department, Medical University Vienna, Austria

Sample size: 104

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition, (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV (SCID)

Mean age: 27.3 years

Sex: 100% female

Comorbidity: "Comorbidity with all other personality disorders and with Axis I disorders except those
mentioned above were allowed [...]." (p. 391) "There were no significant differences between the
groups with regard to sociodemographic and clinical variables at baseline." (p. 391)

Incluson criteria: not stated

Exclusion criteria

1. Schizophrenia
2. Bipolar I and Ii disorder with a major depressive episode
3. Manic or hypomanic episode during the previous 6 months
4. Substance dependency (including alcohol) during the previous 6 months
5. Participants meeting 3 or more DSM-IV criteria for antisocial personality disorder
6. Organic pathology
7. Mental retardation
8. Insufficient command of the German language

Interventions

Experimental group

Treatment name: transference-focused psychotherapy (TFP)

Number randomised to group: 52

Duration: 12 months (twice-weekly, individual psychotherapy sessions)

Control/comparison group

Treatment name: treatment by experienced community psychotherapist (TBE)

Number randomised to group: 52

Duration: 12 months

Both groups

Concomitant psychotherapy: psychotherapy other than the study treatment was not allowed in the
experimental group.

Concomitant pharmacotherapy: Medication treatment was not standardised, its type and amount
were decided on an individual basis by the individuals’ psychiatrists in the community in both groups
and registered continuously.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Doering 2010  (Continued)

Cochrane Database of Systematic Reviews

“There were no significant differences between the groups with regard to medication at baseline and
during the 1-year treatment period (Fig. 3). The only participant who received amphetamines was in
the transference-focused psychotherapy group. There was no significant influence of psychotropic
medication on the outcome variables with the exception of a worse BSI global severity index in med-
icated participants (F = 43.927, d.f.= 1,101, P = 0.04).“ (p. 392)

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the mean number of DSM-IV criteria for border-

line personality disorder obtained

2. Suicidality, assessed by the mean number of patients with suicidal acts in the previous 12 months
3. Self-harming behaviour, assessed by the number of patients with self-harming behaviour in the pre-

vious 12-month period

Secondary

1. Depression, assessed with the Beck Depression Inventory (BDI)

Notes

Sample size calculation: yes

Ethics approval: The study was approved by the ethics commission of the Medical University Inns-
bruck, Austria, on 24 March 2004 (ID: UN1950).

Comments from review authors

1. Information about the randomisation procedure was received by email from Dr Doering.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Comment: the authors used random numbers, matching after inclusion of
35th patient according to severity of self-harming behaviour during the last
year and personality organisation (Doering 2010 [pers comm].

Allocation concealment
(selection bias)

Low risk

Quote: "The results of the first assessments [screening for inclusion criteria]
were sent to a researcher outside the two study centers who performed the
randomization." (Doering 2010, p. 5) "After randomization patients were re-
ferred to a therapist." (Doering 2010, p. 6)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: "Research assistants who conducted assessments before random-
ization and after one year of treatment were blinded for the therapy deliv-
ered." (Doering 2010, p. 7)

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Comment: Last observation carried forward (LOCF)

Selective reporting (re-
porting bias)

Low risk

Comment: Study protocol available (NCT00714311). No indications of selec-
tive reporting

Other bias

Unclear risk

Performence bias: "Video recordings of all [EG] sessions were performed and
used in the group supervision. [...] Every case was supervised at least every
four to six weeks. [...] Experienced community psychotherapists [i.e. CG thera-
pists] attended supervisions according to their usual routine." (Doering 2010,
p. 10f.) "For the assessment of adherence and competence of the transfer-
ence-focused psychotherapists a German translation of a specific Rating of Ad-
herence and Competence [...] was used. [...] The rating was performed by the
supervisor after every video-guided supervision of a therapy session." (Doer-
ing 2010, p. 11)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Doering 2010  (Continued)

Cochrane Database of Systematic Reviews

Allegiance bias: Some of the study authors are experienced TFP therapists,
but none was personally involved in treatment development.

Attention bias: Less attention may have been paid to CG patients depending
on the CTBE therapists' main orientation; however, every participant was pro-
vided the specifically full amount of necessary attention.

Elices 2016 

Study characteristics

Methods

10-week trial with 2 arms

1. Mindfulness training (MT)
2. Interpersonal effectiveness skills training (IE)

Duration of trial: 10 weeks

Country: Spain

Setting: outpatient

Participants

Method of recruitment of participants: participants recruited from the outpatient BPD Unit at the De-
partment of Psychiatry from the Hospital de la Santa Creu in Sant Pau

Sample size: 64

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV axis II personality disorder (SCID-II) and
Diagnostic Interview for Borderlines-Revised (DIB-R). Axis I comorbidities were assessed with the Psy-
chiatric Diagnostic Screening Questionnaire (PDSQ)

Mean age: MT = 31.56 years (standard deviation = 7.25), IE = 31.72 years (standard deviation = 6.82)

Sex: 86% female

Comorbidity: All participants in both groups had at least one comorbid Axis I diagnosis, including anxi-
ety disorders, major depressive disorder, and substance abuse.

Inclusion criteria

1. Fulfillment of BPD diagnostic criteria (SCID-II and DIB-R)
2. Age from 18-45 years

Exclusion criteria

1. Lifetime diagnosis of drug-induced psychosis, organic brain syndrome, bipolar or psychotic disorder

or mental retardation

2. Participation in any sort psychotherapy during the study or had participated in DBT skills groups in

the past

3. Having meditation/yoga experience (having attended more than one session/class in the past

Interventions

Experimental group
Treatment name: mindfulness training (MT)
Number randomised to group: 32
Duration: 10 weeks

Control/comparison group

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Elices 2016  (Continued)

Cochrane Database of Systematic Reviews

Comparison name: interpersonal effectiveness skills training (IE)
Number randomised to group: 32
Duration: 10 weeks

Both groups

Concomitant psychotherapy: no
Concomitant pharmacotherapy: patients under pharmacological treatment were included – provided
that no modifications of the medication type or dose were made during the 10-week intervention peri-
od.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: no statistically significant difference between proportions taking antidepressants (MT: 83.3%, IE:
65.5%, P = 0.12), benzodiazepines (MT: 50.0%, IE: 53.8%; P = 0.77), antipsychotics (MT: 43.3%, IE: 42.3%,
P = 0.93)

Outcomes

Primary

1. Borderline Personality Disorder severity, assessed by Borderline Symptom List - 23 (BSL-23)

Secondary

1. Attrition, in terms of patients lost after randomisation in each group

Some secondary outcomes can be found in a secondary analysis (Soler 2016):

1. Impulsivity, assessed by the the Conners' Continuous Performance Test II (CPT II) Impulsivity Index
2. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes
Ethics approval: yes

Comments from review authors:

1. Only self-reported screening of Axis-I disorders
2. We received this information by email from Dr Soler: "Elices et al. 2016 (paper in Mindfulness) and
Soler et al. 2016 (paper in Borderline Personality Disorder and Emotion Dysregulation) are based on
the same sample of patients. The Carmona i Farres 2018 (paper in Mindfulness) also compares Mind-
fulness to Interpersonal Effectiveness study but are based in a totally different sample of patients."

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “Randomized allocation was performed with the online Research Ran-
domizer (www.randomizer.org/form.htm), a program that generates 16 sets of
4 numbers each (ranging from 1 to 2 for M and IE, respectively). To obtain the
same sample size in each treatment arm, allocation had to be perfectly bal-
anced every four sets. Each group comprised eight individuals corresponding
to four consecutive sets of randomization.” (p. 586)

Allocation concealment
(selection bias)

High risk

Quote: “The research unit coordinator (not blind to treatment condition) was
responsible for the randomization process.”

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: “A trained psychiatrist and two psychologists familiar with screening
interviews, who were blind to treatment arms, conducted diagnostic inter-
views.” (p. 586)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Quote: “(…) analyses were conducted on both per-protocol (PP) and inten-
tion-to-treat (ITT) samples. ITT analyses included all enrolled participants (n
= 64), regardless of whether they completed the intervention or not. PP analy-

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Elices 2016  (Continued)

Cochrane Database of Systematic Reviews

ses comprise only participants who completed at least 80% of the interven-
tion (completers), and for whom, all data points (pre- and post-intervention)
are available (M group: number of participants = 19; IE group: number of par-
ticipants = 25). Missing data were treated with the last observation carried for-
ward (LOCF) method (Little and Rubin 1987)”. (p. 589)

“The dropout rate for mindfulness was higher than in the control group (41
vs.19%)” (p. 590)

Missing data treated with LOCF, a potentially biased imputation method. There
were clear differences in attrition rates between groups which could have
affected outcome estimates. The reasons for dropout also varied between
groups. The attrition rate was also higher than estimated in the power calcula-
tion.

Selective reporting (re-
porting bias)

Low risk

Comment: Matched study protocol

Other bias

Unclear risk

Attention bias: "Participants met once a week in groups of eight for ten con-
secutive weeks, with each session 150 min in duration. Sessions for both inter-
vention modalities (i.e. M and IE) followed the same structure).”

Treatment adherence: “Other team members followed each therapy session
using a closed-circuit television, enabling supervision and feedback.” "Another
limitation of the present study is the absence of a treatment adherence mea-
sure (TAM), in part because no validated TAM is available in Spanish".

Allegiance bias: Last author (JS) is a DBT therapist (http://www.es-
spd.eu/fileadmin/us er_upload/Board/cvs/Soler_CV.p df). The two arms in this
trial were heavily based on DBT. Potential allegiance bias here

Farrell 2009 

Study characteristics

Methods

Randomised controlled trial with 2 treatment arms

1. Group schema focused therapy + individual psychotherapy treatment-as-usual
2. Individual psychotherapy treatment-as-usual

Duration of trial: 8 months

Country: USA

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Sample size: 32

Diagnosis of borderline personality disorder: Diagnostic Interview for Borderlines-Revised (DIB-R)

Means of assessment: Diagnostic Interview for Personality Disorders Revised, Borderline Syndrome In-
dex

Mean age: 35.6 years

Sex: 100% female

Comorbidity: not stated

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Farrell 2009  (Continued)

Inclusion criteria

1. Female
2. Age between 18 and 65 years old

Exclusion criteria

Cochrane Database of Systematic Reviews

1. Axis I diagnosis of a psychotic disorder confirmed by an open clinical interview
2. Below average IQ

Interventions

Experimental group

Treatment name: group schema focused therapy + individual psychotherapy treatment-as-usual
(GSFT + PTAU)

Number randomised to group: 16 (30 sessions)

Duration: 8 months

Control/comparison group

Comparison name: individual psychotherapy treatment-as-usual (PTAU)

Number randomised to group: 16

Duration: 8 months

Both groups

Concomitant psychotherapy: all participants were in individual psychotherapy (eclectic, mainly sup-
portive) throughout the study.

Concomitant pharmacotherapy: psychopharmacological treatment was not controlled for.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: all participants were stable on at least 1 psychotropic medication at the start of the study, mostly
low doses of antipsychotics or selective serotonin reuptake inhibitor, or both.

Outcomes

Primary

1. BPD severity, assessed by the Borderline Syndrome Index (BSI)
2. Mental health status, assessed by the Global Assessment of Function Scale (GAF)

Secondary

1. Affective instability, assessed by the Diagnostic Interview for Borderline Personality Disorders-Revised

(DIB-R) - affect subscale

2. Impulsivity, assessed by the DIB-R - impulsive subscale
3. Interpersonal problems, assessed by the DIB-R - interpersonal subscale
4. Dissociation/stress-related paranoia, assessed by the DIB-R - cognitive subscale

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors:

1. Information about the randomisation and allocation procedure was received by email from Dr Farrel.

Risk of bias

Bias

Authors' judgement

Support for judgement

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

152

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Farrell 2009  (Continued)

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Patients were randomly assigned using a random number table". (p.
319)

Allocation concealment
(selection bias)

Unclear risk

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Comment: no clear details were reported. After screening for eligibility of 40
patients, N = 8 were excluded. Reasons for exclusion were only given for 3 of
them (1 declined participation, 2 did not meet inclusion criteria).Thus, N = 16
were allocated to EG, N = 16 to CG.

Quote: "The DIB-R structured interviews were conducted by two Ph.D. Clin-
ical Psychologists not involved in treatment delivery. Efforts were made to
keep them blind to treatment group membership, but for 10% of the subjects
the blind was broken due to patient report." (, p. 319) "Therapists were given
a GAFS [Global Assessment of Function Scale] checklist to use so that the an-
chors for assigning scores were in front of them when they recorded their rat-
ings. They were chosen as raters since they were removed from the hypothe-
ses of the study, although not blind to their patients' group membership and
no inter-rater reliability was possible." ( p. 319)

Comment: overall, observer-rated outcomes were not assessed by blind
raters.

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Comment: the authors conducted per protocol analyses.

Selective reporting (re-
porting bias)

Unclear risk

Comment: No indication of selective reporting, but Insufficient information to
permit judgement of 'high' or 'low'

Other bias

High risk

Adherence bias: "Two of the three groups had the two program developers
as therapists and the third had one developer and one clinical psychologist
[...] Weekly supervision meetings took place during the course of the study and
random videotapes of sessions were reviewed for fidelity by the program de-
velopers. The manual developed for the study acted as an additional fidelity
check." (p. 322)

Allegiance bias: The two program developers were study therapists and have
authored this study.

Attention bias: more attention paid to SFT-G participants

Feigenbaum 2012 

Study characteristics

Methods

12-month trial with 2 arms

1. Dialectical behavioral therapy (DBT)
2. Treament-as-usual (TAU)

Duration of trial: 1 year
Country: UK

Setting: outpatient

Participants

Method of recruitment of participants: from secondary and tertiary care services

Sample size: 42

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Feigenbaum 2012  (Continued)

Cochrane Database of Systematic Reviews

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV axis II disorders (SCID-II)
Mean age: DBT = 35.4 years (standard deviation = 7.8), treatment-as-usual = 34.6 years (standard devia-
tion = 7.4)
Sex: 72-75% female
Comorbidity: mood disorders, substance abuse, anxiety disorders, eating disorders

Inclusion criteria

1. Confirmed diagnosis of cluster borderline personality disorder
2. Aged 18- 65

Exclusion criteria

1. Long-term psychotherapeutic treatment
2. Met DSM-IV criteria for comorbid psychotic disorder or bipolar I disorder
3. Had opiate dependence requiring specialist treatment
4. Had mental impairment or evidence of organic brain disorder

Interventions

Experimental group
Treatment name: dialectical behavioral therapy (DBT)
Number randomised to group: 26
Duration: 1 year
Control/comparison group
Comparison name: treatment-as-usual (TAU)
Number randomised to group: 16
Duration: 1 year

Both groups
Concomitant psychotherapy: no data
Concomitant pharmacotherapy: yes, including antidepressants, antipsychotics, and mood stabilisers

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: "Patients were on a range of medications at time of randomization (predominantly anti-depres-
sants, anti-psychotics, and mood stabilizers). Those patients entering DBT were reviewed by a consul-
tant psychiatrist for the appropriateness of medication." (p. 129)

Exact proportions of participants in each group unclear

Outcomes

Primary

1. Self-harm,  in  terms  of  frequency  and  severity  of  self-harm  attempts,  assessed  with  Deliberate  self

harm (SASII)

2. Suicide-related outcomes, assessed by the Suicide Attempt SelfInjury Interview (SASII)
3. Psychosocial functioning, assessed by the functionality subscale of Clinical Outcomes in Routine Eval-

uation – Outcome Measure (CORE-OM)

Secondary

1. Anger, assessed by the the Spielberger Anger scale (STAXI); dissociation and psychotic-like symptoms,

assessed by the Dissociative Experience Scale (DES)

2. Depression, assessed by the Beck Depression Inventory (BDI)
3. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes
Ethics approval: yes

Comments from review authors: none

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Feigenbaum 2012  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “Treatment allocation was made offsite via telephone randomization
using a stochastic minimization programme (MINIM) balancing for sector with-
in the regions to avoid differences in terms of differential referral practices,
gender, and presence of BPD. Clients were randomized so that two of three en-
tered DBT and one of three TAU in order to build the caseloads for staff, as this
was a new service with no existing clients.” (p. 124)

Allocation concealment
(selection bias)

Low risk

Quote:"Treatment allocation was made offsite via telephone randomiza-
tion…” (p. 124)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Quote: "While we attempted blinding of assessments, as is often the case with
psychosocial treatment trials, those carrying out the research assessments
could mostly identify the treatment group of the patient.” (p. 137)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Quote: “All results were analyzed using an intention-to-treat analysis based on
treatment assignment, 15/26 dropped out in DBT and only 1/16 in TAU. Sub-
stantial differences. Unclear [for] the discontinued participants whether they
completed the treatment or not.” (p. 127)
“Of the 26 assigned to DBT, one withdrew consent for the data to be used
at end of treatment and five refused to enter the treatment during the pre-
commitment phase. A further nine patients dropped out of therapy between
months 4 and 9 of treatment. (…) Of those assigned to TAU, only one individ-
ual dropped out of receiving any form of treatment.” “Those who discontinued
treatment continued to contribute data and remained in the trial.” (p. 127)

Selective reporting (re-
porting bias)

Unclear risk

Comment: No information

Other bias

Unclear risk

Treartment adherence: “Adherence to the therapy was not formally mea-
sured. However, adherence to the model was monitored by the team through
weekly case discussion, verbal reporting of session content, and listening to
each other’s audio tapes.” (p. 125)

Allegiance bias: First author is Senior international trainer in DBT for British
Isles DBT (https://iris.ucl.ac.uk/iris/browse /profile?upi=JFEIG65).

Attention bias: “Finally, while information was collected on the types of treat-
ments and services utilized in TAU, the number of hours of TAU intervention
was not recorded, thus, it is possible that the differences identified may be due
to differing intensities of treatment”. (p. 138)

Feliu-Soler 2017 

Study characteristics

Methods

3-week trial with 2 arms

1. Loving-kindness and compassion meditations (LKM/CM)
2. Mindfulness continuation training (MCT)

Allocation: 1:1
Duration of trial: 3 weeks
Country: Spain

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Feliu-Soler 2017  (Continued)

Setting: outpatient

Participants

Method of recruitment of participants: not stated
Sample size: 62

Cochrane Database of Systematic Reviews

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition, text revision (DSM-IV-TR)
Means of assessment: Diagnostic Interview for Borderline Personality Disorders-Revised (DIB-R)
Mean age: LKM/CM = 35.13 years (standard deviation = 8.25), MCT = 32.5 years (standard deviation =
6.17)
Sex: 93.8% female

Comorbidity: not stated

Inclusion criteria

1. Borderline personality disorder according to DMS-IV-TR criteria and the Diagnostic Interview for Bor-

derline Personality Disorders-Revised (DIB-R)

Exclusion criteria

1. Diagnosis of drug-induced psychosis
2. Organic brain syndrome
3. Bipolar or psychotic disorder
4. Intellectual disability
5. Participation in any other psychotherapy treatment during the study

Interventions

Experimental group
Treatment name: loving-kindness and compassion meditations (LKM/CM)
Number randomised to group: 16
Duration: 3 weeks

Control/comparison group
Comparison name: mindfulness continuation training
Number randomised to group: 16
Duration: 3 weeks

Both groups
Concomitant psychotherapy: none
Concomitant pharmacotherapy: Psychiatric medication was unaltered during the 3-week study peri-
od.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: exact proportion unclear

Outcomes

Primary

1. Borderline personality disorder severity, assessed with the Borderline Symptoms List—23 (BSL-23)

Secondary

1. Affective instability, assessed by the Inadequate Self, Forms of Self-Criticism/Self-Attacking and Self-

Reassuring Scale (FSCRS)

Sample size calculation: not stated
Ethics approval: yes

Comments from review authors: none

Notes

Risk of bias

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Feliu-Soler 2017  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Quote: “To assess the added value of LKM/CMin this sample, patients were
randomly allocated to either 3 weeks of LKM/CM or mindfulness continuation
training (MCT)”. (p. 2)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Comment: The authors provided insufficient information to make a clear
judgement of risk of bias.

Unclear risk

Comment: the method of concealment was not described.

Unclear risk

Comment: no information of blinding of outcome assessment

Unclear risk

Quote: “Missing data were treated with the last-observation-carried forward
method” (p. 4).

Comment: no data on attrition; a more conservative imputation method than
last-observation-carried- forward could have been used.

Selective reporting (re-
porting bias)

Unclear risk

Comment: no protocol was available to enable a clear judgement of risk of
bias.

Other bias

High risk

Allegiance bias: “The interventions were co-led by two clinical psycholo-
gists (JS and AF) with long-term personal practice in mindfulness meditation
and extensive clinical experience with mindfulness-based programmes and
DBT.” (p. 2)

Comment: First and last authors carried out the interventions.

Adherence bias: no information provided

Attention bias: all participants received 10 weeks of mindfulness training.
Both groups received 3 weeks of LKM/CM or 3 weeks of MCT.

Giesen-Bloo 2006 

Study characteristics

Methods

3-year trial with 2 treatment arms

1. Schema-focused therapy
2. Transference-focused psychotherapy

Duration of trial: 3 years

Country: The Netherlands

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Sample size: 88

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Giesen-Bloo 2006  (Continued)

Cochrane Database of Systematic Reviews

Means of assessment: Structured Clinical Interview for DSM-IV (SCID) and Borderline Personality Dis-
order Severity Index - Version IV (BPDSI-IV)

Mean age: 30.6 years

Sex: 93% female

Comorbidity: "Comorbid Axis I and Axis II disorders were allowed" (p. 650). Numbers of comorbid Axis I
and Axis II disorders were equally distributed across groups.

Inclusion criteria: not stated

Exclusion criteria

1. Borderline personality disorder not main diagnosis
2. Psychotic disorders (except short, reactive psychotic episodes)
3. Bipolar disorder
4. Dissociative identity disorder
5. Antisocial personality disorder
6. Attention-deficit/hyperactivity disorder
7. Addiction of such severity that clinical detoxification was indicated (after which entering treatment

was possible)

8. Psychiatric disorders secondary to medical conditions
9. Mental retardation
10.No Dutch literacy

Interventions

Experimental group

Treatment name: schema-focused therapy (SFT)

Number randomised to group: 45

Duration: 3 years (50-minute sessions, twice a week)

Control/comparison group

Comparison name: transference-focused psychotherapy (TFP)

Number randomised to group: 43

Duration: 3 years (50-minute sessions, twice a week)

Both groups

Concomitant psychotherapy: no additional psychotherapeutic treatment allowed

Concomitant pharmacotherapy: prescribing according to good clinical practice, similar to American
Psychiatric Association guidelines, by psychiatrists from different orientations

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: Unclear. No difference in psychotropic medication use at baseline: SFT 77.3%, TFP 71.4%; P = 0.87

Outcomes

Primary

1. Borderline severity, assessed with Borderline Personality Disorder Severity Index IV (BPDSI-IV)

Notes

Sample size calculation: yes

Ethics approval: The medical ethics committees of the participating centers approved the study.

Comments from review authors: none

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Giesen-Bloo 2006  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Randomization to SFT or TFP was stratified across 4 community men-
tal health centers and was performed [...] after the adaptive biased urn proce-
dure". ( p. 650)

Allocation concealment
(selection bias)

Low risk

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: "Randomization to SFT or TFP [...] was performed by a study indepen-
dent person [...] We used this procedure (1) to keep allocation at each site un-
predictable until the last patient to avoid unintentionally affecting ongoing
screening procedures [...]." ( p. 650)

173 patients were screened for eligibility. 85 of them were excluded, reasons
are given (40 declined participation, 24 did not meet inclusion criteria, 19 met
exclusion criteria, 2 had insufficient availability); 88 randomised, of 45 allocat-
ed to SFT, 44 were included in analyses (1 patient excluded owing to unreliable
assessments due to increased patient blindness), of 43 allocated to TFP, 42
were included in analyses (1 patient excluded because untraceable after ran-
domisation; never met or spoke to therapist).

Quote: "assessments were made [...] by independent research assistants [...]
Study researchers, screeners, research assistant, and SFT/TFP therapists were
masked to treatment allocation during the screening procedure and the first
assessment". ( p. 650) "most research assistants learned their patients' treat-
ment allocation as the study progressed, as patients talked about their treat-
ment and therapists. However, the results of secondary computer-assessed
self-report measures [...] concurred with the observer-rated (interview) find-
ings, making it unlikely that results can be attributed to knowledge of treat-
ment allocation." ( p. 657)

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Quote: "An intention-to-treat approach was applied, using either the last
observation during the 3-year treatment period or the last-observation-car-
ried-forward method [...]." (p. 651)

Selective reporting (re-
porting bias)

Unclear risk

Comment: No indication of selective reporting, but Insufficient information to
permit judgement of 'high' or 'low'

Other bias

Unclear risk

Adherence bias: "Weekly local supervision [...], a 1-day central supervision
every 4 months, and a 2-day central supervision every 9 months. [...] Treat-
ment integrity was monitored by means of supervision. All the raters were in-
dependent of the study and masked to treatment outcome. One psychologist,
masked to allocation, listened to 1 randomly selected tape of each patient,
then stated the treatment administered [...] Other trained therapists for each
orientation assessed the TFP Rating of Adherence and Competence Scale or
the SFT Therapy Adherence and Competence Scale for BPD." (p. 650-651). Is-
sues have been raised about treatment integrity of TFP by the study consul-
tant Dr Yeomans (Yeomans 2015).

Allegiance bias: experts from both therapies supervised therapists. None of
the study authors developed any of the respective therapies.

Attention bias: equal amounts of attention spent to both groups

Gleeson 2012 

Study characteristics

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gleeson 2012  (Continued)

Methods

16 weekly session trial with 2 arms

Participants

1. Helping Young People Early specialist first-episode psychosis treatment (HYPE + SFET)
2. Specialist first-episode psychosis treatment (SFET)

Duration of trial: 16 weekly sessions
Country: Australia

Setting: outpatient and inpatient.

Method of recruitment of participants: participants identified by the research assistant in consul-
tation with the outpatient case manager, using a checklist of the Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition (DSM-IV) for borderline personality disorder criteria
Diagnosis of borderline personality disorder: DSM-IV
Means of assessment: Structured Clinical Interview for the DSM-IV Axis I Disorders, Patient Edition
(SCID-I/P) and the antisocial and borderline personality disorder modules for Axis II disorders (SCID-II)
Mean age: 18.4 years (standard deviation = 2.9)
Sex: 82% female

Comorbidity: 12 participants had a diagnosis of borderline personality disorder (i.e. greater than or
equal to 5 DSM-IV criteria), and 4 cases had sub-syndromal borderline personality disorder (4 DSM-IV
criteria)

Inclusion criteria

1. Participants were required to have 4 or more DSM-IV borderline personality disorder features.

Exclusion criteria

1. Severe and enduring psychotic symptoms (defined as scores of 4 or more on 1 or more psychotic items
of the Brief Psychiatric Rating Scale (BPRS), which had persisted for more than 1 month unless symp-
toms were assessed by treating clinicians as not interfering with psychosocial functioning)

2. Unable to converse in or read English without an interpreter
3. Intellectual deficits precluding meaningful participation in individual psychotherapy
4. Informed  consent  previously  provided  for  another  psychotherapy  trial  at  study  site,  or  already  re-

ceived a course of cognitive analytic therapy, or both

Interventions

Experimental group
Treatment name: HYPE + SFET
Number randomised to group: 8
Duration: 16 weekly sessions
Control/comparison group
Comparison name: SFET
Number randomised to group: 8
Duration: not stated

Both groups
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: eligible for inclusion in study if had less than 6 months of previous
treatment with antipsychotic medication

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: “patients taking medications. There were seven cases in the HYPE + SFET [87.5%] and five cases in
the SFET [62.5%].” (Gleeson 2012, p. 26)

Mean adherence did not differ sig. between groups (P = 0.983). (Tab. 2)

Outcomes

Primary

1. Suicide-related outcomes, assessed by the suicidal subscale of the Overt Aggression Scale - Modified

for outpatients (OAS-M)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gleeson 2012  (Continued)

Secondary

Cochrane Database of Systematic Reviews

1. Anger, assessed by the labile anger subscale of the Anger Irritability and Assault Questionnaire (AIAQ)
2. Depression, assessed by the anhedonia subscale of the Scale for Assessment of Negative Symptoms
3. Attrition, in terms of patients lost after randomisation in each group

Sample size calculation: no
Ethics approval: no

Comments from review authors:

1. We contacted Dr Gleeson by email asking for separate data on the participants older than 18 years
of age. Dr Gleeson could not provide us with these data as very few participants were older than 18
years of age.

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Quote: “Randomization was coordinated by the statistician (SC) and was
based on a computer-generated number list.” (p. 23)

Allocation concealment
(selection bias)

High risk

Quote: “Outcome ratings were made by the study research assistant (RA) who
was independent of the treatment, but not blind to treatment allocation be-
cause of limited resources for conducting the pilot study”. (p. 23)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: “Outcome ratings were made by the study research assistant (RA) who
was independent of the treatment, but not blind to treatment allocation be-
cause of limited resources for conducting the pilot study”. (p. 23)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Comment: attrition rates: HYPE + SFET, number of participants = 4/8 and SFET,
number of participants = 4/8. No reasons for attrition reported. 50% dropout
rate. High risk of bias. No report of imputation method (e.g. ITT, as treated).
Potential risk of bias. Summed up: High risk of bias

Selective reporting (re-
porting bias)

High risk

Comment: no report of primary or secondary outcomes in the study (unlike
the protocol)

Other bias

Unclear risk

Treatment adherence: Fidelity to CAT was managed by weekly group CAT su-
pervision provided by two trained CAT supervisors (AC and LMc). (p. 23)

Allegiance bias: Nothing found.

Attention bias: No report of duration of the SFET group.

Gratz 2006 

Study characteristics

Methods

14-week trial with 2 arms

1. Emotion regulation group intervention + treatment-as-usual (ERG + TAU)
2. Treatment-as-usual + waiting list (TAU + WL)

Duration of trial: 14 weeks

Country: USA

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gratz 2006  (Continued)

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Sample size: 25

Cochrane Database of Systematic Reviews

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV, Zanarini 1996)

Mean age: 33.3 years (standard deviation = 9.98)

Sex: 100% female

Comorbidity: participants excluded if they had comorbid diagnoses

Inclusion criteria

1. A history of repeated deliberate self-harm, with at least 1 episode in the past 6 months

Exclusion criteria

1. Diagnosis of a psychotic disorder
2. Bipolar I disorder
3. Substance dependence
4. Reporting one or more suicide attempts rated as having a high risk of death or greater within the past

6 months according to DIB-R (Zanarini 1989) rating

5. Reporting greater than some chance (i.e. the midpoint of the scale) of attempting suicide within the

next year according to DIB-R (Zanarini 1989) rating

Participation in a dialectical behavior therapy (DBT) skills group within the past 6 months

Interventions

Experimental group

Treatment name: ERG + TAU. 14 weekly, 1.5 hour sessions. Acceptance-based, behavioural group,
combining elements of acceptance and commitment therapy (ACT) and DBT as well as aspects of emo-
tion-focused psychotherapy and traditional behaviour therapy

Number randomised to group: 12

Duration: 14 weeks

Control/comparison group

Comparison name: TAU + WL

Number randomised to group: 10

Duration: 14 weeks

Both groups

Concomitant psychotherapy: Participants were required to have an individual therapist; average
number of individual therapy per week was 1.38 hours. 41% of therapists were clinical psychologists,
27% were psychiatrists, 32% were licensed clinical social workers.

Concomitant pharmacotherapy: All study participants continued with their current outpatient treat-
ment
over the course of the study.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: Unclear. Mean number of psychiatric medications at baseline: ERGT mean = 3.42, SD = 1.39; TAU
mean = 3.90, SD = 2.08 (table 1, p. 28), difference NS

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gratz 2006  (Continued)

Outcomes

Primary

Cochrane Database of Systematic Reviews

1. Borderline  personality  disorder  severity,  assessed  with  the  Borderline  Evaluation  of  Severity  over

Time (BEST)

2. Self-harming behaviour, assessed with the Deliberate Self-Harm Inventory (DSHI) - frequency score

Secondary

1. Affective instability, assessed with the emotion dysregulation subscale of the Difficulties in Emotion

Regulation Scale (DERS; Gratz 2004))

2. Impulsivity, assessed with impulse-control subscale of the (DERS)
3. Depression, assessed with the depression subscale of the Depression, Anxiety and Stress Scale (DASS)

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors:

1. Information about the randomisation procedure was received by email from Dr Gratz.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Participants [...] were matched on level of emotion dysregulation and
number of lifetime incidents of self-harm and randomly assigned to either the
group treatment plus TAU condition or the TAU waitlist condition." (p. 27)

Allocation concealment
(selection bias)

Unclear risk

Comment: No information

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: "Research team members were not blind to condition; however, all
outcome measures were self-report, and there was limited interaction be-
tween participants and assessors." (p. 30)

Outcomes are not likely to be influenced by lack of blinding.

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Comment: per protocol (EG: N = 16, CG: N = 12). 24 participants were includ-
ed and randomised, there were 2 dropouts (one from each condition), with no
reasons given. Final analyses referred to N = 22 patients, N = 12 in EG, N = 10 in
TAU condition.

Selective reporting (re-
porting bias)

Unclear risk

Comment: no indication of selective reporting, but Insufficient information to
permit judgement of 'high' or 'low'

Other bias

High risk

Performance bias: Treatment approach was developed by the first author
who was also the therapist; no further information.

Allegiance bias: First author developed the treatment approach.

Attention bias: more attention paid to ERGT participants

Gratz 2014 

Study characteristics

Methods

14-week trial with 2 arms

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gratz 2014  (Continued)

Cochrane Database of Systematic Reviews

1. Emotion regulation group therapy (ERGT) for self-harm + treatment-as-usual (TAU)
2. Treatment-as-usual

Duration of trial: 14 weeks. On average, 29 days from randomisation to initial assessment + 14 weeks
of treatment + 9 months of follow-up
Country: USA

Setting: outpatient

Participants

Method of recruitment of participants: referral through clinicians and self-referral

Sample size: N = 61

Number of participants screened: 91

Number of participants included: ERGT + TAU = 31, TAU = 30. 100% female

Number of participants followed up: 57

Number of withdrawals: (reason) 5 for ERGT + TAU, 3 for TAU. Reasons in ERGT + TAU: too busy/oth-
er responsibilities (n = 3) , moved away (number of participants = 1), not interested (n = 1). Reasons in
TAU: could not be reached (n = 2) and not interested (n = 1)

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV; Zanarini 1996)

Mean age: ERGT + TAU: 33.3 years, SD = ± 11), TAU: 33.0 years (± 10.9)

IQ: NR

Ethnicity: ethnic minority ERGT + TAU: 16.1%, TAU: 26.7%

Comorbidity: mood disorders, substance use disorder, anxiety disorder, PTSD, eating disorder, Cluster
A, B, C PD

Inclusion criteria

1. Threshold or subthreshold diagnosis of borderline personality disorder
2. A history of repeated deliberate self-harm, with at least 1 episode in the past 6 months
3. Having an individual therapist, psychiatrist or case manager
4. Being a woman
5. Aged 18–60 years

Exclusion criteria

1. Diagnosis of a primary psychotic disorder, bipolar I disorder and current (past month) substance de-

pendence

Experimental group
Treatment name: ERGT + TAU
Number randomised to group: 31
Duration: 90 minutes per week over 14 weeks
Concomitant psychotherapy: yes, ongoing outpatient therapy
Concomitant pharmacotherapy: 1.9 units of psychiatric medication on average per pretreatment. No
information regarding patient

Control/comparison group
Comparison name: TAU
Number randomised to group: 30
Duration: average of 15 months of treatment prior to trial. 14 weeks in trial
Concomitant psychotherapy: TAU consisted of a variety of different psychotherapies

Interventions

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gratz 2014  (Continued)

Concomitant pharmacotherapy: allowed (no further details)

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: Unclear. Mean number of psychiatric medications at baseline: ERGT + TAU 1.9, SD = 1.7; TAU 2.1,
SD = 1.2

Outcomes

Primary

1. BPD severity, assessed by the Zanarini Rating Scale for Borderline Personality Disorder
2. Self-harm, assessed by the Self-Harm Inventory
3. Mental health status, assessed by the Sheehan Disability Scale

Secondary

1. Affective instability, assessed by non acceptance subscale of the Difficulties in Emotion Regulation

Scale (DERS)

2. Impulsivity, assessed by the impulse subscale of the DERS
3. Interpersonal problems, assessed by the borderline personality disorder-related composite of the In-

ventory of Interpersonal Problems

4. Depression, assessed by the Beck Depression Inventory – Second Edition
5. Attrition, in terms of patients lost after randomisation in each group

Notes

Risk of bias

Bias

Sample size calculation: not stated
Ethics approval: yes

Comments from review authors

1. Study could be underpowered due to low sample size
2. Differences in some demographic variables at baseline

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Quote: “…and randomly assigned by the principal investigator (PI) to either
the ERGT + TAU (number of participants = 31) or TAU waitlist (number of partic-
ipants = 30) condition using a stratified randomization procedure.” (p 2100)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: no clear information provided

Low risk

Low risk

Quote: “All assessments were conducted by trained assessors masked to par-
ticipant condition”. (p 2103)

Quote: “We adopted a Bayesian approach to growth modeling (Zhang et al.
2007) and fit the models using the Markov chain Monte Carlo routines in Mplus
(Muthén & Muthén, 1998–2010) using N(0,1010) priors for the intercepts and
paths from Condition to the factors, and G–1 (−1,0) priors for the error vari-
ances. This approach implements a multiple imputation strategy to handle
missing data (Enders, 2010), enabling an analysis of the intent-to-treat (ITT)
sample.” (p 2104)

Selective reporting (re-
porting bias)

Unclear risk

Comment: no protocol was available to enable a clear judgement to be made.

Other bias

High risk

Treatment adherence: “The PI reviewed all group sessions for adherence
and competence (with 25% rated by an independent trained rater with good
reliability; κ = 0.90 for adherence ratings and ICC = 0.86 for competence rat-

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

165

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gratz 2014  (Continued)

Cochrane Database of Systematic Reviews

ings).” (p. 2103). Project therapists were adherent to the protocol, with an av-
erage of 8.1 ± 1.1 of the encouraged elements discussed in each group and on-
ly one minor non-protocol event recorded."; (p 2104).

Allegiance bias: First author has developed the treatment in the experimental
group.

Attention bias: Tau participants had received, on average, 15 months of treat-
ment prior to participation, and 54% received < 1 hour a week during treat-
ment, compared to no reports on previous treatment in ERGT group, which re-
ceived 90 minutes weekly psychotherapy.

Gregory 2008b 

Study characteristics

Methods

12 months trial with 2 arms

1. Dynamic deconstructive psychotherapy (DDP)
2. Treatment-as-usual (TAU)

Duration of trial: 12 months

Country: USA

Setting: outpatient

Participants

Methods of recruitment of participants: clinical setting

Sample size: 30

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: 28.7 years (standard deviation = 7.7)

Sex: 80% female

Comorbidity: comorbid diagnosis of active alcohol abuse or dependence (not in full sustained remis-
sion) required for inclusion

Incluson criteria

1. 18 to 45 years
2. Diagnosis of borderline personality disorder
3. Active alcohol dependence or abuse

Exclusion criteria

1. Schizophrenia
2. Schizoaffective disorder
3. Mental retardation
4. Neurological condition that may produce secondary psychiatric symptoms (e.g. stroke, multiple scle-

rosis, partial complex seizures, or traumatic brain injury)

Interventions

Experimental group

Treatment name: DDP

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gregory 2008b  (Continued)

Number randomised to group: 15

Duration: 12 months (post-treatment), weekly individual

Control/comparison group

Comparison name: TAU

Number randomised to group: 15

Duration: 12 months (post-treatment)

Both groups

Concomitant psychotherapy: If not already in treatment, TAU patients were referred to an alcohol re-
habilitation centre and given names of clinics and therapists in the community. If they had one, TAU
participants were allowed to keep their current psychotherapist. DDP participants were required to
end treatment with their present psychotherapist, unless that person served primarily as a case man-
ager or substance use counsellor. 70.0% of participants received individual psychotherapy or alcohol
counselling, 30.0% received an additional professional group therapy, 36.7% participated in self-help
groups.

Concomitant pharmacotherapy: 63.3% of all participants received separate medication manage-
ment. The mean number of psychotropic medications was 2.9. Medication management was provided
by the DDP therapist for patients in the DDP group according to the American Psychiatric Association
guidelines for borderline personality disorder. Medications specifically targeting substance use disor-
ders were not prescribed.

[The] “average number of psychotropic medications used during first 12 months of treatment: control
group, mean number N = 2.67, SD 1.45; DDP mean number N = 2.34, SD = 1.61" (Gregory 2010, p. 293).

75% of both groups were taking psychotropic medications during the follow-up period; average num-
ber of psychotropic medications used: control group mean number = 1.88 (SD = 1.55), DDP group mean
number = 1.63 (SD = 1.30) (Gregory 2010, p. 294).

Number of psychotropic medications at end of treatment: DDP 2.0 (SD 1.56), TAU 2.89 (SD 1.69) (Grego-
ry 2008, Tab. 2, p. 33).

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: n (%) receiving separate medication management: DDP 0%, TAU 56% (Gregory 2008, Tab. 2, p. 33)

Outcomes

Primary

1. BPD severity, assessed with the Borderline Evaluation of Severity Over Time (BEST)
2. Self-harming behaviour, assessed by the number of patients with parasuicide in the previous 3-month

period

Secondary

1. Dissociation/stress-related paranoia, assessed with the Dissociative Experiences Scale (DES)
2. Depression, assessed with the depression subscale of the The Depression, Anxiety and Stress Scale

(DASS)

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

167

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gregory 2008b  (Continued)

Random sequence genera-
tion (selection bias)

Low risk

Cochrane Database of Systematic Reviews

Quote: "A minimization method was employed for group assignment [...] en-
suring comparability of the two groups on key variables or factors [...] The spe-
cific factors that we adjusted for included: age, gender, alcohol abuse versus
dependence, current alcohol use, antisocial personality disorder, inpatient uti-
lization, and number of parasuicides." ( p. 31-32)

Allocation concealment
(selection bias)

Low risk

Quote: "participants were assigned by the research coordinator to either the
investigation treatment or to treatment-as-usual (TAU) in the community". (p.
31)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Quote:"An independent, trained research assistant administered the prima-
ry and secondary outcome measures [...] blind to treatment group at the time
of interviews, but blindedness was only partial, as she was able to correctly
guess group assignment 67% of the time (50% correct guesses were expected
by chance alone)." (p. 35)

Comment: the authors conducted per protocol analyses (EG: 10/15 allocated;
CG: 9/15 allocated).

Selective reporting (re-
porting bias)

Low risk

Comment: a study protocol is available (NCT00145678) and there were no in-
dications of selective reporting

Other bias

High risk

Performance bias: "Six therapists provided DDP, including the principal inves-
tigator [who is one of the two developers of DDP] (PI; N = 6 study participants)
and five psychiatry residents (N = 9 participants) who were in their third year
of residency training [...] After achieving competency, adherence to technique
and treatment integrity for resident therapists was assured through weekly
group supervision [...] and individual supervision of videotaped sessions with
the PI [principal investigator, developer of DDP] every other week throughout
treatment." (Gregory 2008b, p. 34)

Allegiance bias: Both developers of the experimental treatment were among
the study authors.

Attention bias: Though participants of the control group did not receive an al-
ternate, obligatory control treatment, but were free to join alternative treat-
ments, they did not receive less professional attention.

"[...] DDP participants received fewer overall treatment contact hours than did
participants receiving community care." (p. 39). Also cf. Tab. 2, p. 33.

Haeyen 2018 

Study characteristics

Methods

3-month trial with 2 arms

1. Art therapy (AT)
2. Waiting list (WL)

Duration of trial: 3 months
Country: The Netherlands

Setting: specialised outpatient treatment unit for personality disorders

Participants

Method of recruitment of participants: participants recruited from a waiting list of patients targeted
for PD treatment in a specialised outpatient treatment unit for personality disorders

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

168

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Haeyen 2018  (Continued)

Cochrane Database of Systematic Reviews

Sample size: subsample data = 26
Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
Mean age: no data for subsample. Mean age of dropouts from full sample = 40.35 years (standard devi-
ation = 10.03), mean age of completers from full sample = 36.6 years (standard deviation = 10.52)
Sex: no data for subsample. Approximately 70% in the full sample

Comorbidity: no data on comorbidity in subsample data. Full sample data: paranoid personality disor-
der (AT = 2.6%, WL = 2.8%); narcisstic personality disorder (AT = 2.6%, WL = 0%); borderline personality
disorder (AT = 36.8%, WL = 27.8%); obsessive compulsive personality disorder (AT = 10.5%, WL = 8,3%);
dependent personality disorder (AT = 13.2%, WL = 8.3%); avoidant personality disorder (AT = 15.8%, WL
= 25%); unspecified personality disorder (AT = 18.4%, WL = 27.8%); cluster B (AT = 36.8%, WL = 27.8%);
cluster C (AT = 23.7%, WL = 36.1%); cluster not otherwise specified (AT = 18.4%, WL = 27,6%); 1 personal-
ity disorder (AT = 71.1%, WL = 75%); 2 or more personality disorders (AT = 23.7%, WL = 22.2%)

Inclusion criteria

1. Adults (18+ years) with a primary diagnosis of at least one Axis II Personality Disorder cluster B and/or

C or a personality disorder not otherwise specified (APA 2013),

Interventions

2. An IQ > 80,
3. An adequate mastery of the Dutch language

Exclusion criteria

1. Acute crisis
2. Psychosis
3. Actual and serious suicidal behavior and/or thought
4. Severe brain pathology

Experimental group
Treatment name: art therapy
Number randomised to group: 15
Duration: 3 months

Control/comparison group
Comparison name: waiting list
Number randomised to group: 11
Duration: 3 months

Both groups
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: not stated

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Psychosocial functioning, assessed by the Outcome Questionnaire-45 (OQ-45), total score

Secondary

1. Interpersonal problems, assessed by the Outcome Questionnaire-45 - interpersonal subscale (OQ-45-

I)

2. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes
Ethics approval: yes. Patients who agreed to participate signed the informed consent form approved
by the Medical Ethics Committee of Radboud University.

Comments from review authors:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Haeyen 2018  (Continued)

Risk of bias

Bias

1. We contacted Dr Haeyen in June 2018 asking for more data on some of the outcome scales (number

of patients and means and SD). We received subsample data on 18 August 2018.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Comment: patients who agreed to participate signed the informed consent
form approved by the Medical Ethics Committee of Radboud University and
were assigned randomly to either the experimental or the control group, using
dice (p 3). Randomisation by simple randomisation (dice). Full sample would
be low risk of bias. However, due to the usage of subsample data, we do not
know whether the participants are equally distributed between arms.

Allocation concealment
(selection bias)

Unclear risk

Comment: it was unclear from the reporting who administered the randomi-
sation and how allocation was handled.

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Comment: the outcome assessors were not blind to the intervention.

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Selective reporting (re-
porting bias)

High risk

Comment: dropout must be analysed to make sure that the results of the GLM
repeated measures are not an artifact of a special type of patient quitting the
intervention. There were 17 (23%) patients who quit and 57 (77%) who com-
pleted the intervention. No imputation method used for the 17 who dropped
out. Full sample should be high risk of bias. We compared future dropouts with
completers using observations from the pre-test. Dropouts did not significant-
ly differ from completers on age, dropouts M = 40.35, SD = 10.03; completers
M = 36.6, SD = 10.52, t(72) = 1.31; gender, dropouts 58.8% women, completers
73.7% women, X2(1, n = 74) = 1.38; number of PD diagnoses, dropouts 76.5% 1
PD, 17.6% 2 PDs, completers 71.9% 1 PD, 24.6% 2 PDs, X2(2, n =74) = 0.49; the
distribution of cluster B/C personality disorders, dropouts 41.2% B, 23.5% C,
17.6% NOS, completers 29.8% B 31.6% C, 24.6% NOS, X2(5, n = 74) = 2.92, P >
0.05; and the OQ-45 Total score, dropouts M = 84.41, SD = 16.73, completers
M = 86.33, SD = 22.46, t(72) = 0.33. These results indicate that dropouts can be
considered random and thus will not bias the conclusions. (p 6-7)

Comment: There was no mention of one outcome that would possibly have
been of interest (Dutch Mental Health Continuum-Short Form (MHC-SF)) in the
full report stated as outcomes in trial registry. The authors also failed to follow
the primary and secondary outcome distinctions from the protocol in the full
report.

Other bias

High risk

Adherence to treatment: There was no mention of adherence check-up.

Attention bias: The intervention was compared to a waiting list control.

Allegiance bias: The first author, SH, is the author of an Art Therapy book on
which the protocol was based.

Harned 2014 

Study characteristics

Methods

1-year trial with 2 arms

1. Dialectical behavior therapy (DBT) + Dialectical behavior therapy Prolonged-Exposure (DBT-PE)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Harned 2014  (Continued)

2. Dialectical behavior therapy (DBT)

Duration of trial: 1-year intervention
Country: USA

Setting: outpatient clinic

Cochrane Database of Systematic Reviews

Participants

Method of recruitment of participants: individuals seeking treatment at the clinic, flyers and out-
reach to area treatment providers
Sample size: 26

Interventions

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: International Personality Disorder Examination (IPDE, Loranger 1988)
Mean age: 32.6 years (range = 19-55)
Sex: 100% female

Comorbidity: patients had PTSD, any mood disorder, any anxiety disorder other than PTSD, any eating
disorder, any substance use disorder

Inclusion criteria

1. Meets criteria for borderline personality disorder + post-traumatic stress disorder (PTSD)
2. Female
3. Age 18-60
4. Remember at least some part of the index trauma
5. Recent and recurrent self-injury
6. Lives within commuting (transport) distance from clinic

Exclusion criteria

1. Psychosis, bipolar, mental retardation
2. Legally mandated to treatment
3. Required primary treatment for another debilitating condition

Experimental group 
Treatment name: dialectical behavior therapy (DBT) + dialectical behavior therapy prolonged-expo-
sure (DBT-PE)
Number randomised to group: 17
Duration: 1 year
Control/comparison group 
Comparison name: dialectical behavior therapy (DBT)
Number randomised to group: 9
Duration: 1 year

Both groups 
Concomitant psychotherapy: no
Concomitant pharmacotherapy: yes, allowed. A “…minimization randomisation procedure […] was
used to match participants on […] current use of SSRI medication.” (p. 10 et seq.)

“The standard DBT pharmacotherapy protocol, which makes tapering off psychotropic medications
a treatment goal (but not a requirement), was used for all medications except SSRIs. Given that SSRIs
are an empirically supported treatment for PTSD, patients on SSRIs were asked to either taper off the
medication before starting the DBT-PE protocol or remain at a constant dose during the DBT-PE pro-
tocol portion of the treatment. Psychotropic medications were prescribed by community (non-study)
providers.” (p 10)

No difference in psychotropic medication use at baseline among groups (DBT: 87.5%, DBT + DBT-PE:
88.2%

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Harned 2014  (Continued)

Cochrane Database of Systematic Reviews

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Self-harm, assessed by non-suicidal, self-injury scale
2. Suicide-related outcomes, assessed by the suicide attempt self-injury review
3. Mental health status, assessed by the Global Severity index (GSI)

Secondary

1. Dissociation and psychotic-like symptoms, assessed by the Dissociative Experiences Scale Taxono-

my(DES)

2. Depression, assessed by Hamilton Depression Rating Scale for depression (HRDS)
3. Attrition

Sample size calculation: no
Ethics approval: yes.

Comments from review authors:

1. Information about whether or not the outcome assessors were blinded was received by email from

Dr Harnad.

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Comment: a minimization randomization procedure was used to match par-
ticipants on five primary prognostic variables: (1) number of suicide attempts
in the last year, (2) number of NSSI episodes in the last year, (3) PTSD severity,
(4) dissociation and (5) current use of SSRI medication

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Comment: no clear information was provided on allocation concealment.

Low risk

Low risk

Comment: all assignments were conducted by independent clinical assessors
who were blind to treatment conditions.

Comment: analyses were based on ITT and there seemed not to be any sys-
tematic reason influencing dropout rates which were overall similar in both
treatment arms.

Low risk

Comment: matched study protocol NTR3925

Other bias

High risk

Treatment adherence: the DBT adherence measure was used to code a ran-
dom selection of 10% of all DBT sessions for adherence. Results indicated that
on average therapists in both conditions delivered adherent DBT (M´s = 4.1,
SD = 0.2, ICC = 0.99) and adherence ratings did not differ by condition (t(93) =
0.3, P = 0.80)… DBT PE sessions were also delivered with ‘Excellent’ adherence
to the protocol.

Allegiance bias: Linehan developed DBT and is the last author.

Attention bias: DBT-PE received more attention than DBT alone.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

172

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jahangard 2012 

Study characteristics

Methods

4-week trial with 2 arms

1. Emotional intelligence training (EIT)
2. Treatment-as-usual (control group)

Duration of trial: 4 weeks
Country: Iran

Setting: inpatient

Participants

Method of recruitment of participants: inpatients at the Farshchian Psychiatric Center of Hamadan
were approached.
Sample size: 30

Diagnosis of borderline personality disorder: evaluated with Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition (DSM-IV)
Means of assessment: Millon Clinical Multiaxial Inventory, 3rd edition (MCMI-III) and a score on the
subscale “Personality Disorders” of the MCMI-III of at least 84. Base rate (cut-off score) on the Hamilton
Depression Rating Scale
Mean age: 24.63 years (range = 18-35)
Sex: 53% female

Comorbidity: generalised anxiety disorder (GAD), post-traumatic stress disorder (PTSD), current sub-
stance dependence, and other affective disorders

Inclusion criteria

1. Diagnosed with borderline personality disorder with depression by psychiatrists according to DSM-

IV criteria

2. Except major depressive disorder, lack of other axis I psychiatric disorders based on the clinical psy-
chiatric interview such as Generalised Anxiety Disorder (GAD), Post-traumatic Stress Disorder (PTSD),
current substance dependence, and other affective disorders such as bipolar I and II disorders of dys-
thymia

3. Borderline personality disorder via Millon Clinical Multiaxial Inventory, 3rd Edition (MCMI-III) and score
on the subscale ‘personality disorders’ of the Millon Clinical Multiaxial Inventory, 3rd Edition (MCMI-
III) of at least 84 (cut-off score)

4. Aged 18-35
5. No history of previous hospitalisations or treatments
6. Educational level to third grade

Exclusion criteria

1. Refusal to participate in emotional intelligence components training or discharge from hospital with

personal satisfaction before starting the emotional intelligence training prevention

Experimental group
Treatment name: emotional intelligence training
Number randomised to group: 15
Duration: 4 weeks, at least 3 sessions (45-minute/session) per week
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: at baseline, all had antidepressants (SSRI), and 8/15 had benzodi-
azepines

Control/comparison group
Comparison name: control group
Number randomised to group: 15
Duration: 4 weeks

Interventions

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jahangard 2012  (Continued)

Cochrane Database of Systematic Reviews

Concomitant psychotherapy: no psychoeducation, and no instructions in improving emotional intelli-
gence or other interventions, which might be considered as a supportive psychotherapy
Concomitant pharmacotherapy: “All patients were pharmacologically treated with SSRIs for depres-
sive disorders, and, if necessary, with benzodiazepines in case of acute sleep difficulties.” (p. 199) At
baseline, all had the antidepressants, selective serotonin reuptake Inhibitors (SSRIs).

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: all took SSRIs, benzodiazepines were taken by 87.5% of the EIT group and 66.7% of the control
group (P = 0.44)

Outcomes

Secondary

1. Depression, assessed by the Hamilton Depression Rating Scale
2. Attrition, in terms of patients lost after randomisation in each group

Notes

Risk of bias

Bias

Sample size calculation: no
Ethics approval: yes

Comments from review authors:

1. Information about the randomisation procedure, allocation concealment, missing data and whether

or not the outcome assessors were blinded was received by email from Dr Brand.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "We used a simple sample random software: http://www.secutri-
al.com/blog/2012/05/21/randomisierungen-in- secutrialr/". (Jahangard 2012)
[pers comm]

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

Low risk

Quote: "patients got codes known only to the study supervisor not otherwise
involved in the assessment or intervention". (Jahangard 2012) [pers comm]

Quote: "Raters of the outcome variables were unaware of patients' group allo-
cations".(Jahangard 2012) [pers comm]

Quote: "All patients sticked on the study conditions, accordingly, we had no
missings".(Jahangard 2012) [pers comm]

Selective reporting (re-
porting bias)

Unclear risk

Comment: Outcomes were identical in protocol and publication. However, in
the protocol primary and secondary outcomes were stated and not in the pub-
lication.

Other bias

Unclear risk

Treatment adherence: no information on treatment adherence was provided.

Allegiance bias: no indication of bias

Attention bias: no indication of bias

Vested interest: no indication of bias

Jochems 2015 

Study characteristics

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jochems 2015  (Continued)

Methods

12-month trial with 2 arms

1. Motivation feedback
2. Standard treatment or treatment-as-usual (TAU)

Duration of trial: 12 months
Country: The Netherlands

Setting: Outpatient

Cochrane Database of Systematic Reviews

Participants

Method of recruitment of participants: “Subsequently, clinicians were asked to provide their case-
load to the PI, who randomly selected ten eligible patients for participation (or if fewer than ten eligible
patients were available, all the eligible patients were selected). Clinicians explained to the selected pa-
tients the contents and procedure of the study and asked for participation. To enhance the likelihood
of participation, patients were given an incentive of €15 for participating.“ (quote, p 3053)
Sample size: subsample = 42
Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: “As diagnosed by the psychiatrist of the team using the Diagnostic and Statis-
tical Manual of Mental Disorders-Text Revision [fourth edition] criteria and obtained from the medical
record” (quote, p 3050-51)
Mean age: no data on subsample. Full sample: motivation feedback = 45.47 years (standard deviation =
10,4), TAU = 42.5 years (standard deviation = 10)
Sex: not stated
Comorbidity: no data on subsample; “Our sample largely represents a broad population of outpa-
tients with diagnoses of psychotic and personality disorders with a variety of comorbid psychiatric dis-
orders”. (quote, p 3061)
Inclusion criteria

1. As diagnosed by the psychiatrist of the team using DSM-IV-TR (text revision) criteria and obtained from

medical records

2. Aged between 18 and 65 years
3. Received individual outpatient treatment for their mental disorder

Exclusion criteria

1. Insufficient command of the Dutch language (which was estimated by the clinician who was most

frequently involved with the patient)

2. A documented diagnosis of dementia or chronic toxic encephalopathy

Interventions

Experimental group
Treatment name: motivation feedback
Number randomised to group: subsample = 16
Duration: 12 months
Control/comparison group

Comparison name: treatment-as-usual
Number randomised to group: subsample = 26
Duration: 12 months
Both groups

Concomitant psychotherapy: outpatient care
Concomitant pharmacotherapy: no data on subsample

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Mental health status, assessed by the Dutch version of the Health of the Nations Outcome Scales (HoN-

OS)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jochems 2015  (Continued)

Notes

Sample size calculation: yes
Ethics approval: “This study was approved by the Medical Ethical Committee for Mental Health Care
Institutions (MotivaTe-IT; trial number NTR2968, Netherlands Trial Register, http://www.trialregis-
ter.nl/trialreg/admin/rctview.asp?TC=2968) as well as by the scientific committees of the Western
North Brabant Mental Health Center and Breburg Mental Health Center, the specialty mental health in-
stitutions where the data were collected.” (quote, p 3050)
Comments from review authors:

1. To enhance the likelihood of participation, patients were given an incentive of €15 for participating

(p 3053).

2. We received subsample data on the patient with a BPD diagnosis by email from Dr Jochems on 2 July

2018.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: "a computer-generated list of random numbers was used to random-
ly assign each team to a treatment condition, such that all clinicians and pa-
tients in the same team were randomized to a similar treatment". (p. 3053).
"The randomization sequence was created using software from www.random-
ization.org with a 1:1 allocation ratio using random block sizes of 1, 2, and 3".
(p. 3053)

Quote: "the random allocation sequence was performed by authors ECJ and
HJD prior to approaching treatment teams, such that treatment teams and
their members were still unknown and were numbered blindly before entering
team numbers into the computer program". (p. 3053)

Quote: “At baseline, patients were unaware (blind) as to which treatment con-
dition they had been randomized to. Clinicians had to be made aware of treat-
ment condition as those randomized to MF needed to receive the necessary
training prior to baseline assessments such that MF could start immediately
thereafter. This blinding procedure is common in psychiatric intervention re-
search. At the 12-month assessment, clinicians and patients were not blind to
treatment condition while filling in questionnaires, whereas independent re-
search assistants who looked up information from the medical record and per-
formed interviews with patients were blind to treatment allocation.” (p.3053)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: skewed dropout population of non-ethnic Dutch participants in full
sample. Only observer data used. Unclear handling of data on subsample data

Selective reporting (re-
porting bias)

Low risk

Comment: a protocol was available and the details matched those presented
in the report.

Other bias

Unclear risk

Adherence bias: Adherence to treatment: Patients and clinicians in the MF in-
tervention group were asked to fill in a Short Motivation Feedback List (SMFL)
every month up to 12 months after baseline assessment. (p. 3051). Clinicians
were free to decide for themselves how they would structure this conversation
with the patient, such as discussing only one item or several, or discussing dif-
ferences between patient’s and clinician’s vision, and they were free to decide
how long this would take. The duration and frequency of SMFL assessments
were monitored by the research team. (p. 3051) During the course of the study,
clinicians were regularly contacted by the PI to monitor the MF intervention
and to discuss progress and experiences together with other colleagues who
also participated in the MF intervention. These evaluation sessions took place
four times over the course of the study. (p.3051) We did not seek for uniformity
in TAU as such diversity reflects reality. (p.3051); although we performed eval-

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jochems 2015  (Continued)

Cochrane Database of Systematic Reviews

uation sessions with clinicians about MF alongside the trial, we have limited
insight into what happened during MF sessions as these were neither recorded
nor supervised. (p 3061).

Attention bias: There was no control on the amount of treatment received in
the TAU group, but that was intended from the authors to test the real life set-
ting of psychotherapy.
Allegiance bias: no evidence of allegiance bias found

Jørgensen 2013 

Study characteristics

Methods

18-24 month trial with 2 arms

1. Combined mentalisation based therapy (MBT)
2. Supportive group treatment

Duration of trial: 18-24 months
Country: Denmark

Setting: outpatient

Participants

Method of recruitment of participants: referred from outpatient clinics, community psychiatric
wards, and psychiatrists in private practice
Sample size: 111
Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-III)

Mean age: MBT = 29.2 years (standard deviation = 6.1), supportive group = 29 years (standard deviation
= 6.4)
Sex: 95-96% female
Comorbidity: In the group of patients allocated to mentalisation based therapy (MBT) treatment, 53
(72%) met diagnostic criteria for depression (9 in remission at the time of assessment), 27 (37%) met
criteria for anxiety disorder, 14 (19%) met criteria for an obsessive–compulsive disorder and 36 (49%)
for a (previous or current) eating disorder. On Axis II, 48 (65%) met criteria for at least 1 personality dis-
order other than borderline and 16 (22%) for avoidant personality disorder. In the supportive thera-
py group, 28 (76%) met criteria for depression (11 of these were in remission at assessment), 9 (24%)
met criteria for anxiety disorder, 5 (14%) for an obsessive–compulsive disorder and 14 (38%) for a (past
or current) eating disorder. 32 (86%) met criteria for at least 1 other personality disorder, 10 (27%) for
avoidant personality disorder

Inclusion criteria

1. DSM-IV BPD
2. age 21 years or over
3. GAF score above 34

Exclusion criteria

1. Diagnosis of antisocial or paranoid personality disorder at time of assessment
2. Severe substance abuse
3. Younger than 21 years

Interventions

Experimental group
Treatment name: combined mentalisation-based therapy (MBT)
Number randomised to group: 74
Duration: 18-24 months

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jørgensen 2013  (Continued)

Cochrane Database of Systematic Reviews

Control/comparison group
Comparison name: supportive group treatment
Number randomised to group: 37
Duration: 18-20 months

Both groups
Concomitant psychotherapy: yes, psychoeducational programme once a month for 6 months
Concomitant pharmacotherapy: all participants were offered medical treatment in accordance with
American Psychological Association recommendations

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: “…34% of patients in combined treatment and 48% of patients in supportive therapy had their
medication significantly reduced or withdrawn while in treatment (difference NS, P = 0.24). Only 16%
in combined and 7% in supportive therapy had their medical treatment intensified during the course of
treatment (difference NS, P = 0.49).“ (p. 312)

Outcomes

Primary

1. BPD severity, assessed by the Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
2. Psychosocial functioning, assessed by the Global Assessment of Functioning Scale (GAF)

Secondary

1. Interpersonal problems, assessed by the Inventory of Interpersonal Problems (IIP)
2. Depression, assessed by the Beck Depression Inventory (BDI)
3. Attrition

Sample size calculation: yes
Ethics approval: yes

Comments from review authors:

1. All clinically and statistically significant changes with regard to all symptoms were sustained at fol-

low-up in all outcome measures – no positive or negative changes at follow-up were observed.

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Unclear risk

Quote: “Two-thirds (n = 74) of the 111 patients included in the study were ran-
domized to combined treatment, while one-third (n = 37) were offered sup-
portive group therapy”. “The skewed randomization of patients (…), which
was dictated partly by a desire on the part of the clinic’s management to offer
intensive treatment to as many borderline patients as possible, and partly by
available treatment resources, reduced statistical power”. (p. 307)

Allocation concealment
(selection bias)

Unclear risk

Quote: “Randomization was conducted by individuals outside the clinic.”
"Group allocation was not concealed". (Jørgensen 2013) [pers comm]

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Quote: “(…)GAF score was then assessed by team consensus. The team was
not blind to treatment group when making these ratings as most patients were
known by the team.” (p. 309)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Quote: “Statistical power was further reduced by the relatively high attrition
rate (…) owing to some patients’ refusal to complete all assessments at the as-
signed time points.” “Attrition from the study is relatively high (approximately
43% of included patients with intention to treat, 26% of patients starting treat-
ment)”. “The level of attrition from the two groups was not significantly differ-
ent (Fisher’s exact test, P = .79).” (p. 315)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jørgensen 2013  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

Comment: there was no study protocol available to compare with the report.

Other bias

High risk

Adherence bias: "the two compared treatments were not based on detailed
treatment manuals and our design did not include ongoing systematic moni-
toring of the two treatment modalities (adherence and competence ratings)”.
(p 315)

Attention bias: The combined treatment consisted of 45-min sessions of indi-
vidual psychotherapy carried out weekly over an 18-month period and 1½-h
weekly sessions of group psychotherapy over 18–20 months (starting approxi-
mately 3 months after the individual therapy). Supportive treatment consisted
of one and a half hours of supportive group therapy every fortnight.

Allegiance bias: no allegiance found

Kamalabadi 2012 

Study characteristics

Methods

14-week trial with 2 arms

1. Dialectical behavior therapy couple (DBT-C)
2. Control group (waiting list)

Duration of trial: 14-week intervention
Country: Iran

Setting: outpatient

Participants

Method of recruitment of participants: referred by psychiatrists of Hafez, Ebne Sina and Razy hospi-
tals in Shiraz

Sample size: 30

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Borderline Personality Severity Index - Fourth Version (BPDSI-IV)

Mean age: not stated
Sex: 100% male

Comorbidity: not stated

Inclusion criteria

1. Married males with borderline personality disorder
2. Aged 18-50 years old

Exclusion criteria

1. Lifetime diagnosis of schizophrenia
2. Bipolar disorder
3. Dissociative identity disorder
4. Antisocial personality disorder
5. Drug addiction
6. Mental retardation

Interventions

Experimental group

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kamalabadi 2012  (Continued)

Cochrane Database of Systematic Reviews

Treatment name: DBT-C
Number randomised to group: 15
Duration: 14 weekly sessions

Control/comparison group
Comparison name: waiting list
Number randomised to group: 15
Duration: 14 weekly sessions

Both groups
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: not stated

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. BPD severity, assessed by the BPDSI-IV, total score
2. Suicide-related outcome, assessed by BPDSI-IV, parasuicidal subscale
3. Psychosocial functioning, assessed by the General Health Questionnaire (GHQ), functioning subscale

Secondary

1. Anger, assessed by the BPDSI-IV, anger subscale
2. Affective instability, assessed by the BPDSI-IV, affect subscale
3. Chronic feelings of emptiness, assessed by the BPDSI-IV, emptiness subscale
4. Impulsivity, assessed by the BPDSI- IV, impulsivity subscale
5. Interpersonal problems, assessed by the BPDSI-IV, interpersonal subscale
6. Abandonment, assessed by the BPDSI-IV, abandonment subscale
7. Identity disturbance, assessed by the BPDSI-IV, identity subscale
8. Dissociation and psychotic-like symptoms, assessed by the BPDSI-IV, dissociation subscale
9. Depression, assessed by the GHQ, depression subscale

Notes

Sample size calculation: not stated
Ethics approval: not stated

Comments from review authors:

1. Unclear whether this was, in fact, an RCT
2. A lot of missing information
3. Underpowered sample

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Comment: no information on random sequence generation

Unclear risk

Comment: no information provided on allocation concealment

Unclear risk

Comment: no clear information provided about blinding of outcome asses-
sors

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

180

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kamalabadi 2012  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Cochrane Database of Systematic Reviews

Comment: no information of how many were included and number of
dropouts. ANOVA was applied but data analysis was not specified and attrition
not reported.

Selective reporting (re-
porting bias)

Unclear risk

Comment: no protocol found, therefore we could not assess the risk of bias
due to selective reporting.

Other bias

High risk

Treatment adherence: no clear information provided

Allegiance bias: no indication of bias

Attention bias: more attention paid to the treatment group since control
group was waiting list with no intervention

Vested interest: no indication of bias due to vested interests

Koons 2001a 

Study characteristics

Methods

6-months trial with 2 arms

1. Dialectical behavior therapy (DBT)
2. Treatment-as-usual (TAU)

Duration of trial: 6 months

Country: USA

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Sample size: 28

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
3rd Edition, Revised (DSM-III-R)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: 35.0 years

Sex: 100% female

Comorbidity: excluded patients with several different comorbid diagnoses (see below)

Inclusion criteria:

1. women veterans meeting DSM-III-R criteria for BPD

Exclusion criteria

1. Schizophrenia
2. Bipolar disorder
3. Substance dependence
4. Antisocial personality disorder

Interventions

Experimental group

Treatment name: DBT

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Koons 2001a  (Continued)

Cochrane Database of Systematic Reviews

Number randomised to group: 14

Duration: 6 months (weekly individual therapy)

Control/comparison group

Comparison name: TAU

Number randomised to group: 14

Duration: 6 months (weekly individual therapy)

Both groups

Concomitant psychotherapy: all participants received individual psychotherapy (TAU: 4 of the thera-
pists described themselves as cognitive-behavioural in primary orientation, 2 as psychodynamic, and
2 as eclectic). Group psychotherapy was part of DBT treatment while TAU patients were offered several
group therapies at the hospital (4 out of 10 actually attended group therapy).

Concomitant pharmacotherapy: all participants were offered pharmacotherapy.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: “…all participants, except one in the DBT condition, received pharmacotherapy. In every case,
this included an SSRI, and, for some participants, also included a mood stabiliser and/or low-dose neu-
roleptic.” (p. 376) "Participants, except for 1 in the DBT condition, received pharmacotherapy, includ-
ing selective serotonin reuptake inhibitors (SSRIs) in each case and/or an additional mood stabiliser or
low-dose neuroleptic in "some" cases". (quote, p 376) Pharmacotherapy and psychotherapy were pro-
vided by separate clinicians in all but 1 TAU case.

Outcomes

Primary

1. Borderline personality disorder severity, assessed by DSM-III-R diagnostic criteria for borderline per-

sonality disorder

2. Self-harming behaviour, assessed by mean number of parasuicides in a 3-month period
3. Suicidality, assessed by Beck Scale for Suicide Ideation (BSS)

Secondary

1. Anger, assessed by State-Trait Anger Expression Inventory (STAXI)
2. Dissociation, assessed by Dissociative Experiences Scale (DES)
3. Depression, assessed by Beck Depression Inventory (BDI)

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Quote: "28 women were randomized to treatment." (p 374). No further infor-
mation given

Allocation concealment
(selection bias)

Unclear risk

Comment: no further details. 28 participants were randomised. 8 were not in-
cluded in analyses due to not completing treatment (reasons: 2 did not attend
the first appointment; 1 dropped out after the first appointment after realising
payment was for assessments only, not attending treatment; 2 in TAU and 3
in DBT dropped out after more than one appointment in the first half of treat-
ment citing distance from the medical centre as reason). Analyses referred to
N = 10 patients in the DBT and N = 10 patients in the TAU group.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Koons 2001a  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Quote: "Assesment interviews were conducted by two psychology interns who
[...] were unaware of subjects' treatment condition." (p 376)

High risk

Comment: analyses per protocol (EG: N = 10; CG: N = 10)

Selective reporting (re-
porting bias)

Unclear risk

Comment: no clear indication of selective reporting, but insufficient informa-
tion to permit judgement of 'high' or 'low'

Other bias

Low risk

Performance bias

Quote: EG therapists: "All [DBT therapists] attended the weekly consultation
group, and several received additional individual supervision from each other.
Two clinicians received supervision briefly from a senior trainer from Linehan's
group. [...] All individual and group sessions were videotaped for later coding
for adherence using the DBT Expert Rating Scale [...] At the end of treatment, a
sample of eight tapes from each therapist-patient dyad, including the first ses-
sion and seven others selected randomly, was coded for adherence." (quote,
p 377) CG therapists: "Five [out of eight TAU] clinicians [...] received weekly
supervision on their cases from attending psychiatrists or staff psychologist-
s." (quote, p 378)

Allegiance bias

Comment: no indication

Attention bias

Comment: equal amounts of attention paid to both groups

Kramer 2011 

Study characteristics

Methods

10-week trial with 2 arms

1. Motive-oriented therapeutic relationship + treatment as usual (MOTR + TAU)
2. Treatment-as-usual (TAU)

Duration of trial: 10 weeks
Country: Switzerland

Setting: outpatient clinic

Participants

Method of recruitment of participants: not stated

Sample size: 25

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: MOTR + TAU = 30.29 years (standard deviation = 12.43), TAU = 31.27 years (standard devia-
tion = 8.21)

Sex: 77% female

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kramer 2011  (Continued)

Cochrane Database of Systematic Reviews

Comorbidity: panic disorder, agoraphobia, alcohol abuse, major depression, bulimia, anorexia, so-
matoform disorder

Inclusion criteria

1. Main diagnosis of borderline personality disorder
2. Between 18 and 60 years old
3. Able to speak French

Exclusion criteria

1. An organic disorder
2. A  persistent  substance  abuse/dependence  that  might  affect  brain  function  (memory,  level  of  con-

sciousness, cognitive abilities)

3. A psychotic disorder implying pronounced break in reality testing (chronic or intermittent), such as

schizophrenia, delusional disorder, bipolar affective disorder I

Interventions

4. An acute risk of suicide
5. Severe cognitive impairment

Experimental group
Treatment name: MOTR + TAU
Number randomised to group: 11
Duration: 10 weeks
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: not stated

Control/comparison group
Comparison name: TAU
Number randomised to group: 14
Duration: 10 weeks
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: If necessary, short-term inpatient treatment was organised, as was
adjunct pharmacotherapy

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Psychosocial  functioning,  assessed  by  social  role  subscale  of  the  Outcome  Questionnaire  -  45.2

(OQ-45)

Secondary

1. Interpersonal problems, assessed by the interpersonal problem subscale of OQ-45
2. Attrition, in terms of patients lost after randomisation in each group

Sample size calculation: not stated
Ethics approval: The study was approved by the Ethics Committee of the Psychiatric Department in-
volved. All patients gave written consent for the data to be used for research purposes.

Comments from review authors: none

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Comment: randomisation was performed by blocks of 10 participants, using a
computer-based program

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kramer 2011  (Continued)

Cochrane Database of Systematic Reviews

Allocation concealment
(selection bias)

Low risk

Comment: The preparation of sealed envelopes containing information on the
condition for each participant was done by an independent researcher.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Comment: raters were unaware of the treatment condition.

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Comment: in case of missing values, LOCF used. The process analyses were
carried out on a restricted sample of 20 patients (TAU = 10; MOTR +TAU = 10),
due to missing values (related to early terminations) of 5 individuals having
completed too few sessions to be taken into account.

Selective reporting (re-
porting bias)

High risk

Comment: Borderline Symptoms List reported in the protocol did not appear
in the publication.

Other bias

High risk

Allegiance bias

Comment: Casper involved in the development of analysis plan

Attention bias

Comment: To counterbalance the increased time investment in condition 2,
the therapists in condition 1 filled in a summary form on the patient’s symp-
toms and problems.

Kramer 2014 

Study characteristics

Methods

10-session trial with 2 arms (endpoint data):

1. General psychiatric management (GPM)
2. Motive-oriented therapeutic relationship (MOTR)

Duration of trial: 10 sessions
Country: Switzerland

Setting: Outpatient

Participants

Method of recruitment of participants: not stated 
Sample size: 85

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: DSM-IV diagnoses of borderline personality disorder were established by
trained clinicians or clinician researchers for all patients using the Structured Clinical Interview (SCID-
II) for DSM-IV
Mean age: GPM = 30.95 years (standard deviation = 11). MOTR = 34.64 years (standard deviation = 9.97)
Sex: 68.2% female

Comorbidity: current DSM-IV diagnoses; depressive disorder = 56/74, anxiety disorder = 13/74, eating
disorder = 10/74, substance abuse = 54/74, intelligence limitation = 6/74, sexual disorder = 9/74, atten-
tion disorder = 4/74. Axis II cluster A = 11/74, Axis II cluster B = 23/74, Axis II cluster C = 12/74

Inclusion criteria

1. Presence of a DSM-IV diagnosis of borderline personality disorder
2. Aged between 18 and 65 years old at time of recruitment

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

185

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kramer 2014  (Continued)

Exclusion criteria

Cochrane Database of Systematic Reviews

1. Presence of a DSM-IV diagnosis of psychotic disorder, with mental retardation and substance abuse
at the forefront. Minimal exclusion criteria were formulated in order to increase the external validity
of the trial.

Interventions

Experimental group
Treatment name: GPM
Number randomised to group: 43; analysis on 38 only
Duration: 10 sessions; no further information
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: 23/38 (61%)

Control/comparison group
Comparison name: MOTR
Number randomised to group: 42; analysis on 36 only
Duration:10 sessions; no further information
Concomitant psychotherapy: not stated 
Concomitant pharmacotherapy: medication use at baseline: MOTR group 23/38 (61%), TAU group
21/36 (58%); χ2=.04, P = 0.84

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Borderline Symptom List (BSL-23)
2. Psychosocial functioning, assessed by the social role subscale of the Outcome Questionnaire – 45.2

(OQ-45)

Secondary

1. Interpersonal problems, assessed by the social role subscale of the OQ-45
2. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes

Ethics approval: The research protocol was approved by the local ethics board (clearance number
254/08), as well as the research committee of the university department.

Comments from review authors:

1. All demographic data were based on the 74 participants who completed the trial. Missing data on the

11 participants who dropped out before the session were not reported.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Comment: randomisation was performed using an internet-based block ran-
domisation program; sealed envelopes were prepared by an independent re-
searcher and opened when the patient accepted the study (p 179).

Allocation concealment
(selection bias)

Low risk

Comment: sealed envelopes were prepared by an independent researcher
and opened when the patient accepted the study (p 179).

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Comment: no information regarding blinding of outcome assessors

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

186

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kramer 2014  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Cochrane Database of Systematic Reviews

Comment: 11 participants dropped out before session two. No reasons pro-
vided. No reasons provided either for the 14 who discontinued the treatment.
No demographic data on the entire sample (number of participants = 85). Im-
putation method used = LOCF

Selective reporting (re-
porting bias)

High risk

Comment: Working Alliance Inventory – Short Form, a self-report question-
naire was presented in the full report but there was no mention of this out-
come in protocol.

Other bias

High risk

Treatment adherence

Comment: adherence was assessed at the end of each of the 40 treatments
(see p 180).

Attention bias

Comment: nothing found

Allegiance bias Ueli Kramer, Franz Caspar & Martin Drapeau are all heavily
linked to MOTR.

Vested interest

Comment: nothing found

Kramer 2016 

Study characteristics

Methods

1 year trial with 2 arms:

1. Dialectical behavior therapy (DBT) - informed skills training + TAU
2. Treatment-as-usual (TAU)

Duration of trial: 1 year
Country: Switzerland

Setting: outpatient

Participants

Method of recruitment of participants: Each recruitment wave was advertised within the psychiatry
department where the study took place, in addition to broader information in the community. In or-
der to be included in the treatment, the patients met with the programme-related researcher for 1 to 2
screening sessions, which explained to them the study and the group treatment programme.

Sample size: 41

Diagnosis of Borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: DBT-informed skills training + TAU = 35.14 years (standard deviations = 9.67), TAU = 33.60
years (standard deviations = 8.57)

Sex: 87.8% female

Comorbidity: current DSM-IV diagnoses of depressive disorder, anxiety disorder, eating disorder, sub-
stance abuse, intelligence limitation, sexual disorder, attention disorder, axis II cluster A, axis II cluster
B, axis II cluster C

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kramer 2016  (Continued)

Inclusion criteria

Cochrane Database of Systematic Reviews

Interventions

1. Having a Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV) (American Psy-

chiatric Association, 1994) borderline personality disorder diagnosis

2. Being older than 18 years of age at the time of recruitment
3. Willing to participate in a 20-session skills group therapy, in addition to their individual treatment

Exclusion criteria

1. Presence of a Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV) psychotic

disorder or mental retardation

2. Patients who had already previously benefited from any form of Dialectical behavior therapy (DBT)

treatment in their lives

Experimental group
Treatment name: DBT + TAU
Number randomised to group: 21
Duration: 1 year
Concomitant psychotherapy: Patients in both conditions received TAU, defined as individual treat-
ment (i.e. psychotherapy and psychiatric treatment).
Concomitant pharmacotherapy: medication = 15/21 (71%)

Control/comparison group
Comparison name: TAU
Number randomised to group: 20
Duration: 1 year
Concomitant psychotherapy: Patients in both conditions received TAU, defined as individual treat-
ment (i.e. psychotherapy and psychiatric treatment).

Concomitant pharmacotherapy:

“Psychopharmacological medication was available, if indicated, for all patients as part of the TAU (in
both psychiatric and psychotherapeutic models; Table 1). These frequencies were not different be-
tween the conditions [at baseline] (using chi-square statistics).“ (p.194)

Medication use at baseline: DBT-informed skills group 71%, TAU 65% (P = 0.66)

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Mental  health  status,  assessed  by  the  social  role  subscale  of  the  Outcome  Questionnaire  -  45.2

(OQ-45.2)

Secondary

1. Interpersonal problems, assessed by the interpersonal subscale of the OQ-45.2

Sample size calculation: yes 
Ethics approval: The research protocol was approved by the university and hospital research ethics
board.

Comments from review authors: none

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Comment: an internet-based, block randomisation program was used for
each of the 4 waves separately.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kramer 2016  (Continued)

Allocation concealment
(selection bias)

Low risk

Cochrane Database of Systematic Reviews

Comment: sealed envelopes containing the allocated condition were pre-
pared by an independent researcher and opened when a sufficient number of
patients were recruited to form 2 treatment skills groups, together composing
1 recruitment wave.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Comment: assessments and data handling were carried out mainly by 2 re-
search assistants, with the help of a third; all blinded to participants’ treat-
ment condition.

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: in all ITT analyses a total of 41 patients were included (DBT ITT n =
21; TAU ITT n = 20); in all completer analyses, 31 patients were included (DBT
completers n = 16; TAU completers n = 15); missing data resulted in the strat-
egy of LOCF. 10 participants discontinued treatment (5 from DBT and 5 from
TAU). It was not possible to collect research data for these patients at post-
treatment and follow-up assessment points; discontinuation, if applicable, oc-
curred between sessions 5 and 15.

Selective reporting (re-
porting bias)

Unclear risk

Comment: no protocol available

Other bias

Unclear risk

Treatment adherence

Comment: treatment attrition concerned 10 (24%) patients in total, 5 (24%)
for DBT and 5 (25%) for TAU. These numbers did not differ statistically (χ2(1) =
0.01, P = 0.93) and were below the average reported in the literature for treat-
ments lasting 1 year; moment of discontinuation was not different between
the groups. Due to missing questionnaires post-treatment, the data point at
the 3-month follow-up involved 33 observations (17 for DBT; 16 for TAU; 2 pa-
tients who had dropped out of treatment continued to fill in the question-
naires).

Allegiance bias

Comment: no apparent source of allegiance bias

Attention bias

Comment: appeared as if DBT participants were receiving more therapy time
and in a more structured way.

Vested interest

Comment: no apparent conflicts of interest

Kredlow 2017a 

Study characteristics

Methods

4-6 month trial with 2 arms

1. Cognitive-behavioural treatment (CBT)
2. Treatment-as-usual (TAU)

Duration of trial: 4-6 months
Setting: outpatient clinics

Participants

Method of recruitment of participants: orientation meetings at outpatient centers, referral from clin-
icians

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kredlow 2017a  (Continued)

Cochrane Database of Systematic Reviews

Sample size: 27 
Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
Mean age: 45.7 years (standard deviation = 9.6)
Sex: 96% female
Comorbidity: major depressive disorder = 67%, bipolar = 33%

Inclusion criteria

1. Aged 18 years or older
2. Severe mental illness diagnosis (i.e. DSM-IV, major depression, bipolar disorder, schizoaffective disor-

der, or schizophrenia) and current DSM-IV diagnosis of PTSD

Exclusion criteria

1. Psychiatric hospitalisation or suicide attempt in past 3 months
2. Current substance dependence

Interventions

Experimental group 
Treatment name: CBT
Number randomised to group: 15
Duration: 4-6 months
Control/comparison group 
Comparison name: TAU
Number randomised to group: 12
Duration: 4-6 months

Both groups 
Concomitant psychotherapy: yes, from local community centers
Concomitant pharmacotherapy: yes, from local community centers

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary:

1. Borderline personality disorder
2. PD severity, assessed by SCID-II for borderline personality disorder criteria
3. Mental health status, assessed by the Short Form-12 (SF-12)

Secondary

1. Dissociation and psychotic-like symptoms, assessed by the Brief Psychiatric Rating Scale (BPRS)
2. Depression, assessed by the Beck Depression Inventory (BDI)
3. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes

Ethics approval: yes

Comments from review authors:

1. participants  in  CBT  improved  significantly  more  in  PTSD  symptoms,  depression,  and  self-reported

physical health. Effects maintained 1-year post-treatment

2. We received some additional information from Dr Muser by email on 28 November 2017. He informed
us that the trial was not registered, no protocol had been published, and that they did not assess the
participants' IQ.

Risk of bias

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kredlow 2017a  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “Randomization was conducted at a central location in the research
center by a computer based randomization program with assignments not
known in advance by either clinical or research staff.”

Allocation concealment
(selection bias)

Low risk

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

Quote: “Randomization was conducted at a central location in the research
center by a computer based randomization program with assignments not
known in advance by either clinical or research staff. When a client had com-
pleted the baseline assessment and his or her eligibility for the study was con-
firmed, the interviewer called the research center and a member of the re-
search team obtained the randomized assignment from the computer. The
client was informed about the assignment by the project coordinator”.

Quotes: “All assessments were conducted by Masters or Ph.D. level trained
clinical interviewers who were blind to treatment assignment.”; “No specific
instances of blind breaking were noted in the study”.

Quote: “There were no differences between the groups on any demographic,
diagnostic, or baseline measures, nor in the rates of follow-up assessments".

Selective reporting (re-
porting bias)

Unclear risk

Comment: no protocol was published and so a clear judgement could not be
made.

Other bias

High risk

Treatment adherence

Quote: “No efforts were made to control or modify any of these services pro-
vided to study participants.”

Allegiance bias

Comment: KT Mueser is on the Committee on Research Agenda of the Associ-
ation for the Advancement of Behavior Therapy, and the Task Force on Empiri-
cally Validated Treatments of the American Psychological Association, Division
12 (www.bu.edu/sargent/files/2013/05/MueserCV.pdf).

Attention bias

Comment: 12-16 sessions for EG, no information on length of TAU intervention

Vested interest

Comment: funded by National Institute of Mental Health

Kredlow 2017b 

Study characteristics

Methods

4-6 month trial with 2 arms

1. Cognitive-behavioural treatment (CBT)
2. Brief treatment: breathing, re-training, educational components like CBT, but without cognitive re-

structuring

Duration of trial: 12-16 weeks
Country: USA

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kredlow 2017b  (Continued)

Setting: partial hospital programmes and outpatient programmes

Participants

Method of recruitment of participants: contacted following administration of trauma and PTSD
screening at 5 clinic sites

Sample size: 55

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: 40.4 years (standard deviation = 9.5)

Sex: 78.2% female

Inclusion criteria

1. Aged 18 years or older
2. Severe mental illness diagnosis (i.e. DSM-IV, major depression, bipolar disorder, schizoaffective disor-

der, or schizophrenia) and current DSM-IV diagnosis of PTSD

Interventions

3. criteria for severe PTSD

Exclusion criteria

1. Psychiatric hospitalisation or suicide attempt in past 3 months
2. Current substance dependence

Experimental group
Treatment name: CBT
Number randomised to group: 29
Duration: 12-16 weeks
Control/comparison group
Comparison name: brief treatment programme
Number randomised to group: 26
Duration: 3 sessions

Both groups
Concomitant psychotherapy: all continued to receive case management/usual psychiatric services
(see p 502).
Concomitant pharmacotherapy: all continued to receive pharmacological treatment.

Outcomes

Primary:

1. Mental health status, assessed by the Global Assessment of Functioning (GAF)

Secondary

1. Depression, assessed by the BDI-II
2. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes

Ethics approval: yes

Comments from review authors:

1. Greater improvements in PTSD symptoms and functioning in CBT group than in brief treatment group
2. Effects maintained at 1-year post-treatment
3. We received some additional information from Dr Muser by email on 28 November 2017. He informed
us that the trial was not registered, no protocol had been published where the basic study methodol-
ogy was described, and that they did not assess the participants' IQ.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kredlow 2017b  (Continued)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “Randomization was conducted at a central location in the research
center by a computer based randomization program with assignments not
known in advance by either clinical or research staff.”

Allocation concealment
(selection bias)

Low risk

Quotes: “Randomization was conducted at a central location in the research
center by a computer based randomization program with assignments not
known in advance by either clinical or research staff". "When a client had com-
pleted the baseline assessment and his or her eligibility for the study was con-
firmed, the interviewer called the research center and a member of the re-
search team obtained the randomized assignment from the computer. The
client was informed about the assignment by the project coordinator”.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Low risk

Quotea: “All assessments were conducted by Masters or Ph.D. level trained
clinical interviewers who were blind to treatment assignment.”. “No specific
instances of blind breaking were noted in the study”.

Quote: “There were no differences between the groups on any demographic,
diagnostic, or baseline measures, nor in the rates of follow-up assessments".

Unclear risk

Comment: no protocol published

Other bias

High risk

Treatment adherence

Quote: “No efforts were made to control or modify any of these services pro-
vided to study participants.”

Allegiance bias

Comment: KT Mueser is on the Committee on Research Agenda of the Associ-
ation for the Advancement of Behavior Therapy, and the Task Force on Empiri-
cally Validated Treatments of the American Psychological Association, Division
12 (www.bu.edu/sargent/files/2013/05/MueserCV.pdf).

Attention bias

Comment: 12-16 sessions for EG, no information on length of TAU intervention

Vested interest

Comment: funded by National Institute of Mental Health

Laurenssen 2018 

Study characteristics

Methods

6-month (on average) trial with 2 arms

1. Day hospital mentalisation-based treatment (MBT-DH)
2. Specialist treatment-as-usual (S-TAU)

Duration of trial: 6 months, on average

Country: The Netherlands

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Laurenssen 2018  (Continued)

Setting: inpatient and outpatient

Participants

Interventions

Method of recruitment of participants: 2 mental healthcare centres, both located in Amsterdam,
agreed to participate in this study. The City Crisis Service agreed to run the S-TAU condition. From
March 2009 to July 2012, patients were referred to 1 of the 2 mental healthcare centers in Amsterdam.
Sample size: 95

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis I Personality Disorders (SCID-I),
and a total score on the Borderline Personality Disorder Severity Index (BPDSI) of at least 20, reflecting
severe borderline personality disorder
Mean age: not stated
Sex: 79% female

Comorbidity: avoidant personality disorder, antisocial personality disorder, paranoid personality dis-
order, obsessive-compulsive personality disorder, dependent personality disorder

Inclusion criteria

1. Diagnosis of borderline personality disorder

Exclusion criteria

1. Presence of schizophrenia or bipolar disorder, as determined by the Structured Clinical Interview for

DSM-IV Axis I Personality Disorders (SCID-I)
2. Substance abuse requiring specialist treatment
3. Organic brain disorder
4. IQ below 80
5. Inadequate mastery of the Dutch language

Experimental group
Treatment name: MBT-DH
Number randomised to group: 54
Duration: The mean number of days was 176 (range = 5–402, median = 149). The mean number of
hours in MBT-DH was 1056 (range = 30–2412, median = 894).
Control/comparison group
Comparison name: S-TAU
Number randomised to group: 41
Duration: The mean number of hours was 1473 (range = 5–13099, median = 131).

Both groups
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: Patients could also consult a psychiatrist upon request and medica-
tion was prescribed following American Psychiatric Association guidelines (APA 2000).

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Dutch version of the Personality Assessment

Inventory-Borderline (PAI-BOR)

2. Self-harm, assessed by the Suicide and Self-Harm Inventory (SSHI) (see Risk of bias in included stud-

ies)

3. Suicide-related outcomes, assessed by the SSHI (see Risk of bias in included studies)
4. Mental health status, assessed by the Global Severity Index (GSI)

Secondary

1. Interpersonal problems, assessed by the Inventory of Interpersonal Problems (IIP)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Laurenssen 2018  (Continued)

Cochrane Database of Systematic Reviews

2. Depression, assessed by the Beck Depression Inventory (BDI)
3. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes 
Ethics approval: yes, from the Medical Ethics Review Committee of the University of Rotterdam

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Selective reporting (re-
porting bias)

High risk

Comment: patients agreeing to participate were randomly assigned to either
MBT-DH or S-TAU using block randomisation taking into account the avail-
ability of treatment programs. For this reason, the randomisation was slight-
ly skewed in favor of MBT- DH, because the new MBT-DH groups needed to be
filled. (p 2)

Comment: randomisation was done by an independent researcher, away from
the site, using a computer algorithm. (p 2)

Comment: research assistants were psychologists with an MSc degree, and
were blind for treatment condition. (p 2)

Comment: large attrition rates. Significantly differing rates after baseline. Un-
clear reasons for attrition. ITT analyses conducted. Multiple imputations con-
ducted, but because imputed and non-imputed data were similar, imputed da-
ta were not reported.

Comment: self-harm, suicidal behaviour, subjective experiences of symptoms,
personality functioning and treatment adherence listed as secondary out-
comes in trial registry, but not reported on in study.

Quote: "Preliminary screening of the data showed substantial differences in
the administration of the SSHI between research assistants, and therefore we
decided not to report data using this measure." (p 3, left column)

Other bias

High risk

Adherence to treatment
Comment: adherence was not rated

Attention bias

Comment: differences in total hourly exposure between groups (mean 1473
versus 1056 hours)

Allegiance bias

Comment: Patrick Luyten has been involved in the training and dissemination
of mentalisation-based treatments. The other authors declared no competing
interests. (see p 7)

Leichsenring 2016 

Study characteristics

Methods

2-3 month (approximately) trial with 3 arms

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

195

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Leichsenring 2016  (Continued)

Cochrane Database of Systematic Reviews

1. Manual-guided psychoanalytic-interactional therapy (PIT)
2. Non-manualised psychodynamic therapy by experts in personality disorders (E-PDT)

Duration of trial: mean = 77 to 107 days. PIT = 106.7 mean days (standard deviation = 41.71), E-PDT =
and 76.78 mean days (standard deviation = 21.07)
Country: Germany

Setting: inpatient, Asklepios Clinic, Tiefenbrunn

Participants

Method of recruitment of participants: “Patients who applied for treatment and who had been giv-
en the presumptive diagnosis of a cluster B personality disorder by the referring clinician were asked to
participate in the study.” (quote, p 72)
Sample size: 122

Diagnosis of borderline personality disorder: International Statistical Classification of Diseases and
Related Health Problems, 10th version (ICD-10)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
Mean age: PIT = 28.63 years (standard deviations = 8.71), E-PDT = 30.43 years (standard deviation =
9.05)
Sex: 69% female

Comorbidity: avoidant personality disorder in 14 patients (11%), histrionic personality disorder in 2
patients (2%), and narcisstic personality disorder in 28 patients (23%), assessed by SCID-II. Multiple di-
agnoses for cluster B personality disorders were possible.

Inclusion criteria

1. Aged between 18 and 65 years
2. Diagnosis of a cluster B personality disorder according to SCID-II
3. Provided informed consent

Interventions

Exclusion criteria

1. Psychotic and acute substance-related disorders
2. Acute (uncontrollable) risk of suicide
3. Organic mental disorders
4. Severe medical conditions (according to ICD-10)

Experimental group
Treatment name: PIT
Number randomised to group: 64
Duration: 106.7 mean days (standard deviation = 41.71)
Control/comparison group
Comparison name: E-PDT
Number randomised to group: 58
Duration: 76.78 mean days (standard deviation = 21.07)

Both groups
Concomitant psychotherapy: none (inpatient)
Concomitant pharmacotherapy: allowed

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: “In the PIT group, 37.5% received an antidepressive medication (selective serotonin reuptake in-
hibitors, noradrenalin reuptake inhibitors, or tricyclic antidepressants) as compared with 46.1% in the
E- PDT group. The difference was not significant (p = 0.311). This was also true for neuroleptics (50 vs.
60.3%, p = 0.251) and anxiolytics (4.7 vs. 5.2%, p = 0.902). In total, 76% of the PIT patients and 79.3%
of the E- PDT patients received temporarily some form of pharmacotherapy (p = 0.715). Thus, the two
treatments did not differ with regard to the applied pharmacotherapy.” (quote, p 76)

Outcomes

Primary

1. BPD severity, assessed by the Borderline Personality Inventory (BPI), total score

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

196

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Leichsenring 2016  (Continued)

Cochrane Database of Systematic Reviews

2. Psychosocial functioning, assessed by the Global Severity Index GSI of the Symptom Checklist-90 re-

vised (SCL-90-R)

Secondary

1. Interpersonal problems, assessed by the Inventory of Interpersonal Problems (IIP)
2. Identity disturbance, assessed by the BPI, identity diffusion subscale
3. Depression, assessed by the Beck Depression Inventory
4. Adverse events (not reported by group)

Notes

Sample size calculation: yes
Ethics approval: yes

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Comment: patients fulfilling the inclusion criteria were randomised to either
PIT or E-PDT by use of a computer- generated randomisation list generated by
two of the authors (UJ, OM). Randomisation was stratified for sex. (p 74)

Allocation concealment
(selection bias)

Low risk

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: patients were randomised to treatment by use of a random func-
tion in Microsoft Excel. This was done by two of the authors (OM and UJ) not
involved in any diagnostic assessments pre or post-therapy (third party as-
signment). Thus, the diagnosticians assessing and enrolling patients were un-
aware of the allocation sequence. (email correspondence 28 September 2018)

Comment: 7 specifically trained and independent assessors conducted the in-
terviews. (p 74)

Comment: for ITT analysis, applied multiple imputation by chained equations
to account for the uncertainty resulting from missing outcomes. To generate
conservative estimates, 50 imputations were created and all available vari-
ables were included in the imputation process. (p 74)

Selective reporting (re-
porting bias)

High risk

Comment: Beck Anxiety Inventory was mentioned in protocol, but was not in-
cluded in full report.

Other bias

High risk

Adherence to treatment

Comment: 2 independent masked raters were trained in both PIT and the use
of the checklist by one of the developers of PIT (US). They independently rat-
ed the 30 videotapes. Having seen the videos, they rated (1) whether PIT or E-
PDT was applied and (2) the overall therapist’s competence in applying princi-
ples of PIT. For the latter, a 4-point Likert rating scale was used comparable to
the overall competence rating scale of the Penn Adherence and Competence
Scale. (p 75)

Attention bias

Comment: large difference in duration in the 2 groups. Mean treatment dura-
tion was 106.70 days (SD = 41.71) for PIT and 76.78 days (SD = 21.07) for E-PDT.
As this difference was statistically significant (P < 0.0001), treatment duration
was included as a covariate in the statistical analysis. (p 75)

Allegiance bias

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Leichsenring 2016  (Continued)

Cochrane Database of Systematic Reviews

Comment: last author, Ulrich Streeck, developed PIT

Leppänen 2016 

Study characteristics

Methods

1-year trial with 2 arms

1. Community treatment by experts (CTBE)
2. Treatment-as-usual (TAU)

Duration of trial: 1 year
Country: Finland

Setting: social and health services, including mental services

Participants

Method of recruitment of participants: convenience sampling method
Sample size: 71

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
Mean age: CTBE = 31.9 years (standard deviation = 8.3), TAU = 32.3 years (standard deviation = 8.8)
Sex: 85.9% female

Comorbidity: not stated

Inclusion criteria

1. Fulfilled SCID-II criteria for borderline personality disorder
2. Over 20 years of age
3. Suffered from severe symptoms of borderline personality disorder. Severe symptoms included para-
suicidal behaviour (such as cutting, other forms of self-harm, impulsive overdosing of medicines), at-
tempted suicide, considerable emotional instability affecting social and professional life, and previ-
ous unsuccessful treatments (1 or more), where the patient withdrew from treatment or was still suf-
fering from severe symptoms despite treatment.

Exclusion criteria

1. Schizophrenia spectrum diseases/psychoses
2. Bipolar disorder (type I)
3. Neuropsychiatric disorder
4. Severe substance abuse problem (which clearly impaired commitment to treatment)

Axis I disorders were diagnosed according to Structured Clinical Interview for DSM-IV Axis I Disorders
(SCID-I) , and the presence of neuropsychiatric disorder and substance abuse was assessed by a clini-
cian.

Interventions

Experimental group 
Treatment name: CTBE
Number randomised to group: 24
Duration: 1 year (see p 218)
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: not stated

Control/comparison group 
Comparison name: TAU
Number randomised to group: 47
Duration: approximately 1 year

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

198

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Leppänen 2016  (Continued)

Concomitant psychotherapy: not stated 
Concomitant pharmacotherapy: not stated

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Finnish version of the Borderline Personality

Disorder Severity Index, Fourth version (BPDSI-IV), total score

2. Suicide-related outcomes, assessed by the BPDSI-IV parasuicidality subcale

Secondary

1. Anger, assessed by the BPDSI-IV outburst of anger subscale
2. Affective instability, assessed by the BPDSI-IV affective instability subscale
3. Chronic feelings of emptiness, assessed by the BPDSI-IV emptiness subscale
4. Impulsivity, assessed by the BPDSI-IV impulsivity subscale
5. Interpersonal problems, assessed by the BPDSI-IV unstable relationship subscale
6. Abandonment, assessed by the BPDSI-IV abandonment subscale
7. Identity disturbance, assessed by the BPDSI-IV identity disturbance subscale
8. Dissociation  and  psychotic-like  symptoms  assessed  by  the  BPDSI-IV  paranoid  and  dissociative

ideation subscale

9. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: not stated
Ethics approval: The Ethics Committee of Oulu University Hospital approved the study (18 June 2009,
number: 41/2009).

Comments from review authors:

1. Information  about  randomisation  procedure,  comorbid  diagnoses,  concomitant  use  of  pharma-
cotherapy or psychotherapy (or both), and treatment adherence was received by email from Dr Lep-
pänen on 20 December 2017.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Comment: somewhat unclear, but seems likely that they are referring to a ran-
dom number table.

Quote: “The randomization list was prepared using appropriate statistical
methods by a person who had no contact with the patients.” (p 218)

Allocation concealment
(selection bias)

Unclear risk

Quote: “The randomization list was prepared using appropriate statistical
methods by a person who had no contact with the patients.” (p 218)

Comment: The person mentioned (s)he had no contact with patients, but
could potentially have had contact with the researchers, enabling them to
foresee assignments.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quotes: measure 1: “BPDSI-IV interviews were blinded and conducted by
three interviewers: two psychiatric nurses and a physician.” (p 221); measure
2: “The 15D questionnaires were posted to patients, who were asked to return
the completed questionnaire by pre-paid post.” (p 221)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

199

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Leppänen 2016  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

High risk

Comment: higher attrition in TAU than CTBE – imbalance in numbers and rea-
sons for dropout. 31.9% attrition in TAU may have affected effect size esti-
mates in the continuous outcome measures.

Unclear risk

Comment: no protocol found

Other bias

High risk

Treatment adherence

Comment: They did not mention it in the article but did state supervision in
the active group (see p 219). Some may have considered this good but we do
not think so, especially because it was not videotaped or manualised/rated.

Attention bias

Comment: Lack of attention to comorbidity and reporting of it. And use of
convenience sampling. Potential type 1 and 2 errors
Quote: “During the year long intervention, the CTBE patients made, on aver-
age, 73 visits to Oulu mental health services compared to an average of only
21 visits in TAU patients. Therefore, the possibility of nonspecific treatment ef-
fects may also exist”. (p 228)

Other risk of bias
Quote: “The likelihood for Type I and Type II errors cannot be excluded, since
many statistical comparisons were performed and the subsamples in some
statistical analyses may have been too small, thus reducing the statistical
power and likelihood of revealing truly significant findings. We considered cor-
recting for multiple comparisons but, due to our limited sample size, such cor-
rections were considered to be rather artificial.” (p 226)

Lin 2019 

Study characteristics

Methods

8-week trial with 2 arms:

1. Dialectical behavior therapy skills training group (DBTSTG)
2. Cognitive therapy group (CTG)

Duration of trial: 8 weeks
Country: Taiwan

Setting: outpatient

Participants

Method of recruitment of participants: “A total of 256 college students recruited from two university
counseling centers (UCC) in southern Taiwan participated in this study.” (quote, p 3)
Sample size: 82

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
Mean age: DBTSTG = 20.40 years (standard deviation = 0.76), CTG = 20.47 years (standard deviation =
0.71)
Sex: 87.8% female

Comorbidity: not stated

Inclusion criteria

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

200

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lin 2019  (Continued)

Cochrane Database of Systematic Reviews

1. Met criteria for borderline personality disorder
2. Having experienced at least 1 suicide attempt in the past 6 months

Exclusion criteria

1. A lifetime diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, psychotic disorder
2. A current severe depression and suicide risk indicating the need for inpatient care and crisis interven-

tion

3. Experiencing current neurological signs and substance abuse during the last 6 months

Interventions

Experimental group
Treatment name: DBTSTG
Number randomised to group: 42
Duration: 8 weeks

Control/comparison group
Comparison name: CTG
Number randomised to group: 40
Duration: 8 weeks

Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: none

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: "No participants were currently receiving psychotropic medications." (p. 4)

Outcomes

Primary

1. Borderline personality disorder severity, assessed by Borderline Personality Disorder Features Scale
(BPDFS), a self-report questionnaire designed by Ko and colleagues in reference to the personality
disorder diagnosis from the DSM-IV

2. Suicide-related outcomes, assessed by the 12-item Adult Suicidal Ideation Questionnaire - Shortened

version (ASIQ-S)

Secondary

1. Depression, assessed by Ko´s Depression Inventory (KDI)
2. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes 
Ethics approval: yes

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “Following the completion of the intake assessments, eligible partici-
pants were referred by counseling centers based on freshman screening dur-
ing 2009–2014, and were randomly assigned to either the CTG or the DBTSTG
for intervention using a computerized randomization procedure with a maxi-
mum of 9 cases in one group.” (p 86)

Allocation concealment
(selection bias)

Unclear risk

Comment: not enough clear information provided in order for a judgement to
be made

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Quote: “Blinded assessments were conducted at the baseline and follow-up;
however, blinded assessments during intervention were not possible since the
assessment of a suicide attempt involved an evaluation of the circumstances

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

201

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lin 2019  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Cochrane Database of Systematic Reviews

preceding a suicide attempt and the use of mental health services during post-
attempt, which was essential for clinical management.” (p 87)

Quotes: “Generalized linear model analyses were performed to compare
participants who were included vs. those who were not included by group
(DBTSTG vs. CTG) on the demographic and outcome variables at baseline. In-
tent- to-treat analyses were conducted to aid in the interpretation of findings
by including all those who started treatment but dropped out.” (p 89)

"Sixty-eight participants, including 36 (85.7%) in DBTSTG and 32 (80.0%) in
CTG, completed the intervention. There were no intergroup differences in
dropout rates (DBTSTG: 14.28%; CTG: 20.00%)....Further comparisons between
participants who completed (n = 68) and non-completed (n = 14) across in-
tervention groups on gender were not significant (χ2 = .75, p = .85; χ2 = .42, p
= .47). Moreover, the effects of the sample (included vs. non-included) x group
(DBTSTG vs. CTG) on age, depression and antecedent and response-focused
emotion regulation measures at baseline did not reach significant differences
(age: F = .01 p = .69; depression: F = .01 p = .986; cognitive errors: F = .21, p
= .74; attentional deployment: F = .02, p = .89, cognitive reappraisal: F = 1.51, p
= .219; suppression: F = .75, P = .38 acceptance: F = 3.00, p = .08).” (p 89)

Selective reporting (re-
porting bias)

High risk

Comment: protocol available; data from the Emotion Regulation Scale and
Symptom Check List - 90 - Revised not reported in full report

Other bias

Unclear risk

Attention bias

Comment: nothing found
Treatment adherence

Comment: no ratings

Quote: "Although each session in both conditions was guided by an interven-
tion manual, and the therapist was required to strictly adhere to the interven-
tion manual and rate the checklists for adherence to the CGT or DSTG manual
in an attempt to reduce treatment diffusion, future studies should include in-
dependent adherence ratings by objective observers". (p 95)

Allegiance bias

Comment: no evidence of allegiance bias found

Linehan 1991 

Study characteristics

Methods

12-month trial with 2 arms

1. Dialectical behavior therapy (DBT)
2. Treatment-as-usual (TAU)

Duration of trial: 12 months

Country: USA

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Sample size: 62

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

202

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 1991  (Continued)

Cochrane Database of Systematic Reviews

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
3rd Edition (DSM-III)

Means of assessment: Revised Diagnostic Interview for Borderlines (DIB-R)

Age: not stated

Sex: 100% female

Comorbidity: not stated

Inclusion criteria:

1. Scored at least 7, out of a maximum score of 10, on the Diagnostic Interview for Borderlines and met

DSM-III criteria for borderline personality disorder

2. Had at least 2 incidents of parasuicide in the last 5 years, with 1 during the last 8 weeks
3. Did not meet DSM-III criteria for schizophrenia, bipolar disorder, substance dependence, or mental

retardation

4. Aged between 18 and 45 years
5. Agreed to the study conditions, including termination from other individual psychotherapy if assigned

to DBT

Exclusion criteria

1. Schizophrenia
2. Bipolar disorder
3. Substance dependence
4. Mental retardation

Interventions

Experimental group

Treatment name: DBT

Number randomised to group: 2

Duration: 12 months (weekly individual therapy, weekly group therapy, telephone contact with the in-
dividual therapist between sessions)

Control/comparison group

Comparison name: TAU

Number randomised to group: 22

Duration: 12 months

Both groups

Concomitant psychotherapy: 13 out of 22 TAU participants were in ongoing individual psychotherapy
at pretreatment, 9 out of 22 TAU participants had stable individual therapy for the year.

Concomitant pharmacotherapy: "Subjects had to consent to taper off psychotropic medications be-
fore entering the study. However, once in the study, failure to terminate or resuming use of medication
was not cause for removal from the study." (quote, p 1061)

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Number of patients with self-harming behaviour in the previous 12-month period

Notes

Sample size calculation: not stated

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

203

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 1991  (Continued)

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Subjects were matched on the number of lifetime parasuicides and
psychiatric hospitalization, age, and good vs poor clinical prognosis (with a
subthreshold diagnosis on schizophrenia or substance dependence constitut-
ing poor prognosis) and randomly assigned to a treatment condition." (p 1061)

Allocation concealment
(selection bias)

Unclear risk

Comment: no clear details provided

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: "Screening and assessment interviews were administered by a team
of 13 research assessors. Every effort was made to keep the assessors blind
about treatment condition." ( p 1061)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: 10 dropped out during pretreatment assessment (EG: N = 5, CG: N
= 5). 7 were dropped following pretreatment assessment for refusal or inability
to meet study conditions (EG: N = 3, CG: N = 4). 2 EG participants quit the study
with 4 or fewer DBT sessions and were dropped from all analyses other than
treatment maintenance analyses. Major analyses were conducted for 44 par-
ticipants, N = 22 in EG and N = 22 in CG treatment.

Selective reporting (re-
porting bias)

Unclear risk

Comment: no indication for selective reporting, but Insufficient information to
permit judgement of 'high' or 'low' risk of bias

Other bias

Unclear risk

Comment: no further details

Linehan 1994 

Study characteristics

Methods

12-months trial with 2 arms

1. Dialectical behavior therapy (DBT)
2. Treatment-as-usual (TAU)

Duration of trial: 12 months

Country: USA

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Sample size: 26

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
3rd Edition (DSM-III)

Means of assessment: Structured Clinical Interview for DSM-IV (SCID), and Revised Diagnostic Inter-
view for Borderlines (DIB-R)

Mean age: 26.7 years (standard deviation = 7.8)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

204

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 1994  (Continued)

Sex: 100% female

Comorbidity: not stated

Inclusion criteria

Cochrane Database of Systematic Reviews

1. Scored at least 7, out of a maximum score of 10, on the Diagnostic Interview for Borderlines and met

DSM-III criteria for borderline personality disorder

2. Had at least 2 incidents of parasuicide in the last 5 years, with 1 during the last 8 weeks
3. Did not meet DSM-III criteria for schizophrenia, bipolar disorder, substance dependence, or mental

retardation

4. Aged between 18 and 45 years
5. Agreed to the study conditions, including termination from other individual psychotherapy if assigned

to DBT

Exclusion criteria

1. Participants currently meeting criteria for schizophrenia, bipolar disorder, primary substance depen-

dence, mental retardation

Interventions

Experimental group

Treatment name: DBT

Number randomised to group: 13

Duration: 12 months (weekly individual behavioural psychotherapy, weekly psychoeducational skills
training groups)

Control/comparison group

Comparison name: TAU; participants received alternative therapy referrals and were allowed to partic-
ipate in any type of treatment available in the community

Number randomised to group: 13

Duration: 12 months (weekly individual behavioural psychotherapy, weekly psychoeducational skills
training groups)

Both groups

Concomitant psychotherapy: patients assigned to DBT treatment had to terminate other professional
mental healthcare.

Concomitant pharmacotherapy: no between-group differences in number of participants using psy-
chotropic medications at pretreatment (use of: antidepressants, anticonvulsants, lithium, anxiolytics)

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod:

DBT participants should have tapered off psychotropic medications as 1 goal of therapy, and 8 out of
13 discontinued medication before start of treatment. The remaining 5 DBT participants reported us-
ing a mean of 1.80 medications (sedatives, antidepressants, anxiolytics, lithium) over the treatment
year, while 9 out of 13 TAU participants reported using a mean of 3.89 different medications (antide-
pressants, anxiolytics, neuroleptics, sedatives, anticonvulsants).

Outcomes

Primary

1. Mental health status, assessed with Goal Attainment Scale (GAS)

Secondary

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

205

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 1994  (Continued)

Cochrane Database of Systematic Reviews

1. Anger, assessed with the Søgeresultater Webresultater State-Trait Anger Expression Inventory (STAXI-

Anger)

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quotes: "assignment of subjects to treatment conditions [...] described in de-
tail in the original outcome study [i.e. Linehan 1991]" (p 1772). "Subjects were
matched on the number of lifetime parasuicides and psychiatric hospitaliza-
tion, age, and good vs poor clinical prognosis (with a subthreshold diagnosis
on schizophrenia or substance dependence constituting poor prognosis) and
randomly assigned to a treatment condition." (Linehan 1991, p 1061)

Comment: no further details

Unclear risk

Comments: no further details

Low risk

Quote: "Interviews blind to treatment conditions" (p 1772)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Comment: analyses were conducted on a per protocol basis. 26 women in-
cluded, data set for 26 participants (DBT: N = 13, TAU: N = 13) provided

Selective reporting (re-
porting bias)

Unclear risk

Comment: no indication of selective reporting, but insufficient information to
permit judgement of 'high' or 'low' risk of bias

Other bias

High risk

Performance bias

Comment: no details provided to indicate if supervision or adherence ratings
(or both) had been conducted. However, the same study design was used as
for Linehan 1991 ("two cohorts", cf. Linehan 1994, p 1772), where regular su-
pervision was explicitely defined (cf. Characteristics of included studies, Risk of
bias table for Linehan 1991).

Allegiance bias

Comment: "study was conducted at the institution where the treatment was
developed." (p 1775)

Attention bias

Comment: more attention paid to DBT group

Linehan 2006 

Study characteristics

Methods

12-month trial with 2 arms

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

206

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 2006  (Continued)

1. Dialectical behaviour therapy (DBT)
2. Non-behavioural community treatment by experts (CTBE)

Duration of trial: 12 months

Country: USA

Setting: outpatient

Participants

Method of recruitment of participants: not stated

Sample size: 101

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II) and Interna-
tional personality disorder examination (IPDE)

Mean age: 29.3 years (standard deviation = 7.5)

Sex: 100% female

Comorbidity: Current psychiatric diagnoses (DSM-IV): Major depressive disorder 72.3%, panic disorder
40.6%, PTSD 49.5%, any anxiety disorder 78.2%, any substance use disorder 29.7%, any eating disorder
23.8%, Cluster A PD 1.3%, Cluster B other than BPD 10.9%, Cluster C PD 25.7%.
Prevalence rates did not differ significantly between the two treatment groups.

Inclusion criteria: not stated

Exclusion criteria

1. Lifetime diagnosis of schizophrenia
2. Schizoaffective disorder
3. Bipolar disorder
4. Psychotic disorder not otherwise specified
5. Mental retardation
6. Seizure disorder requiring medication
7. Mandate to treatment
8. Need for primary treatment for another debilitating condition

Interventions

Experimental group

Treatment name: DBT

Number randomised to group: 52

Duration: 12 months (weekly individual psychotherapy, group skills training, telephone consultation)

Control/comparison group

Comparison name: CTBE

Number randomised to group: 49

Duration: 12 months

Both groups

Concomitant psychotherapy: no information given regarding further concomitant psychotherapy

Concomitant pharmacotherapy: There were no differences in the types or amounts of psychotropic
medication used at pretreatment.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

207

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 2006  (Continued)

Cochrane Database of Systematic Reviews

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: exact proportions unclear. The use of psychotropic medications decreased significantly more in
the DBT than the CTBE group during the treatment year.

Outcomes

Primary

1. Suicidality, assessed with the Suicide Behaviors Questionnaire (SBQ)

Secondary

1. Depression, assessed with the Hamilton Depression Scale, 17 items (HAM-D-17)

Notes

Sample size calculation: yes

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quotes: "Using a computerized adaptive minimization randomization pro-
cedure, eligible subjects were matched to treatment condition on 5 primary
prognostic variables: (1 and 2) the number of lifetime suicide attempts or non-
suicidal self-injuries combined and psychiatric hospitalizations; (3) a history
of only suicide attempts, only nonsuicidal self-injury, or both; (4) age; and (5)
a negative prognostic indicator of a Beck Depression Inventory score higher
than 30 or a Global Assessment of Functioning score lower than 45 for a co-
morbid condition [...] Based on 0.8 power to detect significant differences be-
tween conditions (P = .05, 1-sided), this procedure was used to randomize 101
subjects to DBT (n = 52) or to CTBE (n = 49)." ( p 758)." "The randomization pro-
gram assigned clients to DBT and CTBE therapists, matching on sex, doctor-
al vs master's training, and years of clinical experience. Results indicated that
therapists' sex and training did not differ in the 2 conditions. The CTBE ther-
apists, however, had more clinical experience, which was expected because
they were selected for their expertise." (p 760)

Allocation concealment
(selection bias)

Low risk

Quote: "The participant coordinator, who was not blinded to treatment condi-
tion, executed the randomization program". (p 758)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

Comment: improbable that computerised assignment could be foreseen and
thus bias be introduced

Quote: "Assessments were conducted by blinded independent clinical asses-
sors". (p 758)

Comment: analyses were conducted on an ITT basis. 101 participants ran-
domised, and 60 allocated to the EG and 51 to the CG arms. 8 DBT "training
cases" and 2 CBT "pilot cases" excluded from analyses, but the remaining 52
EG and 49 CG participants were analysed regardless of discontinuation or get-
ting lost to follow-up.

Selective reporting (re-
porting bias)

Unclear risk

Comment: no clear indication of selective reporting, but there was insufficient
information to permit a judgement of 'high' or 'low' risk of bias

Other bias

High risk

Performance bias

Quote: "Psychotherapists recommended by colleagues as potentially good
DBT therapists were recruited for the study; 8 had no previous DBT exposure

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

208

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 2006  (Continued)

Cochrane Database of Systematic Reviews

and 8 had experience that ranged from workshop attendance to applied prac-
tice. [...] Training consisted of a 45-hour DBT seminar followed by supervised
practice. [...] Individual therapists were hired once 6 of 8 consecutive training
case sessions were rated as adherent to DBT. During the study, adherence was
assessed by coding a random selection of sessions on the DBT Global Rating
Scale [...] which codes DBT adherence." (p 759)

Allegiance bias

Comment: the primary author (MLL) is developer of DBT

Attention bias

Comment: equal amounts of attention spent to both groups

Vested interest

Comment: first author is the developer of Dialectical Behavioural Therapy
(DBT) – Source: linehaninstitute.org/about/organizations

Linehan 2015a 

Study characteristics

Methods

49-week trial with 3 arms

1. Standard dialectical behaviour therapy (DBT)
2. Dialectical behaviour therapy - individual, no groups (DBT-I)
3. Group dialectical behaviour therapy, no individual (DBT-S)

Duration of trial: 49 weeks
Country: USA

Setting: university clinic and community setting

Participants

Method of recruitment of participants: outreach to healthcare practitioners

Sample size: 99

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II) and Interna-
tional personality disorder examination (IPDE)

Mean age: 30.3 years (range = 18-60)

Sex: 100% female

Comorbidity: not stated

Inclusion criteria

1. Met criteria for borderline personality disorder on the IPDE and the SCID-II
2. At least 2 suicide attempts or non-suicidal self-injury (NSSI) episodes (act), or both, in the past 5 years
3. At least 1 suicide attempt in the 8-week period before entering the study
4. At least 1 suicide attempt in the past year

Exclusion criteria

1. IQ below 70

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

209

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Linehan 2015a  (Continued)

Interventions

2. Current psychotic or bipolar condition
3. Seizure disorder
4. Required primary treatment for another life threatening disorder (e.g. severe anorexia nervosa)

Experimental group
Treatment name: DBT
Number randomised to group: 33
Duration: 52 weeks

Control/comparison group 1
Comparison name: DBT-I
Number randomised to group: 33
Duration: 49 weeks

Control/comparison group 2
Comparison name: DBT-S
Number randomised to group: 33
Duration: 50 weeks

All groups:
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: psychotropic medication allowed

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: exact proportions unclear, but no between-group differences in use of psychotropic medications

Outcomes

Primary

1. Self-harm, in terms of proportion of patients with non-suicidal self-injury (NSSI) (count data)
2. Suicide-related outcomes, assessed by the proportion of patients with suicidal act

Secondary

1. Depression, assessed by the Hamilton Depression Rating Scale (HDRS)
2. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample calculation: yes
Ethics approval: yes

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “A computerized adaptive randomization procedure (5) matched par-
ticipants on age, number of suicide attempts, number of NSSI episodes, psy-
chiatric hospitalizations in the past year, and depression severity”. (p 476)

Allocation concealment
(selection bias)

Unclear risk

Quote: “The participant coordinator, who was not blinded to the treatment
condition, executed the randomization and collected treatment-related data”.
(p 476)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: “Assessments were conducted before treatment and quarterly during
1 year of treatment and 1 year of follow-up by blinded independent assessors
trained by instrument developers or approved trainers (including K.A.C. and
A.M.M.-G.) and evaluated as reliable for each instrument.” (p 476)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: no information on ITT, but all randomised participants were in-
cluded in analysis, so ITT was likely used. No imputation methods seem to
have been used. 26/99 randomised were lost at follow-up. No differences in

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

210

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Linehan 2015a  (Continued)

Selective reporting (re-
porting bias)

High risk

Cochrane Database of Systematic Reviews

rate of dropouts between arms, no evidence that group differences in missing
data biased major outcome variables

Comment: protocol lists 'coping skills' as a secondary outcome. It was not in-
cluded in study. 'Reasons for living' and depression and anxiety outcome mea-
sures were included in the paper. These were not listed in the protocol. Nei-
ther were they mentioned in the paper as post hoc analyses

Other bias

High risk

Treatment adherence

Comment: treatment adherence differed significantly between 2 out of 3
groups

Adherence bias

Comment: first author is the developer of Dialectical Behavioural Therapy
(DBT), see http://www.linehaninstitute.org/ab out-Linehan.php
Attention bias

Quote: “Participants in standard DBT received significantly more individual
sessions than those in DBT-S owing to weekly sessions in standard DBT and
as-needed sessions in DBT-S. Participants in standard DBT and DBT-S received
more group therapy sessions than those in DBT-I owing to the optional na-
ture of group therapy in DBT-I. Participants in standard DBT attended more
groups than those in DBT-S owing to trend-level differences in treatment re-
tention.” (p 477)

McMain 2009 

Study characteristics

Methods

12-months trial with 2 arms

1. Dialectical behaviour therapy (DBT)
2. General psychiatric management

Duration of trial: 12 months

Country: Canada

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Sample size: 190

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: International Personality Disorder Examination (IPDE)

Mean age: 30.4 years (standard deviation = 9.9)

Sex: 86.8% female

Comorbidity: exclusion of several disorders

Inclusion criteria

1. Meet diagnostic and DSM-IV criteria for borderline personality disorder
2. Aged 18–60 years

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

211

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McMain 2009  (Continued)

Cochrane Database of Systematic Reviews

3. Have had at least 2 episodes of suicidal or nonsuicidal self-injurious episodes in the past 5 years, at

least 1 of which was in the 3 months preceding enrollment

Exclusion criteria

1. Psychotic disorder
2. Bipolar I disorder
3. Delirium
4. Dementia
5. Mental retardation
6. Diagnosis of substance dependence in preceding 30 days
7. Having a medical condition that precluded psychiatric medications
8. Living outside a 40-mile radius of Toronto
9. Serious medical condition likely to require hospitalisation within the next year
10.Having plans to leave the province

Interventions

Experimental group

Treatment name: DBT

Number randomised to group: 90

Duration: 12 months (individual sessions 1-hour weekly; skills group 2 hours weekly; phone coaching 2
hours weekly; consultation team for therapists 2 hours weekly)

Control/comparison group

Comparison name: general psychiatric management according to American Psychological Association
(APA) guideline recommendations

Number randomised to group: 90

Duration: 12 months (individual sessions, 1-hour weekly, including management based on structured
drug algorithm, and therapist supervision meeting 90 minutes weekly)

Both groups

Concomitant psychotherapy: non-study treatments, such as individual, group, case management,
day or inpatient treatment were recorded but participants were not prevented from using them.

Concomitant pharmacotherapy:

At baseline, 145 patients (81.6%) reported that they were taking psychotropic medications (mean num-
ber of medications, 3.08 [SD = 1.64]).

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: Exact proportions unclear; during treatment, patients in dialectical behavior therapy averaged
1.84 (SD = 1.44) medications, and those in general psychiatric management 2.09 (SD = 1.65), with no
significant difference between groups.

Outcomes

Primary

1. BPD severity, assessed by Zanarini Rating Scale for Borderline Personality disorder (ZAN-BPD)
2. Parasuicidality, assessed by mean number of suicidal and self-injurious episodes

Secondary

1. Anger, assessed by State-Trait Anger Expression Inventory (STAXI)
2. Interpersonal problems, assessed by Inventory of Interpersonal Problems-Circumplex (IIP-C)
3. Depression, assessed by Beck Depression Inventory (BDI)

Notes

Sample size calcuation: yes

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

212

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McMain 2009  (Continued)

Cochrane Database of Systematic Reviews

Ethics approval: The protocol was approved by each centre’s research ethics board, and patients pro-
vided written informed consent prior to enrollment. Under the Canadia public healthcare system, par-
ticipants did not pay for treatment.

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "eligible participants were randomly assigned to treatment arms using
a pregenerated block randomization scheme developed and held by the statis-
tician." (p 1366)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Low risk

Quote: "[...] statistician, who prepared 45 sealed envelopes, each containing
the group allocations in random order for four participants." (p 1366)

Quote: "[...] assessors who were well trained on study instruments and blind
to treatment assignment. [...] Assessors were polled after the treatment phase
to ascertain whether they could correctly guess participants' treatment assign-
ment; they did not know treatment assignment for 86% of the cases, suggest-
ing that blinding was largely maintained." (p 1366)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: no further details

Selective reporting (re-
porting bias)

Low risk

Comment: study protocol available (NCT00154154). No indication of selective
reporting

Other bias

Unclear risk

Comment: no further details

McMain 2017 

Study characteristics

Methods

20-week trial with 2 arms

1. Dialectical behavior therapy (DBT) skills training group
2. Active waiting list. At the end of the study, participants assigned to the waiting-list group were offered
a place in treatment. During this waiting period, participants could continue with treatment-as-usual
care (medication management or other psychosocial treatments).

Duration of trial: 20 weeks

Country: Canada

Setting: outpatient

Participants

Method of recruitment of participants: not stated

Sample size: 84
Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: International Personality Disorder examination (IPDE)

Mean age: 29.67 years (standard deviation = 8.62)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

213

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McMain 2017  (Continued)

Sex: 78.6% female

Cochrane Database of Systematic Reviews

Comorbidity: current DSM-IV axis I and axis II diagnoses: major depressive disorder, panic disorder,
post-traumatic stress disorder (PTSD), any anxiety disorders, substance abuse, substance dependence,
any eating disorder

Inclusion criteria

1. Meeting the criteria for borderline personality disorder as defined in the DSM-IV
2. Aged 18-60 years
3. Two suicidal or non-suicidal self-harm, or both (NSSI (episodes in the past 5 years, with 1 occurring

within 10 weeks prior to enrolment))

4. Able to understand written and spoken English

Exclusion criteria

1. Meeting DSM-IV criteria for a psychotic disorder, bipolar I disorder or dementia
2. Evidence of an organic brain syndrome or mental retardation based on clinical interview
3. Participation in a DBT programme within the past year

Interventions

Experimental group
Treatment name: DBT skills training group
Number randomised to group: 42
Duration: 20 weeks
Control/comparison group
Comparison name: waiting list
Number randomised to group: 42
Duration: 20 weeks

Both groups

Concomitant psychotherapy: "At baseline, a total of 71 patients (85%) reported that they were receiv-
ing some form of psychosocial treatment from a therapist. During their period on wait list, participants
could continue with treatment as usual (medication management or other psychosocial treatments)".
(quote, p 140)
Concomitant pharmacotherapy: "At baseline, a total of 71 patients (86%) were taking psychotrop-
ic medications, with a mean of 1.79 ± 1.41 medications per participant. There were no significant be-
tween-group differences in either the number of patients on medication (DBT = 33/42; WL = 38/42; v2(1)
= 1.67, P = 0.20) or the mean number of medications taken (DBT = 1.52 ± 0.20; WL = 2.05 ± 0.22; t(80) =
1.73, P > 0.05)."

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: "At 20 weeks, a total of 57 patients (81%) were taking medication and were averaging 1.62 ± 1.67
medications, with the DBT group reporting both fewer patients on medication (23/32) compared to the
WL patients (34/38) and fewer medications (1.52 ± 0.20 vs. 2.05 ± 0.22, t(80) = 2.10, P = 0.04). There was
no significant group difference in the average number of medications at the 32-week follow-up (t(80) =
0.53, P = 0.60)“. (p. 142)

Outcomes

Primary

1. Borderline  Personality  Disorder  symptom  severity,  assessed  by  the  Borderline  Symptom  List-  23

(BSL-23)

2. Self-harm, assessed by the self-report Deliberate Self-Harm Inventory (DSHI)
3. Suicide-related outcomes, assessed by the clinician-administered Lifetime Suicide Attempt Self-In-

jury Interview (LSASI)

4. Psychosocial functioning, assessed by the Symptom Checklist 90 Revised – total score (SCL-90-R)

Secondary

1. Anger, assessed by the State-Trait Anger Expression Inventory, anger expression out scale score (STAXI-

A)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

214

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McMain 2017  (Continued)

Cochrane Database of Systematic Reviews

2. Affective instability, assessed by the Difficulties in Emotion Regulation Scale (DERS)
3. Impulsivity, assessed by the Barrett Impulsiveness Scale-11 (BIS-11)
4. Interpersonal problems, assessed by the Social Adjustment Scale – Self-Report (SAS-SR)
5. Depression, assessed by the Beck Depression Inventory (BDI)
6. Attrition, in terms of patients lost after randomisation in each group, and as measured by the Reasons

for Early Termination from Treatment Questionnaire

Notes

Sample size calculation: yes
Ethics approval: yes. The study was approved by the CAMH Research Ethics Board.

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Comment: participants were assigned to groups using a standard random
block design in block sizes of four.

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

Low risk

Selective reporting (re-
porting bias)

Low risk

Comment: statistician prepared 42 envelopes, each containing 2 allocations
to each of the conditions in random order.

Comment: participants were assessed by 2 doctoral-level psychology stu-
dents and 1 master’s-level clinician who were well trained on the study instru-
ments and were blinded to treatment assignment.

Comment: all analyses were conducted on the ITT sample (N = 84). Low attri-
tion rate (5 in DBT, 3 on waiting list; reasons for dropout were stated)

Quote: “There was no evidence that missing data patterns were biased by
group membership”. (p 142)

Comment: protocol published. All outcomes mentioned in the publication
except the Borderline Evaluation of Severity over time Scale (secondary out-
come), which seems to have been changed to the Borderline Symptom List -
23. Some other outcomes have been added in the publication as well (Beck
Depression Inventory - II, the Social Adjustment Scale - Self-report, the Diffi-
culties in Emotion Regulation Scale, the Distress Tolerance Scale and the Ken-
tucky Inventory of Mindfulness Scale).

Other bias

Unclear risk

Treatment adherence

Comment: Treatment adherence ratings were conducted on 10% (n = 22) of
sessions. The mean score of 4.44 (SD = 0.11) fell within the ‘adherent’ range.

Attention bias

Comment: comparator intervention was waiting list.

Allegiance bias

Comment: authors reported no conflict of interests in relationship to this
study.

Vested interest

Comment: no indication of bias

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

215

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McMurran 2016 

Study characteristics

Methods

12-week trial with 2 arms

Cochrane Database of Systematic Reviews

1. Psychoeducation and problem solving (PEPS) therapy, internet-based control group with no psychoe-

ducation + treatment-as-usual (TAU)

2. TAU

Duration of trial: 12 weeks
Country: UK

Setting: community (outpatient)

Participants

Methods of recruitment of participants: referred to PEPS team. Participants were recruited from
mental health services in 3 UK NHS trusts.
Sample size: subsample = 183

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: International personality disorder examination (IPDE)

Mean age: no data on subsample. Full sample for PEPS therapy = 38.6 years (standard deviation =
10.9), full sample for TAU = 37.8 years (standard deviation = 11)
Sex: approximately 75% female

Comorbidity: not stated

Inclusion criteria

1. At the point of randomisation, participants were required to have one or more personal disorder(s)
(including personality disorder not otherwise specified), identified through the IPDE (Loranger 1995)

2. Aged 18 years or over
3. Living in the community
4. Proficient in spoken English
5. Had capacity to provide informed consent

Exclusion criteria

1. A primary diagnosis of major functional psychosis
2. Insufficient degree of literacy
3. Incomprehension or lack of attention to be able to engage in trial therapy and assessments
4. Engagement in a specific programme of psychological treatment for personality disorder or likely to

start such treatment during the trial period

5. Participation in any other trial

Interventions

Experimental group
Treatment name: PEPS therapy, internet-based control group with no psychoeducation + TAU
Number randomised to group: 93
Duration: 12 weeks

Control/comparison group
Comparison name: TAU
Number randomised to group: 90
Duration: 12 weeks

Both groups
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: allowed

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

216

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McMurran 2016  (Continued)

Cochrane Database of Systematic Reviews

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Psychosocial functioning, assesed by the Social Functioning Questionnaire (SFQ)

Secondary

1. Depression, assessed by the Hospital Anxiety and Depression Scale (HADS)
2. Attrition, in terms of patients lost after randomisation in each group
3. Adverse effects (AE), as assessed by the total number of adverse effects in each group. AE was defined

as death for any reason, inhospitalisation for any reason and any other serious, unexpected AE.

Notes

Sample size calculation: yes

Ethics approval: yes

Comments from review authors:

1. We received additional data on BPD subgroups by email from Dr Murran in 2017 and again in 2018.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Quote: "Randomisation was based on a computer generated pseudo-random
code using random permuted blocks of randomly varying size created by the
Nottingham Clinical Trials Unit [NCTU] in accordance with their standard op-
erating procedure and held on a secure server. Allocation was stratified by re-
cruiting centre and sex." (p xxiv)

Quote: "The sequence of treatment allocations was concealed until recruit-
ment, data collection, and all other trial-related assessments were complete.
The investigator, or an authorised designee, accessed the treatment alloca-
tion for each participant by means of a remote, internet-based randomisation
system developed and maintained by the NCTU. Allocation was therefore fully
concealed from recruiting staff." (p 14)

Quote: "At the start of each follow-up, participants were reminded of the im-
portance of not disclosing their treatment allocation to the research assistant
using a suggested unblinding script (See Appendix 9). If the research assistant
was inadvertently unblinded to treatment allocation before completing the fi-
nal follow-up, a record of the incident of unblinding was made. Researchers al-
so reported whether or not they were aware of the treatment allocation at the
time of completing the primary end-point assessments. Owing to changes in
personnel over the course of the trial, in some cases, end-point assessments
were conducted by researchers who were not unblinded. A record was made
of the blinding status of the researcher conducting the final follow-up data col-
lection." (p 16). "Data analysts remained blinded to allocation during the study
by having access to only aggregate data and no access to data that could re-
veal treatment arm, such as course attendance". "Most of the outcome data
were obtained from self-report questionnaires from participants who were not
blind to treatment allocation". (p 16)

Comment: Participants were analysed as randomised, and all were included
in the primary analysis by imputation of missing data.

Quotes: "We obtained robust variance estimates in all regression models to
allow for the potential clustering effect of receiving therapy in groups in the
PEPS arm." (p 8) "The primary analysis (ITT) compared the mean SFQ score be-

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

217

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McMurran 2016  (Continued)

Cochrane Database of Systematic Reviews

tween PEPS and usual treatment at 72 weeks postrandomisation follow-up,
adjusted for baseline SFQ score and stratification variables (centre and gen-
der), and implemented using maximum likelihood-based generalised linear
modelling." (p 12) "The pattern of missing data was investigated by examining
variables recorded at baseline that were associated with ‘missingness’ of SFQ
score at the 72-week follow-up. Multiple imputation and analysis of multiple
imputed data sets were conducted using ‘mi’ procedures in Stata. The imputa-
tion model contained site, age, sex,ethnicity, social status, PD category (sim-
ple or complex), SFQ at baseline and 24 weeks, baseline EQ-5D health state
score, baseline HADS score, baseline SPSI-R score and baseline three main
problems score, and 20 data sets were imputed." (p 12)

Selective reporting (re-
porting bias)

Low risk

Comment: in terms of outcomes, protocol and full-text report matched.

Other bias

High risk

Treatment adherence

Comment: adherence was self-rated by the therapist.

Attention bias

Comment: mean number of treatment weeks: TAU non-completer = 30 (SD =
25.7), completer = 80.2 (SD = 9,8); PEPS non-completer = 36.7 (SD = 23,4), com-
pleter = 80.3 (SD = 10.4). Seemed that both groups got equal amount of thera-
py.

Allegiance bias

Comment: authors (MM, CD) have allegiance to PEPS therapy.

Vested interest

Comment: The National Institute for Health Research (NIHR) Health Technolo-
gy Assessment programme funded this study. Hywel Williams is the Deputy Di-
rector of this programme but was not involved in the funding decision for this
programme.

Mehlum 2014 

Study characteristics

Methods

19-week trial with 2 arms

1. Dialectical behavior therapy for adolescents (DBT-A)
2. Enhanced usual care

Duration of trial: 19 weeks

Country: Norway

Setting: outpatient

Participants

Method of recruitment of participants: recruited from child and adolescent psychiatric outpatient
clinics in Oslo that screened newly referred patients for current self-harm. Comorbidity in BPD subsam-
ple (N = 14, 35.9% of overall sample) unclear

Inclusion criteria

1. A history of at least 2 episodes of self-harm
2. At least 1 within the last 16 weeks

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

218

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mehlum 2014  (Continued)

Cochrane Database of Systematic Reviews

3. At least 2 DSM-IV criteria for borderline personality disorder (+ the self-destructive criterion) or alter-
natively, at least 1 DSM-IV criterion for borderline personality disorder + at least 2 subthreshold-level
criteria

4. Fluency in Norwegian

Exclusion criteria

1. Diagnosis of bipolar disorder (except bipolar II)
2. Schizophrenia
3. Schizoaffective disorder
4. Psychotic disorder not otherwise specified
5. Intellectual disability
6. Asperger syndrome

Interventions

Experimental group

Treatment name: DBT-A

Number randomised to group: 39

Duration: 19 weeks

Control/comparison group

Comparison name: enhanced usual care

Number randomised to group: 38

Duration: 19 weeks

Both groups:

Concomitant psychotherapy: not stated

Concomitant pharmacotherapy:

Overall sample at baseline (including sub-threshold BPD): "Three DBT-A patients (7.7%) used at least
1 psychotropic drug for a mean number of 94.7 days (SD ¼ 64.3), whereas 5 EUC patients (13.2%) used
such medication for a mean number of 72.8 days (SD ¼ 16.6), with no significant differences.“ (p. 1087)

Medication use in BPD subsample (N = 14, 35.9% of overall sample) unclear

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod:

Overall sample (subthreshold including): “Only 7 participants (4 in the DBT-A group and 3 in the EUC
group) had used any psychotropic medication over the follow-up year (not significant).“ (Mehlum 2016,
p. 297)

Medication use in BPD subsample unclear (N = 14, 35.9% of overall sample) unclear

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Zanarini Rating Scale for Borderline Person-
ality Disorder (Zan-BPD); Borderline Personality Disorder Severity Index, Fourth version (BPDSI-IV);
Clinical Global Imperession Scale for Borderline Personality Disorder Patients (CGI-BPD); or Border-
line Symptom List (BSL)

2. Self-harm, in terms of proportion of participants with self-harming behaviour, or as assessed by De-
liberate Self-harm Inventory (DSHI); Self-harm Behavior Questionnaire; or Lifetime Parasuicide Count
(LPC)

3. Suicide-related outcomes, assessed by the Suicidal Behaviours Questionnaire; Beck Scale for Suici-
dal Ideation, in terms of proportion of patients with suicidal act; or Suicidal Ideation Questionnaire
– Junior

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

219

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mehlum 2014  (Continued)

Cochrane Database of Systematic Reviews

4. Mental  health  status,  assessed  by  the  Global  Assesment  Scale;  Global  Assessment  of  Functioning

Scale; or Social Functioning Questionnaire

Secondary

1. Anger, assessed by the hostility subscale of the Symptom Checklist-90-Revised (SCL-90-R) or the State-

Trait Anger Expression Inventory

2. Affective instability, assessed by the relevant item on the Zan-BPD, CGI-BPD or BPDSI-IV
3. Chronic feelings of emptiness, assessed by the relevant item on the Zan-BPD, CGI-BPD or BPDSI-IV
4. Impulsivity, assessed by the Barrett Impulsiveness Scale, or the Anger, Irritability and Assault Ques-

tionnaire

5. Interpersonal problems, assessed by the Inventory of Interpersonal Problems, or the relevant item on

the Zan-BPD, CGI-BPD, BPDSI-IV, or SCl-90-R

6. Abandonment, assessed by the relevant item on the Zan-BPD, CGI-BPD or BPDSI-IV
7. Identity disturbance, assessed by the relevant item on the Zan-BPD, CGI-BPD or BPDSI-IV
8. Dissociation and psychotic-like symptoms, assessed by the Dissociative Experience Scale or the Brief

Psychiatric Rating Scale

9. Depression, assessed by the Beck Depression Inventory, the Montgomery Åsberg Depression Rating

Scale or the short (13-item) version of the Self-report Mood and Feelings Questionnaire (SMFQ)

10.Attrition, in terms of patients lost after randomisation in each group
11.Adverse effects, measured by use of standardised psychometric rating scales, such as the Systematic

Assessment for Treatment Emergent Events, laboratory values or spontaneous reporting

Notes

Sample size calculation: yes

Ethics approval: The study was approved by the Regional Committee for Medical Research Ethics,
South-East Norway, and all patients and parents provided written informed consent.

Comments from review authors:

1. We contacted Dr Mehlum by email in 2017 about the possibility of getting access to subsample data on
patients with borderline personality disorder and we were informed that they were working on new
publications using the borderline personality disorder - data only.
2. Data extraction was based on a secondary publication of this study.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

Low risk

Quote: “Treatment allocation of participants after baseline assessments was
based on a permuted block randomization procedure with an undisclosed and
variable blocking factor, and daily management of the randomization proce-
dures was performed by an external group.” (p 1083)

Quote: “…and daily management of the randomization procedures was per-
formed by an external group.” (p 1083)

Quote: “Diagnostic assessments were made by experienced clinicians blinded
to treatment allocation.” (p 1083)

Quotes: “Data analysis was by intention to treat.”; “Although some patients
dropped out of treatment, all patients were followed from baseline to trial
completion with no dropouts from the research.”

Comment: All participants were assessed for outcome measures at follow-ups
regardless of treatment exposure (see p 1086). Overall, no differences are seen
in proportion of withdrawals between groups. The study measured follow-up
outcome data on all participants regardless of amount of treatment exposure.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

220

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mehlum 2014  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

Cochrane Database of Systematic Reviews

No information was given on how participants with less exposure were includ-
ed/imputed in the final analyses.

Comment: all outcomes listed in registration were reported on in final paper
of the overall sample, including participants with subthreshold BPD. Addition-
ally, hopelessness and BPD symptoms were reported, which had not been list-
ed in the protocol. These were not described as post hoc analyses in the final
report.

For the sample included here (full-BPD), only some data were available for de-
pression, suicidality and psychosocial functioning.

Other bias

High risk

Treatment adherence

Quote: "adherence to DBT continued to be assessed throughout the trial”. Ad-
herence controlling was conducted for the DBT group. Unclear if it was done
for the control group

Attention bias

Quotes: “Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1
weekly session of individual therapy (60 minutes), 1 weekly session of multi-
family skills training (120 minutes), and family therapy sessions and telephone
coaching with individual therapists outside therapy sessions as needed.” “En-
hanced usual care was 19 weeks of standard care (enhanced for the purpose of
the study by requiring that EUC therapists agree to provide on average no less
than 1 weekly treatment session per patient throughout the trial)”. (p 1084)

Comment: more attention spent on DBT group

Allegiance bias

Comment: first author (L Mehlum) is educated in DBT-therapy
(www.med.uio.no/klinmed/personer/vit/lmehlum). Mehlum is one of the most
prominent DBT people in Norway, and may have edited a handbook of DBT or
received money for educating others in DBT.

Mohamadizadeh 2017 

Study characteristics

Methods

16 sessions trial with 3 arms

1. Dialectical behavior therapy (DBT)
2. Schema therapy (ST)
3. Control (no intervention)

Duration of trial: 16 sessions
Country: Iran

Setting: inpatient

Participants

Method of recruitment of participants: convenience sampling method
Sample size: 36

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
Mean age: not stated
Sex: 100% female

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

221

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mohamadizadeh 2017  (Continued)

Comorbidity: not stated

Inclusion criteria: not stated

Exclusion criteria

Cochrane Database of Systematic Reviews

1. Patients with previous suicide attempt or recurrent suicidal behaviour
2. People with perturbations, such as bipolar disorder, substance abuse and personality disorder, treat-

ed with the drug were initially excluded.

Interventions

Experimental group 1
Treatment name: DBT
Number randomised to group: 12
Duration: 16 sessions for 90 minutes
Experimental group 2
Comparison name: ST
Number randomised to group: 12
Duration: 16 sessions for 90 minutes

Control/comparison group
Comparison name: no treatment
Number randomised to group: 12
Duration: 16 sessions for 90 minutes
Both groups
Concomitant psychotherapy: none
Concomitant pharmacotherapy: none; "The use of any psychiatric medication during training,
from the very first session of treatment, and the use of any type of psychological services were aban-
doned." (quote, p 1027)

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: equal (medication not allowed)

Outcomes

Primary

1. Suicide-related outcomes, assessed by the Beck Scale for Suicidal Ideation, suicidal thoughts subscale

(BSS)

Secondary

1. Depression, assessed by the Beck Depression Inventory (BDI)

Sample size calculation: not stated
Ethics approval: not stated

Comments from review authors: none

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Unclear risk

Comment: insufficient information. It was unclear if the no treatment control
group were randomized or not

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Comment: insufficient information

Unclear risk

Comment: insufficient information

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

222

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mohamadizadeh 2017  (Continued)

Cochrane Database of Systematic Reviews

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: no attrition rates reported; no imputation methods reported

Selective reporting (re-
porting bias)

Unclear risk

Comment: no protocol found, so we could not compare planned methods
with reported methods

Other bias

Unclear risk

Adherence to treatment

Comment: no adherence check stated, but a list over each session was provid-
ed

Attention bias

Comment: no differences between groups
Allegiance bias

Comment: none

Morey 2010 

Study characteristics

Methods

1.5 month trial with 2 arms

1. Manual Assisted Cognitive Therapy (MACT) + Therapeutic Assessment (TA)
2. Manual Assisted Cognitive Therapy (MACT)

Duration of trial: 1.5 months

Country: USA

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Samplse size: 16

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV), and Personality
Assessment Inventory-Borderline Scale (PAI-BOR)

Mean age: 31.1 years

Sex: 81.3% female

Comorbidity: not specified

Inclusion criteria

1. Scores above N70 on Personality Assessment Inventory-Borderline Scale (PAI BOR) and SUI
2. Scores of 5 or more on the PDQ-4 borderline personality disorder
3. Scores above 70 on the SPS total
4. Scores above 5 symptoms of borderline personality disorder on the DIPD-IV

Exclusion criteria

1. Active psychosis

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

223

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Morey 2010  (Continued)

2. History of schizophrenia
3. Substance intoxication or withdrawal

Interventions

Experimental group

Treatment name: MACT + TA

Number randomised to group: 16

Duration: 1.5 months (6 weekly sessions)

Control/comparison group

Comparison name: MACT

Number randomised to group: 16

Duration: 1.5 months (6 weekly sessions)

Both groups

Concomitant psychotherapy: No other psychosocial interventions were allowed.

Concomitant pharmacotherapy: Psychotropic medication was allowed. 56% of participants were tak-
ing psychotropic medication at baseline.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. BPD severity, assessed with the PAI-BOR
2. Suicidality, assessed with the PAI-BOR
3. Parasuicidality, assessed with the PAI-BOR

Secondary

1. Affective instability, assessed with the PAI-BOR
2. Interpersonal problems, assessed with the PAI-BOR
3. Identity disturbance, assessed with the PAI-BOR

Notes

Sample size calculation: yes

Ethics approval: not stated

Comments from the review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Comment: study stated that participants were randomised but the specific
methods were not clear.

Allocation concealment
(selection bias)

Unclear risk

Comment: study stated that participnats were randomised but the specific
methods were not clear.

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Quote: "[...] assessments [...] were conducted by an independent evaluator".
(p 533)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

224

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Morey 2010  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: no further details

Selective reporting (re-
porting bias)

Unclear risk

Comment: no indication of selective reporting, but insufficient information to
permit judgement of 'high' or 'low' risk of bias

Other bias

Low risk

Adherence bias

Quote: "Consenting clients in both conditions were assigned to a project ther-
apist, who worked under the supervision of the primary investigator." (p 532)

Allegiance bias

Quote: study authors not among treatment developers

Attention bias

Quote: both groups received comparable amounts of attention.

Morton 2012 

Study characteristics

Methods

13-week trial with 2 arms

1. Acceptance and commitment therapy (ACT) + treatment-as-usual (TAU)
2. TAU

Duration of trial: 13 weeks of therapy
Country: Australia

Setting: outpatient, within public-sector mental health services, Victoria

Participants

Method of recruitment of participants: potential participants recruited via referrals from public men-
tal health services to Spectrum (personality disorder service for Victoria)

Sample size: 41

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), and Structured
Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: ACT + TAU = 35.6 years (standard deviation = 9.33, range = 19–52), TAU = 34.0 years (standard
deviation = 9.02, range = 21–54)

Sex: 90.5-95% female

Comorbidity: not stated

Inclusion criteria

1. 4 or more criteria of borderline personality disorder
2. A registered client of a public sector adult mental health service
3. Agreement from the public sector service to arrange an inpatient admission or crisis team visit, if re-

quired

4. Any kind of regular contact (at least once in 2 weeks) with a public or private sector clinician, not

necessarily for therapy

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

225

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Morton 2012  (Continued)

Exclusion criteria

Cochrane Database of Systematic Reviews

1. Current positive or negative psychotic symptoms other than reactive psychotic symptoms associated

with borderline personality disorder

2. A significant risk of violent or threatening behavior, or both, to other participants
3. Intellectual disability, cognitive impairment, or difficulty speaking English, severe enough to interfere

Interventions

with participation

Experimental group
Treatment name: ACT + TAU
Number randomised to group: 21
Duration: 26 weeks
Control/comparison group
Comparison name: TAU
Number randomised to group: 20
Duration: also appears to be 26 weeks

Both groups

Concomitant psychotherapy: 11 participants (27% of the total sample population of 41) described the
service they received as therapy or counselling, rather than case management or medication review.
Concomitant pharmacotherapy: TAU offered medications management.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: no data provided specifying medication use in the two groups

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Borderline Evaluation of Severity over Time

(BEST)

Secondary

1. Affective instability, assessed by the Difficulties in Emotion Regulation Scale (DERS)
2. Depression, assessed by the Depression anxiety Stress Scale (DASS)
3. Attrition, in terms of patients lost after randomisation in each group

Sample size calculation: not stated
Ethics approval: not stated

Comments from review authors:

1. Information about randomisation and allocation procedure, as well as about blinding of outcome
assessors and about protocol registration, was recived by email from Dr Morton on 22 December 2017.

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Quotes: "Available participants at each location were randomized to ACT +
TAU or TAU, after stratification of the sample based on the presence or ab-
sence of two or more self-harm episodes in the last year. This stratification of
the sample was done in order to ensure equal base rates across the conditions,
as recent self-harm was not a criterion of inclusion in the trial. This resulted in
four ACT groups in four locations, each with 4 to 6 participants". The random-
ization process was planned as follows and was carried out as described: “Ran-
domisation to immediate treatment or waiting list control: When 16 clients
with four or more of the criteria for BPD, assessed as suitable, have been re-
cruited for a group at a particular location, a randomisation procedure will be
carried out and eight clients will commence treatment as soon as practicable
with the remaining eight commencing three months later (waiting list control

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

226

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Morton 2012  (Continued)

Cochrane Database of Systematic Reviews

group). If this procedure would result in an unreasonable delay, a group may
commence when 10 clients have been recruited (five will be randomised to
an immediate start and five to waiting list). Recruitment will continue for nine
months or until 60 clients have been accepted into phase 1 groups whichever
occurs sooner. The immediate treatment clients will have a three month peri-
od of follow up before phase 2 groups begin. Because change in self-harm is
of interest and yet only about half the sample are expected to be still currently
self-harming, the sample will be stratified based on the presence or absence of
two or more self-harm episodes in the last year. The randomisation procedure
will use a randomisation in blocks of four procedure (Pocock, 1983), using re-
sources available at randomization.com. It will be carried out by an indepen-
dent person who is not part of the research or clinical team.” (personal com-
munication)

Allocation concealment
(selection bias)

High risk

Quote: "Investigators were not blind to group allocation." (personal communi-
cation)

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Quote: "Outcomes were assessed via self-report questionnaires. Outcome as-
sessors were not blind". (personal communication)

Quote: "Scores were analyzed using mixed model procedures, which allowed
for all available data to be used in the analyses. This approach takes into ac-
count the obtained outcomes and missingness for participants with missing
data, somewhat reducing the analytic problem presented by missing data.
Compound symmetry covariance matrices were used as they were found to
provide better model fit with fewer parameters than unstructured matrices as
determined by the restricted log likelihood". (p 537)

Selective reporting (re-
porting bias)

Unclear risk

Quote: "The group protocol was developed based on 10 years of experience in
providing residential and outpatient treatment for people with a diagnosis of
BPD". (p 528)

Other bias

High risk

Treatment adherence

Comment: clinicians were instructed not to include any CBT change strategies
such as cognitive challenge. Efforts were made to ensure treatment fidelity via
review of group materials by ACT trainer Russ Harris and via consultation and
supervision sessions, which included discussion framed by the ACT Competen-
cies.

Allegiance bias

Quote: "An outline of the 12 sessions (of ACT) is provided in Table 2. A copy of
the treatment manual, including the handouts and group session outlines) is
available from Spectrum." (p 534)

Comment: Morton (lead author) developed the treatment manual used in the
experimental group

.Attention bias

Comment: ACT consisted of 12 2-hour sessions. Unclear how the treatment ex-
posure in TAU compared to this

Nadort 2009 

Study characteristics

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

227

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Nadort 2009  (Continued)

Methods

18-month trial with two arms

Cochrane Database of Systematic Reviews

1. Schema-focused therapy
2. Schema-focused therapy + therapist telephone availability outside office hours in case of crisis (SFT

+ TTA)

Duration of trial: 18 months

Country: The Netherlands

Setting: outpatient

Participants

Methods of recruitment of participants: Most of the patients were referred by therapists in secondary
and tertiary community mental health institutes, some patients were referred by primary care physi-
cians of psychotherapists with private practices. All patients were referred based on a clinical diagnosis
of BPD. Patients were then assessed at each study site.

Sample size: 62

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II) and Border-
line Personality Disorder Severity Index - Version IV (BPDSI-IV) score > 20

Mean age: 32.0 years

Sex: 96.8% female

Comorbidity: not specified

Inclusion criteria

1. DSM-IV-based main diagnosis of BPD
2. Age between 18 and 60 years
3. BPSDI-IV score of 20 or higher
4. Dutch literacy

Exclusion criteria

1. Diagnosis of borderline personality disorder not main diagnosis
2. Psychotic disorders (except short, reactive psychotic episodes)
3. Bipolar disorder
4. Dissociative identity disorder
5. Antisocial personality disorder
6. Attention-deficit/hyperactivity disorder
7. Addiction of such severity that clinical detoxification was indicated (after which entering treatment

was possible)

8. Psychiatric disorders secondary to medical conditions
9. Mental retardation
10.No Dutch literacy

Interventions

Experimental group

Treatment name: schema-focused therapy (SFT)

Number randomised to group: N = 30

Duration: 18 months (45-minute individual sessions twice a week for 12 months, one weekly session in
the second year)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

228

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Nadort 2009  (Continued)

Control/comparison group

Cochrane Database of Systematic Reviews

Comparison name: schema-focused therapy + therapist telephone availability outside office hours in
case of crisis (SFT + TTA) (45-minute individual sessions twice a week for 12 months, one weekly session
in the second year)

Number randomised to group: N = 30

Duration: 18 months

Both groups

Concomitant psychotherapy: not stated

Concomitant pharmacotherapy: medication use allowed. 58% of patients used psychotropic medica-
tion at baseline.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Borderline severity, assessed by Borderline Personality Disorder Severity Index (Version IV) (BPDSI-IV)

Notes

Sample size calculation: yes

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Unclear risk

Comment: no clear information provided on method of randomisation

Allocation concealment
(selection bias)

Low risk

Quote: "we used a stratified randomization procedure. The stratification pro-
cedure was performed by a study-independent person and concealed for par-
ticipating therapists, patients and researchers." (p 962)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Quotes: "Study researchers, screeners, research assistants and therapists
were masked to treatment allocation during the screening period and the first
assessment." (p 963) "A limitation of the present study is that the assessments
will be performed by research assistants who cannot remain blinded to the
treatment condition of the included patients, as is always the case in trials
studying the effects of psychotherapy. Nor are the patients blind to treatment
condition. In this study, however, added to the main interview-based outcome
measures, self-report questionnaires will be administered, that will not be in-
fluenced by the research assistants." (p 71)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: no clear details on attrition provided

Selective reporting (re-
porting bias)

Low risk

Comment: published protocol is available (Nadort 2009), with no indication of
selective reporting in the full report.

Other bias

Unclear risk

Comment: no clear details provided

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

229

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Pascual 2015 

Study characteristics

Methods

16-week trial with 2 arms

1. Cognitive rehabilitation (CR)
2. Psychoeducation (PE)

Duration of trial: 16 weeks
Country: Spain

Setting: outpatient

Participants

Method of recruitment of participants: not stated
Sample size: 70

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition, Text Revision (DSM-IV-TR)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II) and Revised
Diagnostic Interview for Borderlines (DIB-R)
Mean age: CR = 32.4 years (standard deviation = 6.04), PE = 32.8 years (standard deviation = 8.8)

Sex: 74.3% female

Comorbidity: No information

Inclusion criteria

1. Outpatients aged 18-45 years
2. Diagnoses of borderline personality disorder according to DSM-IV-TR criteria and evaluated by 2 se-

mi-structured clinical interviews - SCID-II and the DIB-R - to guarantee a correct diagnosis
3. Clinical severity measured with Clinical Global Impression for BPD (CGI- BPD) higher than 4
4. Functional impairment measured with a Global Assessment Functioning (GAF) lower than 65

Exclusion criteria

1. Severe physical conditions, such as organic brain syndrome or neurological disease that could affect

neuropsychological performance

2. Intelligence quotient below 85
3. Major depression disorder (MDD) or substance misuse within the last 6 months evaluated with DSM-

IV-TR criteria and SCID-I specific sections

4. DSM-IV-TR criteria for schizophrenia, severe psychotic disorder or bipolar disorder evaluated by SCID-

I specific sections

5. Previous participation in any psychoeducation or cognitive rehabilitation intervention

Interventions

Experimental group
Treatment name: cognitive rehabilitation (CR)
Number randomised to group: 36
Duration: 16 weeks

Control/comparison group
Comparison name: psychoeducation (PE)
Number randomised to group: 34
Duration: 16 weeks

Both groups
Concomitant psychotherapy: no
Concomitant pharmacotherapy: All patients continued pharmacological treatment if it had been ini-
tiated prior to inclusion. At baseline, 75% of the CR group was taking psychotropic medications, and
67.6% of the PE group. The difference was not significant.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

230

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pascual 2015  (Continued)

Cochrane Database of Systematic Reviews

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. BPD severity, assessed by Borderline Symptom List – 23 (BSL-23)

Secondary

1. Impulsivity, assessed by the Barrett Impulsiveness Scale (BIS)
2. Depression, assessed bythe Beck Depression Inventory (BDI) or the Montgomery Åsberg Depression

Rating Scale

3. Attrition, in terms of patients lost after randomisation in each group
4. Adverse events (final results not reported)

Notes

Sample size calculation: yes
Ethics approval: yes

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “All participants were randomized to receive CR or PE in a 1:1 ratio
stratified by centre, age, and education level. Generation of random allocation
sequence was done with the Research Randomizer (www.randomizer.org)”. (p
2)

Allocation concealment
(selection bias)

Unclear risk

Comment: no clear information provided about whether or not allocation was
concealed

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Quote: “Study design was a multicenter, randomized, rater-blind clinical trial”.
(p 2)

Comment: reasons for dropout fairly balanced between groups. No differ-
ences in overall attrition rates between groups, but the attrition rates exceed-
ed the 30% estimate of the power calculation, which may have increased un-
certainty in the overall effect estimates.

Selective reporting (re-
porting bias)

Unclear risk

Comment: no secondary outcomes were included in the trial registration, but
they were in the published paper. The paper did not categorise them as post
hoc analyses.

Other bias

High risk

Treatment adherence

Quote: "To ensure the reliability among centers regarding the evaluation and
the treatment fidelity, two meetings were organized before the start of the
study to train therapists". (p 2)

Allegiance bias:

Comment: Google search on first and last author did not reveal any allegiance
biases.

Attention bias:

Comment: CR: group sessions, 120 minutes, twice a week during 16 weeks (32
sessions) PE: 16 weekly group sessions of 120 minutes each (16 sessions)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

231

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Philips 2018 

Study characteristics

Methods

15.5-18 month trial with 2 arms

1. Mentalisation-based therapy (MBT)
2. Treatment-as-usual (TAU)

Duration of trial: 18 months
Country: Sweden

Setting: Stockholm Centre for Dependency Disorders

Participants

Method of recruitment of participants: “Patients were recruited through outpatient addiction treat-
ment services throughout Stockholm County, through case-finding among the social service offices in
the region and through advertising in newspapers.” (quote, p 3)

Sample size: 46

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: 36.7 years (standard devtiation = 9.6, range = 20-54)

Sex: 80.4% female

Comorbidity: Current axis I disorders (overall sample, not specified by treatment groups): MDD 28.3%,
other depressive disorder including dysthymia 28.3%, bipolar II disorder 6.5%,  PTSD 15.2%, any anxi-
ety disorder excluding PTSD 65.2%, any eating disorder 6.5%, somatoform disorder 2.2%, any psychot-
ic disorder 0%

Current axis I substance use disorder (overall sample): alcohol 45.7%, amphetamines 13.0%, cannabis
6.5%, opioids 39.1%, sedatives, hypnotics, anxiolytics 21.7%

Inclusion criteria

1. DSM-IV diagnosis of borderline personality disorder and substance dependence
2. Males and females aged 18-65
3. Currently under treatment at substance dependence treatment clinic

Exclusion criteria

1. Schizophrenia, schizoaffective disorder, bipolar disorder type I, cognitive impairment (including mild

cognitive impairment: IQ below 85), autism spectrum disorders, psychopathy

2. Participation in psychotherapy outside of the study (ongoing or terminated less than 90 days before

inclusion)

3. Not being able to communicate in the Swedish language without an interpreter

Interventions

Experimental group
Treatment name: mentalisation-based therapy (MBT)
Number randomised to group: 24
Duration: mean = 15.5 months (mean = 63.3 sessions)
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: not stated

Control/comparison group
Comparison name: treatment-as-usual (TAU)
Number randomised to group: 22
Duration: 18 months (mean = 10.7 therapy sessions)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

232

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Philips 2018  (Continued)

Cochrane Database of Systematic Reviews

Concomitant psychotherapy: of the patients randomised to TAU (n = 22), 11 received some sort of
psychotherapy
Concomitant pharmacotherapy: not stated

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Borderline Personality Disorder Severity In-

dex, Fourth version (BPDSI-IV)

2. Self-harm, assessed by the Deliberate Self-harm Inventory (DSHI)
3. Suicide-related outcomes, by means of suicide attempts, assessed from direct contact with patients

and health care staff and from reviewing case records

4. Mental health status, assessed by the Global Symptom Index (GSI)

Secondary

1. Interpersonal problems, assessed by the Inventory of Interpersonal Problems - Shortened Version (IIP)
2. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: yes

Ethics approval: Stockholm Regional Ethical Review Board (registration number: 2007/642-31/1)

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Quote: “The randomization was conducted by the KTA [Karolinska Trial Al-
liance] using an urn procedure. The randomization was made in blocks and
the researchers were not informed of the block size. KTA prepared sealed ran-
domization envelopes with information about each patient’s treatment as-
signment.” (p 3)

Quote: “The randomization was conducted by the KTA [Karolinska Trial Al-
liance] using an urn procedure. The randomization was made in blocks and
the researchers were not informed of the block size. KTA prepared sealed ran-
domization envelopes with information about each patient’s treatment as-
signment.” (p 3)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Comment: no information on blinding provided by report authors

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Quotes: “Outcome analyses were made both in the form of completer analy-
ses and ITT analysis with the last observation carried forward. Throughout all
measures, completer and ITT analyses gave equivalent results and therefore
only the results from completer analyses are described here (Table 2). Out-
come analyses of the self-report and interview measures were seriously chal-
lenged by the high attrition rates, as only 24 out of 46 patients came to the
measurements at endpoint 18 months (13 out of 24 patients in MBT, and 11 out
of 22 patients in the control group).” (p 5) "Due to the recruitment problems in
the project, our initial power calculation had to be revised." (p 4)

Selective reporting (re-
porting bias)

High risk

Comment: Beck’s Suicidal Intent Scale, Social Adjustment Scale – Self Report
listed as secondary outcomes in trial registration, but not in final report. Out-

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

233

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Philips 2018  (Continued)

Cochrane Database of Systematic Reviews

comes related to health economics and criminality also listed in registration,
but not in full report

Other bias

High risk

Adherence bias

Quote: "Despite significant efforts to train therapists in the MBT model, most
of the them had poor average results on the MDT adherence tests: only 2 ther-
apists passed the threshold for adequate MBT, while the remaining 7 failed to
do so." (p 6)

Attention bias

Quote: "For patients randomized to MBT (n = 24), the treatment duration was
in average 15.5 months (SD 4.1, range 3–18) with a mean of 63.3 MBT sessions
(SD 26.7, range 10–116). Control group patients received on average 10.7 ther-
apy sessions (SD 14.7, range 0–45)". (p 5)

Allegiance bias

Comment: none found

Priebe 2012 

Study characteristics

Methods

12-month trial with 2 arms

1. Dialectical behavior therapy (DBT)
2. Treatment-as-usual (TAU)

Duration of trial: 12 months
Country: UK

Setting: outpatient

Participants

Method of recruitment of participants: referral
Sample size: 70

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: 32.2 years (standard deviation = 10.8)

Sex: 87.5% female

Comorbidity: yes, but not specified. Number of axis 1 disorders = 8

Inclusion criteria

1. 5 days or more with self-harm in the year prior to treatment
2. Aged 16 years or over
3. Diagnosis of at least 1 personality disorder

Exclusion criteria

1. Severe learning difficulties that would interfere with the individual’s ability to participate in Dialectical

behaviour therapy (DBT) treatment
2. An inability to read or write English

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

234

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Priebe 2012  (Continued)

Interventions

Experimental group
Treatment name: dialectical behaviour therapy (DBT)
Number randomised to group: 40
Duration: 12 months
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: not stated

Control/comparison group
Comparison name: treatment-as-usual
Number randomised to group: 40
Duration: 12 months
Concomitant psychotherapy: TAU encompasses many different psychotherapies. It is not specified
what treatments participants in this group received.
Concomitant pharmacotherapy: allowed (utilisation was monitored), no further data

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. BPD severity, assessed by the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD)
2. Self-harm, in terms of proportion of participants with self-harming behaviour
3. Mental health status, assessed by the 24-item Brief Psychiatric Rating Scale (BPRS)

Secondary

1. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: not stated
Ethics approval: yes

Comments from review authors:

1. We contacted Dr Priebe by email on 26 May 2016 asking for the number of BPD participants in the
study sample. We received this answer: "Indeed the precise diagnoses are not reported in the paper,
but my memory says that 79 patients out of 80 did have a BPD diagnosis. I guess no separate analysis
is needed in this case.". We also received some additional data on self-harm from Dr Priebe.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “Randomisation was computer generated with a 1:1 allocation by an
independent statistician, using 6 blocks of 12 randomly permuted treatment
allocation sequences, with a final block of 8.” (p 358)

Allocation concealment
(selection bias)

Low risk

Quote: “Randomisation was computer generated with a 1:1 allocation by an
independent statistician, using 6 blocks of 12 randomly permuted treatment
allocation sequences, with a final block of 8.” (p 358)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Quote: “Interviewers were therefore not masked to treatment allocation.” (p
358)

Unclear risk

Quote: “Of the 40 randomised to receive DBT, 3 people did not start treatment
due to various reasons and a further 18 patients did not complete the 1-year
treatment”. (p 359)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

235

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Priebe 2012  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

Cochrane Database of Systematic Reviews

Comment: The trial registration listed quality of the therapeutic relationship
as an outcome measure; however, this measure was not mentioned in the final
report.

Other bias

Unclear risk

Treatment adherence

Comment: "To establish adherence to the DBT model, individual treatment
sessions were audio recorded and 10% of the available recordings were as-
sessed for adherence by a DBT therapist [...] using a 63-item rating scale”. (p
357) Adherence routines for DBT. No mentioning of adherence routines for TAU

Allegiance bias

Comment: first author is a licensed psychotherapist. Unclear if he has direct
interest in DBT

Attention bias

Comment: few data on what encompassed TAU – large heterogeneity - and
therefore, it may be possible that the participants in the DBT group received
more therapy.

Vested interest

Comment: the authors declared that they have no conflicts of interest.

Reneses 2013 

Study characteristics

Methods

20-24 week trial with 3 arms

1. Psychic Representation focused Psychotherapy (PRFP) + conventional treatment
2. Conventional treatment

Duration of trial: 20-24 weeks
Country: Spain

Setting: outpatient

Participants

Method of recruitment of participants: patients of San Carlos and Hospital Universitario 12 de Oc-
tubre of Madrid included in study. The patients were recruited consecutively over a 12-month period.
Sample size: 53

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition, Text Revision (DSM-IV-TR)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
Mean age: 33.8 years (standard deviation = 7.5)
Sex: 70.5% female

Comorbidity: 47.7% with axis 1

Inclusion criteria

1. Clinical diagnosis of borderline personality disorder following the DSM-IV-TR criterion made by the
treating psychiatrist during the selection phase and using the SCID-II interview in the inclusion phases

2. Aged 18 to 50 years
3. Having a clinical situation of outpatient treatment and having accepted the study conditions by in-

formed consent

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

236

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Reneses 2013  (Continued)

Exclusion criteria

Cochrane Database of Systematic Reviews

Interventions

1. Having active suicide risk symptoms, violent or unmanageable heteroaggressive behaviors on the out-

patient level at the time of recruitment

2. Comorbidity with diagnosis of eating behavior disorder on Axis I, with toxic dependence disorder or

current severe physical disease

Experimental group
Treatment name: psychic representation focused psychotherapy (PRFP) + conventional treatment
Number randomised to group: 25
Duration: 20 weeks
Control/comparison group
Comparison name: conventional treatment (pharmacological treatment and psychological advice)
Number randomised to group: 28
Duration: 24 weeks

Both groups

Concomitant psychotherapy: optionally, patients could receive nonstandard outpatient psychologi-
cal advice, but any type of standard psychotherapy excluded
Concomitant pharmacotherapy: all participants were receiving drug treatment, 90% of whom were
receiving antidepressants, more than 40% mood stabilisers and 30% antipsychotics.

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Zanarini Rating Scale for Borderline Person-

ality Disorder, total score (Zan-BPD)

2. Suicide-related outcomes, assessed by the suicidality subscale of the ZAN-BPD
3. Psychosocial functioning, assessed by the Social Adaptation Self-evaluation Scale (SASS)

Secondary

1. Affective instability, assessed by the affective instability subscale of the ZAN-BPD
2. Chronic feelings of emptiness, assessed by the feeling of emptiness subscale of the ZAN-BPD
3. Impulsivity, assessed by the impulsivity subscale of the ZAN-BPD
4. Interpersonal problems, assessed by the relations subscale of the ZAN-BPD
5. Identity disturbance, assessed by the identity subscale of the ZAN-BPD
6. Depression, assessed by the Montgomery Åsberg Depression Rating Scale (MADRS)
7. Attrition, in terms of patients lost after randomisation in each group

Notes

Risk of bias

Bias

Sample size calculation: not reported
Ethics approval: yes

Comments from review authors: none

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “The subjects who met the inclusion criteria were assigned to one of
the two intervention groups through the generation of simple random sam-
pling through a sequence of randomized numbers generated with EPIDAT
3.1.” (p 141)

Allocation concealment
(selection bias)

Unclear risk

Comment: no clear information on allocation concealment was provided by
the authors

Blinding of outcome as-
sessment (detection bias)

Unclear risk

Comment: the authors did not mention whether or not outcome assessors
were blinded

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

237

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Reneses 2013  (Continued)

All outcomes

Cochrane Database of Systematic Reviews

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: high attrition rates. Data were imputed with the LOCF, which is po-
tentially inappropriate. Dropout reasons of lack of satisfaction were over-rep-
resented in control group relative to EG

Selective reporting (re-
porting bias)

Unclear risk

Comment: we could not find a published protocol so could not provide a clear
judgement of 'high' or 'low' risk of bias

Other bias

High risk

Treatment adherence

Comment: adherence routines for EG, no information on CG

Quote: “The supervision method consisted in random control by the external
supervisor of the project of five sessions of each psychotherapist.” (p 141)
Allegiance bias

Comment: time-limited, manualised PDT developed by the research group.
Attention bias

Comment: EG received 20 weeks of treatment, whereas CG received 24 weeks

Robinson 2016 

Study characteristics

Methods

1-year trial with 2 arms

1. Mentalisation-based treatment for eating disorders (MBT-ED)
2. Specialist supportive clinical management for eating disorders (SSCM-ED)

Duration of trial: 1 year
Country: UK

Setting: outpatient

Participants

Method of recruitment of participants: participants recruited from clinical centres by referral from
doctors working in the outpatient services of each centre. Referrals received by trial manager, who con-
tacted the potential participant and provided the participant information sheet.
Sample size: 68

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
Mean age: 31.1 years (standard deviation = 9.9)
Sex: 92.7% female

Comorbidity: anorexia = 5.9%, bulimia = 63.2%, binge eating disorder = 2.9%, eating disorder not oth-
erwise specified (EDNOS) = 27.9%

Inclusion criteria

1. Aged 18 years or older
2. Had a DSM-IV diagnosis of an eating disorder
3. Fulfilled either DSM-IV criteria for borderline personality disorder or had borderline personality dis-
order symptoms. The criteria for borderline personality disorder symptoms were both of the behav-
ioural criteria of DSM-IV.

4. Impulsivity in at least 2 areas that are potentially self-damaging (e.g. spending, sexual behaviour, sub-

stance abuse, reckless driving, binge eating)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

238

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Robinson 2016  (Continued)

Cochrane Database of Systematic Reviews

Interventions

5. Recurrent suicidal behaviour or self-mutilating behaviour

Exclusion criteria

1. Current psychosis based on the Mini International Neuropsychiatric Schedule (MINI) examination
2. Current inpatient or day-patient (attending 3 or more days per week)
3. Currently in individual or group psychological therapy
4. Received MBT less than 6 months prior to randomisation
5. Organic brain disease leading to significant cognitive impairment or body mass index (BMI) less than

15 kg/m2 (normal range = 18.5–25)

Experimental group 
Treatment name: mentalisation-based treatment for eating-disorders (MBT-ED)
Number randomised to group: 34
Duration: 1 year
Control/comparison group 
Comparison name: specialist supportive clinical management for eating disorders (SSCM-ED)
Number randomised to group: 34
Duration: 1 year

Both groups 
Concomitant psychotherapy: no (excluded if currently in individual or group psychological therapy)
Concomitant pharmacotherapy: not stated

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Zanarini Rating Scale for Borderline Person-

ality Disorder (ZAN-BPD)

2. Mental health status, assessed by the Global Assessment of Functioning Scale (GAF)

Secondary

1. Affective instability, assessed by the relevant item or subscale on the ZAN-BPD
2. Chronic feelings of emptiness, assessed by the relevant item or subscale on the ZAN-BPD
3. Impulsivity, assessed by the relevant item or subscale on the ZAN-BPD
4. Interpersonal problems, assessed by the relevant item or subscale on the ZAN-BPD
5. Abandonment, assessed by the relevant item or subscale on the ZAN-BPD
6. Identity disturbance, assessed by the relevant item or subscale on the ZAN-BPD
7. Depression, assessed by The Depression, Anxiety and Stress Scale - 21 Items (DASS-21)
8. Attrition, in terms of patients lost after randomisation in each group
9. Adverse effects, measured by spontaneous reporting

Sample size calculation: yes
Ethics approval: yes

Comments from review authors:

1. We received additional subsample data on BPD patients only at two time points by email from Dr

Hellier on 3 January and 27 March 2018.

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Quote: “The method of randomisation of participants was block randomisa-
tion stratified by BMI (15.0–18.5, 18.6–24.9, 25).” (p 552)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

239

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Robinson 2016  (Continued)

Allocation concealment
(selection bias)

Unclear risk

Cochrane Database of Systematic Reviews

Quote: “Randomly varying block sizes were implemented in order to maintain
pre randomisation allocation concealment. The trial manager used the ran-
domisation result to allocate participants to a treatment.” (p 552)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: “single-blind (researchers and statisticians are blind)”, “the trial statis-
tician and research workers responsible for the collection of the assessments
remained blind to treatment allocation during the trial and primary analy-
ses.” (p 550)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Selective reporting (re-
porting bias)

Low risk

Comment: 15/35 in SSCM-ED and 5/34 in MBT-ED did not receive interven-
tions – significant differences. Reasons were similar across groups. 41/61 par-
ticipants were included in the analyses, so this can be said to be a partial ITT
analysis. Did not comply with the level of attendance calculated a priori.

Quotes: “Participants allocated to SSCM-ED were significantly more likely to
drop out before the start of therapy than those allocated to MBT-ED.” (p 15)
"We set a level of 50% attendance [10] to indicate compliance. That level was
achieved by 47.1 % in the MBT- ED arm and 37.1% in the SSCM- ED arm". (p
556)

Quote: "Not all questionnaires and interviews anticipated in the protocol were
included in this analysis. Some were excluded because the small numbers re-
maining at follow-up did not justify statistical analysis of outcome over time,
and others (the Object Relations Inventory (ORI), treatment adherence, Read-
ing the Mind in the Eyes test and the Reflective Uncelar – they do not use all
but it makes sense in statistical terms. Functioning Questionnaire (RFQ)) will
be de-scribed elsewhere". (p 563)

Other bias

High risk

Adherence bias

Quotes: “Adherence to the treatment model was tested by the supervisors. Af-
ter the trial, seven recorded and transcribed sessions each of MBT-ED (individ-
ual therapy, four therapists) and SSCM-ED (seven therapists) were randomly
selected and subjected to adherence rating.” (p 552) "The adherence scores
(with number of sessions scoring that level in brackets) were 7 (1), 6 (3), 4 (3).
Competence scores were identical to adherence scores". (p 552)

Allegiance bias

Comment: trial was conducted with support from A Bateman

Attention bias

Comment: total number of hours in MBT-ED was 102.7 hours over 12 months;
total number of hours in SSCM- ED was 20-26 hours over 12 months.

Rossouw 2012b 

Study characteristics

Methods

12-month trial with 2 arms

1. Mentalisation-based therapy for adolescents (MBT-A)
2. Treatment-as-usual (TAU)

Duration of trial: 12 months
Country: UK

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

240

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rossouw 2012b  (Continued)

Setting: mental health services

Participants

Method of recruitment of participants: from consecutive case individuals presenting with self-harm
to community mental health services or acute hospital emergency rooms
Sample size: 80

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Childhood Interview for DSM-IV Borderline Personality Disorder (CI-BPD)
Mean age: MBT-A = 15.4 years (standard deviation = 1.3), TAU = 14.8 years (standard deviation = 1.2)
Sex: 85% female

Comorbidity: MBT-A: 30 had borderline personality disorder, TAU = 28 had borderline personality dis-
order. For the entire sample, 20 had alcohol problems in the MBT-A group and 15 in TAU, 13 had sub-
stance misuse in the MBT-A group and 9 in TAU, 39 had depression in the MBT-A group and 38 in TAU

Inclusion criteria

1. Aged 12-17 years
2. Presented with at least 1 episode of confirmed self-harm within the past month and for whom self-

harm was the primary reason for referral and was confirmed intentional

Exclusion criteria

1. Psychosis
2. Severe learning disabiliy (IQ below 65)
3. Pervasive developmental disorder
4. Eating disorder in the absence of self-harm
5. Chemical dependence

Interventions

Experimental group
Treatment name: mentalisation-based therapy for adolescents (MBT-A)
Number randomised to group: 40
Duration: 12 months
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: Participants who were severely depressed were likely to be offered
antidepressants; 16 (40%) received medication during the trial.

Control/comparison group
Comparison name: treatment-as-usual (TAU)
Number randomised to group: 40
Duration: 12 months
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: 40% of the MBT-A group and 43% of the TAU group received medica-
tion at baseline.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the Childhood Interview for DSM-IV Borderline

Personality Disorder (CI-BPD)

2. Self-harm, assessed by the self-harm subscale of the Risk-Taking and Self-Harm Inventory (RTSHI)

Secondary

1. Interpersonal problems assessed by the Experiences in Close Relationships Scale – Avoidance and

Anxiety subscales (ECR)

2. Depression, assessed by the Mood and Feelings Questionnaire (MFQ)
3. Attrition, in terms of patients lost after randomisation in each group

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

241

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rossouw 2012b  (Continued)

Notes

Sample size calculation: yes
Ethics approval: The study was approved by the North East London NHS Foundation Trust Institution-
al Review Board, REC 3.

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Comment: eligible consenting participants were randomised by an indepen-
dent statistician working off-site using an adaptive minimisation algorithm

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Selective reporting (re-
porting bias)

High risk

Comment: allocations were sent in separate envelopes to an administrator
who informed the relevant clinicians

Comment: assessors and participants were both blinded to treatment assign-
ment

Comment: ITT analyses were conducted. Only 37 out of 80 randomised partic-
ipants completed therapy

Comment: there were several outcomes in the protocol that were not men-
tioned in the publication (Millon Adolescent Clinical Inventory, the Reading the
Mind in the Eyes Test, trust game and questionnaire, IQ, as well as assessments
given by the adolescents’ parent or guardian: Millon Clinical Multiaxial Inven-
tory III, Systemic Inventory of Change, the Reading the Mind in the Eyes Test)

Other bias

High risk

Treatment adherence

Comment: supervision sessions included listening to audiotaped sessions
and scoring for adherence by consensus using specially developed adherence
scales (a copy of the adherence scales is available from the first author on re-
quest, see p 1313). However, results of adherence ratings were not presented.

Allegiance bias

Comment: one of the authors (Fonagy) is one of the developers of MBT and
both authors designed and manualised the 12-month intervention program
MBT-A

Attention bias

Comment: number of hours of clinical attention received by the two groups
did not differ

Salzer 2014 

Study characteristics

Methods

6-month trial with 2 arms

1. Inpatient psychodynamic therapy (PDT)
2. Waiting-list/treatment-as-usual (WL/TAU)

Duration of trial: 6 months

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

242

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Salzer 2014  (Continued)

Country: Germany

Setting: inpatient and outpatient

Participants

Method of recruitment of participants: during initial interview at a child and adolescent psychiatric
outpatient clinic

Sample size: 66

Diagnosis of borderline personality disorder: 10th revision of the International Statistical Classifica-
tion of Diseases and Related Health Problems (ICD-10)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: 16.49 years (range = 14-19 years)

Sex: 77.7% female

Comorbidity: all participants fulfilled ICD-10 criteria for a diagnosis of F92 (mixed disorder of conduct
and emotions)

Inclusion criteria

1. Mixed disorder of conduct and emotions (ICD-10, F92)
2. Aged 14-19 years
3. Willing to undergo inpatient treatment

Exclusion criteria

1. Significant prenatal or perinatal impairment
2. IQ below 80
3. Psychotic or psychotic-like disorders
4. Acute alcohol/substance abuse
5. Severe antisocial behaviour

Interventions

Experimental group
Treatment name: PDT

Number randomised to group: 32
Duration: 6 months
Concomitant psychotherapy: inpatient treatment programme, additional treatment
Concomitant pharmacotherapy: tempory pharmacologic treatment to prevent premature discharge
in cases of serious impulse control difficulties

Control/comparison group
Comparison name: WL/TAU
Number randomised to group: 34
Duration: 6 months
Concomitant psychotherapy: allowed to make use of any alternative psychotherapeutic treatments
Concomitant pharmacotherapy: allowed to make use of any psychopharmacological treatments

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod:

“In the treatment group, 21 patients (65.6%) received pharmacotherapy during inpatient treatment;
neuroleptics (n = 2) or atypical neuroleptics (n = 11), tricyclic antidepressants (n = 5), selective sero-
tonin reuptake inhibitors (n = 3), methylphenidate (n = 3) and an anticonvulsant medication (n = 1)
were used.“ (p. 2218); medication use in control group not specified.

Outcomes

Secondary

1. Anger, assessed with the hostility subscale of the Symptom Checklist-90-Revised (SCL-90-R)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

243

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Salzer 2014  (Continued)

Cochrane Database of Systematic Reviews

2. Interpersonal problems, assessed with the interpersonal sensitivity subscale of the SCL-90-R

Notes

Sample size calculation: yes

Ethics approval: approved by the ethics committee at the University of Goettingen. Adolescent pa-
tients and their parents were asked for written consent.

Comments from review authors:

1. We received additional data from Dr Salzer by email on 15 July 2018.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Quote: "randomly assigned [...] by simple randomization that was conducted
by the staff of the out-patient clinic." (p 2214)

Comment: not enough information to make a clear judgement of 'high' or
'low' risk of bias

Allocation concealment
(selection bias)

Unclear risk

Quote: "randomly assigned [...] by simple randomization that was conducted
by the staff of the out-patient clinic." (p 2214)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Comment: not enough information to make a clear judgement of 'high' or
'low' risk of bias

Quotes: "Independent assessor" (p 2214). "An independent, trained assessor
provided all diagnoses based on a structured interview with the adolescent.
This clinical psychologist completed intensive training on the SCID and was
not involved in the randomization process, treatment planning or therapy." ( p
2216)

Quotes: "For all analyses, the ITT sample was used. In case of missing scores,
the last observation carried forward (LOCF) method was applied." (p 2217)
"The comparable dropout rates were 15.6% (n = 5) in the treatment group and
17.6% (n = 6) in the WL/TAU condition (p = 0.71). We found no significant dif-
ferences between the patients who dropped out versus those who remained
within the trial regarding number of diagnoses or symptom impairment either
within the conditions or in the overall sample (all p > 0.29)." (p 2217)

Selective reporting (re-
porting bias)

Unclear risk

Comment: a study protocol was not available; therefore, there was insufficient
information to permit judgement of high or low risk of bias.

Other bias

High risk

Affiliation bias

Comment: treatment developer (A Streeck-Fischer) of the the treatment under
investigation is the senior author of the study.

Treatment adherence

Quote: "All therapists were trained in the PDT and attended an intensive work-
shop that covered the treatment manual. The therapists were under weekly
supervision by the manual’s author. To further ensure treatment fidelity, sev-
eral videotaped treatment sessions were discussed during the supervision.
Treatment adherence was checked in randomly selected videotaped sessions
by independent raters based on manual checklists." (p 2214)

Attention bias

Comment: Participants in the experimental group received inpatient treat-
ment, whereas participants in the control group were put a waiting list and did

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

244

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Salzer 2014  (Continued)

Cochrane Database of Systematic Reviews

not receive any treatment by default (though they were allowed to optionally
use alternate treatments if necessary).

Santisteban 2015 

Study characteristics

Methods

7-month trial with 2 arms

Participants

Interventions

1. Integrative borderline personality disorder-oriented adolescent family therapy (I-BAFT)
2. Individual drug counseling (IDC)

Duration of trial: 7 months
Country: USA

Setting: university centre

Method of recruitment of participants: About two-thirds of youths were referred from the juvenile
justice system: 38% from the Miami-Dade Juvenile Services Department and 32% from a juvenile addic-
tions receiving facility. 30% were referred by school counselors or the community in general.
Sample size: 40

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Revised Diagnostic Interview for Borderlines (RDIB)

Mean age: I-BAFT = 16 years (standard deviations = 0.8), IDC = 15.6 years (standard deviations = 0.8)

Sex: 35-40% female

Comorbidity: substance use disorder on the basis of the last 12 months (even if there was no docu-
mented use in the past 30 days), depression (I-BAFT = 35%, IDC = 40%)

Inclusion criteria

1. Aged 14-17 years
2. Meeting criteria for borderline personality disorder
3. Meeting criteria for substance abuse (in the last 12 months)
4. At least 1 caregiver in each family should participate

Exclusion criteria: none stated

Experimental group
Treatment name: I-BAFT
Number randomised to group: 20
Duration: 7 months

Control/comparison group
Comparison name: IDC
Number randomised to group: 20
Duration: 7 months

Both groups
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: not stated

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

245

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Santisteban 2015  (Continued)

Outcomes

Primary

Cochrane Database of Systematic Reviews

1. Borderline personality disorder severity, assessed by the RDIB and adolescent reports on the Border-

line Personality subscale of the Millon Adolescent Clinical Inventory (MACI)

Secondary

1. Depression, assessed by the Diagnostic Interview Schedule for Children – Predictive Scales (DPS)
2. Attrition, in terms of patients lost after randomisation in each group
3. Adverse effects, measured by spontaneous reporting (reports of inpatients)

Notes

Sample size calculation: no
Ethics approval: yes

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “Permuted block randomization stratified by gender, race/ethnicity
and drug use severity in the past 30 days”. (p 57)

Allocation concealment
(selection bias)

Unclear risk

Comment: not enough information provided to enable a judgement of high or
low bias

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Quote: “Assessors were not blind to the intervention.” (p 57)

Unclear risk

Comment: no sensitivity analysis was performed after multiple imputations.
Relatively high dropout (33% self-reported substance, 38% urine samples,
33% borderline personality disorder behavior)

Selective reporting (re-
porting bias)

Unclear risk

Comment: no protocol was available to enable a clear assessment of selective
reporting bias.

Other bias

High risk

Treatment adherence

Quote: ”Each therapist was trained by an expert in their respective conditions
and met weekly with a supervsor and fellow therapists to view videotaped
therapy sessions and to discuss the implementation of the manualised inter-
ventions with a high degree of adherence and fidelity”. (p 58)

Comment: unclear whether adherence ratings were applied

Allegiance bias

Comment: I-BAFT was developed by the authors.

Attention bias

Comment: matched dosage I-BAFT

Quotes: “I-BAFT delivered weekly family therapy, individual herapy, and skills-
building intervention in a two-sessions-per-week format over a 7-month pe-
riod”. (p 58) “IDC was administered in a two-sessions-per-week format imple-
mented over a 7-month period”. (p 58)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

246

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Schilling 2018 

Study characteristics

Methods

4-week trial with 2 arms

1. Metacognitive training for borderline patients (B-MACT)
2. Active control intervention (PMR)

Duration of trial: 4 weeks
Duration of participation: 4 weeks

Country: Germany

Setting: not stated

Participants

Method of recruitment of participants: recruited from the Deparment of Psychiatry of the Asklepios
clinic, Germany
Sample size: 48

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
Mean age: B-MACT = 29.36 years (standard deviation = 10.46), PMR = 31.15 years (standard deviation =
9.59)
Sex: 91.7% female

Comorbidity: 31% = major depressive disorder, 23% = any anxiety disorder (including 12 patients with
PTSD), 7% = alcohol or substance abuse, 9% = dependence

Inclusion criteria

1. Diagnosis of borderline personality disorder
2. Aged 18-65 years old

Exclusion criteria

1. History of severe neurological disorder
2. Intelligent quotient less than 70
3. Diagnosis of bipolar disorder
4. Schizophrenia or dementia
5. Alcohol or substance dependence with consumption in last 4 weeks

Interventions

Experimental group
Treatment name: B-MACT
Number randomised to group: 22
Duration: 4 weeks
Control/comparison group
Comparison name: PMR
Number randomised to group: 26
Duration: 4 weeks

Both groups
Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: yes; 56 of the 74 treated with psychotropic medication, not specified
by group

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

247

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schilling 2018  (Continued)

Cochrane Database of Systematic Reviews

1. Borderline personality disorder severity, assessed by a translation of the clinician-administered Za-

narini Rating Scale for BPD (ZAN-BPD)

Secondary

1. Depression, assessed by the Beck Depression Inventory
2. Attrition, in terms of patients lost after randomisation in each group

Notes

Sample size calculation: no sample calculation
Ethics approval: yes

Comments from review authors:

1. We received an additional article sent by email from Dr Schilling on 22 January 2019.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Comment: no information about randomisation method provided

Unclear risk

Comment: no information about allocation concealment provided

Unclear risk

Comment: no information about the blinding of assessors provided

Unclear risk

Comment: no data on attrition, no mention of ITT or imputation method

Selective reporting (re-
porting bias)

Unclear risk

Comment: no protocol found preventing us from making a clear assessment
of reporting bias

Other bias

High risk

Treatment adherence

Comment: no data on treatment adherence

Allegiance bias

Comment: first author was principal investigator and delivered both interven-
tions. She also developed the manual for B- MACT.

Attention bias

Comment: interventions were similar in length.

Schuppert 2012 

Study characteristics

Methods

17-week trial with 2 arms

1. Emotion regulation training (ERT)
2. Treatment-as-usual (TAU)

Duration of trial: 17 weeks

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

248

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schuppert 2012  (Continued)

Country: The Netherlands

Setting: outpatient

Cochrane Database of Systematic Reviews

Participants

Method of recruitment of participants: referral from 1 of 4 mental health centers (for emotion regula-
tion problems or borderline personality disorder features)

Sample size: 109

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV) (at least 2 borderline personality disorder criteria); 73% of final sample met full cri-
teria for borderline personality disorder.

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: 15.98 years (standard deviation = 1.22)

Sex: not stated

Comorbidity: 33 % had excessive use of alcohol, 29 % used addictive drugs and psychotropic medica-
tions (however, substance-dependent patients were excluded).

Inclusion criteria

1. Met a minimum of 2 borderline personality disorder criteria according to SCID II
2. Anxiety  disorders,  mood  disorders,  or  attention-deficit/hyperactivity  disorder  (ADHD)  could  be

present as comorbid disorders but not the primary diagnosis

Exclusion criteria

1. Psychotic disorders
2. Conduct disorders
3. Substance dependence
4. IQ below 80

Interventions

Experimental group

Treatment name: ERT

Number randomised to group: 54

Duration: 17 weeks

Control/comparison group

Comparison name: TAU

Number randomised to group: 55

Duration: not specified

Both groups

Concomitant psychotherapy: yes, free to use mental health care services

Concomitant pharmacotherapy: yes, 29.4% on any medication at baseline

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod:

no significant differences between groups with regard to medication at baseline or follow-up

Outcomes

Primary

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

249

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schuppert 2012  (Continued)

Cochrane Database of Systematic Reviews

1. Borderline personality disorder severity, assessed by Borderline Personality Disorder Severity Index,

Version IV, for adolescents (BPDSI-IV-A)

Secondary

1. Affective instability, assessed by the affective instability subscale of the BPDSI-IV-A

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Comment: stratified randomisation

Low risk

Low risk

Quote: “Randomization by drawing lots was performed by an independent,
masked research assistant who was not involved in the project.” (p 1316)

Quote: “Randomization by drawing lots was performed by an independent,
masked research assistant who was not involved in the project.” (p 1316)

Quote: “The assessments were conducted by research psychologists who
were blinded to the treatment condition.” (p 1317)

Unclear risk

Comment: 19% attrition in total. ITT analysis used. Reasons for attrition were
not stated – could have been unevenly distributed across groups.

Selective reporting (re-
porting bias)

High risk

Comment: In the protocol, the following outcomes were mentioned: Life
Problems Inventory, measuring main symptoms of BPD (however, only the
subscale on affective instability reported), Rutgers Alcohol Problems Index,
Strengths and Difficulties Questionnaire, raising style, parental stress and
parental functioning, consumption of public health services and global func-
tioning. None of these outcomes were reported in the final report. In particu-
lar, data from the Children's Depression Inventory (which would have been rel-
evant for this review) were missing. Number of non-completers (flow-chart) in-
conclusive and not reported for the TAU group

Other bias

High risk

Treatment adherence

Quotes: “To increase treatment adherence and comparability among the cen-
ters, the manuals were highly structured. The treatment integrity of a random
sample of 20 audiotaped sessions was checked by an independent rater.” (p
1317); "The competence of all therapists was found to be accurate. On aver-
age, the sessions covered 92.4% of the ERT manual."

Allegiance bias

Quote: "Drs. Schuppert, van Gemert, and Wiersema are authors of the manual
on Emotion Regulation Training that is commercially available in the Nether-
lands." (p 1323)

Attention bias

Comment: no information about the duration of the treatment-as-usual group

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

250

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sinnaeve 2018 

Study characteristics

Methods

9-12-month trial with 2 arms

1. Step down dialectical behaviour therapy (DBT) (9 months)
2. Standard outpatient DBT (12 months)

Duration of trial: 9 months for step-down DBT, and 12 months for standard outpatient DBT

Country: The Netherlands

Setting: inpatient and outpatient

Participants

Method of recruitment of participants: not stated

Sample size: 84

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition, Text Revision (DSM-IV-TR)

Means of assessment: Participants were screened with the Vragenlijst Kenmerken Persoonlijkheid.
Presence of Axis 1 and Axis 2 disorders assessed with the Mini-International Neuropsychiatric Interview
and the Structured Clinical Interview for DSM Disorders

Mean age: step-down DBT = 26.15 years (standard deviation = 6.18), standard outpatient DBT = 25.63
years (standard deviation = 7.45)

Sex: 95% female

Comorbidity: “Almost one third of the sample reported a history of sexual abuse (N = 16, 29%) and
more than half experienced physical abuse (N = 30, 55%). One out of three participants suffered from
post-traumatic stress disorder (N = 17, 31%), half were diagnosed with major depression (N = 28, 51%),
and one out of three participants fulfilled criteria of substance dependence (N = 17, 31%)". (quote, p5)

Inclusion criteria

1. Provided written informed consent
2. Met DSM-IV-TR criteria for borderline personality disorder (identical to the criteria in DSM-5)
3. Aged between 18–45 years old
4. Scored higher than 24 on the BPDSI-IV
5. Reported at least 1 episode of self-injurious behavior within the month before intake. If there was no
episode of self-injurious behaviour 1 month before the intake, then a BPDSI-IV score of at least 30 was
required to be eligible for the study.

Exclusion criteria

1. Chronic psychotic disorder
2. Bipolar I disorder
3. Intellectual disability
4. Substance dependence requiring detoxification
5. Involuntary psychiatric treatment
6. Insufficient command of Dutch or living outside of travelling distance from the treatment centre

Interventions

Experimental group

Treatment name: step-down DBT

Number randomised to group: 42

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

251

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sinnaeve 2018  (Continued)

Cochrane Database of Systematic Reviews

Duration: 9 months

Control/comparison group

Comparison name: standard outpatient DBT

Number randomised to group: 42

Duration: 12 months

Both groups:

Concomitant psychotherapy: not stated

Concomitant pharmacotherapy: not stated

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

1. Borderline personality disorder severity, assessed by the BPDSI-IV
2. Self-harm, assessed by the BPDSI-IV
3. Suicide-related outcomes, assessed by the BPDSI-IV
4. Mental health status, assessed by the 5-level EQ-5D

Secondary

1. Anger, assessed by the BPDSI-IV
2. Affective instability, assessed by the corresponding subscale of the BPDSI-IV
3. Chronic feelings of emptiness, assessed by the BPDSI-IV
4. Impulsivity, assessed by the BPDSI-IV
5. Interpersonal problems, assessed by the BPDSI-IV
6. Abandonment, assessed by the BPDSI-IV
7. Dissociation and psychotic-like symptoms, assessed by the BPDSI-IV
8. Attrition, in terms of patients lost after randomisation in each group
9. Adverse effects, assessed by spontaneous reporting

Notes

Sample size calculation: yes

Ethics approval: The protocol adhered to the principles outlined in the Declaration of Helsinki, ap-
proved by the Institutional Review Board and registered in www.clinicaltrials.gov.

Comments from review authors:

1. We received an unpublished copy of a new paper on 11 June 2018 from Dr Sinneva, as well as addi-
tional data sheets on subsample data on borderline personality disorder from Dr Sinneva on 9 Octo-
ber, and additional information about the data sheets on 15 November 2018.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "a computer program, developed by the Amsterdam Medical Centre,
generated the sequence. To increase the likelihood of comparable treatment
groups, a minimization method was used. Minimization variables were BPDSI
score ≥ 40, total lifetime LPC score ≥ 14 and age". (p 14)

Allocation concealment
(selection bias)

Low risk

Quote: "we ensured that interventions were allocated by means of a con-
cealed randomization procedure." (p 19)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

252

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sinnaeve 2018  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Quote: "data collectors were not blind to the assigned intervention." (p 19)

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Selective reporting (re-
porting bias)

High risk

QuoteS: "In step-down DBT, 53% of the participants who started DBT finished
the entire 9-month program. Twelve months of outpatient DBT showed a re-
tention rate of 63%. The results of the Kaplan Meier statistic indicated that
there were no significant differences in the time to drop out between condi-
tions, Χ2(1) = .36, p = .55." (p 17) In outpatient DBT, 23 out of 42 participants did
not start the allocated treatment. This could be partially due to the fact that
waiting times appeared to be longer in outpatient DBT. One participant died by
suicide before he received outpatient DBT." (p 16)

Comment: high attrition rates in outpatient DBT

Quote: "There are three differences between the study protocol in Trials and
this report. First, the name of the residential program was changed from ‘in-
patient DBT’ to ‘residential DBT’. Second, our study ended prematurely due to
an unexpected close-down of the Centre for Personality Disorders Jelgersma
(CPJ). Third, because of unforeseen waiting list issues, participants who were
randomized to outpatient DBT had to wait longer before they met their ther-
apist." (p 14); "...the protocol was published in advance and all analyses were
performed by independent experts" (p 19)

Comment: The authors addressed changes made from protocol to full report.
However, assessing change in level of psychopathological symptoms with The
Brief Symptomatology Inventory (BSI)) was excluded as secondary outcome.

Other bias

High risk

Treatment adherence

Comment: treatment adherence was evaluated in both conditions (see p 19).

Attention bias

Comment: differences in duration of treatment (9 months vs 12 months)

Allegiance bias

Comment: nothing found

Smith 2012 

Study characteristics

Methods

36-week trial with 2 arms

1. Interpersonal psychotherapy (IPT)
2. Treatment-as-usual (TAU)

Duration of trial: 36 weeks
Country: USA

Setting: inpatient and outpatient

Participants

Method of recruitment of participants: " In total, 1,100 women seeking treatment in the clinic were
screened by intake clinicians for study eligibility on the basis of presence of depressive symptoms and
self- report of sexual abuse before age 18 and absence of exclusion criteria." (quote, p 2)
Sample size: subsample = 70

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

253

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Smith 2012  (Continued)

Cochrane Database of Systematic Reviews

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: no data for subsample. Full sample = 36.39 years (standard deviation = 9.86)

Sex: 100% female

Comorbidity: no data for subsample

Inclusion criteria

1. 18 years or older
2. English speaking
3. Current major depression and childhood sexual abuse

Exclusion criteria

1. Active psychosis
2. History of schizophrenia or bipolar disorder
3. Intellectual disability
4. Substance abuse or dependence within the previous 3 months
5. Current involvement in psychotherapy

Experimental group
Treatment name: IPT
Number randomised to group: 17 (out of full sample of 37)
Duration: 36 weeks

Control/comparison group
Comparison name: TAU
Number randomised to group: 9 (out of full sample of 33)
Duration: 36

Both groups

Interventions

Concomitant psychotherapy: “TAU was individual psychotherapy, TAU therapists described as sup-
portive (53%), cognitive-behavioral or dialectical-behavioral (27%), integrated/eclectic (13%), and
client-centered (7%)” (quote, p 4)
Concomitant pharmacotherapy:

“Women were permitted to enter the study regardless of antidepressant prescription status. A total of
43 women reported having been prescribed antidepressant medications at the baseline assessment
(23 of those in the IPT condition, 20 of those in the TAU condition).” (p 125)

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Secondary

1. Depression, assessed by the Beck Depression Inventory

Notes

Risk of bias

Sample size calculation: yes
Ethics approval: yes

Comments from review authors:

1. We received additional data on BPD subsamples from Dr Smith on 5 July 2018.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

254

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Smith 2012  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Unclear risk

Comment: no clear information on randomisation procedure was available

Unclear risk

Comment: no clear information on allocation concealment was provided

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Quote: "One master’s-level research assistant, who was aware of patients’
treatment assignments, conducted all assessments." (p 125)

Quote: “In intention-to-treat analyses, change over time was assessed with
generalized linear models with inference based on generalized estimating
equations (GEEs) (32). To test the assumption that data were missing com-
pletely at random (MCAR), logistic modeling was performed to determine
whether missing assessment data depended on individual patients’ observed
responses in previous assessments (Table 2). When the probability of missing
values was modeled for each outcome, we found that the shame subscale of
the Differential Emotions Scale had informative dropout (P=.04) and violated
the MCAR assumption. In that case, weighted GEEs were applied with individ-
ual weights estimated from the logistic model for missing data. Women with
lower shame scores in earlier assessments were more likely to have missing
data in later assessments.”

Selective reporting (re-
porting bias)

High risk

Comment: extra outcomes included in full report, but not mentioned in the
protocol are:

1. trauma history, assessed with the Childhood Trauma Questionnaire – Short

Form, and with the Traumatic Life Events Questionnaire

2. PTSD symptoms, measured with the Modified PTSD Symptom Scale – Self Re-

port

3. mental  health–related  functioning,  assessed  with  the  Medical  Outcomes

Study 36-Item Short-Form Health Survey summary score

4. social functioning, measured by the Social Adjustment Scale–Self Report
5. shame, assessed with the corresponding subscale of the Differential Emo-

tions Scale

Several outcomes included in full report. Not addressed. No clear differences
between primary and secondary outcomes such as in protocol

Other bias

High risk

Attention bias

Quote: "Interpersonal psychotherapy participants attended approximately
twice as many sessions (12.9±6.5) as those in usual care (6.3±4.2), a significant
between-group difference". (p 127)

Adherence bias

Comment: all interpersonal psychotherapy sessions were audiotaped or
videotaped. The principal investigator reviewed 20% of taped sessions for
treatment fidelity and addressed deviations from the model with the therapist.
(See p 126)

Allegiance bias

Comment: none found

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

255

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Soler 2009 

Study characteristics

Methods

3-month trial with 2 arms

1. DBT skills training (DBT-ST)
2. Standard group therapy (SGT)

Duration of trial: 3 months

Country: Spain

Setting: outpatient

Participants

Methods of recruitment of participants: recruited from the outpatient borderline personality disor-
der unit at the Department of Psychiatry, Hospital de la Santa Creu i Sant Pau

Sample size: 59

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II) and Revised
Diagnostic Interview for Borderlines (DIB-R)

Mean age: 29.2 years

Sex: 81.3% female

Comorbidity: not stated

Inclusion criteria:

1. Fulfilled diagnostic criteria for borderline personality disorder on SCID-II and DIB-R
2. Aged from 18–45 years (inclusive)

Exclusion criteria

1. Schizophrenia
2. Drug-induced psychosis
3. Organic brain syndrome
4. Alcohol or other psychoactive substance dependence
5. Bipolar disorder
6. Mental retardation
7. Major depressive episode in course
8. CGI-S score ≤ 4 (i.e. not at all, borderline, or mildly ill)

Interventions

Experimental group

Treatment name: DBT-ST

Number randomised to group: 32

Duration: 3 months (13 psychotherapy sessions of 120 minutes each)

Control/comparison group

Comparison name: SGT

Number randomised to group: 32

Duration: 3 months (13 psychotherapy sessions of 120 minutes each)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

256

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Soler 2009  (Continued)

Both groups

Cochrane Database of Systematic Reviews

Concomitant psychotherapy: participants did not receive any other individual or group psychothera-
py.

Concomitant pharmacotherapy: pharmacological therapy was continued if initiated prior to inclu-
sion, but type and doses could not be modified during the study period.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary:

1. BPD severity, assessed by the CGI-BPD
2. Mental health status, assessed by the Clinical Global Impression (CGI) scale
3. Suicidality, assessed by the CGI, suicidality subscale

Secondary:

1. Anger, assessed by the CBI-BPD item on anger
2. Affective instability, assessed by the CGI-BPD item on affective instability
3. Chronic feelings of emptiness, assessed by the CGI-BPD item on emptiness
4. Impulsivity, assessed by the CGI-BPD item on impulsivity
5. Interpersonal problems, assessed by the CGI-BPD item on unstable relations
6. Dissociative/psychotic pathology, assessed by Brief Psychiatric Rating Scale
7. Depression, assessed by Hamilton Depression scale 17-items (Ham-D-17)

Notes

Sample size calculation: not stated

Ethics approval: The study was approved by the ethics committee of the Hospital de la Santa Creu i
Sant Pau and carried out in accordance with the Declaration of Helsinki.

Comments from review authors:

1. We received information from Dr Soler by email on 15 December 2010.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "Blocks of four generated using the SPSS software program served for
the randomisation to DBT-ST or SGT." (p 354)

Allocation concealment
(selection bias)

Unclear risk

Comment: no further details

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quotes: "... participants were evaluated every two weeks by experienced psy-
chiatrists. Subjects were instructed not to disclose any information about
the group (topics, group members or therapists) to maintain blind condition-
s." (p 354); "Assessment and drug control were carried out by two psychiatrists
who were masked to the experimental conditions." (p 355); "We are unable
to affirm that all participants refrained from disclosing information about the
therapy or the therapists with the psychiatric raters during assessment visits.
[...] Indeed, the observer-rater scales obtained during the interview visits and
the results from self-reported measures filled in by patients during the study
showed a good concordance." (p 357)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: no further details

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

257

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Soler 2009  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

Cochrane Database of Systematic Reviews

Comment: no indication of selective reporting from the published paper, but
as there was no protocol available, there was insufficient information to per-
mit judgement of 'high' or 'low' risk of bias

Other bias

Unclear risk

Comment: no further details

Stanley 2017 

Study characteristics

Methods

12-month trial with 4 arms

1. Dialectical behavior therapy (DBT) + fluoxetine
2. DBT + placebo
3. Supportive therapy + fluoxetine
4. supportive therapy + placebo

Duration of trial: 12 months
Country: USA

Setting: inpatient

Participants

Method of recruitment of participants: recruited from emergency departments, clinician referrals
and advertisements. Recruitment period ended 6 months prior to study end date.
Sample size: 86

Diagnosis of borderline personality disorder: not stated
Means of assessment: not stated
Age: not stated
Sex: not stated

Comorbidity: not stated

Inclusion criteria

1. Meets criteria for diagnosis of borderline personality disorder
2. History of at least 1 suicide attempt or self-mutilation episode 12 months prior to study entry
3. Experiences continued urges to self-mutilate or attempt suicide
4. Stable living situation
5. Use of effective birth control if sexually active
6. Clinically stable enough to tolerate placebo condition
7. Not participating in other forms of treatment during the study

Exclusion criteria

1. Any current organic mental syndromes, lifetime schizophrenic or bipolar disorders, psychotic disor-

ders, or mental retardation

2. Inability to complete psychiatric interview due to lack of cooperation or lack of comprehension
3. Unable to tolerate fluoxetine or DBT
4. Currently receiving treatment for an acute medical illness or other debilitating problem, including

substance abuse or anorexia nervosa

5. History of major depression lasting more than 3 months
6. Current Hamilton depression score above 22 and not receiving treatment
7. Pregnant or breastfeeding

Interventions

Experimental group

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

258

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Stanley 2017  (Continued)

Cochrane Database of Systematic Reviews

Treatment name: DBT + fluoxetine
Number randomised to group: 18
Duration: 12 months

Control/comparison group 1
Comparison name: DBT + placebo
Number randomised to group: 19
Duration: 12 months

Control/comparison group 2

Comparison name: supportive therapy + fluoxetine
Number randomised to group: 20
Duration: 12 months

Control/comparison group 3
Comparison name: supportive therapy + placebo
Number randomised to group: 18
Duration: 12 months

All groups

Concomitant psychotherapy: not stated
Concomitant pharmacotherapy: all participants were washed out of psychotropic medications and
received fluoxetine or placebo, depending on randomisation (50% of each group received fluoxetine or
placebo). Benzodiazapines were permitted for sleep.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: 50% of each group were taking fluoxetine.

Outcomes

Primary

1. Suicide-related outcomes, assessed by total counts of attempted suicide attempts over the course of

the 12-month treatment period (sum of 6, bimonthly assessments during the treatment phase)

Secondary

1. Attrition, in terms of patients lost after randomisation in each group
2. Adverse effects, measured by spontaneous reporting

Sample size calculation: not stated 
Ethics approval: not stated

Comments from review authors:

1. Data available at clinicaltrials.gov/ct2/show/results/NCT00533117

Authors' judgement

Support for judgement

Unclear risk

Comment: no clear information on randomisation method was provided

Unclear risk

Comment: no clear information on allocation concealment was provided

Low risk

Comment: outcome assessors were masked to treatment allocation

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

259

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Stanley 2017  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Comment: dropout rates were even across groups, total rates were around
¼ of participants; no information provided on ITT, but all randomised partici-
pants were analysed

Low risk

Comment: NCT00533117: no apparent bias

Other bias

Unclear risk

Treatment adherence

Comment: adherence not stated

Attention bias

Comment: equal treatment in four groups

Allegiance bias

Comment: nothing found

Turner 2000 

Study characteristics

Methods

12-month trial with two arms

1. Dialectical behavior therapy - oriented treatment (DBT)
2. Client-centered therapy (CCT)

Duration of trial: 12 months

Country: USA

Setting: outpatient

Participants

Methods of recruitment of participants: not stated

Sample size: 24

Diagnosis of borderline personality disorders: Diagnostic and Statistical Manual of Mental Disorders,
3rd Edition revised (DSM-III-R)

Means of assessment: Revised Diagnostic Interview for Borderlines (DIB-R)

Mean age: 22 years

Sex: 79.2% female

Comorbidity: 23 patients met criteria for a comorbid Axis I disorder. The majority was diagnosed with
dysthymia + comorbid generalised anxiety disorder (n = 17). 3 patients met criteria for major depres-
sive disorder, 3 met criteria for dysthymia, 18 met criteria for alcohol abuse, and 20 met criteria for sub-
stance abuse. Most patients (n = 18) met criteria for 2 additional personality disorders.

Inclusion criteria

1. Diagnosis of borderline personality disorder

Exclusion criteria

1. Schizophrenia
2. Schizoaffective disorder
3. Bipolar disorder

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

260

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Turner 2000  (Continued)

4. Organic mental disorders
5. Mental retardation

Interventions

Experimental group

Cochrane Database of Systematic Reviews

Treatment name: DBT

Number randomised to group: 12

Duration: 12 months

Control/comparison group

Comparison name: client-centered therapy (CCT)

Number randomised to group: 12

Duration: 12 months

Both groups

Concomitant psychotherapy: not stated

Concomitant pharmacotherapy: pharmacotherapy was not included in the study treatment regi-
mens; at baseline, 19 patients were out of 24 reported taking prescribed psychotropic medications.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: At post-treatment, 4 DBT patients and 10 CCT patients were taking any medication, difference not
significant.

Outcomes

Primary

1. Suicidal ideation, assessed by Beck Scale for Suicide Ideation
2. Parasuicidality, assessed by Target Behaviour Rating (TBR) - frequency of parasuicide

Secondary

1. Anger, assessed by TBR - anger
2. Impulsivity, assessed by TBR - impulsiveness
3. Depression, assessed by Beck depression Inventory
4. Dissociative/psychotic symptoms, assessed by Brief Psychiatric Rating Scale

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Quote: "Following the initial assessments, patients were randomly assigned to
either DBT or CCT." (p 415)

Comment: no further details provided

Allocation concealment
(selection bias)

Unclear risk

Quote: "Next, patients were sequentially assigned to a mental health clini-
cian." (p 415)

Comment: no further details provided

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

261

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Turner 2000  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Cochrane Database of Systematic Reviews

Quote: "The outcome evaluation consisted of independent assessor ratings
and patient self-report. The independent assessor was unaware of the pa-
tients' treatment condition but was aware of the purpose of the study." (p 415)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: 24 participants were randomly assigned to either DBT (n = 12) or
CCT (n = 12). In spite of dropouts from treatment (DBT: n = 4, CCT: n = 6), as-
sessments were available for all 24 participants at all times of assessment.

Selective reporting (re-
porting bias)

Unclear risk

Comment: no indication of selective reporting, but Insufficient information to
permit judgement of 'high' or 'low' risk of bias

Other bias

Unclear risk

Comment: no further details

Van den Bosch 2005 

Study characteristics

Methods

12-month trial with two arms

1. Dialectical behavior therapy (DBT)
2. Treatment-as-usual (TAU)

Duration of trial: 12 months

Country: The Netherlands

Setting: outpatient

Participants

Methods of recruitment of participants: recruited from mental health institutions (n = 39) and addic-
tion treatment services (n = 19)

Sample size: 58

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)

Mean age: 34.9 years (standard deviation = 7.7)

Sex: 100% female

Comorbidity: with or without substance use disorder

Inclusion criteria

1. Female
2. Age 18–65 years
3. DSM-IV diagnosis of borderline personality disorder according to the SCID-II with at least 6 diagnostic

criteria of borderline personality disorder present

Exclusion criteria

1. Bipolar disorder
2. (Chronic) psychotic disorder
3. Severe cognitive impairments
4. Insufficient command of the Dutch language

Interventions

Experimental group

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

262

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Van den Bosch 2005  (Continued)

Treatment name: dialectical behavior therapy (DBT)

Number randomised to group: 27

Duration: 12 months

Control/comparison group

Comparison name: treatment-as-usual

Number randomised to group: 21

Duration: 12 months

Both groups

Concomitant psychotherapy: not stated

Concomitant pharmacotherapy: no significant differences between the 2 groups with regard to med-
ication use at baseline

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: "Medication use was monitored [...9. The greater improvement in the dialectical behaviour thera-
py group could not be explained by greater or other use of psychotropic medications by these patients.
In both conditions, three-quarters of the patients reported use of medication from one or more of the
following categories: benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), tricyclic antide-
pressants, mood stabilisers and neuroleptics. Use of SSRIs was reported by 14 (52%) of the dialectical
behaviour therapy patients and 19 (61%) of treatment-as-usual patients (χ2=0.44; P=0.509). These find-
ings eliminate the possibility of confounding by medication use". (Verheul 2003, p 137)

Outcomes

Primary:

1. Parasuicidal behaviour, assessed by Lifetime Parasuicide Count (LPC) self-mutilative acts during pre-

vious 3-month period

Secondary:

1. Impulsivity, assessed by the Borderline Personality Disorder Severity Index-IV (BPDSI-IV- impulsivity)

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: "...patients were randomly assigned to treatment conditions. A minimi-
sation method was used to ensure comparability of the two treatment condi-
tions on age, alcohol problems, drug problems and social problems (as mea-
sured by the European version of the Addiction Severity Index [...]". (Verheul
2003, p 135)

Allocation concealment
(selection bias)

Unclear risk

Comment: no further details

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quote: "although the research assessors were not informed about the treat-
ment condition of their interviewees, it is unlikely that they remained 'masked'
throughout the project. Patients might have given them this information, or it

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

263

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Van den Bosch 2005  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

could easily have been derived from some of the interviews." (Verheul 2003, p
139)

Unclear risk

Comment: no further details

Selective reporting (re-
porting bias)

Unclear risk

Comment: no indication of selective reporting, but Insufficient information to
permit judgement of 'high' or 'low' risk of bias

Other bias

Unclear risk

Comment: no further details

Weinberg 2006 

Study characteristics

Methods

Randomised controlled trial

Duration of trial: 6 weekly sessions

Country: USA

Setting: outpatient

Participants

Methods of recruitment of participants: from community through advertising

Sample size: 30

Diagnossis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II) and Revised
Diagnostic Interview for Borderlines (DIB-R)

Mean age: 28.2 years

Sex: 100% female

Comorbidity: patients with comorbid disorders were excluded

Inclusion criteria:

1. SCID-II and DIB-R - both sets of criteria had to be met for inclusion

Exclusion criteria

1. Comorbid psychotic disorders
2. Bipolar I disorder
3. Substance dependence
4. Elevated suicide risk

Interventions

Experimental group

Treatment name: manual-assisted cognitive treatment (MACT)

Number randomised to group: 15

Duration: 6 sessions

Control/comparison group

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

264

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Weinberg 2006  (Continued)

Comparison name: treatment-as-usual (TAU)

Number randomised to group: 15

Duration: 6 sessions

Both groups

Cochrane Database of Systematic Reviews

Concomitant psychotherapy: both manual-assisted cognitive treatment (MACT) and treatment-as-
usual (TAU) participants received treatment as usual; all participants took part in additional treatments
that were not further specified.

Concomitant pharmacotherapy: both manual-assisted cognitive treatment (MACT) and treatment-as-
usual (TAU) participants received treatment-as-usual; proportions of participants with medication did
not differ at baseline; Fisher = 0.36, df = 1.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary:

1. Suicidality, assessed by The Suicide Behaviors Questionnaire (SBQ)
2. Parasuicidality, assessed by the Parasuicide History Interview (PHI) - deliberate self-harm frequency

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

Quote: "randomly assigned" (p 485)

Comment: no further details provided regarding randomisation method

Unclear risk

Comment: no further details

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Quotes: "The baseline assessment and administration of the MACT [i.e. the
treatment under test] were performed by the primary investigator." (p 486);
"Interviewers were randomly assigned for following assessments. The inter-
viewers were blind to baseline ratings and to participants' group allocation".
(p 487)

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Comment: After screening of 60 referrals by phone, 37 were invited for further
assessments. Reasons for exclusion of 7 participants given. 30 participants in-
cluded in the final sample; n = 15 assigned to the EG and n = 15 to the CG

Selective reporting (re-
porting bias)

Low risk

Comment: no indications for selective reporting

Other bias

Unclear risk

Comment: no further details

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

265

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Zanarini 2008 

Study characteristics

Methods

12-week trials with two arms

1. Psychoeducation workshop (PEW)
2. Waiting list (WL)

Duration of trial: 12 weeks

Country: USA

Setting: outpatient

Participants

Methods of recruitment of participants: from community through advertising

Sample size: 50

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)

Means of assessment: Revised Diagnostic Interview for Borderlines (DIB-R) and Diagnostic Interview
for DSM-IV Personality Disorders (DIPD-IV)

Mean age: 19.3 years (standard deviation = 1.4)

Sex: 100% female

Comorbidity: lifetime axis I disorders: 39 (78%) met criteria for a mood disorder (mostly major depres-
sion), 20 (40%) met criteria for a substance use disorder, 14 (28%) met criteria for an anxiety disorder,
and 25 (50%) for an eating disorder. Current prevalence not specified

Inclusion criteria

1. DIB-R and DIPD-IV - both sets of criteria had to be met for inclusion.

Exclusion criteria

1. Current of lifetime schizophrenia
2. Schizoaffective disorder
3. Bipolar I disorder
4. Current substance dependence (except for nicotine dependence)
5. Any type of current psychiatric treatment

Interventions

Experimental group

Treatment name: psychoeducation workshop (PEW)

Number randomised to group: 30

Duration: 12 weeks

Control/comparison group

Comparison name: waiting list (WL)

Number randomised to group: 20

Duration: 12 weeks

Both groups

Concomitant psychotherapy: participants that were in any type of current psychiatric treatment were
not eligible for study participation.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

266

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Zanarini 2008  (Continued)

Cochrane Database of Systematic Reviews

Concomitant pharmacotherapy No significant differences at baseline on treatment histories. 20%
had taken medication previously.

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary:

1. Impulsivity, assessed by Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD)
2. Psychological functioning, assessed by ZAN-BPD

Notes

Sample size calculation: not stated

Ethics approval: not stated

Comments from review authors: none

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Quote: "Using a 3:2 ratio, subjects were either randomized to a workshop that
took place within a week of diagnostic disclosure or a waitlist." (p 286)

Comment: no further details on method of randomisation provided

Allocation concealment
(selection bias)

Unclear risk

Quote: "Fifty subjects were found to meet study criteria for BPD and five who
were interviewed did not. These 50 subjects were either randomized to imme-
diate (N = 30) or delayed (N = 20) psychoeducation." (p 286)

Comment: no information given about dropouts during the study course

Unclear risk

Comment: no information given if assessors were blind to treatment alloca-
tion

Unclear risk

Comment: no clear details are provided about attrition rate

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Comment: no indication of selective reporting, but there was Insufficient in-
formation to permit a clear judgement of 'high' or 'low' risk of bias

Other bias

Unclear risk

Comment: no further details

Zanarini 2018 

Study characteristics

Methods

12 month trial with 2 arms

1. Internet-based psychoeducation treatment group
2. Internet-based control group with no psychoeducation

Duration of trial: 12 months
Country: USA

Setting: outpatient

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

267

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Zanarini 2018  (Continued)

Participants

Method of recruitment of participants: “Recruitment of 80 women between the ages of 18 and 30
years was accomplished through internet-based advertising in Boston area (primarily on Craiglist)”.
(quote, p 53)
Sample size: 80

Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV)
Means of assessment: Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II), Revised Diag-
nostic Interview for Borderlines (DIB-R), Background Information Schedule, nonborderline modules of
the Diagnostic Interview for DSM-IV Personality Disorders, and clinician-administered version of the Za-
narini Rating Scale or Borderline Personality Disorder
Mean age: internet-based psychoeducation treatment group = 21.9 years (standard deviation = 3.7), in-
ternet-based control group with no psychoeducation = 20.9 years (standard deviation = 3.1)
Sex: 100% female

Comorbidity: any mood disorder (58/80), any anxiety disorder (51/80), any substance use disorder
(25/80), any eating disorder (16/80). Personality disorders: odd cluster (14/80), anxious cluster (45/80),
dramatic cluster (excluding borderline personality disorder) (13/80)

Inclusion criteria

1. Met both criteria for DIB-R and DSM-IV (dual diagnostic) to ensure inclusion of borderline personality

disorder patients with serious psychopathology

2. From trial registry inclusion: a) female, b) aged 18 to 30 years, c) meets criteria for borderline person-

ality disorder, d) intelligence quotient must be 71 or higher

Exclusion criteria

1. Current or lifetime criteria for schizophrenia or schizoaffective disorder.
2. If they had a physical condition that can cause serious psychiatric symptoms (eg. Lupus, multiple scle-

rosis)

3. Serious substance abuse
4. Mental retardation
5. Acutely suicidal
6. Fully manic at the time of diagnostic assessment
7. Patient was excluded if they were in any type of psychiatric treatment
8. Exclusion criteria from trial registry: a) Males, b) Schizophrenia, Schizoaffective Disorder, Bipolar I, c)

Serious Substance Use Disorder, d) Subjects cannot be in treatment at baseline

Interventions

Experimental group
Treatment name: internet-based psychoeducation treatment
Number randomised to group: 40
Duration: 12 months

Control/comparison group
Comparison name: internet-based control group with no psychoeducation
Number randomised to group: 40
Duration: 12 months

Both groups
Concomitant psychotherapy: not stated but patients were excluded if they were in any type of psychi-
atric treatment
Concomitant pharmacotherapy: patients in both groups were taking standing medication as needed
at baseline; tendency of more medication use in active group, but not significantly so (treatment group:
32.5% with standing medication at baseline, control group: 15.0%)

Proportions of participants taking standing psychotropic medication during trial observation pe-
riod: unclear

Outcomes

Primary

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

268

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Zanarini 2018  (Continued)

Cochrane Database of Systematic Reviews

1. BPD severity, assessed by the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD),

total score

2. Psychosocial functioning, assessed by the Sheehan Disability Scale

Secondary

1. Affective instability, assessed by the ZAN-BPD item on affective symptoms
2. Impulsivity, assessed by the ZAN-BPD items on impulsivity symptoms
3. Interpersonal problems, assessed by the ZAN-BPD items on interpersonal symptoms
4. Depression, assessed by the Clinically Useful Depression Outcome Scale
5. Attrition, in terms of patients lost after randomisation in each group

Notes

Risk of bias

Bias

Sample size calculation: not stated
Ethics approval: yes

Comments from review authors: none

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Quote: “Using a computer-generated list devised by our study statistician”. (p
53)

Allocation concealment
(selection bias)

Unclear risk

Comment: no clear information was provided about allocation concealment.

Blinding of outcome as-
sessment (detection bias)
All outcomes

High risk

Comment: the trial was open-label meanng there was no blinding. Outcome
measurements were based on self-report completed on the internet, all as-
sesssments were thus unblinded.

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Comment: low attrition rate. 98% completion in EG, and 95% completion in
CG. Authors conducted ITT analyses, but did not provide information on impu-
tation method.

Selective reporting (re-
porting bias)

High risk

Comment: Work and Social Adjustment Scale was in the protocol but was ex-
cluded from final report. The self-report version of the ZAN-BPD was included
as an extra outcome in full report relative to the trial registry. No clear indica-
tion in trial of which outcome were designated primary and secondary in the
registry. 'Borderline evaluation of severity over time' was the only primary out-
come.

Other bias

Unclear risk

Attention bias

Quote: “Both groups participated in 15 assessment periods that were divided
into an acute phase (weeks 1-12), and a maintenance phase (months 6, 9, 12)”.
(p 54)

Treatment adherence

Comment: no information

Allegiance bias

Comment: none found

ACT: acceptance and commitment therapy
ADHD: attention deficit hyperactivity disorder
AE: adverse events

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

269

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

AIAQ: Anger, Irritability and Assault Questionnaire
ANOVA: analysis of variance
APA: American Psychiatric Association
ASIQ-S: Adult Suicidal Ideation Questionnaire
AT: art therapy
AUDIT: Alcohol Use Disorders Identification Test
BPDFS:  Borderline Personality Disorder Feature Scale
BPDSI-IV: Borderline Severity Index, version IV
BDI: Beck Depression Inventory
BDI-II: Beck Depression Inventory-Revision
BEST: Borderline Evaluation of Severity over Time
BHS: Beck Hopelessness Scale
BIS: Barrett Impulsiveness Scale
B-MACT: meta-cognitive training for borderline patients
BMI: body mass index
BPD-40: Borderline Personality Disorder Checklist-40
BPDSI-IV(-A): Borderline Severity Index, Version IV, for Adolescents
BPI: Borderline Personality Inventory
BPRS: Brief Psychiatric Rating Scale
BSI: Borderline Severity Index
BSL-23: Borderline Symptom List-23
BSS: Beck Scale for Suicidal Ideation
CAT: cognitive analytic therapy
CCT: client-centred therapy
CG: control group
CGI-BPD: Clinical Global Impression Scale for Borderline Personality Disorder Patients
CGI-S: Clinical Global Impression Scale-Severity scale
CI: confidence interval
CM: clinical management
CORE-OM: Clinical Outcomes in Routine Evaluation–Outcome Measure
CP: combination psychotherapy
CPT II: Conners' Continuous Performance Test II
CR: clinician-rated
CT: cognitive therapy
CTBE: community treatment by experts
DASS: Depression, Anxiety and Stress-Scale
DASS(-21): Depression, Anxiety and Stress Scale-21 items
DBT: dialectical behavior therapy
DBT-A: DBT adapted for adolescents
DB T-C: DBT couple therapy
DBT-I: DBT individual therapy plus activity group
DBT-IE: DBT interpersonal effectiveness group
DBT-M: DBT mindfulness group
DBT-PE: DBT-prolonged exposure
DBT-S: DBT skills group plus case management (DBT-S)
DBT-ST: DBT skills training
DDP: dynamic deconstructive psychotherapy
DERS: Difficulties in Emotion Regulation Scale
DES: Dissociative Experiences Scale
DHP: day-hospital psychotherapy
DIB-R: Revised Diagnostic Interview for Borderlines
DIPD-IV: Diagnostic Interview for DSM-IV Personality Disorders
DPS: Diagnostic Interview Schedule for Children-Predictive scales
DSH: deliberate self-harm
DSHI: Deliberate Self-Harm Inventory
DSM: Diagnostic and Statistical Manual of Mental Disorders
DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision
DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
ECR: Experiences in Close Relationships Scale
EIT: emotional intelligence training

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

270

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

EG: experimental group
E-PDT: psychodynmaic therapy by experts in personality disorders
EQ-5D: EuroQol-5 Dimensions Questionnaire
ERGT: emotion regulation group therapy
ERT: emotion regulation training
EUC: enhanced usual care
FSCRS: Forms of Self-Criticism/Self-Attacking and Self-Reassuring Scale
GAD: generalised anxiety disorder
GAF(S): Global Assessment of Functioning
GAS: Global Assessment Scale
GHQ: General Health Questionnaire
GPM: general psychiatric management
GSFT: group schema-focused therapy
GSI: Global Severity Index of the SCL-90-R
HADS: Hospital Anxiety and Depression Scale
HAM-D-17: Hamilton Depression Scale-17 items
HDRS-17: Hamilton Rating Scale for Depression
HoN-OS: Dutch version of the Health of the Nations Outcome Scales
HYPE: helping young people early
I-BAFT: integrative borderline personality disorder-oriented adolescent family therapy
ICD-10: International Classification of Diseases, 10th Revision
IDC: individual drug counselling
IIP(-C)(-SC): Inventory of Interpersonal Problems - Circumflex version/64-item version
IPDE: Interpersonal Personality Disorder Examination
IPT: interpersonal psychotherapy
IQ: intelligence quotient
IRR: incidence rate ratio
ITT: intention to treat
JCP: joint crisis plan
KDI: Ko's Depression Inventory
LIT: limited individual therapy
LKM/CM: loving-kindness and compassion meditation
LOCF: last observation carried forward
LPC: lifetime parasuicide count
LSASI: Lifetime Suicide Attempt Self-Injury interview
MADRS: Montgomery Asberg Depression Rating Scale
MCAR: missing completely at random
MACI: Millon Adolescent Clinical Inventory
MACT: manual-assisted cognitive psychotherapy
MBT: mentalisation-based treatment
MBT-A: MBT for adolescents
MBT-DH: day hospital MBT
MBT-ED: MBT for eating disorders
MBT-OP: outpatient MBT
MCMI-III: Millon Clinical Multiaxial Inventory, 3rd Edition
MCT: meta-cognitive training
MDD: major depressive disorder
MF:  motivation feedback
MFQ: Mood and Feelings Questionnaire
MINI: Mini International Neuropsychiatric Interview
MOTR: motive-oriented therapeutic relationship
MSc: Master of Science
MT: mindfulness training
NOS: not otherwise specified
NR: not rated
ns: not specified
NSSI: non-suicidal self-injury
OAS-M: Overt Aggression Scale-Modified for outpatients
OIP: outpatient individual psychotherapy
OQ-45: Outcome Questionnaire-45
ORI: Object Relations Inventory
PAI-BOR: Personality Assessment Inventory - Borderline scale

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

271

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

PD: personality disorder
PDT: psychodynamic therapy
PDQ: Personality Disorders Questionnaire
PDSQ: Psychiatric Diagnostic Screening Questionnaire
PE: psychoeducation
PEPS: psychoeducation and problem solving therapy
PEW: psychoeducation workshop
PI: principal investigator
PIT: psychoanalytic-interactional therapy
PHI: Parasuicide History Interview
PP: per protocol
PRFP: psychic representation-focused psychotherapy
PTSD: post-traumatic stress disorder
RDIB: Revised Diagnostic Interview for Borderlines
SAPAS: Standardised Assessment of Personality: Abbreviated Scale
SASS: Social Adaptation Self-evaluation Scale
SASII: Suicide Attempt Self-Injury Interview
SAS-SR: Social Adaptation Scale-Self-Report
SB-APP: sequential brief Adlerian psychodynamic psychotherapy
SBQ: Social Behaviour Questionnaire
SCID-I/P: Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition
SCID-I: Structured Clinical Interview for DSM-IV Axis I Disorders
SCID-II: Structured Clinical Interview for DSM-IV Axis II Personality Disorders
SCL-90-R: Symptom Checklist-90-Revised
SCM-OP: structured clinical management-outpatient
SD: standard deviation
SF-12: 12-Item Short Form Health Survey
SFT(-G): schema-focused therapy -group
SFET: specialist first-episode psychosis treatment
SFQ: Social Functioning Questionnaire
SGT: standard group therapy
SHBCL: Self-Harming Behaviours Checklist
SIDP-IV: Structured Interview for DSM-IV Personality Disorders
SMFL: Short Motivation Feedback List
SMFQ: Self-report Mood and Feelings Questionnaire
SPS: Social Provisions Scale
SSCM-ED: specialist supportive clinical management for patients with eating disorders
SSHI: Suicide and Self-Harm Inventory
ST: schema therapy
S-TAU: specialist treatment as usual
STAXI: State-Trait Anger Expression Inventory
STEPPS: systems training for emotional predictability and problem solving
STM: supervised team management
SUD: substance use disorder
TA: therapeutic assessment
TAU: treatment-as-usual
TBR: Target Behaviour Rating
TTA: therapist telephone availability
UK: United Kingdom
WEMBS: Warwick-Edinburgh Mental Well-Being Scale
WHOQOL-BREF: World Health Organisation Quality of Life Instruments
WL: waiting list
WSAS: Work and Social Adjustment Scale
ZAN-BPD: Zanarini Rating Scale for Borderline Personality Disorder

Characteristics of excluded studies [ordered by study ID]

Study

Ahmed 2016

Reason for exclusion

Ineligible patient population

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

272

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Andover 2017

Ineligible patient population

Andreasson 2016

Apsche 2006

Asarnow 2017

Bamelis 2012a

Proportion of included participants with full BPD unclear. Unable to retreive further infor-
mation

Ineligible patient population

Ineligible patient population

Ineligible patient population

Bateman 2019b

Ineligible patient population

Bertsch 2013

Ineligible intervention

Bira 2014

Brent 2018

Brune 2012

Buric 2019

Cailhol 2014

Carta 2014

Carter 2013

Chanen 2008

Charney 2015

Coccaro 1997

Cornelius 1993

Cottrell 2018

Ineligible patient population

Ineligible patient population

Ineligible intervention

Ineligible patient population

Ineligible intervention

Ineligible intervention

Ineligible patient population

ineligible population (less than 70% BPD)

Ineligible patient population

Ineligible patient population

Ineligible intervention

Ineligible patient population

Crawford 2018b

Ineligible patient population

Cullen 2012a

De Beurs 2013

DeSaeger 2014

Dunlop 2012

Ehlers 2013

Ekeblad 2016

Ineligible patient population

Ineligible intervention

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible patient population

EUCTR 2010-020956-69

Ineligible intervention

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

273

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

EUCTR 2015-000749-21

Ineligible intervention

Fleischer 2015

Furuno 2018

Ineligible outcomes

Ineligible patient populaiton

Ghahramanlou Holloway 2012

Ineligible patient population

Ginty 2016

Gold 2013

Green 2011

Ineligible patient population

Ineligible intervention

Ineligible patient population

Grimholt 2015

Ineligible patient population

Ha 2016

Ineligible patient population

Haddock 2016

Ineligible patient population

Hassanzadeh 2010

Ineligible patient population

Hatcher 2015

Hazell 2009

Hesse 2010

Hewage 2018

Hirayasu 2009

Holder 2017

Hooley 2018

Husain 2011

Husain 2014

Johansson 2010

Kawanishi 2014

Keefe 2016

Keefe 2018

Kellett 2014

Keng 2018

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible intervention

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible patient population

Kennard 2018

Ineligible patient population

Koenigsberg 2003

Ineligible intervention

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

274

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Krause Utz 2016

Krause Utz 2017

Linehan 1999

Linehan 2002

Reason for exclusion

Ineligible intervention

Ineligible intervention

Ineligible outcomes

Ineligible outcomes

Lorentzen 2013

Ineligible patient population

Maffei 2018

Mahlke 2015

Ineligible patient population

Ineligible intervention

Marasinghe 2012

Ineligible patient population

Marchesi 2006

McAuliffe 2014

Merolla 2017

Moran 2010

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible intervention

Munroe-Blum 1995

Ineligible outcomes

NCT01311193

NCT02728778

NCT03498937

Nickel 2007a

Nickel 2007b

Nickel 2008

Ineligible intervention

Ineligible intervention

Ineligible intervention

Ineligible intervention

Ineligible intervention

Ineligible intervention

NL1680/NTR1781

Ineligible comparator

NL5802/NTR5957

Ineligible intervention

O'Connor 2017

Oquendo 2012

Ougrin 2011

Ower 2014

Roberts 2018

Rombold 2014

Rosa 2009

Ineligible patient population

Ineligible patient population

Ineligible patient population

Ineligible intervention

Ineligible patient population

Ineligible patient population

Ineligible patient population

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

275

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Roussignol 2010

Ineligible intervention

Santamarina Pérez 2017

Ineligible patient population

Schuiringa 2017

Schuppert 2009

Sharp 2015

Ineligible patient population

Proportion of participants with full BPD unclear; unable to retreive further information

Ineligible intervention

Thunnissen 2009

Ineligible patient population

TufekciogIu 2015

Ineligible patient population

Tyrer 2003a

Van Beek 2009

Van Dijk 2019

Ineligible patient population

Ineligible patient population

Ineligible patient population

Van Spijker 2010

Ineligible patient population

Vidal 2013

Ineligible patient population

Vijayakumar 2011

Ineligible patient population

Waltz 2009

Watzke 2012

Ineligible intervention

Ineligible patient population

Weertman 2007

Ineligible patient population

Wilks 2018

Ineligible patient population

Wingenfeld 2013

Ineligible intervention

Wingenfeld 2014

Ineligible intervention

Wölwer 2001

Ineligible patient population

BPD: borderline personality disorder

Characteristics of studies awaiting classification [ordered by study ID]

Abdelkarim 2016 

Methods

Not known

Participants

People with borderline personality disorder

Interventions

Parallel social media in combination with dialectical behaviour therapy (DBT)

Outcomes

Compliance to DBT; adverse effects

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

276

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Abdelkarim 2016  (Continued)

Cochrane Database of Systematic Reviews

Notes

Conference abstract - no publication yet to enable a definite decision

Akbari 2009 

Methods

Randomised controlled trial

Participants

People with borderline personality disorder

Interventions

Combined cognitive behavioural therapy and pharmacotherapy

Outcomes

Notes

Depression; anger

Translation required. We will translate it for the next update of this review.

Cowperthwait 2017 

Methods

Randomised controlled trial

Participants

Adolescents

Interventions

Outpatient dialectical behaviour

Outcomes

Depression; borderline personality disorder symptoms; emotion dysregulation symptoms; dialecti-
cal behaviour therapy skills use

Notes

Unable to retrieve paper through contacting the author and help of information retrieval experts

Dorrepaal 2012 

Methods

Randomised controlled trial

Participants

People with complex post-traumatic stress disorder (PTSD) and severe comorbidity

Interventions

Psychoeducation and cognitive behavioural therapy

Outcomes

Notes

PTSD symptoms; stress

Subsample data concerning only people with borderline personality disorder is needed. Previous
contact with the authors was unsuccessful. We will contact authors again at the next update of this
review.

Ducasse 2018 

Methods

Randomised controlled trial

Participants

Suicidal, adults

Interventions

Acceptance and commitment therapy

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

277

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ducasse 2018  (Continued)

Cochrane Database of Systematic Reviews

Outcomes

Notes

Einy 2018 

Methods

Suicide severity; depressive symptomatology; psychological pain; anxiety; hopelessness; anger;
quality of life, and therapeutic processes

Subsample concerning people with borderline personality disorder needed. We will contact au-
thors at next update of this review.

Randomised controlled trial

Participants

People with borderline personality disorder

Interventions

Mentalisation-based therapy and cognitive-analytical therapy

Outcomes

Notes

Isaia 2017 

Methods

Insecure attachment; social inefficiency

Translation required. We will translate it for the update of this review.

Not known

Participants

People with borderline personality disorder

Interventions

Systems training for emotional predictability and problem-solving (STEPPS)

Outcomes

Notes

Borderline personality disorder symptomatology; emotion regulation skills

Unable to retrieve paper though contacting the author and help of information retrieval experts

Johnson 2017 

Methods

Not known

Participants

People with borderline personality disorder

Interventions

Cognitive analytic therapy

Outcomes

Notes

McCauley 2018 

Methods

Not known

Unable to retrieve paper though contacting the author and help of information retrieval experts

Randomised controlled trial

Participants

Adolescents at high risk of suicide

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

278

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

McCauley 2018  (Continued)

Interventions

Dialectical behaviour therapy

Outcomes

Notes

Suicide attempts; non-suicidal self-injury; self-harm

Subsample data consisting only of people with borderline personality disorder is needed. We will
contact authors again at the next update of this review.

Ostermeier 2017 

Methods

Not known

Participants

Borderline personality disorder

Interventions

Dialectical behaviour therapy

Outcomes

Notes

Not known

Unable to retrieve paper despite contacting the author twice

Santamarina 2017 

Methods

Randomised controlled trial

Participants

Adolescents with suicidal behaviour

Interventions

Dialectical behaviour therapy

Outcomes

Self-harming behaviour (assessed by number of self-reported self-harm episodes); suicidal ideation
(assessed with Suicidal Ideation Questionnaire); Clinical Global Impression (CGI) scale for suicide

Notes

Conference abstract - no subsequent reports identified for this study

CGI: Clinical Global Impression scale
DBT: dialectical behaviour therapy
PTSD: post-traumatic stress disorder
STEPPS: systems training for emotional predictability and problem-solving

Characteristics of ongoing studies [ordered by study ID]

ACTRN12610000100099 

Study name

Public title: A randomised controlled trial of three forms of psychosocial early intervention for bor-
derline personality disorder in youth

Scientific title: MOBY: a randomised controlled trial (RCT) of specialised early intervention, with
individual cognitive analytic therapy, specialised early intervention without individual psychother-
apy, and standard youth mental health care for first-presentation borderline personality disorder in
youth

Methods

Randomised controlled trial

Participants

Inclusion criteria:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

279

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ACTRN12610000100099  (Continued)

1. Males and females
2. Aged 15 to 25 years
3. Diagnosed with of borderline personality disorder (BPD)

Interventions

1. Specialised early intervention service for BPD
2. Youth mental healthcare
3. Befriending

Outcomes

Primary outcomes:

Cochrane Database of Systematic Reviews

1. Interpersonal problems, measured by the Inventory of Interpersonal Problems Circumplex Ver-

sion (IIP-C)

2. Social adjustment, measured by the Social Adjustment Scale Self Report (SAS-SR)

Starting date

17 March 2011

Contact information

Name: Dr Andrew Chanen

Address: Locked Bag 10, Parkville VIC 3052, Australia

E-mail: achanen@unimelb.edu.au

Telephone: +61393422800

Notes

None

ACTRN12612000951853 

Study name

Public title: A clinical trial of mentalization based therapy treatment for borderline personality dis-
order

Scientific title: Outcome effects of a mentalization based treatment service (mindsight) for people
with borderline personality disorder in urban Christchurch: a clinical trial and evaluative study

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. People with BPD

Interventions

Individual psychotherapy session with a therapist trained in mentalisation-based treatment
method

Outcomes

Primary outcomes:

1. Incident rate of self harm

Starting date

1 September 2009 (anticipated)

Contact information

Name: Dr David Carlyle

Address: Department of Psychological Medicine, University of Otago, PO Box 4345, Christchurch
8011

E-mail: dave.carlyle@otago.ac.nz

Telephone: +64 03 3720400

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

280

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ACTRN12612000951853  (Continued)

Notes

None

Cochrane Database of Systematic Reviews

ACTRN12612001187831 

Study name

Public title: Exploring dialectical behaviour therapy vs conversational model in the treatment of
borderline personality disorder: a randomised clinical trial

Scientific title: Randomised clinical trial of dialectical behaviour therapy compared to conversa-
tional model in the treatment of borderline personality disorder in reducing parasuicidal behaviour
and depression

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. People with BPD

Interventions

Dialectical behaviour therapy

Outcomes

Primary Outcome: Depression scores as measured by Beck Depression Inventory II (BDI-II)

Primary Outcome:

Secondary Outcome: Number and severity of BPD symptoms as measured by Borderline Personali-
ty Disorder Severity Index (BPDSI)

Secondary Outcome: Interpersonal problems as measured by the Inventory of Interpersonal Prob-
lems (IIP)

Secondary Outcome: Mindfulness skills as measured by the Kentucky Inventory of Mindfulness
Scale (KIMS)

Secondary Outcome: Dissociation as measured by the Dissociative Experiences Scale (DES)

Secondary Outcome: Emotion regulation as measured by the Difficulties in Emotion Regulation
Scale (DERS)

Secondary Outcome: Sense of self as measured by the Sense of Self Inventory (SSI)

Starting date

12 April 2007 (anticipated)

Contact information

Name: Dr Carla Walton

Address: Hunter New England Mental Health Service, PO Box 833, Newcastle NSW 2300, Australia

E-mail: Carla.Walton@hnehealth.nsw.gov.au

Telephone: + 61 2 4924 6820

Notes

None

ACTRN12616000236493 

Study name

Public title: Effectiveness of dialectical behaviour therapy (DBT) group skills training for borderline
personality disorder (BPD) in community mental health

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

281

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ACTRN12616000236493  (Continued)

Scientific title: same as public title

Methods

Not known

Participants

Inclusion criteria:

1. BPD

Interventions

Dialectical Behaviour Therapy (DBT) Group Skills Training

Outcomes

Primary outcomes:

1. Borderline-related symptomology

Starting date

13 January 2015

Contact information

Name: Ms Brooke Packham

Address: c/o Bordertown Community Health, PO Box 196, Bordertown SA 5268, Australia

E-mail: brooke.packham@sa.gov.au

Telephone: + 61887211507

Notes

None

DRKS00003605 

Study name

Title: Short-term psychotherapeutic treatment in adolescents engaging in non-suicidal self-injury:
a randomised controlled trial

Methods

Not known

Participants

Inclusion criteria:

1. Participants aged between 12 and 17 years
2. Participants who name nonsuicidal self-injury in terms of snags and burn injuries and similar in-
juries in at least 5 cases in the last 6 months by means of a structured clinical interview. The last
nonsuicidal self-injury should not date back longer than a month.

Interventions

The used short-term treatment programme called “The Cutting Down-Program” is a manualised
short-term therapy, which is designed for 8 to 12 therapy sessions. It includes elements of the cog-
nitive-behavioural therapy but also elements of the dialectic-behavioural therapy.

Outcomes

Primary outcomes:

1. Frequency of nonsuicidal self-injury, measured with the Self-Injurous Thoughts and Behaviours
Interview-German  (SITBI-G)  at  baseline  (before  therapy),  post-line  (directly  after  therapy),  fol-
low-up (6 months after therapy) and follow-up 2 (24-48 months after baseline)

Starting date

17 September 2010

Contact information

Name: Mr Dr Michael Kaess

Address: Klinik für Kinder- und Jugendpsychiatrie Psychosoziales Zentrum Universitätsklinikum
Heidelberg, Blumenstraße 8, 69115 Heidelberg, Germany

E-mail: michael.kaess at med.uni-heidelberg.de

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

282

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

DRKS00003605  (Continued)

Telephone: 06221-566914

Notes

None

Cochrane Database of Systematic Reviews

DRKS00011534 

Study name

Title: PRO*BPD: Effectiveness of outpatient treatment PROgrammes for Borderline Personality Dis-
order: a comparison of schema therapy and dialectical behaviour therapy

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Emotionally unstable personality disorder

Interventions

Intensive outpatient treatment programme of schema-focused therapy with one individual and
one group session per week for 1.5 years

Outcomes

Primary outcomes:

1. Change in BPD symptom severity, assessed with the mean score of the BPD Severity Index at 1-

year follow-up

Starting date

26 November 2014

Contact information

Name: Ms Dr Med Eva Faßbinder

Address: Klinik für Psychiatrie und Psychotherapie, Universität zu Lübeck, Ratzeburger Allee 160,
23538 Lübeck, Germany

E-mail: eva.fassbinder at uksh.de

Telephone: 0451-50098702

Notes

None

ISRCTN21802136 

Study name

Public title: Coping with Unusual ExperienceS for 12-18 (CUES+)

Scientific title: Coping with Unusual ExperienceS for 12-18 year olds (CUES+): a transdiagnostic
randomised controlled trial of the effectiveness of cognitive therapy in reducing distress associat-
ed with unusual experiences in adolescent mental health services: study protocol for a randomised
controlled trial

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Presenting to local CAMHS
2. Current unusual experiences associated with distress (UED)
3. Aged 12-18 years
4. Available for the study duration
5. Sufficient English language ability to be able to complete assessment measures and therapy (with

interpreter support if necessary)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

283

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ISRCTN21802136  (Continued)

Interventions

Therapy will consist of up to 16 sessions, given over 16 weeks, including individual cognitive behav-
ioural therapy for psychosis adapted for adolescents, and 3-4 family support sessions. Family work
comprises recognition and understanding of the child’s difficulties, sharing the intervention plan,
and troubleshooting any key family difficulties. Individual work focuses on developing a collabora-
tive understanding of UEDs, together with skills in affect regulation, managing negative automatic
thoughts, behavioural tests, dealing with social difficulties and adverse life events, recognising and
compensating for cognitive biases and a section on taking the work forward and preventing future
difficulties. Therapy is tailored to take account of the developmental stage and presenting issues of
the child/young person. Therapy materials have been designed to be fun, interactive and engaging.

Outcomes

Primary outcomes:

1. Distress at 16 weeks, assessed using the Emotional Problems subscale of the child reported ver-

sion of the Strengths and Difficulties Questionnaire (SDQ)

Starting date

5 January 2015

Contact information

Name: Dr Suzanne Jolley

Address: King's College London, Institute of Psychiatry, Department of Psychology (PO77), 16 De
Crespigny Park, London SE5 8AF, United Kingdom

E-mail: not provided

Telephone: not provided

Notes

None

NCT00603421 

Study name

Title: Effectiveness of a 24 hour phone line on the rate of suicide attempts in people affected by
borderline personality disorder

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Persons with Borderline Personality Disorder (male or female)
2. Aged 18 to 40 years

Interventions

One year of
1. Treatment-as-usual (TAU) + access to a 24 hour crisis phone line
2. TAU

Outcomes

Primary outcomes:

1. Rate of suicide attempts

Starting date

February 2009

Contact information

Name: Alexandra Pham-Scottez; Daniel Guelfi

Address: Hôpital St. Anne, Paris, France 75014

E-mail: a.pham@ch-sainte-anne.fr; jd.guelfi@ch-sainte-anne.fr

Telephone: not provided

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

284

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT00603421  (Continued)

Notes

None

Cochrane Database of Systematic Reviews

NCT01531634 

Study name

Title: Promoting recovery processes in women with borderline personality disorder using a dy-
namic cognitive intervention

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Borderline personality disorder
2. Women

Interventions

Behavioural: dynamic cognitive intervention group

Outcomes

Primary outcomes:

1. Change in Recovery Assessment Scale. Time frame: change from baseline in Recovery Assessment

Scale at 12th meeting (6 up to 12 weeks)

Starting date

Not provided. First received 3 February 2012

Contact information

Name: Orly Tsabar, BOT

Address: Tel Aviv University

E-mail: orly.tsabar@gmail.com

Telephone: 972-54-6852344

Notes

None

NCT01823120 

Study name

Public title: Text message intervention to reduce repeat self-harm

Scientific title: Text message intervention to reduce repeat self-harm in patients presenting to the
emergency department

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. All patients 18 years and over, presenting to the ED with self-harm. All patients should have a mo-
bile phone, be familiar with text messaging technology and be willing to take part in the study.

Interventions

Supportive and interactive text messages

Outcomes

Primary outcomes:

1. Repetition of self-harm
2. Change scores on the Suicide Behaviours Questionnaire from baseline

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

285

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT01823120  (Continued)

Starting date

March 2015. Specific date not provided

Contact information

Name: Vincent IO Agyapong, MRCPsych MD

Address: University of Dublin, Trinity College Dublin

E-mail: not provided

Telephone: not provided

Notes

None

NCT02068326 

Study name

Public title: MBT in groups for adolescents with BPD or subthreshold BPD versus TAU - the M-GAB
randomized controlled trial (M-GAB)

Scientific title: Mentalization-based treatment in groups for adolescents with borderline person-
ality disorder (BPD) or subthreshold BPD versus treatment-as-usual - the M-GAB randomised con-
trolled trial (M-GAB)

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Borderline personality disorder

Interventions

Mentalisation-based treatment

Outcomes

Primary outcomes:

1. The Borderline Personality Feature Scale for Children (BPFS-C)

Starting date

September 2015. Specific date not provided

Contact information

Name: Erik Simonsen, PhD

Address: Child and Adolescent Psychiatric Department, Region Zealand, Denmark

E-mail: not provided

Telephone: not provided

Notes

None

NCT02125942 

Study name

Public title: Central meditation and imagery therapy for augmentation of borderline personality
disorder treatment

Scientific title: Pilot study of central meditation and imagery therapy for borderline personality
disorder

Methods

Randomised controlled trial

Participants

Inclusion criteria:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

286

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT02125942  (Continued)

1. Borderline personality disorder

Interventions

Central meditation and imagery therapy

Outcomes

Primary outcomes:

1. Borderline Symptoms List

Starting date

April 2014

Contact information

Name: Felipe Jain, Clinical Instructor of Psychiatry

Address: University of California, Los Angeles

E-mail: not provided

Telephone: not provided

Notes

None

NCT02126787 

Study name

Public title: Short-term, intensive psychodynamic group therapy versus cognitive-behavioral
group therapy in the day treatment

Scientific title: Short-term, intensive psychodynamic group therapy versus cognitive-behavioral
group therapy in the day treatment of anxiety disorders and comorbid depressive or personality
disorders

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Anxiety disorders
2. Depressive disorders
3. Personality disorders

Interventions

Intensive group analytic psychotherapy

Outcomes

Primary outcomes:

1. Depression
2. Anxiety

Starting date

September 2014. Specific date not provided

Contact information

Name: Andrzej Kokoszka, MD, PhD

Address: Hospital of Wola, Warsaw, Poland, 01-211

E-mail: andrzej.kokoszka@wum.edu.pl

Telephone: +48603128361

Notes

None

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

287

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT02134223 

Study name

Public title: Methylation status of BDNF gene after dialectical behavior therapy in BPD

Scientific title: Changes in methylation status of BDNF gene after receiving dialectical behavior
therapy in patients with borderline personality disorder

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Borderline personality disorder

Interventions

Dialectical behaviour therapy

Outcomes

Primary outcomes:

1. Borderline Symptom Checklist (BSL-23)

Starting date

April 2014. Specific date not provided

Contact information

Name: Shu-I Wu

Address: Mackay Memorial Hospital, Taipei, Taiwan

E-mail: shuiwu624@gmail.com

Telephone: +886-2-88094661 ext 3055

Notes

None

NCT02387736 

Study name

Public title: DBT for chronically self-harming individuals with BPD: evaluating the clinical & cost ef-
fectiveness of a 6 mo treatment (FASTER-DBT)

Scientific title: Dialectical behaviour therapy for chronically self-harming individuals with BPD:
evaluating the clinical and cost effectiveness of a 6-month treatment

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Borderline personality disorder

Interventions

Dialectical behaviour therapy - 6 months

Outcomes

Primary outcomes:

1. Change in frequency and severity of suicide and self-harm behaviours over time, as measured by

the Suicide Attempt Self-Injury Interview (SASII)

Starting date

February 2015. Specific date not provided

Contact information

Name: Shelly McMain

Address: Centre for Addiction and Mental Health, 60 White Squirrel Way, Toronto, ON M6J 1H4,
Canada

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

288

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT02387736  (Continued)

E-mail: not provided

Telephone: not provided

Notes

None

Cochrane Database of Systematic Reviews

NCT02517723 

Study name

Public title: Narrative exposure therapy in women with borderline personality disorder and post-
traumatic stress disorder

Scientific title: A randomized controlled clinical trial (RCCT) to test the effectiveness of narrative
exposure therapy (NET) versus dialectical-behavioral therapy in reducing trauma related symp-
toms in women suffering from borderline personality disorder (BPD) and post-traumatic stress dis-
order (PTSD)

Methods

Randomised controlled trial

Participants

Inclusion criteria:

Interventions

1. Borderline personality disorder
2. Stress disorders, post-traumatic

1. Behavioural: narrative exposure therapy
2. Behavioural: dialectical behaviour therapy
3. Behavioural: standard inpatient care

Outcomes

Primary outcomes:

1. Change from first investigation in post-traumatic symptom severity at 18 months (Clinician-Ad-

ministered PTSD Scale; CAPS)

Starting date

April 2014. Specific date not provided

Contact information

Name: Professor, Dr Med Martin Driessen; Evangelisches Krankenhaus Bielefeld

Address: Clinic of Psychiatry, Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany 33617

E-mail: not provided

Telephone: not provided

Notes

None

NCT02685943 

Study name

Public title: A randomised trial for suicidal patients

Scientific title: 'Collaborative assessment and management of suicidality' (CAMS) in comparison
to 'Treatment-as-usual' (TAU) for suicidal patients: a randomized controlled trial

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Suicidal Ideation

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

289

 
 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT02685943  (Continued)

2. Attempted Suicide
3. Suicide

Interventions

Psychotherapy

Outcomes

Primary outcomes:

1. Changes in scores on Beck's Scale for Suicide Ideation (BSSI)

Starting date

April 2015. Specific date not provided

Contact information

Name: Dr Roar Fosse

Address: Vestre Viken Helseforetak, Drammen, Norway, 3004

E-mail: not provided

Telephone: not provided

Notes

None

NCT02771691 

Study name

Public title: Mentalization-based group therapy for adolescents

Scientific title: Efficacy of mentalization-based group therapy for adolescents: a pilot randomised
controlled trial

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Deliberate self-harm

Interventions

Mentalisation-based group therapy for adolescents

Outcomes

Primary outcomes:

1. Self-harm as measured by the self-harm subscale of the Risk-taking and Self-harm Inventory for

Adolescents (Vrouva 2010)

2. Self-harm and related hospital use as reported in National Health Service patient records

Starting date

February 2016. Specific date not provided

Contact information

Name: not provided

Address: CAMHS, Edinburgh, Lothian, United Kingdom

E-mail: not provided

Telephone: not provided

Notes

None

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

290

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT02985047 

Study name

Public title: Brief admission Skåne: replacing general admission for individuals with self-harm and
acute risk of suicide (BAS)

Scientific title: Brief admission Skåne: can brief admission replace general admission for individu-
als with self-harm and acute risk of suicide

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Self-injurious behaviour
2. Suicidal ideation
3. Suicide, attempted
4. Borderline personality disorder
5. Emergency services, psychiatric

Interventions

Brief admission

Outcomes

Primary outcomes:

1. Number of days with hospital admission

Starting date

1 September 2015

Contact information

Name: Sofie Westling, MD, PhD

Address: Division of Psychiatry, Region Skåne, Lund, Skåne, Sweden, 22185

E-mail: not provided

Telephone: not provided

Notes

None

NCT02991586 

Study name

Public title: Effectiveness study of a dialectical behavioral treatment for families of adolescents
with emotional instability (FAL)

Scientific title: Effectiveness study of a dialectical behavioral treatment for families of adolescents
with emotional instability

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Emotional instability

Interventions

Dialectical behaviour therapy

Outcomes

Primary outcomes:

1. Difficulties in Emotional Regulation Scale (DERS)
2. Automatic Anger and Hostility Thoughts Scale (IPRI)
3. Coping Styles and Strategies Scale (COPE)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

291

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT02991586  (Continued)

Starting date

May 2016. Specific date not provided

Contact information

Name: María Mayoral, Clinical Psychologist

Address: Instituto Provincial de Psiquiatria, Hospital General Universitario Gregorio Maranon. Calle
Ibiza 43, Madrid, Spain, 28009

E-mail: maria.mayoral@iisgm.com

Telephone: +34 914265005

Notes

None

NCT03011190 

Study name

Public title: Effectiveness of the iconic therapy for borderline personality disorder symptoms

Scientific title: Effectiveness of the iconic therapy in youth with suicidal ideation/self-injuring be-
havior and borderline personality traits: study protocol for a randomized controlled trial

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Personality disorder, borderline

Interventions

Emotional regulation

Outcomes

Primary outcomes:

1. Change  on  the  severity  of  borderline  personality  disorder  measured  by  Borderline  Personality

Symptom List (BSL-23). Time frame: baseline and up to 12 months after inclusion

Starting date

September 2015. Specific date not provided

Contact information

Name: Silvia Elisa Hurtado Santiago, Principal investigator

Address: University of Malaga, Malaga, Spain 29190

E-mail: not provided

Telephone: not provided

Notes

None

NCT03092271 

Study name

Public title: Randomised trial of stepped care for suicide prevention in teens and young adults
(Step2Health)

Scientific title: Randomized trial of stepped care for suicide prevention in teens and young adults

Methods

Randomised controlled trial

Participants

Inclusion criteria:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

292

 
 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT03092271  (Continued)

1. Suicidal behaviour
2. Self-harm, deliberate
3. Suicidal ideation
4. Suicide

Interventions

Behavioural: stepped care for suicide prevention

Behavioural: zero suicide quality improvement

Outcomes

Primary outcomes:

1. Suicide attempt behaviour

Starting date

3 April 2017

Contact information

Name: Dr Joan R Asarnow

Address: University of California Los Angeles (UCLA), Los Angeles, California, United States,
90095-6968

E-mail: jasarnow@mednet.ucla.edu

Telephone: 310 825-0408

Notes

None

NCT03185026 

Study name

Public title: Psychoeducation for suicidal behavior (PEPSUI)

Scientific title: Effectiveness of the first French psychoeducational program for suicidal behavior:
a randomized controlled trial

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Suicide, attempted
2. Suicidal behaviour

Interventions

PEPSUI psychoeducational programme

Outcomes

Primary outcomes:

1. Suicide re-attempt rate reduction, assessed using the Columbia Suicide Severity Rating Scale (C-

SSRS)

Starting date

1 July 2017 (estimated)

Contact information

Name: Déborah DUCASSE, MD

Address: University Hospital, Montpellier

E-mail: d-ducasse@chu-montpellier.fr

Telephone: 00 33 4 67 33 82 89

Notes

None

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

293

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT03191565 

Study name

Public title: Using smartphones for self-monitoring of skill-use in dialectical behavior therapy
(mDIARY)

Scientific title: The mDIARY study: using smartphones for daily self-monitoring of skill-use and
outcome in dialectical behavior therapy with borderline personality disorder: a combined RCT and
time series study

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Borderline personality disorder
2. Emotional instability
3. Skill, coping

Interventions

Monsenso dialectical behaviour therapy (DBT)-app and IT monitoring programme

Outcomes

Primary outcomes:

1. Mean number of days required to learn a new DBT-skill

Starting date

15 June 2017

Contact information

Name: Stig Helweg-Jørgensen PhD

Address: Region of Southern Denmark, Denmark

E-mail: not provided

Telephone: not provided

Notes

None

NCT03297840 

Study name

Public title: Change in mindfulness in borderline personality disorder

Scientific title: Change in mindfulness in borderline personality disorder after dialectic-behaviour-
al therapy (DBT): a pre-post-comparison

Methods

Registry stated "current observational study" (quote)

Participants

Inclusion criteria:

1. Mindfulness
2. Borderline personality disorder

Interventions

Dialectical behavioural therapy (DBT)

Outcomes

Primary outcomes:

1. Change in mindfulness
2. Change in borderline symptom severity
3. Change in overall psychiatric symptom severity

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

294

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT03297840  (Continued)

4. Change in severity in symptoms of depression

Starting date

4 May 2017

Contact information

Name: Katharina Bachmann, Psych Msc

Address: Department of Psychiatry and Psychotherapy - University Hospital, University of Olden-
burg, Bad Zwischenahn, Germany, 26160

E-mail: Katharina.Bachmann@uni-oldenburg.de

Telephone: 00494119615 1506

Notes

None

NCT03376113 

Study name

Title: The effect of a brief psychological intervention on reducing self-harm repetition: feasibility
study

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Suicide
2. Self-harm

Interventions

The volitional help sheet

Outcomes

Primary outcomes:

1. Acceptability of the intervention to patients
2. Feasibility of intervention delivery at the ER setting
3. Patient recruitment
4. Proportion of participating patients who can be reached by telephone contact at the 3-month

follow-up

5. Proportion of participating patients who can be reached by telephone contact at the 6-month

follow-up

6. Proportion of participating patients who can be traced from the hospital record at the 3-month

follow-up

7. Proportion of participating patients who can be traced from the hospital record at the 6-month

follow-up

8. Proportion of participating patients whose identity card number can be linked to the nationwide

self-harm registry at the 6-month follow-up

9. Proportion of participating patients whose identity card number can be linked to the nationwide

self-harm registry at the 3-month follow-up

10.Change in scores on a self-report suicidal behaviours assessment from baseline to 3 months
11.Change in scores on a self-report suicidal behaviours assessment from baseline to 6 months
12.Number of repeat self-harm episodes per person in 3 months after intervention based on hospital

records

13.Number of repeat self-harm episodes per person in 3 months after intervention recorded in the

nationwide self-harm registry

14.Number of repeat self-harm episodes per person in 6 months after intervention based on hospital

records

15.Number of repeat self-harm episodes per person in 6 months after intervention recorded in the

nationwide self-harm registry

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

295

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT03376113  (Continued)

16.Time to next self-harm repetition (in days) following randomisation

Starting date

3 November 2017

Contact information

Name: Shu-Sen Chang, MD, MSc, PhD

Address: National Taiwan University Hospital, Taipei, Taiwan, 100

E-mail: shusenchang@ntu.edu.tw

Telephone: +886 2 33668062

Notes

None

NCT03418142 

Study name

Public title: Evaluating an Internet-based self-management intervention for borderline (REVISIT)

Scientific title: Research evaluating the effectiVeness of adding an Internet-based self-manage-
ment intervention to usual care in the treatment of borderline personality disorder - REVISIT BPD

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Borderline personality disorder

Interventions

Internet-based self-management intervention for borderline personality disorder (REVISIT)

Outcomes

Primary outcomes:

1. Score of the Borderline Personality Disorder Severity Index (BPDSI)

Starting date

29 January 2018

Contact information

Name: Andrea Hauer

Address: Gaia AG Hamburg, Germany, 20144

E-mail: andrea.hauer@gaia-group.com

Telephone: +4940349930382

Notes

None

NCT03677037 

Study name

Public title: The short-term MBT project (MBT-RCT)

Scientific title: Short-term versus long-term mentalization-based therapy for outpatients with
subthreshold or diagnosed borderline personality disorder: a randomized clinical trial

Methods

Randomised controlled trial

Participants

Inclusion criteria:

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

296

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT03677037  (Continued)

1. Borderline personality disorder

Interventions

1. Other: short-term MBT
2. Other: long-term MBT

Outcomes

Primary outcomes:

1. Change in severity of borderline personality disorder, assessed with the Zanarini Rating Scale for

Borderline Personality Disorder (ZAN-BPD) interview

Starting date

24 September 2018

Contact information

Name: Sophie Juul Msc

Address: Stolpegaard Psychotherapy Centre, Mental Health Services, Capital Region of Denmark,
Gentofte, Denmark, 2820

E-mail: sophie.juul@regionh.dk

Telephone: 004538645324

Notes

None

NCT03833453 

Study name

Public title: Effectiveness of PTSD-treatment compared to integrated PTSD-PD-treatment in adult
patients with comorbid PTSD and BPD (PROSPER-B)

Scientific title: Prediction and outcome study in PTSD and (borderline) personality disorders

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Post-traumatic stress disorder (PTSD)
2. Borderline personality disorder (BPD)

Interventions

behavioural: dialectical behaviour therapy

Outcomes

Primary outcomes:

1. CAPS-5 (Clinician Administered PTSD Scale). Time frame: 12 months

Starting date

1 June 2018

Contact information

Name: Aishah Snoek, MSc

Address: Sinai Centrum, Amstelveen, Noord-Holand, Netherlands, 1180EB

E-mail: aishah.snoek@sinaicentrum.nl

Telephone: 0031-20-5457200

Notes

None

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

297

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NL1144/NTR1186 

Study name

Public title: SFT for forensic PD patients

Scientific title: Efficacy of schema-focused therapy (SFT) versus usual treatment in forensic pa-
tients with personality disorders: a three-year randomised clinical trial

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Forensic people with antisocial, borderline, narcissistic, or paranoid personality disorder

Interventions

Forensic setting, three years of individual SFT

Outcomes

Primary outcomes:

1. Severity of personality disorder symptoms
2. Risk of recidivism and violence

Secondary outcomes:

1. Therapy process variables (e.g. therapeutic engagement, quality of the therapeutic alliance)
2. Changes in the psychological processes (i.e. early maladaptive schemas, schema modes) that are

hypothesised to mediate changes in personality disorders in the SFT model

Starting date

1 October 2007

Contact information

Name: Professor David Bernstein

Address: University of Maastricht, Departement of Clinical Psychological Science, PO Box 616, 6200
MD, Maastricht, The Netherlands

E-mail: D.Bernstein@dmkep.unimaas.nl

Telephone: +31 478 635 200

Notes

None

NL2168/NTR2292 

Study name

Public title: Dosage-trial mentalisation-based treatment (MBT): intensive outpatient MBT versus
day hospital MBT

Scientific title: Intensive outpatient mentalisation-based treatment versus day hospital mentali-
sation-based treatment: a randomised controlled trial

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Referral to the MBT-programme as implemented by De Viersprong
2. At least one personality disorder as diagnosed according to DSM-IV criteria

Interventions

The MBT-programme offers 18-month psychotherapy designed specifically for treatment refractory
people with complex personality disorders, often complicated by multi-morbidity, who have typi-
cally had a history of unsuccessful treatments. Day hospital MBT (DH-MBT) consists of daily group
psychotherapy, weekly individual psychotherapy, individual crisis planning from a mentalising per-
spective, art therapy twice a week, and writing therapy. Intensive outpatient MBT (IOP-MBT) con-

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

298

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NL2168/NTR2292  (Continued)

Cochrane Database of Systematic Reviews

sists of group psychotherapy twice a week, weekly individual psychotherapy, and individual crisis
planning from a mentalising perspective.

Outcomes

Primary outcomes:

1. Frequency and severity of manifestations of (borderline) personality disorder
2. Symptomatic functioning
3. Quality of life
4. Care consumption

Secondary outcomes:

1. Axis I diagnoses
2. Interpersonal and personality functioning
3. Mentalisation
4. Treatment adherence

Starting date

8 February 2010

Contact information

Name: Helene Andrea

Address: Viersprong Institute for Studies on Personality Disorders (VISPD), PO Box 7, 4660 AA Hal-
steren, The Netherlands

E-mail: helene.andrea@deviersprong.nl

Telephone: +31 (0)164 632200

Notes

None

NL2266/NTR2392 

Study name

Public title: Group schema therapy for borderline personality disorder

Scientific title: Multi-Site RCT of group schema therapy for borderline personality disorder

Methods

Randomised controlled trial

Participants

Inclusion criteria:

1. Age 18-65 years
2. Primary DSM-IV diagnosis of BPD (assessed with the SCID-II interview)
3. BPD severity above 20 on the BPDSI interview

Interventions

1. 118 group schema therapy sessions over 2 years with maximum of 17 individual sessions
2. 64 group schema therapy over 2 years with maximum of 61 individual sessions
3. TAU - the standard treatment given for that patient at the treatment centre

Outcomes

Primary outcomes:

1. BPD severity index - mean score

Starting date

1 February 2010

Contact information

Name: Professor Arnoud Arntz

Address: University Maastricht (UM), DMKEP, PO Box 616, 6200 MD Maastricht, The Netherlands

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

299

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NL2266/NTR2392  (Continued)

E-mail: Arnoud.Arntz@MP.Unimaas.nl

Telephone: +31 (0)43 3881228

Notes

None

Cochrane Database of Systematic Reviews

NL3856/NTR4016 

Study name

Public title: Toetsing van een geïntegreerd behandelprotocol voor patiënten met een bipolaire
stoornis en een comorbide borderline persoonlijkheidskenmerken. Een randomized clinical trial

Scientific title: The addition of STEPPS in the treatment of people with bipolar disorder and co-
morbid borderline personality features: a protocol for a randomised controlled trial

Methods

Randomised controlled trial

Participants

Inclusion criteria:

Interventions

1. Age 18–65 years
2. Diagnosis  of  bipolar  disorder-I,  bipolar  disorder-II,  or  bipolar  disorder-not  otherwise  specified

(NOS)

3. Comorbid borderline personality disorder or borderline personality features (at least 3 of 9 DSM-

IV-TR criteria, including at least impulsivity and anger bursts).

Investigational treatment of the study will be the STEPPS training added to individual TAU for bipo-
lar disorder. The STEPPS training is a group treatment developed for people with BPD to improve
their emotion regulation. The training consists of 20 weekly sessions of approximately 2.5 hours
and consists of 4 parts: psychoeducation, emotion regulation skills, behavioural skills and emotion
handling plan.

Outcomes

Primary outcomes:

1. Frequency and severity of manic and depressive episodes
2. Symptoms, course and burden of borderline personality features

Starting date

25 August 2013

Contact information

Name: G Riemann

Address: Saxion Hogescholen Academie Mens en Arbeid Handelskade 75, 7417 DH Deventer, The
Netherlands

E-mail: g.riemann@saxion.nl

Telephone: not provided

Notes

None

BAS: Brief Admission Skåne
BDI(-II): Beck Depression Inventory (-Revised)
IIBDNF: brain-derived neurotrophic factor
BPD: borderline personality disorder
BPDSI: Borderline Personality Severity Index
BPFS-C: Borderline Personality Features Scale for Children
BSL-23: Borderline Symptom List-23
BSSI: Beck Scale for Suicide Ideation
CAMHS: children and adolescents mental health services

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

300

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

CAMS: Cognitive and Affective Mindfulness Scale
CAPS(-5): Clinician-Administered PTSD Scale for DSM-5
COPE: Coping Orientation to Problems Experienced Inventory
C-SSRS: Columbia Suicide Severity Rating Scale
CUES+: Coping with Unusual Experiences for 12–18 year olds
DBT: dialectical behavior therapy
DERS: Developmental Environmental Rating Scale
DES: Dissociative Experiences Scale
DH: day hospital
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
ED: emergency department
ER: emergency room
FAL: families of adolescents with emotional instability
FASTER-DBT: the feasibility of a shorter treatment and evaluating responses for dialectical behavior therapy
IIP-C: Inventory of Interpersonal Problems Circumplex Scales
IOP: intensive outpatient
IPRI: Automatic Anger and Hostility Thoughts Scale
IT: information technology
KIMS: Kentucky Inventory of Mindfulness Skills
MBT: mentalisation-based treatment
mDIARY: using smartphones for self-monitoring of skill-use in dialectical behavior therapy
M-GAB:  Mentalization-based  treatment  in  Groups  for  Adolescence  with  Borderline  personality  disorder  or  subthreshold  borderline
personality disorder
MOBY: Monitoring Outcomes of Borderline personality disorder in Youth
NET: narrative exposure therapy
NOS: bipolar disorder-not otherwise specified
PD: personality disorder
PEPSUI: psychoeducation for suicidal behavior
PRO*BPD: PROgrams for Borderline Personality Disorder
PROSPER-B: Prediction and Outcome Study in PTSD and (Borderline) Personality disorders
PTSD: post-traumatic stress disorder
RCCT: Rogers' client centred therapy
RCT: randomised controlled trial
REVISIT: Research Ealuating the effectiVeness of adding an Internet-based Self-management Intervention to usual care in the Treatment
of Borderline Personality disorder
SASII: Suicide Attempt Self-Injury Interview
SAS-SR: Social Adjustment Scale Self-Report
SCID-II: Structured Clinical Interview for DSM Axis II disorders
SDQ: Strengths and Difficulties Questionnaire
SFT: schema focused therapy
SITBI-G: Self-Injurious Thoughts and Behaviors Interview-German version
SSI: Scale for Suicidal Ideation
Step2Health: randomised trial of stepped care for suicide prevention in teens and young adults
STEPPS: systems training for emotional predictability and problem solving
TAU: treatment-as-usual
UED: Unusual Experiences associated with Distress
ZAN-BPD: Zanarini Rating Scale for Borderline Personality disorder

D A T A   A N D   A N A L Y S E S

Comparison 1.   Psychotherapy vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1 Primary: BPD symptom
severity (continuous)

23

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

301

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1.1 End of treatment

22

1244

1.1.2 0-6 months follow-up

1.1.3 6-12 months follow-up

1.1.4 12 months and over fol-
low-up

1.2 Primary: BPD symptom
severity (dichotomous), at
above 12 months follow-up

1.3 Primary: self-harm (contin-
uous)

1.3.1 End of treatment

1.3.2 0-6 months follow-up

1.3.3 6-12 months follow-up

1.4 Primary: self-harm (di-
chotomous)

1.4.1 End of treatment

1.4.2 0-6 months follow-up

1.4.3 6-12 months follow-up

1.4.4 12 months and over fol-
low-up

1.5 Primary: suicide-related
outcomes (continuous)

1.5.1 End of treatment

1.5.2 0-6 months follow-up

1.5.3 6-12 months follow-up

1.5.4 Above 12 months fol-
low-up

2

2

2

1

13

13

1

3

6

6

1

1

1

13

13

2

2

1

41

157

97

616

28

174

513

41

41

41

666

36

109

76

Std. Mean Difference (IV, Random,
95% CI)

-0.52 [-0.70, -0.33]

Std. Mean Difference (IV, Random,
95% CI)

-0.59 [-1.23, 0.05]

Std. Mean Difference (IV, Random,
95% CI)

-0.04 [-0.36, 0.27]

Std. Mean Difference (IV, Random,
95% CI)

-0.94 [-2.58, 0.70]

Risk Ratio (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.32 [-0.49, -0.14]

Std. Mean Difference (IV, Random,
95% CI)

-0.52 [-1.28, 0.23]

Std. Mean Difference (IV, Random,
95% CI)

-0.18 [-0.48, 0.12]

Risk Ratio (IV, Random, 95% CI)

Subtotals only

Risk Ratio (IV, Random, 95% CI)

0.85 [0.63, 1.14]

Risk Ratio (IV, Random, 95% CI)

0.14 [0.04, 0.56]

Risk Ratio (IV, Random, 95% CI)

0.27 [0.10, 0.68]

Risk Ratio (IV, Random, 95% CI)

0.33 [0.15, 0.76]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.34 [-0.57, -0.11]

Std. Mean Difference (IV, Random,
95% CI)

-0.43 [-1.10, 0.23]

Std. Mean Difference (IV, Random,
95% CI)

-0.42 [-0.80, -0.04]

Std. Mean Difference (IV, Random,
95% CI)

-0.31 [-0.77, 0.14]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

302

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.6 Primary: suicide-related
outcomes (dichotomous)

1.6.1 End of treatment

1.6.2 0-6 months follow-up

1.6.3 Above 12 months fol-
low-up

1.7 Primary: psychosocial
functioning (continuous)

1.7.1 End of treatment

1.7.2 0-6 months follow-up

1.7.3 6-12 months follow-up

1.7.4 Above 12 months fol-
low-up

1.8 Secondary: anger (continu-
ous)

1.8.1 End of treatment

1.8.2 0-6 months follow-up

1.8.3 6-12 months follow-up

1.8.4 Above 12 months fol-
low-up

1.9 Secondary: affective insta-
bility (continuous)

1.9.1 End of treatment

1.9.2 6-12 months follow-up

1.10 Secondary: chronic feel-
ings of emptiness (continuous)

1.10.1 End of treatment

5

5

1

1

23

22

1

3

6

8

8

1

2

1

12

12

1

4

4

396

41

41

1314

9

247

499

323

8

111

80

620

33

187

Risk Ratio (IV, Random, 95% CI)

Subtotals only

Risk Ratio (IV, Random, 95% CI)

0.27 [0.11, 0.67]

Risk Ratio (IV, Random, 95% CI)

0.25 [0.06, 1.05]

Risk Ratio (IV, Random, 95% CI)

0.29 [0.11, 0.74]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.45 [-0.68, -0.22]

Std. Mean Difference (IV, Random,
95% CI)

-1.23 [-2.74, 0.29]

Std. Mean Difference (IV, Random,
95% CI)

-0.09 [-0.40, 0.23]

Std. Mean Difference (IV, Random,
95% CI)

-0.27 [-0.60, 0.05]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.38 [-0.64, -0.12]

Std. Mean Difference (IV, Random,
95% CI)

-1.20 [-2.82, 0.41]

Std. Mean Difference (IV, Random,
95% CI)

-0.12 [-0.50, 0.25]

Std. Mean Difference (IV, Random,
95% CI)

0.02 [-0.42, 0.46]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.68 [-0.98, -0.39]

Std. Mean Difference (IV, Random,
95% CI)

-0.52 [-1.21, 0.18]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.39 [-0.69, -0.10]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

303

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.10.2 6-12 months follow-up

1

33

1.11 Secondary: impulsivity
(continuous)

1.11.1 End of treatment

1.11.2 6-12 months follow-up

1.12 Secondary: impulsivity
(dichotomous), at end of treat-
ment

1.13 Secondary: interpersonal
problems (continuous)

1.13.1 End of treatment

1.13.2 0-6 months follow-up

1.13.3 6-12 months follow-up

1.13.4 Above 12 months fol-
low-up

1.14 Secondary: abandonment
(continuous)

1.14.1 End of treatment

1.14.2 6-12 months follow-up

1.15 Secondary: identity dis-
turbance (continuous)

1.15.1 End of treatment

1.15.2 6-12 months follow-up

1.16 Secondary: dissociation
and psychotic-like symptoms
(continuous)

1.16.1 End of treatment

10

10

2

1

18

18

1

2

3

2

2

1

4

4

1

6

6

491

77

1159

53

132

172

84

33

250

33

244

Std. Mean Difference (IV, Random,
95% CI)

-0.58 [-1.28, 0.11]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.54 [-0.84, -0.25]

Std. Mean Difference (IV, Random,
95% CI)

0.32 [-0.13, 0.77]

Risk Ratio (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.42 [-0.68, -0.16]

Std. Mean Difference (IV, Random,
95% CI)

-0.41 [-1.01, 0.20]

Std. Mean Difference (IV, Random,
95% CI)

-0.17 [-0.65, 0.32]

Std. Mean Difference (IV, Random,
95% CI)

0.00 [-0.54, 0.54]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.22 [-0.66, 0.21]

Std. Mean Difference (IV, Random,
95% CI)

-0.39 [-1.08, 0.30]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.37 [-0.84, 0.10]

Std. Mean Difference (IV, Random,
95% CI)

-1.09 [-1.83, -0.35]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.47 [-0.85, -0.10]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

304

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.16.2 0-6 months follow-up

1.16.3 6-12 months follow-up

1.16.4 12 months and over fol-
low-up

1.17 Secondary: depression
(continuous)

1.17.1 End of treatment

1.17.2 0-6 months follow-up

1.17.3 6-12 months follow-up

1.17.4 12 months and over fol-
low-up

1.18 Secondary: depression
(dichotomous), at end of treat-
ment

1.19 Secondary: attrition (di-
chotomous)

1.19.1 End of treatment

1.19.2 0-6 months follow-up

1.20 Secondary: non-serious
adverse effects (dichotomous),
at end of treatment

1.21 Secondary: serious ad-
verse effects (dichotomous), at
end of treatment

2

1

1

22

22

4

3

5

1

33

32

1

2

4

35

33

24

1568

125

260

311

2225

60

381

Std. Mean Difference (IV, Random,
95% CI)

-0.97 [-1.69, -0.26]

Std. Mean Difference (IV, Random,
95% CI)

-0.59 [-1.29, 0.11]

Std. Mean Difference (IV, Random,
95% CI)

-0.01 [-0.81, 0.79]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.39 [-0.61, -0.17]

Std. Mean Difference (IV, Random,
95% CI)

-0.80 [-1.26, -0.34]

Std. Mean Difference (IV, Random,
95% CI)

-0.40 [-0.95, 0.16]

Std. Mean Difference (IV, Random,
95% CI)

-0.40 [-0.74, -0.06]

Risk Ratio (IV, Fixed, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

1.00 [0.83, 1.20]

Risk Ratio (M-H, Random, 95% CI)

0.58 [0.34, 1.00]

Risk Ratio (M-H, Random, 95% CI)

0.92 [0.45, 1.88]

571

Risk Ratio (IV, Fixed, 95% CI)

0.86 [0.14, 5.09]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

305

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.1.   Comparison 1: Psychotherapy vs TAU, Outcome 1: Primary: BPD symptom severity (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.1.1 End of treatment
Amianto 2011 (1)
Blum 2008 (2)
Bos 2010 (3)
Doering 2010 (4)
Farrell 2009 (5)
Gratz 2006 (6)
Gratz 2014 (6)
Gregory 2008b (6)
Jørgensen 2013 (7)
Koons 2001a (8)
Kredlow 2017a (7)
Laurenssen 2018 (9)
Leichsenring 2016 (10)
Leppänen 2016 (11)
Morton 2012 (12)
Philips 2018 (13)
Priebe 2012 (14)
Reneses 2013 (15)
Robinson 2016 (16)
Rossouw 2012b (17)
Schuppert 2012 (18)
Soler 2009 (19)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.10; Chi² = 48.68, df = 21 (P = 0.0006); I² = 57%
Test for overall effect: Z = 5.51 (P < 0.00001)

1
8.0623
25.8
1.54
9.47
5.72
6.59
12.4
2.5
1.6
1.17
11.45
8.6
10.14
12.47
9.1
6.9
7.9
7.41
0.5385
9.53
1.2

3.3
9.8
79.7
4.79
18.81
25.83
27.47
33.6
2.8
3.6
1.17
20.63
18.76
17.54
32.76
17
13.1
13
9.64
2.79
13.29
3.5

3.3
13.4
95.1
5.63
32.75
34.7
35.88
38.4
3.6
4.2
4.25
21.39
19.41
21.48
47.42
20.7
15.9
19.1
9.27
3.06
15.39
4.44

16
65
26
52
16
12
31
10
42
10
14
54
64
19
21
13
33
18
12
29
48
29
634

1.1
7.6811
29.1
1.47
5.9
10.81
5.59
8.62
2.1
2.3
3.2
10.43
9.38
11.41
11
9.1
7.5
6.9
7.39
65.7267
9
0.52

17
59
26
52
12
10
30
13
24
10
12
41
58
32
20
11
37
26
11
30
49
30
610

3.9%
6.5%
4.8%
6.2%
2.9%
2.8%
4.8%
3.1%
5.2%
2.9%
3.0%
6.1%
6.5%
4.7%
4.0%
3.2%
5.5%
4.3%
3.2%
5.2%
6.1%
4.9%
100.0%

0.00 [-0.68 , 0.68]
-0.45 [-0.81 , -0.10]
-0.55 [-1.11 , 0.00]
-0.55 [-0.95 , -0.16]
-1.66 [-2.54 , -0.78]
-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.44 [-1.28 , 0.39]
-0.33 [-0.84 , 0.17]
-0.29 [-1.17 , 0.59]
-1.28 [-2.14 , -0.42]
-0.07 [-0.47 , 0.34]
-0.07 [-0.43 , 0.28]
-0.35 [-0.93 , 0.22]
-1.22 [-1.89 , -0.55]
-0.39 [-1.20 , 0.42]
-0.38 [-0.86 , 0.09]
-0.82 [-1.45 , -0.19]
0.05 [-0.77 , 0.87]
-0.01 [-0.52 , 0.50]
-0.22 [-0.62 , 0.17]
-1.01 [-1.55 , -0.47]
-0.52 [-0.70 , -0.33]

1.1.2 0-6 months follow-up
Kredlow 2017a (20)
Robinson 2016 (16)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.17, df = 1 (P = 0.68); I² = 0%
Test for overall effect: Z = 1.79 (P = 0.07)

2.7
6.19

2.86
7.1

14
10
24

4.88
10

1.1.3 6-12 months follow-up
Amianto 2011 (21)
Blum 2008 (22)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.72, df = 1 (P = 0.40); I² = 0%
Test for overall effect: Z = 0.27 (P = 0.79)

1
18.5432

16
65
81

3.1
33

3.4
32.4

3
7.97

12
5
17

65.0%
35.0%
100.0%

-0.69 [-1.49 , 0.11]
-0.40 [-1.49 , 0.68]
-0.59 [-1.23 , 0.05]

0.9
26.1159

17
59
76

20.8%
79.2%
100.0%

-0.31 [-1.00 , 0.38]
0.03 [-0.33 , 0.38]
-0.04 [-0.36 , 0.27]

5.3
2.7

19
16
35

49.0%
51.0%
100.0%

-1.79 [-2.53 , -1.06]
-0.12 [-0.70 , 0.46]
-0.94 [-2.58 , 0.70]

-1
Favours Psychotherapies

-2

0

1
2
Favours TAU

1.1.4 12 months and over follow-up
Bateman 1999 (23)
Jørgensen 2013 (7)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.29; Chi² = 12.25, df = 1 (P = 0.0005); I² = 92%
Test for overall effect: Z = 1.12 (P = 0.26)

15.1
2.5

22
40
62

5.5
2.2

5.2
2.4

Footnotes
(1) Clinician rated: CGI-BPD
(2) Zan-BPD - total (CR)
(3) Self reported: BPD-40
(4) Clinician-rated: Mean number of DSM-IV BPD criteria met
(5) Self rated: BSI
(6) BEST (SR)
(7) SCID-BPD (CR)
(8) SCID-II - mean number of BPD criteria met (CR)
(9) BPDSI-IV (CR)
(10) Self rated: Borderline Personality Inventory

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

306

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.1.   (Continued)

(8) SCID-II - mean number of BPD criteria met (CR)
(9) BPDSI-IV (CR)
(10) Self rated: Borderline Personality Inventory
(11) Clinician-rated: BPDSI-IV
(12) Self rated: BEST
(13) BPDSI-IV-total (CR)
(14) ZAN-BPD total (CR)
(15) Clinician rated: ZAN-BPD
(16) Zan-BPD-total (CR)
(17) BPFS-C (SR)
(18) BPDSI-IV total
(19) CCGI-BPD global (CR)
(20) Observer-rated: SCID-II BPD
(21) Clinician-rated: CGI-BPD
(22) BEST - total (CR)
(23) Clinician-rated: ZAN-BPD total

Analysis 1.2.   Comparison 1: Psychotherapy vs TAU, Outcome 2: Primary:
BPD symptom severity (dichotomous), at above 12 months follow-up

Study or Subgroup

Psychotherapies
Total
Events

TAU

Events

Total

Risk Ratio
IV, Fixed, 95% CI

Risk Ratio
IV, Fixed, 95% CI

Davidson 2006 (1)

19

43

16

33

0.91 [0.56 , 1.48]

Test for subgroup differences: Not applicable

Footnotes
(1) Participants still meeting BPD diagnostic criteria

0.01

0.1

1

Favours Psychotherapies

10
Favour TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

307

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.3.   Comparison 1: Psychotherapy vs TAU, Outcome 3: Primary: self-harm (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.3.1 End of treatment
Amianto 2011 (1)
Borschmann 2013 (2)
Carter 2010 (3)
Feigenbaum 2012 (4)
Gratz 2006 (5)
Gratz 2014 (5)
Koons 2001a (6)
Linehan 1991 (7)
Linehan 2006 (4)
Philips 2018 (8)
Priebe 2012 (9)
Van den Bosch 2005 (10)
Weinberg 2006 (11)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 14.23, df = 12 (P = 0.29); I² = 16%
Test for overall effect: Z = 3.46 (P = 0.0005)

2.2
20.6
5.2
2.4
2.05
0.69
0.4
0.55
14.17
2.3
39.2
3.31
0.6

2.8
89.71
7.47
3.2
0.93
0.35
1.3
0.94
37.63
5.5
73.4
13.15
0.91

1.9
20
8.42
3.1
4.48
0.97
1
9.33
18.94
2.2
63.7
41.6
3.63

16
36
20
25
12
31
10
20
52
13
38
22
15
310

2
55.6
26.92
3.4
3.39
0.35
2.2
26.95
40.73
4.8
92.9
78.76
4.8

17
36
31
16
10
30
10
21
49
11
38
24
13
306

6.0%
11.5%
8.4%
6.9%
3.7%
9.4%
3.8%
7.1%
14.7%
4.5%
11.9%
7.6%
4.7%
100.0%

0.12 [-0.56 , 0.80]
0.01 [-0.45 , 0.47]
-0.15 [-0.71 , 0.42]
-0.21 [-0.84 , 0.42]
-0.98 [-1.88 , -0.09]
-0.79 [-1.31 , -0.27]
-0.32 [-1.20 , 0.57]
-0.45 [-1.07 , 0.17]
-0.12 [-0.51 , 0.27]
0.02 [-0.78 , 0.82]
-0.29 [-0.74 , 0.16]
-0.65 [-1.25 , -0.06]
-0.88 [-1.67 , -0.10]
-0.32 [-0.49 , -0.14]

1.3.2 0-6 months follow-up
Weinberg 2006 (11)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.36 (P = 0.17)

1.98

3.57

15
15

6.69

12.23

13
13

100.0%
100.0%

-0.52 [-1.28 , 0.23]
-0.52 [-1.28 , 0.23]

1.3.3 6-12 months follow-up
Amianto 2011 (1)
Linehan 2006 (12)
Van den Bosch 2005 (13)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.06, df = 2 (P = 0.59); I² = 0%
Test for overall effect: Z = 1.19 (P = 0.23)

0.8
6.19
34.28

0.4
5.43
10.9

16
52
18
86

0.3
15.93
33.9

0.6
60.96
99.39

17
49
22
88

19.1%
58.2%
22.7%
100.0%

0.14 [-0.55 , 0.82]
-0.24 [-0.64 , 0.15]
-0.29 [-0.92 , 0.34]
-0.18 [-0.48 , 0.12]

-1
Favours Psychotherapies

-2

0

1
2
Favour TAU

Footnotes
(1) self-harming incidents
(2) SHQ - number of suicidal and self-injurious episodes (past 6 months) (SR)
(3) number of self-harm episodes 3 to 6 months
(4) SASII - frequency of self-harm (CR)
(5) DSHI (SR)
(6) PHI - deliberate self-harm frequency (last 3 months) (CR)
(7) Mean number of parasuicidal acts (last 3 months)
(8) DSHI-SF (SR)
(9) Days of self-harm and type of deliberate self-harm recorded in an interview (CR)
(10) LPC - self-mutilation (last 3 months) (CR)
(11) PHI - deliberate self-harm frequency (CR)
(12) Observer-rated: SASII - NSSI
(13) LPC self-mutilation (last 3 months)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

308

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.4.   Comparison 1: Psychotherapy vs TAU, Outcome 4: Primary: self-harm (dichotomous)

Study or Subgroup

Psychotherapies
Total
Events

TAU

Events

Total

Weight

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.4.1 End of treatment
Bateman 1999 (1)
Bateman 2009 (1)
Bos 2010 (2)
Davidson 2006 (3)
Doering 2010 (4)
Rossouw 2012b
Subtotal (95% CI)
137
Total events:
Heterogeneity: Tau² = 0.09; Chi² = 18.43, df = 5 (P = 0.002); I² = 73%
Test for overall effect: Z = 1.09 (P = 0.28)

19
71
28
52
52
40
262

19
63
30
47
52
40
251

16
27
13
27
35
34

7
17
16
35
38
24

152

11.8%
14.3%
13.9%
19.3%
20.8%
19.9%
100.0%

0.44 [0.24 , 0.81]
0.56 [0.34 , 0.92]
1.32 [0.78 , 2.22]
1.17 [0.86 , 1.60]
1.09 [0.84 , 1.40]
0.71 [0.53 , 0.94]
0.85 [0.63 , 1.14]

1.4.2 0-6 months follow-up
Bateman 1999 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.78 (P = 0.005)

2

2

1.4.3 6-12 months follow-up
Bateman 1999 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.77 (P = 0.006)

4

4

1.4.4 12 months and over follow-up
Bateman 1999 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.61 (P = 0.009)

5

5

22
22

22
22

22
22

12

12

13

13

13

13

19
19

100.0%
100.0%

0.14 [0.04 , 0.56]
0.14 [0.04 , 0.56]

19
19

100.0%
100.0%

0.27 [0.10 , 0.68]
0.27 [0.10 , 0.68]

19
19

100.0%
100.0%

0.33 [0.15 , 0.76]
0.33 [0.15 , 0.76]

Footnotes
(1) SSHI - number of participants with self-mutilating behaviour (last 6 months) (CR)
(2) participants scoring above BPDSI-IV-parasuicide cut-off score
(3) DSHI - participants with self-harming behaviour (12 months of treatment) (SR)
(4) CISSB - participants with self-harming behaviour (last 12 months) (SR)

0.01

0.1

1

Favours Psychotherapies

10
Favour TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

309

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.5.   Comparison 1: Psychotherapy vs TAU, Outcome 5: Primary: suicide-related outcomes (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.5.1 End of treatment
Amianto 2011 (1)
Andreoli 2016 (2)
Davidson 2006 (3)
Feigenbaum 2012 (4)
Gleeson 2012 (5)
Gregory 2008b (6)
Koons 2001a (7)
Leppänen 2016 (8)
Linehan 2006 (4)
Mehlum 2014 (9)
Reneses 2013 (10)
Soler 2009 (11)
Weinberg 2006 (12)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 21.22, df = 12 (P = 0.05); I² = 43%
Test for overall effect: Z = 2.87 (P = 0.004)

0.7
0.6082
1.14
0.43
1
0.64
8
0.49
1.46
6.3
1.2
1.24
16.92

1.4
0.35
0.69
0.24
0.8
0.32
26.2
0.41
0.98
26.5
0.9
2.44
27.47

1.5
1
1.22
0.06
2.2
0.44
41.5
0.51
1.37
41.7
1.3
2.55
42.69

16
140
43
25
4
11
10
19
52
5
18
29
15
387

1.5.2 0-6 months follow-up
Gleeson 2012 (5)
Weinberg 2006 (12)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 1.28 (P = 0.20)

0.5
18.68

0.3
37.96

4
15
19

0.8
45.69

1.5.3 6-12 months follow-up
Amianto 2011 (13)
Davidson 2006 (14)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.90); I² = 0%
Test for overall effect: Z = 2.15 (P = 0.03)

1.4
0.93

0.6
1.58

16
43
59

1.7
2.09

0.8
1.1
2.67
0.25
3
0.55
14.3
0.76
1.87
28.9
1.3
0.88
17.67

17
30
33
16
5
13
10
32
49
5
26
30
13
279

7.3%
12.2%
11.1%
7.9%
2.6%
5.8%
4.4%
9.0%
12.5%
2.8%
8.4%
10.0%
6.1%
100.0%

-0.13 [-0.81 , 0.55]
-0.90 [-1.31 , -0.50]
-0.27 [-0.72 , 0.19]
0.48 [-0.16 , 1.11]
-0.53 [-1.88 , 0.83]
-0.20 [-1.00 , 0.61]
-1.26 [-2.24 , -0.29]
-0.15 [-0.71 , 0.42]
-0.23 [-0.62 , 0.16]
-0.66 [-1.95 , 0.64]
-0.31 [-0.92 , 0.29]
-0.10 [-0.61 , 0.41]
-0.86 [-1.64 , -0.07]
-0.34 [-0.57 , -0.11]

1.5
14.38

4
13
17

22.2%
77.8%
100.0%

-0.39 [-1.80 , 1.02]
-0.45 [-1.20 , 0.31]
-0.43 [-1.10 , 0.23]

0.9
3.58

17
33
50

30.7%
69.3%
100.0%

-0.38 [-1.07 , 0.31]
-0.44 [-0.89 , 0.02]
-0.42 [-0.80 , -0.04]

1.5.4 Above 12 months follow-up
1.88
Davidson 2006 (15)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.34 (P = 0.18)

3.19

3.03

4.16

43
43

33
33

100.0%
100.0%

-0.31 [-0.77 , 0.14]
-0.31 [-0.77 , 0.14]

-1
Favours Psychotherapies

-2

0

1

2
Favour TAU

Footnotes
(1) CGI-BPD, suicidality and self-damaging acts (CR)
(2) Episode of suicidal ideation, with or without deliberate self-harm
(3) DSHI - cumulative number of suicide attempts
(4) SASII-suicide attempts (CR)
(5) OAS-M - suicidality (CR)
(6) LPC - parasuicides per last 3 months
(7) BSS (SR)
(8) BPDSI-IV - Parasuicidality, suicide plans and attempts (CR)
(9) SIQ-jr (SR)
(10) Clinician-rated: LSASI
(11) CGI-BPD, suicidality (CR)
(12) SBQ (SR)
(13) Clinician-rated: CGI-BPD, suicidality and self-damaging acts
(14) Number of suicide attempts (cumulative average at 12 months follow-up)
(15) Number of suicide attempts (cumulative average at 30 month follow-up)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

310

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.6.   Comparison 1: Psychotherapy vs TAU, Outcome 6: Primary: suicide-related outcomes (dichotomous)

Study or Subgroup

Psychotherapies
Total
Events

TAU

Events

Total

Weight

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.6.1 End of treatment
Bateman 1999 (1)
Bateman 2009 (1)
Doering 2010 (2)
Philips 2018 (3)
Stanley 2017
Subtotal (95% CI)
13
Total events:
Heterogeneity: Tau² = 0.45; Chi² = 7.30, df = 4 (P = 0.12); I² = 45%
Test for overall effect: Z = 2.82 (P = 0.005)

19
71
51
24
37
202

12
16
11
3
6

19
63
52
22
38
194

1
2
7
0
3

48

14.7%
21.4%
32.6%
7.9%
23.4%
100.0%

0.08 [0.01 , 0.58]
0.11 [0.03 , 0.46]
0.65 [0.27 , 1.54]
0.13 [0.01 , 2.41]
0.51 [0.14 , 1.90]
0.27 [0.11 , 0.67]

1.6.2 0-6 months follow-up
Bateman 1999 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.90 (P = 0.06)

2

2

1.6.3 Above 12 months follow-up
Bateman 1999 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.57 (P = 0.01)

4

4

22
22

22
22

7

7

12

12

19
19

100.0%
100.0%

0.25 [0.06 , 1.05]
0.25 [0.06 , 1.05]

19
19

100.0%
100.0%

0.29 [0.11 , 0.74]
0.29 [0.11 , 0.74]

Test for subgroup differences: Chi² = 0.03, df = 2 (P = 0.98), I² = 0%

0.001

0.1
Favours Psychotherapies

1

10

1000

Favour TAU

Footnotes
(1) SSHI - number of participants with life-threatening suicide attempts (last 6 months)
(2) CISSB - participants with suicide attempts (last 12 months) (SR)
(3) participants with suicide attempts (recorded via direct contact with patients and health care staff, as well as from reviewing the case records)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

311

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.7.   Comparison 1: Psychotherapy vs TAU, Outcome 7: Primary: psychosocial functioning (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.7.1 End of treatment
Amianto 2011 (1)
Andreoli 2016 (2)
Bateman 1999 (3)
Bateman 2009 (3)
Blum 2008 (4)
Borschmann 2013 (5)
Carter 2010 (6)
Davidson 2006 (7)
Doering 2010 (1)
Farrell 2009 (1)
Feigenbaum 2012 (8)
Gleeson 2012 (9)
Gratz 2014 (10)
Gregory 2008b (11)
Jochems 2015 (12)
Jørgensen 2013 (3)
Kramer 2016 (13)
Linehan 1994 (4)
Mehlum 2014 (14)
Reneses 2013 (15)
Salzer 2014 (16)
Soler 2009 (17)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.20; Chi² = 74.18, df = 21 (P < 0.00001); I² = 72%
Test for overall effect: Z = 3.84 (P = 0.0001)

11.2
6.2343
0.6
0.5
12.9
7.98
11.48
4.4
8.04
10.17
0.85
8.3
6.24
8.1
6.36
0.5
7.79
9.71
6.6
8.9
9.84
0.9

-66.4
-57.6
3.4
2.17
-43.5
25.81
13.07
13.1
-56.06
-50.08
2.22
-50.6
16.01
6.9
13.22
2.1
16
-40.43
-54.2
27.6
-51.82
3.57

-65.9
-62.95
2.7
1.76
-50.5
26.06
8.15
13.1
-58.62
-60.5
2.48
-67
14.25
-9.7
12.8
2.2
12.76
-51.42
-59.4
35.4
-65
3.27

16
140
20
71
65
36
20
52
52
16
25
4
31
11
16
42
21
13
5
18
17
29
720

13
7.6
0.6
0.64
12.29
8.94
11.59
4.6
6.87
5.07
0.92
14.1
6.24
6.7
5.8
0.6
5.42
10.8
6.1
10.8
6.82
1.13

17
30
19
63
59
36
28
47
52
12
16
5
30
13
27
24
20
13
5
26
22
30
594

4.3%
5.7%
4.3%
6.0%
5.9%
5.4%
4.8%
5.8%
5.8%
3.7%
4.6%
1.7%
5.2%
2.8%
4.6%
5.2%
4.6%
3.6%
2.1%
4.6%
4.1%
5.2%
100.0%

0.04 [-0.64 , 0.72]
-0.82 [-1.22 , -0.42]
-1.14 [-1.83 , -0.46]
-0.72 [-1.07 , -0.36]
-0.55 [-0.91 , -0.19]
0.03 [-0.43 , 0.49]
-0.42 [-1.00 , 0.16]
0.00 [-0.39 , 0.39]
-0.34 [-0.73 , 0.05]
-1.20 [-2.03 , -0.38]
0.29 [-0.34 , 0.92]
-1.22 [-2.73 , 0.30]
-0.28 [-0.78 , 0.23]
-2.17 [-3.22 , -1.13]
-0.07 [-0.69 , 0.55]
0.18 [-0.32 , 0.69]
-0.47 [-1.09 , 0.15]
-1.04 [-1.86 , -0.21]
-0.74 [-2.05 , 0.57]
0.76 [0.14 , 1.38]
-1.56 [-2.29 , -0.83]
-0.29 [-0.80 , 0.22]
-0.45 [-0.68 , -0.22]

1.7.2 0-6 months follow-up
Gleeson 2012 (9)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.58 (P = 0.11)

-69.3

4.3

-53.5

14.7

4
4

5
5

100.0%
100.0%

-1.23 [-2.74 , 0.29]
-1.23 [-2.74 , 0.29]

1.7.3 6-12 months follow-up
Amianto 2011 (1)
Blum 2008 (4)
Davidson 2006 (7)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 2.85, df = 2 (P = 0.24); I² = 30%
Test for overall effect: Z = 0.54 (P = 0.59)

13.4
16.12
5

-65.6
-53
13

-66.2
-47.1
12.3

16
65
43
124

1.7.4 Above 12 months follow-up
-65.6
Andreoli 2016 (2)
-58.3
Bateman 1999 (1)
10.3
Davidson 2006 (7)
-14.3
Gregory 2008b (11)
2.1
Jørgensen 2013 (3)
14.1
McMurran 2016 (18)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.09; Chi² = 12.57, df = 5 (P = 0.03); I² = 60%
Test for overall effect: Z = 1.66 (P = 0.10)

-58.1
-51.8
11.2
-10.6
2.2
12.5

140
22
43
8
40
60
313

11.6
10.5
5
8.7
0.5
6.75

11.9
20.74
5.3

17
59
47
123

17.5%
45.2%
37.3%
100.0%

0.05 [-0.64 , 0.73]
-0.32 [-0.67 , 0.04]
0.13 [-0.28 , 0.55]
-0.09 [-0.40 , 0.23]

12.3
5.7
5
9
0.8
7.59

30
18
47
8
24
59
186

20.3%
13.5%
19.8%
7.8%
17.1%
21.5%
100.0%

-0.64 [-1.04 , -0.24]
-0.73 [-1.38 , -0.09]
-0.18 [-0.59 , 0.24]
-0.40 [-1.39 , 0.60]
-0.16 [-0.66 , 0.35]
0.22 [-0.14 , 0.58]
-0.27 [-0.60 , 0.05]

Footnotes
(1) Clinician-rated: GAF
(2) Clinician-rated: GAS
(3) SAS-SR (SR)
(4) GAS (CR)
(5) WSAS (SR)
(6) BDQ-days out of role (SR)

-4
Favours Psychotherapies

-2

0

2

4

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

312

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.7.   (Continued)

(4) GAS (CR)
(5) WSAS (SR)
(6) BDQ-days out of role (SR)
(7) Self-rated: SFQ
(8) CORE-OM (SR)
(9) SOFAS (CR)
(10) Self-rated: SDS
(11) SPS - "How many days were you paid for working in the past 30 days?") (SR)
(12) Clinician-rated: HoNOS
(13) OQ45, social role at discharge (SR)
(14) C-GAS (CR)
(15) Self-reported: SAS-SR (higher scores indicate poorer functioning)
(16) GAF (CR)
(17) CGI-global improvement, patient-rated (SR)
(18) SFQ (SR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

313

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.8.   Comparison 1: Psychotherapy vs TAU, Outcome 8: Secondary: anger (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.8.1 End of treatment
Amianto 2011 (1)
Feigenbaum 2012 (2)
Gleeson 2012 (3)
Koons 2001a (4)
Leppänen 2016 (5)
Linehan 1994 (6)
Linehan 2006 (7)
Soler 2009 (8)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 8.82, df = 7 (P = 0.27); I² = 21%
Test for overall effect: Z = 2.83 (P = 0.005)

2.6
83.4
13.3
14.5
0.8
32.15
1.84
3.11

1.1
20.36
5.4
3.9
1.3
7.19
0.51
1.02

2.6
83.3
15.2
17.9
1.27
40.08
1.93
3.88

16
25
4
10
19
13
48
29
164

1.4
17.94
3.4
6.1
1.52
8.37
0.57
0.78

17
16
5
10
32
13
36
30
159

11.7%
13.4%
3.6%
7.3%
15.5%
8.6%
22.7%
17.1%
100.0%

0.00 [-0.68 , 0.68]
0.01 [-0.62 , 0.63]
-0.39 [-1.72 , 0.95]
-0.64 [-1.54 , 0.27]
-0.32 [-0.89 , 0.25]
-0.98 [-1.81 , -0.16]
-0.17 [-0.60 , 0.27]
-0.84 [-1.37 , -0.30]
-0.38 [-0.64 , -0.12]

1.8.2 0-6 months follow-up
Gleeson 2012 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.46 (P = 0.14)

10

2.6

14.5

3.8

4
4

4
4

100.0%
100.0%

-1.20 [-2.82 , 0.41]
-1.20 [-2.82 , 0.41]

1.8.3 6-12 months follow-up
Amianto 2011 (9)
Linehan 2006 (7)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.18, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 0.64 (P = 0.52)

1.3
0.53

2.4
1.89

16
44
60

2.4
1.99

1.3
0.61

17
34
51

30.1%
69.9%
100.0%

0.00 [-0.68 , 0.68]
-0.17 [-0.62 , 0.27]
-0.12 [-0.50 , 0.25]

1.8.4 Above 12 months follow-up
1.9
Linehan 2006 (7)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.09 (P = 0.93)

0.43

1.89

0.52

45
45

35
35

100.0%
100.0%

0.02 [-0.42 , 0.46]
0.02 [-0.42 , 0.46]

Footnotes
(1) Clinician-rated: CGI-BPD – anger reaction
(2) STAXI - anger out (geometric mean after log transformation) (SR)
(3) AIAQ - labile anger (SR)
(4) STAXI - anger out (SR)
(5) Clinician-rated: BPDSI-IV, anger
(6) STAXI, anger trait (SR)
(7) STAXI-anger out (SR)
(8) CGI-BPD, anger (CR)
(9) Clinician-rated: CGI-BPD

-4
Favours Psychotherapies

-2

0

2

4

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

314

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.9.   Comparison 1: Psychotherapy vs TAU, Outcome 9: Secondary: affective instability (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.9.1 End of treatment
Amianto 2011 (1)
Bianchini 2019 (2)
Blum 2008 (3)
Farrell 2009 (4)
Gratz 2006 (5)
Gratz 2014 (5)
Leppänen 2016 (6)
Morton 2012 (7)
Reneses 2013 (8)
Salzer 2014 (9)
Schuppert 2012 (10)
Soler 2009 (11)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.16; Chi² = 31.18, df = 11 (P = 0.001); I² = 65%
Test for overall effect: Z = 4.60 (P < 0.00001)

2.9
65.1
4.9
9.83
115.8
113.62
6.26
140.04
2.6
5.55
4.29
4.66

0.9
9.4
3.2249
3.44
23.97
15.6
2.83
17.64
1.2
3.35
2.37
1.19

2.2
65.6
3.9
5.88
79.75
95.27
5.65
113.04
1.9
4.71
3.88
3.61

16
10
65
16
12
31
19
21
18
17
48
29
302

1.4
15.57
3.0725
1.12
16.74
15.6
2.65
20.88
1
2.26
2.48
0.7

17
11
59
12
10
30
32
20
26
22
49
30
318

7.7%
6.3%
11.4%
6.3%
5.3%
9.3%
9.0%
7.8%
8.5%
8.3%
10.9%
9.2%
100.0%

-0.58 [-1.28 , 0.12]
0.04 [-0.82 , 0.89]
-0.32 [-0.67 , 0.04]
-1.41 [-2.26 , -0.57]
-1.65 [-2.65 , -0.65]
-1.16 [-1.71 , -0.62]
-0.22 [-0.79 , 0.35]
-1.37 [-2.06 , -0.69]
-0.63 [-1.25 , -0.02]
-0.30 [-0.93 , 0.34]
-0.17 [-0.57 , 0.23]
-1.07 [-1.61 , -0.52]
-0.68 [-0.98 , -0.39]

1.9.2 6-12 months follow-up
Amianto 2011 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.46 (P = 0.15)

2.1

1.1

16
16

2.8

1.5

17
17

100.0%
100.0%

-0.52 [-1.21 , 0.18]
-0.52 [-1.21 , 0.18]

-4

-2

0

Favours Psychotherapies

2
Favour TAU

4

Test for subgroup differences: Chi² = 0.19, df = 1 (P = 0.66), I² = 0%

Footnotes
(1) Clinician-rated: CGI-BPD, affective instability
(2) DERS total score (SR)
(3) ZAN-BPD - affective instability (CR)
(4) Clinician-rated: DIB-R, affect
(5) DERS - total (SR)
(6) Clinician-rated: BPDSI-IV, affective instability
(7) Self-rated: DERS, emotion dysregulation
(8) Clinician-rated: ZAN-BPD, affective instability
(9) Strengths and Difficulties Questionnaire - emotional problems (SR)
(10) BPDS-IV - affective instability
(11) CGI-BPD, affective instability (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

315

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.10.   Comparison 1: Psychotherapy vs TAU, Outcome
10: Secondary: chronic feelings of emptiness (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.10.1 End of treatment
Amianto 2011 (1)
Leppänen 2016 (2)
Reneses 2013 (3)
Soler 2009 (4)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.10, df = 3 (P = 0.55); I² = 0%
Test for overall effect: Z = 2.61 (P = 0.009)

2.6
3.55
1.8
4.33

1.1
3.24
1.3
1.57

16
19
18
29
82

2.8
4.14
2.7
5

0.8
3.31
1.1
1.5

17
32
26
30
105

18.5%
26.8%
22.3%
32.4%
100.0%

-0.20 [-0.89 , 0.48]
-0.18 [-0.75 , 0.39]
-0.75 [-1.37 , -0.12]
-0.43 [-0.95 , 0.09]
-0.39 [-0.69 , -0.10]

1.10.2 6-12 months follow-up
Amianto 2011 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.64 (P = 0.10)

2.2

1.1

16
16

2.8

0.9

17
17

100.0%
100.0%

-0.58 [-1.28 , 0.11]
-0.58 [-1.28 , 0.11]

Footnotes
(1) Clinician-rated: CGI-BPD
(2) Clinician-rated: BPDSI-IV, emptiness
(3) Clinician rated: Zan-BPD, feeling of emptiness
(4) CGI-BPD, emptiness (CR)
(5) Clinician-rated: CGI-BPD, emptiness

-2
Favours Psychotherapies

-4

0

2

4
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

316

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.11.   Comparison 1: Psychotherapy vs TAU, Outcome 11: Secondary: impulsivity (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1
18.42
2.3043
2.68
5.34
3.83
0.81
1.2
0.6
0.84

17
11
59
12
10
30
32
26
30
25
252

9.3%
7.3%
14.7%
6.6%
6.5%
11.6%
11.0%
10.3%
11.7%
11.0%
100.0%

-0.19 [-0.87 , 0.50]
-0.07 [-0.93 , 0.79]
-0.17 [-0.52 , 0.18]
-1.92 [-2.85 , -1.00]
-1.30 [-2.24 , -0.36]
-0.90 [-1.43 , -0.38]
-0.29 [-0.86 , 0.28]
-0.55 [-1.17 , 0.06]
-0.61 [-1.14 , -0.09]
-0.17 [-0.74 , 0.39]
-0.54 [-0.84 , -0.25]

0.6
0.57

17
24
41

42.9%
57.1%
100.0%

0.35 [-0.34 , 1.04]
0.30 [-0.30 , 0.90]
0.32 [-0.13 , 0.77]

-4

-2

0

2

4

Favours Psychotherapies

Favours TAU

1.11.1 End of treatment
Amianto 2011 (1)
Bianchini 2019 (2)
Blum 2008 (3)
Farrell 2009 (4)
Gratz 2006 (5)
Gratz 2014 (5)
Leppänen 2016 (6)
Reneses 2013 (7)
Soler 2009 (8)
Van den Bosch 2005 (9)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 21.18, df = 9 (P = 0.01); I² = 58%
Test for overall effect: Z = 3.59 (P = 0.0003)

1.1
10.7
2.4187
1.37
3.85
3.83
0.76
1.3
0.97
0.74

2
51.75
2.3
5.58
17.1
18.74
1.22
2.3
4.11
1.06

1.8
50.66
1.9
1.56
10.92
15.23
0.99
1.6
3.61
0.92

16
10
65
16
12
31
19
18
29
23
239

1.11.2 6-12 months follow-up
Amianto 2011 (10)
Van den Bosch 2005 (11)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 1.40 (P = 0.16)

0.5
0.93

2.3
1.08

16
20
36

2.1
0.85

Footnotes
(1) Clinician-rated: CGI-BPD
(2) BIS-11 total score (SR)
(3) Zan-BPD - impulsivity subscale
(4) Clinician-rated: DIB-R, impulses
(5) DERS-impulse (SR)
(6) Clinician-rated: BPDSI-IV, impulsivity
(7) Clinician-rated: ZAN-BPD, impulsivity
(8) CGI-BPD - impulsivity (CR)
(9) BPDSI-IV - impulsivity (CR)
(10) Clinician-rated: CGI-BPD, impulsivity
(11) Observer rated: BPDSI-IV, impulsivity

Analysis 1.12.   Comparison 1: Psychotherapy vs TAU, Outcome
12: Secondary: impulsivity (dichotomous), at end of treatment

Study or Subgroup

Psychotherapies
Total
Events

TAU

Events

Total

Risk Ratio
IV, Fixed, 95% CI

Risk Ratio
IV, Fixed, 95% CI

Bos 2010 (1)

19

28

22

30

0.93 [0.66 , 1.29]

Test for subgroup differences: Not applicable

Footnotes
(1) participants scoring above BPDSI-IV-impulsivity cut-off score

0.05
Favours Psychotherapies

0.2

1

5

20
Favour TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

317

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.13.   Comparison 1: Psychotherapy vs TAU, Outcome 13: Secondary: interpersonal problems (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.13.1 End of treatment
Amianto 2011 (1)
Bateman 1999 (2)
Bateman 2009 (2)
Blum 2008 (3)
Bos 2010 (4)
Carter 2010 (5)
Davidson 2006 (6)
Farrell 2009 (7)
Gratz 2014 (8)
Jørgensen 2013 (2)
Kramer 2016 (9)
Laurenssen 2018 (2)
Leichsenring 2016 (2)
Leppänen 2016 (10)
Philips 2018 (2)
Reneses 2013 (11)
Salzer 2014 (12)
Soler 2009 (13)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.23; Chi² = 74.97, df = 17 (P < 0.00001); I² = 77%
Test for overall effect: Z = 3.16 (P = 0.002)

1.1
0.36
0.13
2.4187
3.5
19.36
23.9
4.02
0.57
0.6
8.48
0.63
4.49
0.72
0.54
1.1
1.72
0.8

2.8
2.6
1.65
3.2
-12
-49.73
55
12
1.94
1.3
21.7
2.75
11.57
1.34
1.7
2.3
3.95
4.44

2.4
1.86
1.28
2.2
-13
-48.75
60.4
4.88
1.45
1.2
21.05
2.78
13.21
1.01
1.5
1.9
2.76
4.22

16
19
71
65
27
20
52
16
31
42
21
54
64
19
13
18
17
29
594

1.3
0.29
0.55
2.3043
3.7
30.23
22.3
2.8
0.57
0.8
7.65
0.57
5.37
0.97
0.56
0.9
1.86
0.72

17
19
63
59
26
28
47
12
30
24
20
41
58
32
11
26
22
30
565

4.9%
4.3%
6.6%
6.6%
5.7%
5.5%
6.4%
3.8%
5.8%
5.9%
5.3%
6.4%
6.6%
5.5%
4.3%
5.3%
5.1%
5.8%
100.0%

-0.32 [-1.01 , 0.36]
-2.22 [-3.04 , -1.39]
-0.95 [-1.30 , -0.59]
-0.42 [-0.78 , -0.06]
-0.27 [-0.81 , 0.27]
0.04 [-0.54 , 0.61]
0.23 [-0.16 , 0.63]
-1.94 [-2.87 , -1.02]
-0.85 [-1.37 , -0.32]
-0.15 [-0.65 , 0.36]
-0.08 [-0.69 , 0.53]
0.05 [-0.36 , 0.46]
0.33 [-0.03 , 0.69]
-0.37 [-0.94 , 0.21]
-0.35 [-1.16 , 0.46]
-0.40 [-1.01 , 0.21]
-0.65 [-1.30 , 0.00]
-0.29 [-0.80 , 0.23]
-0.42 [-0.68 , -0.16]

1.13.2 0-6 months follow-up
Jørgensen 2013 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.32 (P = 0.19)

1.2

0.7

38
38

1.5

0.8

15
15

100.0%
100.0%

-0.41 [-1.01 , 0.20]
-0.41 [-1.01 , 0.20]

1.13.3 6-12 months follow-up
Amianto 2011 (14)
Davidson 2006 (6)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 1.63, df = 1 (P = 0.20); I² = 39%
Test for overall effect: Z = 0.67 (P = 0.50)

2.8
53.7

1.1
23.9

16
52
68

2.2
54

1.13.4 Above 12 months follow-up
1.5
Bateman 1999 (2)
60.4
Davidson 2006 (6)
1.2
Jørgensen 2013 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.15; Chi² = 5.75, df = 2 (P = 0.06); I² = 65%
Test for overall effect: Z = 0.00 (P = 1.00)

21
43
40
104

2.5
48.7
1.4

4
23.7
0.8

1.2
24.1

0.5
24.6
0.9

17
47
64

34.2%
65.8%
100.0%

-0.51 [-1.20 , 0.19]
0.01 [-0.38 , 0.41]
-0.17 [-0.65 , 0.32]

19
33
16
68

30.4%
37.4%
32.2%
100.0%

-0.34 [-0.96 , 0.29]
0.48 [0.02 , 0.94]
-0.24 [-0.82 , 0.34]
0.00 [-0.54 , 0.54]

-1
Favours Psychotherapies

-2

0

1
2
Favours TAU

Footnotes
(1) Clinician-rated: CGI-BPD, disturbed relationships
(2) IIP-64 (SR)
(3) ZAN-BPD - disturbed relationships (CR)
(4) Self-reported: WHOQOL-Bref, social relationships
(5) Self-reported: WHOQOL-Bref social relationships
(6) IIP-32 (SR)
(7) Clinician-rated: DIB-R, interpersonal
(8) IIP-BPD (SR)
(9) OQ45.2 - interpersonal (SR)
(10) Clinician-rated: BPDSI-IV, unstable relationships
(11) Clinician-rated: ZAN-BPD, disturbed relationships
(12) Strengths and Difficulties Questionnaire - problems in relationships (SR)
(13) CGI-BPD, unstable relations (CR)
(14) Clinician rated: CGI-BPD, disturbed relationships

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

318

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.13.   (Continued)

(12) Strengths and Difficulties Questionnaire - problems in relationships (SR)
(13) CGI-BPD, unstable relations (CR)
(14) Clinician rated: CGI-BPD, disturbed relationships

Analysis 1.14.   Comparison 1: Psychotherapy vs TAU, Outcome 14: Secondary: abandonment (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.14.1 End of treatment
Amianto 2011 (1)
Leppänen 2016 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 1.00 (P = 0.32)

2.4
1.42

1.1
1.39

16
19
35

2.6
1.88

1.1
1.97

17
32
49

41.0%
59.0%
100.0%

-0.18 [-0.86 , 0.51]
-0.25 [-0.82 , 0.32]
-0.22 [-0.66 , 0.21]

1.14.2 6-12 months follow-up
Amianto 2011 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.11 (P = 0.27)

2.3

1

16
16

2.7

1

17
17

100.0%
100.0%

-0.39 [-1.08 , 0.30]
-0.39 [-1.08 , 0.30]

Footnotes
(1) Clinician-rated: CGI-BPD
(2) Clinician-rated: BPDSI-IV, abandonment
(3) Clinician-rated: CGI-BPD, fear of abandoment

-1
Favours Psychotherapies

-2

0

1

2
Favours TAU

Analysis 1.15.   Comparison 1: Psychotherapy vs TAU, Outcome 15: Secondary: identity disturbance (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.15.1 End of treatment
Amianto 2011 (1)
Leichsenring 2016 (2)
Leppänen 2016 (3)
Reneses 2013 (4)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 8.61, df = 3 (P = 0.03); I² = 65%
Test for overall effect: Z = 1.56 (P = 0.12)

16
64
19
18
117

3.2
4.28
3.02
2.3

2.2
4.45
2.17
2

0.1
2.9
1.78
1.2

1.2
2.91
2.06
1.1

17
58
32
26
133

19.7%
32.0%
24.6%
23.7%
100.0%

-1.13 [-1.87 , -0.39]
0.06 [-0.30 , 0.41]
-0.43 [-1.00 , 0.15]
-0.26 [-0.86 , 0.35]
-0.37 [-0.84 , 0.10]

1.15.2 6-12 months follow-up
Amianto 2011 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.90 (P = 0.004)

2

1.2

Footnotes
(1) Clinician-rated: CGI-BPD identity distortion
(2) Self-reported: BPI
(3) Clinician-rated: BPDSI-IV, identity disturbance
(4) Clinician-rated: Zan-BPD, identity
(5) Clinician-rated: CGI-BPD, identity distortion

3.4

1.3

16
16

17
17

100.0%
100.0%

-1.09 [-1.83 , -0.35]
-1.09 [-1.83 , -0.35]

-4 -2
Favours Psychotherapies

0

4

2
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

319

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.16.   Comparison 1: Psychotherapy vs TAU, Outcome 16:
Secondary: dissociation and psychotic-like symptoms (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.16.1 End of treatment
Amianto 2011 (1)
Blum 2008 (2)
Farrell 2009 (3)
Gleeson 2012 (4)
Gregory 2008b (5)
Kredlow 2017a (4)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 8.01, df = 5 (P = 0.16); I² = 38%
Test for overall effect: Z = 2.50 (P = 0.01)

0.9
2.4187
2.02
6.5
21.4
8.7

16
65
16
4
11
14
126

2.3
3
4.25
49.6
22.3
41.3

1.6
2
1.69
43.5
27.7
39

1.16.2 0-6 months follow-up
Gleeson 2012 (4)
Kredlow 2017a (6)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 2.67 (P = 0.008)

33.8
42

4
14
18

6.4
7.6

45.5
55.4

1.5
2.3043
1.49
7.1
20.6
8.3

17
59
12
5
13
12
118

17.6%
32.6%
13.7%
6.1%
14.6%
15.4%
100.0%

-0.55 [-1.25 , 0.15]
-0.42 [-0.78 , -0.06]
-1.37 [-2.21 , -0.53]
-0.79 [-2.19 , 0.61]
0.25 [-0.56 , 1.06]
-0.26 [-1.04 , 0.51]
-0.47 [-0.85 , -0.10]

12.1
18.3

5
12
17

24.0%
76.0%
100.0%

-1.03 [-2.49 , 0.43]
-0.95 [-1.78 , -0.13]
-0.97 [-1.69 , -0.26]

16
16

11
11

2.1

1.3

17
17

100.0%
100.0%

-0.59 [-1.29 , 0.11]
-0.59 [-1.29 , 0.11]

28.6

18.7

13
13

100.0%
100.0%

-0.01 [-0.81 , 0.79]
-0.01 [-0.81 , 0.79]

-4

-2

0

2

4

Favours Psychotherapies

Favour TAU

1.16.3 6-12 months follow-up
Amianto 2011 (7)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.64 (P = 0.10)

1.4

1

1.16.4 12 months and over follow-up
Gregory 2008b (8)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.02 (P = 0.98)

28.4

28.9

Footnotes
(1) Clinician-rated: CGI-BPD dissociative symptoms
(2) Clinical-rated: ZAN-BPD, cognitive subscale
(3) Clinician-rated: DIB-R cognition
(4) BPRS (CR)
(5) DES (SR)
(6) Observer-rated: BPRS, total
(7) Clinician-rated: CGI-BPD, dissociative symptoms
(8) Self-rated: DES

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

320

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.17.   Comparison 1: Psychotherapy vs TAU, Outcome 17: Secondary: depression (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.17.1 End of treatment
Andreoli 2016 (1)
Bateman 1999 (2)
Bateman 2009 (2)
Blum 2008 (3)
Borschmann 2013 (4)
Davidson 2006 (5)
Davidson 2014 (6)
Doering 2010 (2)
Gleeson 2012 (7)
Gratz 2006 (8)
Gratz 2014 (8)
Gregory 2008b (9)
Jahangard 2012 (10)
Jørgensen 2013 (5)
Kredlow 2017a (5)
Laurenssen 2018 (2)
Leichsenring 2016 (11)
Leppänen 2016 (12)
McMurran 2016 (13)
Morton 2012 (14)
Reneses 2013 (15)
Zanarini 2018 (16)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.19; Chi² = 84.66, df = 21 (P < 0.00001); I² = 75%
Test for overall effect: Z = 3.44 (P = 0.0006)

5.6912
7
8.55
16.1245
3.54
14.8
9.86
13.25
8
6.52
5.63
11.4
1.34
11.5
14.4
16.57
10.75
1.7
7.4
14.73
13.2
16.15

13.4
35.2
18.68
25.8
10.2
31.3
33.5
20.02
22
23.2
21.3
25.1
2.67
22.8
39.6
21.11
24.39
1.84
26.3
31
22.8
31.21

9.95
20.6
14.8
22
10.47
29.6
21.73
21.67
12.3
9
13.04
21
3.93
18.8
24.5
22.5
27.95
1.55
24.6
22.67
15.9
24.18

140
19
71
65
36
52
11
52
4
12
31
11
15
42
14
54
64
19
80
21
18
39
870

6.4
7.4
8.76
15.3623
4.96
16.6
2.38
13.22
7.8
15.32
5.63
6.4
0.82
13.7
13.6
9.1
11.21
1.45
9.6
8.51
11.2
16.62

30
19
63
59
36
47
4
52
5
10
30
13
15
24
12
41
58
32
64
20
26
38
698

5.5%
3.6%
5.8%
5.7%
5.2%
5.5%
2.1%
5.6%
1.7%
3.1%
4.7%
3.5%
3.7%
5.0%
3.5%
5.5%
5.7%
4.7%
5.8%
4.4%
4.4%
5.3%
100.0%

-0.59 [-0.99 , -0.19]
-1.98 [-2.78 , -1.19]
-0.45 [-0.79 , -0.10]
-0.24 [-0.59 , 0.11]
0.06 [-0.40 , 0.52]
-0.11 [-0.50 , 0.29]
-1.27 [-2.53 , -0.01]
0.12 [-0.26 , 0.51]
-1.09 [-2.57 , 0.38]
-1.20 [-2.13 , -0.28]
-1.45 [-2.02 , -0.88]
-0.44 [-1.25 , 0.38]
1.10 [0.33 , 1.88]
-0.32 [-0.83 , 0.18]
-1.04 [-1.87 , -0.21]
0.10 [-0.31 , 0.51]
0.32 [-0.04 , 0.68]
-0.18 [-0.75 , 0.38]
-0.20 [-0.53 , 0.13]
-0.67 [-1.31 , -0.04]
-0.56 [-1.18 , 0.05]
-0.42 [-0.88 , 0.03]
-0.39 [-0.61 , -0.17]

1.17.2 0-6 months follow-up
Bateman 1999 (9)
Gleeson 2012 (7)
Jørgensen 2013 (5)
Kredlow 2017a (17)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 3.89, df = 3 (P = 0.27); I² = 23%
Test for overall effect: Z = 3.44 (P = 0.0006)

19
10.8
17.8
23.1

7.4
4.6
14
12.7

28.7
14.5
23.2
35.8

22
4
38
14
78

1.17.3 6-12 months follow-up
Bateman 1999 (9)
Blum 2008 (3)
Davidson 2006 (17)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 8.70, df = 2 (P = 0.01); I² = 77%
Test for overall effect: Z = 1.40 (P = 0.16)

6
20.9619
14.8

22
65
52
139

13.3
24
26.5

21.5
23.4
31.1

1.17.4 12 months and over follow-up
Bateman 1999 (9)
Davidson 2006 (17)
Gregory 2008b (2)
Jørgensen 2013 (9)
McMurran 2016 (13)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 7.58, df = 4 (P = 0.11); I² = 47%
Test for overall effect: Z = 2.30 (P = 0.02)

22
43
11
38
69
183

3.3
15.3
11.5
13.5
10.7

11.9
26.5
16
17.5
20.3

20.4
28.8
23.8
22.2
22

7.4
7.1
13.9
13

16
4
15
12
47

29.6%
9.2%
37.3%
23.9%
100.0%

-1.28 [-2.00 , -0.57]
-0.54 [-1.97 , 0.90]
-0.38 [-0.98 , 0.22]
-0.96 [-1.78 , -0.14]
-0.80 [-1.26 , -0.34]

8
29.1884
16.6

15
59
47
121

25.7%
37.9%
36.4%
100.0%

-1.17 [-1.88 , -0.45]
0.02 [-0.33 , 0.38]
-0.29 [-0.69 , 0.11]
-0.40 [-0.95 , 0.16]

10.5
15.7
10.6
15.8
12.1

15
33
13
15
52
128

15.0%
24.7%
12.2%
18.6%
29.5%
100.0%

-1.17 [-1.88 , -0.45]
-0.15 [-0.60 , 0.31]
-0.68 [-1.51 , 0.15]
-0.33 [-0.93 , 0.27]
-0.15 [-0.51 , 0.21]
-0.40 [-0.74 , -0.06]

Footnotes
(1) Clinician-rated: HDRS-17
(2) Self-rated: BDI
(3) Self-reported: BDI
(4) Self-rated: HADS, depression

-4

-2

0

Favours Psychotherapies

2
Favour TAU

4

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

321

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.17.   (Continued)

(2) Self-rated: BDI
(3) Self-reported: BDI
(4) Self-rated: HADS, depression
(5) BDI-II (SR)
(6) HADS - total score (SR)
(7) MADRS (CR)
(8) DASS-Depression (SR)
(9) BDI (SR)
(10) HDRS (CR)
(11) Clinician-rated: BDI
(12) Clinician-rated: BPDSI-IV, paranoid ideation
(13) HADS (SR)
(14) Self-rated: DASS, depression
(15) Clinician-rated: MADRS
(16) Self-rated: The Clinically Useful Depression Outcome Scale, total score
(17) Self-rated: BDI-II

Analysis 1.18.   Comparison 1: Psychotherapy vs TAU, Outcome
18: Secondary: depression (dichotomous), at end of treatment

Study or Subgroup

Psychotherapies
Total
Events

TAU

Events

Total

Risk Ratio
IV, Fixed, 95% CI

Risk Ratio
IV, Fixed, 95% CI

Rossouw 2012b (1)

20

40

28

40

0.71 [0.49 , 1.03]

Test for subgroup differences: Not applicable

Footnotes
(1) MFQ - participants beyond depression cut-off

0.01

0.1

1

Favours Psychotherapies

10
Favour TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

322

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.19.   Comparison 1: Psychotherapy vs TAU, Outcome 19: Secondary: attrition (dichotomous)

Study or Subgroup

Psychotherapies
Total
Events

TAU

Events

Total

Weight

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

1.19.1 End of treatment
Amianto 2011
Andreoli 2016
Bateman 1999
Bateman 2009
Borschmann 2013
Bos 2010
Carter 2010
Davidson 2006
Doering 2010
Farrell 2009
Feigenbaum 2012
Gleeson 2012
Gratz 2006
Gratz 2014
Jørgensen 2013
Koons 2001a
Kramer 2016
Laurenssen 2018
Leichsenring 2016 (1)
Leppänen 2016
Linehan 1991
Linehan 1994
Linehan 2006
Morton 2012
Philips 2018
Priebe 2012
Reneses 2013
Robinson 2016
Rossouw 2012b
Stanley 2017
Van den Bosch 2005
Zanarini 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.10; Chi² = 61.81, df = 31 (P = 0.0008); I² = 50%
Test for overall effect: Z = 0.02 (P = 0.98)

18
30
22
63
42
37
35
52
52
16
16
8
11
30
27
15
20
41
58
47
31
13
49
20
22
40
28
34
40
38
33
40
1028

17
140
22
71
46
42
38
54
52
16
26
8
13
31
58
13
21
54
64
24
30
13
52
21
24
40
25
34
40
37
31
40
1197

1
17
3
19
9
10
18
2
20
0
15
4
1
26
19
3
5
16
19
20
10
3
16
7
11
21
3
12
20
9
14
1

1
2
3
16
6
6
4
4
35
4
1
3
1
27
8
5
5
12
19
32
9
1
35
6
11
6
4
9
23
11
26
2

337

354

0.4%
1.4%
1.3%
4.7%
2.6%
2.7%
2.4%
1.0%
6.2%
0.4%
0.8%
2.0%
0.4%
8.0%
3.9%
1.7%
2.1%
4.3%
5.0%
7.4%
3.5%
0.7%
5.7%
2.7%
4.4%
3.3%
1.4%
3.7%
6.1%
3.5%
5.9%
0.5%
100.0%

1.06 [0.07 , 15.62]
1.82 [0.44 , 7.47]
1.00 [0.23 , 4.42]
1.05 [0.59 , 1.87]
1.37 [0.53 , 3.52]
1.47 [0.59 , 3.65]
4.14 [1.55 , 11.06]
0.48 [0.09 , 2.52]
0.57 [0.39 , 0.85]
0.11 [0.01 , 1.91]
9.23 [1.35 , 63.35]
1.33 [0.43 , 4.13]
0.85 [0.06 , 12.01]
0.93 [0.77 , 1.13]
1.11 [0.56 , 2.20]
0.69 [0.20 , 2.35]
0.95 [0.32 , 2.80]
1.01 [0.54 , 1.90]
0.91 [0.53 , 1.54]
1.22 [0.94 , 1.60]
1.15 [0.54 , 2.42]
3.00 [0.36 , 25.21]
0.43 [0.28 , 0.67]
1.11 [0.45 , 2.74]
0.92 [0.50 , 1.68]
3.50 [1.58 , 7.75]
0.84 [0.21 , 3.39]
1.33 [0.65 , 2.74]
0.87 [0.58 , 1.31]
0.84 [0.39 , 1.79]
0.57 [0.37 , 0.88]
0.50 [0.05 , 5.30]
1.00 [0.83 , 1.20]

1.19.2 0-6 months follow-up
Soler 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.97 (P = 0.05)

11

11

30
30

19

19

30
30

100.0%
100.0%

0.58 [0.34 , 1.00]
0.58 [0.34 , 1.00]

Footnotes
(1) lost to follow-up for any reason

0.1
0.002
Favours Psychotherapies

1

10

500

Favour TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

323

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.20.   Comparison 1: Psychotherapy vs TAU, Outcome 20:
Secondary: non-serious adverse effects (dichotomous), at end of treatment

Study or Subgroup

Psychotherapies
Total
Events

TAU

Events

Total

Weight

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

McMurran 2016 (1)
Stanley 2017 (2)

13
0

154
37

Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable

13

191

100.0%

152
38

0.92 [0.45 , 1.88]
Not estimable

190

100.0%

0.92 [0.45 , 1.88]

14
0

14

0.001

0.1
Favours Psychotherapies

1

10

1000

Favour TAU

Footnotes
(1) participants with adverse event other than death for any reason or hospitalisation
(2) adverse events others than serious adverse events

Analysis 1.21.   Comparison 1: Psychotherapy vs TAU, Outcome 21:
Secondary: serious adverse effects (dichotomous), at end of treatment

Psychotherapies
Total
Events

TAU

Events

Total

Weight

Risk Ratio
IV, Fixed, 95% CI

Risk Ratio
IV, Fixed, 95% CI

Study or Subgroup

Andreoli 2016 (1)
Davidson 2006 (1)
McMurran 2016 (1)
Stanley 2017 (1)

0
1
2
0

140
14
154
37

Total (95% CI)
Total events:
Heterogeneity: Chi² = 3.68, df = 2 (P = 0.16); I² = 46%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable

345

3

30
6
152
38

31.5%
33.7%
34.7%

0.07 [0.00 , 1.76]
1.40 [0.06 , 30.23]
4.94 [0.24 , 101.96]
Not estimable

226

100.0%

0.86 [0.14 , 5.09]

1
0
0
0

1

0.001

0.1
Favours Psychotherapies

1

10

1000

Favour TAU

Footnotes
(1) died by suicide

Comparison 2.   Acceptance and commitment therapy (ACT) vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.1 Primary: BPD symptom severity (con-
tinuous), at end of treatment

2.2 Secondary: affective instability (con-
tinuous), at end of treatment

2.3 Secondary: depression (continuous),
at end of treatment

2.4 Secondary: attrition (dichotomous), at
end of treatment

1

1

1

1

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

324

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.1.   Comparison 2: Acceptance and commitment therapy (ACT) vs TAU,
Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Mean

ACT
SD

Total

Mean

TAU
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Morton 2012 (1)

32.76

12.47

21

47.42

11

20

-14.66 [-21.85 , -7.47]

Test for subgroup differences: Not applicable

Footnotes
(1) Self-rated: BEST

-100

-50
Favours ACT

0

50
Favours TAU

100

Analysis 2.2.   Comparison 2: Acceptance and commitment therapy (ACT) vs TAU,
Outcome 2: Secondary: affective instability (continuous), at end of treatment

Study or Subgroup

Mean

ACT
SD

Total

Mean

TAU
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Morton 2012 (1)

113.04

17.64

21

140.04

20.88

20

-27.00 [-38.86 , -15.14]

Test for subgroup differences: Not applicable

Footnotes
(1) Self-rated: DERS, emotion dysregulation

-100 -50
Favours ACT

0

50 100
Favours TAU

Analysis 2.3.   Comparison 2: Acceptance and commitment therapy (ACT) vs
TAU, Outcome 3: Secondary: depression (continuous), at end of treatment

Study or Subgroup

Mean

ACT
SD

Total

Mean

TAU
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Morton 2012 (1)

22.67

14.73

21

31

8.51

20

-8.33 [-15.65 , -1.01]

Test for subgroup differences: Not applicable

Footnotes
(1) Self-rated: DASS, depression

-100

-50
Favours ACT

0

50
Favours TAU

100

Analysis 2.4.   Comparison 2: Acceptance and commitment therapy (ACT) vs
TAU, Outcome 4: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

ACT

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Morton 2012

7

21

6

20

1.11 [0.45 , 2.74]

Test for subgroup differences: Not applicable

0.01

0.1
Favours ACT

1

10
Favours TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

325

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 3.   Dialectical behavior therapy (DBT) vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3.1 Primary: BPD symptom severity
(continuous), at end of treatment

3.2 Primary, self-harm (continuous)

3.2.1 End of treatment

3.2.2 6-12 months follow-up

3.3 Primary: suicide-related out-
comes (continuous), at end of treat-
ment

3.4 Primary: suicide-related out-
comes, attempts (dichotomous), at
end of treatment

3.5 Primary: psychosocial functioning
(continuous), at end of treatment

3.6 Secondary: anger (continuous)

3.6.1 End of treatment

3.6.2 6-12 months follow-up

3.6.3 Above 12 months follow-up

3.7 Secondary: affective instability
(continuous), at end of treatment

3.8 Secondary: chronic feelings of
emptiness (continuous), at end of
treatment

3.9 Secondary: impulsivity (continu-
ous)

3.9.1 End of treatment

3.9.2 6-12 months follow-up

3.10 Secondary: interpersonal prob-
lems (continuous), at end of treat-
ment

3

7

7

2

5

1

6

5

5

1

1

2

1

3

3

1

3

149

376

141

231

225

230

78

80

80

128

44

148

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.60 [-1.05,
-0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-0.48,
-0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.26 [-0.59, 0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.68, 0.23]

Risk Ratio (M-H, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.69,
-0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.47 [-0.86,
-0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.17 [-0.62, 0.27]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.02 [-0.42, 0.46]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.57 [-1.64, 0.51]

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.35 [-0.71,
-0.00]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.30 [-0.30, 0.90]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.12 [-0.45, 0.20]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

326

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3.11 Secondary: dissociation and psy-
chotic-like symptoms (continuous),
at end of treatment

3.12 Secondary: depression (continu-
ous)

3.12.1 End of treatment

3.12.2 6-12 months follow-up

3.13 Secondary: attrition (dichoto-
mous)

3.13.1 End of treatment

3.13.2 0-6 months follow-up

3.14 Secondary: adverse effects (di-
chotomous), at end of treatment

3.15 Secondary: serious adverse ef-
fects (dichotomous), at end of treat-
ment

4

5

5

1

11

10

1

1

1

194

219

81

591

60

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.45 [-0.73,
-0.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.47 [-0.98, 0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.67, 0.21]

Risk Ratio (M-H, Random, 95%
CI)

Subtotals only

Risk Ratio (M-H, Random, 95%
CI)

1.27 [0.70, 2.31]

Risk Ratio (M-H, Random, 95%
CI)

0.58 [0.34, 1.00]

Risk Ratio (M-H, Fixed, 95% CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95% CI)

Subtotals only

Analysis 3.1.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU,
Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Koons 2001a (1)
Priebe 2012 (2)
Soler 2009 (3)

3.6
13.1
3.5

1.6
6.9
1.2

10
33
29

4.2
15.9
4.44

2.3
7.5
0.52

10
37
30

20.0%
42.7%
37.3%

-0.29 [-1.17 , 0.59]
-0.38 [-0.86 , 0.09]
-1.01 [-1.55 , -0.47]

Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 3.45, df = 2 (P = 0.18); I² = 42%
Test for overall effect: Z = 2.57 (P = 0.01)
Test for subgroup differences: Not applicable

72

Footnotes
(1) SCID-II - mean number of BPD criteria met (CR)
(2) ZAN-BPD total (CR)
(3) CCGI-BPD global (CR)

77

100.0%

-0.60 [-1.05 , -0.14]

-2
-1
Favours DBT

0

1

2
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

327

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.2.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 2: Primary, self-harm (continuous)

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

3.2.1 End of treatment
Carter 2010 (1)
Feigenbaum 2012 (2)
Koons 2001a (3)
Linehan 1991 (4)
Linehan 2006 (2)
Priebe 2012 (5)
Van den Bosch 2005 (6)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.69, df = 6 (P = 0.85); I² = 0%
Test for overall effect: Z = 2.65 (P = 0.008)

7.47
3.2
1.3
0.94
37.63
73.4
13.15

5.2
2.4
0.4
0.55
14.17
39.2
3.31

20
25
10
20
52
38
22
187

8.42
3.1
1
9.33
18.94
63.7
41.6

3.2.2 6-12 months follow-up
Linehan 2006 (7)
Van den Bosch 2005 (8)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.90); I² = 0%
Test for overall effect: Z = 1.52 (P = 0.13)

6.19
34.28

5.43
10.9

52
18
70

15.93
33.9

26.92
3.4
2.2
26.95
40.73
92.9
78.76

31
16
10
21
49
38
24
189

13.2%
10.6%
5.4%
10.9%
27.5%
20.5%
11.9%
100.0%

-0.15 [-0.71 , 0.42]
-0.21 [-0.84 , 0.42]
-0.32 [-1.20 , 0.57]
-0.45 [-1.07 , 0.17]
-0.12 [-0.51 , 0.27]
-0.29 [-0.74 , 0.16]
-0.65 [-1.25 , -0.06]
-0.28 [-0.48 , -0.07]

60.96
99.39

49
22
71

71.9%
28.1%
100.0%

-0.24 [-0.64 , 0.15]
-0.29 [-0.92 , 0.34]
-0.26 [-0.59 , 0.07]

Footnotes
(1) number of self-harm episodes 3 to 6 months
(2) SASII - frequency of self-harm (CR)
(3) PHI - deliberate self-harm frequency (last 3 months) (CR)
(4) Mean number of parasuicidal acts (last 3 months)
(5) Days of self-harm and type of deliberate self-harm recorded in an interview (CR)
(6) LPC - self-mutilation (last 3 months) (CR)
(7) Observer rated: SASII - NSSI
(8) LPC self-mutilation (last 3 months)

-4

-2

0

2

4

Favours DBT

Favours TAU

Analysis 3.3.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome
3: Primary: suicide-related outcomes (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Feigenbaum 2012 (1)
Koons 2001a (2)
Linehan 2006 (1)
Mehlum 2014 (3)
Soler 2009 (4)

0.24
26.2
0.98
26.5
2.44

0.43
8
1.46
6.3
1.24

25
10
52
5
29

0.06
41.5
1.37
41.7
2.55

0.25
14.3
1.87
28.9
0.88

16
10
49
5
30

21.7%
13.7%
29.6%
9.3%
25.6%

0.48 [-0.16 , 1.11]
-1.26 [-2.24 , -0.29]
-0.23 [-0.62 , 0.16]
-0.66 [-1.95 , 0.64]
-0.10 [-0.61 , 0.41]

Total (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 9.45, df = 4 (P = 0.05); I² = 58%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable

121

110

100.0%

-0.23 [-0.68 , 0.23]

-5

-10
Favours DBT

0

5

10
Favours TAU

Footnotes
(1) SASII-suicide attempts (CR)
(2) BSS (SR)
(3) SIQ-jr (SR)
(4) CGI-BPD, suicidality (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

328

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.4.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 4:
Primary: suicide-related outcomes, attempts (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

DBT

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Stanley 2017

3

37

6

38

0.51 [0.14 , 1.90]

Test for subgroup differences: Not applicable

0.005

0.1

1

10

200

Favours DBT

Favours TAU

Analysis 3.5.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU,
Outcome 5: Primary: psychosocial functioning (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Carter 2010 (1)
Feigenbaum 2012 (2)
Kramer 2016 (3)
Linehan 1994 (4)
Mehlum 2014 (5)
Soler 2009 (6)

8.15
2.48
12.76
-51.42
-59.4
3.27

11.48
0.85
7.79
9.71
6.6
0.9

20
25
21
13
5
29

13.07
2.22
16
-40.43
-54.2
3.57

11.59
0.92
5.42
10.8
6.1
1.13

28
16
20
13
5
30

20.6%
18.5%
18.8%
12.5%
5.8%
23.9%

-0.42 [-1.00 , 0.16]
0.29 [-0.34 , 0.92]
-0.47 [-1.09 , 0.15]
-1.04 [-1.86 , -0.21]
-0.74 [-2.05 , 0.57]
-0.29 [-0.80 , 0.22]

Total (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 7.20, df = 5 (P = 0.21); I² = 31%
Test for overall effect: Z = 2.14 (P = 0.03)
Test for subgroup differences: Not applicable

113

112

100.0%

-0.36 [-0.69 , -0.03]

-4
-2
Favours DBT

0

2

4
Favours TAU

Footnotes
(1) BDQ-days out of role (SR)
(2) CORE-OM (SR)
(3) OQ45, social role at discharge (SR)
(4) GAS (CR)
(5) C-GAS (CR)
(6) CGI-global improvement, patient-rated (SR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

329

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.6.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 6: Secondary: anger (continuous)

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

3.6.1 End of treatment
Feigenbaum 2012 (1)
Koons 2001a (2)
Linehan 1994 (3)
Linehan 2006 (4)
Soler 2009 (5)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.09; Chi² = 7.47, df = 4 (P = 0.11); I² = 46%
Test for overall effect: Z = 2.41 (P = 0.02)

83.4
14.5
32.15
1.84
3.11

20.36
3.9
7.19
0.51
1.02

83.3
17.9
40.08
1.93
3.88

25
10
13
48
29
125

17.94
6.1
8.37
0.57
0.78

16
10
13
36
30
105

20.3%
12.8%
14.6%
28.4%
23.9%
100.0%

0.01 [-0.62 , 0.63]
-0.64 [-1.54 , 0.27]
-0.98 [-1.81 , -0.16]
-0.17 [-0.60 , 0.27]
-0.84 [-1.37 , -0.30]
-0.47 [-0.86 , -0.09]

3.6.2 6-12 months follow-up
Linehan 2006 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.76 (P = 0.44)

1.89

0.53

3.6.3 Above 12 months follow-up
1.9
Linehan 2006 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.09 (P = 0.93)

0.43

44
44

45
45

1.99

0.61

34
34

100.0%
100.0%

-0.17 [-0.62 , 0.27]
-0.17 [-0.62 , 0.27]

1.89

0.52

35
35

100.0%
100.0%

0.02 [-0.42 , 0.46]
0.02 [-0.42 , 0.46]

Footnotes
(1) STAXI - anger out (geometric mean after log transformation) (SR)
(2) STAXI - anger out (SR)
(3) STAXI, anger trait (SR)
(4) STAXI-anger out (SR)
(5) CGI-BPD, anger (CR)

-4
-2
Favours DBT

0

2
4
Favours TAU

Analysis 3.7.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU,
Outcome 7: Secondary: affective instability (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Bianchini 2019 (1)
Soler 2009 (2)

65.6
3.61

9.4
1.19

10
29

65.1
4.66

15.57
0.7

11
30

45.4%
54.6%

0.04 [-0.82 , 0.89]
-1.07 [-1.61 , -0.52]

Total (95% CI)
Heterogeneity: Tau² = 0.47; Chi² = 4.52, df = 1 (P = 0.03); I² = 78%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable

39

Footnotes
(1) DERS total score (SR)
(2) CGI-BPD, affective instability (CR)

41

100.0%

-0.57 [-1.64 , 0.51]

-10

-20
Favours DBT

0

10

20
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

330

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.8.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome
8: Secondary: chronic feelings of emptiness (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Soler 2009 (1)

4.33

1.57

29

5

1.5

30

-0.67 [-1.45 , 0.11]

Test for subgroup differences: Not applicable

Footnotes
(1) CGI-BPD, emptiness (CR)

-20

-10

0

10

20

Favours DBT

Favours TAU

Analysis 3.9.   Comparison 3: Dialectical behavior therapy
(DBT) vs TAU, Outcome 9: Secondary: impulsivity (continuous)

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

3.9.1 End of treatment
Bianchini 2019 (1)
Soler 2009 (2)
Van den Bosch 2005 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.77, df = 2 (P = 0.41); I² = 0%
Test for overall effect: Z = 1.98 (P = 0.05)

50.66
3.61
0.92

10.7
0.97
0.74

10
29
23
62

51.75
4.11
1.06

18.42
0.6
0.84

11
30
25
66

16.8%
45.0%
38.2%
100.0%

-0.07 [-0.93 , 0.79]
-0.61 [-1.14 , -0.09]
-0.17 [-0.74 , 0.39]
-0.35 [-0.71 , -0.00]

3.9.2 6-12 months follow-up
Van den Bosch 2005 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.98 (P = 0.33)

1.08

0.93

20
20

0.85

0.57

24
24

100.0%
100.0%

0.30 [-0.30 , 0.90]
0.30 [-0.30 , 0.90]

Footnotes
(1) BIS-11 total score (SR)
(2) CGI-BPD - impulsivity (CR)
(3) BPDSI-IV - impulsivity (CR)
(4) Observer rated: BPDSI-IV, impulsivity

-4
-2
Favours DBT

0

2
4
Favours TAU

Analysis 3.10.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome
10: Secondary: interpersonal problems (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Carter 2010 (1)
Kramer 2016 (2)
Soler 2009 (3)

-48.75
21.05
4.22

19.36
8.48
0.8

20
21
29

-49.73
21.7
4.44

30.23
7.65
0.72

28
20
30

32.0%
28.1%
40.0%

0.04 [-0.54 , 0.61]
-0.08 [-0.69 , 0.53]
-0.29 [-0.80 , 0.23]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.70, df = 2 (P = 0.70); I² = 0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable

70

Footnotes
(1) Self reported: WHOQOL-Bref social relationships
(2) OQ45.2 - interpersonal (SR)
(3) CGI-BPD, unstable relations (CR)

78

100.0%

-0.12 [-0.45 , 0.20]

-4
-2
Favours DBT

0

2
4
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

331

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.11.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome 11:
Secondary: dissociation and psychotic-like symptoms (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Feigenbaum 2012 (1)
Koons 2001a (1)
Priebe 2012 (2)
Soler 2009 (2)

28.52
13.2
48
8.74

25.12
12
11.7
5.06

25
10
40
29

34.9
30.6
51
11.89

17.83
23.3
10.9
4.4

16
10
34
30

20.9%
9.6%
39.4%
30.1%

-0.28 [-0.91 , 0.35]
-0.90 [-1.83 , 0.03]
-0.26 [-0.72 , 0.20]
-0.66 [-1.18 , -0.13]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.42, df = 3 (P = 0.49); I² = 0%
Test for overall effect: Z = 3.03 (P = 0.002)
Test for subgroup differences: Not applicable

104

90

100.0%

-0.45 [-0.73 , -0.16]

-10

-5

0

5

10

Favours DBT

Favours TAU

Footnotes
(1) DES (SR)
(2) BPRS (CR)

Analysis 3.12.   Comparison 3: Dialectical behavior therapy
(DBT) vs TAU, Outcome 12: Secondary: depression (continuous)

Study or Subgroup

Mean

DBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

3.12.1 End of treatment
Feigenbaum 2012 (1)
Koons 2001a (2)
Linehan 2006 (3)
Mehlum 2014 (4)
Soler 2009 (5)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.20; Chi² = 11.09, df = 4 (P = 0.03); I² = 64%
Test for overall effect: Z = 1.83 (P = 0.07)

32.2
13.4
14
19.6
11.11

25
10
50
5
29
119

12.8
7.5
7.3
8.6
3.99

28.1
29.3
17
21.4
16

13.7
17.7
8.2
3.8
5.78

16
10
39
5
30
100

22.1%
15.2%
27.3%
11.0%
24.3%
100.0%

0.31 [-0.33 , 0.94]
-1.12 [-2.08 , -0.16]
-0.39 [-0.81 , 0.04]
-0.24 [-1.49 , 1.00]
-0.97 [-1.51 , -0.43]
-0.47 [-0.98 , 0.03]

3.12.2 6-12 months follow-up
Linehan 2006 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.01 (P = 0.31)

12.6

Footnotes
(1) BDI-II (SR)
(2) BDI (SR)
(3) Ham-D 17 (SR)
(4) MADRS (CR)
(5) Ham-D-17 (CR)

6.8

46
46

14.4

9.1

35
35

100.0%
100.0%

-0.23 [-0.67 , 0.21]
-0.23 [-0.67 , 0.21]

-10

-5

0

5

10

Favours DBT

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

332

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.13.   Comparison 3: Dialectical behavior therapy
(DBT) vs TAU, Outcome 13: Secondary: attrition (dichotomous)

Study or Subgroup

Events

Total

Events

Total

Weight

DBT

TAU

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

3.13.1 End of treatment
Carter 2010
Feigenbaum 2012
Koons 2001a
Kramer 2016
Linehan 1991
Linehan 1994
Linehan 2006
Priebe 2012
Stanley 2017
Van den Bosch 2005
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.65; Chi² = 46.77, df = 9 (P < 0.00001); I² = 81%
Test for overall effect: Z = 0.80 (P = 0.42)

35
16
15
20
31
13
49
40
38
33
290

38
26
13
21
30
13
52
40
37
31
301

4
1
5
5
9
1
35
6
11
26

18
15
3
5
10
3
16
21
9
14

103

114

10.2%
5.7%
8.8%
9.6%
11.6%
5.0%
13.1%
11.3%
11.5%
13.2%
100.0%

4.14 [1.55 , 11.06]
9.23 [1.35 , 63.35]
0.69 [0.20 , 2.35]
0.95 [0.32 , 2.80]
1.15 [0.54 , 2.42]
3.00 [0.36 , 25.21]
0.43 [0.28 , 0.67]
3.50 [1.58 , 7.75]
0.84 [0.39 , 1.79]
0.57 [0.37 , 0.88]
1.27 [0.70 , 2.31]

3.13.2 0-6 months follow-up
Soler 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.97 (P = 0.05)

11

11

30
30

19

19

30
30

100.0%
100.0%

0.58 [0.34 , 1.00]
0.58 [0.34 , 1.00]

0.005

0.1

1

Favours DBT

10

200
Favours TAU

Analysis 3.14.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU,
Outcome 14: Secondary: adverse effects (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

DBT

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Stanley 2017 (1)

0

37

0

38

Not estimable

Test for subgroup differences: Not applicable

Footnotes
(1) adverse events others than serious adverse events

0.01

0.1
Favours DBT

1

10
Favours TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

333

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.15.   Comparison 3: Dialectical behavior therapy (DBT) vs TAU, Outcome
15: Secondary: serious adverse effects (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

DBT

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Stanley 2017 (1)

1

37

2

38

0.51 [0.05 , 5.42]

Test for subgroup differences: Not applicable

0.001

0.1
Favours DBT

1

10

1000

Favours TAU

Footnotes
(1) adverse effects that results in death, threatens life, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect

Comparison 4.   Mentalisation based therapy (MBT) vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.1 Primary: BPD symptom severity
(continuous)

4.1.1 End of treatment

4.1.2 0-6 months follow-up

4.1.3 Above 12 months follow-up

4.2 Primary: self-harm (continuous),
at end of treatment

4.3 Primary: self-harm (dichotomous)

4.3.1 End of treatment

4.3.2 0-6 months follow-up

4.3.3 6-12 months follow-up

4.3.4 Above 12 months follow-up

4.4 Primary: suicide-related out-
comes (dichotomous)

4.4.1 End of treatment

4.4.2 0-6 months follow-up

6

5

1

2

1

3

3

1

1

1

3

3

1

267

15

97

252

41

41

41

218

41

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.38, 0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.40 [-1.49, 0.68]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.94 [-2.58, 0.70]

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

0.62 [0.49, 0.80]

Risk Ratio (IV, Random, 95%
CI)

0.14 [0.04, 0.56]

Risk Ratio (IV, Random, 95%
CI)

0.27 [0.10, 0.68]

Risk Ratio (IV, Random, 95%
CI)

0.33 [0.15, 0.76]

Risk Ratio (M-H, Random, 95%
CI)

Subtotals only

Risk Ratio (M-H, Random, 95%
CI)

0.10 [0.04, 0.30]

Risk Ratio (M-H, Random, 95%
CI)

0.25 [0.06, 1.05]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

334

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.4.3 Above 12 months follow-up

4.5 Primary: psychosocial functioning
(continuous)

4.5.1 End of treatment

4.5.2 Above 12 months follow-up

4.6 Secondary: interpersonal prob-
lems (continuous)

4.6.1 End of treatment

4.6.2 0-6 months follow-up

4.6.3 Above 12 months follow-up

4.7 Secondary: depression (continu-
ous)

4.7.1 End of treatment

4.7.2 0-6 months follow-up

4.7.3 6-12 months follow-up

4.7.4 Above 12 months follow-up

4.8 Secondary: depression (dichoto-
mous), at end of treatment

4.9 Secondary: attrition (dichoto-
mous), at end of treatment

4.10 Secondary: adverse effects (di-
chotomous), at end of treatment

4.11 Mentalisation-based treatment
for eating disorders (MBT-ED) versus
specialist supportive clinical manage-
ment (SSCM-ED) (generic inverse vari-
ance)

1

3

3

2

5

5

1

2

4

4

2

1

2

1

7

1

1

41

239

104

357

53

96

333

91

37

90

552

Risk Ratio (M-H, Random, 95%
CI)

0.29 [0.11, 0.74]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.54 [-1.24, 0.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.97, 0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.68 [-1.33,
-0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-1.01, 0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-0.71, 0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.22, 0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.81 [-1.69, 0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.17 [-1.88,
-0.45]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.72 [-1.55, 0.10]

Risk Ratio (IV, Fixed, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95%
CI)

0.99 [0.79, 1.25]

Risk Ratio (M-H, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

335

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.11.1 Primary: psychosocial func-
tioning (continuous), at end of treat-
ment

4.11.2 Primary: psychosocial func-
tioning (dichotomous), at 0-6 months
follow-up

4.11.3 Secondary: interpersonal prob-
lems (continuous), at end of treat-
ment

4.11.4 Secondary: interpersonal prob-
lems (continuous), at 0-6 months fol-
low-up

4.11.5 Secondary: depression (contin-
uous), at end of treatment

4.11.6 Secondary: depression (contin-
uous), at 0-6 months follow-up

1

1

1

1

1

1

Mean Difference (IV, Fixed, 95%
CI)

-0.07 [-0.86, 0.72]

Mean Difference (IV, Fixed, 95%
CI)

-0.44 [-1.52, 0.64]

Mean Difference (IV, Fixed, 95%
CI)

-0.10 [-0.89, 0.69]

Mean Difference (IV, Fixed, 95%
CI)

-0.06 [-1.15, 1.03]

Mean Difference (IV, Fixed, 95%
CI)

0.19 [-0.60, 0.98]

Mean Difference (IV, Fixed, 95%
CI)

0.51 [-0.62, 1.64]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

336

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.1.   Comparison 4: Mentalisation based therapy (MBT)
vs TAU, Outcome 1: Primary: BPD symptom severity (continuous)

Study or Subgroup

Mean

MBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

4.1.1 End of treatment
Jørgensen 2013 (1)
Laurenssen 2018 (2)
Philips 2018 (3)
Robinson 2016 (4)
Rossouw 2012b (5)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.53, df = 4 (P = 0.82); I² = 0%
Test for overall effect: Z = 1.09 (P = 0.28)

2.5
11.45
9.1
7.41
0.5385

2.8
20.63
17
9.64
2.79

42
54
13
12
29
150

3.6
21.39
20.7
9.27
3.06

2.1
10.43
9.1
7.39
65.7267

24
41
11
11
30
117

23.3%
36.0%
9.0%
8.9%
22.8%
100.0%

-0.33 [-0.84 , 0.17]
-0.07 [-0.47 , 0.34]
-0.39 [-1.20 , 0.42]
0.05 [-0.77 , 0.87]
-0.01 [-0.52 , 0.50]
-0.13 [-0.38 , 0.11]

4.1.2 0-6 months follow-up
Robinson 2016 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.73 (P = 0.47)

7.1

6.19

10
10

10

7.97

5
5

100.0%
100.0%

-0.40 [-1.49 , 0.68]
-0.40 [-1.49 , 0.68]

4.1.3 Above 12 months follow-up
5.5
Bateman 1999 (6)
2.2
Jørgensen 2013 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.29; Chi² = 12.25, df = 1 (P = 0.0005); I² = 92%
Test for overall effect: Z = 1.12 (P = 0.26)

15.1
2.5

22
40
62

5.2
2.4

Footnotes
(1) SCID-BPD (CR)
(2) BPDSI-IV (CR)
(3) BPDSI-IV-total (CR)
(4) Zan-BPD-total (CR)
(5) BPFS-C (SR)
(6) Clinician rated: ZAN-BPD total

5.3
2.7

19
16
35

49.0%
51.0%
100.0%

-1.79 [-2.53 , -1.06]
-0.12 [-0.70 , 0.46]
-0.94 [-2.58 , 0.70]

-20

-10

0

10

20

Favours MBT

Favours TAU

Analysis 4.2.   Comparison 4: Mentalisation based therapy (MBT) vs
TAU, Outcome 2: Primary: self-harm (continuous), at end of treatment

Study or Subgroup

Mean

MBT
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Philips 2018 (1)

2.3

5.5

13

2.2

4.8

11

0.10 [-4.02 , 4.22]

Test for subgroup differences: Not applicable

Footnotes
(1) DSHI-SF (SR)

-100

-50
Favours MBT

0

50
Favours TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

337

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.3.   Comparison 4: Mentalisation based therapy
(MBT) vs TAU, Outcome 3: Primary: self-harm (dichotomous)

Study or Subgroup

Events

Total

Events

Total

Weight

MBT

TAU

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

4.3.1 End of treatment
Bateman 1999 (1)
Bateman 2009 (1)
Rossouw 2012b
Subtotal (95% CI)
48
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 2.16, df = 2 (P = 0.34); I² = 7%
Test for overall effect: Z = 3.76 (P = 0.0002)

19
71
40
130

16
27
34

7
17
24

19
63
40
122

77

15.2%
22.5%
62.3%
100.0%

0.44 [0.24 , 0.81]
0.56 [0.34 , 0.92]
0.71 [0.53 , 0.94]
0.62 [0.49 , 0.80]

4.3.2 0-6 months follow-up
Bateman 1999 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.78 (P = 0.005)

2

2

4.3.3 6-12 months follow-up
Bateman 1999 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.77 (P = 0.006)

4

4

22
22

22
22

4.3.4 Above 12 months follow-up
5
Bateman 1999 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.61 (P = 0.009)

5

22
22

12

12

13

13

13

13

19
19

100.0%
100.0%

0.14 [0.04 , 0.56]
0.14 [0.04 , 0.56]

19
19

100.0%
100.0%

0.27 [0.10 , 0.68]
0.27 [0.10 , 0.68]

19
19

100.0%
100.0%

0.33 [0.15 , 0.76]
0.33 [0.15 , 0.76]

Footnotes
(1) SSHI - number of participants with self-mutilating behaviour (last 6 months) (CR)

0.002

0.1
Favours MBT

1

10

500

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

338

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.4.   Comparison 4: Mentalisation based therapy (MBT) vs
TAU, Outcome 4: Primary: suicide-related outcomes (dichotomous)

Study or Subgroup

Events

Total

Events

Total

Weight

MBT

TAU

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

4.4.1 End of treatment
Bateman 1999 (1)
Bateman 2009 (1)
Philips 2018 (2)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 4.14 (P < 0.0001)

19
71
24
114

12
16
3

19
63
22
104

1
2
0

31

3

30.5%
56.0%
13.5%
100.0%

0.08 [0.01 , 0.58]
0.11 [0.03 , 0.46]
0.13 [0.01 , 2.41]
0.10 [0.04 , 0.30]

4.4.2 0-6 months follow-up
Bateman 1999 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.90 (P = 0.06)

2

2

4.4.3 Above 12 months follow-up
4
Bateman 1999 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.57 (P = 0.01)

4

22
22

22
22

7

7

12

12

19
19

100.0%
100.0%

0.25 [0.06 , 1.05]
0.25 [0.06 , 1.05]

19
19

100.0%
100.0%

0.29 [0.11 , 0.74]
0.29 [0.11 , 0.74]

Test for subgroup differences: Chi² = 2.07, df = 2 (P = 0.35), I² = 3.4%

0.001

0.1
Favours MBT

1

10

1000

Favours TAU

Footnotes
(1) SSHI - number of participants with life-threatening suicide attempts (last 6 months)
(2) participants with suicide attempts (recorded via direct contact with patients and health care staff, as well as from reviewing the case records)

Analysis 4.5.   Comparison 4: Mentalisation based therapy (MBT) vs
TAU, Outcome 5: Primary: psychosocial functioning (continuous)

Study or Subgroup

Mean

MBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

4.5.1 End of treatment
Bateman 1999 (1)
Bateman 2009 (1)
Jørgensen 2013 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.32; Chi² = 11.92, df = 2 (P = 0.003); I² = 83%
Test for overall effect: Z = 1.50 (P = 0.13)

20
71
42
133

3.4
2.17
2.1

2.7
1.76
2.2

0.6
0.5
0.5

4.5.2 Above 12 months follow-up
-58.3
Bateman 1999 (2)
2.1
Jørgensen 2013 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 1.89, df = 1 (P = 0.17); I² = 47%
Test for overall effect: Z = 1.43 (P = 0.15)

-51.8
2.2

10.5
0.5

22
40
62

0.6
0.64
0.6

19
63
24
106

29.4%
36.9%
33.7%
100.0%

-1.14 [-1.83 , -0.46]
-0.72 [-1.07 , -0.36]
0.18 [-0.32 , 0.69]
-0.54 [-1.24 , 0.16]

5.7
0.8

18
24
42

43.7%
56.3%
100.0%

-0.73 [-1.38 , -0.09]
-0.16 [-0.66 , 0.35]
-0.41 [-0.97 , 0.15]

Footnotes
(1) SAS-SR (SR)
(2) Clinician rated: GAF

-10
Favours MBT

-5

0

5

10
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

339

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.6.   Comparison 4: Mentalisation based therapy (MBT) vs
TAU, Outcome 6: Secondary: interpersonal problems (continuous)

Study or Subgroup

Mean

MBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

4.6.1 End of treatment
Bateman 1999 (1)
Bateman 2009 (1)
Jørgensen 2013 (1)
Laurenssen 2018 (1)
Philips 2018 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.47; Chi² = 31.45, df = 4 (P < 0.00001); I² = 87%
Test for overall effect: Z = 2.02 (P = 0.04)

19
71
42
54
13
199

1.86
1.28
1.2
2.78
1.5

0.36
0.13
0.6
0.63
0.54

2.6
1.65
1.3
2.75
1.7

0.29
0.55
0.8
0.57
0.56

19
63
24
41
11
158

17.3%
22.3%
21.0%
21.9%
17.5%
100.0%

-2.22 [-3.04 , -1.39]
-0.95 [-1.30 , -0.59]
-0.15 [-0.65 , 0.36]
0.05 [-0.36 , 0.46]
-0.35 [-1.16 , 0.46]
-0.68 [-1.33 , -0.02]

4.6.2 0-6 months follow-up
Jørgensen 2013 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.32 (P = 0.19)

1.2

0.7

38
38

1.5

0.8

15
15

100.0%
100.0%

-0.41 [-1.01 , 0.20]
-0.41 [-1.01 , 0.20]

4.6.3 Above 12 months follow-up
1.5
Bateman 1999 (1)
1.2
Jørgensen 2013 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.82); I² = 0%
Test for overall effect: Z = 1.30 (P = 0.19)

21
40
61

4
0.8

2.5
1.4

0.5
0.9

19
16
35

46.4%
53.6%
100.0%

-0.34 [-0.96 , 0.29]
-0.24 [-0.82 , 0.34]
-0.28 [-0.71 , 0.14]

Footnotes
(1) IIP-64 (SR)

-4

-2

0

2

4

Favours MBT

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

340

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.7.   Comparison 4: Mentalisation based therapy
(MBT) vs TAU, Outcome 7: Secondary: depression (continuous)

Study or Subgroup

Mean

MBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

4.7.1 End of treatment
Bateman 1999 (1)
Bateman 2009 (1)
Jørgensen 2013 (2)
Laurenssen 2018 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.35; Chi² = 21.33, df = 3 (P < 0.0001); I² = 86%
Test for overall effect: Z = 1.81 (P = 0.07)

35.2
18.68
22.8
21.11

7
8.55
11.5
16.57

19
71
42
54
186

20.6
14.8
18.8
22.5

4.7.2 0-6 months follow-up
Bateman 1999 (4)
Jørgensen 2013 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.29; Chi² = 3.60, df = 1 (P = 0.06); I² = 72%
Test for overall effect: Z = 1.80 (P = 0.07)

19
17.8

28.7
23.2

22
38
60

7.4
14

7.4
8.76
13.7
9.1

7.4
13.9

19
63
24
41
147

20.4%
27.6%
25.2%
26.7%
100.0%

-1.98 [-2.78 , -1.19]
-0.45 [-0.79 , -0.10]
-0.32 [-0.83 , 0.18]
0.10 [-0.31 , 0.51]
-0.58 [-1.22 , 0.05]

16
15
31

47.7%
52.3%
100.0%

-1.28 [-2.00 , -0.57]
-0.38 [-0.98 , 0.22]
-0.81 [-1.69 , 0.07]

4.7.3 6-12 months follow-up
Bateman 1999 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.21 (P = 0.001)

13.3

6

21.5

8

22
22

15
15

100.0%
100.0%

-1.17 [-1.88 , -0.45]
-1.17 [-1.88 , -0.45]

4.7.4 Above 12 months follow-up
11.9
Bateman 1999 (4)
17.5
Jørgensen 2013 (4)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.24; Chi² = 3.12, df = 1 (P = 0.08); I² = 68%
Test for overall effect: Z = 1.72 (P = 0.08)

20.4
22.2

3.3
13.5

22
38
60

Footnotes
(1) Self rated: BDI
(2) BDI-II (SR)
(3) Self-rated: BDI
(4) BDI (SR)

10.5
15.8

15
15
30

47.3%
52.7%
100.0%

-1.17 [-1.88 , -0.45]
-0.33 [-0.93 , 0.27]
-0.72 [-1.55 , 0.10]

-2
-4
Favours MBT

0

2

4
Favours TAU

Analysis 4.8.   Comparison 4: Mentalisation based therapy (MBT) vs TAU,
Outcome 8: Secondary: depression (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

MBT

TAU

Risk Ratio
IV, Fixed, 95% CI

Risk Ratio
IV, Fixed, 95% CI

Rossouw 2012b (1)

20

40

28

40

0.71 [0.49 , 1.03]

Test for subgroup differences: Not applicable

Footnotes
(1) MFQ - participants beyond depression cut-off

0.01

0.1
Favours MBT

1

10
Favours TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

341

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.9.   Comparison 4: Mentalisation based therapy (MBT) vs TAU,
Outcome 9: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

Weight

MBT

TAU

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Bateman 1999
Bateman 2009
Jørgensen 2013
Laurenssen 2018
Philips 2018
Robinson 2016
Rossouw 2012b

3
19
19
16
11
12
20

22
71
58
54
24
34
40

3
16
8
12
11
9
23

22
63
27
41
22
34
40

2.4%
16.3%
11.2%
13.5%
14.6%
10.2%
31.8%

1.00 [0.23 , 4.42]
1.05 [0.59 , 1.87]
1.11 [0.56 , 2.20]
1.01 [0.54 , 1.90]
0.92 [0.50 , 1.68]
1.33 [0.65 , 2.74]
0.87 [0.58 , 1.31]

303

Total (95% CI)
100
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 1.28, df = 6 (P = 0.97); I² = 0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable

82

249

100.0%

0.99 [0.79 , 1.25]

0.2

0.05
Favours MBT

1

5

20
Favours TAU

Analysis 4.10.   Comparison 4: Mentalisation based therapy (MBT) vs TAU,
Outcome 10: Secondary: adverse effects (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

MBT-ED

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Robinson 2016

1

34

0

34

3.00 [0.13 , 71.15]

Test for subgroup differences: Not applicable

0.01

0.1
Favours MBT

1

10
Favours TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

342

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.11.   Comparison 4: Mentalisation based therapy (MBT) vs TAU,
Outcome 11: Mentalisation-based treatment for eating disorders (MBT-ED) versus
specialist supportive clinical management (SSCM-ED) (generic inverse variance)

Study or Subgroup

MD

SE

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

4.11.1 Primary: psychosocial functioning (continuous), at end of treatment
Robinson 2016 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.17 (P = 0.86)

-0.07 [-0.86 , 0.72]
-0.07 [-0.86 , 0.72]

100.0%
100.0%

0.4031

-0.07

4.11.2 Primary: psychosocial functioning (dichotomous), at 0-6 months follow-up
0.551
Robinson 2016 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.80 (P = 0.42)

-0.44 [-1.52 , 0.64]
-0.44 [-1.52 , 0.64]

100.0%
100.0%

-0.44

4.11.3 Secondary: interpersonal problems (continuous), at end of treatment
-0.10 [-0.89 , 0.69]
Robinson 2016 (2)
-0.10 [-0.89 , 0.69]
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.25 (P = 0.80)

100.0%
100.0%

0.4031

-0.1

4.11.4 Secondary: interpersonal problems (continuous), at 0-6 months follow-up
0.5561
Robinson 2016 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.11 (P = 0.91)

-0.06 [-1.15 , 1.03]
-0.06 [-1.15 , 1.03]

100.0%
100.0%

-0.06

4.11.5 Secondary: depression (continuous), at end of treatment
0.19
Robinson 2016 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.47 (P = 0.64)

100.0%
100.0%

0.4031

0.19 [-0.60 , 0.98]
0.19 [-0.60 , 0.98]

4.11.6 Secondary: depression (continuous), at 0-6 months follow-up
Robinson 2016 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.88 (P = 0.38)

100.0%
100.0%

0.5765

0.51

0.51 [-0.62 , 1.64]
0.51 [-0.62 , 1.64]

Footnotes
(1) Clinician-rated: GAF
(2) WHOQOL - social relationships (SR)
(3) EQ-5D - social relationships (SR)
(4) Self-reported: DASS-21

-4
Favours MBT-ED

-2

0

2

4
Favours SSCM-ED

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

343

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 5.   Cognitive behavioural therapy (CBT) and related treatments vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

5.1 Primary: BPD symptom
severity (continuous)

5.1.1 End of treatment

5.1.2 0-6 months follow-up

5.2 Primary: BPD symptom
severity (dichotomous), at
above 12 months follow-up

5.3 Primary: self-harm (continu-
ous)

5.3.1 End of treatment

5.3.2 0-6 months follow-up

5.4 Primary: self-harm (dichoto-
mous), at end of treatment

5.5 Primary: suicide-related out-
comes (continuous)

5.5.1 End of treatment

5.5.2 0-6 months follow-up

5.5.3 6-12 months follow-up

5.5.4 Above 12 months fol-
low-up

5.6 Primary: psychosocial func-
tioning (continuous)

5.6.1 End of treatment

5.6.2 6-12 months follow-up

5.6.3 Above 12 months fol-
low-up

5.7 Secondary: interpersonal
problems (continuous)

5.7.1 End of treatment

1

1

1

1

1

1

1

1

2

2

1

1

1

2

1

1

2

1

1

26

26

76

28

28

104

28

76

76

99

90

209

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-3.08 [-4.99, -1.17]

Mean Difference (IV, Fixed, 95% CI)

-2.02 [-4.23, 0.19]

Risk Ratio (IV, Fixed, 95% CI)

0.91 [0.56, 1.48]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-3.03 [-5.68, -0.38]

Mean Difference (IV, Fixed, 95% CI)

-4.71 [-11.60, 2.18]

Risk Ratio (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.47 [-1.02, 0.08]

Std. Mean Difference (IV, Random,
95% CI)

-0.45 [-1.20, 0.31]

Std. Mean Difference (IV, Random,
95% CI)

-0.44 [-0.89, 0.02]

Std. Mean Difference (IV, Random,
95% CI)

-0.31 [-0.77, 0.14]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.00 [-0.39, 0.39]

Std. Mean Difference (IV, Random,
95% CI)

0.13 [-0.28, 0.55]

Std. Mean Difference (IV, Random,
95% CI)

0.04 [-0.36, 0.43]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

99

Mean Difference (IV, Fixed, 95% CI)

5.40 [-3.70, 14.50]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

344

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

5.7.2 6-12 months follow-up

5.7.3 Above 12 months fol-
low-up

5.8 Secondary: dissociation and
psychotic-like symptoms (con-
tinuous)

5.8.1 End of treatment

5.8.2 0-6 months follow-up

5.9 Secondary: depression (con-
tinuous)

5.9.1 End of treatment

5.9.2 0-6 months follow-up

5.9.3 6-12 months follow-up

5.9.4 Above 12 months fol-
low-up

5.10 Secondary: attrition (di-
chotomous), at end of treat-
ment

5.11 Secondary: adverse effects
(dichotomous), at end of treat-
ment

5.11.1 Non-serious adverse ef-
fects

5.11.2 Serious adverse effects

1

1

1

1

1

5

5

1

1

2

1

2

1

2

99

76

26

26

314

26

99

197

306

326

Mean Difference (IV, Fixed, 95% CI)

0.30 [-9.17, 9.77]

Mean Difference (IV, Fixed, 95% CI)

11.70 [0.72, 22.68]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-2.30 [-8.84, 4.24]

Mean Difference (IV, Fixed, 95% CI)

Std. Mean Difference (IV, Random,
95% CI)

-13.40 [-24.49,
-2.31]

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.21 [-0.77, 0.35]

Std. Mean Difference (IV, Random,
95% CI)

-0.96 [-1.78, -0.14]

Std. Mean Difference (IV, Random,
95% CI)

-0.29 [-0.69, 0.11]

Std. Mean Difference (IV, Random,
95% CI)

-0.15 [-0.43, 0.13]

Risk Ratio (M-H, Fixed, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

Subtotals only

Risk Ratio (M-H, Random, 95% CI)

0.92 [0.45, 1.88]

Risk Ratio (M-H, Random, 95% CI)

2.65 [0.31, 22.93]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

345

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.1.   Comparison 5: Cognitive behavioural therapy (CBT) and related
treatments vs TAU, Outcome 1: Primary: BPD symptom severity (continuous)

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

5.1.1 End of treatment
Kredlow 2017a (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.16 (P = 0.002)

1.17

1.17

5.1.2 0-6 months follow-up
Kredlow 2017a (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.79 (P = 0.07)

2.86

2.7

Footnotes
(1) SCID-BPD (CR)
(2) Observer rated: SCID-II BPD

14
14

14
14

4.25

3.2

12
12

100.0%
100.0%

-3.08 [-4.99 , -1.17]
-3.08 [-4.99 , -1.17]

4.88

3

12
12

100.0%
100.0%

-2.02 [-4.23 , 0.19]
-2.02 [-4.23 , 0.19]

-20

-10

0

10

20

Favours CBT

Favours TAU

Analysis 5.2.   Comparison 5: Cognitive behavioural therapy (CBT) and related treatments vs
TAU, Outcome 2: Primary: BPD symptom severity (dichotomous), at above 12 months follow-up

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

TAU

Risk Ratio
IV, Fixed, 95% CI

Risk Ratio
IV, Fixed, 95% CI

Davidson 2006 (1)

19

43

16

33

100.0%

0.91 [0.56 , 1.48]

Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable

19

43

33

100.0%

0.91 [0.56 , 1.48]

16

0.01

0.1
Favours CBT

1

10
Favours TAU

100

Footnotes
(1) Participants still meeting BPD diagnostic criteria

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

346

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.3.   Comparison 5: Cognitive behavioural therapy (CBT) and
related treatments vs TAU, Outcome 3: Primary: self-harm (continuous)

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

5.3.1 End of treatment
Weinberg 2006 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.24 (P = 0.03)

0.6

0.91

5.3.2 0-6 months follow-up
Weinberg 2006 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.34 (P = 0.18)

1.98

3.57

15
15

15
15

3.63

4.8

13
13

100.0%
100.0%

-3.03 [-5.68 , -0.38]
-3.03 [-5.68 , -0.38]

6.69

12.23

13
13

100.0%
100.0%

-4.71 [-11.60 , 2.18]
-4.71 [-11.60 , 2.18]

Footnotes
(1) PHI - deliberate self-harm frequency (CR)

-50

-25

0

25

50

Favours CBT

Favours TAU

Analysis 5.4.   Comparison 5: Cognitive behavioural therapy (CBT) and related
treatments vs TAU, Outcome 4: Primary: self-harm (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

CBT

TAU

Risk Ratio
IV, Fixed, 95% CI

Risk Ratio
IV, Fixed, 95% CI

Davidson 2006 (1)

35

52

27

47

1.17 [0.86 , 1.60]

Test for subgroup differences: Not applicable

0.01

0.1
Favours CBT

1

10
Favours TAU

100

Footnotes
(1) DSHI - participants with self-harming behaviour (12 months of treatment) (SR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

347

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.5.   Comparison 5: Cognitive behavioural therapy (CBT) and related
treatments vs TAU, Outcome 5: Primary: suicide-related outcomes (continuous)

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

5.5.1 End of treatment
Davidson 2006 (1)
Weinberg 2006 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 1.62, df = 1 (P = 0.20); I² = 38%
Test for overall effect: Z = 1.69 (P = 0.09)

1.14
16.92

1.22
42.69

0.69
27.47

43
15
58

2.67
17.67

33
13
46

65.2%
34.8%
100.0%

-0.27 [-0.72 , 0.19]
-0.86 [-1.64 , -0.07]
-0.47 [-1.02 , 0.08]

5.5.2 0-6 months follow-up
Weinberg 2006 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.16 (P = 0.25)

37.96

18.68

5.5.3 6-12 months follow-up
Davidson 2006 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.86 (P = 0.06)

0.93

1.58

5.5.4 Above 12 months follow-up
1.88
Davidson 2006 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.34 (P = 0.18)

3.19

15
15

43
43

43
43

45.69

14.38

13
13

100.0%
100.0%

-0.45 [-1.20 , 0.31]
-0.45 [-1.20 , 0.31]

2.09

3.58

33
33

100.0%
100.0%

-0.44 [-0.89 , 0.02]
-0.44 [-0.89 , 0.02]

3.03

4.16

33
33

100.0%
100.0%

-0.31 [-0.77 , 0.14]
-0.31 [-0.77 , 0.14]

Footnotes
(1) DSHI - cumulative number of suicide attempts
(2) SBQ (SR)
(3) Number of suicide attempts (cumulative average at 12 months follow-up)
(4) Number of suicide attempts (cumulative average at 30 month follow-up)

-4
-2
Favours CBT

0

2
4
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

348

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.6.   Comparison 5: Cognitive behavioural therapy (CBT) and related
treatments vs TAU, Outcome 6: Primary: psychosocial functioning (continuous)

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

5.6.1 End of treatment
Davidson 2006 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)

13.1

4.4

5.6.2 6-12 months follow-up
Davidson 2006 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.64 (P = 0.52)

13

5

52
52

43
43

13.1

4.6

47
47

100.0%
100.0%

0.00 [-0.39 , 0.39]
0.00 [-0.39 , 0.39]

12.3

5.3

47
47

100.0%
100.0%

0.13 [-0.28 , 0.55]
0.13 [-0.28 , 0.55]

5.6.3 Above 12 months follow-up
10.3
Davidson 2006 (1)
14.1
McMurran 2016 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 2.04, df = 1 (P = 0.15); I² = 51%
Test for overall effect: Z = 0.18 (P = 0.86)

5
6.7506

43
60
103

11.2
12.5

5
7.5895

47
59
106

46.6%
53.4%
100.0%

-0.18 [-0.59 , 0.24]
0.22 [-0.14 , 0.58]
0.04 [-0.36 , 0.43]

Footnotes
(1) Self rated: SFQ
(2) SFQ (SR)

-4

-2

0

Favours CBT

2

4
Favours TAU

Analysis 5.7.   Comparison 5: Cognitive behavioural therapy (CBT) and related
treatments vs TAU, Outcome 7: Secondary: interpersonal problems (continuous)

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

5.7.1 End of treatment
Davidson 2006 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.16 (P = 0.24)

60.4

23.9

5.7.2 6-12 months follow-up
Davidson 2006 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.06 (P = 0.95)

54

23.9

5.7.3 Above 12 months follow-up
60.4
Davidson 2006 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.09 (P = 0.04)

23.7

Footnotes
(1) IIP-32 (SR)

52
52

52
52

43
43

55

22.3

47
47

100.0%
100.0%

5.40 [-3.70 , 14.50]
5.40 [-3.70 , 14.50]

53.7

24.1

47
47

100.0%
100.0%

0.30 [-9.17 , 9.77]
0.30 [-9.17 , 9.77]

48.7

24.6

33
33

100.0%
100.0%

11.70 [0.72 , 22.68]
11.70 [0.72 , 22.68]

-50 -25
Favours CBT

0

25
50
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

349

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.8.   Comparison 5: Cognitive behavioural therapy (CBT) and related treatments
vs TAU, Outcome 8: Secondary: dissociation and psychotic-like symptoms (continuous)

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

41.3

8.3

12
12

100.0%
100.0%

-2.30 [-8.84 , 4.24]
-2.30 [-8.84 , 4.24]

55.4

18.3

12
12

100.0%
100.0%

-13.40 [-24.49 , -2.31]
-13.40 [-24.49 , -2.31]

5.8.1 End of treatment
Kredlow 2017a (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.69 (P = 0.49)

39

5.8.2 0-6 months follow-up
Kredlow 2017a (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.37 (P = 0.02)

42

8.7

7.6

14
14

14
14

Footnotes
(1) BPRS (CR)
(2) Observer rated: BPRS, total

-100

-50
Favours CBT

0

50
Favours TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

350

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.9.   Comparison 5: Cognitive behavioural therapy (CBT) and
related treatments vs TAU, Outcome 9: Secondary: depression (continuous)

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

5.9.1 End of treatment
Davidson 2006 (1)
Davidson 2014 (2)
Jahangard 2012 (3)
Kredlow 2017a (1)
McMurran 2016 (4)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.28; Chi² = 17.62, df = 4 (P = 0.001); I² = 77%
Test for overall effect: Z = 0.73 (P = 0.47)

29.6
21.73
3.93
24.5
24.6

52
11
15
14
80
172

14.8
9.86
1.34
14.4
7.4

31.3
33.5
2.67
39.6
26.3

16.6
2.38
0.82
13.6
9.6

47
4
15
12
64
142

25.4%
11.8%
18.7%
17.8%
26.4%
100.0%

-0.11 [-0.50 , 0.29]
-1.27 [-2.53 , -0.01]
1.10 [0.33 , 1.88]
-1.04 [-1.87 , -0.21]
-0.20 [-0.53 , 0.13]
-0.21 [-0.77 , 0.35]

5.9.2 0-6 months follow-up
Kredlow 2017a (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.29 (P = 0.02)

23.1

12.7

5.9.3 6-12 months follow-up
Davidson 2006 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.44 (P = 0.15)

26.5

14.8

14
14

52
52

35.8

13

12
12

100.0%
100.0%

-0.96 [-1.78 , -0.14]
-0.96 [-1.78 , -0.14]

31.1

16.6

47
47

100.0%
100.0%

-0.29 [-0.69 , 0.11]
-0.29 [-0.69 , 0.11]

5.9.4 Above 12 months follow-up
26.5
Davidson 2006 (5)
20.3
McMurran 2016 (4)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.99); I² = 0%
Test for overall effect: Z = 1.03 (P = 0.30)

43
69
112

15.3
10.7

28.8
22

Footnotes
(1) BDI-II (SR)
(2) HADS - total score (SR)
(3) HDRS (CR)
(4) HADS (SR)
(5) Self rated: BDI-II

15.7
12.1

33
52
85

38.6%
61.4%
100.0%

-0.15 [-0.60 , 0.31]
-0.15 [-0.51 , 0.21]
-0.15 [-0.43 , 0.13]

-4 -2 0

Favours CBT

4

2
Favours TAU

Analysis 5.10.   Comparison 5: Cognitive behavioural therapy (CBT) and related
treatments vs TAU, Outcome 10: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

CBT

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Davidson 2006

2

54

4

52

0.48 [0.09 , 2.52]

Test for subgroup differences: Not applicable

0.001

0.1
Favours CBT

1

10

1000

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

351

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 5.11.   Comparison 5: Cognitive behavioural therapy (CBT) and related treatments
vs TAU, Outcome 11: Secondary: adverse effects (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

TAU

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

5.11.1 Non-serious adverse effects
13
McMurran 2016 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.24 (P = 0.81)

13

154
154

14

14

152
152

100.0%
100.0%

0.92 [0.45 , 1.88]
0.92 [0.45 , 1.88]

5.11.2 Serious adverse effects
Davidson 2014 (2)
McMurran 2016 (2)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.33, df = 1 (P = 0.56); I² = 0%
Test for overall effect: Z = 0.89 (P = 0.38)

14
154
168

6
152
158

1
2

0
0

3

0

49.3%
50.7%
100.0%

1.40 [0.06 , 30.23]
4.94 [0.24 , 101.96]
2.65 [0.31 , 22.93]

Footnotes
(1) number of adverse event reports other than suicide or hospitalization
(2) commited suicide

Comparison 6.   Psychodynamic psychotherapy vs TAU

0.001

0.1
Favours CBT

1

10

1000

Favours TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6.1 Primary: BPD symptom
severity (continuous)

6.1.1 End of treatment

6.1.2 6-12 months follow-up

6.2 Primary: self-harm (con-
tinuous)

6.2.1 End of treatment

6.2.2 6-12 months follow-up

6.3 Primary: suicide-related
outcomes (continuous)

6.3.1 End of treatment

6.3.2 6-12 months follow-up

4

4

1

1

1

1

3

3

1

222

33

33

33

101

33

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.29 [-0.66, 0.09]

Std. Mean Difference (IV, Random,
95% CI)

-0.31 [-1.00, 0.38]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

0.12 [-0.56, 0.80]

Std. Mean Difference (IV, Random,
95% CI)

0.14 [-0.55, 0.82]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.22 [-0.62, 0.17]

Std. Mean Difference (IV, Random,
95% CI)

-0.38 [-1.07, 0.31]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

352

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6.4 Primary: psychosocial
functioning (continuous)

6.4.1 End of treatment

6.4.2 6-12 months follow-up

6.4.3 Above 12 months fol-
low-up

6.5 Secondary: anger (contin-
uous)

6.5.1 End of treatment

6.5.2 6-12 months follow-up

6.6 Secondary: affective in-
stability (continuous)

6.6.1 End of treatment

6.6.2 6-12 months follow-up

6.7 Secondary: chronic feel-
ings of emptiness (continu-
ous)

6.7.1 End of treatment

6.7.2 6-12 months follow-up

6.8 Secondary: impulsivity
(continuous)

6.8.1 End of treatment

6.8.2 6-12 months follow-up

6.9 Secondary: interpersonal
problems (continuous)

6.9.1 End of treatment

6.9.2 6-12 months follow-up

4

4

1

1

1

1

1

3

3

1

2

2

1

2

2

1

4

4

1

140

33

16

33

33

116

33

77

33

77

33

238

33

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.69 [-1.98, 0.59]

Std. Mean Difference (IV, Random,
95% CI)

0.05 [-0.64, 0.73]

Std. Mean Difference (IV, Random,
95% CI)

-0.40 [-1.39, 0.60]

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

0.00 [-0.86, 0.86]

Mean Difference (IV, Fixed, 95% CI)

0.00 [-0.89, 0.89]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.50 [-0.87, -0.13]

Std. Mean Difference (IV, Random,
95% CI)

-0.52 [-1.21, 0.18]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.49 [-1.02, 0.04]

Std. Mean Difference (IV, Random,
95% CI)

-0.58 [-1.28, 0.11]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.39 [-0.85, 0.07]

Std. Mean Difference (IV, Random,
95% CI)

0.35 [-0.34, 1.04]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.21 [-0.71, 0.29]

Std. Mean Difference (IV, Random,
95% CI)

-0.51 [-1.20, 0.19]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

353

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

6.10 Secondary: abandon-
ment (continuous)

6.10.1 End of treatment

6.10.2 6-12 months follow-up

6.11 Secondary: identity dis-
turbance (continuous)

6.11.1 End of treatment

6.11.2 6-12 months follow-up

6.12 Secondary: dissociation
and psychotic-like symptoms
(continuous)

6.12.1 End of treatment

6.12.2 6-12 months follow-up

6.12.3 Above 12 months fol-
low-up

6.13 Secondary: depression
(continuous)

6.13.1 End of treatment

6.13.2 Above 12 months fol-
low-up

6.14 Secondary: attrition (di-
chotomous), at end of treat-
ment

1

1

1

3

3

1

2

2

1

1

3

3

1

3

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

Mean Difference (IV, Fixed, 95% CI)

-0.20 [-0.95, 0.55]

Mean Difference (IV, Fixed, 95% CI)

-0.40 [-1.08, 0.28]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.38 [-1.02, 0.27]

Std. Mean Difference (IV, Random,
95% CI)

-1.09 [-1.83, -0.35]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.18 [-0.96, 0.60]

Std. Mean Difference (IV, Random,
95% CI)

-0.59 [-1.29, 0.11]

Std. Mean Difference (IV, Random,
95% CI)

-0.01 [-0.81, 0.79]

Std. Mean Difference (IV, Random,
95% CI)

Subtotals only

Std. Mean Difference (IV, Random,
95% CI)

-0.17 [-0.81, 0.47]

Std. Mean Difference (IV, Random,
95% CI)

-0.68 [-1.51, 0.15]

Risk Ratio (M-H, Random, 95% CI)

0.90 [0.56, 1.47]

33

33

199

33

57

33

24

190

24

210

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

354

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.1.   Comparison 6: Psychodynamic psychotherapy vs
TAU, Outcome 1: Primary: BPD symptom severity (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.1.1 End of treatment
Amianto 2011 (1)
Gregory 2008b (2)
Leichsenring 2016 (3)
Reneses 2013 (4)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.06; Chi² = 4.83, df = 3 (P = 0.18); I² = 38%
Test for overall effect: Z = 1.50 (P = 0.13)

3.3
38.4
19.41
19.1

3.3
33.6
18.76
13

16
10
64
18
108

1
12.4
8.6
7.9

1.1
8.62
9.38
6.9

17
13
58
26
114

20.5%
15.3%
41.2%
23.0%
100.0%

0.00 [-0.68 , 0.68]
-0.44 [-1.28 , 0.39]
-0.07 [-0.43 , 0.28]
-0.82 [-1.45 , -0.19]
-0.29 [-0.66 , 0.09]

6.1.2 6-12 months follow-up
Amianto 2011 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.88 (P = 0.38)

3.1

1

16
16

3.4

0.9

17
17

100.0%
100.0%

-0.31 [-1.00 , 0.38]
-0.31 [-1.00 , 0.38]

Footnotes
(1) Clinician rated: CGI-BPD
(2) BEST (SR)
(3) Self rated: Borderline Personality Inventory
(4) Clinician rated: ZAN-BPD

-2
Favours Psychodynamic

-4

0

2

4
Favours TAU

Analysis 6.2.   Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 2: Primary: self-harm (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

6.2.1 End of treatment
Amianto 2011 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.35 (P = 0.73)

2.2

6.2.2 6-12 months follow-up
Amianto 2011 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.40 (P = 0.69)

0.4

2.8

0.8

16
16

16
16

Footnotes
(1) self-harming incidents

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.9

2

17
17

100.0%
100.0%

0.12 [-0.56 , 0.80]
0.12 [-0.56 , 0.80]

0.3

0.6

17
17

100.0%
100.0%

0.14 [-0.55 , 0.82]
0.14 [-0.55 , 0.82]

-4

-2

0

Favours Psychodynamic

2
Favours TAU

4

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

355

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.3.   Comparison 6: Psychodynamic psychotherapy vs
TAU, Outcome 3: Primary: suicide-related outcomes (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.3.1 End of treatment
Amianto 2011 (1)
Gregory 2008b (2)
Reneses 2013 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.16, df = 2 (P = 0.92); I² = 0%
Test for overall effect: Z = 1.11 (P = 0.27)

1.4
0.32
0.9

0.7
0.64
1.2

16
11
18
45

1.5
0.44
1.3

0.8
0.55
1.3

17
13
26
56

33.4%
24.0%
42.6%
100.0%

-0.13 [-0.81 , 0.55]
-0.20 [-1.00 , 0.61]
-0.31 [-0.92 , 0.29]
-0.22 [-0.62 , 0.17]

6.3.2 6-12 months follow-up
Amianto 2011 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.08 (P = 0.28)

1.4

0.6

16
16

1.7

0.9

17
17

100.0%
100.0%

-0.38 [-1.07 , 0.31]
-0.38 [-1.07 , 0.31]

Footnotes
(1) CGI-BPD, suicidality and self-damaging acts (CR)
(2) LPC - parasuicides per last 3 months
(3) Clinician rated: LSASI
(4) Clinician rated: CGI-BPD, suicidality and self-damaging acts

-2

-1

0

1

2

Favours Psychodynamic

Favours TAU

Analysis 6.4.   Comparison 6: Psychodynamic psychotherapy vs
TAU, Outcome 4: Primary: psychosocial functioning (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.4.1 End of treatment
Amianto 2011 (1)
Gregory 2008b (2)
Reneses 2013 (3)
Salzer 2014 (4)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.57; Chi² = 35.63, df = 3 (P < 0.00001); I² = 92%
Test for overall effect: Z = 1.06 (P = 0.29)

-66.4
6.9
27.6
-51.82

-65.9
-9.7
35.4
-65

11.2
8.1
8.9
9.84

16
11
18
17
62

13
6.7
10.8
6.82

17
13
26
22
78

25.6%
23.3%
25.9%
25.3%
100.0%

0.04 [-0.64 , 0.72]
-2.17 [-3.22 , -1.13]
0.76 [0.14 , 1.38]
-1.56 [-2.29 , -0.83]
-0.69 [-1.98 , 0.59]

6.4.2 6-12 months follow-up
Amianto 2011 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.13 (P = 0.89)

-65.6

13.4

6.4.3 Above 12 months follow-up
-14.3
Gregory 2008b (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.78 (P = 0.44)

8.7

16
16

8
8

-66.2

11.9

17
17

100.0%
100.0%

0.05 [-0.64 , 0.73]
0.05 [-0.64 , 0.73]

-10.6

9

8
8

100.0%
100.0%

-0.40 [-1.39 , 0.60]
-0.40 [-1.39 , 0.60]

Footnotes
(1) Clinician rated: GAF
(2) SPS - "How many days were you paid for working in the past 30 days?") (SR)
(3) Self reported: SAS-SR (higher scores indicate poorer functioning)
(4) GAF (CR)

-4 -2
Favours Psychodynamic

0

4

2
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

356

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.5.   Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome 5: Secondary: anger (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

6.5.1 End of treatment
Amianto 2011 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)

2.6

6.5.2 6-12 months follow-up
Amianto 2011 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)

2.4

1.1

1.3

16
16

16
16

Footnotes
(1) Clinician rated: CGI-BPD – anger reaction
(2) Clinician rated: CGI-BPD

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

2.6

1.4

17
17

100.0%
100.0%

0.00 [-0.86 , 0.86]
0.00 [-0.86 , 0.86]

2.4

1.3

17
17

100.0%
100.0%

0.00 [-0.89 , 0.89]
0.00 [-0.89 , 0.89]

-2
Favours Psychodynamic

-4

0

2
4
Favours TAU

Analysis 6.6.   Comparison 6: Psychodynamic psychotherapy vs
TAU, Outcome 6: Secondary: affective instability (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.6.1 End of treatment
Amianto 2011 (1)
Reneses 2013 (2)
Salzer 2014 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.62, df = 2 (P = 0.73); I² = 0%
Test for overall effect: Z = 2.62 (P = 0.009)

2.2
1.9
4.71

0.9
1.2
3.35

16
18
17
51

2.9
2.6
5.55

1.4
1
2.26

17
26
22
65

28.7%
36.8%
34.5%
100.0%

-0.58 [-1.28 , 0.12]
-0.63 [-1.25 , -0.02]
-0.30 [-0.93 , 0.34]
-0.50 [-0.87 , -0.13]

6.6.2 6-12 months follow-up
Amianto 2011 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.46 (P = 0.15)

2.1

1.1

16
16

2.8

1.5

17
17

100.0%
100.0%

-0.52 [-1.21 , 0.18]
-0.52 [-1.21 , 0.18]

Footnotes
(1) Clinician rated: CGI-BPD, affective instability
(2) Clinician rated: ZAN-BPD, affective instability
(3) Strengths and Difficulties Questionnaire - emotional problems (SR)

-2
Favours Psychodynamic

-4

0

4
2
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

357

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.7.   Comparison 6: Psychodynamic psychotherapy vs TAU,
Outcome 7: Secondary: chronic feelings of emptiness (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.7.1 End of treatment
Amianto 2011 (1)
Reneses 2013 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 1.32, df = 1 (P = 0.25); I² = 24%
Test for overall effect: Z = 1.83 (P = 0.07)

16
18
34

2.6
1.8

1.1
1.3

2.8
2.7

0.8
1.1

17
26
43

46.4%
53.6%
100.0%

-0.20 [-0.89 , 0.48]
-0.75 [-1.37 , -0.12]
-0.49 [-1.02 , 0.04]

6.7.2 6-12 months follow-up
Amianto 2011 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.64 (P = 0.10)

2.2

1.1

16
16

2.8

0.9

17
17

100.0%
100.0%

-0.58 [-1.28 , 0.11]
-0.58 [-1.28 , 0.11]

Footnotes
(1) Clinician rated: CGI-BPD
(2) Clinician rated: Zan-BPD, feeling of emptiness
(3) Clinician rated: CGI-BPD, emptiness

Favours Psychodynamic

-4 -2 0

4

2
Favours TAU

Analysis 6.8.   Comparison 6: Psychodynamic psychotherapy
vs TAU, Outcome 8: Secondary: impulsivity (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.8.1 End of treatment
Amianto 2011 (1)
Reneses 2013 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.62, df = 1 (P = 0.43); I² = 0%
Test for overall effect: Z = 1.67 (P = 0.09)

16
18
34

1.8
1.6

1.1
1.3

2
2.3

1
1.2

17
26
43

44.5%
55.5%
100.0%

-0.19 [-0.87 , 0.50]
-0.55 [-1.17 , 0.06]
-0.39 [-0.85 , 0.07]

6.8.2 6-12 months follow-up
Amianto 2011 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.00 (P = 0.32)

2.3

0.5

16
16

2.1

0.6

17
17

100.0%
100.0%

0.35 [-0.34 , 1.04]
0.35 [-0.34 , 1.04]

Footnotes
(1) Clinician rated: CGI-BPD
(2) Clinician rated: ZAN-BPD, impulsivity
(3) Clinician rated: CGI-BPD, impulsivity

-2
Favours Psychodynamic

-4

0

2

4
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

358

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.9.   Comparison 6: Psychodynamic psychotherapy vs
TAU, Outcome 9: Secondary: interpersonal problems (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.9.1 End of treatment
Amianto 2011 (1)
Leichsenring 2016 (2)
Reneses 2013 (3)
Salzer 2014 (4)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.17; Chi² = 9.46, df = 3 (P = 0.02); I² = 68%
Test for overall effect: Z = 0.83 (P = 0.41)

2.4
13.21
1.9
2.76

2.8
11.57
2.3
3.95

16
64
18
17
115

1.1
4.49
1.1
1.72

1.3
5.37
0.9
1.86

17
58
26
22
123

21.8%
31.4%
24.0%
22.8%
100.0%

-0.32 [-1.01 , 0.36]
0.33 [-0.03 , 0.69]
-0.40 [-1.01 , 0.21]
-0.65 [-1.30 , 0.00]
-0.21 [-0.71 , 0.29]

6.9.2 6-12 months follow-up
Amianto 2011 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.43 (P = 0.15)

2.2

1.1

16
16

2.8

1.2

17
17

100.0%
100.0%

-0.51 [-1.20 , 0.19]
-0.51 [-1.20 , 0.19]

Footnotes
(1) Clinician rated: CGI-BPD, disturbed relationships
(2) IIP-64 (SR)
(3) Clinician rated: ZAN-BPD, disturbed relationships
(4) Strengths and Difficulties Questionnaire - problems in relationships (SR)

-4

-2

0

2

4

Favours Psychodynamic

Favours TAU

Analysis 6.10.   Comparison 6: Psychodynamic psychotherapy
vs TAU, Outcome 10: Secondary: abandonment (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

6.10.1 End of treatment
Amianto 2011 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.52 (P = 0.60)

2.4

1.1

6.10.2 6-12 months follow-up
Amianto 2011 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.15 (P = 0.25)

2.3

1

16
16

16
16

Footnotes
(1) Clinician rated: CGI-BPD
(2) Clinician rated: CGI-BPD, fear of abandoment

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

2.6

1.1

17
17

100.0%
100.0%

-0.20 [-0.95 , 0.55]
-0.20 [-0.95 , 0.55]

2.7

1

17
17

100.0%
100.0%

-0.40 [-1.08 , 0.28]
-0.40 [-1.08 , 0.28]

-4
Favours Psychodynamic

-2

0

2

4

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

359

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.11.   Comparison 6: Psychodynamic psychotherapy vs
TAU, Outcome 11: Secondary: identity disturbance (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.11.1 End of treatment
Amianto 2011 (1)
Leichsenring 2016 (2)
Reneses 2013 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.24; Chi² = 8.06, df = 2 (P = 0.02); I² = 75%
Test for overall effect: Z = 1.15 (P = 0.25)

2.2
4.45
2

3.2
4.28
2.3

16
64
18
98

0.1
2.9
1.2

1.2
2.91
1.1

17
58
26
101

28.2%
39.6%
32.2%
100.0%

-1.13 [-1.87 , -0.39]
0.06 [-0.30 , 0.41]
-0.26 [-0.86 , 0.35]
-0.38 [-1.02 , 0.27]

6.11.2 6-12 months follow-up
Amianto 2011 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.90 (P = 0.004)

2

1.2

Footnotes
(1) Clinician rated: CGI-BPD identity distortion
(2) Self reported: BPI
(3) Clinician rated: Zan-BPD, identity
(4) Clinician rated: CGI-BPD, identity distortion

3.4

1.3

16
16

17
17

100.0%
100.0%

-1.09 [-1.83 , -0.35]
-1.09 [-1.83 , -0.35]

-10
Favours Psychodynamic

-5

0

5

10
Favours TAU

Analysis 6.12.   Comparison 6: Psychodynamic psychotherapy vs TAU, Outcome
12: Secondary: dissociation and psychotic-like symptoms (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.12.1 End of treatment
Amianto 2011 (1)
Gregory 2008b (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.17; Chi² = 2.14, df = 1 (P = 0.14); I² = 53%
Test for overall effect: Z = 0.44 (P = 0.66)

1.6
27.7

0.9
21.4

2.3
22.3

16
11
27

1.5
20.6

17
13
30

53.4%
46.6%
100.0%

-0.55 [-1.25 , 0.15]
0.25 [-0.56 , 1.06]
-0.18 [-0.96 , 0.60]

6.12.2 6-12 months follow-up
Amianto 2011 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.64 (P = 0.10)

1.4

1

6.12.3 Above 12 months follow-up
28.4
Gregory 2008b (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.02 (P = 0.98)

28.9

16
16

11
11

Footnotes
(1) Clinician rated: CGI-BPD dissociative symptoms
(2) DES (SR)
(3) Clinician rated: CGI-BPD, dissociative symptoms
(4) Self rated: DES

2.1

1.3

17
17

100.0%
100.0%

-0.59 [-1.29 , 0.11]
-0.59 [-1.29 , 0.11]

28.6

18.7

13
13

100.0%
100.0%

-0.01 [-0.81 , 0.79]
-0.01 [-0.81 , 0.79]

-2
Favours Psychodynamic

-4

0

2

4
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

360

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 6.13.   Comparison 6: Psychodynamic psychotherapy
vs TAU, Outcome 13: Secondary: depression (continuous)

Study or Subgroup

Mean

Psychodynamic
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

6.13.1 End of treatment
Gregory 2008b (1)
Leichsenring 2016 (2)
Reneses 2013 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.23; Chi² = 7.42, df = 2 (P = 0.02); I² = 73%
Test for overall effect: Z = 0.52 (P = 0.61)

11.4
10.75
13.2

21
27.95
15.9

25.1
24.39
22.8

11
64
18
93

6.4
11.21
11.2

13
58
26
97

26.6%
40.7%
32.7%
100.0%

-0.44 [-1.25 , 0.38]
0.32 [-0.04 , 0.68]
-0.56 [-1.18 , 0.05]
-0.17 [-0.81 , 0.47]

6.13.2 Above 12 months follow-up
16
Gregory 2008b (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.61 (P = 0.11)

11.5

Footnotes
(1) BDI (SR)
(2) Clinician rated: BDI
(3) Clinician rated: MADRS
(4) Self rated: BDI

23.8

10.6

11
11

13
13

100.0%
100.0%

-0.68 [-1.51 , 0.15]
-0.68 [-1.51 , 0.15]

-4 -2
Favours Psychodynamic

0

4

2
Favours TAU

Analysis 6.14.   Comparison 6: Psychodynamic psychotherapy vs TAU,
Outcome 14: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Psychodynamic
Total
Events

TAU

Events

Total

Weight

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Amianto 2011
Leichsenring 2016 (1)
Reneses 2013

1
19
3

17
64
25

1
19
4

18
58
28

3.3%
84.7%
12.1%

1.06 [0.07 , 15.62]
0.91 [0.53 , 1.54]
0.84 [0.21 , 3.39]

106

Total (95% CI)
23
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 2 (P = 0.99); I² = 0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable

24

104

100.0%

0.90 [0.56 , 1.47]

0.001

0.1
Favours Psychodynamic

1

10

1000

Favours TAU

Footnotes
(1) lost to follow-up for any reason

Comparison 7.   Schema-focused therapy (SFT) vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

7.1 Primary: BPD symptom severity (con-
tinuous), at end of treatment

7.2 Primary: psychosocial functioning (con-
tinuous), at end of treatment

1

1

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

361

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

7.3 Secondary: affective instability (contin-
uous), at end of treatment

7.4 Secondary: impulsivity (continuous), at
end of treatment

7.5 Secondary: interpersonal problems
(continuous), at end of treatment

7.6 Secondary: dissociation and psychot-
ic-like symptoms (continuous), at end of
treatment

7.7 Secondary: attrition (dichotomous), at
end of treatment

1

1

1

1

1

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Subtotals only

Subtotals only

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Analysis 7.1.   Comparison 7: Schema-focused therapy (SFT) vs TAU, Outcome
1: Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Mean

SFT
SD

Total

Mean

TAU
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Farrell 2009 (1)

18.81

9.47

16

32.75

5.9

12

-13.94 [-19.66 , -8.22]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: BSI

-50

-25
Favours SFT

0

25

50

Favours TAU

Analysis 7.2.   Comparison 7: Schema-focused therapy (SFT) vs TAU, Outcome
2: Primary: psychosocial functioning (continuous), at end of treatment

Study or Subgroup

Mean

SFT
SD

Total

Mean

TAU
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Farrell 2009 (1)

-60.5

10.17

16

-50.08

5.07

12

-10.42 [-16.17 , -4.67]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician rated: GAF

-100

-50
Favours SFT

0

50
Favours TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

362

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.3.   Comparison 7: Schema-focused therapy (SFT) vs TAU, Outcome
3: Secondary: affective instability (continuous), at end of treatment

Study or Subgroup

Mean

SFT
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Farrell 2009 (1)

5.88

3.44

16

9.83

1.12

12

-3.95 [-5.75 , -2.15]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician rated: DIB-R, affect

-10 -5
Favours SFT

0

5
10
Favours TAU

Analysis 7.4.   Comparison 7: Schema-focused therapy (SFT) vs TAU,
Outcome 4: Secondary: impulsivity (continuous), at end of treatment

Study or Subgroup

Mean

SFT
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Farrell 2009 (1)

1.56

1.37

16

5.58

2.68

12

-4.02 [-5.68 , -2.36]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician rated: DIB-R, impulses

-20

-10
Favours SFT

0

10

20

Favours TAU

Analysis 7.5.   Comparison 7: Schema-focused therapy (SFT) vs TAU, Outcome
5: Secondary: interpersonal problems (continuous), at end of treatment

Study or Subgroup

Mean

SFT
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Farrell 2009 (1)

4.88

4.02

16

12

2.8

12

-7.12 [-9.65 , -4.59]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician rated: DIB-R, interpersonal

-50

-25

0

Favours SFT

25

50
Favours TAU

Analysis 7.6.   Comparison 7: Schema-focused therapy (SFT) vs TAU, Outcome 6:
Secondary: dissociation and psychotic-like symptoms (continuous), at end of treatment

Study or Subgroup

Mean

SFT
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Farrell 2009 (1)

1.69

2.02

16

4.25

1.49

12

-2.56 [-3.86 , -1.26]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician rated: DIB-R cognition

-10

-20
Favours SFT

0

10

20
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

363

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 7.7.   Comparison 7: Schema-focused therapy (SFT) vs TAU,
Outcome 7: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

SFT

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Farrell 2009

0

16

4

16

0.11 [0.01 , 1.91]

Test for subgroup differences: Not applicable

0.001

0.1
Favours SFT

1

10

1000

Favours TAU

Comparison 8.   Systems training for emotional predictability and problem solving (STEPPS) vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

8.1 Primary: BPD symptom severity
(continuous), at end of treatment

8.1.1 End of treatment

8.1.2 6-12 months follow-up

8.2 Primary: self-harm (dichtomous), at
end of treatment

8.3 Primary: psychosocial functioning
(continuous)

8.3.1 End of treatment

8.3.2 6-12 months follow-up

8.4 Secondary: affective instability
(continuous), at end of treatment

8.5 Secondary: impulsivity (continu-
ous), at end of treatment

8.6 Secondary: impulsivity (dichoto-
mous), at end of treatment

8.7 Secondary: interpersonal problems
(continuous), at end of treatment

8.8 Secondary: dissociation and psy-
chotic-like symptoms (continuous), at
end of treatment

8.9 Secondary: depression (continu-
ous), at end of treatment

3

3

1

1

1

1

1

2

1

1

2

1

1

273

124

124

124

221

177

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.39 [-0.63,
-0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.03 [-0.33, 0.38]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

-7.00 [-11.43,
-2.57]

Mean Difference (IV, Fixed,
95% CI)

-5.90 [-12.49,
0.69]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.25 [-0.52, 0.02]

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Risk Ratio (IV, Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-0.67,
-0.08]

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

364

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

8.9.1 End of treatment

8.9.2 6-12 months follow-up

8.10 Secondary: attrition (dichoto-
mous), at end of treatment

1

1

1

124

124

Mean Difference (IV, Fixed,
95% CI)

-3.80 [-9.34, 1.74]

Mean Difference (IV, Fixed,
95% CI)

0.60 [-8.42, 9.62]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Analysis 8.1.   Comparison 8: Systems training for emotional predictability and problem solving
(STEPPS) vs TAU, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Mean

STEPPS
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

8.1.1 End of treatment
Blum 2008 (1)
Bos 2010 (2)
Schuppert 2012 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.11, df = 2 (P = 0.58); I² = 0%
Test for overall effect: Z = 3.18 (P = 0.001)

8.0623
25.8
9.53

9.8
79.7
13.29

65
26
48
139

13.4
95.1
15.39

7.6811
29.1
9

59
26
49
134

45.2%
18.7%
36.1%
100.0%

-0.45 [-0.81 , -0.10]
-0.55 [-1.11 , 0.00]
-0.22 [-0.62 , 0.17]
-0.39 [-0.63 , -0.15]

8.1.2 6-12 months follow-up
Blum 2008 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.15 (P = 0.88)

33

18.5432

Footnotes
(1) Zan-BPD - total (CR)
(2) Self reported: BPD-40
(3) BPDSI-IV total
(4) BEST - total (CR)

32.4

26.1159

65
65

59
59

100.0%
100.0%

0.03 [-0.33 , 0.38]
0.03 [-0.33 , 0.38]

-2
-1
Favours STEPPS

0

1

2

Favours TAU

Analysis 8.2.   Comparison 8: Systems training for emotional predictability and problem
solving (STEPPS) vs TAU, Outcome 2: Primary: self-harm (dichtomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

STEPPS

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Bos 2010 (1)

16

28

13

30

1.32 [0.78 , 2.22]

Test for subgroup differences: Not applicable

Footnotes
(1) participants scoring above BPDSI-IV-parasuicide cut-off score

0.01
Favours STEPPS

0.1

1

10
Favours TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

365

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.3.   Comparison 8: Systems training for emotional predictability and problem
solving (STEPPS) vs TAU, Outcome 3: Primary: psychosocial functioning (continuous)

Study or Subgroup

Mean

STEPPS
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

8.3.1 End of treatment
Blum 2008 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.09 (P = 0.002)

-50.5

12.8996

8.3.2 6-12 months follow-up
Blum 2008 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.76 (P = 0.08)

-53

16.1245

65
65

65
65

-43.5

12.2898

59
59

100.0%
100.0%

-7.00 [-11.43 , -2.57]
-7.00 [-11.43 , -2.57]

-47.1

20.7391

59
59

100.0%
100.0%

-5.90 [-12.49 , 0.69]
-5.90 [-12.49 , 0.69]

Footnotes
(1) GAS (CR)

-50

-25

0

Favours STEPPS

25

50
Favours TAU

Analysis 8.4.   Comparison 8: Systems training for emotional predictability and problem solving
(STEPPS) vs TAU, Outcome 4: Secondary: affective instability (continuous), at end of treatment

Study or Subgroup

Mean

STEPPS
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Blum 2008 (1)
Schuppert 2012 (2)

3.9
3.88

3.2249
2.37

65
48

4.9
4.29

3.0725
2.48

59
49

55.8%
44.2%

-0.32 [-0.67 , 0.04]
-0.17 [-0.57 , 0.23]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.29, df = 1 (P = 0.59); I² = 0%
Test for overall effect: Z = 1.85 (P = 0.06)
Test for subgroup differences: Not applicable

113

Footnotes
(1) ZAN-BPD - affective instability (CR)
(2) BPDS-IV - affective instability

108

100.0%

-0.25 [-0.52 , 0.02]

-2

-1

0

1

2

Favours STEPPS

Favours TAU

Analysis 8.5.   Comparison 8: Systems training for emotional predictability and problem
solving (STEPPS) vs TAU, Outcome 5: Secondary: impulsivity (continuous), at end of treatment

Study or Subgroup

Mean

STEPPS
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Blum 2008 (1)

1.9

2.4187

65

2.3

2.3043

59

-0.40 [-1.23 , 0.43]

Test for subgroup differences: Not applicable

Footnotes
(1) Zan-BPD - impulsivity subscale

-2
Favours STEPPS

-4

0

2
4
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

366

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.6.   Comparison 8: Systems training for emotional predictability and problem solving
(STEPPS) vs TAU, Outcome 6: Secondary: impulsivity (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

STEPPS

TAU

Risk Ratio
IV, Fixed, 95% CI

Risk Ratio
IV, Fixed, 95% CI

Bos 2010 (1)

19

28

22

30

0.93 [0.66 , 1.29]

Test for subgroup differences: Not applicable

Footnotes
(1) participants scoring above BPDSI-IV-impulsivity cut-off score

0.02

0.1

1

Favours STEPPS

50
10
Favours TAU

Analysis 8.7.   Comparison 8: Systems training for emotional predictability and problem solving
(STEPPS) vs TAU, Outcome 7: Secondary: interpersonal problems (continuous), at end of treatment

Study or Subgroup

Mean

STEPPS
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Blum 2008 (1)
Bos 2010 (2)

2.2
-13

2.4187
3.5

65
27

3.2
-12

2.3043
3.7

59
26

69.8%
30.2%

-0.42 [-0.78 , -0.06]
-0.27 [-0.81 , 0.27]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.20, df = 1 (P = 0.66); I² = 0%
Test for overall effect: Z = 2.48 (P = 0.01)
Test for subgroup differences: Not applicable

92

Footnotes
(1) ZAN-BPD - disturbed relationships (CR)
(2) Self reported: WHOQOL-Bref, social relationships

85

100.0%

-0.38 [-0.67 , -0.08]

-4

-2

0

2

4

Favours STEPPS

Favours TAU

Analysis 8.8.   Comparison 8: Systems training for emotional predictability and problem solving (STEPPS)
vs TAU, Outcome 8: Secondary: dissociation and psychotic-like symptoms (continuous), at end of treatment

Study or Subgroup

Mean

STEPPS
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Blum 2008 (1)

2

2.4187

65

3

2.3043

59

-1.00 [-1.83 , -0.17]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinical rated: ZAN-BPD, cognitive subscale

-10
Favours STEPPS

-5

0

5
Favours TAU

10

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

367

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 8.9.   Comparison 8: Systems training for emotional predictability and problem
solving (STEPPS) vs TAU, Outcome 9: Secondary: depression (continuous), at end of treatment

Study or Subgroup

Mean

STEPPS
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

8.9.1 End of treatment
Blum 2008 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.34 (P = 0.18)

22

16.1245

8.9.2 6-12 months follow-up
Blum 2008 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.13 (P = 0.90)

24

20.9619

65
65

65
65

25.8

15.3623

59
59

100.0%
100.0%

-3.80 [-9.34 , 1.74]
-3.80 [-9.34 , 1.74]

23.4

29.1884

59
59

100.0%
100.0%

0.60 [-8.42 , 9.62]
0.60 [-8.42 , 9.62]

Footnotes
(1) Self reported: BDI

-100
Favours STEPPS

-50

0

50
Favours TAU

100

Analysis 8.10.   Comparison 8: Systems training for emotional predictability and problem
solving (STEPPS) vs TAU, Outcome 10: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

STEPPS

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Bos 2010

10

42

6

37

1.47 [0.59 , 3.65]

0.1
0.001
Favours STEPPS

1

10

1000

Favours TAU

Comparison 9.   Cognitive analytic therapy (CAT) vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

9.1 Primary: suicide-related out-
comes (continuous)

9.1.1 End of treatment

9.1.2 0-6 months follow-up

9.2 Primary: psychosocial func-
tioning (continuous)

9.2.1 End of treatment

9.2.2 0-6 months follow-up

1

1

1

1

1

1

9

8

9

9

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

-1.40 [-4.21, 1.41]

Mean Difference (IV, Fixed, 95%
CI)

-0.50 [-2.05, 1.05]

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

-16.40 [-31.20,
-1.60]

Mean Difference (IV, Fixed, 95%
CI)

-15.80 [-29.36,
-2.24]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

368

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

9.3 Secondary: anger (continu-
ous)

9.3.1 End of treatment

9.3.2 0-6 months follow-up

9.4 Secondary: dissociation and
psychotic-like symptoms (con-
tinuous)

9.4.1 End of treatment

9.4.2 0-6 months follow-up

9.5 Secondary: depression (con-
tinuous)

9.5.1 End of treatment

9.5.2 0-6 months follow-up

9.6 Secondary: attrition (di-
chotomous), at end of treat-
ment

1

1

1

1

1

1

1

1

1

1

9

8

9

9

9

8

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

-1.90 [-7.97, 4.17]

Mean Difference (IV, Fixed, 95%
CI)

-4.50 [-9.01, 0.01]

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

-6.10 [-15.01, 2.81]

Mean Difference (IV, Fixed, 95%
CI)

-11.70 [-24.02, 0.62]

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

-9.70 [-20.10, 0.70]

Mean Difference (IV, Fixed, 95%
CI)

-3.70 [-11.99, 4.59]

Risk Ratio (M-H, Fixed, 95% CI)

Subtotals only

Analysis 9.1.   Comparison 9: Cognitive analytic therapy (CAT) vs
TAU, Outcome 1: Primary: suicide-related outcomes (continuous)

Study or Subgroup

Mean

CAT
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

9.1.1 End of treatment
Gleeson 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.98 (P = 0.33)

0.8

1

9.1.2 0-6 months follow-up
Gleeson 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.63 (P = 0.53)

0.3

0.5

4
4

4
4

Footnotes
(1) OAS-M - suicidality (CR)

2.2

3

5
5

100.0%
100.0%

-1.40 [-4.21 , 1.41]
-1.40 [-4.21 , 1.41]

0.8

1.5

4
4

100.0%
100.0%

-0.50 [-2.05 , 1.05]
-0.50 [-2.05 , 1.05]

-20

-10

0

10

20

Favours CAT

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

369

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.2.   Comparison 9: Cognitive analytic therapy (CAT) vs
TAU, Outcome 2: Primary: psychosocial functioning (continuous)

Study or Subgroup

Mean

CAT
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

9.2.1 End of treatment
Gleeson 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.17 (P = 0.03)

-67

9.2.2 0-6 months follow-up
Gleeson 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.28 (P = 0.02)

-69.3

8.3

4.3

4
4

4
4

Footnotes
(1) SOFAS (CR)

-50.6

14.1

5
5

100.0%
100.0%

-16.40 [-31.20 , -1.60]
-16.40 [-31.20 , -1.60]

-53.5

14.7

5
5

100.0%
100.0%

-15.80 [-29.36 , -2.24]
-15.80 [-29.36 , -2.24]

-100

-50
Favours CAT

0

50
Favours TAU

100

Analysis 9.3.   Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome 3: Secondary: anger (continuous)

Study or Subgroup

Mean

CAT
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

9.3.1 End of treatment
Gleeson 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.61 (P = 0.54)

13.3

9.3.2 0-6 months follow-up
Gleeson 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.95 (P = 0.05)

10

5.4

2.6

4
4

4
4

Footnotes
(1) AIAQ - labile anger (SR)

15.2

3.4

5
5

100.0%
100.0%

-1.90 [-7.97 , 4.17]
-1.90 [-7.97 , 4.17]

14.5

3.8

4
4

100.0%
100.0%

-4.50 [-9.01 , 0.01]
-4.50 [-9.01 , 0.01]

-100

-50
Favours CAT

0

50
Favours TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

370

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 9.4.   Comparison 9: Cognitive analytic therapy (CAT) vs TAU, Outcome
4: Secondary: dissociation and psychotic-like symptoms (continuous)

Study or Subgroup

Mean

CAT
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

9.4.1 End of treatment
Gleeson 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.34 (P = 0.18)

43.5

9.4.2 0-6 months follow-up
Gleeson 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.86 (P = 0.06)

33.8

6.5

6.4

4
4

4
4

Footnotes
(1) BPRS (CR)

49.6

7.1

5
5

100.0%
100.0%

-6.10 [-15.01 , 2.81]
-6.10 [-15.01 , 2.81]

45.5

12.1

5
5

100.0%
100.0%

-11.70 [-24.02 , 0.62]
-11.70 [-24.02 , 0.62]

-100

-50
Favours CAT

0

50
Favours TAU

100

Analysis 9.5.   Comparison 9: Cognitive analytic therapy (CAT)
vs TAU, Outcome 5: Secondary: depression (continuous)

Study or Subgroup

Mean

CAT
SD

Total

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

9.5.1 End of treatment
Gleeson 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.83 (P = 0.07)

12.3

8

9.5.2 0-6 months follow-up
Gleeson 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.87 (P = 0.38)

10.8

4.6

4
4

4
4

Footnotes
(1) MADRS (CR)

22

7.8

5
5

100.0%
100.0%

-9.70 [-20.10 , 0.70]
-9.70 [-20.10 , 0.70]

14.5

7.1

4
4

100.0%
100.0%

-3.70 [-11.99 , 4.59]
-3.70 [-11.99 , 4.59]

-100

-50
Favours CAT

0

50
Favours TAU

100

Analysis 9.6.   Comparison 9: Cognitive analytic therapy (CAT) vs TAU,
Outcome 6: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

CAT

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Gleeson 2012

4

8

3

8

1.33 [0.43 , 4.13]

Test for subgroup differences: Not applicable

0.001

0.1
Favours CAT

1

10

1000

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

371

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comparison 10.   Motivation feedback (MF) vs TAU

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

10.1 Primary: psychosocial functioning, at
end of treatment

1

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Analysis 10.1.   Comparison 10: Motivation feedback (MF) vs TAU,
Outcome 1: Primary: psychosocial functioning, at end of treatment

Study or Subgroup

Mean

MF
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Jochems 2015 (1)

12.8

6.36

16

13.22

5.8

27

-0.42 [-4.23 , 3.39]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician-rated: HoNOS

Comparison 11.   Psychoeducation vs TAU

-20

-10
Favours MF

0

10

20

Favours TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

11.1 Secondary: depression (continuous),
at end of treatment

11.2 Secondary: attrition (dichotomous),
at end of treatment

1

1

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Odds Ratio (M-H, Fixed,
95% CI)

Subtotals only

Analysis 11.1.   Comparison 11: Psychoeducation vs TAU, Outcome
1: Secondary: depression (continuous), at end of treatment

Study or Subgroup

Psychoeducation
SD

Total

Mean

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Zanarini 2018 (1)

24.18

16.15

39

31.21

16.62

38

-7.03 [-14.35 , 0.29]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: The Clinically Useful Depression Outcome Scale, total score

-100

-50

0

Favours Psychoeducation

50
Favours TAU

100

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

372

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 11.2.   Comparison 11: Psychoeducation vs TAU, Outcome
2: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Psychoeducation
Total
Events

TAU

Events

Total

Odds Ratio
M-H, Fixed, 95% CI

Odds Ratio
M-H, Fixed, 95% CI

Zanarini 2018

1

40

2

40

0.49 [0.04 , 5.60]

Test for subgroup differences: Not applicable

0.001

0.1
Favours Psychoeducation

1

10

1000

Favours TAU

Comparison 12.   Transference-focused psychotherapy (TFP) vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

12.1 Primary: BPD symptom severity (con-
tinuous), at end of treatment

12.2 Primary: self-harm (dichotomous), at
end of treatment

12.3 Primary: suicide-related outcomes (di-
chotomous), at end of treatment

12.4 Primary: psychosocial functioning
(continuous), at end of treatment

12.5 Secondary: depression (continuous),
at end of treatment

12.6 Secondary: attrition (dichotomous), at
end of treatment

1

1

1

1

1

1

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Analysis 12.1.   Comparison 12: Transference-focused psychotherapy (TFP) vs TAU,
Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Mean

TFP
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Doering 2010 (1)

4.79

1.54

52

5.63

1.47

52

-0.84 [-1.42 , -0.26]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician-rated: Mean number of DSM-IV BPD criteria met

-4 -2
Favours TFP

0

4

2
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

373

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.2.   Comparison 12: Transference-focused psychotherapy (TFP)
vs TAU, Outcome 2: Primary: self-harm (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

TFP

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Doering 2010 (1)

38

52

35

52

1.09 [0.84 , 1.40]

Test for subgroup differences: Not applicable

Footnotes
(1) CISSB - participants with self-harming behaviour (last 12 months) (SR)

0.1 0.2

0.5
Favours TFP

1

5

10
2
Favours TAU

Analysis 12.3.   Comparison 12: Transference-focused psychotherapy (TFP) vs TAU,
Outcome 3: Primary: suicide-related outcomes (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

TFP

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Doering 2010 (1)

7

51

11

52

0.65 [0.27 , 1.54]

Test for subgroup differences: Not applicable

Footnotes
(1) CISSB - participants with suicide attempts (last 12 months) (SR)

0.01

0.1
Favours TFP

1

10
Favours TAU

100

Analysis 12.4.   Comparison 12: Transference-focused psychotherapy (TFP) vs TAU,
Outcome 4: Primary: psychosocial functioning (continuous), at end of treatment

Study or Subgroup

Mean

TFP
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Doering 2010 (1)

-58.62

8.04

52

-56.06

6.87

52

-2.56 [-5.43 , 0.31]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician-rated: GAF

-10

-20
Favours TFP

0

10

20

Favours TAU

Analysis 12.5.   Comparison 12: Transference-focused psychotherapy (TFP)
vs TAU, Outcome 5: Secondary: depression (continuous), at end of treatment

Study or Subgroup

Mean

TFP
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Doering 2010 (1)

21.67

13.25

52

20.02

13.22

52

1.65 [-3.44 , 6.74]

Test for subgroup differences: Not applicable

Footnotes
(1) Self-rated: BDI

-20

-10
Favours TFP

0

10

20

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

374

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 12.6.   Comparison 12: Transference-focused psychotherapy (TFP)
vs TAU, Outcome 6: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

TFP

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Doering 2010

20

52

35

52

0.57 [0.39 , 0.85]

Test for subgroup differences: Not applicable

0.02

0.1
Favours TFP

1

10
Favours TAU

50

Comparison 13.   Once-only interventions (individual setting) vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

13.1 Primary: self-harm (continuous), at
end of treatment

13.2 Primary: psychosocial functioning
(continuous), at end of treatment

13.3 Secondary: depression (continuous),
at end of treatment

13.4 Secondary: attrition (dichotomous),
at end of treatment

1

1

1

1

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Analysis 13.1.   Comparison 13: Once-only interventions (individual setting)
vs TAU, Outcome 1: Primary: self-harm (continuous), at end of treatment

Study or Subgroup

Mean

Once only
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Borschmann 2013 (1)

20.6

89.71

36

20

55.6

36

0.60 [-33.88 , 35.08]

Test for subgroup differences: Not applicable

Footnotes
(1) SHQ - number of suicidal and self-injurious episodes (past 6 months) (SR)

-200 -100
Favours once only

0

100 200
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

375

 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 13.2.   Comparison 13: Once-only interventions (individual setting) vs TAU,
Outcome 2: Primary: psychosocial functioning (continuous), at end of treatment

Study or Subgroup

Mean

Once only
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Borschmann 2013 (1)

26.06

7.98

36

25.81

8.94

36

0.25 [-3.66 , 4.16]

Test for subgroup differences: Not applicable

Footnotes
(1) WSAS (SR)

-20 -10
Favours once only

0

10 20
Favours TAU

Analysis 13.3.   Comparison 13: Once-only interventions (individual setting)
vs TAU, Outcome 3: Secondary: depression (continuous), at end of treatment

Study or Subgroup

Mean

Once only
SD

Total

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Borschmann 2013 (1)

10.47

3.54

36

10.2

4.96

36

0.27 [-1.72 , 2.26]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: HADS, depression

-10
Favours once only

-5

0

5

10

Favours TAU

Analysis 13.4.   Comparison 13: Once-only interventions (individual setting)
vs TAU, Outcome 4: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

Once only

TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Borschmann 2013

9

46

6

42

1.37 [0.53 , 3.52]

Test for subgroup differences: Not applicable

0.005
Favours once only

0.1

1

10

200

Favours TAU

Comparison 14.   Eclectic treatments vs TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

14.1 Primary: BPD symptom severity
(continuous), at end of treatment

14.2 Primary: self-harm (continuous), at
end of treatment

14.3 Primary: suicide-related outcomes
(continuous), at end of treatment

14.4 Primary: psychosocial functioning
(continuous)

3

2

2

2

134

83

221

Std. Mean Difference (IV,
Random, 95% CI)

-0.90 [-1.57,
-0.23]

Std. Mean Difference (IV,
Random, 95% CI)

-0.84 [-1.29,
-0.39]

Std. Mean Difference (IV,
Random, 95% CI)

-0.55 [-1.29, 0.19]

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

376

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

14.4.1 End of treatment

14.4.2 Above 12 months follow-up

14.5 Secondary: anger (continuous), at
end of treatment

14.6 Secondary: affective instability
(continuous), at end of treatment

14.7 Secondary: chronic feelings of
emptiness (continuous), at end of treat-
ment

14.8 Secondary: impulsivity (continu-
ous), at end of treatment

14.9 Secondary: interpersonal problems
(continuous), at end of treatment

14.10 Secondary: abandonment (contin-
uous), at end of treatment

14.11 Secondary: identity disturbance
(continuous), at end of treatment

14.12 Secondary: depression (continu-
ous), at end of treatment

14.13 Secondary: attrition (dichotomu-
ous), at end of treatment

14.14 Secondary: adverse effects (di-
chotomous), at end of treatment

2

1

1

3

1

3

2

1

1

4

4

1

231

170

134

134

112

304

326

Std. Mean Difference (IV,
Random, 95% CI)

-0.57 [-1.10,
-0.04]

Std. Mean Difference (IV,
Random, 95% CI)

-0.64 [-1.04,
-0.24]

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

-0.95 [-1.74,
-0.15]

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

-0.76 [-1.30,
-0.22]

Std. Mean Difference (IV,
Random, 95% CI)

-0.62 [-1.09,
-0.15]

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

-0.82 [-1.38,
-0.26]

Risk Ratio (M-H, Random,
95% CI)

1.06 [0.85, 1.32]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

377

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.1.   Comparison 14: Eclectic treatments vs TAU, Outcome
1: Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Gratz 2006 (1)
Gratz 2014 (1)
Leppänen 2016 (2)

25.83
27.47
17.54

5.72
6.59
10.14

12
31
19

34.7
35.88
21.48

10.81
5.59
11.41

10
30
32

26.2%
37.1%
36.7%

-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.35 [-0.93 , 0.22]

Total (95% CI)
Heterogeneity: Tau² = 0.23; Chi² = 6.11, df = 2 (P = 0.05); I² = 67%
Test for overall effect: Z = 2.64 (P = 0.008)
Test for subgroup differences: Not applicable

62

Footnotes
(1) BEST (SR)
(2) Clinician-rated: BPDSI-IV

72

100.0%

-0.90 [-1.57 , -0.23]

-10

-5

0

Favours Eclectic

5

10
Favours TAU

Analysis 14.2.   Comparison 14: Eclectic treatments vs TAU,
Outcome 2: Primary: self-harm (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Gratz 2006 (1)
Gratz 2014 (1)

2.05
0.69

0.93
0.35

12
31

4.48
0.97

3.39
0.35

10
30

25.3%
74.7%

-0.98 [-1.88 , -0.09]
-0.79 [-1.31 , -0.27]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.13, df = 1 (P = 0.71); I² = 0%
Test for overall effect: Z = 3.64 (P = 0.0003)
Test for subgroup differences: Not applicable

43

40

100.0%

-0.84 [-1.29 , -0.39]

-4 -2
Favours Eclectic

0

4

2
Favours TAU

Footnotes
(1) DSHI (SR)

Study or Subgroup

Analysis 14.3.   Comparison 14: Eclectic treatments vs TAU, Outcome 3:
Primary: suicide-related outcomes (continuous), at end of treatment

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Andreoli 2016 (1)
Leppänen 2016 (2)

0.35
0.41

0.6082
0.49

140
19

1
0.51

1.1
0.76

30
32

53.6%
46.4%

-0.90 [-1.31 , -0.50]
-0.15 [-0.71 , 0.42]

Total (95% CI)
Heterogeneity: Tau² = 0.22; Chi² = 4.49, df = 1 (P = 0.03); I² = 78%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable

159

Footnotes
(1) Episode of suicidal ideation, with or without deliberate self-harm
(2) BPDSI-IV - Parasuicidality, suicide plans and attempts (CR)

62

100.0%

-0.55 [-1.29 , 0.19]

-4 -2 0

Favours Eclectic

4

2
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

378

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.4.   Comparison 14: Eclectic treatments vs TAU,
Outcome 4: Primary: psychosocial functioning (continuous)

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

14.4.1 End of treatment
Andreoli 2016 (1)
Gratz 2014 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.09; Chi² = 2.70, df = 1 (P = 0.10); I² = 63%
Test for overall effect: Z = 2.12 (P = 0.03)

6.2343
6.24

-62.95
14.25

140
31
171

-57.6
16.01

7.6
6.24

30
30
60

54.0%
46.0%
100.0%

-0.82 [-1.22 , -0.42]
-0.28 [-0.78 , 0.23]
-0.57 [-1.10 , -0.04]

14.4.2 Above 12 months follow-up
-65.6
Andreoli 2016 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.12 (P = 0.002)

11.6

Footnotes
(1) Clinician rated: GAS
(2) Self rated: SDS

-58.1

12.3

140
140

30
30

100.0%
100.0%

-0.64 [-1.04 , -0.24]
-0.64 [-1.04 , -0.24]

-4
Favours Eclectic

-2

0

2

4

Favours TAU

Analysis 14.5.   Comparison 14: Eclectic treatments vs TAU,
Outcome 5: Secondary: anger (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Leppänen 2016 (1)

0.8

1.3

19

1.27

1.52

32

-0.47 [-1.26 , 0.32]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician-rated: BPDSI-IV, anger

-2
Favours Eclectic

-4

0

4
2
Favours TAU

Analysis 14.6.   Comparison 14: Eclectic treatments vs TAU, Outcome
6: Secondary: affective instability (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Gratz 2006 (1)
Gratz 2014 (1)
Leppänen 2016 (2)

79.75
95.27
5.65

23.97
15.6
2.83

12
31
19

115.8
113.62
6.26

16.74
15.6
2.65

10
30
32

26.4%
37.1%
36.5%

-1.65 [-2.65 , -0.65]
-1.16 [-1.71 , -0.62]
-0.22 [-0.79 , 0.35]

Total (95% CI)
Heterogeneity: Tau² = 0.37; Chi² = 8.41, df = 2 (P = 0.01); I² = 76%
Test for overall effect: Z = 2.33 (P = 0.02)
Test for subgroup differences: Not applicable

62

Footnotes
(1) DERS - total (SR)
(2) Clinician-rated: BPDSI-IV, affective instability

72

100.0%

-0.95 [-1.74 , -0.15]

-10
Favours Eclectic

-5

0

5

10

Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

379

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.7.   Comparison 14: Eclectic treatments vs TAU, Outcome 7:
Secondary: chronic feelings of emptiness (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Leppänen 2016 (1)

3.55

3.24

19

4.14

3.31

32

-0.59 [-2.44 , 1.26]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician-rated: BPDSI-IV, emptiness

-10

-5

0

5

10

Favours Eclectic

Favours TAU

Analysis 14.8.   Comparison 14: Eclectic treatments vs TAU, Outcome
8: Secondary: impulsivity (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Gratz 2006 (1)
Gratz 2014 (1)
Leppänen 2016 (2)

10.92
15.23
0.99

3.85
3.83
0.76

12
31
19

17.1
18.74
1.22

5.34
3.83
0.81

10
30
32

22.0%
40.2%
37.8%

-1.30 [-2.24 , -0.36]
-0.90 [-1.43 , -0.38]
-0.29 [-0.86 , 0.28]

Total (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 4.14, df = 2 (P = 0.13); I² = 52%
Test for overall effect: Z = 2.74 (P = 0.006)
Test for subgroup differences: Not applicable

62

Footnotes
(1) DERS-impulse (SR)
(2) Clinician-rated: BPDSI-IV, impulsivity

72

100.0%

-0.76 [-1.30 , -0.22]

-10
Favours Eclectic

-5

0

5

10

Favours TAU

Analysis 14.9.   Comparison 14: Eclectic treatments vs TAU, Outcome 9:
Secondary: interpersonal problems (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Gratz 2014 (1)
Leppänen 2016 (2)

1.45
1.01

0.57
0.72

31
19

1.94
1.34

0.57
0.97

30
32

52.9%
47.1%

-0.85 [-1.37 , -0.32]
-0.37 [-0.94 , 0.21]

Total (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 1.48, df = 1 (P = 0.22); I² = 32%
Test for overall effect: Z = 2.58 (P = 0.010)
Test for subgroup differences: Not applicable

50

Footnotes
(1) IIP-BPD (SR)
(2) Clinician-rated: BPDSI-IV, unstable relationships

62

100.0%

-0.62 [-1.09 , -0.15]

-4 -2
Favours Eclectic

0

4

2
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

380

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.10.   Comparison 14: Eclectic treatments vs TAU, Outcome
10: Secondary: abandonment (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Leppänen 2016 (1)

1.42

1.39

19

1.88

1.97

32

-0.46 [-1.39 , 0.47]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician-rated: BPDSI-IV, abandonment

-4
-2
Favours Eclectic

0

2

4
Favours TAU

Analysis 14.11.   Comparison 14: Eclectic treatments vs TAU, Outcome
11: Secondary: identity disturbance (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Leppänen 2016 (1)

2.17

1.78

19

3.02

2.06

32

-0.85 [-1.92 , 0.22]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician-rated: BPDSI-IV, identity disturbance

-10
Favours Eclectic

-5

0

5

10

Favours TAU

Analysis 14.12.   Comparison 14: Eclectic treatments vs TAU, Outcome
12: Secondary: depression (continuous), at end of treatment

Study or Subgroup

Andreoli 2016 (1)
Gratz 2006 (2)
Gratz 2014 (2)
Leppänen 2016 (3)

Eclectic treatments
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

9.95
9
13.04
1.55

5.6912
6.52
5.63
1.7

140
12
31
19

13.4
23.2
21.3
1.84

6.4
15.32
5.63
1.45

30
10
30
32

30.1%
18.0%
26.0%
26.0%

-0.59 [-0.99 , -0.19]
-1.20 [-2.13 , -0.28]
-1.45 [-2.02 , -0.88]
-0.18 [-0.75 , 0.38]

Total (95% CI)
Heterogeneity: Tau² = 0.23; Chi² = 11.13, df = 3 (P = 0.01); I² = 73%
Test for overall effect: Z = 2.87 (P = 0.004)
Test for subgroup differences: Not applicable

202

Footnotes
(1) Clinician rated: HDRS-17
(2) DASS-Depression (SR)
(3) Clinician-rated: BPDSI-IV, paranoid ideation

102

100.0%

-0.82 [-1.38 , -0.26]

-4 -2 0

Favours Eclectic

4

2
Favours TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

381

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 14.13.   Comparison 14: Eclectic treatments vs TAU, Outcome
13: Secondary: attrition (dichotomuous), at end of treatment

Study or Subgroup

Eclectic treatments
Total
Events

TAU

Events

Total

Weight

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Andreoli 2016
Gratz 2006
Gratz 2014
Leppänen 2016

17
1
26
20

140
13
31
24

2
1
27
32

30
11
30
47

2.4%
0.7%
55.9%
41.0%

1.82 [0.44 , 7.47]
0.85 [0.06 , 12.01]
0.93 [0.77 , 1.13]
1.22 [0.94 , 1.60]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.01; Chi² = 3.99, df = 3 (P = 0.26); I² = 25%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable

208

62

64

118

100.0%

1.06 [0.85 , 1.32]

0.01
Favours Eclectic

0.1

1

10
Favours TAU

100

Analysis 14.14.   Comparison 14: Eclectic treatments vs TAU, Outcome
14: Secondary: adverse effects (dichotomous), at end of treatment

Study or Subgroup

Eclectic treatments
Total
Events

TAU

Events

Total

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Andreoli 2016

1

140

0

30

0.66 [0.03 , 15.81]

Test for subgroup differences: Not applicable

0.001

0.1
Favours Eclectic

1

10

1000

Favours TAU

Comparison 15.   Psychotherapy vs waiting list or no treatment

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

15.1 Primary: BPD symptom severity
(continuous), at end of treatment

15.2 Primary: self-harm (continuous),
at end of treatment

15.3 Primary: suicide-related out-
comes (continuous), at end of treat-
ment

15.4 Primary: psychosocial function-
ing (continuous)

15.4.1 End of treatment

15.4.2 0-6 months follow-up

15.4.3 6-12 months follow-up

3

2

2

5

5

1

1

161

128

108

219

30

30

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.49 [-0.93,
-0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.17 [-0.52, 0.18]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-5.62 [-16.39,
5.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.56 [-1.01,
-0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.89 [-1.65,
-0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.04 [-1.81,
-0.27]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

382

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

15.4.4 Above 12 months follow-up

15.5 Secondary: anger (continuous),
at end of treatment

15.6 Secondary: affective instability
(continuous)

15.6.1 End of treatment

15.6.2 0-6 months follow-up

15.6.3 6-12 months follow-up

15.6.4 Above 12 months follow-up

15.7 Secondary: chronic feelings of
emptiness (continuous), at end of
treatment

15.8 Secondary: impulsivity (continu-
ous)

15.8.1 End of treatment

15.8.2 0-6 months follow-up

15.8.3 6-12 months follow-up

15.8.4 Above 12 months follow-up

15.9 Secondary: interpersonal prob-
lems (continuous)

15.9.1 End of treatment

15.9.2 0-6 months follow-up

15.9.3 6-12 months follow-up

15.9.4 Above 12 months follow-up

1

2

2

2

1

1

1

1

3

3

1

1

1

3

3

1

1

1

28

128

128

30

30

30

178

30

30

30

120

30

30

30

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-1.14, 0.37]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.58 [-1.70, 0.55]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.99 [-1.36,
-0.62]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.47 [-1.20, 0.26]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-1.10, 0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-1.01, 0.44]

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.52 [-0.82,
-0.22]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.90 [-1.66,
-0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.79 [-1.54,
-0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.75 [-1.50,
-0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.85 [-1.23,
-0.47]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.40 [-2.21,
-0.59]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.90 [-1.66,
-0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.86 [-1.62,
-0.11]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

383

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

15.10 Secondary: abandonment (con-
tinuous), at end of treatment

15.11 Secondary: identity distur-
bance (continuous), at end of treat-
ment

15.12 Secondary: dissociation and
psychotic-like symptoms (continu-
ous), at end of treatment

15.13 Secondary: depression (contin-
uous), at end of treatment

15.14 Secondary: attrition (dichoto-
mous), at end of treatment

1

1

2

6

3

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.65, 0.39]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.28 [-2.21,
-0.34]

Risk Ratio (M-H, Random, 95%
CI)

0.55 [0.20, 1.50]

77

239

144

Analysis 15.1.   Comparison 15: Psychotherapy vs waiting list or no treatment,
Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Bellino 2010 (1)
Bohus 2013 (2)
McMain 2017 (3)

33.27
3.24
33.72

5.96
2.14
18.7

22
17
42

33.46
4.62
48.48

5.95
1.67
22.21

22
16
42

31.8%
25.6%
42.6%

-0.03 [-0.62 , 0.56]
-0.70 [-1.40 , 0.01]
-0.71 [-1.15 , -0.27]

Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 3.60, df = 2 (P = 0.17); I² = 44%
Test for overall effect: Z = 2.19 (P = 0.03)
Test for subgroup differences: Not applicable

81

80

100.0%

-0.49 [-0.93 , -0.05]

-2
Favours Psychotherapies

-4

0

4

2
Favours Waiting list

Footnotes
(1) Clinician-rated: BPDSI-IV
(2) IPDE-BPD criteria (CR)
(3) Self rated: BSL

Analysis 15.2.   Comparison 15: Psychotherapy vs waiting list or no
treatment, Outcome 2: Primary: self-harm (continuous), at end of treatment

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Bellino 2010 (1)
McMain 2017 (2)

2.02
1.14

1.92
3.26

22
42

1.99
2.59

1.87
6.9

22
42

34.6%
65.4%

0.02 [-0.58 , 0.61]
-0.27 [-0.70 , 0.16]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.57, df = 1 (P = 0.45); I² = 0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable

64

Footnotes
(1) Clinician rated: BPDSI-IV, parasuicidal behaviour
(2) Self rated: DSHI

64

100.0%

-0.17 [-0.52 , 0.18]

-2

-1

0

1

2

Favours Psychotherapies

Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

384

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.3.   Comparison 15: Psychotherapy vs waiting list or no treatment,
Outcome 3: Primary: suicide-related outcomes (continuous), at end of treatment

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list/no treatment
Total
SD
Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

McMain 2017 (1)
Mohamadizadeh 2017 (2)

1.14
15.25

3.26
1.65

42
12

2.59
31

6.9
0.96

42
12

51.4%
48.6%

-0.27 [-0.70 , 0.16]
-11.27 [-14.84 , -7.69]

Total (95% CI)
Heterogeneity: Tau² = 58.81; Chi² = 35.82, df = 1 (P < 0.00001); I² = 97%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable

54

54

100.0%

-5.62 [-16.39 , 5.16]

Favours Psychotherapies

Favours WL/NT

-20 -10 0 10 20

Footnotes
(1) Self rated: DSHI
(2) Self rated: BSS

Study or Subgroup

Analysis 15.4.   Comparison 15: Psychotherapy vs waiting list or no
treatment, Outcome 4: Primary: psychosocial functioning (continuous)

Psychotherapies
SD

Total

Mean

Waiting list
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

15.4.1 End of treatment
Bellino 2006 (1)
Bellino 2010 (2)
Bohus 2013 (3)
Haeyen 2018 (4)
McMain 2017 (5)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.15; Chi² = 9.75, df = 4 (P = 0.04); I² = 59%
Test for overall effect: Z = 2.44 (P = 0.01)

3
4.35
-40.88
64.91
2.88

2.9
4.37
-47.88
46.27
2.5

16
22
17
15
42
112

0.9
0.49
7.8
9.77
0.56

0.7
0.48
6.64
17.42
0.59

16
22
16
11
42
107

19.0%
21.7%
18.2%
15.0%
26.1%
100.0%

-0.12 [-0.81 , 0.57]
0.04 [-0.55 , 0.63]
-0.94 [-1.66 , -0.22]
-1.34 [-2.21 , -0.47]
-0.65 [-1.09 , -0.22]
-0.56 [-1.01 , -0.11]

15.4.2 0-6 months follow-up
Bellino 2010 (6)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.31 (P = 0.02)

-67.99

14.45

15.4.3 6-12 months follow-up
Bellino 2010 (6)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.65 (P = 0.008)

-70.12

13.2

15.4.4 Above 12 months follow-up
-70
Bellino 2010 (6)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.99 (P = 0.32)

13.1

Footnotes
(1) Clinician rated: CGI-S
(2) Observer rated:CGI-S
(3) Clinician rated: GAF
(4) Self reported: OQ45, total score
(5) Self rated: SAS-SR
(6) SAT-P social functioning

16
16

16
16

16
16

-55.6

12.4

14
14

100.0%
100.0%

-0.89 [-1.65 , -0.13]
-0.89 [-1.65 , -0.13]

-56.53

12.1

14
14

100.0%
100.0%

-1.04 [-1.81 , -0.27]
-1.04 [-1.81 , -0.27]

-55.32

55.32

12
12

100.0%
100.0%

-0.38 [-1.14 , 0.37]
-0.38 [-1.14 , 0.37]

-4
Favours Psychotherapies

-2

0

2

4

Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

385

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.5.   Comparison 15: Psychotherapy vs waiting list or no
treatment, Outcome 5: Secondary: anger (continuous), at end of treatment

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Bellino 2010 (1)
McMain 2017 (2)

5.26
29.73

0.71
9.27

22
42

5.25
41.18

0.69
10.68

22
42

48.7%
51.3%

0.01 [-0.58 , 0.60]
-1.13 [-1.60 , -0.67]

Total (95% CI)
Heterogeneity: Tau² = 0.59; Chi² = 9.00, df = 1 (P = 0.003); I² = 89%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable

64

Footnotes
(1) Observer rated: BPDSI-IV, anger
(2) Self rated: STAXI, trait anger

64

100.0%

-0.58 [-1.70 , 0.55]

-4

-2

0

Favours Psychotherapies

2

4
Favours Waiting list

Analysis 15.6.   Comparison 15: Psychotherapy vs waiting list or no
treatment, Outcome 6: Secondary: affective instability (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

15.6.1 End of treatment
Bellino 2010 (1)
McMain 2017 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.07, df = 1 (P = 0.79); I² = 0%
Test for overall effect: Z = 5.25 (P < 0.00001)

5.61
106.55

1.18
20.22

22
42
64

6.63
126.7

0.99
18.76

22
42
64

34.8%
65.2%
100.0%

-0.92 [-1.54 , -0.30]
-1.02 [-1.48 , -0.57]
-0.99 [-1.36 , -0.62]

15.6.2 0-6 months follow-up
Bellino 2010 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.26 (P = 0.21)

5.96

0.9

15.6.3 6-12 months follow-up
Bellino 2010 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.03 (P = 0.30)

5.99

0.88

15.6.4 Above 12 months follow-up
6.06
Bellino 2010 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.77 (P = 0.44)

1.22

Footnotes
(1) Observer rated: BPDSI-IV, affective instability
(2) Self rated: DERS
(3) Observer rated: BPDSI-IV affective instability

16
16

16
16

16
16

6.42

1.01

14
14

100.0%
100.0%

-0.47 [-1.20 , 0.26]
-0.47 [-1.20 , 0.26]

6.38

1.12

14
14

100.0%
100.0%

-0.38 [-1.10 , 0.34]
-0.38 [-1.10 , 0.34]

6.4

1.1

14
14

100.0%
100.0%

-0.28 [-1.01 , 0.44]
-0.28 [-1.01 , 0.44]

-2
Favours Psychotherapies

-4

0

4

2
Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

386

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.7.   Comparison 15: Psychotherapy vs waiting list or no treatment,
Outcome 7: Secondary: chronic feelings of emptiness (continuous), at end of treatment

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean

Mean Difference
IV, Fixed, 95% CI

Bellino 2010 (1)

7.16

0.42

22

7.12

0.43

22

0.04 [-0.21 , 0.29]

Test for subgroup differences: Not applicable

Footnotes
(1) Observer rated: BPDSI-IV, chronic feelings of emptiness

Favours Psychotherapies

-1 -0.5 0

1

0.5
Favours Waiting list

Analysis 15.8.   Comparison 15: Psychotherapy vs waiting list or
no treatment, Outcome 8: Secondary: impulsivity (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

15.8.1 End of treatment
Bellino 2010 (1)
McMain 2017 (2)
Zanarini 2008 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.98, df = 2 (P = 0.37); I² = 0%
Test for overall effect: Z = 3.40 (P = 0.0007)

5.23
52.79
-0.43

1.11
9.72
0.94

22
42
30
94

6.26
56.2
0.05

1.12
8.54
1.1

22
42
20
84

23.4%
48.9%
27.7%
100.0%

-0.91 [-1.53 , -0.28]
-0.37 [-0.80 , 0.06]
-0.47 [-1.04 , 0.10]
-0.52 [-0.82 , -0.22]

15.8.2 0-6 months follow-up
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.33 (P = 0.02)

5.1

1.21

15.8.3 6-12 months follow-up
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.08 (P = 0.04)

4.95

1.45

15.8.4 Above 12 months follow-up
4.89
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.98 (P = 0.05)

1.52

16
16

16
16

16
16

6.2

1.16

14
14

100.0%
100.0%

-0.90 [-1.66 , -0.14]
-0.90 [-1.66 , -0.14]

6.05

1.22

14
14

100.0%
100.0%

-0.79 [-1.54 , -0.04]
-0.79 [-1.54 , -0.04]

5.98

1.26

14
14

100.0%
100.0%

-0.75 [-1.50 , -0.01]
-0.75 [-1.50 , -0.01]

Footnotes
(1) Observer rated: BPDSI-V - impulsivity
(2) Self rated: BIS-11
(3) ZAN-BPD-impulsivity (effects calculated from baseline-to-endpoint change scores)

-2
Favours Psychotherapies

-4

0

4

2
Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

387

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.9.   Comparison 15: Psychotherapy vs waiting list or no
treatment, Outcome 9: Secondary: interpersonal problems (continuous)

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

15.9.1 End of treatment
Bellino 2010 (1)
Haeyen 2018 (2)
Zanarini 2008 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.50, df = 2 (P = 0.78); I² = 0%
Test for overall effect: Z = 4.39 (P < 0.0001)

5.83
14.2
-0.93

1.42
3.03
0.94

22
15
30
67

6.97
19.09
-0.05

1.3
5.52
1.43

22
11
20
53

37.8%
20.2%
42.0%
100.0%

-0.82 [-1.44 , -0.20]
-1.11 [-1.96 , -0.27]
-0.75 [-1.33 , -0.16]
-0.85 [-1.23 , -0.47]

15.9.2 0-6 months follow-up
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.38 (P = 0.0007)

5.03

1.51

15.9.3 6-12 months follow-up
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.32 (P = 0.02)

5.45

1.99

15.9.4 Above 12 months follow-up
5.72
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.24 (P = 0.02)

2.01

16
16

16
16

16
16

7.03

1.24

14
14

100.0%
100.0%

-1.40 [-2.21 , -0.59]
-1.40 [-2.21 , -0.59]

7.01

1.26

14
14

100.0%
100.0%

-0.90 [-1.66 , -0.14]
-0.90 [-1.66 , -0.14]

7.2

1.15

14
14

100.0%
100.0%

-0.86 [-1.62 , -0.11]
-0.86 [-1.62 , -0.11]

Footnotes
(1) Observer rated: BPDS-IV interpersonal relationships
(2) Self reported: OQ45, interpersonal relations
(3) Zan-BPD - stormy relatioships (effect based on baseline-to-endpoint change scores)

-4
Favours Psychotherapies

-2

0

2

4

Favours Waiting list

Analysis 15.10.   Comparison 15: Psychotherapy vs waiting list or no treatment,
Outcome 10: Secondary: abandonment (continuous), at end of treatment

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean

Mean Difference
IV, Fixed, 95% CI

Bellino 2010 (1)

6.11

1.57

22

6.1

1.52

22

0.01 [-0.90 , 0.92]

Test for subgroup differences: Not applicable

Footnotes
(1) Observer rated: BPDSI-IV abandonment

-2
Favours Psychotherapies

-4

0

4

2
Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

388

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.11.   Comparison 15: Psychotherapy vs waiting list or no treatment,
Outcome 11: Secondary: identity disturbance (continuous), at end of treatment

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean

Mean Difference
IV, Fixed, 95% CI

Bellino 2010 (1)

2.46

0.9

22

2.49

0.88

22

-0.03 [-0.56 , 0.50]

Test for subgroup differences: Not applicable

Footnotes
(1) Observer rated: BPDSI-IV identity disturbance

-4

-2

0

2

4

Favours Psychotherapies

Favours Waiting list

Analysis 15.12.   Comparison 15: Psychotherapy vs waiting list or no treatment, Outcome
12: Secondary: dissociation and psychotic-like symptoms (continuous), at end of treatment

Study or Subgroup

Psychotherapies
SD

Total

Mean

Waiting list
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Bellino 2010 (1)
Bohus 2013 (2)

4.32
24.35

2.11
14.79

22
17

4.09
30.8

2.24
14.68

22
16

55.9%
44.1%

0.10 [-0.49 , 0.70]
-0.43 [-1.12 , 0.26]

Total (95% CI)
Heterogeneity: Tau² = 0.03; Chi² = 1.31, df = 1 (P = 0.25); I² = 24%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable

39

Footnotes
(1) Observer rated: BPDSI-IV paranoid ideation
(2) Self rated: DES

38

100.0%

-0.13 [-0.65 , 0.39]

-2
Favours Psychotherapies

-4

0

4

2
Favours Waiting list

Analysis 15.13.   Comparison 15: Psychotherapy vs waiting list or no treatment,
Outcome 13: Secondary: depression (continuous), at end of treatment

Study or Subgroup

Bellino 2006 (1)
Bellino 2010 (2)
Bohus 2013 (3)
McMain 2017 (3)
Mohamadizadeh 2017 (4)
Smith 2012 (1)

Psychotherapies
SD

Total

Mean

Waiting list/no treatment
Total
SD
Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

9.1
10.75
25.32
22.76
24.16
18.7

3
1.5
11.79
12.55
2.7
6.2

16
22
17
42
12
15

12
10.82
41.75
29.73
53.75
23.3

3.3
1.53
9.31
13.5
2.13
3.4

16
22
16
42
12
7

18.9%
19.7%
18.6%
20.4%
4.8%
17.6%

-0.90 [-1.63 , -0.16]
-0.05 [-0.64 , 0.55]
-1.50 [-2.29 , -0.72]
-0.53 [-0.97 , -0.09]
-11.75 [-15.47 , -8.03]
-0.80 [-1.74 , 0.13]

Total (95% CI)
Heterogeneity: Tau² = 1.06; Chi² = 43.48, df = 5 (P < 0.00001); I² = 89%
Test for overall effect: Z = 2.68 (P = 0.007)
Test for subgroup differences: Not applicable

124

115

100.0%

-1.28 [-2.21 , -0.34]

-4

-2

0

Favours Psychotherapies

2

4
Favours WL/NT

Footnotes
(1) Ham-D (CR)
(2) Observer rated: Ham-D
(3) Self rated: BDI-II
(4) Self rated: BDI

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

389

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 15.14.   Comparison 15: Psychotherapy vs waiting list or no treatment,
Outcome 14: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Psychotherapies
Total
Events

Waiting list

Events

Total

Weight

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Bellino 2006
Bellino 2010
Zanarini 2008 (1)

3
2
0

19
27
30

4
6
0

55.3%
44.7%

20
28
20

0.79 [0.20 , 3.07]
0.35 [0.08 , 1.57]
Not estimable

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.64, df = 1 (P = 0.42); I² = 0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable

10

76

5

68

100.0%

0.55 [0.20 , 1.50]

0.001

0.1
Favours Psychotherapies

1

10

1000

Favours Waiting list

Footnotes
(1) all participants attended all visits, no drop-outs

Comparison 16.   Dialectical behavior therapy (DBT) vs waiting list or no treatment

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

16.1 Primary: BPD symptom severity (con-
tinuous), at end of treatment

16.2 Primary: self-harm (continuous), at
end of treatment

16.3 Primary: suicide-related outcomes
(continuous), at end of treatment

16.4 Primary: psychosocial functioning
(continuous), at end of treatment

16.5 Secondary: anger (continuous), at end
of treatment

16.6 Secondary: affective instability (con-
tinuous), at end of treatment

16.7 Secondary: impulsivity (continuous),
at end of treatment

16.8 Secondary: dissociation and psychot-
ic-like symptoms (continuous), at end of
treatment

16.9 Secondary: depression (continuous),
at end of treatment

16.10 DBT-couple therapy (CDBT) vs wait-
ing list (generic inverse variance)

16.10.1 Primary: BPD severity (continuous),
at end of treatment

2

1

2

2

1

1

1

1

3

1

1

117

108

117

Std. Mean Difference (IV,
Random, 95% CI)

-0.71 [-1.08,
-0.33]

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

-5.62 [-16.39,
5.16]

Std. Mean Difference (IV,
Random, 95% CI)

-0.73 [-1.11,
-0.36]

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Subtotals only

Subtotals only

Subtotals only

141

Std. Mean Difference (IV,
Random, 95% CI)

-3.20 [-5.57,
-0.83]

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

-27.15 [-31.59,
-22.71]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

390

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

16.10.2 Primary: suicide-related outcomes
(continuous), at end of treatment

16.10.3 Primary: psychosocial functioning
(continuous), at end of treatment

16.10.4 Secondary: anger (continuous), at
end of treatment

16.10.5 Secondary: affective instability
(continuous), at end of treatment

16.10.6 Secondary: chronic feelings of
emptiness (continuous), at end of treat-
ment

16.10.7 Secondary: impulsivity (continu-
ous), at end of treatment

16.10.8 Secondary: interpersonal problems
(continuous), at end of treatment

16.10.9 Secondary: abandonment (contin-
uous), at end of treatment

16.10.10 Secondary: identity disturbance
(continuous), at end of treatment

16.10.11 Secondary: dissociation or psy-
chotic-like symptoms (continuous), at end
of treatment

16.10.12 Secondary: depression (continu-
ous), at end of treatment

1

1

1

1

1

1

1

1

1

1

1

Mean Difference (IV,
Fixed, 95% CI)

-0.94 [-1.24,
-0.64]

Mean Difference (IV,
Fixed, 95% CI)

-10.70 [-12.31,
-9.09]

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

-1.42 [-1.72,
-1.12]

-4.01 [-5.44,
-2.58]

-3.54 [-4.81,
-2.27]

-0.51 [-0.72,
-0.30]

-1.98 [-2.47,
-1.49]

-0.86 [-1.09,
-0.63]

-2.44 [-2.77,
-2.11]

-1.92 [-2.46,
-1.38]

Mean Difference (IV,
Fixed, 95% CI)

-10.43 [-11.86,
-9.00]

Analysis 16.1.   Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no
treatment, Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

Waiting list
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Bohus 2013 (1)
McMain 2017 (2)

3.24
33.72

2.14
18.7

17
42

4.62
48.48

1.67
22.21

16
42

28.1%
71.9%

-0.70 [-1.40 , 0.01]
-0.71 [-1.15 , -0.27]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.97); I² = 0%
Test for overall effect: Z = 3.71 (P = 0.0002)
Test for subgroup differences: Not applicable

59

Footnotes
(1) IPDE-BPD criteria (CR)
(2) Self rated: BSL

58

100.0%

-0.71 [-1.08 , -0.33]

-4 -2
Favours DBT

0

4

2
Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

391

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.2.   Comparison 16: Dialectical behavior therapy (DBT) vs waiting list
or no treatment, Outcome 2: Primary: self-harm (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

McMain 2017 (1)

1.14

3.26

42

2.59

6.9

42

-1.45 [-3.76 , 0.86]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: DSHI

-10

-5

0

5

10

Favours DBT

Favours Waiting list

Analysis 16.3.   Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no
treatment, Outcome 3: Primary: suicide-related outcomes (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Waiting list/no treatment
Total
SD
Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

McMain 2017 (1)
Mohamadizadeh 2017 (2)

1.14
15.25

3.26
1.65

42
12

2.59
31

6.9
0.96

42
12

51.4%
48.6%

-0.27 [-0.70 , 0.16]
-11.27 [-14.84 , -7.69]

Total (95% CI)
Heterogeneity: Tau² = 58.81; Chi² = 35.82, df = 1 (P < 0.00001); I² = 97%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable

54

54

100.0%

-5.62 [-16.39 , 5.16]

-25

-50
Favours DBT

0

25

50

Favours WL/NT

Footnotes
(1) Clinician rated: LSASI
(2) Self reported: BSS

Analysis 16.4.   Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no
treatment, Outcome 4: Primary: psychosocial functioning (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

Waiting list
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Bohus 2013 (1)
McMain 2017 (2)

-47.88
2.5

7.8
0.56

17
42

-40.88
2.88

6.64
0.59

16
42

26.9%
73.1%

-0.94 [-1.66 , -0.22]
-0.65 [-1.09 , -0.22]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.44, df = 1 (P = 0.51); I² = 0%
Test for overall effect: Z = 3.82 (P = 0.0001)
Test for subgroup differences: Not applicable

59

58

100.0%

-0.73 [-1.11 , -0.36]

-4

-2

0

Favours DBT

2

4
Favours Waiting list

Footnotes
(1) Clinician rated: GAF
(2) Self rated: SAS-SR

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

392

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.5.   Comparison 16: Dialectical behavior therapy (DBT) vs waiting list
or no treatment, Outcome 5: Secondary: anger (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

McMain 2017 (1)

29.73

9.27

42

41.18

10.68

42

-11.45 [-15.73 , -7.17]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: STAXI, trait anger

-25

-50
Favours DBT

0

25

50

Favours Waiting list

Analysis 16.6.   Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no
treatment, Outcome 6: Secondary: affective instability (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

McMain 2017 (1)

106.55

20.22

42

126.7

18.76

42

-20.15 [-28.49 , -11.81]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: DERS

-100

-50
Favours DBT

0

50

100

Favours Waiting list

Analysis 16.7.   Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or
no treatment, Outcome 7: Secondary: impulsivity (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

McMain 2017 (1)

52.79

9.72

42

56.2

8.54

42

-3.41 [-7.32 , 0.50]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: BIS-11

-20 -10 0 10 20

Favours DBT

Favours Waiting list

Analysis 16.8.   Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment,
Outcome 8: Secondary: dissociation and psychotic-like symptoms (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Bohus 2013 (1)

24.35

14.79

17

30.8

14.68

16

-6.45 [-16.51 , 3.61]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: DES

-100

-50
Favours DBT

0

50

100

Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

393

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.9.   Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or
no treatment, Outcome 9: Secondary: depression (continuous), at end of treatment

Study or Subgroup

Mean

DBT
SD

Total

Waiting list/no treatment
Total
SD
Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Bohus 2013 (1)
McMain 2017 (1)
Mohamadizadeh 2017 (2)

25.32
22.76
24.16

11.79
12.55
2.7

17
42
12

41.75
29.73
53.75

9.31
13.5
2.13

16
42
12

39.2%
40.4%
20.4%

-1.50 [-2.29 , -0.72]
-0.53 [-0.97 , -0.09]
-11.75 [-15.47 , -8.03]

Total (95% CI)
Heterogeneity: Tau² = 3.57; Chi² = 37.66, df = 2 (P < 0.00001); I² = 95%
Test for overall effect: Z = 2.64 (P = 0.008)
Test for subgroup differences: Not applicable

71

70

100.0%

-3.20 [-5.57 , -0.83]

-20

-10
Favours DBT

0

10

20
Favours WL/NT

Footnotes
(1) Self rated: BDI-II
(2) Self rated: BDI

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

394

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 16.10.   Comparison 16: Dialectical behavior therapy (DBT) vs waiting list or no treatment, Outcome 10:
DBT-couple therapy (CDBT) vs waiting list (generic inverse variance)

Study or Subgroup

MD

SE

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

16.10.1 Primary: BPD severity (continuous), at end of treatment
Kamalabadi 2012 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 11.98 (P < 0.00001)

100.0%
100.0%

-27.15

2.267

-27.15 [-31.59 , -22.71]
-27.15 [-31.59 , -22.71]

16.10.2 Primary: suicide-related outcomes (continuous), at end of treatment
Kamalabadi 2012 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 6.06 (P < 0.00001)

100.0%
100.0%

-0.94 [-1.24 , -0.64]
-0.94 [-1.24 , -0.64]

0.155

-0.94

16.10.3 Primary: psychosocial functioning (continuous), at end of treatment
Kamalabadi 2012 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 13.03 (P < 0.00001)

100.0%
100.0%

-10.70 [-12.31 , -9.09]
-10.70 [-12.31 , -9.09]

0.821

-10.7

16.10.4 Secondary: anger (continuous), at end of treatment
Kamalabadi 2012 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 9.28 (P < 0.00001)

100.0%
100.0%

0.153

-1.42

-1.42 [-1.72 , -1.12]
-1.42 [-1.72 , -1.12]

16.10.5 Secondary: affective instability (continuous), at end of treatment
Kamalabadi 2012 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 5.48 (P < 0.00001)

100.0%
100.0%

0.732

-4.01

-4.01 [-5.44 , -2.58]
-4.01 [-5.44 , -2.58]

16.10.6 Secondary: chronic feelings of emptiness (continuous), at end of treatment
0.646
Kamalabadi 2012 (6)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 5.48 (P < 0.00001)

-3.54 [-4.81 , -2.27]
-3.54 [-4.81 , -2.27]

100.0%
100.0%

-3.54

16.10.7 Secondary: impulsivity (continuous), at end of treatment
Kamalabadi 2012 (7)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.68 (P < 0.00001)

100.0%
100.0%

0.109

-0.51

-0.51 [-0.72 , -0.30]
-0.51 [-0.72 , -0.30]

16.10.8 Secondary: interpersonal problems (continuous), at end of treatment
Kamalabadi 2012 (8)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 7.98 (P < 0.00001)

100.0%
100.0%

-1.98 [-2.47 , -1.49]
-1.98 [-2.47 , -1.49]

0.248

-1.98

16.10.9 Secondary: abandonment (continuous), at end of treatment
Kamalabadi 2012 (9)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 7.48 (P < 0.00001)

100.0%
100.0%

0.115

-0.86

-0.86 [-1.09 , -0.63]
-0.86 [-1.09 , -0.63]

16.10.10 Secondary: identity disturbance (continuous), at end of treatment

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

395

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 16.10.   (Continued)

Cochrane Database of Systematic Reviews

16.10.10 Secondary: identity disturbance (continuous), at end of treatment
Kamalabadi 2012 (10)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 14.44 (P < 0.00001)

100.0%
100.0%

0.169

-2.44

-2.44 [-2.77 , -2.11]
-2.44 [-2.77 , -2.11]

16.10.11 Secondary: dissociation or psychotic-like symptoms (continuous), at end of treatment
Kamalabadi 2012 (11)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 7.03 (P < 0.00001)

-1.92 [-2.46 , -1.38]
-1.92 [-2.46 , -1.38]

100.0%
100.0%

0.273

-1.92

16.10.12 Secondary: depression (continuous), at end of treatment
Kamalabadi 2012 (12)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 14.25 (P < 0.00001)

100.0%
100.0%

-10.43

0.732

-10.43 [-11.86 , -9.00]
-10.43 [-11.86 , -9.00]

-20

-10

0

Favours CDBT

10

20
Favours Waiting list

Footnotes
(1) Observer rated: BPDSI-IV, total score
(2) Observer rated: BPDSI, parasuicidal
(3) Observer rated: GHQ, functioning
(4) Observer rated: BPDSI-IV, anger
(5) Observer rated: BPDSI-IV, affect
(6) Observer rated: BPDSI-IV, emptiness
(7) Observer rated: BPDSI-IV, impulsivity
(8) Observer rated: BPDSI, interpersonal
(9) Observer rated: BPDSI, abandonment
(10) Observer rated: BPDSI, identity
(11) Observer rated: BPDSI, dissociation
(12) Self-rated: GHQ, depression

Comparison 17.   Schema-focused therapy (SFT) vs no treatment

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

17.1 Primary: suicide-related outcomes
(continuous), at end of treatment

17.2 Secondary: depression (continuous),
at end of treatment

1

1

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

396

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 17.1.   Comparison 17: Schema-focused therapy (SFT) vs no treatment,
Outcome 1: Primary: suicide-related outcomes (continuous), at end of treatment

Study or Subgroup

Mean

SFT
SD

Total

Mean

No treatment
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Mohamadizadeh 2017 (1)

14.33

1.55

12

31

0.96

12

-16.67 [-17.70 , -15.64]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: BSS

-20

-10
Favours SFT

0

10

20

Favours no treatment

Analysis 17.2.   Comparison 17: Schema-focused therapy (SFT) vs no treatment,
Outcome 2: Secondary: depression (continuous), at end of treatment

Study or Subgroup

Mean

SFT
SD

Total

Mean

No treatment
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Mohamadizadeh 2017 (1)

19.83

1.53

12

53.75

2.13

12

-33.92 [-35.40 , -32.44]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: BDI

-50 -25
Favours SFT

0

50

25
Favours no treatment

Comparison 18.   Interpersonal psychotherapy (IPT) vs waiting list

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

18.1 Primary: BPD symptom severity
(continuous), at end of treatment

18.2 Primary: self-harm (continu-
ous), at end of treatment

18.3 Primary: psychosocial function-
ing (continuous)

18.3.1 End of treatment

18.3.2 0-6 months follow-up

18.3.3 6-12 months follow-up

18.3.4 Above 12 months follow-up

18.4 Secondary: anger (continuous),
at end of treatment

18.5 Secondary: affective instability
(continuous)

1

1

2

2

1

1

1

1

1

76

30

30

28

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.03 [-0.48, 0.42]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.89 [-1.65, -0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.04 [-1.81, -0.27]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-1.14, 0.37]

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

397

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

18.5.1 End of treatment

18.5.2 0-6 months follow-up

18.5.3 6-12 months follow-up

18.5.4 Above 12 months follow-up

18.6 Secondary: chronic feelings of
emptiness (continuous), at end of
treatment

18.7 Secondary: impulsivity (contin-
uous)

18.7.1 End of treatment

18.7.2 0-6 months follow-up

18.7.3 6-12 months follow-up

18.7.4 Above 12 months follow-up

18.8 Secondary: interpersonal prob-
lems (continuous)

18.8.1 End of treatment

18.8.2 0-6 months follow-up

18.8.3 6-12 months follow-up

18.8.4 Above 12 months follow-up

18.9 Secondary: abandonment (con-
tinuous), at end of treatment

18.10 Secondary: identity distur-
bance (continuous), at end of treat-
ment

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

44

30

30

30

44

30

30

30

44

30

30

30

Mean Difference (IV, Fixed, 95%
CI)

-1.02 [-1.66, -0.38]

Mean Difference (IV, Fixed, 95%
CI)

-0.46 [-1.15, 0.23]

Mean Difference (IV, Fixed, 95%
CI)

-0.39 [-1.12, 0.34]

Mean Difference (IV, Fixed, 95%
CI)

-0.34 [-1.17, 0.49]

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

-1.03 [-1.69, -0.37]

Mean Difference (IV, Fixed, 95%
CI)

-1.10 [-1.95, -0.25]

Mean Difference (IV, Fixed, 95%
CI)

-1.10 [-2.06, -0.14]

Mean Difference (IV, Fixed, 95%
CI)

-1.09 [-2.09, -0.09]

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

-1.14 [-1.94, -0.34]

Mean Difference (IV, Fixed, 95%
CI)

-2.00 [-2.98, -1.02]

Mean Difference (IV, Fixed, 95%
CI)

-1.56 [-2.74, -0.38]

Mean Difference (IV, Fixed, 95%
CI)

-1.48 [-2.63, -0.33]

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

398

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

18.11 Secondary: dissociation and
psychotic-like symptoms (continu-
ous), at end of treatment

18.12 Secondary outcome: depres-
sion (continuous), at end of treat-
ment

18.13 Secondary outcome: attrition
(dichotomous), at end of treatment

1

3

2

Mean Difference (IV, Fixed, 95%
CI)

Subtotals only

98

94

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.52 [-1.11, 0.06]

Risk Ratio (M-H, Random, 95%
CI)

0.55 [0.20, 1.50]

Analysis 18.1.   Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list,
Outcome 1: Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Bellino 2010 (1)

33.27

5.96

22

33.46

5.95

22

-0.19 [-3.71 , 3.33]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician rated: BPDSI-IV

-10

-20
Favours IPT

0

10

20
Favours Waiting list

Analysis 18.2.   Comparison 18: Interpersonal psychotherapy (IPT) vs waiting
list, Outcome 2: Primary: self-harm (continuous), at end of treatment

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Bellino 2010 (1)

2.02

1.92

22

1.99

1.87

22

0.03 [-1.09 , 1.15]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinician rated: BPDSI-IV, parasuicidal behaviour

-4 -2 0

Favours IPT

4

2
Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

399

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.3.   Comparison 18: Interpersonal psychotherapy (IPT) vs
waiting list, Outcome 3: Primary: psychosocial functioning (continuous)

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

18.3.1 End of treatment
Bellino 2006 (1)
Bellino 2010 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.12, df = 1 (P = 0.73); I² = 0%
Test for overall effect: Z = 0.12 (P = 0.91)

2.9
4.37

0.9
0.49

16
22
38

3
4.35

0.7
0.48

16
22
38

42.1%
57.9%
100.0%

-0.12 [-0.81 , 0.57]
0.04 [-0.55 , 0.63]
-0.03 [-0.48 , 0.42]

18.3.2 0-6 months follow-up
Bellino 2010 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.31 (P = 0.02)

-67.99

14.45

18.3.3 6-12 months follow-up
Bellino 2010 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.65 (P = 0.008)

-70.12

13.2

18.3.4 Above 12 months follow-up
-70
Bellino 2010 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.99 (P = 0.32)

13.1

Footnotes
(1) Clinician rated: CGI-S
(2) Observer rated:CGI-S
(3) SAT-P social functioning

16
16

16
16

16
16

-55.6

12.4

14
14

100.0%
100.0%

-0.89 [-1.65 , -0.13]
-0.89 [-1.65 , -0.13]

-56.53

12.1

14
14

100.0%
100.0%

-1.04 [-1.81 , -0.27]
-1.04 [-1.81 , -0.27]

-55.32

55.32

12
12

100.0%
100.0%

-0.38 [-1.14 , 0.37]
-0.38 [-1.14 , 0.37]

-10

-5

0

5

10

Favours IPT

Favours Waiting list

Analysis 18.4.   Comparison 18: Interpersonal psychotherapy (IPT) vs
waiting list, Outcome 4: Secondary: anger (continuous), at end of treatment

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Bellino 2010 (1)

5.26

0.71

22

5.25

0.69

22

0.01 [-0.40 , 0.42]

Test for subgroup differences: Not applicable

Footnotes
(1) Observer rated: BPDSI-IV, anger

-4

-2

0

2

4

Favours IPT

Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

400

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.5.   Comparison 18: Interpersonal psychotherapy (IPT) vs
waiting list, Outcome 5: Secondary: affective instability (continuous)

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

18.5.1 End of treatment
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.11 (P = 0.002)

5.61

1.18

18.5.2 0-6 months follow-up
Bellino 2010 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.31 (P = 0.19)

5.96

0.9

18.5.3 6-12 months follow-up
Bellino 2010 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.05 (P = 0.29)

5.99

0.88

18.5.4 Above 12 months follow-up
6.06
Bellino 2010 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.80 (P = 0.42)

1.22

Footnotes
(1) Observer rated: BPDSI-IV, affective instability
(2) Observer rated: BPDSI-IV affective instability

22
22

16
16

16
16

16
16

6.63

0.99

22
22

100.0%
100.0%

-1.02 [-1.66 , -0.38]
-1.02 [-1.66 , -0.38]

6.42

1.01

14
14

100.0%
100.0%

-0.46 [-1.15 , 0.23]
-0.46 [-1.15 , 0.23]

6.38

1.12

14
14

100.0%
100.0%

-0.39 [-1.12 , 0.34]
-0.39 [-1.12 , 0.34]

6.4

1.1

14
14

100.0%
100.0%

-0.34 [-1.17 , 0.49]
-0.34 [-1.17 , 0.49]

-2
-4
Favours IPT

0

4

2
Favours Waiting list

Analysis 18.6.   Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list,
Outcome 6: Secondary: chronic feelings of emptiness (continuous), at end of treatment

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Bellino 2010 (1)

7.16

0.42

22

7.12

0.43

22

0.04 [-0.21 , 0.29]

Test for subgroup differences: Not applicable

Footnotes
(1) Observer rated: BPDSI-IV, chronic feelings of emptiness

-1

-2
Favours IPT

0

1

2
Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

401

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.7.   Comparison 18: Interpersonal psychotherapy (IPT)
vs waiting list, Outcome 7: Secondary: impulsivity (continuous)

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

18.7.1 End of treatment
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.06 (P = 0.002)

5.23

1.11

18.7.2 0-6 months follow-up
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.54 (P = 0.01)

5.1

1.21

18.7.3 6-12 months follow-up
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.26 (P = 0.02)

4.95

1.45

18.7.4 Above 12 months follow-up
4.89
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.15 (P = 0.03)

1.52

Footnotes
(1) Observer rated: BPDSI-V - impulsivity

22
22

16
16

16
16

16
16

6.26

1.12

22
22

100.0%
100.0%

-1.03 [-1.69 , -0.37]
-1.03 [-1.69 , -0.37]

6.2

1.16

14
14

100.0%
100.0%

-1.10 [-1.95 , -0.25]
-1.10 [-1.95 , -0.25]

6.05

1.22

14
14

100.0%
100.0%

-1.10 [-2.06 , -0.14]
-1.10 [-2.06 , -0.14]

5.98

1.26

14
14

100.0%
100.0%

-1.09 [-2.09 , -0.09]
-1.09 [-2.09 , -0.09]

-10 -5
Favours IPT

0

10

5
Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

402

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.8.   Comparison 18: Interpersonal psychotherapy (IPT) vs
waiting list, Outcome 8: Secondary: interpersonal problems (continuous)

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

18.8.1 End of treatment
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.78 (P = 0.005)

5.83

1.42

18.8.2 0-6 months follow-up
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.98 (P < 0.0001)

5.03

1.51

18.8.3 6-12 months follow-up
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.60 (P = 0.009)

5.45

1.99

18.8.4 Above 12 months follow-up
5.72
Bellino 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.51 (P = 0.01)

2.01

22
22

16
16

16
16

16
16

6.97

1.3

22
22

100.0%
100.0%

-1.14 [-1.94 , -0.34]
-1.14 [-1.94 , -0.34]

7.03

1.24

14
14

100.0%
100.0%

-2.00 [-2.98 , -1.02]
-2.00 [-2.98 , -1.02]

7.01

1.26

14
14

100.0%
100.0%

-1.56 [-2.74 , -0.38]
-1.56 [-2.74 , -0.38]

7.2

1.15

14
14

100.0%
100.0%

-1.48 [-2.63 , -0.33]
-1.48 [-2.63 , -0.33]

Footnotes
(1) Observer rated: BPDS-IV interpersonal relationships

-20

-10
Favours IPT

0

10

20

Favours Waiting list

Analysis 18.9.   Comparison 18: Interpersonal psychotherapy (IPT) vs waiting
list, Outcome 9: Secondary: abandonment (continuous), at end of treatment

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Bellino 2010 (1)

6.11

1.57

22

6.1

1.52

22

0.01 [-0.90 , 0.92]

Test for subgroup differences: Not applicable

Footnotes
(1) Observer rated: BPDSI-IV abandonment

-4 -2 0

Favours IPT

4

2
Favours Waiting list

Analysis 18.10.   Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list,
Outcome 10: Secondary: identity disturbance (continuous), at end of treatment

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Bellino 2010 (1)

2.46

0.9

22

2.49

0.88

22

-0.03 [-0.56 , 0.50]

Test for subgroup differences: Not applicable

Footnotes
(1) Observer rated: BPDSI-IV identity disturbance

-2

-4
Favours IPT

0

2

4
Favours Waitng list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

403

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 18.11.   Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list, Outcome
11: Secondary: dissociation and psychotic-like symptoms (continuous), at end of treatment

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Bellino 2010 (1)

4.32

2.11

22

4.09

2.24

22

0.23 [-1.06 , 1.52]

Test for subgroup differences: Not applicable

Footnotes
(1) Observer rated: BPDSI-IV paranoid ideation

-10 -5
Favours IPT

0

10

5
Favours Waiting list

Analysis 18.12.   Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list,
Outcome 12: Secondary outcome: depression (continuous), at end of treatment

Study or Subgroup

Mean

IPT
SD

Total

Mean

Waiting list
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Bellino 2006 (1)
Bellino 2010 (2)
Smith 2012 (1)

9.1
10.75
18.7

3
1.5
6.2

16
22
15

12
10.82
23.3

3.3
1.53
3.4

16
22
7

33.6%
41.1%
25.2%

-0.90 [-1.63 , -0.16]
-0.05 [-0.64 , 0.55]
-0.80 [-1.74 , 0.13]

Total (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 3.77, df = 2 (P = 0.15); I² = 47%
Test for overall effect: Z = 1.75 (P = 0.08)
Test for subgroup differences: Not applicable

53

45

100.0%

-0.52 [-1.11 , 0.06]

-4 -2
Favours IPT

0

4

2
Favours Waiting list

Footnotes
(1) Ham-D (CR)
(2) Observer rated: Ham-D

Analysis 18.13.   Comparison 18: Interpersonal psychotherapy (IPT) vs waiting list,
Outcome 13: Secondary outcome: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

Weight

IPT

Waiting list

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Bellino 2006
Bellino 2010

3
2

19
27

4
6

20
28

55.3%
44.7%

0.79 [0.20 , 3.07]
0.35 [0.08 , 1.57]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.64, df = 1 (P = 0.42); I² = 0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable

46

10

5

48

100.0%

0.55 [0.20 , 1.50]

0.001

0.1
Favours IPT

1

10

1000

Favours Waiting list

Comparison 19.   Once-only interventions (individual setting) vs waiting list

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

19.1 Secondary: impulsivity (continuous),
at end of treatment

1

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

404

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

19.2 Secondary: interpersonal problems
(continuous), at end of treatment

19.3 Secondary: attrition (dichotomous), at
end of treatment

1

1

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Analysis 19.1.   Comparison 19: Once-only interventions (individual setting) vs
waiting list, Outcome 1: Secondary: impulsivity (continuous), at end of treatment

Study or Subgroup

Once-only intervention
Total
SD

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean

Mean Difference
IV, Fixed, 95% CI

Zanarini 2008 (1)

-0.43

0.94

30

0.05

1.1

20

-0.48 [-1.07 , 0.11]

Test for subgroup differences: Not applicable

Footnotes
(1) ZAN-BPD-impulsivity (effects calculated from baseline-to-endpoint change scores)

-2
Favours Once-only

-4

0

4

2
Favours Waiting list

Analysis 19.2.   Comparison 19: Once-only interventions (individual setting) vs waiting
list, Outcome 2: Secondary: interpersonal problems (continuous), at end of treatment

Study or Subgroup

Once-only intervention
Total
SD

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean

Mean Difference
IV, Fixed, 95% CI

Zanarini 2008 (1)

-0.93

0.94

30

-0.05

1.43

20

-0.88 [-1.59 , -0.17]

Test for subgroup differences: Not applicable

Footnotes
(1) Zan-BPD - stormy relatioships (effect based on baseline-to-endpoint change scores)

-4 -2 0

Favours Once-only

4

2
Favours Waiting list

Analysis 19.3.   Comparison 19: Once-only interventions (individual setting) vs
waiting list, Outcome 3: Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Once-only intervention
Events

Total

Waiting list

Events

Total

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Zanarini 2008 (1)

0

30

0

20

Not estimable

Test for subgroup differences: Not applicable

Footnotes
(1) all participants attended all visits, no drop-outs

0.02

0.1

1

10

50

Favours Once-only

Favours Waiting list

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

405

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comparison 20.   Eclectic treatments vs waiting list

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

20.1 Primary outcome: psychosocial func-
tioning (continuous), at end of treatment

20.2 Secondary outcome: interpersonal
problems (continuous), at end of treatment

1

1

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Subtotals only

Analysis 20.1.   Comparison 20: Eclectic treatments vs waiting list, Outcome 1:
Primary outcome: psychosocial functioning (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Waiting list
SD

Total

Mean

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Haeyen 2018 (1)

46.27

9.77

15

64.91

17.42

11

-18.64 [-30.06 , -7.22]

Test for subgroup differences: Not applicable

Footnotes
(1) Self reported: OQ45, total score

-50 -25 0

Favours Eclectic

25 50
Favours Waiting list

Analysis 20.2.   Comparison 20: Eclectic treatments vs waiting list, Outcome 2:
Secondary outcome: interpersonal problems (continuous), at end of treatment

Study or Subgroup

Eclectic treatments
SD

Total

Mean

Waiting list
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean

Mean Difference
IV, Fixed, 95% CI

Haeyen 2018 (1)

14.2

3.03

15

19.09

5.52

11

-4.89 [-8.49 , -1.29]

Test for subgroup differences: Not applicable

Footnotes
(1) Self reported: OQ45, interpersonal relations

-50

-25

0

25

50

Favours Eclectic

Favours Waiting list

Comparison 21.   Dialectical behavior therapy (DBT) and related treatments vs active treatment

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21.1 Standard DBT (DBT) vs client-centred
therapy (CCT) (continuous)

21.1.1 Primary: self-harm (continuous), at
end of treatment

21.1.2 Primary: suicide-related outcomes
(continuous), at end of treatment

21.1.3 Secondary: anger (continuous), at
end of treatment

1

1

1

1

24

24

24

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

-2.75 [-4.42,
-1.08]

Mean Difference (IV,
Fixed, 95% CI)

-7.75 [-14.66,
-0.84]

Mean Difference (IV,
Fixed, 95% CI)

-1.00 [-1.98,
-0.02]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

406

 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21.1.4 Secondary: impulsivity (continuous),
at end of treatment

21.1.5 Secondary: dissociation and psychot-
ic-like symptoms (continuous), at end of
treatment

21.1.6 Secondary: depression (continuous),
at end of treatment

21.2 DBT vs CCT, secondary: attrition (di-
chotomous), at end of treatment

21.3 Standard DBT (DBT) vs good psychiatric
management (GPM) (continuous)

21.3.1 Primary: BPD severity (continuous), at
end of treatment

21.3.2 Primary: self-harm (continuous), at
end of treatment

21.3.3 Secondary: anger (continuous), at
end of treatment

21.3.4 Secondary: interpersonal problems
(continuous), at end of treatment

21.3.5 Secondary: depression (continuous),
at end of treatment

21.4 DBT vs GPM, secondary: attrition (di-
chotomous), at end of treatment

21.5 Standard DBT (DBT) vs individual DBT
therapy + activities group (DBT-I) (continu-
ous)

21.5.1 Primary: self-harm (continuous), at
end of treatment

21.5.2 Primary: self-harm (continuous), at
6-12 months follow-up

21.5.3 Primary: suicide-related outcomes
(continuous), at end of treatment

21.5.4 Primary: suicide-related outcomes
(continuous), at 6-12 months follow-up

21.5.5 Secondary: depression (continuous),
at end of treatment

21.5.6 Secondary: depression (continuous),
at 6-12 months follow-up

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

24

24

24

180

180

180

180

180

66

66

66

66

66

66

Mean Difference (IV,
Fixed, 95% CI)

-1.50 [-2.60,
-0.40]

Mean Difference (IV,
Fixed, 95% CI)

-7.16 [-12.15,
-2.17]

Mean Difference (IV,
Fixed, 95% CI)

-9.16 [-14.79,
-3.53]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

-0.23 [-1.97, 1.51]

Mean Difference (IV,
Fixed, 95% CI)

-8.58 [-19.38,
2.22]

Mean Difference (IV,
Fixed, 95% CI)

-0.15 [-1.65, 1.35]

Mean Difference (IV,
Fixed, 95% CI)

-1.34 [-15.36,
12.68]

Mean Difference (IV,
Fixed, 95% CI)

-2.65 [-7.18, 1.88]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

-10.40 [-22.99,
2.19]

Mean Difference (IV,
Fixed, 95% CI)

-8.10 [-19.59,
3.39]

Mean Difference (IV,
Fixed, 95% CI)

0.50 [-1.37, 2.37]

Mean Difference (IV,
Fixed, 95% CI)

-1.60 [-2.79,
-0.41]

Mean Difference (IV,
Fixed, 95% CI)

-5.90 [-9.74,
-2.06]

Mean Difference (IV,
Fixed, 95% CI)

1.30 [-3.10, 5.70]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

407

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21.6 DBT vs DBT-I, secondary: attrition (di-
chotomous), at end of treatment

21.7 Standard DBT (DBT) vs skills training
group + individual case management (DBT-
S) (continuous)

21.7.1 Primary: self-harm (continuous), at
end of treatment

21.7.2 Primary: self-harm (continuous), at
6-12 months follow-up

21.7.3 Primary: suicide-related outcomes
(continuous), at end of treatment

21.7.4 Primary: suicide-related outcomes
(continuous), at 6-12 months follow-up

21.7.5 Secondary: depression (continuous),
at end of treatment

21.7.6 Secondary: depression (continuous),
at 6-12 months follow-up

21.8 DBT vs DBT-S, secondary: attrition (di-
chotomous), at 6-12 months follow-up

21.9 Standard DBT (DBT) vs step-down DBT
(DBT-SD) (continuous)

21.9.1 Primary: BPD symptom severity (con-
tinuous), at end of treatment

21.9.2 Primary: self-harm (continuous), at
end of treatment

21.9.3 Primary: suicide-related outcomes
(continuous), at end of treatment

21.9.4 Secondary: anger (continuous), at
end of treatment

21.9.5 Secondary: affective instability (con-
tinuous), at end of treatment

21.9.6 Secondary: chronic feeling of empti-
ness (continuous), at end of treatment

21.9.7 Secondary: impulsivity (continuous),
at end of treatment

21.9.8 Secondary: interpersonal problems
(continuous), at end of treatment

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

0.30 [-8.42, 9.02]

-1.50 [-9.04, 6.04]

0.80 [-1.06, 2.66]

0.50 [-0.02, 1.02]

1.90 [-1.60, 5.40]

3.30 [-0.90, 7.50]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

-2.83 [-11.21,
5.55]

Mean Difference (IV,
Fixed, 95% CI)

4.10 [-4.07,
12.27]

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

0.30 [-0.73, 1.33]

-0.53 [-1.48, 0.43]

-0.71 [-2.51, 1.09]

0.18 [-1.68, 2.04]

0.24 [-0.26, 0.75]

Mean Difference (IV,
Fixed, 95% CI)

-1.31 [-2.05,
-0.57]

66

66

66

66

66

66

38

38

38

41

41

41

41

41

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

408

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21.9.9 Secondary: abandonment (continu-
ous), at end of treatment

21.9.10 Secondary: dissociation and psy-
chotic-like symptoms (continuous), at end
of treatment

21.10 DBT vs DBT-SD, secondary: attrition
(dichotomous), at end of treatment

21.11 Standard DBT (DBT) vs DBT Prolonged
Exposure (PE) (continuous)

21.11.1 Primary: self-harm (continuous), end
of treatment

21.11.2 Primary: self-harm (continuous), at
0-6 months follow-up

21.11.3 Primary: suicide-related outcomes
(continuous), end of treatment

21.11.4 Primary: suicide-related outcomes
(continuous), at 0-6 months follow-up

21.11.5 Primary: psychosocial functioning
(continuous), end of treatment

21.11.6 Primary: psychosocial functioning
(continuous), at 0-6 months follow-up

21.11.7 Secondary: interpersonal problems
(continuous), end of treatment

21.11.8 Secondary: interpersonal problems
(continuous), at 0-6 months follow-up

21.11.9 Secondary: dissociation or psychot-
ic-like symptoms (continuous), end of treat-
ment

21.11.10 Secondary: dissociation or psy-
chotic-like symptoms (continuous), at 0-6
months follow-up

21.11.11 Secondary: depression (continu-
ous), end of treatment

21.11.12 Secondary: depression (continu-
ous), at 0-6 months follow-up

21.12 DBT vs DBT-PE, secondary: attrition
(dichotomous), at 0-6 months follow-up

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

41

41

84

18

18

18

18

18

18

18

18

18

18

18

18

Mean Difference (IV,
Fixed, 95% CI)

-1.11 [-2.14,
-0.08]

Mean Difference (IV,
Fixed, 95% CI)

-0.44 [-1.56, 0.68]

Risk Ratio (M-H, Fixed,
95% CI)

0.37 [0.17, 0.78]

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

0.10 [-1.86, 2.06]

-0.30 [-1.09, 0.49]

Not estimable

Not estimable

Mean Difference (IV,
Fixed, 95% CI)

5.27 [-2.06,
12.60]

Mean Difference (IV,
Fixed, 95% CI)

2.00 [-6.27,
10.27]

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

0.14 [-0.42, 0.70]

0.19 [-0.48, 0.86]

Mean Difference (IV,
Fixed, 95% CI)

4.60 [-9.24,
18.44]

Mean Difference (IV,
Fixed, 95% CI)

6.00 [-9.46,
21.46]

Mean Difference (IV,
Fixed, 95% CI)

3.70 [-3.19,
10.59]

Mean Difference (IV,
Fixed, 95% CI)

4.30 [-1.08, 9.68]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

409

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21.13 DBT skills group + case management
(DBT-S) vs DBT individual therapy + activity
group (DBT-I) (continuous)

21.13.1 Primary: self-harm (continuous), at
end of treatment

21.13.2 Primary: self-harming behaviour
(continuous), at 6-12 months follow-up

21.13.3 Primary: suicide-related outcomes
(continuous), at end of treatment

21.13.4 Primary: suicide-related outcomes
(continuous), at 6-12 months follow-up

21.13.5 Secondary: depression (continuous),
at end of treatment

21.13.6 Secondary: depression (continuous),
at 6-12 months follow-up

21.14 DBT-S vs DBT-I, secondary: attrition
(dichotomous), at 6-12 months follow-up

21.15 DBT skills group (DBT-S) vs cognitive
therapy group (CT-G) (continuous)

21.15.1 Primary: BPD symptom severity
(continuous), at end of treatment

21.15.2 Primary: BPD symptom severity
(continuous), at 0-6 months follow-up

21.15.3 Primary: suicide-related outcomes
(continuous), at end of treatment

21.15.4 Primary: suicide-related outcomes
(continuous), at 0-6 months follow-up

21.15.5 Secondary: depression (continuous),
at end of treatment

21.15.6 Secondary: depression (continuous),
at 0-6 months follow-up

21.16 DBT-S vs CT-G, secondary: attrition (di-
chotomous), at end of treatment

21.17 DBT skills group (DBT-S) vs schema-fo-
cused therapy group (SFT-G)

21.17.1 Primary: suicide-related outcomes
(continuous), at end of treatment

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

-10.70 [-22.47,
1.07]

Mean Difference (IV,
Fixed, 95% CI)

-6.60 [-19.72,
6.52]

Mean Difference (IV,
Fixed, 95% CI)

-0.30 [-1.72, 1.12]

Mean Difference (IV,
Fixed, 95% CI)

-2.10 [-3.21,
-0.99]

Mean Difference (IV,
Fixed, 95% CI)

-7.80 [-11.27,
-4.33]

Mean Difference (IV,
Fixed, 95% CI)

-2.00 [-6.44, 2.44]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

0.26 [-0.13, 0.65]

Mean Difference (IV,
Fixed, 95% CI)

-0.96 [-1.15,
-0.77]

Mean Difference (IV,
Fixed, 95% CI)

0.46 [-2.47, 3.39]

Mean Difference (IV,
Fixed, 95% CI)

-2.69 [-4.89,
-0.49]

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

-2.12 [-5.25, 1.01]

-1.60 [-5.07, 1.87]

Risk Ratio (M-H, Ran-
dom, 95% CI)

Subtotals only

Mean Difference (IV,
Random, 95% CI)

Mean Difference (IV,
Random, 95% CI)

Subtotals only

0.92 [-0.36, 2.20]

66

66

66

66

66

66

82

82

82

82

82

82

24

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

410

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21.17.2 Secondary: depression (continuous),
at end of treatment

21.18 DBT mindfulness group (DBT-M) vs
DBT interpersonal effectiveness group (DBT-
IE) (continuous)

21.18.1 Primary: BPD symptom severity
(continuous), at end of treatment

21.18.2 Secondary: impulsivity (continuous),
at end of treatment

21.19 DBT-M vs DBT-IE, secondary: attrition
(dichotomous), at end of treatment

21.20 DBT mindfulness group (DBT-M) vs lov-
ing-kindness and compassion meditation
(LK/CM), primary: BPD symptom severity
(continuous), at end of treatment

1

2

2

2

2

1

24

113

91

134

Mean Difference (IV,
Random, 95% CI)

4.33 [2.57, 6.09]

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

-0.45 [-1.47, 0.58]

Std. Mean Difference (IV,
Random, 95% CI)

-0.36 [-0.77, 0.06]

Risk Ratio (M-H, Ran-
dom, 95% CI)

1.86 [1.07, 3.23]

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

411

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.1.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs
active treatment, Outcome 1: Standard DBT (DBT) vs client-centred therapy (CCT) (continuous)

Study or Subgroup

Mean

DBT
SD

Total

Mean

CCT
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

21.1.1 Primary: self-harm (continuous), at end of treatment
Turner 2000 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.23 (P = 0.001)

12
12

1.98

1.5

4.25

2.18

12
12

100.0%
100.0%

-2.75 [-4.42 , -1.08]
-2.75 [-4.42 , -1.08]

21.1.2 Primary: suicide-related outcomes (continuous), at end of treatment
9.21
Turner 2000 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.20 (P = 0.03)

12
12

11.58

8.03

3.83

12
12

100.0%
100.0%

-7.75 [-14.66 , -0.84]
-7.75 [-14.66 , -0.84]

21.1.3 Secondary: anger (continuous), at end of treatment
Turner 2000 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.00 (P = 0.05)

12
12

4.67

1.3

5.67

1.15

12
12

100.0%
100.0%

-1.00 [-1.98 , -0.02]
-1.00 [-1.98 , -0.02]

21.1.4 Secondary: impulsivity (continuous), at end of treatment
6.08
4.58
Turner 2000 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.67 (P = 0.008)

12
12

1.62

1.08

12
12

100.0%
100.0%

-1.50 [-2.60 , -0.40]
-1.50 [-2.60 , -0.40]

21.1.5 Secondary: dissociation and psychotic-like symptoms (continuous), at end of treatment
100.0%
Turner 2000 (5)
100.0%
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.81 (P = 0.005)

12
12

12
12

18.17

25.33

3.94

7.9

-7.16 [-12.15 , -2.17]
-7.16 [-12.15 , -2.17]

21.1.6 Secondary: depression (continuous), at end of treatment
24.08
14.92
Turner 2000 (6)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.19 (P = 0.001)

12
12

8.26

Footnotes
(1) Target Behaviour Rating (TBR) - frequency of parasuicide
(2) BSS (Beck Scale for Suicidal Ideation)
(3) TBR - anger
(4) TBR - impulsiveness
(5) Brief Psychiatric Rating Scale (BPRS)
(6) BDI

5.55

12
12

100.0%
100.0%

-9.16 [-14.79 , -3.53]
-9.16 [-14.79 , -3.53]

-10

-20
Favours DBT

0

10

20
Favours CCT

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

412

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.2.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs
active treatment, Outcome 2: DBT vs CCT, secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

DBT

CCT

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Turner 2000 (1)

3

12

6

12

0.50 [0.16 , 1.55]

Test for subgroup differences: Not applicable

Footnotes
(1) quit treatment

0.001

0.1
Favours DBT

1

10

1000

Favours CCT

Analysis 21.3.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 3: Standard DBT (DBT) vs good psychiatric management (GPM) (continuous)

Study or Subgroup

Mean

DBT
SD

Total

Mean

GPM
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

21.3.1 Primary: BPD severity (continuous), at end of treatment
8.16
7.93
McMain 2009 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.26 (P = 0.80)

90
90

6.11

21.3.2 Primary: self-harm (continuous), at end of treatment
McMain 2009 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.56 (P = 0.12)

90
90

9.32

4.29

12.87

5.79

90
90

100.0%
100.0%

-0.23 [-1.97 , 1.51]
-0.23 [-1.97 , 1.51]

51.45

90
90

100.0%
100.0%

-8.58 [-19.38 , 2.22]
-8.58 [-19.38 , 2.22]

21.3.3 Secondary: anger (continuous), at end of treatment
McMain 2009 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.20 (P = 0.85)

90
90

15.81

5.19

15.96

5.11

90
90

100.0%
100.0%

-0.15 [-1.65 , 1.35]
-0.15 [-1.65 , 1.35]

21.3.4 Secondary: interpersonal problems (continuous), at end of treatment
McMain 2009 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.19 (P = 0.85)

100.24

101.58

90
90

45.19

50.62

90
90

100.0%
100.0%

-1.34 [-15.36 , 12.68]
-1.34 [-15.36 , 12.68]

21.3.5 Secondary: depression (continuous), at end of treatment
24.83
22.18
McMain 2009 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.15 (P = 0.25)

90
90

16.14

Footnotes
(1) Observer rated: ZAN-BPD
(2) SASII - number of suicidal and self-injurious episodes (CR)
(3) Self reported: STAXI, anger out
(4) Self reported: IIP-C
(5) Self reported: BDI

14.83

90
90

100.0%
100.0%

-2.65 [-7.18 , 1.88]
-2.65 [-7.18 , 1.88]

-20 -10 0

Favours DBT

10 20
Favours GPM

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

413

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.4.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 4: DBT vs GPM, secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

DBT

GPM

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

McMain 2009

35

90

34

90

1.03 [0.71 , 1.49]

Test for subgroup differences: Not applicable

0.005

0.1

1

Favours DBT

10

200
Favours GPM

Analysis 21.5.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 5: Standard DBT (DBT) vs individual DBT therapy + activities group (DBT-I) (continuous)

Study or Subgroup

Standard DBT
SD

Mean

Total

Mean

DBT-I
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

21.5.1 Primary: self-harm (continuous), at end of treatment
Linehan 2015a (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.62 (P = 0.11)

33
33

16.3

10.2

20.6

21.5.2 Primary: self-harm (continuous), at 6-12 months follow-up
7.9
Linehan 2015a (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.38 (P = 0.17)

33
33

8.5

16

33.1

33
33

100.0%
100.0%

-10.40 [-22.99 , 2.19]
-10.40 [-22.99 , 2.19]

32.6

33
33

100.0%
100.0%

-8.10 [-19.59 , 3.39]
-8.10 [-19.59 , 3.39]

21.5.3 Primary: suicide-related outcomes (continuous), at end of treatment
3
Linehan 2015a (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.52 (P = 0.60)

33
33

3.4

2.9

4.6

21.5.4 Primary: suicide-related outcomes (continuous), at 6-12 months follow-up
Linehan 2015a (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.63 (P = 0.009)

33
33

3.2

1.4

3.6

2

21.5.5 Secondary: depression (continuous), at end of treatment
18.2
12.3
Linehan 2015a (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.01 (P = 0.003)

33
33

8

21.5.6 Secondary: depression (continuous), at 6-12 months follow-up
Linehan 2015a (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.58 (P = 0.56)

33
33

13.9

15.2

8.6

7.9

9.6

33
33

100.0%
100.0%

0.50 [-1.37 , 2.37]
0.50 [-1.37 , 2.37]

33
33

100.0%
100.0%

-1.60 [-2.79 , -0.41]
-1.60 [-2.79 , -0.41]

33
33

100.0%
100.0%

-5.90 [-9.74 , -2.06]
-5.90 [-9.74 , -2.06]

33
33

100.0%
100.0%

1.30 [-3.10 , 5.70]
1.30 [-3.10 , 5.70]

Footnotes
(1) SASII-NASSI (SR)
(2) Number of suicide attempts
(3) Self reported: HRDS

-20

-10
Favours DBT

0

10

20

Favours DBT-I

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

414

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.6.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 6: DBT vs DBT-I, secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

DBT

DBT-I

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Linehan 2015a

8

33

16

33

0.50 [0.25 , 1.01]

Test for subgroup differences: Not applicable

0.01

0.1
Favours DBT

1

10

100

Favours DBT-I

Analysis 21.7.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment,
Outcome 7: Standard DBT (DBT) vs skills training group + individual case management (DBT-S) (continuous)

Study or Subgroup

Mean

DBT
SD

Total

Mean

DBT-S
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

21.7.1 Primary: self-harm (continuous), at end of treatment
Linehan 2015a (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.07 (P = 0.95)

33
33

10.2

16.3

9.9

19.7

33
33

100.0%
100.0%

0.30 [-8.42 , 9.02]
0.30 [-8.42 , 9.02]

21.7.2 Primary: self-harm (continuous), at 6-12 months follow-up
7.9
Linehan 2015a (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.39 (P = 0.70)

33
33

9.4

8.5

20.4

33
33

100.0%
100.0%

-1.50 [-9.04 , 6.04]
-1.50 [-9.04 , 6.04]

21.7.3 Primary: suicide-related outcomes (continuous), at end of treatment
2.9
Linehan 2015a (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.85 (P = 0.40)

33
33

2.6

4.6

3.4

21.7.4 Primary: suicide-related outcomes (continuous), at 6-12 months follow-up
Linehan 2015a (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.89 (P = 0.06)

33
33

0.6

1.4

1.5

2

21.7.5 Secondary: depression (continuous), at end of treatment
10.4
12.3
Linehan 2015a (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.07 (P = 0.29)

33
33

8

21.7.6 Secondary: depression (continuous), at 6-12 months follow-up
Linehan 2015a (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.54 (P = 0.12)

33
33

15.2

11.9

8.6

6.4

8.8

33
33

100.0%
100.0%

0.80 [-1.06 , 2.66]
0.80 [-1.06 , 2.66]

33
33

100.0%
100.0%

0.50 [-0.02 , 1.02]
0.50 [-0.02 , 1.02]

33
33

100.0%
100.0%

1.90 [-1.60 , 5.40]
1.90 [-1.60 , 5.40]

33
33

100.0%
100.0%

3.30 [-0.90 , 7.50]
3.30 [-0.90 , 7.50]

Footnotes
(1) SASII-NASSI (SR)
(2) Number of suicide attempts
(3) Self reported: HRDS

-10
Favours DBT

-5

0

5

10

Favours DBT-S

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

415

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.8.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 8: DBT vs DBT-S, secondary: attrition (dichotomous), at 6-12 months follow-up

Study or Subgroup

Events

Total

Events

Total

DBT

DBT-S

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Linehan 2015a

8

33

13

33

0.62 [0.29 , 1.29]

Test for subgroup differences: Not applicable

0.01

0.1
Favours DBT

1

10

100
Favours DBT-SM

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

416

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.9.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment,
Outcome 9: Standard DBT (DBT) vs step-down DBT (DBT-SD) (continuous)

Study or Subgroup

Mean

DBT
SD

Total

Mean

DBT-SD
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

21.9.1 Primary: BPD symptom severity (continuous), at end of treatment
Sinnaeve 2018 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.66 (P = 0.51)

13.1332

14
14

19.69

16.86

11.9535

24
24

100.0%
100.0%

-2.83 [-11.21 , 5.55]
-2.83 [-11.21 , 5.55]

21.9.2 Primary: self-harm (continuous), at end of treatment
Sinnaeve 2018 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.98 (P = 0.33)

14
14

8.6

14

4.5

9

24
24

100.0%
100.0%

4.10 [-4.07 , 12.27]
4.10 [-4.07 , 12.27]

21.9.3 Primary: suicide-related outcomes (continuous), at end of treatment
0.7
Sinnaeve 2018 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.57 (P = 0.57)

14
14

0.2

1.9

0.5

24
24

100.0%
100.0%

0.30 [-0.73 , 1.33]
0.30 [-0.73 , 1.33]

21.9.4 Secondary: anger (continuous), at end of treatment
Sinnaeve 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.08 (P = 0.28)

1.42847

1.1664

14
14

1.6915

1.5559

27
27

100.0%
100.0%

-0.53 [-1.48 , 0.43]
-0.53 [-1.48 , 0.43]

21.9.5 Secondary: affective instability (continuous), at end of treatment
Sinnaeve 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.77 (P = 0.44)

4.7704

4.0614

2.9328

14
14

2.4972

21.9.6 Secondary: chronic feeling of emptiness (continuous), at end of treatment
2.9899
Sinnaeve 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.19 (P = 0.85)

2.9259

3.1071

2.6772

14
14

27
27

100.0%
100.0%

-0.71 [-2.51 , 1.09]
-0.71 [-2.51 , 1.09]

27
27

100.0%
100.0%

0.18 [-1.68 , 2.04]
0.18 [-1.68 , 2.04]

21.9.7 Secondary: impulsivity (continuous), at end of treatment
Sinnaeve 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.95 (P = 0.34)

0.7251

1.2871

14
14

1.0422

0.8933

27
27

100.0%
100.0%

0.24 [-0.26 , 0.75]
0.24 [-0.26 , 0.75]

21.9.8 Secondary: interpersonal problems (continuous), at end of treatment
1.745
Sinnaeve 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.49 (P = 0.0005)

0.6291

0.5814

1.8911

14
14

27
27

100.0%
100.0%

-1.31 [-2.05 , -0.57]
-1.31 [-2.05 , -0.57]

21.9.9 Secondary: abandonment (continuous), at end of treatment
Sinnaeve 2018
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.12 (P = 0.03)

2.07963

1.32307

0.96929

14
14

2.0056

27
27

100.0%
100.0%

-1.11 [-2.14 , -0.08]
-1.11 [-2.14 , -0.08]

21.9.10 Secondary: dissociation and psychotic-like symptoms (continuous), at end of treatment
100.0%
Sinnaeve 2018
100.0%
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.77 (P = 0.44)

1.4419

1.0014

2.0358

27
27

14
14

1.548

-0.44 [-1.56 , 0.68]
-0.44 [-1.56 , 0.68]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

417

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.9.   (Continued)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.77 (P = 0.44)

Footnotes
(1) BPDSI-IV total
(2) LPC-NSSI - self-injurious behaviour without suicidal intention
(3) LPC-sui - self-injurious behaviour with suicidal intention

-20

-10

0

Favours DBT

10

20
Favours DBT-SD

Analysis 21.10.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 10: DBT vs DBT-SD, secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

Weight

DBT

DBT-SD

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Sinnaeve 2018 (1)

7

42

19

42

100.0%

0.37 [0.17 , 0.78]

Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.60 (P = 0.009)
Test for subgroup differences: Not applicable

7

42

42

100.0%

0.37 [0.17 , 0.78]

19

0.002

0.1

1

Favours DBT

10

500
Favours DBT-SD

Footnotes
(1) discontinued intervention

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

418

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.11.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment,
Outcome 11: Standard DBT (DBT) vs DBT Prolonged Exposure (PE) (continuous)

Study or Subgroup

Mean

DBT
SD

Total

Mean

DBT-PE
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

21.11.1 Primary: self-harm (continuous), end of treatment
Harned 2014 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.10 (P = 0.92)

6
6

1

2

0.9

2

12
12

100.0%
100.0%

0.10 [-1.86 , 2.06]
0.10 [-1.86 , 2.06]

21.11.2 Primary: self-harm (continuous), at 0-6 months follow-up
0.3
Harned 2014 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.75 (P = 0.46)

0.5

0.6

6
6

1.2

12
12

100.0%
100.0%

-0.30 [-1.09 , 0.49]
-0.30 [-1.09 , 0.49]

21.11.3 Primary: suicide-related outcomes (continuous), end of treatment
0
Harned 2014 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable

0.4

0.2

6
6

0

21.11.4 Primary: suicide-related outcomes (continuous), at 0-6 months follow-up
Harned 2014 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable

0.3

0.1

6
6

0

0

21.11.5 Primary: psychosocial functioning (continuous), end of treatment
10.23
Harned 2014 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.41 (P = 0.16)

-58.27

5.62

-53

6
6

21.11.6 Primary: psychosocial functioning (continuous), at 0-6 months follow-up
Harned 2014 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.47 (P = 0.64)

12.33

-55.4

-57.4

5.55

6
6

21.11.7 Secondary: interpersonal problems (continuous), end of treatment
0.67
Harned 2014 (6)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.49 (P = 0.62)

1.63

1.49

0.51

6
6

21.11.8 Secondary: interpersonal problems (continuous), at 0-6 months follow-up
Harned 2014 (6)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.56 (P = 0.58)

2.01

1.82

0.94

0.5

6
6

12
12

12
12

Not estimable
Not estimable

Not estimable
Not estimable

12
12

100.0%
100.0%

5.27 [-2.06 , 12.60]
5.27 [-2.06 , 12.60]

12
12

100.0%
100.0%

2.00 [-6.27 , 10.27]
2.00 [-6.27 , 10.27]

12
12

100.0%
100.0%

0.14 [-0.42 , 0.70]
0.14 [-0.42 , 0.70]

12
12

100.0%
100.0%

0.19 [-0.48 , 0.86]
0.19 [-0.48 , 0.86]

21.11.9 Secondary: dissociation or psychotic-like symptoms (continuous), end of treatment
Harned 2014 (7)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.65 (P = 0.51)

12
12

14.6

12.5

16.9

6
6

10

100.0%
100.0%

4.60 [-9.24 , 18.44]
4.60 [-9.24 , 18.44]

21.11.10 Secondary: dissociation or psychotic-like symptoms (continuous), at 0-6 months follow-up
Harned 2014 (7)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.76 (P = 0.45)

100.0%
100.0%

12
12

17.3

15.3

16.7

11.3

6
6

6.00 [-9.46 , 21.46]
6.00 [-9.46 , 21.46]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

419

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 21.11.   (Continued)

Heterogeneity: Not applicable
Test for overall effect: Z = 0.76 (P = 0.45)

21.11.11 Secondary: depression (continuous), end of treatment
15.5
Harned 2014 (8)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.05 (P = 0.29)

6.5

6
6

11.8

21.11.12 Secondary: depression (continuous), at 0-6 months follow-up
Harned 2014 (8)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.57 (P = 0.12)

12.5

16.8

3.4

6
6

Footnotes
(1) Self reported: SASII-NSSI acts
(2) Self reported: Non-suicidal self-injury scale
(3) Self reported: SASII - suicide attempts
(4) Self reported: SASII
(5) Clinician-rated: GAS
(6) IIP-25 (SR)
(7) Self reported: DES-T
(8) Self reported: HRDS

Cochrane Database of Systematic Reviews

8

12
12

100.0%
100.0%

3.70 [-3.19 , 10.59]
3.70 [-3.19 , 10.59]

8.2

12
12

100.0%
100.0%

4.30 [-1.08 , 9.68]
4.30 [-1.08 , 9.68]

-20

-10
Favours DBT

0

10
20
Favours DBT-PE

Analysis 21.12.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 12: DBT vs DBT-PE, secondary: attrition (dichotomous), at 0-6 months follow-up

Study or Subgroup

Events

Total

Events

Total

DBT

DBT-PE

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Harned 2014

5

17

3

9

0.88 [0.27 , 2.88]

Test for subgroup differences: Not applicable

0.001

0.1
Favours DBT

1

10

1000
Favours DBT-PE

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

420

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.13.   Comparison 21: Dialectical behavior therapy (DBT) and related
treatments vs active treatment, Outcome 13: DBT skills group + case management
(DBT-S) vs DBT individual therapy + activity group (DBT-I) (continuous)

Study or Subgroup

Mean

DBT-S
SD

Total

Mean

DBT-I
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

21.13.1 Primary: self-harm (continuous), at end of treatment
Linehan 2015a (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.78 (P = 0.07)

33
33

9.7

9.9

20.6

33.1

33
33

100.0%
100.0%

-10.70 [-22.47 , 1.07]
-10.70 [-22.47 , 1.07]

21.13.2 Primary: self-harming behaviour (continuous), at 6-12 months follow-up
20.4
Linehan 2015a (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.99 (P = 0.32)

33
33

32.6

9.4

16

21.13.3 Primary: suicide-related outcomes (continuous), at end of treatment
Linehan 2015a (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.41 (P = 0.68)

33
33

2.9

2.6

2.9

3

33
33

100.0%
100.0%

-6.60 [-19.72 , 6.52]
-6.60 [-19.72 , 6.52]

33
33

100.0%
100.0%

-0.30 [-1.72 , 1.12]
-0.30 [-1.72 , 1.12]

21.13.4 Primary: suicide-related outcomes (continuous), at 6-12 months follow-up
0.6
Linehan 2015a (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.71 (P = 0.0002)

33
33

1.5

3.2

3.6

33
33

100.0%
100.0%

-2.10 [-3.21 , -0.99]
-2.10 [-3.21 , -0.99]

21.13.5 Secondary: depression (continuous), at end of treatment
18.2
10.4
Linehan 2015a (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.41 (P < 0.0001)

33
33

6.4

21.13.6 Secondary: depression (continuous), at 6-12 months follow-up
Linehan 2015a (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.88 (P = 0.38)

33
33

13.9

11.9

8.8

7.9

9.6

33
33

100.0%
100.0%

-7.80 [-11.27 , -4.33]
-7.80 [-11.27 , -4.33]

33
33

100.0%
100.0%

-2.00 [-6.44 , 2.44]
-2.00 [-6.44 , 2.44]

Footnotes
(1) SASII-NASSI (SR)
(2) mean number of suicide attempts
(3) Self rated: HRDS

-20 -10 0 10 20

Favours DBT-S

Favours DBT-I

Analysis 21.14.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 14: DBT-S vs DBT-I, secondary: attrition (dichotomous), at 6-12 months follow-up

Study or Subgroup

Events

Total

Events

Total

DBT-S

DBT-I

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Linehan 2015a

22

33

27

33

0.81 [0.61 , 1.09]

Test for subgroup differences: Not applicable

0.2

0.5
Favours DBT-S

1

2

5

Favours DBT-I

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

421

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.15.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 15: DBT skills group (DBT-S) vs cognitive therapy group (CT-G) (continuous)

Study or Subgroup

Mean

DBT-S
SD

Total

Mean

CT-G
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

21.15.1 Primary: BPD symptom severity (continuous), at end of treatment
0.81
Lin 2019 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.31 (P = 0.19)

42
42

5.74

0.98

6

21.15.2 Primary: BPD symptom severity (continuous), at 0-6 months follow-up
Lin 2019 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 9.91 (P < 0.00001)

42
42

4.91

5.87

0.18

0.6

21.15.3 Primary: suicide-related outcomes (continuous), at end of treatment
Lin 2019 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.31 (P = 0.76)

42
42

48.54

7.01

6.5

49

21.15.4 Primary: suicide-related outcomes (continuous), at 0-6 months follow-up
4.91
Lin 2019 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.40 (P = 0.02)

42
42

40.27

42.96

5.23

40
40

100.0%
100.0%

0.26 [-0.13 , 0.65]
0.26 [-0.13 , 0.65]

40
40

100.0%
100.0%

-0.96 [-1.15 , -0.77]
-0.96 [-1.15 , -0.77]

40
40

100.0%
100.0%

0.46 [-2.47 , 3.39]
0.46 [-2.47 , 3.39]

40
40

100.0%
100.0%

-2.69 [-4.89 , -0.49]
-2.69 [-4.89 , -0.49]

21.15.5 Secondary: depression (continuous), at end of treatment
19.2
Lin 2019 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.33 (P = 0.18)

42
42

17.08

6.02

21.15.6 Secondary: depression (continuous), at 0-6 months follow-up
Lin 2019 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.90 (P = 0.37)

42
42

23.33

21.73

8.38

8.21

40
40

100.0%
100.0%

-2.12 [-5.25 , 1.01]
-2.12 [-5.25 , 1.01]

7.65

40
40

100.0%
100.0%

-1.60 [-5.07 , 1.87]
-1.60 [-5.07 , 1.87]

Footnotes
(1) BPDFS
(2) ASIQ-S
(3) Ko’s Depression Inventory

-2
Favours DBT-S

-4

0

4

2
Favours CT-G

Analysis 21.16.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 16: DBT-S vs CT-G, secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

DBT-S

CT-G

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Lin 2019

6

42

8

40

0.71 [0.27 , 1.88]

Test for subgroup differences: Not applicable

0.005
Favours DBT-S

0.1

1

10

200
Favours CT-G

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

422

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.17.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs
active treatment, Outcome 17: DBT skills group (DBT-S) vs schema-focused therapy group (SFT-G)

Study or Subgroup

Mean

DBT-S
SD

Total

Mean

SFT-G
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

21.17.1 Primary: suicide-related outcomes (continuous), at end of treatment
1.55
Mohamadizadeh 2017 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.41 (P = 0.16)

12
12

15.25

14.33

1.65

12
12

100.0%
100.0%

0.92 [-0.36 , 2.20]
0.92 [-0.36 , 2.20]

21.17.2 Secondary: depression (continuous), at end of treatment
Mohamadizadeh 2017 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.83 (P < 0.00001)

12
12

24.16

2.7

19.83

Footnotes
(1) Self rated: BSS
(2) Self rated: BDI

1.53

12
12

100.0%
100.0%

4.33 [2.57 , 6.09]
4.33 [2.57 , 6.09]

-4 -2 0

Favours DBT-S

4

2
Favours SFT-G

Analysis 21.18.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active treatment,
Outcome 18: DBT mindfulness group (DBT-M) vs DBT interpersonal effectiveness group (DBT-IE) (continuous)

Study or Subgroup

Mean

DBT-M
SD

Total

Mean

DBT-IE
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

21.18.1 Primary: BPD symptom severity (continuous), at end of treatment
Carmona í Farrés 2019 (1)
Elices 2016 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.47; Chi² = 7.10, df = 1 (P = 0.008); I² = 86%
Test for overall effect: Z = 0.86 (P = 0.39)

26.3
20.97

43.77
33.46

41.77
52.5

22
32
54

22.3
18.1

27
32
59

49.4%
50.6%
100.0%

0.08 [-0.48 , 0.64]
-0.96 [-1.48 , -0.44]
-0.45 [-1.47 , 0.58]

21.18.2 Secondary: impulsivity (continuous), at end of treatment
Carmona í Farrés 2019 (2)
Elices 2016 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 1 (P = 0.78); I² = 0%
Test for overall effect: Z = 1.67 (P = 0.09)

27.38
21.05

3.85
5.83

21
19
40

28.92
23.48

Footnotes
(1) Self rated: BSL-23
(2) BIS-11 - non planning
(3) BIS-11 - non-planning

5.87
5.56

26
25
51

52.1%
47.9%
100.0%

-0.30 [-0.88 , 0.28]
-0.42 [-1.02 , 0.18]
-0.36 [-0.77 , 0.06]

-4

-2

0

2

4

Favours DBT-M

Favours DBT-IE

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

423

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 21.19.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments vs active
treatment, Outcome 19: DBT-M vs DBT-IE, secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

Weight

DBT-M

DBT-IE

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Carmona í Farrés 2019
Elices 2016

13
13

35
32

7
7

35
32

49.2%
50.8%

1.86 [0.84 , 4.09]
1.86 [0.85 , 4.04]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 2.19 (P = 0.03)
Test for subgroup differences: Not applicable

26

67

14

67

100.0%

1.86 [1.07 , 3.23]

0.01
Favours DBT-M

0.1

1

10

100
Favours DBT-IE

Analysis 21.20.   Comparison 21: Dialectical behavior therapy (DBT) and related treatments
vs active treatment, Outcome 20: DBT mindfulness group (DBT-M) vs loving-kindness and
compassion meditation (LK/CM), primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Mean

DBT-M
SD

Total

Mean

LKM/CM
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Feliu-Soler 2017 (1)

1.39

1.02

16

1.35

1

16

0.04 [-0.66 , 0.74]

Test for subgroup differences: Not applicable

Footnotes
(1) Self rated: BSL

-2

-1

0

Favours DBT-M

1

2
Favours LKM/CM

Comparison 22.   Cognitive behavioural therapy (CBT) and related treatments vs active treatment

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

22.1 CBT vs trauma- and anxiety-related
group psychoeducation (continuous)

22.1.1 Primary: BPD symptom severity (con-
tinuous), at end of treatment

22.1.2 Primary: BPD symptom severity (con-
tinuous), at 0-6 months follow-up

22.1.3 Primary: BPD symptom severity (con-
tinuous), at 6-12 months follow-up

22.1.4 Primary: psychosocial functioning
(continuous), at end of treatment

22.1.5 Primary: psychosocial functioning
(continuous), at 0-6 months follow-up

22.1.6 Primary: psychosocial functioning
(continuous), at 6-12 months follow-up

1

1

1

1

1

1

1

50

50

50

50

50

50

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

-0.26 [-1.46, 0.94]

-0.39 [-1.60, 0.82]

0.57 [-0.48, 1.62]

-0.64 [-5.76, 4.48]

-1.23 [-6.94, 4.48]

0.61 [-5.00, 6.22]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

424

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

22.1.7 Secondary: depression (continuous),
at end of treatment

22.1.8 Secondary: depression (continuous),
at 0-6 months follow-up

22.1.9 Secondary: depression (continuous),
at 6-12 months follow-up

22.2 CBT vs trauma- and anxiety-related
group psychoeducation, secondary: attrition
(dichotomous), at end of treatment

22.3 CBT vs interpersonal psychotherapy
(IPT) (continuous)

22.3.1 Primary: psychosocial functioning
(continuous), at end of treatment

22.3.2 Secondary: depression (continuous),
at end of treatment

22.4 CBT vs IPT, secondary: attrition (di-
chotomous), at end of treatment

22.5 CBT vs Rogerian supportive therapy
(continuous)

22.5.1 Primary: self-harm (continuous), end
of treatment

22.5.2 Primary: self-harm (continuous), at
6-12 months follow-up

22.5.3 Primary: suicide-related outcomes
(continuous), at end of treatment

22.5.4 Primary: suicide-related outcomes
(continuous), at 6-12 months follow-up

22.5.5 Primary: psychosocial functioning
(continuous), at end of treatment

22.5.6 Primary: psychosocial functioning
(continuous), at 6-12 months follow-up

22.5.7 Secondary: impulsivity (continuous),
at end of treatment

22.5.8 Secondary: impulsivity (continuous),
at 6-12 months follow-up

22.5.9 Secondary: depression (continuous),
at end of treatment

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

50

50

50

26

26

38

21

38

21

38

21

38

21

38

Mean Difference (IV,
Fixed, 95% CI)

0.76 [-8.20, 9.72]

Mean Difference (IV,
Fixed, 95% CI)

3.13 [-4.05,
10.31]

Mean Difference (IV,
Fixed, 95% CI)

0.77 [-7.08, 8.62]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

-5.30 [-12.36,
1.76]

Mean Difference (IV,
Fixed, 95% CI)

-0.40 [-4.72, 3.92]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

0.74 [-0.03, 1.51]

-0.63 [-1.75, 0.49]

0.69 [-2.60, 3.98]

-2.43 [-6.14, 1.28]

-0.43 [-1.31, 0.45]

-0.98 [-2.02, 0.06]

-1.01 [-3.85, 1.83]

-2.18 [-5.91, 1.55]

1.04 [-5.59, 7.67]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

425

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

22.5.10 Secondary: depression (continuous),
at 6-12 months follow-up

22.6 CBT vs Rogerian supportive therapy,
secondary: attrition (dichotomous), end of
treatment

22.7 MACT (Manual-assisted Cognitive Ther-
apy) vs MACT + therapeutic assessment
(MACT + TA) (continuous)

22.7.1 Primary: BPD symptom severity (con-
tinuous), at end of treatment

22.7.2 Primary: self-harm (continuous), at
end of treatment

22.7.3 Primary: suicide-related outcomes
(continuous), at end of treatment

22.7.4 Secondary: affective instability (con-
tinuous), at end of treatment

22.7.5 Secondary: interpersonal problems
(continuous), at end of treatment

22.7.6 Secondary: identity disturbance (con-
tinuous), at end of treatment

22.8 MACT vs MACT + TA, secondary: attrition
(dichotomous), at end of treatment

22.9 Meta-Cognitive training for BPD (B-MCT)
vs progressive muscle relaxation training
(PMR)

22.9.1 Primary: BPD symptom severity (con-
tinuous), at end of treatment

22.9.2 Primary: BPD symptom severity (con-
tinuous), at 0-6 months follow up

22.9.3 Secondary: depression (continuous),
at end of treatment

22.9.4 Secondary: depression (continuous),
at 0-6 months follow-up

22.10 B-MCT vs progressive muscle relax-
ation (PMR) training + TAU (dichotomous).
Secondary: attrition (dichotomous), at end
of treatment

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

21

16

16

16

16

16

16

49

39

54

47

Mean Difference (IV,
Fixed, 95% CI)

-5.15 [-9.38,
-0.92]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Mean Difference (IV,
Random, 95% CI)

Subtotals only

Mean Difference (IV,
Random, 95% CI)

-3.75 [-14.17,
6.67]

Mean Difference (IV,
Random, 95% CI)

1.75 [-18.71,
22.21]

Mean Difference (IV,
Random, 95% CI)

-0.63 [-17.71,
16.45]

Mean Difference (IV,
Random, 95% CI)

-5.25 [-12.10,
1.60]

Mean Difference (IV,
Random, 95% CI)

-0.50 [-11.24,
10.24]

Mean Difference (IV,
Random, 95% CI)

-4.88 [-14.98,
5.22]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

-1.80 [-4.97, 1.37]

Mean Difference (IV,
Fixed, 95% CI)

-3.60 [-7.16,
-0.04]

Mean Difference (IV,
Fixed, 95% CI)

Mean Difference (IV,
Fixed, 95% CI)

-3.20 [-9.91, 3.51]

8.50 [2.03, 14.97]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

426

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

22.11 MOTR (Motive-Oriented Therapeutic
Relationship) vs Good Psychiatric Manage-
ment (GPM) (continuous)

22.11.1 Primary: BPD symptom severity
(continuous), at end of treatment

22.11.2 Primary: psychosocial functioning
(continuous), at end of treatment

22.11.3 Secondary: interpersonal problems
(continuous), at end of treatment

22.12 MOTR vs (GPM), secondary: attrition
(dichotomous), at end of treatment

2

1

2

2

2

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

0.07 [-0.39, 0.53]

Std. Mean Difference (IV,
Random, 95% CI)

-0.45 [-0.85,
-0.05]

Std. Mean Difference (IV,
Random, 95% CI)

-0.56 [-0.97,
-0.16]

Risk Ratio (M-H, Ran-
dom, 95% CI)

0.61 [0.26, 1.41]

74

99

99

110

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

427

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 22.1.   Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active
treatment, Outcome 1: CBT vs trauma- and anxiety-related group psychoeducation (continuous)

Study or Subgroup

Mean

CBT
SD

Total

Psychoeducation
SD

Total

Mean

22.1.1 Primary: BPD symptom severity (continuous), at end of treatment
2.48
Kredlow 2017b (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.42 (P = 0.67)

27
27

3.32

3.58

1.7

22.1.2 Primary: BPD symptom severity (continuous), at 0-6 months follow-up
Kredlow 2017b (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.63 (P = 0.53)

27
27

3.42

2.17

2.17

3.81

22.1.3 Primary: BPD symptom severity (continuous), at 6-12 months follow-up
Kredlow 2017b (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.06 (P = 0.29)

27
27

1.54

3.24

2.14

2.67

22.1.4 Primary: psychosocial functioning (continuous), at end of treatment
9.94
Kredlow 2017b (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.24 (P = 0.81)

-53.36

-52.72

27
27

8.28

22.1.5 Primary: psychosocial functioning (continuous), at 0-6 months follow-up
Kredlow 2017b (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.42 (P = 0.67)

-50.04

-48.81

27
27

10.74

9.7

22.1.6 Primary: psychosocial functioning (continuous), at 6-12 months follow-up
Kredlow 2017b (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.21 (P = 0.83)

-53.04

-53.65

27
27

11.52

8.1

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

23
23

100.0%
100.0%

-0.26 [-1.46 , 0.94]
-0.26 [-1.46 , 0.94]

23
23

100.0%
100.0%

-0.39 [-1.60 , 0.82]
-0.39 [-1.60 , 0.82]

23
23

100.0%
100.0%

0.57 [-0.48 , 1.62]
0.57 [-0.48 , 1.62]

23
23

100.0%
100.0%

-0.64 [-5.76 , 4.48]
-0.64 [-5.76 , 4.48]

23
23

100.0%
100.0%

-1.23 [-6.94 , 4.48]
-1.23 [-6.94 , 4.48]

23
23

100.0%
100.0%

0.61 [-5.00 , 6.22]
0.61 [-5.00 , 6.22]

22.1.7 Secondary: depression (continuous), at end of treatment
30.44
31.2
Kredlow 2017b (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.17 (P = 0.87)

27
27

14.49

22.1.8 Secondary: depression (continuous), at 0-6 months follow-up
Kredlow 2017b (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.85 (P = 0.39)

27
27

12.64

29.25

32.38

17.38

23
23

100.0%
100.0%

0.76 [-8.20 , 9.72]
0.76 [-8.20 , 9.72]

13.15

23
23

100.0%
100.0%

3.13 [-4.05 , 10.31]
3.13 [-4.05 , 10.31]

22.1.9 Secondary: depression (continuous), at 6-12 months follow-up
Kredlow 2017b (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.19 (P = 0.85)

27
27

14.63

25.83

26.6

13.67

Footnotes
(1) Clinician rated: SCID-BPD
(2) Clinician rated: ZAN-BPD
(3) Clinician rated: GAF
(4) Clinician rated: SDS
(5) Clinician rated: BDI-II

23
23

100.0%
100.0%

0.77 [-7.08 , 8.62]
0.77 [-7.08 , 8.62]

-10

-5
Favours CBT

0

5

10

Favours Psychoeducation

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

428

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 22.2.   Comparison 22: Cognitive behavioural therapy (CBT) and related
treatments vs active treatment, Outcome 2: CBT vs trauma- and anxiety-related
group psychoeducation, secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

CBT

Psychoeducation
Total
Events

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Kredlow 2017b

7

27

3

23

1.99 [0.58 , 6.82]

Test for subgroup differences: Not applicable

0.01

0.1
Favours CBT

1

10

100

Favours Psychoeducation

Analysis 22.3.   Comparison 22: Cognitive behavioural therapy (CBT) and related treatments
vs active treatment, Outcome 3: CBT vs interpersonal psychotherapy (IPT) (continuous)

Study or Subgroup

Mean

CBT
SD

Total

Mean

IPT
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

22.3.1 Primary: psychosocial functioning (continuous), at end of treatment
8.6
Bellino 2007 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.47 (P = 0.14)

12
12

-70.3

-65

9.6

14
14

100.0%
100.0%

-5.30 [-12.36 , 1.76]
-5.30 [-12.36 , 1.76]

22.3.2 Secondary: depression (continuous), at end of treatment
14.1
13.7
Bellino 2007 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.18 (P = 0.86)

12
12

5.7

5.5

14
14

100.0%
100.0%

-0.40 [-4.72 , 3.92]
-0.40 [-4.72 , 3.92]

Footnotes
(1) Clinician rated: SOFAS
(2) Clinician rated: Ham-D

-20 -10 0

Favours CBT

10 20
Favours IPT

Analysis 22.4.   Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs
active treatment, Outcome 4: CBT vs IPT, secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

CBT

IPT

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Bellino 2007

4

16

2

16

2.00 [0.42 , 9.42]

Test for subgroup differences: Not applicable

0.001

0.1
Favours CBT

1

10

1000

Favours IPT

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

429

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 22.5.   Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment,
Outcome 5: CBT vs Rogerian supportive therapy (continuous)

Study or Subgroup

Mean

CBT
SD

Total

Rogerian support
SD

Total

Mean

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

22.5.1 Primary: self-harm (continuous), end of treatment
Cottraux 2009 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.88 (P = 0.06)

20
20

1.36

1.8

1.06

1.06

18
18

100.0%
100.0%

0.74 [-0.03 , 1.51]
0.74 [-0.03 , 1.51]

22.5.2 Primary: self-harm (continuous), at 6-12 months follow-up
Cottraux 2009 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.10 (P = 0.27)

10
10

0.73

1.19

1.36

1.43

11
11

100.0%
100.0%

-0.63 [-1.75 , 0.49]
-0.63 [-1.75 , 0.49]

22.5.3 Primary: suicide-related outcomes (continuous), at end of treatment
4.98
Cottraux 2009 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.41 (P = 0.68)

20
20

7.25

5.37

6.56

22.5.4 Primary: suicide-related outcomes (continuous), at 6-12 months follow-up
Cottraux 2009 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.29 (P = 0.20)

10
10

4.84

7.73

5.3

3.8

22.5.5 Primary: psychosocial functioning (continuous), at end of treatment
1.35
Cottraux 2009 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.96 (P = 0.34)

20
20

1.42

3.35

3.78

22.5.6 Primary: psychosocial functioning (continuous), at 6-12 months follow-up
Cottraux 2009 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.84 (P = 0.07)

10
10

1.03

3.18

1.4

2.2

18
18

100.0%
100.0%

0.69 [-2.60 , 3.98]
0.69 [-2.60 , 3.98]

11
11

100.0%
100.0%

-2.43 [-6.14 , 1.28]
-2.43 [-6.14 , 1.28]

18
18

100.0%
100.0%

-0.43 [-1.31 , 0.45]
-0.43 [-1.31 , 0.45]

11
11

100.0%
100.0%

-0.98 [-2.02 , 0.06]
-0.98 [-2.02 , 0.06]

22.5.7 Secondary: impulsivity (continuous), at end of treatment
8.61
7.6
Cottraux 2009 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.70 (P = 0.49)

20
20

3.82

22.5.8 Secondary: impulsivity (continuous), at 6-12 months follow-up
Cottraux 2009 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.14 (P = 0.25)

10
10

4.55

4.66

6.73

22.5.9 Secondary: depression (continuous), at end of treatment
12.56
13.6
Cottraux 2009 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.31 (P = 0.76)

20
20

11.29

4.97

18
18

100.0%
100.0%

-1.01 [-3.85 , 1.83]
-1.01 [-3.85 , 1.83]

4

11
11

100.0%
100.0%

-2.18 [-5.91 , 1.55]
-2.18 [-5.91 , 1.55]

9.56

18
18

100.0%
100.0%

1.04 [-5.59 , 7.67]
1.04 [-5.59 , 7.67]

22.5.10 Secondary: depression (continuous), at 6-12 months follow-up
Cottraux 2009 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.38 (P = 0.02)

10
10

11.55

4.48

6.4

5.41

11
11

100.0%
100.0%

-5.15 [-9.38 , -0.92]
-5.15 [-9.38 , -0.92]

Footnotes
(1) SHBCL (CR)

-10
Favours CBT

-5

0

5

10

Favours Rogerian support

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

430

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 22.5.   (Continued)

Footnotes
(1) SHBCL (CR)
(2) BHS (SR)
(3) CGI-S (CR)
(4) IVE-impulsivity (SR)
(5) BDI (SR)

Cochrane Database of Systematic Reviews

-10
Favours CBT

-5

0

5

10

Favours Rogerian support

Analysis 22.6.   Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment,
Outcome 6: CBT vs Rogerian supportive therapy, secondary: attrition (dichotomous), end of treatment

Study or Subgroup

Events

Total

CBT

Rogerian support
Total
Events

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Cottraux 2009

13

33

14

32

0.90 [0.51 , 1.60]

Test for subgroup differences: Not applicable

0.01

0.1
Favours CBT

1

10

100

Favours Rogerian support

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

431

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 22.7.   Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active treatment,
Outcome 7: MACT (Manual-assisted Cognitive Therapy) vs MACT + therapeutic assessment (MACT + TA) (continuous)

Study or Subgroup

Mean

MACT
SD

Total

Mean

MACT + TA
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

22.7.1 Primary: BPD symptom severity (continuous), at end of treatment
12.07
Morey 2010 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.71 (P = 0.48)

82.75

8.96

8
8

79

8
8

100.0%
100.0%

-3.75 [-14.17 , 6.67]
-3.75 [-14.17 , 6.67]

22.7.2 Primary: self-harm (continuous), at end of treatment
73.38
Morey 2010 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.17 (P = 0.87)

22.41

8
8

71.63

19.23

8
8

100.0%
100.0%

1.75 [-18.71 , 22.21]
1.75 [-18.71 , 22.21]

22.7.3 Primary: suicide-related outcomes (continuous), at end of treatment
18.93
Morey 2010 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.07 (P = 0.94)

80.88

80.25

15.78

8
8

22.7.4 Secondary: affective instability (continuous), at end of treatment
Morey 2010 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.50 (P = 0.13)

79.88

74.63

5.66

8
8

8.11

22.7.5 Secondary: interpersonal problems (continuous), at end of treatment
Morey 2010 (5)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.09 (P = 0.93)

74.38

73.88

12.1

9.68

8
8

22.7.6 Secondary: identity disturbance (continuous), at end of treatment
Morey 2010 (6)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.95 (P = 0.34)

78.13

73.25

5.95

8
8

13.31

8
8

100.0%
100.0%

-0.63 [-17.71 , 16.45]
-0.63 [-17.71 , 16.45]

8
8

100.0%
100.0%

-5.25 [-12.10 , 1.60]
-5.25 [-12.10 , 1.60]

8
8

100.0%
100.0%

-0.50 [-11.24 , 10.24]
-0.50 [-11.24 , 10.24]

8
8

100.0%
100.0%

-4.88 [-14.98 , 5.22]
-4.88 [-14.98 , 5.22]

Footnotes
(1) Personality Assessment Inventory (PAI)-BOR-total
(2) PAI-BOR-S
(3) PAI-SI
(4) PAI-BOR-A
(5) PAI-BOR-N
(6) PAI-BOR-I

-50

-25

0

25

50

Favours MACT

Favours MACT + TA

Analysis 22.8.   Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active
treatment, Outcome 8: MACT vs MACT + TA, secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

MACT

MACT + TA

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Morey 2010

4

8

5

8

0.80 [0.33 , 1.92]

Test for subgroup differences: Not applicable

0.01

0.1

1

10

100

Favours MACT

Favours MACT + TA

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

432

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 22.9.   Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active
treatment, Outcome 9: Meta-Cognitive training for BPD (B-MCT) vs progressive muscle relaxation training (PMR)

Study or Subgroup

Mean

B-MCT
SD

Total

Mean

PMR
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

22.9.1 Primary: BPD symptom severity (continuous), at end of treatment
6.2
Schilling 2018 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.11 (P = 0.27)

24
24

9.7

7.9

5.1

22.9.2 Primary: BPD symptom severity (continuous), at 0-6 months follow up
Schilling 2018 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.98 (P = 0.05)

16
16

11.4

4.9

7.8

6

25
25

100.0%
100.0%

-1.80 [-4.97 , 1.37]
-1.80 [-4.97 , 1.37]

23
23

100.0%
100.0%

-3.60 [-7.16 , -0.04]
-3.60 [-7.16 , -0.04]

22.9.3 Secondary: depression (continuous), at end of treatment
22.8
19.6
Schilling 2018 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.93 (P = 0.35)

28
28

12.2

22.9.4 Secondary: depression (continuous), at 0-6 months follow-up
Schilling 2018 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.58 (P = 0.01)

22
22

13.9

11.1

5.4

12.9

26
26

100.0%
100.0%

-3.20 [-9.91 , 3.51]
-3.20 [-9.91 , 3.51]

11.5

25
25

100.0%
100.0%

8.50 [2.03 , 14.97]
8.50 [2.03 , 14.97]

Footnotes
(1) Clinician rated: BSL
(2) Self rated: BDI

-20

-10

0

10

20

Favours B-MCT

Favours PRM

Analysis 22.10.   Comparison 22: Cognitive behavioural therapy (CBT) and related
treatments vs active treatment, Outcome 10: B-MCT vs progressive muscle relaxation (PMR)
training + TAU (dichotomous). Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

B-MCT

PMR + TAU

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Schilling 2018

10

38

10

36

0.95 [0.45 , 2.00]

Test for subgroup differences: Not applicable

0.001

0.1
Favours B-MCT

1

10

1000

Favours PMR + TAU

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

433

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 22.11.   Comparison 22: Cognitive behavioural therapy (CBT) and
related treatments vs active treatment, Outcome 11: MOTR (Motive-Oriented
Therapeutic Relationship) vs Good Psychiatric Management (GPM) (continuous)

Study or Subgroup

Mean

MOTR
SD

Total

Mean

GPM
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

22.11.1 Primary: BPD symptom severity (continuous), at end of treatment
0.97
Kramer 2014 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.30 (P = 0.76)

36
36

1.51

0.99

1.58

22.11.2 Primary: psychosocial functioning (continuous), at end of treatment
Kramer 2011 (2)
Kramer 2014 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.83); I² = 0%
Test for overall effect: Z = 2.22 (P = 0.03)

-0.43
14.97

-1.81
11.97

3.23
5.98

3.93
6.41

11
36
47

22.11.3 Secondary: interpersonal problems (continuous), at end of treatment
Kramer 2011 (3)
Kramer 2014 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.53, df = 1 (P = 0.47); I² = 0%
Test for overall effect: Z = 2.73 (P = 0.006)

-0.71
14.97

-3.18
11.97

2.16
5.98

3.6
6.41

11
36
47

38
38

100.0%
100.0%

0.07 [-0.39 , 0.53]
0.07 [-0.39 , 0.53]

14
38
52

25.2%
74.8%
100.0%

-0.38 [-1.17 , 0.42]
-0.48 [-0.94 , -0.02]
-0.45 [-0.85 , -0.05]

14
38
52

23.8%
76.2%
100.0%

-0.83 [-1.66 , -0.00]
-0.48 [-0.94 , -0.02]
-0.56 [-0.97 , -0.16]

Footnotes
(1) Self rated: BSL-23
(2) Self rated: OQ45, social role
(3) OQ-45 - interpersonal problems (SR)

-4
Favours CBT-related

-2

0

2

4
Favours Active control

Analysis 22.12.   Comparison 22: Cognitive behavioural therapy (CBT) and related treatments vs active
treatment, Outcome 12: MOTR vs (GPM), secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

Weight

MOTR

GPM

Risk Ratio
M-H, Random, 95% CI

Risk Ratio
M-H, Random, 95% CI

Kramer 2011
Kramer 2014

2
11

11
42

8
14

14
43

30.1%
69.9%

0.32 [0.08 , 1.21]
0.80 [0.41 , 1.56]

Total (95% CI)
13
Total events:
Heterogeneity: Tau² = 0.15; Chi² = 1.51, df = 1 (P = 0.22); I² = 34%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable

53

57

22

100.0%

0.61 [0.26 , 1.41]

0.005

0.1

1

10

200

Favours MOTR

Favours GPM

Comparison 23.   Schema-focused therapy (SFT) vs active treatment

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

23.1 SFT vs TFP. Primary: BPD symptom
severity (continuous), at end of treatment

23.2 SFT vs TFP. Secondary: attrition (dichoto-
mous), at 0-6 months follow-up

1

1

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

434

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

23.3 SFT vs SFT + therapist availability (TA).
Primary: BPD symptom severity (continuous),
at end of treatment

23.4 SFT vs SFT + TA. Secondary: attrition (di-
chotomous), 0-6 months follow-up

1

1

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Analysis 23.1.   Comparison 23: Schema-focused therapy (SFT) vs active treatment,
Outcome 1: SFT vs TFP. Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Mean

SFT
SD

Total

Mean

TFP
SD

Mean Difference
IV, Fixed, 95% CI

Total

Mean Difference
IV, Fixed, 95% CI

Giesen-Bloo 2006 (1)

17.7631

11.3231

44

22.7148

10.6149

42

-4.95 [-9.59 , -0.31]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinical rated: BPDSI-IV

-20 -10 0

Favours SFT

10 20
Favours TFP

Analysis 23.2.   Comparison 23: Schema-focused therapy (SFT) vs active treatment,
Outcome 2: SFT vs TFP. Secondary: attrition (dichotomous), at 0-6 months follow-up

Study or Subgroup

Events

Total

Events

Total

SFT

TFP

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Giesen-Bloo 2006

12

45

22

43

0.52 [0.30 , 0.92]

Test for subgroup differences: Not applicable

0.01

0.1
Favours SFT

1

10
Favours TFP

100

Analysis 23.3.   Comparison 23: Schema-focused therapy (SFT) vs active treatment, Outcome 3: SFT
vs SFT + therapist availability (TA). Primary: BPD symptom severity (continuous), at end of treatment

Study or Subgroup

Mean

SFT
SD

Total

Mean

SFT + TA
SD

Total

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

Nadort 2009 (1)

16.77

9.91

30

17.07

10.86

31

-0.30 [-5.51 , 4.91]

Test for subgroup differences: Not applicable

Footnotes
(1) Clinical rated: BPDSI-IV

-20 -10
Favours SFT

0

10 20
Favours SFT + TA

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

435

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 23.4.   Comparison 23: Schema-focused therapy (SFT) vs active treatment,
Outcome 4: SFT vs SFT + TA. Secondary: attrition (dichotomous), 0-6 months follow-up

Study or Subgroup

Events

Total

Events

Total

SFT

SFT + TA

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Nadort 2009

6

30

7

32

0.91 [0.35 , 2.41]

Test for subgroup differences: Not applicable

0.2

0.05
Favours SFT

1

5

20

Favours SFT + TA

Comparison 24.   Systems training for emotional predictability and problem solving-based psychoeducation
(STEPPS-PE) vs cognitive rehabilitation (CR)

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

24.1 STEPPS-PE vs CR

24.1.1 Primary: BPD symptom severity
(continuous), at end of treatment

24.1.2 Primary: BPD symptom severity
(continuous), at 0-6 months follow-up

24.1.3 Secondary: impulsivity (continu-
ous), at end of treatment

24.1.4 Secondary: impulsivity (continu-
ous), at 0-6 months follow-up

24.1.5 Secondary: depression (continu-
ous), at end of treatment

24.1.6 Secondary: depression (continu-
ous), at 0-6 months follow-up

24.2 STEPPS-PE vs CR. Secondary: attri-
tion (dichotomous), at end of treatment

1

1

1

1

1

1

1

1

46

42

46

42

48

42

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

-3.67 [-6.52,
-0.82]

Mean Difference (IV, Fixed,
95% CI)

4.68 [1.42, 7.94]

Mean Difference (IV, Fixed,
95% CI)

1.99 [0.06, 3.92]

Mean Difference (IV, Fixed,
95% CI)

9.92 [7.38, 12.46]

Mean Difference (IV, Fixed,
95% CI)

-2.58 [-3.62,
-1.54]

Mean Difference (IV, Fixed,
95% CI)

-10.11 [-11.35,
-8.87]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

436

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 24.1.   Comparison 24: Systems training for emotional predictability and problem solving-
based psychoeducation (STEPPS-PE) vs cognitive rehabilitation (CR), Outcome 1: STEPPS-PE vs CR

Study or Subgroup

Mean

STEPPS-PE
SD

Total

Mean

CR
SD

Total

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

24.1.1 Primary: BPD symptom severity (continuous), at end of treatment
5
Pascual 2015 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.52 (P = 0.01)

24
24

38.89

42.56

4.86

24.1.2 Primary: BPD symptom severity (continuous), at 0-6 months follow-up
Pascual 2015 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.81 (P = 0.005)

22
22

39.59

34.91

5.25

5.53

22
22

100.0%
100.0%

-3.67 [-6.52 , -0.82]
-3.67 [-6.52 , -0.82]

20
20

100.0%
100.0%

4.68 [1.42 , 7.94]
4.68 [1.42 , 7.94]

24.1.3 Secondary: impulsivity (continuous), at end of treatment
65.93
67.92
Pascual 2015 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.02 (P = 0.04)

24
24

3.33

24.1.4 Secondary: impulsivity (continuous), at 0-6 months follow-up
Pascual 2015 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 7.66 (P < 0.00001)

22
22

67.06

57.14

4.35

24.1.5 Secondary: depression (continuous), at end of treatment
19.16
16.58
Pascual 2015 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.86 (P < 0.00001)

24
24

1.85

24.1.6 Secondary: depression (continuous), at 0-6 months follow-up
Pascual 2015 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 15.94 (P < 0.00001)

22
22

20.02

9.91

2.13

3.34

22
22

100.0%
100.0%

1.99 [0.06 , 3.92]
1.99 [0.06 , 3.92]

4.04

20
20

100.0%
100.0%

9.92 [7.38 , 12.46]
9.92 [7.38 , 12.46]

1.83

24
24

100.0%
100.0%

-2.58 [-3.62 , -1.54]
-2.58 [-3.62 , -1.54]

1.98

20
20

100.0%
100.0%

-10.11 [-11.35 , -8.87]
-10.11 [-11.35 , -8.87]

Footnotes
(1) BSL-23 (SR)
(2) BIS (SR)
(3) MADRS (CR)

-20

-10

0

Favours STEPPS-PE

10
Favours CR

20

Analysis 24.2.   Comparison 24: Systems training for emotional predictability and
problem solving-based psychoeducation (STEPPS-PE) vs cognitive rehabilitation (CR),
Outcome 2: STEPPS-PE vs CR. Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

STEPPS-PE

CR

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Pascual 2015

10

34

14

36

0.76 [0.39 , 1.47]

Test for subgroup differences: Not applicable

0.02

0.1

1

Favours STEPPS-PE

10
Favours CR

50

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

437

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 25.   Eclectic treatments vs active treatment

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

25.1 Combined inpatient and outpatient psy-
chotherapy versus outpatient psychotherapy

25.1.1 Primary: psychosocial functioning
(continuous), at end of treatment

25.1.2 Primary: psychosocial functioning
(continuous), at above 12 months follow-up

25.1.3 Secondary: interpersonal problems
(continuous), at end of treatment

25.1.4 Secondary: interpersonal problems
(continuous), at above 12 months follow-up

25.1.5 Secondary: identity disturbance (con-
tinuous), at end of treatment

25.1.6 Secondary: identity disturbance (con-
tinuous), at above 12 months follow-up

25.1.7 Secondary: depression (continuous), at
end of treatment

25.1.8 Secondary: depression (continuous), at
above 12 months follow-up

25.2 Combined inpatient and outpatient psy-
chotherapy versus outpatient psychotherapy.
Secondary: attrition (dichotomous), at end of
treatment

25.3 integrative BPD-oriented adolescent
family therapy (I-BAFT) vs individual drug
counselling (IDC)

25.3.1 Primary: BPD symptom severity (di-
chotomous), at end of treatment

25.3.2 Secondary: attrition (dichotomous), at
6-12 months follow-up

1

1

1

1

1

1

1

1

1

1

1

1

1

52

52

52

52

52

52

52

52

40

40

Mean Difference (IV,
Fixed, 95% CI)

Subtotals only

Mean Difference (IV,
Fixed, 95% CI)

6.50 [-0.06,
13.06]

Mean Difference (IV,
Fixed, 95% CI)

-5.70 [-13.33,
1.93]

Mean Difference (IV,
Fixed, 95% CI)

0.05 [-0.24, 0.34]

Mean Difference (IV,
Fixed, 95% CI)

-0.42 [-0.77,
-0.07]

Mean Difference (IV,
Fixed, 95% CI)

-0.25 [-0.59, 0.09]

Mean Difference (IV,
Fixed, 95% CI)

-0.47 [-0.78,
-0.16]

Mean Difference (IV,
Fixed, 95% CI)

-0.40 [-6.25, 5.45]

Mean Difference (IV,
Fixed, 95% CI)

-4.70 [-11.02,
1.62]

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

Subtotals only

Risk Ratio (M-H, Fixed,
95% CI)

0.91 [0.50, 1.64]

Risk Ratio (M-H, Fixed,
95% CI)

0.50 [0.18, 1.40]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

438

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 25.1.   Comparison 25: Eclectic treatments vs active treatment, Outcome 1:
Combined inpatient and outpatient psychotherapy versus outpatient psychotherapy

Study or Subgroup

Combined psychotherapy
Total
SD
Mean

Outpatient psychotherapy
Total
SD
Mean

Weight

Mean Difference
IV, Fixed, 95% CI

Mean Difference
IV, Fixed, 95% CI

25.1.1 Primary: psychosocial functioning (continuous), at end of treatment
Antonsen 2017 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.94 (P = 0.05)

27
27

-58.5

13.2

-65

10.9

25
25

100.0%
100.0%

6.50 [-0.06 , 13.06]
6.50 [-0.06 , 13.06]

25.1.2 Primary: psychosocial functioning (continuous), at above 12 months follow-up
12.9
Antonsen 2017 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.46 (P = 0.14)

27
27

-64.2

-58.5

15

25.1.3 Secondary: interpersonal problems (continuous), at end of treatment
Antonsen 2017 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.33 (P = 0.74)

27
27

1.31

1.36

0.4

0.64

25.1.4 Secondary: interpersonal problems (continuous), at above 12 months follow-up
0.62
Antonsen 2017 (2)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.36 (P = 0.02)

27
27

0.66

1.42

1

25
25

100.0%
100.0%

-5.70 [-13.33 , 1.93]
-5.70 [-13.33 , 1.93]

25
25

100.0%
100.0%

0.05 [-0.24 , 0.34]
0.05 [-0.24 , 0.34]

25
25

100.0%
100.0%

-0.42 [-0.77 , -0.07]
-0.42 [-0.77 , -0.07]

25.1.5 Secondary: identity disturbance (continuous), at end of treatment
Antonsen 2017 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.45 (P = 0.15)

27
27

-2.78

-2.53

0.6

0.64

25
25

100.0%
100.0%

-0.25 [-0.59 , 0.09]
-0.25 [-0.59 , 0.09]

25.1.6 Secondary: identity disturbance (continuous), at above 12 months follow-up
Antonsen 2017 (3)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.97 (P = 0.003)

27
27

-2.43

0.59

0.55

-2.9

25
25

100.0%
100.0%

-0.47 [-0.78 , -0.16]
-0.47 [-0.78 , -0.16]

25.1.7 Secondary: depression (continuous), at end of treatment
13.4
Antonsen 2017 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.13 (P = 0.89)

27
27

11.7

13.8

9.8

25
25

100.0%
100.0%

-0.40 [-6.25 , 5.45]
-0.40 [-6.25 , 5.45]

25.1.8 Secondary: depression (continuous), at above 12 months follow-up
Antonsen 2017 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.46 (P = 0.14)

27
27

10.7

16.3

11.6

Footnotes
(1) Clinician rated: GAF
(2) Self reported: CIP
(3) Self reported: SIPP
(4) Self rated: BDI

12.4

25
25

100.0%
100.0%

-4.70 [-11.02 , 1.62]
-4.70 [-11.02 , 1.62]

-20

-10

0

Favours Combined

10

20
Favours Outpatient alone

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

439

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 25.2.   Comparison 25: Eclectic treatments vs active treatment, Outcome
2: Combined inpatient and outpatient psychotherapy versus outpatient
psychotherapy. Secondary: attrition (dichotomous), at end of treatment

Study or Subgroup

Events

Total

Events

Total

Combined psychotherapy

Outpatient psychotherapy

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

Antonsen 2017 (1)

6

27

9

25

0.62 [0.26 , 1.49]

Footnotes
(1) drop-outs at 3-year follow-up (time point closest to average treatment end at 28 months)

0.1
0.001
Favours Combined

1

10

1000

Favours Outpatient alone

Analysis 25.3.   Comparison 25: Eclectic treatments vs active treatment, Outcome 3: integrative
BPD-oriented adolescent family therapy (I-BAFT) vs individual drug counselling (IDC)

Study or Subgroup

Events

Total

Events

Total

Weight

I-BAFT

IDC

Risk Ratio
M-H, Fixed, 95% CI

Risk Ratio
M-H, Fixed, 95% CI

25.3.1 Primary: BPD symptom severity (dichotomous), at end of treatment
100.0%
Santisteban 2015 (1)
100.0%
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.32 (P = 0.75)

20
20

20
20

10

10

11

11

25.3.2 Secondary: attrition (dichotomous), at 6-12 months follow-up
Santisteban 2015
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.32 (P = 0.19)

20
20

20
20

8

4

8

4

100.0%
100.0%

0.91 [0.50 , 1.64]
0.91 [0.50 , 1.64]

0.50 [0.18 , 1.40]
0.50 [0.18 , 1.40]

Test for subgroup differences: Chi² = 0.98, df = 1 (P = 0.32), I² = 0%

0.01
Favours I-BAFT

0.1

1

10
Favours IDC

100

Footnotes
(1) not improved or recovered

Comparison 26.   Subgroup analysis: therapeutic approaches

Outcome or sub-
group title

No. of studies

No. of partici-
pants

Statistical method

Effect size

26.1 BPD symptom
severity

26.1.1 DBT

26.1.2 MBT

26.1.3 Psychodynamic
psychotherapy

23

3

5

4

149

267

222

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.60 [-1.05, -0.14]

Std. Mean Difference (IV, Random, 95%
CI)

-0.13 [-0.38, 0.11]

Std. Mean Difference (IV, Random, 95%
CI)

-0.29 [-0.66, 0.09]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

440

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

No. of studies

No. of partici-
pants

Statistical method

Effect size

Outcome or sub-
group title

26.1.4 STEPPS

26.1.5 Eclectic treat-
ments

26.1.6 ACT

26.1.7 CBT

26.1.8 SFT

26.1.9 CAT

26.1.10 Tranfer-
ence-focused psy-
chotherapy

3

3

1

1

1

1

1

26.2 Psychosocial
functioning

22

26.2.1 DBT

26.2.2 MBT

26.2.3 Psychodynamic
psychotherapy

26.2.4 Eclectic treat-
ments

26.2.5 CBT

26.2.6 SFT

26.2.7 STEPPS

26.2.8 CAT

26.2.9 Motivation
feedback

26.2.10 Tranfer-
ence-focused psy-
chotherapy

6

3

4

2

1

1

1

1

1

1

273

134

41

26

28

9

104

225

239

140

231

99

28

124

9

43

104

Std. Mean Difference (IV, Random, 95%
CI)

-0.39 [-0.63, -0.15]

Std. Mean Difference (IV, Random, 95%
CI)

-0.90 [-1.57, -0.23]

Std. Mean Difference (IV, Random, 95%
CI)

-1.22 [-1.89, -0.55]

Std. Mean Difference (IV, Random, 95%
CI)

-1.28 [-2.14, -0.42]

Std. Mean Difference (IV, Random, 95%
CI)

-1.66 [-2.54, -0.78]

Std. Mean Difference (IV, Random, 95%
CI)

-0.53 [-1.88, 0.83]

Std. Mean Difference (IV, Random, 95%
CI)

-0.55 [-0.95, -0.16]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.36 [-0.69, -0.03]

Std. Mean Difference (IV, Random, 95%
CI)

-0.54 [-1.24, 0.16]

Std. Mean Difference (IV, Random, 95%
CI)

-0.69 [-1.98, 0.59]

Std. Mean Difference (IV, Random, 95%
CI)

-0.57 [-1.10, -0.04]

Std. Mean Difference (IV, Random, 95%
CI)

0.00 [-0.39, 0.39]

Std. Mean Difference (IV, Random, 95%
CI)

-1.20 [-2.03, -0.38]

Std. Mean Difference (IV, Random, 95%
CI)

-0.55 [-0.91, -0.19]

Std. Mean Difference (IV, Random, 95%
CI)

-1.22 [-2.73, 0.30]

Std. Mean Difference (IV, Random, 95%
CI)

-0.07 [-0.69, 0.55]

Std. Mean Difference (IV, Random, 95%
CI)

-0.34 [-0.73, 0.05]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

441

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or sub-
group title

No. of studies

No. of partici-
pants

Statistical method

Effect size

26.2.11 Once-only in-
tervention

1

72

Std. Mean Difference (IV, Random, 95%
CI)

0.03 [-0.43, 0.49]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

442

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 26.1.   Comparison 26: Subgroup analysis: therapeutic approaches, Outcome 1: BPD symptom severity

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

26.1.1 DBT
Koons 2001a (1)
Priebe 2012 (2)
Soler 2009 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 3.45, df = 2 (P = 0.18); I² = 42%
Test for overall effect: Z = 2.57 (P = 0.01)

3.6
13.1
3.5

4.2
15.9
4.44

10
33
29
72

1.6
6.9
1.2

26.1.2 MBT
Jørgensen 2013 (4)
Laurenssen 2018 (5)
Philips 2018 (6)
Robinson 2016 (7)
Rossouw 2012b (8)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.53, df = 4 (P = 0.82); I² = 0%
Test for overall effect: Z = 1.09 (P = 0.28)

2.5
11.45
9.1
7.41
0.5385

2.8
20.63
17
9.64
2.79

42
54
13
12
29
150

3.6
21.39
20.7
9.27
3.06

26.1.3 Psychodynamic psychotherapy
Amianto 2011 (9)
Gregory 2008b (10)
Leichsenring 2016 (11)
Reneses 2013 (12)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.06; Chi² = 4.83, df = 3 (P = 0.18); I² = 38%
Test for overall effect: Z = 1.50 (P = 0.13)

3.3
33.6
18.76
13

3.3
38.4
19.41
19.1

16
10
64
18
108

1
12.4
8.6
7.9

26.1.4 STEPPS
Blum 2008 (13)
Bos 2010 (14)
Schuppert 2012 (15)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.11, df = 2 (P = 0.58); I² = 0%
Test for overall effect: Z = 3.18 (P = 0.001)

8.0623
25.8
9.53

9.8
79.7
13.29

65
26
48
139

13.4
95.1
15.39

26.1.5 Eclectic treatments
Gratz 2006 (10)
Gratz 2014 (10)
Leppänen 2016 (16)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.23; Chi² = 6.11, df = 2 (P = 0.05); I² = 67%
Test for overall effect: Z = 2.64 (P = 0.008)

25.83
27.47
17.54

5.72
6.59
10.14

34.7
35.88
21.48

12
31
19
62

2.3
7.5
0.52

10
37
30
77

20.0%
42.7%
37.3%
100.0%

-0.29 [-1.17 , 0.59]
-0.38 [-0.86 , 0.09]
-1.01 [-1.55 , -0.47]
-0.60 [-1.05 , -0.14]

2.1
10.43
9.1
7.39
65.7267

24
41
11
11
30
117

23.3%
36.0%
9.0%
8.9%
22.8%
100.0%

-0.33 [-0.84 , 0.17]
-0.07 [-0.47 , 0.34]
-0.39 [-1.20 , 0.42]
0.05 [-0.77 , 0.87]
-0.01 [-0.52 , 0.50]
-0.13 [-0.38 , 0.11]

1.1
8.62
9.38
6.9

17
13
58
26
114

20.5%
15.3%
41.2%
23.0%
100.0%

0.00 [-0.68 , 0.68]
-0.44 [-1.28 , 0.39]
-0.07 [-0.43 , 0.28]
-0.82 [-1.45 , -0.19]
-0.29 [-0.66 , 0.09]

7.6811
29.1
9

59
26
49
134

45.2%
18.7%
36.1%
100.0%

-0.45 [-0.81 , -0.10]
-0.55 [-1.11 , 0.00]
-0.22 [-0.62 , 0.17]
-0.39 [-0.63 , -0.15]

10.81
5.59
11.41

10
30
32
72

26.2%
37.1%
36.7%
100.0%

-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.35 [-0.93 , 0.22]
-0.90 [-1.57 , -0.23]

26.1.6 ACT
Morton 2012 (17)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.56 (P = 0.0004)

32.76

12.47

26.1.7 CBT
Kredlow 2017a (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.92 (P = 0.003)

1.17

1.17

26.1.8 SFT
Farrell 2009 (18)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.68 (P = 0.0002)

18.81

9.47

21
21

14
14

16
16

47.42

11

20
20

100.0%
100.0%

-1.22 [-1.89 , -0.55]
-1.22 [-1.89 , -0.55]

4.25

3.2

12
12

100.0%
100.0%

-1.28 [-2.14 , -0.42]
-1.28 [-2.14 , -0.42]

32.75

5.9

12
12

100.0%
100.0%

-1.66 [-2.54 , -0.78]
-1.66 [-2.54 , -0.78]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

443

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 26.1.   (Continued)

Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.68 (P = 0.0002)

26.1.9 CAT
Gleeson 2012 (19)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.76 (P = 0.45)

0.8

1

26.1.10 Tranference-focused psychotherapy
1.54
Doering 2010 (20)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.77 (P = 0.006)

4.79

4
4

52
52

-1.66 [-2.54 , -0.78]

2.2

3

5
5

100.0%
100.0%

-0.53 [-1.88 , 0.83]
-0.53 [-1.88 , 0.83]

5.63

1.47

52
52

100.0%
100.0%

-0.55 [-0.95 , -0.16]
-0.55 [-0.95 , -0.16]

Test for subgroup differences: Chi² = 25.65, df = 9 (P = 0.002), I² = 64.9%

-4
Favours Psychotherapies

-2

0

2

4
Favours TAU

Footnotes
(1) SCID-II - mean number of BPD criteria met (CR)
(2) ZAN-BPD total (CR)
(3) CCGI-BPD global (CR)
(4) SCID-BPD (CR)
(5) BPDSI-IV (CR)
(6) BPDSI-IV-total (CR)
(7) Zan-BPD-total (CR)
(8) BPFS-C (SR)
(9) Clinician rated: CGI-BPD
(10) BEST (SR)
(11) Self rated: Borderline Personality Inventory
(12) Clinician rated: ZAN-BPD
(13) Zan-BPD - total (CR)
(14) Self reported: BPD-40
(15) BPDSI-IV total
(16) Clinician-rated: BPDSI-IV
(17) Self rated: BEST
(18) Self rated: BSI
(19) OAS-M - suicidality (CR)
(20) Clinician-rated: Mean number of DSM-IV BPD criteria met

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

444

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 26.2.   Comparison 26: Subgroup analysis: therapeutic approaches, Outcome 2: Psychosocial functioning

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

26.2.1 DBT
Carter 2010 (1)
Feigenbaum 2012 (2)
Kramer 2016 (3)
Linehan 1994 (4)
Mehlum 2014 (5)
Soler 2009 (6)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 7.20, df = 5 (P = 0.21); I² = 31%
Test for overall effect: Z = 2.14 (P = 0.03)

8.15
2.48
12.76
-51.42
-59.4
3.27

13.07
2.22
16
-40.43
-54.2
3.57

11.48
0.85
7.79
9.71
6.6
0.9

20
25
21
13
5
29
113

26.2.2 MBT
Bateman 1999 (7)
Bateman 2009 (7)
Jørgensen 2013 (7)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.32; Chi² = 11.92, df = 2 (P = 0.003); I² = 83%
Test for overall effect: Z = 1.50 (P = 0.13)

20
71
42
133

2.7
1.76
2.2

3.4
2.17
2.1

0.6
0.5
0.5

26.2.3 Psychodynamic psychotherapy
Amianto 2011 (8)
Gregory 2008b (9)
Reneses 2013 (10)
Salzer 2014 (11)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.57; Chi² = 35.63, df = 3 (P < 0.00001); I² = 92%
Test for overall effect: Z = 1.06 (P = 0.29)

-66.4
6.9
27.6
-51.82

-65.9
-9.7
35.4
-65

11.2
8.1
8.9
9.84

16
11
18
17
62

26.2.4 Eclectic treatments
Andreoli 2016 (12)
Gratz 2014 (13)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.09; Chi² = 2.70, df = 1 (P = 0.10); I² = 63%
Test for overall effect: Z = 2.12 (P = 0.03)

6.2343
6.24

-62.95
14.25

140
31
171

-57.6
16.01

11.59
0.92
5.42
10.8
6.1
1.13

0.6
0.64
0.6

13
6.7
10.8
6.82

7.6
6.24

28
16
20
13
5
30
112

20.6%
18.5%
18.8%
12.5%
5.8%
23.9%
100.0%

-0.42 [-1.00 , 0.16]
0.29 [-0.34 , 0.92]
-0.47 [-1.09 , 0.15]
-1.04 [-1.86 , -0.21]
-0.74 [-2.05 , 0.57]
-0.29 [-0.80 , 0.22]
-0.36 [-0.69 , -0.03]

19
63
24
106

29.4%
36.9%
33.7%
100.0%

-1.14 [-1.83 , -0.46]
-0.72 [-1.07 , -0.36]
0.18 [-0.32 , 0.69]
-0.54 [-1.24 , 0.16]

17
13
26
22
78

25.6%
23.3%
25.9%
25.3%
100.0%

0.04 [-0.64 , 0.72]
-2.17 [-3.22 , -1.13]
0.76 [0.14 , 1.38]
-1.56 [-2.29 , -0.83]
-0.69 [-1.98 , 0.59]

30
30
60

54.0%
46.0%
100.0%

-0.82 [-1.22 , -0.42]
-0.28 [-0.78 , 0.23]
-0.57 [-1.10 , -0.04]

26.2.5 CBT
Davidson 2006 (14)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)

13.1

4.4

26.2.6 SFT
Farrell 2009 (8)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.87 (P = 0.004)

-60.5

10.17

26.2.7 STEPPS
Blum 2008 (4)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.01 (P = 0.003)

-50.5

12.8996

26.2.8 CAT
Gleeson 2012 (15)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.58 (P = 0.11)

-67

8.3

26.2.9 Motivation feedback

52
52

16
16

65
65

4
4

13.1

4.6

47
47

100.0%
100.0%

0.00 [-0.39 , 0.39]
0.00 [-0.39 , 0.39]

-50.08

5.07

12
12

100.0%
100.0%

-1.20 [-2.03 , -0.38]
-1.20 [-2.03 , -0.38]

-43.5

12.2898

59
59

100.0%
100.0%

-0.55 [-0.91 , -0.19]
-0.55 [-0.91 , -0.19]

-50.6

14.1

5
5

100.0%
100.0%

-1.22 [-2.73 , 0.30]
-1.22 [-2.73 , 0.30]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

445

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 26.2.   (Continued)

Test for overall effect: Z = 1.58 (P = 0.11)

26.2.9 Motivation feedback
Jochems 2015 (16)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.22 (P = 0.83)

12.8

6.36

26.2.10 Tranference-focused psychotherapy
8.04
Doering 2010 (17)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.72 (P = 0.09)

-58.62

26.2.11 Once-only intervention
Borschmann 2013 (18)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.12 (P = 0.90)

26.06

7.98

16
16

52
52

36
36

13.22

5.8

27
27

100.0%
100.0%

-0.07 [-0.69 , 0.55]
-0.07 [-0.69 , 0.55]

-56.06

6.87

52
52

100.0%
100.0%

-0.34 [-0.73 , 0.05]
-0.34 [-0.73 , 0.05]

25.81

8.94

36
36

100.0%
100.0%

0.03 [-0.43 , 0.49]
0.03 [-0.43 , 0.49]

Favours Psychotherapies

-4 -2 0

4

2
Favours TAU

Test for subgroup differences: Chi² = 14.26, df = 10 (P = 0.16), I² = 29.9%

Footnotes
(1) BDQ-days out of role (SR)
(2) CORE-OM (SR)
(3) OQ45, social role at discharge (SR)
(4) GAS (CR)
(5) C-GAS (CR)
(6) CGI-global improvement, patient-rated (SR)
(7) SAS-SR (SR)
(8) Clinician rated: GAF
(9) SPS - "How many days were you paid for working in the past 30 days?") (SR)
(10) Self reported: SAS-SR (higher scores indicate poorer functioning)
(11) GAF (CR)
(12) Clinician rated: GAS
(13) Self rated: SDS
(14) Self rated: SFQ
(15) SOFAS (CR)
(16) Clinician-rated: HoNOS
(17) Clinician-rated: GAF
(18) WSAS (SR)

Comparison 27.   Subgroup analysis: age

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

27.1 BPD symptom severity

22

27.1.1 15 to 18 years old

2

27.1.2 Above 18 years old

20

156

1088

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.14 [-0.46, 0.17]

Std. Mean Difference (IV, Random, 95%
CI)

-0.57 [-0.76, -0.37]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

446

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 27.1.   Comparison 27: Subgroup analysis: age, Outcome 1: BPD symptom severity

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

27.1.1 15 to 18 years old
Rossouw 2012b (1)
Schuppert 2012 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.44, df = 1 (P = 0.51); I² = 0%
Test for overall effect: Z = 0.88 (P = 0.38)

0.5385
9.53

2.79
13.29

29
48
77

3.06
15.39

65.7267
9

30
49
79

38.0%
62.0%
100.0%

-0.01 [-0.52 , 0.50]
-0.22 [-0.62 , 0.17]
-0.14 [-0.46 , 0.17]

27.1.2 Above 18 years old
Amianto 2011 (3)
Blum 2008 (4)
Bos 2010 (5)
Doering 2010 (6)
Farrell 2009 (7)
Gratz 2006 (8)
Gratz 2014 (8)
Gregory 2008b (8)
Jørgensen 2013 (9)
Koons 2001a (10)
Kredlow 2017a (9)
Laurenssen 2018 (11)
Leichsenring 2016 (12)
Leppänen 2016 (13)
Morton 2012 (14)
Philips 2018 (15)
Priebe 2012 (16)
Reneses 2013 (17)
Robinson 2016 (18)
Soler 2009 (19)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.11; Chi² = 43.86, df = 19 (P = 0.0010); I² = 57%
Test for overall effect: Z = 5.63 (P < 0.00001)

1
8.0623
25.8
1.54
9.47
5.72
6.59
12.4
2.5
1.6
1.17
11.45
8.6
10.14
12.47
9.1
6.9
7.9
7.41
1.2

3.3
9.8
79.7
4.79
18.81
25.83
27.47
33.6
2.8
3.6
1.17
20.63
18.76
17.54
32.76
17
13.1
13
9.64
3.5

3.3
13.4
95.1
5.63
32.75
34.7
35.88
38.4
3.6
4.2
4.25
21.39
19.41
21.48
47.42
20.7
15.9
19.1
9.27
4.44

16
65
26
52
16
12
31
10
42
10
14
54
64
19
21
13
33
18
12
29
557

1.1
7.6811
29.1
1.47
5.9
10.81
5.59
8.62
2.1
2.3
3.2
10.43
9.38
11.41
11
9.1
7.5
6.9
7.39
0.52

17
59
26
52
12
10
30
13
24
10
12
41
58
32
20
11
37
26
11
30
531

4.5%
7.3%
5.5%
7.0%
3.3%
3.2%
5.4%
3.5%
5.9%
3.3%
3.4%
6.8%
7.3%
5.3%
4.5%
3.7%
6.2%
4.9%
3.6%
5.5%
100.0%

0.00 [-0.68 , 0.68]
-0.45 [-0.81 , -0.10]
-0.55 [-1.11 , 0.00]
-0.55 [-0.95 , -0.16]
-1.66 [-2.54 , -0.78]
-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.44 [-1.28 , 0.39]
-0.33 [-0.84 , 0.17]
-0.29 [-1.17 , 0.59]
-1.28 [-2.14 , -0.42]
-0.07 [-0.47 , 0.34]
-0.07 [-0.43 , 0.28]
-0.35 [-0.93 , 0.22]
-1.22 [-1.89 , -0.55]
-0.39 [-1.20 , 0.42]
-0.38 [-0.86 , 0.09]
-0.82 [-1.45 , -0.19]
0.05 [-0.77 , 0.87]
-1.01 [-1.55 , -0.47]
-0.57 [-0.76 , -0.37]

Test for subgroup differences: Chi² = 5.03, df = 1 (P = 0.02), I² = 80.1%

-4
Favours Psychotherapies

-2

0

2

4
Favours TAU

Footnotes
(1) BPFS-C (SR)
(2) BPDSI-IV total
(3) Clinician rated: CGI-BPD
(4) Zan-BPD - total (CR)
(5) Self reported: BPD-40
(6) Clinician-rated: Mean number of DSM-IV BPD criteria met
(7) Self rated: BSI
(8) BEST (SR)
(9) SCID-BPD (CR)
(10) SCID-II - mean number of BPD criteria met (CR)
(11) BPDSI-IV (CR)
(12) Self rated: Borderline Personality Inventory
(13) Clinician-rated: BPDSI-IV
(14) Self rated: BEST
(15) BPDSI-IV-total (CR)
(16) ZAN-BPD total (CR)
(17) Clinician rated: ZAN-BPD
(18) Zan-BPD-total (CR)
(19) CCGI-BPD global (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

447

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comparison 28.   Subgroup analysis: duration

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

28.1 BPD symptom sever-
ity

28.1.1 Less than 6
months

22

8

28.1.2 6 to 12 months

11

28.1.3 Above 12 months

3

28.2 Psychosocial func-
tioning

28.2.1 Less than 6
months

20

6

28.2.2 6 to 12 months

10

28.2.3 Over 12 months

4

525

606

113

468

535

263

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.76 [-1.10, -0.42]

Std. Mean Difference (IV, Random, 95%
CI)

-0.36 [-0.60, -0.12]

Std. Mean Difference (IV, Random, 95%
CI)

-0.37 [-0.75, 0.01]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.31 [-0.73, 0.11]

Std. Mean Difference (IV, Random, 95%
CI)

-0.25 [-0.49, -0.01]

Std. Mean Difference (IV, Random, 95%
CI)

-0.86 [-1.62, -0.10]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

448

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 28.1.   Comparison 28: Subgroup analysis: duration, Outcome 1: BPD symptom severity

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

28.1.1 Less than 6 months
Blum 2008 (1)
Bos 2010 (2)
Gratz 2006 (3)
Gratz 2014 (3)
Leichsenring 2016 (4)
Morton 2012 (5)
Reneses 2013 (6)
Soler 2009 (7)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.16; Chi² = 22.82, df = 7 (P = 0.002); I² = 69%
Test for overall effect: Z = 4.40 (P < 0.0001)

8.0623
25.8
5.72
6.59
8.6
12.47
7.9
1.2

9.8
79.7
25.83
27.47
18.76
32.76
13
3.5

13.4
95.1
34.7
35.88
19.41
47.42
19.1
4.44

65
26
12
31
64
21
18
29
266

28.1.2 6 to 12 months
Amianto 2011 (8)
Doering 2010 (9)
Farrell 2009 (10)
Koons 2001a (11)
Kredlow 2017a (12)
Laurenssen 2018 (13)
Leppänen 2016 (14)
Priebe 2012 (15)
Robinson 2016 (16)
Rossouw 2012b (17)
Schuppert 2012 (18)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 19.85, df = 10 (P = 0.03); I² = 50%
Test for overall effect: Z = 2.93 (P = 0.003)

1
1.54
9.47
1.6
1.17
11.45
10.14
6.9
7.41
0.5385
9.53

3.3
5.63
32.75
4.2
4.25
21.39
21.48
15.9
9.27
3.06
15.39

3.3
4.79
18.81
3.6
1.17
20.63
17.54
13.1
9.64
2.79
13.29

16
52
16
10
14
54
19
33
12
29
48
303

28.1.3 Above 12 months
Gregory 2008b (3)
Jørgensen 2013 (12)
Philips 2018 (19)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 2 (P = 0.97); I² = 0%
Test for overall effect: Z = 1.90 (P = 0.06)

33.6
2.8
17

12.4
2.5
9.1

10
42
13
65

38.4
3.6
20.7

7.6811
29.1
10.81
5.59
9.38
11
6.9
0.52

1.1
1.47
5.9
2.3
3.2
10.43
11.41
7.5
7.39
65.7267
9

59
26
10
30
58
20
26
30
259

17
52
12
10
12
41
32
37
11
30
49
303

15.7%
12.6%
8.1%
12.5%
15.8%
10.9%
11.5%
12.8%
100.0%

7.7%
13.0%
5.4%
5.5%
5.7%
12.7%
9.4%
11.2%
6.1%
10.5%
12.8%
100.0%

-0.45 [-0.81 , -0.10]
-0.55 [-1.11 , 0.00]
-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.07 [-0.43 , 0.28]
-1.22 [-1.89 , -0.55]
-0.82 [-1.45 , -0.19]
-1.01 [-1.55 , -0.47]
-0.76 [-1.10 , -0.42]

0.00 [-0.68 , 0.68]
-0.55 [-0.95 , -0.16]
-1.66 [-2.54 , -0.78]
-0.29 [-1.17 , 0.59]
-1.28 [-2.14 , -0.42]
-0.07 [-0.47 , 0.34]
-0.35 [-0.93 , 0.22]
-0.38 [-0.86 , 0.09]
0.05 [-0.77 , 0.87]
-0.01 [-0.52 , 0.50]
-0.22 [-0.62 , 0.17]
-0.36 [-0.60 , -0.12]

8.62
2.1
9.1

13
24
11
48

20.8%
57.1%
22.1%
100.0%

-0.44 [-1.28 , 0.39]
-0.33 [-0.84 , 0.17]
-0.39 [-1.20 , 0.42]
-0.37 [-0.75 , 0.01]

Test for subgroup differences: Chi² = 3.86, df = 2 (P = 0.15), I² = 48.2%

-1
Favours Psychotherapies

-2

0

1
2
Favours TAU

Footnotes
(1) Zan-BPD - total (CR)
(2) Self reported: BPD-40
(3) BEST (SR)
(4) Self rated: Borderline Personality Inventory
(5) Self rated: BEST
(6) Clinician rated: ZAN-BPD
(7) CCGI-BPD global (CR)
(8) Clinician rated: CGI-BPD
(9) Clinician-rated: Mean number of DSM-IV BPD criteria met
(10) Self rated: BSI
(11) SCID-II - mean number of BPD criteria met (CR)
(12) SCID-BPD (CR)
(13) BPDSI-IV (CR)
(14) Clinician-rated: BPDSI-IV
(15) ZAN-BPD total (CR)
(16) Zan-BPD-total (CR)
(17) BPFS-C (SR)
(18) BPDSI-IV total
(19) BPDSI-IV-total (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

449

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 28.2.   Comparison 28: Subgroup analysis: duration, Outcome 2: Psychosocial functioning

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

28.2.1 Less than 6 months
Andreoli 2016 (1)
Blum 2008 (2)
Gratz 2014 (3)
Mehlum 2014 (4)
Reneses 2013 (5)
Soler 2009 (6)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.19; Chi² = 18.80, df = 5 (P = 0.002); I² = 73%
Test for overall effect: Z = 1.47 (P = 0.14)

6.2343
12.8996
6.24
6.6
8.9
0.9

-62.95
-50.5
14.25
-59.4
35.4
3.27

-57.6
-43.5
16.01
-54.2
27.6
3.57

140
65
31
5
18
29
288

7.6
12.2898
6.24
6.1
10.8
1.13

28.2.2 6 to 12 months
Amianto 2011 (7)
Borschmann 2013 (8)
Carter 2010 (9)
Davidson 2006 (10)
Doering 2010 (11)
Farrell 2009 (7)
Feigenbaum 2012 (12)
Jochems 2015 (13)
Kramer 2016 (14)
Linehan 1994 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 16.31, df = 9 (P = 0.06); I² = 45%
Test for overall effect: Z = 2.02 (P = 0.04)

-66.4
25.81
13.07
13.1
-56.06
-50.08
2.22
13.22
16
-40.43

-65.9
26.06
8.15
13.1
-58.62
-60.5
2.48
12.8
12.76
-51.42

11.2
7.98
11.48
4.4
8.04
10.17
0.85
6.36
7.79
9.71

16
36
20
52
52
16
25
16
21
13
267

28.2.3 Over 12 months
Bateman 1999 (15)
Bateman 2009 (15)
Gregory 2008b (16)
Jørgensen 2013 (15)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.49; Chi² = 20.82, df = 3 (P = 0.0001); I² = 86%
Test for overall effect: Z = 2.21 (P = 0.03)

20
71
11
42
144

2.7
1.76
-9.7
2.2

3.4
2.17
6.9
2.1

0.6
0.5
8.1
0.5

13
8.94
11.59
4.6
6.87
5.07
0.92
5.8
5.42
10.8

0.6
0.64
6.7
0.6

30
59
30
5
26
30
180

17
36
28
47
52
12
16
27
20
13
268

20.0%
20.8%
18.1%
7.2%
15.9%
17.9%
100.0%

8.2%
12.6%
10.0%
14.4%
14.6%
6.3%
9.0%
9.3%
9.2%
6.3%
100.0%

-0.82 [-1.22 , -0.42]
-0.55 [-0.91 , -0.19]
-0.28 [-0.78 , 0.23]
-0.74 [-2.05 , 0.57]
0.76 [0.14 , 1.38]
-0.29 [-0.80 , 0.22]
-0.31 [-0.73 , 0.11]

0.04 [-0.64 , 0.72]
0.03 [-0.43 , 0.49]
-0.42 [-1.00 , 0.16]
0.00 [-0.39 , 0.39]
-0.34 [-0.73 , 0.05]
-1.20 [-2.03 , -0.38]
0.29 [-0.34 , 0.92]
-0.07 [-0.69 , 0.55]
-0.47 [-1.09 , 0.15]
-1.04 [-1.86 , -0.21]
-0.25 [-0.49 , -0.01]

19
63
13
24
119

24.6%
28.8%
19.4%
27.1%
100.0%

-1.14 [-1.83 , -0.46]
-0.72 [-1.07 , -0.36]
-2.17 [-3.22 , -1.13]
0.18 [-0.32 , 0.69]
-0.86 [-1.62 , -0.10]

-4
Favours Psychotherapies

-2

0

2

4
Favours TAU

Test for subgroup differences: Chi² = 2.24, df = 2 (P = 0.33), I² = 10.9%

Footnotes
(1) Clinician rated: GAS
(2) GAS (CR)
(3) Self rated: SDS
(4) C-GAS (CR)
(5) Self reported: SAS-SR (higher scores indicate poorer functioning)
(6) CGI-global improvement, patient-rated (SR)
(7) Clinician rated: GAF
(8) WSAS (SR)
(9) BDQ-days out of role (SR)
(10) Self rated: SFQ
(11) Clinician-rated: GAF
(12) CORE-OM (SR)
(13) Clinician-rated: HoNOS
(14) OQ45, social role at discharge (SR)
(15) SAS-SR (SR)
(16) SPS - "How many days were you paid for working in the past 30 days?") (SR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

450

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comparison 29.   Subgroup analysis: mode of therapy

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

29.1 BPD symptom sever-
ity

22

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

29.1.1 Individual therapy

29.1.2 Group therapy

29.1.3 Mixed therapy

8

8

6

29.2 Psychosocial func-
tioning

22

29.2.1 Individual therapy

29.2.2 Group therapy

29.2.3 Mixed therapy

8

7

7

520

438

286

570

366

378

Std. Mean Difference (IV, Random, 95%
CI)

-0.39 [-0.63, -0.16]

Std. Mean Difference (IV, Random, 95%
CI)

-0.89 [-1.21, -0.57]

Std. Mean Difference (IV, Random, 95%
CI)

-0.15 [-0.38, 0.09]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.31 [-0.75, 0.12]

Std. Mean Difference (IV, Random, 95%
CI)

-0.44 [-0.65, -0.23]

Std. Mean Difference (IV, Random, 95%
CI)

-0.63 [-1.14, -0.13]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

451

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 29.1.   Comparison 29: Subgroup analysis: mode of therapy, Outcome 1: BPD symptom severity

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

29.1.1 Individual therapy
Amianto 2011 (1)
Doering 2010 (2)
Kredlow 2017a (3)
Leichsenring 2016 (4)
Philips 2018 (5)
Priebe 2012 (6)
Reneses 2013 (7)
Schuppert 2012 (8)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 11.44, df = 7 (P = 0.12); I² = 39%
Test for overall effect: Z = 3.26 (P = 0.001)

3.3
4.79
1.17
18.76
17
13.1
13
13.29

3.3
5.63
4.25
19.41
20.7
15.9
19.1
15.39

1
1.54
1.17
8.6
9.1
6.9
7.9
9.53

16
52
14
64
13
33
18
48
258

29.1.2 Group therapy
Blum 2008 (9)
Bos 2010 (10)
Farrell 2009 (11)
Gratz 2006 (12)
Gratz 2014 (12)
Leppänen 2016 (13)
Morton 2012 (14)
Soler 2009 (15)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 16.44, df = 7 (P = 0.02); I² = 57%
Test for overall effect: Z = 5.42 (P < 0.00001)

8.0623
25.8
9.47
5.72
6.59
10.14
12.47
1.2

13.4
95.1
32.75
34.7
35.88
21.48
47.42
4.44

9.8
79.7
18.81
25.83
27.47
17.54
32.76
3.5

65
26
16
12
31
19
21
29
219

29.1.3 Mixed therapy
Gregory 2008b (12)
Jørgensen 2013 (3)
Koons 2001a (16)
Laurenssen 2018 (17)
Robinson 2016 (18)
Rossouw 2012b (19)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.77, df = 5 (P = 0.88); I² = 0%
Test for overall effect: Z = 1.24 (P = 0.22)

12.4
2.5
1.6
11.45
7.41
0.5385

33.6
2.8
3.6
20.63
9.64
2.79

10
42
10
54
12
29
157

38.4
3.6
4.2
21.39
9.27
3.06

1.1
1.47
3.2
9.38
9.1
7.5
6.9
9

7.6811
29.1
5.9
10.81
5.59
11.41
11
0.52

8.62
2.1
2.3
10.43
7.39
65.7267

17
52
12
58
11
37
26
49
262

59
26
12
10
30
32
20
30
219

13
24
10
41
11
30
129

8.8%
17.5%
6.2%
19.2%
6.8%
14.3%
10.0%
17.2%
100.0%

17.9%
13.6%
8.4%
8.1%
13.5%
13.3%
11.4%
13.8%
100.0%

7.9%
21.7%
7.1%
33.6%
8.3%
21.3%
100.0%

0.00 [-0.68 , 0.68]
-0.55 [-0.95 , -0.16]
-1.28 [-2.14 , -0.42]
-0.07 [-0.43 , 0.28]
-0.39 [-1.20 , 0.42]
-0.38 [-0.86 , 0.09]
-0.82 [-1.45 , -0.19]
-0.22 [-0.62 , 0.17]
-0.39 [-0.63 , -0.16]

-0.45 [-0.81 , -0.10]
-0.55 [-1.11 , 0.00]
-1.66 [-2.54 , -0.78]
-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.35 [-0.93 , 0.22]
-1.22 [-1.89 , -0.55]
-1.01 [-1.55 , -0.47]
-0.89 [-1.21 , -0.57]

-0.44 [-1.28 , 0.39]
-0.33 [-0.84 , 0.17]
-0.29 [-1.17 , 0.59]
-0.07 [-0.47 , 0.34]
0.05 [-0.77 , 0.87]
-0.01 [-0.52 , 0.50]
-0.15 [-0.38 , 0.09]

Test for subgroup differences: Chi² = 13.23, df = 2 (P = 0.001), I² = 84.9%

-4
Favours Psychotherapies

-2

0

2

4
Favours TAU

Footnotes
(1) Clinician rated: CGI-BPD
(2) Clinician-rated: Mean number of DSM-IV BPD criteria met
(3) SCID-BPD (CR)
(4) Self rated: Borderline Personality Inventory
(5) BPDSI-IV-total (CR)
(6) ZAN-BPD total (CR)
(7) Clinician rated: ZAN-BPD
(8) BPDSI-IV total
(9) Zan-BPD - total (CR)
(10) Self reported: BPD-40
(11) Self rated: BSI
(12) BEST (SR)
(13) Clinician-rated: BPDSI-IV
(14) Self rated: BEST
(15) CCGI-BPD global (CR)
(16) SCID-II - mean number of BPD criteria met (CR)
(17) BPDSI-IV (CR)
(18) Zan-BPD-total (CR)
(19) BPFS-C (SR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

452

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 29.2.   Comparison 29: Subgroup analysis: mode of therapy, Outcome 2: Psychosocial functioning

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

17
30
36
47
52
5
26
22
235

59
12
30
27
20
5
30
183

19
63
28
16
13
24
13
176

11.9%
14.7%
14.2%
14.8%
14.9%
5.5%
12.5%
11.4%
100.0%

34.0%
6.5%
17.3%
11.5%
11.4%
2.6%
16.7%
100.0%

14.1%
17.3%
15.1%
14.6%
10.4%
15.9%
12.5%
100.0%

0.04 [-0.64 , 0.72]
-0.82 [-1.22 , -0.42]
0.03 [-0.43 , 0.49]
0.00 [-0.39 , 0.39]
-0.34 [-0.73 , 0.05]
-1.22 [-2.73 , 0.30]
0.76 [0.14 , 1.38]
-1.56 [-2.29 , -0.83]
-0.31 [-0.75 , 0.12]

-0.55 [-0.91 , -0.19]
-1.20 [-2.03 , -0.38]
-0.28 [-0.78 , 0.23]
-0.07 [-0.69 , 0.55]
-0.47 [-1.09 , 0.15]
-0.74 [-2.05 , 0.57]
-0.29 [-0.80 , 0.22]
-0.44 [-0.65 , -0.23]

-1.14 [-1.83 , -0.46]
-0.72 [-1.07 , -0.36]
-0.42 [-1.00 , 0.16]
0.29 [-0.34 , 0.92]
-2.17 [-3.22 , -1.13]
0.18 [-0.32 , 0.69]
-1.04 [-1.86 , -0.21]
-0.63 [-1.14 , -0.13]

-4
Favours Psychotherapies

-2

0

2

4
Favours TAU

29.2.1 Individual therapy
Amianto 2011 (1)
Andreoli 2016 (2)
Borschmann 2013 (3)
Davidson 2006 (4)
Doering 2010 (5)
Gleeson 2012 (6)
Reneses 2013 (7)
Salzer 2014 (8)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.29; Chi² = 35.46, df = 7 (P < 0.00001); I² = 80%
Test for overall effect: Z = 1.42 (P = 0.16)

11.2
6.2343
7.98
4.4
8.04
8.3
8.9
9.84

-66.4
-57.6
25.81
13.1
-56.06
-50.6
27.6
-51.82

-65.9
-62.95
26.06
13.1
-58.62
-67
35.4
-65

16
140
36
52
52
4
18
17
335

13
7.6
8.94
4.6
6.87
14.1
10.8
6.82

29.2.2 Group therapy
Blum 2008 (9)
Farrell 2009 (1)
Gratz 2014 (10)
Jochems 2015 (11)
Kramer 2016 (12)
Mehlum 2014 (13)
Soler 2009 (14)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 6.01, df = 6 (P = 0.42); I² = 0%
Test for overall effect: Z = 4.14 (P < 0.0001)

12.8996
10.17
6.24
6.36
7.79
6.6
0.9

-50.5
-60.5
14.25
12.8
12.76
-59.4
3.27

65
16
31
16
21
5
29
183

-43.5
-50.08
16.01
13.22
16
-54.2
3.57

12.2898
5.07
6.24
5.8
5.42
6.1
1.13

29.2.3 Mixed therapy
Bateman 1999 (15)
Bateman 2009 (15)
Carter 2010 (16)
Feigenbaum 2012 (17)
Gregory 2008b (18)
Jørgensen 2013 (15)
Linehan 1994 (9)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.35; Chi² = 29.46, df = 6 (P < 0.0001); I² = 80%
Test for overall effect: Z = 2.46 (P = 0.01)

3.4
2.17
13.07
2.22
6.9
2.1
-40.43

2.7
1.76
8.15
2.48
-9.7
2.2
-51.42

0.6
0.5
11.48
0.85
8.1
0.5
9.71

20
71
20
25
11
42
13
202

0.6
0.64
11.59
0.92
6.7
0.6
10.8

Test for subgroup differences: Chi² = 0.89, df = 2 (P = 0.64), I² = 0%

Footnotes
(1) Clinician rated: GAF
(2) Clinician rated: GAS
(3) WSAS (SR)
(4) Self rated: SFQ
(5) Clinician-rated: GAF
(6) SOFAS (CR)
(7) Self reported: SAS-SR (higher scores indicate poorer functioning)
(8) GAF (CR)
(9) GAS (CR)
(10) Self rated: SDS
(11) Clinician-rated: HoNOS
(12) OQ45, social role at discharge (SR)
(13) C-GAS (CR)
(14) CGI-global improvement, patient-rated (SR)
(15) SAS-SR (SR)
(16) BDQ-days out of role (SR)
(17) CORE-OM (SR)
(18) SPS - "How many days were you paid for working in the past 30 days?") (SR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

453

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comparison 30.   Subgroup analysis: setting

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

30.1 BPD symptom
severity

30.1.1 Inpatient

30.1.2 Outpatient

30.2 Psychosocial func-
tioning

30.2.1 Inpatient

30.2.2 Outpatient

30.2.3 Inpatient and
outpatient

22

2

20

22

2

18

2

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.07 [-0.34, 0.20]

Std. Mean Difference (IV, Random, 95% CI)

-0.58 [-0.77, -0.39]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.85 [-1.24, -0.46]

Std. Mean Difference (IV, Random, 95% CI)

-0.31 [-0.54, -0.08]

Std. Mean Difference (IV, Random, 95% CI)

-1.34 [-1.84, -0.84]

217

1027

179

1057

78

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

454

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 30.1.   Comparison 30: Subgroup analysis: setting, Outcome 1: BPD symptom severity

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

30.1.1 Inpatient
Laurenssen 2018 (1)
Leichsenring 2016 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.99); I² = 0%
Test for overall effect: Z = 0.52 (P = 0.61)

54
64
118

20.63
18.76

11.45
8.6

21.39
19.41

10.43
9.38

41
58
99

43.4%
56.6%
100.0%

-0.07 [-0.47 , 0.34]
-0.07 [-0.43 , 0.28]
-0.07 [-0.34 , 0.20]

30.1.2 Outpatient
Amianto 2011 (3)
Blum 2008 (4)
Bos 2010 (5)
Doering 2010 (6)
Farrell 2009 (7)
Gratz 2006 (8)
Gratz 2014 (8)
Gregory 2008b (8)
Jørgensen 2013 (9)
Koons 2001a (10)
Kredlow 2017a (9)
Leppänen 2016 (11)
Morton 2012 (12)
Philips 2018 (13)
Priebe 2012 (14)
Reneses 2013 (15)
Robinson 2016 (16)
Rossouw 2012b (17)
Schuppert 2012 (18)
Soler 2009 (19)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.09; Chi² = 38.98, df = 19 (P = 0.004); I² = 51%
Test for overall effect: Z = 5.95 (P < 0.00001)

1
8.0623
25.8
1.54
9.47
5.72
6.59
12.4
2.5
1.6
1.17
10.14
12.47
9.1
6.9
7.9
7.41
0.5385
9.53
1.2

3.3
13.4
95.1
5.63
32.75
34.7
35.88
38.4
3.6
4.2
4.25
21.48
47.42
20.7
15.9
19.1
9.27
3.06
15.39
4.44

3.3
9.8
79.7
4.79
18.81
25.83
27.47
33.6
2.8
3.6
1.17
17.54
32.76
17
13.1
13
9.64
2.79
13.29
3.5

16
65
26
52
16
12
31
10
42
10
14
19
21
13
33
18
12
29
48
29
516

1.1
7.6811
29.1
1.47
5.9
10.81
5.59
8.62
2.1
2.3
3.2
11.41
11
9.1
7.5
6.9
7.39
65.7267
9
0.52

17
59
26
52
12
10
30
13
24
10
12
32
20
11
37
26
11
30
49
30
511

4.5%
7.7%
5.5%
7.3%
3.2%
3.1%
5.5%
3.5%
6.0%
3.2%
3.3%
5.4%
4.5%
3.6%
6.4%
4.9%
3.6%
6.0%
7.2%
5.6%
100.0%

0.00 [-0.68 , 0.68]
-0.45 [-0.81 , -0.10]
-0.55 [-1.11 , 0.00]
-0.55 [-0.95 , -0.16]
-1.66 [-2.54 , -0.78]
-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.44 [-1.28 , 0.39]
-0.33 [-0.84 , 0.17]
-0.29 [-1.17 , 0.59]
-1.28 [-2.14 , -0.42]
-0.35 [-0.93 , 0.22]
-1.22 [-1.89 , -0.55]
-0.39 [-1.20 , 0.42]
-0.38 [-0.86 , 0.09]
-0.82 [-1.45 , -0.19]
0.05 [-0.77 , 0.87]
-0.01 [-0.52 , 0.50]
-0.22 [-0.62 , 0.17]
-1.01 [-1.55 , -0.47]
-0.58 [-0.77 , -0.39]

Test for subgroup differences: Chi² = 9.18, df = 1 (P = 0.002), I² = 89.1%

-2

-1

0

1

2

Favours Psychotherapies

Favours TAU

Footnotes
(1) BPDSI-IV (CR)
(2) Self rated: Borderline Personality Inventory
(3) Clinician rated: CGI-BPD
(4) Zan-BPD - total (CR)
(5) Self reported: BPD-40
(6) Clinician-rated: Mean number of DSM-IV BPD criteria met
(7) Self rated: BSI
(8) BEST (SR)
(9) SCID-BPD (CR)
(10) SCID-II - mean number of BPD criteria met (CR)
(11) Clinician-rated: BPDSI-IV
(12) Self rated: BEST
(13) BPDSI-IV-total (CR)
(14) ZAN-BPD total (CR)
(15) Clinician rated: ZAN-BPD
(16) Zan-BPD-total (CR)
(17) BPFS-C (SR)
(18) BPDSI-IV total
(19) CCGI-BPD global (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

455

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 30.2.   Comparison 30: Subgroup analysis: setting, Outcome 2: Psychosocial functioning

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

30.2.1 Inpatient
Andreoli 2016 (1)
Gleeson 2012 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.25, df = 1 (P = 0.62); I² = 0%
Test for overall effect: Z = 4.25 (P < 0.0001)

6.2343
8.3

-62.95
-67

140
4
144

-57.6
-50.6

7.6
14.1

30
5
35

93.4%
6.6%
100.0%

-0.82 [-1.22 , -0.42]
-1.22 [-2.73 , 0.30]
-0.85 [-1.24 , -0.46]

30.2.2 Outpatient
Amianto 2011 (3)
Bateman 2009 (4)
Blum 2008 (5)
Borschmann 2013 (6)
Carter 2010 (7)
Davidson 2006 (8)
Doering 2010 (9)
Farrell 2009 (3)
Feigenbaum 2012 (10)
Gratz 2014 (11)
Gregory 2008b (12)
Jochems 2015 (13)
Jørgensen 2013 (4)
Kramer 2016 (14)
Linehan 1994 (5)
Mehlum 2014 (15)
Reneses 2013 (16)
Soler 2009 (17)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.15; Chi² = 51.90, df = 17 (P < 0.0001); I² = 67%
Test for overall effect: Z = 2.67 (P = 0.008)

11.2
0.5
12.8996
7.98
11.48
4.4
8.04
10.17
0.85
6.24
8.1
6.36
0.5
7.79
9.71
6.6
8.9
0.9

-66.4
2.17
-43.5
25.81
13.07
13.1
-56.06
-50.08
2.22
16.01
6.9
13.22
2.1
16
-40.43
-54.2
27.6
3.57

-65.9
1.76
-50.5
26.06
8.15
13.1
-58.62
-60.5
2.48
14.25
-9.7
12.8
2.2
12.76
-51.42
-59.4
35.4
3.27

16
71
65
36
20
52
52
16
25
31
11
16
42
21
13
5
18
29
539

13
0.64
12.2898
8.94
11.59
4.6
6.87
5.07
0.92
6.24
6.7
5.8
0.6
5.42
10.8
6.1
10.8
1.13

17
63
59
36
28
47
52
12
16
30
13
27
24
20
13
5
26
30
518

5.0%
7.4%
7.3%
6.6%
5.7%
7.1%
7.1%
4.1%
5.3%
6.2%
3.1%
5.4%
6.3%
5.4%
4.1%
2.3%
5.4%
6.2%
100.0%

0.04 [-0.64 , 0.72]
-0.72 [-1.07 , -0.36]
-0.55 [-0.91 , -0.19]
0.03 [-0.43 , 0.49]
-0.42 [-1.00 , 0.16]
0.00 [-0.39 , 0.39]
-0.34 [-0.73 , 0.05]
-1.20 [-2.03 , -0.38]
0.29 [-0.34 , 0.92]
-0.28 [-0.78 , 0.23]
-2.17 [-3.22 , -1.13]
-0.07 [-0.69 , 0.55]
0.18 [-0.32 , 0.69]
-0.47 [-1.09 , 0.15]
-1.04 [-1.86 , -0.21]
-0.74 [-2.05 , 0.57]
0.76 [0.14 , 1.38]
-0.29 [-0.80 , 0.22]
-0.31 [-0.54 , -0.08]

30.2.3 Inpatient and outpatient
Bateman 1999 (4)
Salzer 2014 (18)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.68, df = 1 (P = 0.41); I² = 0%
Test for overall effect: Z = 5.26 (P < 0.00001)

0.6
9.84

20
17
37

2.7
-65

3.4
-51.82

0.6
6.82

19
22
41

53.4%
46.6%
100.0%

-1.14 [-1.83 , -0.46]
-1.56 [-2.29 , -0.83]
-1.34 [-1.84 , -0.84]

-4

-2

0

2

4

Favours Psychotherapies

Favours TAU

Test for subgroup differences: Chi² = 15.99, df = 2 (P = 0.0003), I² = 87.5%

Footnotes
(1) Clinician rated: GAS
(2) SOFAS (CR)
(3) Clinician rated: GAF
(4) SAS-SR (SR)
(5) GAS (CR)
(6) WSAS (SR)
(7) BDQ-days out of role (SR)
(8) Self rated: SFQ
(9) Clinician-rated: GAF
(10) CORE-OM (SR)
(11) Self rated: SDS
(12) SPS - "How many days were you paid for working in the past 30 days?") (SR)
(13) Clinician-rated: HoNOS
(14) OQ45, social role at discharge (SR)
(15) C-GAS (CR)
(16) Self reported: SAS-SR (higher scores indicate poorer functioning)
(17) CGI-global improvement, patient-rated (SR)
(18) GAF (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

456

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comparison 31.   Subgroup analysis: types of raters

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

31.1 BPD symptom
severity

31.1.1 Self-rated

31.1.2 Clinician-rated

31.2 Psychosocial func-
tioning

31.2.1 Self-rated

31.2.2 Clinician-rated

22

8

14

22

12

10

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.74 [-1.19, -0.29]

Std. Mean Difference (IV, Random, 95% CI)

-0.42 [-0.58, -0.25]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.29 [-0.60, 0.03]

Std. Mean Difference (IV, Random, 95% CI)

-0.66 [-0.96, -0.37]

408

836

728

586

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

457

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 31.1.   Comparison 31: Subgroup analysis: types of raters, Outcome 1: BPD symptom severity

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

31.1.1 Self-rated
Bos 2010 (1)
Farrell 2009 (2)
Gratz 2006 (3)
Gratz 2014 (3)
Gregory 2008b (3)
Leichsenring 2016 (4)
Morton 2012 (5)
Rossouw 2012b (6)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.30; Chi² = 30.26, df = 7 (P < 0.0001); I² = 77%
Test for overall effect: Z = 3.25 (P = 0.001)

25.8
9.47
5.72
6.59
12.4
8.6
12.47
0.5385

95.1
32.75
34.7
35.88
38.4
19.41
47.42
3.06

79.7
18.81
25.83
27.47
33.6
18.76
32.76
2.79

26
16
12
31
10
64
21
29
209

29.1
5.9
10.81
5.59
8.62
9.38
11
65.7267

31.1.2 Clinician-rated
Amianto 2011 (7)
Blum 2008 (8)
Doering 2010 (9)
Jørgensen 2013 (10)
Koons 2001a (11)
Kredlow 2017a (10)
Laurenssen 2018 (12)
Leppänen 2016 (13)
Philips 2018 (14)
Priebe 2012 (15)
Reneses 2013 (16)
Robinson 2016 (17)
Schuppert 2012 (18)
Soler 2009 (19)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 17.14, df = 13 (P = 0.19); I² = 24%
Test for overall effect: Z = 4.94 (P < 0.00001)

1
8.0623
1.54
2.5
1.6
1.17
11.45
10.14
9.1
6.9
7.9
7.41
9.53
1.2

3.3
13.4
5.63
3.6
4.2
4.25
21.39
21.48
20.7
15.9
19.1
9.27
15.39
4.44

3.3
9.8
4.79
2.8
3.6
1.17
20.63
17.54
17
13.1
13
9.64
13.29
3.5

16
65
52
42
10
14
54
19
13
33
18
12
48
29
425

1.1
7.6811
1.47
2.1
2.3
3.2
10.43
11.41
9.1
7.5
6.9
7.39
9
0.52

26
12
10
30
13
58
20
30
199

17
59
52
24
10
12
41
32
11
37
26
11
49
30
411

13.6%
10.3%
10.1%
13.5%
10.7%
15.5%
12.4%
14.0%
100.0%

4.9%
12.6%
11.2%
7.9%
3.1%
3.3%
10.7%
6.5%
3.6%
8.7%
5.6%
3.6%
11.0%
7.1%
100.0%

-0.55 [-1.11 , 0.00]
-1.66 [-2.54 , -0.78]
-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.44 [-1.28 , 0.39]
-0.07 [-0.43 , 0.28]
-1.22 [-1.89 , -0.55]
-0.01 [-0.52 , 0.50]
-0.74 [-1.19 , -0.29]

0.00 [-0.68 , 0.68]
-0.45 [-0.81 , -0.10]
-0.55 [-0.95 , -0.16]
-0.33 [-0.84 , 0.17]
-0.29 [-1.17 , 0.59]
-1.28 [-2.14 , -0.42]
-0.07 [-0.47 , 0.34]
-0.35 [-0.93 , 0.22]
-0.39 [-1.20 , 0.42]
-0.38 [-0.86 , 0.09]
-0.82 [-1.45 , -0.19]
0.05 [-0.77 , 0.87]
-0.22 [-0.62 , 0.17]
-1.01 [-1.55 , -0.47]
-0.42 [-0.58 , -0.25]

Test for subgroup differences: Chi² = 1.79, df = 1 (P = 0.18), I² = 44.2%

-4

-2

0

Favours Psychotherapies

2
Favours TAU

4

Footnotes
(1) Self reported: BPD-40
(2) Self rated: BSI
(3) BEST (SR)
(4) Self rated: Borderline Personality Inventory
(5) Self rated: BEST
(6) BPFS-C (SR)
(7) Clinician rated: CGI-BPD
(8) Zan-BPD - total (CR)
(9) Clinician-rated: Mean number of DSM-IV BPD criteria met
(10) SCID-BPD (CR)
(11) SCID-II - mean number of BPD criteria met (CR)
(12) BPDSI-IV (CR)
(13) Clinician-rated: BPDSI-IV
(14) BPDSI-IV-total (CR)
(15) ZAN-BPD total (CR)
(16) Clinician rated: ZAN-BPD
(17) Zan-BPD-total (CR)
(18) BPDSI-IV total
(19) CCGI-BPD global (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

458

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 31.2.   Comparison 31: Subgroup analysis: types of raters, Outcome 2: Psychosocial functioning

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

19
63
36
28
47
16
30
13
24
20
26
30
352

17
30
59
52
12
5
27
13
5
22
242

7.5%
10.0%
9.2%
8.3%
9.7%
7.9%
8.9%
5.1%
8.9%
7.9%
7.9%
8.8%
100.0%

9.9%
15.1%
16.1%
15.5%
8.0%
3.2%
10.9%
7.9%
4.1%
9.2%
100.0%

-1.14 [-1.83 , -0.46]
-0.72 [-1.07 , -0.36]
0.03 [-0.43 , 0.49]
-0.42 [-1.00 , 0.16]
0.00 [-0.39 , 0.39]
0.29 [-0.34 , 0.92]
-0.28 [-0.78 , 0.23]
-2.17 [-3.22 , -1.13]
0.18 [-0.32 , 0.69]
-0.47 [-1.09 , 0.15]
0.76 [0.14 , 1.38]
-0.29 [-0.80 , 0.22]
-0.29 [-0.60 , 0.03]

0.04 [-0.64 , 0.72]
-0.82 [-1.22 , -0.42]
-0.55 [-0.91 , -0.19]
-0.34 [-0.73 , 0.05]
-1.20 [-2.03 , -0.38]
-1.22 [-2.73 , 0.30]
-0.07 [-0.69 , 0.55]
-1.04 [-1.86 , -0.21]
-0.74 [-2.05 , 0.57]
-1.56 [-2.29 , -0.83]
-0.66 [-0.96 , -0.37]

-4
Favours Psychotherapies

-2

0

2

4
Favours TAU

31.2.1 Self-rated
Bateman 1999 (1)
Bateman 2009 (1)
Borschmann 2013 (2)
Carter 2010 (3)
Davidson 2006 (4)
Feigenbaum 2012 (5)
Gratz 2014 (6)
Gregory 2008b (7)
Jørgensen 2013 (1)
Kramer 2016 (8)
Reneses 2013 (9)
Soler 2009 (10)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.23; Chi² = 45.87, df = 11 (P < 0.00001); I² = 76%
Test for overall effect: Z = 1.78 (P = 0.07)

2.7
1.76
26.06
8.15
13.1
2.48
14.25
-9.7
2.2
12.76
35.4
3.27

3.4
2.17
25.81
13.07
13.1
2.22
16.01
6.9
2.1
16
27.6
3.57

0.6
0.5
7.98
11.48
4.4
0.85
6.24
8.1
0.5
7.79
8.9
0.9

20
71
36
20
52
25
31
11
42
21
18
29
376

0.6
0.64
8.94
11.59
4.6
0.92
6.24
6.7
0.6
5.42
10.8
1.13

31.2.2 Clinician-rated
Amianto 2011 (11)
Andreoli 2016 (12)
Blum 2008 (13)
Doering 2010 (14)
Farrell 2009 (11)
Gleeson 2012 (15)
Jochems 2015 (16)
Linehan 1994 (13)
Mehlum 2014 (17)
Salzer 2014 (18)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.11; Chi² = 19.65, df = 9 (P = 0.02); I² = 54%
Test for overall effect: Z = 4.39 (P < 0.0001)

11.2
6.2343
12.8996
8.04
10.17
8.3
6.36
9.71
6.6
9.84

-66.4
-57.6
-43.5
-56.06
-50.08
-50.6
13.22
-40.43
-54.2
-51.82

-65.9
-62.95
-50.5
-58.62
-60.5
-67
12.8
-51.42
-59.4
-65

16
140
65
52
16
4
16
13
5
17
344

13
7.6
12.2898
6.87
5.07
14.1
5.8
10.8
6.1
6.82

Test for subgroup differences: Chi² = 2.86, df = 1 (P = 0.09), I² = 65.1%

Footnotes
(1) SAS-SR (SR)
(2) WSAS (SR)
(3) BDQ-days out of role (SR)
(4) Self rated: SFQ
(5) CORE-OM (SR)
(6) Self rated: SDS
(7) SPS - "How many days were you paid for working in the past 30 days?") (SR)
(8) OQ45, social role at discharge (SR)
(9) Self reported: SAS-SR (higher scores indicate poorer functioning)
(10) CGI-global improvement, patient-rated (SR)
(11) Clinician rated: GAF
(12) Clinician rated: GAS
(13) GAS (CR)
(14) Clinician-rated: GAF
(15) SOFAS (CR)
(16) Clinician-rated: HoNOS
(17) C-GAS (CR)
(18) GAF (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

459

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Comparison 32.   Subgroup analysis: types of TAU

Cochrane Database of Systematic Reviews

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

32.1 BPD symptom sever-
ity

32.1.1 Obligatory TAU

32.1.2 Optional TAU

32.2 Psychosocial func-
tioning

32.2.1 Obligatory TAU

32.2.2 Optional TAU

22

19

3

22

17

5

1071

173

1002

312

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.50 [-0.70, -0.30]

Std. Mean Difference (IV, Random, 95%
CI)

-0.63 [-1.09, -0.17]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.32 [-0.56, -0.09]

Std. Mean Difference (IV, Random, 95%
CI)

-0.96 [-1.62, -0.30]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

460

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 32.1.   Comparison 32: Subgroup analysis: types of TAU, Outcome 1: BPD symptom severity

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

32.1.1 Obligatory TAU
Amianto 2011 (1)
Bos 2010 (2)
Doering 2010 (3)
Farrell 2009 (4)
Gratz 2006 (5)
Gratz 2014 (5)
Jørgensen 2013 (6)
Koons 2001a (7)
Laurenssen 2018 (8)
Leichsenring 2016 (9)
Leppänen 2016 (10)
Morton 2012 (11)
Philips 2018 (12)
Priebe 2012 (13)
Reneses 2013 (14)
Robinson 2016 (15)
Rossouw 2012b (16)
Schuppert 2012 (17)
Soler 2009 (18)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 45.07, df = 18 (P = 0.0004); I² = 60%
Test for overall effect: Z = 4.80 (P < 0.00001)

1
25.8
1.54
9.47
5.72
6.59
2.5
1.6
11.45
8.6
10.14
12.47
9.1
6.9
7.9
7.41
0.5385
9.53
1.2

3.3
95.1
5.63
32.75
34.7
35.88
3.6
4.2
21.39
19.41
21.48
47.42
20.7
15.9
19.1
9.27
3.06
15.39
4.44

3.3
79.7
4.79
18.81
25.83
27.47
2.8
3.6
20.63
18.76
17.54
32.76
17
13.1
13
9.64
2.79
13.29
3.5

16
26
52
16
12
31
42
10
54
64
19
21
13
33
18
12
29
48
29
545

1.1
29.1
1.47
5.9
10.81
5.59
2.1
2.3
10.43
9.38
11.41
11
9.1
7.5
6.9
7.39
65.7267
9
0.52

17
26
52
12
10
30
24
10
41
58
32
20
11
37
26
11
30
49
30
526

4.6%
5.5%
7.0%
3.4%
3.3%
5.5%
6.0%
3.4%
6.8%
7.3%
5.4%
4.6%
3.8%
6.2%
5.0%
3.7%
5.9%
6.9%
5.6%
100.0%

0.00 [-0.68 , 0.68]
-0.55 [-1.11 , 0.00]
-0.55 [-0.95 , -0.16]
-1.66 [-2.54 , -0.78]
-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.33 [-0.84 , 0.17]
-0.29 [-1.17 , 0.59]
-0.07 [-0.47 , 0.34]
-0.07 [-0.43 , 0.28]
-0.35 [-0.93 , 0.22]
-1.22 [-1.89 , -0.55]
-0.39 [-1.20 , 0.42]
-0.38 [-0.86 , 0.09]
-0.82 [-1.45 , -0.19]
0.05 [-0.77 , 0.87]
-0.01 [-0.52 , 0.50]
-0.22 [-0.62 , 0.17]
-1.01 [-1.55 , -0.47]
-0.50 [-0.70 , -0.30]

32.1.2 Optional TAU
Blum 2008 (19)
Gregory 2008b (5)
Kredlow 2017a (6)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.06; Chi² = 3.11, df = 2 (P = 0.21); I² = 36%
Test for overall effect: Z = 2.68 (P = 0.007)

8.0623
12.4
1.17

9.8
33.6
1.17

13.4
38.4
4.25

65
10
14
89

7.6811
8.62
3.2

59
13
12
84

56.3%
22.3%
21.4%
100.0%

-0.45 [-0.81 , -0.10]
-0.44 [-1.28 , 0.39]
-1.28 [-2.14 , -0.42]
-0.63 [-1.09 , -0.17]

Test for subgroup differences: Chi² = 0.25, df = 1 (P = 0.61), I² = 0%

-4

-2

0

Favours Psychotherapies

2
Favours TAU

4

Footnotes
(1) Clinician rated: CGI-BPD
(2) Self reported: BPD-40
(3) Clinician-rated: Mean number of DSM-IV BPD criteria met
(4) Self rated: BSI
(5) BEST (SR)
(6) SCID-BPD (CR)
(7) SCID-II - mean number of BPD criteria met (CR)
(8) BPDSI-IV (CR)
(9) Self rated: Borderline Personality Inventory
(10) Clinician-rated: BPDSI-IV
(11) Self rated: BEST
(12) BPDSI-IV-total (CR)
(13) ZAN-BPD total (CR)
(14) Clinician rated: ZAN-BPD
(15) Zan-BPD-total (CR)
(16) BPFS-C (SR)
(17) BPDSI-IV total
(18) CCGI-BPD global (CR)
(19) Zan-BPD - total (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

461

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 32.2.   Comparison 32: Subgroup analysis: types of TAU, Outcome 2: Psychosocial functioning

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

32.2.1 Obligatory TAU
Amianto 2011 (1)
Andreoli 2016 (2)
Bateman 1999 (3)
Bateman 2009 (3)
Borschmann 2013 (4)
Carter 2010 (5)
Doering 2010 (6)
Farrell 2009 (1)
Feigenbaum 2012 (7)
Gleeson 2012 (8)
Gratz 2014 (9)
Jochems 2015 (10)
Jørgensen 2013 (3)
Kramer 2016 (11)
Mehlum 2014 (12)
Reneses 2013 (13)
Soler 2009 (14)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.15; Chi² = 45.74, df = 16 (P = 0.0001); I² = 65%
Test for overall effect: Z = 2.68 (P = 0.007)

11.2
6.2343
0.6
0.5
7.98
11.48
8.04
10.17
0.85
8.3
6.24
6.36
0.5
7.79
6.6
8.9
0.9

-66.4
-57.6
3.4
2.17
25.81
13.07
-56.06
-50.08
2.22
-50.6
16.01
13.22
2.1
16
-54.2
27.6
3.57

-65.9
-62.95
2.7
1.76
26.06
8.15
-58.62
-60.5
2.48
-67
14.25
12.8
2.2
12.76
-59.4
35.4
3.27

16
140
20
71
36
20
52
16
25
4
31
16
42
21
5
18
29
562

13
7.6
0.6
0.64
8.94
11.59
6.87
5.07
0.92
14.1
6.24
5.8
0.6
5.42
6.1
10.8
1.13

17
30
19
63
36
28
52
12
16
5
30
27
24
20
5
26
30
440

5.4%
7.6%
5.4%
8.1%
7.1%
6.2%
7.8%
4.5%
5.8%
1.9%
6.8%
5.9%
6.8%
5.8%
2.4%
5.8%
6.7%
100.0%

0.04 [-0.64 , 0.72]
-0.82 [-1.22 , -0.42]
-1.14 [-1.83 , -0.46]
-0.72 [-1.07 , -0.36]
0.03 [-0.43 , 0.49]
-0.42 [-1.00 , 0.16]
-0.34 [-0.73 , 0.05]
-1.20 [-2.03 , -0.38]
0.29 [-0.34 , 0.92]
-1.22 [-2.73 , 0.30]
-0.28 [-0.78 , 0.23]
-0.07 [-0.69 , 0.55]
0.18 [-0.32 , 0.69]
-0.47 [-1.09 , 0.15]
-0.74 [-2.05 , 0.57]
0.76 [0.14 , 1.38]
-0.29 [-0.80 , 0.22]
-0.32 [-0.56 , -0.09]

59
47
13
13
22
154

23.7%
23.3%
15.5%
18.2%
19.4%
100.0%

-0.55 [-0.91 , -0.19]
0.00 [-0.39 , 0.39]
-2.17 [-3.22 , -1.13]
-1.04 [-1.86 , -0.21]
-1.56 [-2.29 , -0.83]
-0.96 [-1.62 , -0.30]

-4

-2

0

2

4

Favours Psychotherapies

Favours TAU

32.2.2 Optional TAU
Blum 2008 (15)
Davidson 2006 (16)
Gregory 2008b (17)
Linehan 1994 (15)
Salzer 2014 (18)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.44; Chi² = 25.34, df = 4 (P < 0.0001); I² = 84%
Test for overall effect: Z = 2.85 (P = 0.004)

12.8996
4.4
8.1
9.71
9.84

-43.5
13.1
6.9
-40.43
-51.82

-50.5
13.1
-9.7
-51.42
-65

65
52
11
13
17
158

12.2898
4.6
6.7
10.8
6.82

Test for subgroup differences: Chi² = 3.18, df = 1 (P = 0.07), I² = 68.6%

Footnotes
(1) Clinician rated: GAF
(2) Clinician rated: GAS
(3) SAS-SR (SR)
(4) WSAS (SR)
(5) BDQ-days out of role (SR)
(6) Clinician-rated: GAF
(7) CORE-OM (SR)
(8) SOFAS (CR)
(9) Self rated: SDS
(10) Clinician-rated: HoNOS
(11) OQ45, social role at discharge (SR)
(12) C-GAS (CR)
(13) Self reported: SAS-SR (higher scores indicate poorer functioning)
(14) CGI-global improvement, patient-rated (SR)
(15) GAS (CR)
(16) Self rated: SFQ
(17) SPS - "How many days were you paid for working in the past 30 days?") (SR)
(18) GAF (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

462

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Comparison 33.   Subgroup analysis: type of comparison group

Outcome or subgroup
title

No. of studies

No. of partici-
pants

Statistical method

Effect size

33.1 BPD symptom
severity

33.1.1 TAU

33.1.2 Waiting list

33.2 Psychosocial func-
tioning

33.2.1 TAU

33.2.2 Waiting list

25

22

3

27

22

5

1244

161

1314

219

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.52 [-0.70, -0.33]

Std. Mean Difference (IV, Random, 95%
CI)

-0.49 [-0.93, -0.05]

Std. Mean Difference (IV, Random, 95%
CI)

Subtotals only

Std. Mean Difference (IV, Random, 95%
CI)

-0.45 [-0.68, -0.22]

Std. Mean Difference (IV, Random, 95%
CI)

-0.56 [-1.01, -0.11]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

463

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 33.1.   Comparison 33: Subgroup analysis: type of comparison group, Outcome 1: BPD symptom severity

Study or Subgroup

Psychotherapies
SD

Total

Mean

Control group
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

33.1.1 TAU
Amianto 2011 (1)
Blum 2008 (2)
Bos 2010 (3)
Doering 2010 (4)
Farrell 2009 (5)
Gratz 2006 (6)
Gratz 2014 (6)
Gregory 2008b (6)
Jørgensen 2013 (7)
Koons 2001a (8)
Kredlow 2017a (7)
Laurenssen 2018 (9)
Leichsenring 2016 (10)
Leppänen 2016 (11)
Morton 2012 (12)
Philips 2018 (13)
Priebe 2012 (14)
Reneses 2013 (15)
Robinson 2016 (16)
Rossouw 2012b (17)
Schuppert 2012 (18)
Soler 2009 (19)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.10; Chi² = 48.68, df = 21 (P = 0.0006); I² = 57%
Test for overall effect: Z = 5.51 (P < 0.00001)

1
8.0623
25.8
1.54
9.47
5.72
6.59
12.4
2.5
1.6
1.17
11.45
8.6
10.14
12.47
9.1
6.9
7.9
7.41
0.5385
9.53
1.2

3.3
9.8
79.7
4.79
18.81
25.83
27.47
33.6
2.8
3.6
1.17
20.63
18.76
17.54
32.76
17
13.1
13
9.64
2.79
13.29
3.5

3.3
13.4
95.1
5.63
32.75
34.7
35.88
38.4
3.6
4.2
4.25
21.39
19.41
21.48
47.42
20.7
15.9
19.1
9.27
3.06
15.39
4.44

16
65
26
52
16
12
31
10
42
10
14
54
64
19
21
13
33
18
12
29
48
29
634

1.1
7.6811
29.1
1.47
5.9
10.81
5.59
8.62
2.1
2.3
3.2
10.43
9.38
11.41
11
9.1
7.5
6.9
7.39
65.7267
9
0.52

17
59
26
52
12
10
30
13
24
10
12
41
58
32
20
11
37
26
11
30
49
30
610

3.9%
6.5%
4.8%
6.2%
2.9%
2.8%
4.8%
3.1%
5.2%
2.9%
3.0%
6.1%
6.5%
4.7%
4.0%
3.2%
5.5%
4.3%
3.2%
5.2%
6.1%
4.9%
100.0%

0.00 [-0.68 , 0.68]
-0.45 [-0.81 , -0.10]
-0.55 [-1.11 , 0.00]
-0.55 [-0.95 , -0.16]
-1.66 [-2.54 , -0.78]
-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.44 [-1.28 , 0.39]
-0.33 [-0.84 , 0.17]
-0.29 [-1.17 , 0.59]
-1.28 [-2.14 , -0.42]
-0.07 [-0.47 , 0.34]
-0.07 [-0.43 , 0.28]
-0.35 [-0.93 , 0.22]
-1.22 [-1.89 , -0.55]
-0.39 [-1.20 , 0.42]
-0.38 [-0.86 , 0.09]
-0.82 [-1.45 , -0.19]
0.05 [-0.77 , 0.87]
-0.01 [-0.52 , 0.50]
-0.22 [-0.62 , 0.17]
-1.01 [-1.55 , -0.47]
-0.52 [-0.70 , -0.33]

33.1.2 Waiting list
Bellino 2010 (20)
Bohus 2013 (21)
McMain 2017 (22)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 3.60, df = 2 (P = 0.17); I² = 44%
Test for overall effect: Z = 2.19 (P = 0.03)

33.27
3.24
33.72

33.46
4.62
48.48

5.96
2.14
18.7

22
17
42
81

5.95
1.67
22.21

22
16
42
80

31.8%
25.6%
42.6%
100.0%

-0.03 [-0.62 , 0.56]
-0.70 [-1.40 , 0.01]
-0.71 [-1.15 , -0.27]
-0.49 [-0.93 , -0.05]

Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.92), I² = 0%

-1
Favours Psychotherapies

-2

0

1

2

Favours Control group

Footnotes
(1) Clinician rated: CGI-BPD
(2) Zan-BPD - total (CR)
(3) Self reported: BPD-40
(4) Clinician-rated: Mean number of DSM-IV BPD criteria met
(5) Self rated: BSI
(6) BEST (SR)
(7) SCID-BPD (CR)
(8) SCID-II - mean number of BPD criteria met (CR)
(9) BPDSI-IV (CR)
(10) Self rated: Borderline Personality Inventory
(11) Clinician-rated: BPDSI-IV
(12) Self rated: BEST
(13) BPDSI-IV-total (CR)
(14) ZAN-BPD total (CR)
(15) Clinician rated: ZAN-BPD
(16) Zan-BPD-total (CR)
(17) BPFS-C (SR)
(18) BPDSI-IV total
(19) CCGI-BPD global (CR)
(20) Clinician rated: BPDSI-IV
(21) IPDE-BPD criteria (CR)
(22) Self rated: BSL

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

464

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 33.2.   Comparison 33: Subgroup analysis: type of comparison group, Outcome 2: Psychosocial functioning

Study or Subgroup

Psychotherapies
SD

Total

Mean

Control group
SD

Mean

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

33.2.1 TAU
Amianto 2011 (1)
Andreoli 2016 (2)
Bateman 1999 (3)
Bateman 2009 (3)
Blum 2008 (4)
Borschmann 2013 (5)
Carter 2010 (6)
Davidson 2006 (7)
Doering 2010 (8)
Farrell 2009 (1)
Feigenbaum 2012 (9)
Gleeson 2012 (10)
Gratz 2014 (11)
Gregory 2008b (12)
Jochems 2015 (13)
Jørgensen 2013 (3)
Kramer 2016 (14)
Linehan 1994 (4)
Mehlum 2014 (15)
Reneses 2013 (16)
Salzer 2014 (17)
Soler 2009 (18)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.20; Chi² = 74.18, df = 21 (P < 0.00001); I² = 72%
Test for overall effect: Z = 3.84 (P = 0.0001)

11.2
6.2343
0.6
0.5
12.8996
7.98
11.48
4.4
8.04
10.17
0.85
8.3
6.24
8.1
6.36
0.5
7.79
9.71
6.6
8.9
9.84
0.9

-66.4
-57.6
3.4
2.17
-43.5
25.81
13.07
13.1
-56.06
-50.08
2.22
-50.6
16.01
6.9
13.22
2.1
16
-40.43
-54.2
27.6
-51.82
3.57

-65.9
-62.95
2.7
1.76
-50.5
26.06
8.15
13.1
-58.62
-60.5
2.48
-67
14.25
-9.7
12.8
2.2
12.76
-51.42
-59.4
35.4
-65
3.27

16
140
20
71
65
36
20
52
52
16
25
4
31
11
16
42
21
13
5
18
17
29
720

13
7.6
0.6
0.64
12.2898
8.94
11.59
4.6
6.87
5.07
0.92
14.1
6.24
6.7
5.8
0.6
5.42
10.8
6.1
10.8
6.82
1.13

17
30
19
63
59
36
28
47
52
12
16
5
30
13
27
24
20
13
5
26
22
30
594

4.3%
5.7%
4.3%
6.0%
5.9%
5.4%
4.8%
5.8%
5.8%
3.7%
4.6%
1.7%
5.2%
2.8%
4.6%
5.2%
4.6%
3.6%
2.1%
4.6%
4.1%
5.2%
100.0%

0.04 [-0.64 , 0.72]
-0.82 [-1.22 , -0.42]
-1.14 [-1.83 , -0.46]
-0.72 [-1.07 , -0.36]
-0.55 [-0.91 , -0.19]
0.03 [-0.43 , 0.49]
-0.42 [-1.00 , 0.16]
0.00 [-0.39 , 0.39]
-0.34 [-0.73 , 0.05]
-1.20 [-2.03 , -0.38]
0.29 [-0.34 , 0.92]
-1.22 [-2.73 , 0.30]
-0.28 [-0.78 , 0.23]
-2.17 [-3.22 , -1.13]
-0.07 [-0.69 , 0.55]
0.18 [-0.32 , 0.69]
-0.47 [-1.09 , 0.15]
-1.04 [-1.86 , -0.21]
-0.74 [-2.05 , 0.57]
0.76 [0.14 , 1.38]
-1.56 [-2.29 , -0.83]
-0.29 [-0.80 , 0.22]
-0.45 [-0.68 , -0.22]

33.2.2 Waiting list
Bellino 2006 (19)
Bellino 2010 (20)
Bohus 2013 (1)
Haeyen 2018 (21)
McMain 2017 (22)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.15; Chi² = 9.75, df = 4 (P = 0.04); I² = 59%
Test for overall effect: Z = 2.44 (P = 0.01)

2.9
4.37
-47.88
46.27
2.5

3
4.35
-40.88
64.91
2.88

16
22
17
15
42
112

0.9
0.49
7.8
9.77
0.56

0.7
0.48
6.64
17.42
0.59

16
22
16
11
42
107

19.0%
21.7%
18.2%
15.0%
26.1%
100.0%

-0.12 [-0.81 , 0.57]
0.04 [-0.55 , 0.63]
-0.94 [-1.66 , -0.22]
-1.34 [-2.21 , -0.47]
-0.65 [-1.09 , -0.22]
-0.56 [-1.01 , -0.11]

-1
Favours Psychotherapies

-2

0

2

1
Favours Control group

Test for subgroup differences: Chi² = 0.18, df = 1 (P = 0.67), I² = 0%

Footnotes
(1) Clinician rated: GAF
(2) Clinician rated: GAS
(3) SAS-SR (SR)
(4) GAS (CR)
(5) WSAS (SR)
(6) BDQ-days out of role (SR)
(7) Self rated: SFQ
(8) Clinician-rated: GAF
(9) CORE-OM (SR)
(10) SOFAS (CR)
(11) Self rated: SDS
(12) SPS - "How many days were you paid for working in the past 30 days?") (SR)
(13) Clinician-rated: HoNOS
(14) OQ45, social role at discharge (SR)
(15) C-GAS (CR)
(16) Self reported: SAS-SR (higher scores indicate poorer functioning)
(17) GAF (CR)
(18) CGI-global improvement, patient-rated (SR)
(19) Clinician rated: CGI-S
(20) Observer rated:CGI-S
(21) Self reported: OQ45, total score
(22) Self rated: SAS-SR

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

465

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 33.2.   (Continued)

(21) Self reported: OQ45, total score
(22) Self rated: SAS-SR

Cochrane Database of Systematic Reviews

Comparison 34.   Subgroup analysis: types of scales

Outcome or sub-
group title

No. of studies

No. of partici-
pants

Statistical method

Effect size

34.1 BPD symptom
severity

22

34.1.1 ZAN-BPD

34.1.2 SCID

34.1.3 BEST

34.1.4 BPDSI

34.1.5 BPP-40

34.1.6 CGI-BPD

34.1.7 CCGI-BPD

34.1.8 BPT

34.1.9 BPFS-C

34.1.10 BSI

34.1.11 Mean num-
ber of DSM-IV symp-
toms

4

3

4

4

1

1

1

1

1

1

1

34.2 Psychosocial
functioning

22

34.2.1 GAF

34.2.2 GAS

34.2.3 SAS

34.2.4 SPS

34.2.5 QQ45

34.2.6 WSAS

34.2.7 CORE-OM

34.2.8 BDQ

34.2.9 SOFAS

4

4

4

1

1

1

1

1

1

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.45 [-0.69, -0.20]

Std. Mean Difference (IV, Random, 95% CI)

-0.58 [-1.16, -0.00]

Std. Mean Difference (IV, Random, 95% CI)

-1.10 [-1.47, -0.72]

Std. Mean Difference (IV, Random, 95% CI)

-0.21 [-0.45, 0.04]

Std. Mean Difference (IV, Random, 95% CI)

-0.55 [-1.11, 0.00]

Std. Mean Difference (IV, Random, 95% CI)

0.00 [-0.68, 0.68]

Std. Mean Difference (IV, Random, 95% CI)

-1.01 [-1.55, -0.47]

Std. Mean Difference (IV, Random, 95% CI)

-0.07 [-0.43, 0.28]

Std. Mean Difference (IV, Random, 95% CI)

-0.01 [-0.52, 0.50]

Std. Mean Difference (IV, Random, 95% CI)

-1.66 [-2.54, -0.78]

Std. Mean Difference (IV, Random, 95% CI)

-0.55 [-0.95, -0.16]

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

Std. Mean Difference (IV, Random, 95% CI)

-0.73 [-1.41, -0.05]

Std. Mean Difference (IV, Random, 95% CI)

-0.71 [-0.96, -0.46]

Std. Mean Difference (IV, Random, 95% CI)

-0.23 [-0.99, 0.53]

Std. Mean Difference (IV, Random, 95% CI)

-2.17 [-3.22, -1.13]

Std. Mean Difference (IV, Random, 95% CI)

-0.47 [-1.09, 0.15]

Std. Mean Difference (IV, Random, 95% CI)

0.03 [-0.43, 0.49]

Std. Mean Difference (IV, Random, 95% CI)

0.29 [-0.34, 0.92]

Std. Mean Difference (IV, Random, 95% CI)

-0.42 [-1.00, 0.16]

Std. Mean Difference (IV, Random, 95% CI)

-1.22 [-2.73, 0.30]

261

112

147

267

52

33

59

122

59

28

104

204

330

283

24

41

72

41

48

9

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

466

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or sub-
group title

No. of studies

No. of partici-
pants

Statistical method

Effect size

34.2.10 SFQ

34.2.11 SDS

34.2.12 CGI

34.2.13 HoNOS

1

1

1

1

99

61

59

43

Std. Mean Difference (IV, Random, 95% CI)

0.00 [-0.39, 0.39]

Std. Mean Difference (IV, Random, 95% CI)

-0.28 [-0.78, 0.23]

Std. Mean Difference (IV, Random, 95% CI)

-0.29 [-0.80, 0.22]

Std. Mean Difference (IV, Random, 95% CI)

-0.07 [-0.69, 0.55]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

467

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 34.1.   Comparison 34: Subgroup analysis: types of scales, Outcome 1: BPD symptom severity

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

34.1.1 ZAN-BPD
Blum 2008 (1)
Priebe 2012 (2)
Reneses 2013 (3)
Robinson 2016 (4)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.82, df = 3 (P = 0.42); I² = 0%
Test for overall effect: Z = 3.53 (P = 0.0004)

8.0623
6.9
7.9
7.41

65
33
18
12
128

9.8
13.1
13
9.64

13.4
15.9
19.1
9.27

34.1.2 SCID
Jørgensen 2013 (5)
Koons 2001a (6)
Kredlow 2017a (5)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 3.79, df = 2 (P = 0.15); I² = 47%
Test for overall effect: Z = 1.97 (P = 0.05)

3.6
4.2
4.25

2.5
1.6
1.17

2.8
3.6
1.17

42
10
14
66

34.1.3 BEST
Gratz 2006 (7)
Gratz 2014 (7)
Gregory 2008b (7)
Morton 2012 (8)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 3.32, df = 3 (P = 0.34); I² = 10%
Test for overall effect: Z = 5.74 (P < 0.00001)

25.83
27.47
33.6
32.76

34.7
35.88
38.4
47.42

5.72
6.59
12.4
12.47

12
31
10
21
74

34.1.4 BPDSI
Laurenssen 2018 (9)
Leppänen 2016 (10)
Philips 2018 (11)
Schuppert 2012 (12)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.91, df = 3 (P = 0.82); I² = 0%
Test for overall effect: Z = 1.67 (P = 0.10)

11.45
10.14
9.1
9.53

20.63
17.54
17
13.29

54
19
13
48
134

21.39
21.48
20.7
15.39

7.6811
7.5
6.9
7.39

59
37
26
11
133

48.0%
27.3%
15.6%
9.1%
100.0%

-0.45 [-0.81 , -0.10]
-0.38 [-0.86 , 0.09]
-0.82 [-1.45 , -0.19]
0.05 [-0.77 , 0.87]
-0.45 [-0.69 , -0.20]

2.1
2.3
3.2

24
10
12
46

45.6%
26.7%
27.6%
100.0%

-0.33 [-0.84 , 0.17]
-0.29 [-1.17 , 0.59]
-1.28 [-2.14 , -0.42]
-0.58 [-1.16 , -0.00]

10.81
5.59
8.62
11

10.43
11.41
9.1
9

10
30
13
20
73

16.1%
37.8%
18.5%
27.5%
100.0%

-1.02 [-1.92 , -0.11]
-1.36 [-1.92 , -0.80]
-0.44 [-1.28 , 0.39]
-1.22 [-1.89 , -0.55]
-1.10 [-1.47 , -0.72]

41
32
11
49
133

35.9%
18.1%
9.0%
37.1%
100.0%

-0.07 [-0.47 , 0.34]
-0.35 [-0.93 , 0.22]
-0.39 [-1.20 , 0.42]
-0.22 [-0.62 , 0.17]
-0.21 [-0.45 , 0.04]

34.1.5 BPP-40
Bos 2010 (13)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.95 (P = 0.05)

79.7

25.8

34.1.6 CGI-BPD
Amianto 2011 (14)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)

3.3

1

34.1.7 CCGI-BPD
Soler 2009 (15)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.64 (P = 0.0003)

3.5

1.2

34.1.8 BPT
Leichsenring 2016 (16)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.40 (P = 0.69)

18.76

8.6

34.1.9 BPFS-C

26
26

16
16

29
29

64
64

95.1

29.1

26
26

100.0%
100.0%

-0.55 [-1.11 , 0.00]
-0.55 [-1.11 , 0.00]

3.3

1.1

17
17

100.0%
100.0%

0.00 [-0.68 , 0.68]
0.00 [-0.68 , 0.68]

4.44

0.52

30
30

100.0%
100.0%

-1.01 [-1.55 , -0.47]
-1.01 [-1.55 , -0.47]

19.41

9.38

58
58

100.0%
100.0%

-0.07 [-0.43 , 0.28]
-0.07 [-0.43 , 0.28]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

468

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 34.1.   (Continued)

Test for overall effect: Z = 0.40 (P = 0.69)

Cochrane Database of Systematic Reviews

34.1.9 BPFS-C
Rossouw 2012b (17)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.02 (P = 0.98)

2.79

0.5385

34.1.10 BSI
Farrell 2009 (18)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.68 (P = 0.0002)

18.81

9.47

34.1.11 Mean number of DSM-IV symptoms
1.54
Doering 2010 (19)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.77 (P = 0.006)

4.79

29
29

16
16

52
52

3.06

65.7267

30
30

100.0%
100.0%

-0.01 [-0.52 , 0.50]
-0.01 [-0.52 , 0.50]

32.75

5.9

12
12

100.0%
100.0%

-1.66 [-2.54 , -0.78]
-1.66 [-2.54 , -0.78]

5.63

1.47

52
52

100.0%
100.0%

-0.55 [-0.95 , -0.16]
-0.55 [-0.95 , -0.16]

Test for subgroup differences: Chi² = 36.04, df = 10 (P < 0.0001), I² = 72.3%

-2
Favours Psychotherapies

-4

0

2
4
Favours TAU

Footnotes
(1) Zan-BPD - total (CR)
(2) ZAN-BPD total (CR)
(3) Clinician rated: ZAN-BPD
(4) Zan-BPD-total (CR)
(5) SCID-BPD (CR)
(6) SCID-II - mean number of BPD criteria met (CR)
(7) BEST (SR)
(8) Self rated: BEST
(9) BPDSI-IV (CR)
(10) Clinician-rated: BPDSI-IV
(11) BPDSI-IV-total (CR)
(12) BPDSI-IV total
(13) Self reported: BPD-40
(14) Clinician rated: CGI-BPD
(15) CCGI-BPD global (CR)
(16) Self rated: Borderline Personality Inventory
(17) BPFS-C (SR)
(18) Self rated: BSI
(19) Clinician-rated: Mean number of DSM-IV BPD criteria met

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

469

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 34.2.   Comparison 34: Subgroup analysis: types of scales, Outcome 2: Psychosocial functioning

Study or Subgroup

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

34.2.1 GAF
Amianto 2011 (1)
Doering 2010 (2)
Farrell 2009 (1)
Salzer 2014 (3)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.37; Chi² = 13.79, df = 3 (P = 0.003); I² = 78%
Test for overall effect: Z = 2.10 (P = 0.04)

-66.4
-56.06
-50.08
-51.82

-65.9
-58.62
-60.5
-65

11.2
8.04
10.17
9.84

16
52
16
17
101

34.2.2 GAS
Andreoli 2016 (4)
Blum 2008 (5)
Linehan 1994 (5)
Mehlum 2014 (6)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.63, df = 3 (P = 0.65); I² = 0%
Test for overall effect: Z = 5.52 (P < 0.00001)

6.2343
12.8996
9.71
6.6

-62.95
-50.5
-51.42
-59.4

140
65
13
5
223

-57.6
-43.5
-40.43
-54.2

13
6.87
5.07
6.82

17
52
12
22
103

24.6%
29.6%
22.1%
23.7%
100.0%

0.04 [-0.64 , 0.72]
-0.34 [-0.73 , 0.05]
-1.20 [-2.03 , -0.38]
-1.56 [-2.29 , -0.83]
-0.73 [-1.41 , -0.05]

7.6
12.2898
10.8
6.1

30
59
13
5
107

38.5%
48.7%
9.2%
3.7%
100.0%

-0.82 [-1.22 , -0.42]
-0.55 [-0.91 , -0.19]
-1.04 [-1.86 , -0.21]
-0.74 [-2.05 , 0.57]
-0.71 [-0.96 , -0.46]

34.2.3 SAS
Bateman 1999 (7)
Bateman 2009 (7)
Jørgensen 2013 (7)
Reneses 2013 (8)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.53; Chi² = 25.85, df = 3 (P < 0.0001); I² = 88%
Test for overall effect: Z = 0.59 (P = 0.55)

20
71
42
18
151

2.7
1.76
2.2
35.4

3.4
2.17
2.1
27.6

0.6
0.5
0.5
8.9

0.6
0.64
0.6
10.8

19
63
24
26
132

23.3%
27.1%
25.5%
24.1%
100.0%

-1.14 [-1.83 , -0.46]
-0.72 [-1.07 , -0.36]
0.18 [-0.32 , 0.69]
0.76 [0.14 , 1.38]
-0.23 [-0.99 , 0.53]

34.2.4 SPS
Gregory 2008b (9)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.07 (P < 0.0001)

-9.7

8.1

34.2.5 QQ45
Kramer 2016 (10)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.49 (P = 0.14)

12.76

7.79

34.2.6 WSAS
Borschmann 2013 (11)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.12 (P = 0.90)

26.06

7.98

34.2.7 CORE-OM
Feigenbaum 2012 (12)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.90 (P = 0.37)

2.48

0.85

34.2.8 BDQ
Carter 2010 (13)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.42 (P = 0.16)

8.15

11.48

34.2.9 SOFAS
Gleeson 2012 (14)
Subtotal (95% CI)

-67

8.3

11
11

21
21

36
36

25
25

20
20

4
4

6.9

6.7

13
13

100.0%
100.0%

-2.17 [-3.22 , -1.13]
-2.17 [-3.22 , -1.13]

16

5.42

20
20

100.0%
100.0%

-0.47 [-1.09 , 0.15]
-0.47 [-1.09 , 0.15]

25.81

8.94

36
36

100.0%
100.0%

0.03 [-0.43 , 0.49]
0.03 [-0.43 , 0.49]

2.22

0.92

16
16

100.0%
100.0%

0.29 [-0.34 , 0.92]
0.29 [-0.34 , 0.92]

13.07

11.59

28
28

100.0%
100.0%

-0.42 [-1.00 , 0.16]
-0.42 [-1.00 , 0.16]

-50.6

14.1

5
5

100.0%
100.0%

-1.22 [-2.73 , 0.30]
-1.22 [-2.73 , 0.30]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

470

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 34.2.   (Continued)

Cochrane Database of Systematic Reviews

-67

Gleeson 2012 (14)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.58 (P = 0.11)

8.3

34.2.10 SFQ
Davidson 2006 (15)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)

13.1

4.4

34.2.11 SDS
Gratz 2014 (16)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.08 (P = 0.28)

14.25

6.24

34.2.12 CGI
Soler 2009 (17)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.10 (P = 0.27)

3.27

0.9

34.2.13 HoNOS
Jochems 2015 (18)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.22 (P = 0.83)

12.8

6.36

4
4

52
52

31
31

29
29

16
16

-50.6

14.1

5
5

100.0%
100.0%

-1.22 [-2.73 , 0.30]
-1.22 [-2.73 , 0.30]

13.1

4.6

47
47

100.0%
100.0%

0.00 [-0.39 , 0.39]
0.00 [-0.39 , 0.39]

16.01

6.24

30
30

100.0%
100.0%

-0.28 [-0.78 , 0.23]
-0.28 [-0.78 , 0.23]

3.57

1.13

30
30

100.0%
100.0%

-0.29 [-0.80 , 0.22]
-0.29 [-0.80 , 0.22]

13.22

5.8

27
27

100.0%
100.0%

-0.07 [-0.69 , 0.55]
-0.07 [-0.69 , 0.55]

-2
Favours Psychotherapies

-4

0

2
4
Favours TAU

Test for subgroup differences: Chi² = 32.38, df = 12 (P = 0.001), I² = 62.9%

Footnotes
(1) Clinician rated: GAF
(2) Clinician-rated: GAF
(3) GAF (CR)
(4) Clinician rated: GAS
(5) GAS (CR)
(6) C-GAS (CR)
(7) SAS-SR (SR)
(8) Self reported: SAS-SR (higher scores indicate poorer functioning)
(9) SPS - "How many days were you paid for working in the past 30 days?") (SR)
(10) OQ45, social role at discharge (SR)
(11) WSAS (SR)
(12) CORE-OM (SR)
(13) BDQ-days out of role (SR)
(14) SOFAS (CR)
(15) Self rated: SFQ
(16) Self rated: SDS
(17) CGI-global improvement, patient-rated (SR)
(18) Clinician-rated: HoNOS

Comparison 35.   TSA sensitivity analyses: psychotherapy versus TAU

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

35.1 Primary: BPD symptom sever-
ity, at end of treatment

35.2 Primary: self-harm

22

13

1244

616

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.47 [-0.63, -0.31]

Mean Difference (IV, Random,
95% CI)

-0.42 [-0.69, -0.15]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

471

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

35.3 Primary: suicide-related out-
comes

35.4 Primary: psychosocial func-
tioning, at end of treatment

35.5 Secondary: depression

13

22

22

676

1314

1568

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.30 [-0.47, -0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.55, -0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.34 [-0.54, -0.14]

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

472

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 35.1.   Comparison 35: TSA sensitivity analyses: psychotherapy
versus TAU, Outcome 1: Primary: BPD symptom severity, at end of treatment

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

17
59
26
52
12
10
30
13
24
10
12
41
58
32
20
11
37
26
11
30
49
30

3.7%
7.1%
4.8%
6.6%
2.8%
2.6%
4.8%
2.8%
5.3%
2.6%
2.8%
6.4%
7.1%
4.6%
3.9%
2.9%
5.6%
4.2%
2.9%
5.2%
6.5%
4.9%

0.00 [-0.68 , 0.68]
-0.45 [-0.81 , -0.10]
-0.53 [-1.09 , 0.02]
-0.53 [-0.92 , -0.14]
-1.37 [-2.21 , -0.53]
-0.91 [-1.80 , -0.02]
-1.20 [-1.75 , -0.66]
-0.42 [-1.25 , 0.42]
-0.32 [-0.83 , 0.18]
-0.28 [-1.16 , 0.61]
-1.11 [-1.95 , -0.27]
-0.07 [-0.48 , 0.34]
-0.07 [-0.42 , 0.29]
-0.34 [-0.91 , 0.23]
-1.09 [-1.76 , -0.43]
-0.37 [-1.19 , 0.44]
-0.38 [-0.86 , 0.09]
-0.77 [-1.39 , -0.14]
0.05 [-0.77 , 0.87]
-0.01 [-0.52 , 0.50]
-0.22 [-0.62 , 0.18]
-0.94 [-1.48 , -0.40]

610

100.0%

-0.47 [-0.63 , -0.31]

-4
Favours Psychotherapies

-2

0

2

4
Favours TAU

Study or Subgroup

Amianto 2011 (1)
Blum 2008 (2)
Bos 2010 (3)
Doering 2010 (4)
Farrell 2009 (5)
Gratz 2006 (6)
Gratz 2014 (6)
Gregory 2008b (6)
Jørgensen 2013 (7)
Koons 2001a (8)
Kredlow 2017a (7)
Laurenssen 2018 (9)
Leichsenring 2016 (10)
Leppänen 2016 (11)
Morton 2012 (12)
Philips 2018 (13)
Priebe 2012 (14)
Reneses 2013 (15)
Robinson 2016 (16)
Rossouw 2012b (17)
Schuppert 2012 (18)
Soler 2009 (19)

10
9.8
12
11
11
10
10
10
10
10
10
10
10
10
10
10
13.1
10
9.64
10
10
10

7.12
8.0623
7.2832
10.3
8.4038
7.7071
7.9654
7.2512
7.1908
7.1778
7.9817
7.1448
7.1708
7.2508
7.8095
7.2009
6.9
7.5011
7.41
7.1424
7.0908
7.5648

16
65
26
52
16
12
31
10
42
10
14
54
64
19
21
13
33
18
12
29
48
29

10
13.4
15.93
16.5
22.87
17.29
19.72
13.15
12.36
12.07
19.15
10.5
10.5
12.5
18.72
12.79
15.9
15.86
9.27
10.07
11.57
17.22

7.12
7.6811
7.2832
10.3
8.4038
7.7071
7.9654
7.2512
7.1908
7.1778
7.9817
7.1448
7.1708
7.2508
7.8095
7.2009
7.5
7.5011
7.39
7.1424
7.0908
7.5648

Total (95% CI)
Heterogeneity: Tau² = 0.06; Chi² = 38.89, df = 21 (P = 0.01); I² = 46%
Test for overall effect: Z = 5.66 (P < 0.00001)
Test for subgroup differences: Not applicable

634

Footnotes
(1) Clinician rated: CGI-BPD
(2) Zan-BPD - total (CR)
(3) Self reported: BPD-40
(4) Clinician-rated: Mean number of DSM-IV BPD criteria met
(5) Self rated: BSI
(6) BEST (SR)
(7) SCID-BPD (CR)
(8) SCID-II - mean number of BPD criteria met (CR)
(9) BPDSI-IV (CR)
(10) Self rated: Borderline Personality Inventory
(11) Clinician-rated: BPDSI-IV
(12) Self rated: BEST
(13) BPDSI-IV-total (CR)
(14) ZAN-BPD total (CR)
(15) Clinician rated: ZAN-BPD
(16) Zan-BPD-total (CR)
(17) BPFS-C (SR)
(18) BPDSI-IV total
(19) CCGI-BPD global (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

473

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 35.2.   Comparison 35: TSA sensitivity analyses: psychotherapy versus TAU, Outcome 2: Primary: self-harm

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

17
36
31
16
10
30
10
21
49
11
38
24
13

2.3%
4.9%
3.4%
2.7%
1.4%
63.9%
1.4%
2.8%
6.8%
0.4%
5.2%
3.0%
1.7%

0.31 [-1.43 , 2.05]
0.03 [-1.15 , 1.21]
-0.38 [-1.81 , 1.05]
-0.54 [-2.14 , 1.06]
-2.50 [-4.79 , -0.21]
-0.28 [-0.46 , -0.10]
-0.82 [-3.06 , 1.42]
-1.15 [-2.73 , 0.43]
-0.31 [-1.30 , 0.68]
0.10 [-4.02 , 4.22]
-0.74 [-1.89 , 0.41]
-1.66 [-3.19 , -0.13]
-2.24 [-4.26 , -0.22]

306

100.0%

-0.42 [-0.69 , -0.15]

-10

-5

0

5

10

Favours Psychotherapies

Favours TAU

Study or Subgroup

Amianto 2011 (1)
Borschmann 2013 (2)
Carter 2010 (3)
Feigenbaum 2012 (4)
Gratz 2006 (5)
Gratz 2014 (5)
Koons 2001a (6)
Linehan 1991 (7)
Linehan 2006 (4)
Philips 2018 (8)
Priebe 2012 (9)
Van den Bosch 2005 (10)
Weinberg 2006 (11)

1.9
2.3
3.2
2.1
2.6
0.69
1.9
1.2
2.1
2.3
2.3
2.1
2.4

2.5488
2.5543
2.5439
2.5498
2.7288
0.35
2.5556
2.5801
2.537
5.5
2.5576
2.6447
2.7198

16
36
20
25
12
31
10
20
52
13
38
22
15

1.59
2.27
3.58
2.64
5.1
0.97
2.72
2.35
2.41
2.2
3.04
3.76
4.64

2.5488
2.5543
2.5439
2.5498
2.7288
0.35
2.5556
2.5801
2.537
4.8
2.5576
2.6447
2.7198

Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 12.79, df = 12 (P = 0.38); I² = 6%
Test for overall effect: Z = 3.08 (P = 0.002)
Test for subgroup differences: Not applicable

310

Footnotes
(1) self-harming incidents
(2) SHQ - number of suicidal and self-injurious episodes (past 6 months) (SR)
(3) number of self-harm episodes 3 to 6 months
(4) SASII - frequency of self-harm (CR)
(5) DSHI (SR)
(6) PHI - deliberate self-harm frequency (last 3 months) (CR)
(7) Mean number of parasuicidal acts (last 3 months)
(8) DSHI-SF (SR)
(9) Days of self-harm and type of deliberate self-harm recorded in an interview (CR)
(10) LPC - self-mutilation (last 3 months) (CR)
(11) PHI - deliberate self-harm frequency (CR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

474

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 35.3.   Comparison 35: TSA sensitivity analyses: psychotherapy
versus TAU, Outcome 3: Primary: suicide-related outcomes

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

17
30
33
26
5
13
10
32
49
5
26
30
13

5.6%
16.6%
12.6%
8.6%
1.4%
4.0%
2.9%
8.1%
17.0%
1.6%
7.1%
10.0%
4.4%

-0.11 [-0.79 , 0.57]
-0.38 [-0.77 , 0.02]
-0.27 [-0.73 , 0.19]
-0.32 [-0.88 , 0.23]
-0.46 [-1.80 , 0.89]
-0.20 [-1.01 , 0.60]
-1.09 [-2.05 , -0.14]
-0.15 [-0.72 , 0.42]
-0.24 [-0.63 , 0.15]
-0.56 [-1.84 , 0.72]
-0.32 [-0.93 , 0.28]
-0.08 [-0.59 , 0.43]
-0.77 [-1.55 , -0.00]

289

100.0%

-0.30 [-0.47 , -0.14]

-4

-2

0

2

4

Favours Psychotherapies

Favours TAU

Study or Subgroup

Amianto 2011 (1)
Andreoli 2016 (2)
Davidson 2006 (3)
Feigenbaum 2012 (4)
Gleeson 2012 (5)
Gregory 2008b (6)
Koons 2001a (7)
Leppänen 2016 (8)
Linehan 2006 (4)
Mehlum 2014 (9)
Reneses 2013 (10)
Soler 2009 (11)
Weinberg 2006 (12)

0.4
0.2
0.3
0.43
0.5
0.36
0.6
0.4
0.5
0.25
0.3
0.4
0.43

0.3516
0.5833
0.3307
0.2732
0.3499
0.3363
0.3765
0.3347
0.3331
0.355
0.3328
0.3527
0.3635

16
140
43
25
4
11
10
19
52
5
18
29
15

0.44
0.42
0.39
0.52
0.68
0.43
1.03
0.45
0.58
0.47
0.41
0.43
0.72

0.3516
0.5833
0.3307
0.2732
0.3499
0.3363
0.3765
0.3347
0.3331
0.355
0.3328
0.3527
0.3635

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 5.89, df = 12 (P = 0.92); I² = 0%
Test for overall effect: Z = 3.68 (P = 0.0002)
Test for subgroup differences: Not applicable

387

Footnotes
(1) CGI-BPD, suicidality and self-damaging acts (CR)
(2) Episode of suicidal ideation, with or without deliberate self-harm
(3) DSHI - cumulative number of suicide attempts
(4) SASII-suicide attempts (CR)
(5) OAS-M - suicidality (CR)
(6) LPC - parasuicides per last 3 months
(7) BSS (SR)
(8) BPDSI-IV - Parasuicidality, suicide plans and attempts (CR)
(9) SIQ-jr (SR)
(10) Clinician rated: LSASI
(11) CGI-BPD, suicidality (CR)
(12) SBQ (SR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

475

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 35.4.   Comparison 35: TSA sensitivity analyses: psychotherapy versus
TAU, Outcome 4: Primary: psychosocial functioning, at end of treatment

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

17
30
19
63
59
36
28
47
52
12
16
5
30
13
27
24
20
13
5
26
22
30

4.0%
6.1%
4.3%
6.5%
6.4%
5.6%
4.7%
6.1%
6.2%
3.4%
4.4%
1.5%
5.3%
2.8%
4.5%
5.3%
4.4%
3.3%
1.8%
4.4%
3.9%
5.2%

0.04 [-0.65 , 0.72]
-0.48 [-0.88 , -0.08]
-0.57 [-1.21 , 0.07]
-0.64 [-0.98 , -0.29]
-0.64 [-1.01 , -0.28]
0.03 [-0.43 , 0.49]
-0.41 [-0.99 , 0.17]
0.00 [-0.39 , 0.39]
-0.33 [-0.72 , 0.06]
-1.05 [-1.86 , -0.25]
0.28 [-0.35 , 0.91]
-0.94 [-2.38 , 0.49]
-0.28 [-0.78 , 0.23]
-1.60 [-2.55 , -0.66]
-0.07 [-0.69 , 0.55]
0.18 [-0.32 , 0.68]
-0.46 [-1.08 , 0.17]
-0.94 [-1.76 , -0.13]
-0.63 [-1.92 , 0.66]
0.72 [0.10 , 1.35]
-1.32 [-2.03 , -0.62]
-0.29 [-0.80 , 0.23]

594

100.0%

-0.36 [-0.55 , -0.17]

-4

-2

0

2

4

Favours Psychotherapies

Favours TAU

Study or Subgroup

Amianto 2011 (1)
Andreoli 2016 (2)
Bateman 1999 (3)
Bateman 2009 (3)
Blum 2008 (4)
Borschmann 2013 (5)
Carter 2010 (6)
Davidson 2006 (7)
Doering 2010 (8)
Farrell 2009 (1)
Feigenbaum 2012 (9)
Gleeson 2012 (10)
Gratz 2014 (11)
Gregory 2008b (12)
Jochems 2015 (13)
Jørgensen 2013 (3)
Kramer 2016 (14)
Linehan 1994 (4)
Mehlum 2014 (15)
Reneses 2013 (16)
Salzer 2014 (17)
Soler 2009 (18)

60
61
58
59
62
57
61
60
59
62
62
60
61
58
61
59
62
63
60
60
57
60

9.5359
9.1804
9.3646
9.0498
9.2216
9.005
9.1318
8.9487
9.1836
10.0204
9.0678
10.3819
9.0047
11.819
9.0724
9.0126
9.1448
9.6389
9.5515
9.3183
10.428
9.0321

16
140
20
71
65
36
20
52
52
16
25
4
31
11
16
42
21
13
5
18
17
29

59.64
65.43
63.42
64.79
67.97
56.73
64.8
60
62.07
72.85
59.38
71.03
63.53
77.62
61.63
57.37
66.25
72.4
66.69
53.13
71.1
62.62

9.5359
9.1804
9.3646
9.0498
9.2216
9.005
9.1318
8.9487
9.1836
10.0204
9.0678
10.3819
9.0047
11.819
9.0724
9.0126
9.1448
9.6389
9.5515
9.3183
10.428
9.0321

Total (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 53.41, df = 21 (P = 0.0001); I² = 61%
Test for overall effect: Z = 3.66 (P = 0.0003)
Test for subgroup differences: Not applicable

720

Footnotes
(1) Clinician rated: GAF
(2) Clinician rated: GAS
(3) SAS-SR (SR)
(4) GAS (CR)
(5) WSAS (SR)
(6) BDQ-days out of role (SR)
(7) Self rated: SFQ
(8) Clinician-rated: GAF
(9) CORE-OM (SR)
(10) SOFAS (CR)
(11) Self rated: SDS
(12) SPS - "How many days were you paid for working in the past 30 days?") (SR)
(13) Clinician-rated: HoNOS
(14) OQ45, social role at discharge (SR)
(15) C-GAS (CR)
(16) Self reported: SAS-SR (higher scores indicate poorer functioning)
(17) GAF (CR)
(18) CGI-global improvement, patient-rated (SR)

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

476

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 35.5.   Comparison 35: TSA sensitivity analyses:
psychotherapy versus TAU, Outcome 5: Secondary: depression

Psychotherapies
SD

Total

Mean

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

30
19
63
59
36
47
4
52
5
10
30
13
15
24
12
41
58
32
64
20
26
38

5.6%
3.7%
6.0%
5.9%
5.2%
5.7%
1.9%
5.7%
1.6%
2.9%
4.7%
3.3%
3.5%
5.0%
3.3%
5.6%
5.9%
4.6%
6.1%
4.2%
4.3%
5.3%

-0.58 [-0.98 , -0.18]
-1.54 [-2.27 , -0.80]
-0.45 [-0.79 , -0.10]
-0.24 [-0.59 , 0.11]
0.06 [-0.40 , 0.52]
-0.11 [-0.50 , 0.28]
-1.27 [-2.53 , -0.01]
0.12 [-0.27 , 0.50]
-0.86 [-2.28 , 0.56]
-1.04 [-1.95 , -0.14]
-1.26 [-1.81 , -0.71]
-0.42 [-1.24 , 0.39]
1.00 [0.23 , 1.76]
-0.31 [-0.81 , 0.19]
-0.94 [-1.75 , -0.12]
0.10 [-0.31 , 0.50]
0.31 [-0.04 , 0.67]
-0.18 [-0.74 , 0.39]
-0.20 [-0.53 , 0.13]
-0.63 [-1.26 , 0.00]
-0.53 [-1.14 , 0.08]
-0.40 [-0.85 , 0.05]

698

100.0%

-0.34 [-0.54 , -0.14]

-4

-2

0

2

4

Favours Psychotherapies

Favours TAU

Study or Subgroup

Andreoli 2016 (1)
Bateman 1999 (2)
Bateman 2009 (2)
Blum 2008 (3)
Borschmann 2013 (4)
Davidson 2006 (5)
Davidson 2014 (6)
Doering 2010 (7)
Gleeson 2012 (8)
Gratz 2006 (9)
Gratz 2014 (9)
Gregory 2008b (10)
Jahangard 2012 (11)
Jørgensen 2013 (5)
Kredlow 2017a (5)
Laurenssen 2018 (7)
Leichsenring 2016 (12)
Leppänen 2016 (13)
McMurran 2016 (14)
Morton 2012 (15)
Reneses 2013 (16)
Zanarini 2018 (17)

9
10
9.6
9.7
10.47
8.9
21.73
9.9
8.7
9.6
9.8
10.1
10.3
10
10.1
9.3
10.1
8.7
11.1
9.9
9.8
10.1

6.3908
7.9258
6.3083
6.2423
3.54
6.2362
9.86
6.2178
7.081
6.9709
7.1519
6.3392
6.7628
6.4005
6.77
6.3548
6.3604
6.3243
6.2976
6.581
6.4895
6.4913

140
19
71
65
36
52
11
52
4
12
31
11
15
42
14
54
64
19
80
21
18
39

12.71
22.45
12.43
11.21
10.2
9.59
33.5
9.15
15.56
17.15
18.92
12.87
3.38
12.01
16.64
8.67
8.09
9.83
12.36
14.11
13.32
12.74

6.3908
7.9258
6.3083
6.2423
4.96
6.2362
2.38
6.2178
7.081
6.9709
7.1519
6.3392
6.7628
6.4005
6.77
6.3548
6.3604
6.3243
6.2976
6.581
6.4895
6.4913

Total (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 68.69, df = 21 (P < 0.00001); I² = 69%
Test for overall effect: Z = 3.38 (P = 0.0007)
Test for subgroup differences: Not applicable

870

Footnotes
(1) Clinician rated: HDRS-17
(2) Self rated: BDI
(3) Self reported: BDI
(4) Self rated: HADS, depression
(5) BDI-II (SR)
(6) HADS - total score (SR)
(7) Self-rated: BDI
(8) MADRS (CR)
(9) DASS-Depression (SR)
(10) BDI (SR)
(11) HDRS (CR)
(12) Clinician rated: BDI
(13) Clinician-rated: BPDSI-IV, paranoid ideation
(14) HADS (SR)
(15) Self rated: DASS, depression
(16) Clinician rated: MADRS
(17) Self rated: The Clinically Useful Depression Outcome Scale, total score

A D D I T I O N A L   T A B L E S

Table 1.   Unused methods 

Section

Protocol (Storebø 2018)

Unit of analysis issues

Cross-over trials

We would have included cross-over trials. We planned to include data up to
the point of first cross-over (first period only; Curtin 2002). We did not intend

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

477

Review

We did not include any
cross-over trial. 

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Table 1.   Unused methods  (Continued)

Cochrane Database of Systematic Reviews

to use data from subsequent periods due to the likelihood of carry-over effects
from the preceding treatment(s). We planned not to combine repeated partici-
pant interventions in one meta-analysis.

Cluster-randomised trials

Had trials used cluster randomisation, we would have anticipated that inves-
tigators would have presented their results after appropriately controlling for
clustering effects (robust standard errors or hierarchical linear models). If it
had been unclear whether a cluster-randomised trial had used appropriate
controls for clustering, we would have contacted the investigators for further
information. We would have requested and re-analysed individual patient da-
ta using multilevel models that controlled for clustering, if appropriate con-
trols had not been used. Following this, we would have analysed effect sizes
and standard errors in RevMan 5 (Review Manager 2014), using the generic in-
verse method (Higgins 2011). If there had been insufficient information to con-
trol for clustering, we would have entered outcome data using individuals as
the units of analysis, and then conducted a sensitivity analysis to assess the
potential biasing effects of inadequately controlled cluster-randomised trials
(Donner 2002). If individual participant data had not been available, we would
have looked for information on intra-class correlation coefficients to adjust for
the potential clustering effects.  

Adjustment for multiplicity

We planned to adjust the P values and CIs for multiplicity due to the many sec-
ondary outcome comparisons following the method described by Jakobsen
2014.

We did not include any
cluster-randomised tri-
al.

We only adjusted the
primary outcomes and
one secondary out-
comes for multiplicity,
i.e. those outcomes pre-
sented in the SoF table.

Dealing with missing
data

Had dichotomous data not been presented on the basis of ITT data, we would
have added the number of participants lost in each group to the participants
with unfavourable results, acting on the assumption that most people with
BPD do not get lost at random.

We were unable to per-
form this analysis due
to insufficient informa-
tion

Subgroup analysis and
investigation of het-
erogeneity

We intended to conduct subgroup analyses to make hypotheses about the
subgroups mentioned below.

1. Sex (male versus female)
2. Comorbidity (people with comorbidity versus people without comorbidity)
3. Treatment intensity (once a week compared to more than once a week
4. Concurrent-drug  interventions  (trials  with  concurrent-drug  interventions

compared to those without)

We did not conduct
these preplanned
analyses because of
lack of data.

Sensitivity analysis

We intended to assess the impact of heterogeneity on the overall pooled effect
estimate by removing studies ('outliers') that contributed to heterogeneity. We
intended to remove outliers one by one and assess the impact on the overall
outcome.

We were not able to
perform these analy-
ses, due to a lack of suf-
ficient data.

1. Decisions  made  during  the  review  process  (our  assessment  of  the  level  of

clinical heterogeneity)

2. Impact of bias (studies with low and high risk of bias)
3. Type of data collection (for example, different ways to measure depression)
4. Imputed data (comparing analyses with available outcome data with those

using an ITT approach)

TSA

We intended to calculate post hoc, low bias, risk diversity-adjusted required
information size TSA analyses for the primary outcomes.

We were not able to
perform these analyses

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

478

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Table 1.   Unused methods  (Continued)

Cochrane Database of Systematic Reviews

with low risk of bias tri-
als.

BPD: borderline personality disorder; CI: confidence interval;ITT: intention to treat; TAU: treatment-as-usual

Table 2.   Key demographic characteristics of the included studies 

Category

Study frequency

Study ID

Sample size

Sample size above 100
participants

Setting

Studies with inpatient
settings

Studies with both in-
patient and outpatient
settings

Gender

5

5

7

Only females included

17

Only males included

Diagnostic classification

DSM-III diagnosis

DSM-III-R diagnosis

DSM-IV diagnosis

2

1

4

6

DSM-IV-TR diagnosis

54

Andreoli 2016; Antonsen 2017; Linehan 2006; McMain 2009; McMurran 2016

Jahangard 2012; Leichsenring 2016; Mohamadizadeh 2017; Schilling 2018;
Stanley 2017

Antonsen 2017; Bateman 1999; Davidson 2014; Gleeson 2012; Kredlow 2017b;
Laurenssen 2018; Smith 2012

Carter 2010; Doering 2010; Farrell 2009; Gratz 2006; Gratz 2014; Harned 2014;
Koons 2001a; Linehan 1991; Linehan 1994; Linehan 2006; Linehan 2015a; Mo-
hamadizadeh 2017; Smith 2012; Van den Bosch 2005; Weinberg 2006; Zanarini
2008; Zanarini 2018

Bianchini 2019; Kamalabadi 2012

Linehan 1991

Bateman 1999; Koons 2001a; Linehan 1994; Turner 2000

Borschmann 2013; McMurran 2016; Mohamadizadeh 2017; Priebe 2012;
Rossouw 2012b; Schilling 2018

Andreoli 2016; Antonsen 2017; Bateman 2009; Bellino 2006; Bellino 2007; Belli-
no 2010; Blum 2008; Bos 2010; Carter 2010; Cottraux 2009; Davidson 2006;
Davidson 2014; Doering 2010; Elices 2016; Feigenbaum 2012; Feliu-Soler
2017; Giesen-Bloo 2006; Gleeson 2012; Gratz 2006; Gratz 2014; Gregory 2008b;
Haeyen 2018; Harned 2014; Jahangard 2012; Jochems 2015; Jørgensen 2013;
Kamalabadi 2012; Kramer 2011; Kramer 2014; Kramer 2016: Kredlow 2017a;
Kredlow 2017b; Laurenssen 2018; Leppänen 2016; Lin 2019; Linehan 2006; Mc-
Main 2009; McMain 2017; Morey 2010; Morton 2012; Nadort 2009; Pascual 2015;
Philips 2018; Reneses 2013; Robinson 2016; Santisteban 2015; Schilling 2018;
Sinnaeve 2018; Soler 2009; Smith 2012; Van den Bosch 2005; Weinberg 2006;
Zanarini 2008; Zanarini 2018

ICD-10 diagnosis

1

Leichsenring 2016

Diagnostic assessment

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

479

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 2.   Key demographic characteristics of the included studies  (Continued)

BPDSI-IV (Arntz 2003)

CI-BPD (Zanarini 2003b)

DIB (Gunderson 1981)
or DIB-R (Zanarini 1989)

DIB-R (Zanarini 1989)
and the BSI (Conte
1980)

DIB-R (Zanarini 1989)
plus any other DSM-ori-
ented diagnostic inter-
view SCID-II (First 1997)

DIPD-IV (Zanarini 1987)

IPDE (Loranger 1995)

IPDE-self-rating screen-
ing and questionnaire,
with the preliminary
findings confirmed in
clinical interviews by a
psychiatrist

Millon Clinical Multiaxi-
al Inventory, 3rd Edition
(MCMI-III)

PDE (Loranger 1988)

1

1

4

1

1

3

4

1

1

1

SCID-II (First 1997)

46

Kamalabadi 2012

Rossouw 2012b

Cottraux 2009; Feliu-Soler 2017; Linehan 1991; Zanarini 2008

Farrell 2009

Bateman 1999

Gratz 2006; Gratz 2014; Morey 2010

Andreoli 2016; Harned 2014; McMain 2017; McMurran 2016

Carter 2010

Jahangard 2012

Turner 2000

Amianto 2011; Antonsen 2017; Bateman 1999; Bateman 2009; Bellino 2006;
Bellino 2007; Bellino 2010; Borschmann 2013; Bos 2010; Davidson 2006; David-
son 2014; Doering 2010; Elices 2016; Feigenbaum 2012; Giesen-Bloo 2006;
Gleeson 2012; Gregory 2008b; Haeyen 2018; Jørgensen 2013; Koons 2001a;
Kramer 2011; Kramer 2014; Kramer 2016; Kredlow 2017a; Kredlow 2017b; Lau-
renssen 2018; Leichsenring 2016; Leppänen 2016; Lin 2019; Linehan 1994; Line-
han 2006; Linehan 2015a; Koons 2001a; Morton 2012; Nadort 2009; Pascual
2015; Philips 2018; Priebe 2012; Reneses 2013; Robinson 2016; Schilling 2018;
Soler 2009; Smith 2012; Van den Bosch 2005; Weinberg 2006; Zanarini 2018

SIDP-IV (Pfohl 1997)

1

Blum 2008

Exclusion criteria in included studies

Participants with sub-
stance abuse or depen-
dence excluded

43

Amianto 2011; Andreoli 2016; Antonsen 2017; Bateman 1999; Bateman 2009;
Bellino 2006; Bellino 2007; Bellino 2010; Blum 2008; Carmona í Farrés 2019;
Cottraux 2009; Davidson 2006; Doering 2010; Feigenbaum 2012; Giesen-Bloo
2006; Gratz 2006; Gratz 2014; Jørgensen 2013; Kamalabadi 2012; Koons 2001a;
Kramer 2011; Kredlow 2017a; Laurenssen 2018; Leichsenring 2016; Leppänen
2016; Lin 2019; Linehan 1991; Linehan 1994; McMain 2009; Mohamadizadeh
2017; Morey 2010; Nadort 2009; Pascual 2015; Rossouw 2012b; Schilling 2018;
Schuppert 2012; Sinnaeve 2018; Soler 2009; Stanley 2017; Smith 2012; Wein-
berg 2006; Zanarini 2008; Zanarini 2018

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

480

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 2.   Key demographic characteristics of the included studies  (Continued)

Alcohol or substance
abuse and dependence
included

Antisocial features or
full antisocial personali-
ty disorders excluded

4

9

Duration of interventions

Less than six months

36

Between six months
and 12 months

32

Longer than 12 months

7

Formats of interventions

Individual treatment

33

Group treatment

22

Combination of indi-
vidual and group treat-
ment

16

Concomitant medication

Allowed, if needed

59

Davidson 2014; Gregory 2008b; Robinson 2016; Santisteban 2015

Antonsen 2017; Carter 2010; Cottraux 2009; Doering 2010; Giesen-Bloo 2006;
Jørgensen 2013; Kamalabadi 2012; Koons 2001a; Nadort 2009

Andreoli 2016; Antonsen 2017; Blum 2008; Bohus 2013; Borschmann 2013; Bos
2010; Davidson 2014; Elices 2016; Feliu-Soler 2017; Gleeson 2012; Gratz 2006;
Gratz 2014; Haeyen 2018; Jahangard 2012; Kamalabadi 2012; Kramer 2011;
Kramer 2014; Kramer 2016; Kredlow 2017a; Kredlow 2017b; Leichsenring 2016;
Lin 2019; McMain 2017; McMurran 2016; Mehlum 2014; Mohamadizadeh 2017;
Morey 2010; Morton 2012; Pascual 2015; Reneses 2013; Schilling 2018; Schup-
pert 2012; Soler 2009; Weinberg 2006; Zanarini 2008; Zanarini 2018

Amianto 2011; Bellino 2006; Bellino 2007; Bellino 2010; Bianchini 2019; Car-
mona í Farrés 2019; Carter 2010; Cottraux 2009; Davidson 2006; Doering 2010;
Farrell 2009; Feigenbaum 2012; Gregory 2008b; Harned 2014; Jochems 2015;
Koons 2001a; Leppänen 2016; Linehan 1991; Linehan 1994; Linehan 2006; Line-
han 2015a; McMain 2009; Priebe 2012; Robinson 2016; Rossouw 2012b; Salzer
2014; Santisteban 2015; Sinnaeve 2018; Stanley 2017; Smith 2012; Turner 2000;
Van den Bosch 2005

Bateman 1999; Bateman 2009; Giesen-Bloo 2006; Jørgensen 2013; Laurenssen
2018; Nadort 2009; Philips 2018

Amianto 2011; Andreoli 2016; Borschmann 2013; Bellino 2006; Bellino 2007;
Bellino 2010; Cottraux 2009; Davidson 2006; Davidson 2014; Doering 2010;
Giesen-Bloo 2006; Gleeson 2012; Harned 2014; Jahangard 2012; Kramer 2011;
Kramer 2014; Kredlow 2017a; Kredlow 2017b; Leichsenring 2016; McMain 2009;
McMurran 2016; Mohamadizadeh 2017; Morey 2010; Nadort 2009; Philips 2018;
Priebe 2012; Reneses 2013; Salzer 2014; Stanley 2017; Smith 2012; Weinberg
2006; Zanarini 2008; Zanarini 2018

Antonsen 2017; Blum 2008; Bohus 2013; Bos 2010; Elices 2016; Farrell 2009; Fe-
liu-Soler 2017; Gratz 2006; Gratz 2014; Haeyen 2018; Jochems 2015; Kamalaba-
di 2012; Kramer 2016; Leppänen 2016; Lin 2019; Linehan 2015a; McMain 2017;
Morton 2012; Pascual 2015; Santisteban 2015; Schilling 2018; Soler 2009

Bateman 1999; Bateman 2009; Bianchini 2019; Carter 2010; Feigenbaum 2012;
Gregory 2008b; Jørgensen 2013; Koons 2001a; Linehan 1991; Linehan 1994;
Linehan 2006; Laurenssen 2018; Robinson 2016; Rossouw 2012b; Turner 2000;
Van den Bosch 2005

Amianto 2011; Andreoli 2016; Antonsen 2017; Bateman 1999; Bateman 2009;
Blum 2008; Bohus 2013; Borschmann 2013; Bos 2010; Carmona í Farrés 2019;
Cottraux 2009; Davidson 2006; Doering 2010; Elices 2016; Farrell 2009; Feigen-
baum 2012; Feliu-Soler 2017; Giesen-Bloo 2006; Gleeson 2012; Gratz 2006;
Gratz 2014; Gregory 2008b; Harned 2014; Jochems 2015; Jørgensen 2013;
Koons 2001a; Kramer 2011; Kramer 2014; Kramer 2016; Kredlow 2017a; Kred-
low 2017b; Laurenssen 2018; Leichsenring 2016; Linehan 1991; Linehan 1994;
Linehan 2006; Linehan 2015a; McMain 2009; McMain 2017; McMurran 2016;

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

481

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 2.   Key demographic characteristics of the included studies  (Continued)

All participants of each
group received the
same kind of concomi-
tant medication

Partly (50% of each
group concomitantly
received a specified,
concurrent medication,
50% placebo)

Not allowed

Not specified

4

1

2

9

Control interventions

Obligatory

42

Optional

Funding

Funded by grants from
universities, authorities
or research foundations

13

62

No funding received

Unclear funding

4

9

Mehlum 2014; Morey 2010; Morton 2012; Nadort 2009; Pascual 2015; Priebe
2012; Reneses 2013; Rossouw 2012b; Salzer 2014; Schilling 2018; Schuppert
2012; Sinnaeve 2018; Smith 2012; Soler 2009; Turner 2000; Van den Bosch
2005; Weinberg 2006; Zanarini 2008; Zanarini 2018

Bellino 2006; Bellino 2007; Bellino 2010; Jahangard 2012

Stanley 2017

Lin 2019; Mohamadizadeh 2017

Bianchini 2019; Carter 2010; Davidson 2014; Haeyen 2018; Kamalabadi 2012;
Leppänen 2016; Philips 2018; Robinson 2016; Santisteban 2015

Amianto 2011; Andreoli 2016; Bateman 1999; Bateman 2009; Bellino 2006;
Bellino 2010; Bianchini 2019; Borschmann 2013; Bos 2010; Carter 2010; David-
son 2014; Doering 2010; Farrell 2009; Feigenbaum 2012; Gleeson 2012; Gratz
2006; Gratz 2014; Jahangard 2012; Jochems 2015;Jørgensen 2013; Koons
2001a; Kramer 2016; Laurenssen 2018; Leichsenring 2016; Leppänen 2016;
Linehan 2006; McMurran 2016; Mehlum 2014; Morton 2012; Mohamadizadeh
2017; Philips 2018; Priebe 2012; Reneses 2013; Robinson 2016; Rossouw 2012b;
Schuppert 2012; Soler 2009; Stanley 2017; Smith 2012; Van den Bosch 2005;
Weinberg 2006; Zanarini 2018

Blum 2008; Bohus 2013; Davidson 2006; Gregory 2008b; Haeyen 2018; Kamal-
abadi 2012; Kredlow 2017a; Linehan 1991; Linehan 1994; McMain 2017; Mo-
hamadizadeh 2017; Salzer 2014; Zanarini 2008

Amianto 2011; Antonsen 2017; Bateman 1999; Bateman 2009; Blum 2008; Bo-
hus 2013; Borschmann 2013; Bos 2010; Carmona í Farrés 2019; Cottraux 2009;
Davidson 2006; Davidson 2014; Doering 2010; Elices 2016; Farrell 2009; Feigen-
baum 2012; Feliu-Soler 2017; Giesen-Bloo 2006; Gleeson 2012; Gratz 2006;
Gratz 2014; Gregory 2008b; Haeyen 2018; Harned 2014; Jochems 2015; Jør-
gensen 2013; Kramer 2011; Kramer 2014; Kramer 2016; Kredlow 2017a; Kred-
low 2017b; Laurenssen 2018; Leichsenring 2016; Lin 2019; Linehan 1991; Line-
han 1994; Linehan 2006; Linehan 2015a; McMain 2009; McMain 2017; McMur-
ran 2016; Mehlum 2014; Morey 2010; Nadort 2009; Pascual 2015; Philips 2018;
Priebe 2012; Reneses 2013; Robinson 2016; Rossouw 2012b; Salzer 2014; San-
tisteban 2015; Schilling 2018; Schuppert 2012; Sinnaeve 2018; Smith 2012; Sol-
er 2009; Stanley 2017; Van den Bosch 2005; Weinberg 2006; Zanarini 2008; Za-
narini 2018

Bellino 2006; Bellino 2007; Bellino 2010; Jahangard 2012

Andreoli 2016; Bianchini 2019; Carter 2010; Kamalabadi 2012; Koons 2001a;
Leppänen 2016; Mohamadizadeh 2017; Morton 2012; Turner 2000

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

482

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 2.   Key demographic characteristics of the included studies  (Continued)

BPDSI-IV: Borderline Personality Disorder Severity Index; BSI: Borderline Syndrome Index; CI-BPD: Childhood Interview for DSM-IV
Borderline Personality Disorder; DIB: Diagnostic Interview for Borderline Patients; DIB-R: Diagnostic Interview for Borderline Patients
- revised version; DIPD-IV: Diagnostic Interview for DSM-IV Personality Disorders; DSM-III: Diagnostic and Statistical Manual of Mental
Disorders, Third Edition; DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised; DSM-IV: Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition; DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision; ICD-10: International Classification of Diseases, Tenth Revision; IPDE: International Personality Disorder Ex-
amination; PDE: Personality Disorders Examination; SCID-II: Structured Clinical Interview for DSM DSM-IV Axis II Personality Disor-
ders (SCID-II); SIDP-IV: Structured Interview for DSM-IV Personality

A P P E N D I C E S

Appendix 1. DSM diagnostic criteria for BPD (301.83)

DSM - Third Edition (DSM-III;APA 1980)

DSM - Fourth Edition - Text Revision
(DSM-IV-TR;APA 2000)

DSM - Fifth Edition (DSM-5; APA 2013)

301.83 BPD

301.83 BPD

301.83 BPD

Diagnostic criterion A

5 of the following are required

1. Impulsivity  or  unpredictability  in  at
least 2 areas that are potentially self-
damaging  (e.g.  spending,  sex,  sub-
stance  use,  shoplifting,  overeating,
physically self-damaging acts)
2. A  pattern  of  unstable  and 

in-
tense interpersonal relationships (e.g.
marked  shifts  of  attitude,  idealisa-
tion, devaluation, manipulation (con-
sistently  using  others  for  one's  own
ends))

3. Inappropriate,  intense  anger  or  lack
of control of anger (e.g. frequent dis-
plays of temper, constant anger)
4. Identity  disturbance  manifested  by
uncertainty  about  several  issues  re-
lating to identity, such as self-image,
gender identity, long-term goals or ca-
reer  choice,  friendship  patterns,  val-
ues,  and  loyalties  (e.g.  'Who  am  I',  'I
feel  like  I  am  my  sister  when  I  am
good')
5. Affective 

instability,  marked  shifts
from normal mood to depression, ir-
ritability  or  anxiety,  usually  lasting  a
few hours and only rarely more than
a  few  days,  with  a  return  to  normal
mood

6. Intolerance  of  being  alone  (e.g.  fran-
tic  efforts  to  avoid  being  alone,  de-
pressed when alone)

A pervasive pattern of instability of inter-
personal relationships, self-image, and af-
fects, and marked impulsivity beginning by
early adulthood and present in a variety of
contexts, as indicated by 5 (or more) of the
following

A pervasive pattern of instability of inter-
personal relationships, self-image, and af-
fects and marked impulsivity, beginning by
early adulthood and present in a variety of
contexts, as indicated by 5 (or more) of the
following

1. Frantic efforts to avoid real or imagined
abandonment (note: do not include sui-
cidal  or  self-mutilating  behavior,  which
is covered in criterion 5)

1. Frantic efforts to avoid real or imagined
abandonment (note: do not include sui-
cidal  or  self-mutilating  behavior,  which
is covered in criterion 5)

2. A pattern of unstable and intense inter-
personal  relationships  characterised  by
alternating between extremes of ideali-
sation and devaluation

2. A pattern of unstable and intense inter-
personal  relationships  characterised  by
alternating between extremes of ideali-
sation and devaluation

3. Identity disturbance: markedly and per-
sistently unstable self-image or sense of
self

3. Identity disturbance: markedly and per-
sistently unstable self-image or sense of
self

4. Impulsivity in at least 2 areas that are po-
tentially  self-damaging  (e.g.  spending,
sex,  substance  abuse,  reckless  driving,
binge eating) (note: do not include suici-
dal or self-mutilating behavior, which is
covered in criterion 5)

5. Recurrent suicidal behavior, gestures, or
threats, or self-mutilating behavior
6. Affective instability due to a marked re-
activity  of  mood  (e.g.  intense  episodic
dysphoria, instability, or anxiety usually
lasting a few hours and only rarely more
than a few days)

4. Impulsivity in at least 2 areas that are po-
tentially  self-damaging  (e.g.  spending,
sex,  substance  abuse,  reckless  driving,
binge eating) (note: do not include suici-
dal or self-mutilating behavior, which is
covered in criterion 5)

5. Recurrent suicidal behavior, gestures or
threats, or self-mutilating behavior
6. Affective instability due to a marked re-
activity  of  mood  (e.g.  intense  episod-
ic  dysphoria,  irritability  or  anxiety  of
mood)  usually  lasting  a  few  hours  and
only rarely more than a few days

7. Chronic feelings of emptiness

7. Chronic feelings of emptiness

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

483

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

  (Continued)

7. Physically  self-damaging  acts  (e.g.
suicidal  gestures,  self-mutilation,  re-
current accidents or physical fights)
8. Chronic feelings of emptiness or bore-

8. Inappropriate, intense anger or difficul-
ty  controlling  anger  (e.g.  frequent  dis-
plays  of  temper,  constant  anger,  recur-
rent physical fights)

8. Inappropriate, intense anger or difficul-
ty  controlling  anger  (e.g.  frequent  dis-
plays  of  temper,  constant  anger,  recur-
rent physical fights)

dom

9. Transient, 

paranoid
stress-related 
ideation or severe dissociate symptoms

9. Transient, 

paranoid
stress-related 
ideation  or  severe  dissociative  symp-
toms

Diagnostic criterion B

If under 18, does not meet the criteria
for identity disorder

-

-

BPD: Borderline personality disorder; DSM: Diagnostic and Statistical Manual of Mental Disorders

Appendix 2. ICD-10 research criteria for emotionally unstable personality disorder (F60.3)

F60.30: Emotionally unstable personality disorder, impulsive
type

F60.31: Emotionally unstable personality disorder, border-
line type

Diagnostic criterion A

The general criteria of personality disorder (F60) must be met

The general criteria of personality disorder (F60) must be met

Diagnostic criterion B

At least 3 of the following must be present, 1 of which is 2

1. Marked tendency to act unexpectedly and without consideration
of the consequences

2. Marked tendency to quarrelsome behaviour and to conflicts with
others, especially when impulsive acts are thwarted or criticised

3. Liability of outbursts of anger or violence, with inability to control
the resulting behavioural explosions

At least 3 of the symptoms mentioned above in criterion B
(F60.30) must be present, and, in addition, at least 2 of the fol-
lowing

6. Disturbances in, and uncertainty about, self-image, aims
and internal preferences (including sexual)

7. Liability to become involved in intense and unstable rela-
tionships, often leading to emotional crises

4. Difficulty in maintaining any course of action that offers no im-
mediate reward

8. Excessive efforts to avoid abandonment

9. Recurrent threats or acts of self-harm

5. Unstable and capricious mood

10. Chronic feelings of emptiness

ICD-10: International Classification of Diseases, Tenth Edition

Appendix 3. Search strategies

Cochrane Central Register of Controlled Trials, in the Cochrane Library

#1 MeSH descriptor: [Borderline Personality Disorder] explode all trees
#2 borderline next state*
#3 borderline next personalit*
#4 "axis II" or "cluster B"
#5 idealization next devaluation
#6 (vulnerable or hyperbolic) next temper*

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

484

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

#7 (((unstab* or instab* or poor or disturb* or fail* or weak* or dysregulat*) next (self* or impuls* or interperson* or identit* or relation* or
emotion* or affect*)) and (person* or character or PD))
#8 impulsiv* near personalit*
#9 (self next (injur* or damag* or destruct* or harm* or hurt* or mutilat*))
#10 suicidal next behavio?r
#11 (feel* next (empt* or bored*))
#12 (anger next control*)
#13 (risk-taking next (behavior or behaviour))
#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13

Medline Ovid

1 Borderline Personality Disorder/
2 ((borderline or border-line) adj3 (state* or personalit*)).kf,tw.
3 ("Axis II" or "Cluster B" or flamboyant or "F60.3" or "F60.30" or "F60.31").kf,tw.
4 (idealization adj5 devaluation).kf,tw.
5 ((vulnerable or hyperbolic) adj3 temperament).kf,tw.
6 (((unstab* or instab* or poor or disturb* or fail* or weak or dysregulat*) adj3 (self* or impuls* or interperson* or identit* or relationship*
or emotion* or affect*)) and (personality or character or PD)).kf,tw.
7 (impulsiv* adj5 (behavio?r or character or personalit*)).kf,tw.
8 (self adj3 (injur* or damag* or destruct* or harm* or hurt* or mutilat*)).kf,tw.
9 (suicidal adj3 behavio?r).kf,tw.
10 (feel* adj3 (empt* or bored*)).kf,tw.
11 (anger adj5 control*).kf,tw.
12 (risk-taking adj3 behavio?r).kf,tw.
13 or/1-12
14 randomised controlled trial.pt.
15 controlled clinical trial.pt.
16 randomi#ed.ab.
17 placebo.ab.
18 randomly.ab.
19 trial.ab.
20 groups.ab.
21 drug therapy.fs.
22 or/14-21
23 exp Animals/ not Humans/
24 22 not 23
25 13 and 24

Embase Ovid

1 borderline state/
2 ((borderline or border-line) adj3 (personalit* or state*)).kw,tw.
3 ("Axis II" or "Cluster B" or flamboyant or "F60.3" or "F60.30" or "F60.31").kw,tw.)
4 (idealization adj5 devaluation).kw,tw.
5 ((vulnerable or hyberbolic) adj3 temperament).kw,tw.
6 (((unstab* or instab* or poor or disturb* or fail* or weak or dysregulat*) adj3 (self* or impuls* or interperson* or identit* or relationship*
or emotion* or affect*)) and (personality or character or PD)).kw,tw.
7 (impulsiv* adj5 (behavio?r or character or personalit*)).kw,tw.
8 (self adj3 (injur* or damag* or destruct* or harm* or hurt* or mutilat*)).kw,tw.
9 (suicidal adj3 (behavior or behaviour)).kw,tw.
10 (feel* adj3 (empt* or bored*)).kw,tw.
11 "anger adj5 control*".kw,tw.
12 (risk-taking adj3 (behavior or behaviour)).kw,tw.
13 or/1-12
14 randomised controlled trial/
15 double blind procedure/
16 crossover procedure/
17 single blind procedure/
18 (random* or factorial* or crossover* or cross-over* or placebo* or double-blind* or doubleblind* or single-blind* or singleblind* or
assign* or allocat* or volunteer*).ab,pt,sh,de,ti.
19 or/14-18
20 13 and 19

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

485

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

CINAHL EBSCOhost (Cumulative Index to Nursing and Allied Health Literature

S1 (MH "Borderline Personality Disorder")
S2 TX borderline N3 (state* or personalit*)
S3 TX "Axis II" OR "Cluster B"
S4 TX idealization N3 devaluation
S5 TX ((vulnerable OR hyperbolic) N3 temperament)
S6 TX (((unstab* or instab* or poor or disturb* or fail* or weak or dysregulat*) N3 (self or impuls* or interperson* or identit* or relationship*
or emotion* or affect*)) AND (person* or character or PD))
S7 TX (impulsiv* N3 (behavio?r OR character or personalit*))
S8 TX (feel* N3 (empt* OR bored*))
S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8
S10 (MH "randomised Controlled Trials") OR (MH "Random Assignment") OR (MH "Random Sample+")
S11 TX random* N4 (trial* OR study OR studies)
S12 TX random* N4 (allocat* OR allot* OR assign* OR basis OR divid* OR order)
S13 AB placebo*
S14 AB trial
S15 (MH "Drug Therapy+")
S16 S10 OR S11 OR S12 OR S13 OR S14 OR S15
S17 S9 AND S16

PsycINFO Ovid

1 exp Borderline Personality Disorder/
2 borderline adj3 (personalit* or state*).id,ti,ab.
3 ("Axis II" or "Cluster B").id,ti,ab.
4 (idealization adj5 devaluation).ab,id,ti.
5 ((vulnerable or hyperbolic) adj3 temperament).id,ab,ti.
6 (((unstab* or instab* or poor or disturb* or fail* or weak or dysregulat*) adj3 (self* or impuls* or interperson* or identit* or relationship*
or emotion* or affect*)) and (personality or character or PD)).id,ab,ti.
7 (impulsiv* adj5 (behavio?r or character or personalit*)).id,ab,ti.
8 (self adj3 (injur* or damag* or destruct* or harm* or hurt* or mutilat*)).id,ab,ti.
9 (suicidal adj3 behavio?r).id,ab,ti.
10 (feel* adj3 (empt* or bored*)).ab,id,ti.
11 "anger adj5 control*".ab,id,ti.
12 (risk-taking adj3 behavio?r).id,ab,ti.
13 or/1-12
14 exp Clinical Trials/ (
15 (random* adj allocat*).ab.
16 randomi?ed.ab.
17 placebo.ab.
18 randomly.ab.
19 trial.ab.
20 groups.ab.
21 drug therapy.sh.
22 exp Animals/ not Humans/
23 or/14-21
24 23 not 22
25 13 and 24

ERIC EBSCOhost (Education Resources Information Center)

S23 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22
S22 TX risk-taking N5 behaviour
S21 TX anger N5 control*
S20 TX feel* N3 (empt* or bored*)
S19 TX suicidal N3 behavior
S18  TX  (  (unstab*  or  instab*  or  poor  or  disturb*  or  fail*  or  weak  or  dysregulat*)  N3  TX  (self  or  impuls*  or  interperson*  or  identit*  or
relationship* or emotion* or affect*)) AND TX ( personality OR character OR PD )
S17 AB (self AND (injur* or damag* or destruct* or harm or hurt* or mutilat*))
S16 AB impulsivity
S15 TI impulsivity
S14 TX impulsiv* N3 person*
S13 TX "Axis II" OR "Cluster B"

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

486

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

S12 TX borderline N3 state
S11 TX borderline personality
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9
S9 AB drug
S8 AB trial
S7 AB randomly
S6 AB placebo
S5 AB randomi?ed
S4 AB controlled clinical trial*
S3 SU controlled clinical trial
S2 TX controlled clinical trial
S1 DE "randomised Controlled Trials"

BIOSIS Previews Web of Science Clarivate Analytics (1969 to 20 March 2019)

#1 TOPIC: (borderline personality disorder)
#2 TOPIC: ((borderline NEAR/3 (state))
#3 TOPIC: ((borderline NEAR/3 personalit*))
#4 TOPIC: (("Axis II" OR "Cluster B"))
#5 TOPIC: (idealization NEAR/5 devaluation)
#6 TOPIC: ((vulnerable OR hyperbolic) NEAR/3 temperament*)
#7 TOPIC: (impulsiv* NEAR/5 personalit*)
#8 TOPIC: ((self NEAR/3 (injur* OR damag* OR destruct* OR harm* OR hurt* OR mutilat*)))
#9 TOPIC: ((((unstab* OR instab* OR poor OR disturb* OR fail* OR weak OR dysregulat*) NEAR/3 (self* OR impuls* OR interperson* OR
identit* OR relationship* OR emotion* OR affect*)) AND (personality OR character OR PD)))
#10 TOPIC: (suicidal NEAR/3 behavio?r)
#11 TOPIC: (((feel* NEAR/3 (empt* OR bored*))))
#12 TOPIC: ((anger NEAR/5 control*))
#13 TOPIC: (risk-taking NEAR/3 behavio?r)
#14 #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#15 TOPIC: (controlled clinical trial)
#16 TOPIC: (randomised controlled trial)
#17 #16 OR #15
#18 #17 AND #14

Web of Science Core Collection Clarivate Analytics

#18 #17 AND #14
#17 #16 OR #15
#16 TOPIC: (controlled clinical trial)
#15 TOPIC: (randomised controlled trial)
#14 #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#13 TITLE: ((risk-taking NEAR/3 behavio?r))
#12 TOPIC: ((risk-taking NEAR/3 behavio?r))
#11 TITLE: ((anger NEAR/5 control*))
#10 TOPIC: ((feel* NEAR/3 (empt* OR bored*)))
#9 TITLE: ((feel* NEAR/3 (empt* OR bored*)))
#8 TITLE: (suicidal NEAR/3 behavio?r)
#7 TITLE: (impulsivity)
#6 TOPIC: ((((unstab* OR instab* OR poor OR disturb* OR fail* OR weak OR dysregulat*) NEAR/3 (self* OR impuls* OR interperson* OR
identit* OR relationship* OR emotion* OR affect*)) AND (personality OR character OR PD)))
#5 TOPIC: ((vulnerable or hyperbolic) NEAR/3 temperament)
#4 TOPIC: ((idealization NEAR/5 devaluation))
#3 TOPIC: ("axis II" OR "Cluster B")
#2 TOPIC: (borderline NEAR/3 state)
#1 TOPIC: (borderline personality disorder)

Sociological Abstracts ProQuest

(((randomised controlled trial) OR (controlled clinical trial) OR SU.exact("CLINICAL TRIALS")) OR AB(randomi?ed) OR AB(randomly) OR
AB(placebo)  OR  AB(trial))  AND  ((borderline  personality)  OR  "axis  II"  OR  "Cluster  B"  OR  (idealization  AND  devaluation)  OR  ((vulnerable
OR hyperbolic) AND temperament) OR (((unstab* OR instab* or poor or disturb* or fail* or weak or dysregulat*) AND (self* or impuls* or
interperson* or identit* or relationship* or emotion* or affect*)) AND (personality OR character OR PD)) OR (self AND (injur* OR damag* OR
destruct* OR harm OR hurt* OR mutilat*)) OR "suicidal behavio?r" OR "self destructive behavio?r" OR (feel* AND (empt* OR bored*)))

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

487

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

LILACS (Latin American and Caribbean Health Science Information Database)

“Borderline personality disorder”, limits: Controlled clinical study

ProQuest Dissertations A&I

(SU(borderline  personality  disorder)  OR  AB("Axis  II")  OR  AB("Cluster  B"))  AND  (("randomised  controlled  study"  OR  "controlled  clinical
study") OR AB(randomi?ed) OR AB(placebo) OR AB(randomly))

OpenGrey:

“Borderline personality disorder”

NDLTD

“Borderline personality disorder”

DART Europe E-theses portal

“Borderline personality disorder”

ANZCTR

“Borderline personality disorder”

ClinicalTrials.gov

“Borderline personality disorder”

ISRCTN

“Borderline personality disorder”

WHO ICTRP:

“Borderline personality disorder”

UK Clinical Trials Gateway

“Borderline personality disorder”

EU Clinical Trials Register

“Borderline personality disorder”

Library HubDiscover (previously COPAC)

“Borderline personality disorder”

Appendix 4. Table of outcomes

Primary outcomes

1. BPD symptom severity

Name of scale/means of assessment

Abbreviation

Borderline Personality Disorder Checklist - 40

BDP-40

Borderline Evaluation of Severity over Time

BEST

Borderline Personality Disorder Features Scale

BPDFS

Clinician-rated
(CR)/self-rated
(SR) 

SR

SR

SR

Study

Bos 2010

Blum 2008 (12-month follow-up
data); Gratz 2006; Gratz 2014; Gre-
gory 2008b; Morton 2012

Lin 2019

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

488

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Borderline Personality Features Scale for Chil-
dren

BPFS-C

Borderline Personality Inventory

Borderline Personality Disorder Severity Index -
4th Edition

BPI

BPDSI-IV

Borderline Personality Disorder Severity Index -
4th Edition for adolescents

BPDSI-IV-adol

Borderline Syndrome Index

Borderline Symptom List - 23 items

BSI

BSL-23

Clinical Global Impression scale for Borderline
Personality Disorder patients

CGI-BPD

International Personality Disorder Examination -
Borderline Personality Disorder criteria

IPDE-BPD

Millon Adolescent Clinical Inventory

MACI

Personality Assessment Inventory - Borderline
Scale

PAI-BOR

Structured Clinical Interview for DSM-IV Axis
II Personality Disorders, Number of borderline
criteria met

SCID-II, Number of
borderline criteria
met

Structured Clinical Interview for DSM-IV Axis
II Personality Disorders, Still meeting borderline
criteria

SCID-II, Still meet-
ing borderline crite-
ria

Zanarini Rating Scale for Borderline Personality
Disorder

ZAN-BPD

SR

SR

CR

CR

SR

SR

CR

CR

CR

SR

CR

CR

CR

2. Self-harm

Cochrane Database of Systematic Reviews

Rossouw 2012b

Leichsenring 2016

Bellino 2010; Giesen-Bloo 2006;
Kamalabadi 2012; Laurenssen
2018; Leppänen 2016; Nadort
2009; Philips 2018; Sinnaeve 2018

Schuppert 2012

Farrell 2009

Carmona í Farrés 2019; Elices
2016; Feliu-Soler 2017; McMain
2017; Kramer 2014; Pascual 2015;
Schilling 2018

Amianto 2011; Soler 2009

Bohus 2013

Santisteban 2015

Morey 2010

Doering 2010; Jørgensen 2013;
Koons 2001a; Kredlow 2017a;
Kredlow 2017b

Davidson 2006

Bateman 1999; Blum 2008 (post-
treatment data); Gratz 2014; Mc-
Main 2009; Priebe 2012; Reneses
2013; Robinson 2016; Zanarini
2018

Name of scale/means of assessment

Abbreviation

Clinician-rated
(CR)/self-rated
(SR)

Study

Borderline Personality Disorder Severity Index - 4th Edition,
Parasuicidal Behaviour

BPDSI-IV, parasuici-
dal behaviour

CR

Bellino 2010

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

489

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

Cornell Interview for Suicidal and Self-Harming Behavior-Self-
Report

CISSB

SR

Doering 2010

Days of self-harm and type of deliberate self-harm were record-
ed in an interview on a structured form

None

None

Priebe 2012

Deliberate Self-Harm Inventory

DSHI

Deliberate Self-Harm Inventory - Short Form

DSHI-SF

Deliberate Self-Harm Inventory - participants with self-harm
during previous 12 months

DSHI - participants
with self-harm

Lifetime Parasuicide Count - Self-Mutilative Accts

LPC

SR

SR

SR

CR

Gratz 2006; Gratz
2014; McMain 2017

Philips 2018

Davidson 2006

Gregory 2008b; Sin-
naeve 2018; Van
den Bosch 2005

Number of self-harming incidents during previous 12-month
period

Unclear

Unclear

Amianto 2011

Number of self-harming acts during previous three-month peri-
od

Unclear

Unclear

Carter 2010

Suicide and Self-Harm Inventory - number of patients with self-
harming behaviour during previous six-month period

SSHI - patients with
self-harm

Personality Assessment Inventory, Borderline Features Scale -
Self-Harm

PAI-BOR-S

Parasuicide History Interview - deliberate self-harm frequency

PHI - deliberate
self-harm frequen-
cy

Parasuicide History Interview - patients with self-harming be-
haviour during previous 12-month period

PHI - patients with
self-harm

Risk-Taking and Self-Harm Inventory - participants with self-
harming behaviour

RTSHI - patients
with self-harm

Suicide Attempt and Self-Injury Interview, Non-Suicidal Self-In-
jury scale

SASII - NSSI/self-
harm

Suicide Attempt and Self-Injury Interview - number of suicidal
and self-injurious episodes

SASII - suicidal
and self-injurious
episodes

Self-Harming Behaviours Checklist

SHBCL

Self-Harm Questionnaire - number of suicidal and self-injurious
episodes

Target Behaviour Rating - frequency of parasuicide

SHQ - suicidal
and self-injurious
episodes

TBR - frequency of
parasuicide

CR

SR

CR

CR

SR

CR

CR

CR

SR

CR

Bateman 1999;
Bateman 2009

Morey 2010

Koons 2001a; Wein-
berg 2006

Linehan 1991

Rossouw 2012b

Feigenbaum 2012;
Harned 2014; Line-
han 2006; Linehan
2015a;

McMain 2009

Cottraux 2009

Borschmann 2013

Turner 2000

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

490

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

3. Suicide-related outcomes

Cochrane Database of Systematic Reviews

Study

Lin 2019

Cottraux 2009

Davidson 2014;
Koons 2001a; Mo-
hamadizadeh 2017;
Turner 2000

Amianto 2011; Soler
2009

Davidson 2006

McMain 2017; Rene-
ses 2013

Philips 2018

Name of scale/means of assessment

Abbreviation

The 12-item Adult Suicidal Ideation Questionnaire— Short-
ened Version

ASIQ-S

Beck Hopelessness Scale

Beck Scale for Suicidal Ideation

BHS

BSS

Clinician-rated
(CR)/self-rated
(SR)

SR

SR

SR

Clinical Global Impression scale for Borderline Personality Dis-
order patients, suicidality

CGI-BPD, Suicidality

CR

CR

CR

CR

Deliberate Self-Harm Inventory, suicide attempts (cumulative
average)

DSHI, Suicide At-
tempts (cumulative
average)

Lifetime Suicide Attempt Self-Injury Interview

Number of participants with suicide attempt (recorded via di-
rect contact with patients and health care staff, as well as from
reviewing the case records)

Number of suicide attempts

Personality Assessment Inventory - suicidal ideation

Borderline Personality Disorder Severity Index - 4th Edition,
parasuicidality, suicide plans and attempts

Suicidal Behaviours Questionnaire

Suicidal Ideation Questionnaire - Junior

Suicide attempt and self-injury interview,  suicide attempts

LSASI

None

None

PAI-SI

BPDSI-IV, parasuici-
dality, suicide plans
and attempts

SBQ

SIQ-JR

SASII, suicide at-
tempts

Self-Harm Inventory  (number of participants with life-threat-
ening suicide attempts in the last 6 months)

SSHI

None

Stanley 2017

SR

CR

SR

SR

CR

CR

Morey 2010

Leppänen 2016

Weinberg 2006

Mehlum 2014

Feigenbaum 2012;
Harned 2014; Line-
han 2006; Linehan
2015a

Bateman 1999; Bate-
man 2009

Overt Aggression Scale - Modified for outpatients, suicidality

OAS-M, suicidality

CR

Gleeson 2012

Borderline Personality Disorder Severity Index, parasuicidal

BPDSI, parasuicidal

CR

Kamalabadi 2012

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

491

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

4. Psychosocial functioning

Cochrane Database of Systematic Reviews

Name of scale/means of assessment

Abbreviation

Clinician-rated
(CR)/self-rated
(SR)

Study

Brief Disability Questionnaire, days out of role

Children's Global Assessment Scalea

Clinical Global Impressions scale - severity of ill-
ness

BDQ, days out of
role

C-GAS

CGI-S

Clinical Global Impressions scale - improvement -
self-rated

CGI-I-SR

Dutch version of the Health of the Nations Out-
come Scales

HoNOS

Clinical Outcomes in Routine Evaluation – out-
come measure, Functioning subscale

CORE-OM, Func-
tioning subscale

Global Assessment of Functioning scalea

GAF

Global Assessment Scalea

GAS

General Health Questionnaire, functioning

GHQ, functioning

Outcome Questionnaire—45.2, social role

OQ45, social role

Social Functioning Questionnaire

Sheehan Disability Scale

SFQ

SDS

Social Adjustment Scale - self-rating

SAS-SR

Satisfaction Profile, social functioning

Social and Occupational Functioning Assessment
Scalea

None

SOFAS

Social Provisions Scale - "How many days were
you paid for working in the past 30 days?"a

SPS - days paid for
working

Total Outcome Questionnaire 45

Work and Social Adjustment Scale

OQ45

WSAS

SR

CR

CR

SR

CR

SR

CR

CR

CR

SR

SR

SR

SR

SR

CR

SR

SR

SR

Carter 2010

Mehlum 2014

Bellino 2006; Bellino 2010; Cot-
traux 2009;

Soler 2009

Jochems 2015

Feigenbaum 2012

Amianto 2011; Antonsen 2017;
Bohus 2013; Doering 2010; Farrell
2009; Kredlow 2017b; Robinson
2016; Salzer 2014

Andreoli 2016; Blum 2008;
Harned 2014; Linehan 1994

Kamalabadi 2012

Haeyen 2018; Kramer 2011;
Kramer 2014; Kramer 2016

Davidson 2006; McMurran 2016

Gratz 2014; Zanarini 2018

Bateman 1999; Bateman 2009;
Jørgensen 2013; McMain 2017;
Reneses 2013

Bellino 2010

Bellino 2007; Gleeson 2012

Gregory 2008b

Haeyen 2018

Borschmann 2013

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

492

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

aFor these scales, higher scores indicate better functioning, as opposed to most other clinical outcome scales (where higher scores indicate
higher burden). Scores were multiplied by ( −1) before entering for effect size calculation, to ensure that a negative direction of effect
indicates a beneficial effect (like for most other clinical outcomes).

Secondary outcomes

1. Anger

Name of scale/means of assessment

Abbreviation

Clinician-rated
(CR)/self-rated
(SR)

Study

Anger Irritability and Assault Questionnaire, Labile Anger
subscale

AIAQ, Labile Anger
subscale

Borderline Personality Disorder Severity Index - 4th Edi-
tion, anger

BPDSI-IV, anger

Clinical Global Impression scale for Borderline Personali-
ty Disorder patients, anger

CGI-BPD, anger

SR

CR

CR

Gleeson 2012

Bellino 2010; Kamalabadi
2012; Leppänen 2016

Amianto 2011; Soler 2009

Overt Aggression Scale - Modified, labile anger 

OAS-M, labile anger

CR

Gleeson 2012

Spielberger Anger Expression Scale, anger out

STAXI, anger out

SR

Spielberger Anger Expression Scale, trait anger

STAXI, trait anger

SR

Feigenbaum 2012; Koons
2001a; Linehan 2006; Mc-
Main 2009

Linehan 1994; McMain
2017

Target Behaviour Rating, anger

TBR, anger

CR

Turner 2000

2. Affective instability

Name of scale/means of assessment

Abbreviation

Clinician-rated
(CR)/self-rated
(SR)

Study

Borderline Personality Disorder Severity Index - 4th Edi-
tion, affective instability

BPDSI-IV, affective in-
stability

Borderline Personality Disorder Severity Index - 4th Edi-
tion for adolescents, affective instability

BPDSI-IV-adol, affec-
tive instability

Clinical Global Impression scale for Borderline Personality
Disorder patients, affective instability

CGI-BPD, affective in-
stability

CR

CR

CR

Bellino 2010; Kamal-
abadi 2012; Leppänen
2016

Schuppert 2012

Amianto 2011; Soler
2009

Revised Diagnostic Interview for Borderlines, Affect sub-
scale

DIB-R, Affect subscale

CR

Farrell 2009

Difficulties in Emotion Regulation Scale, Total score

DERS, Total score

SR

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Bianchini 2019; Gratz
2006; Gratz 2014; Mc-

493

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Personality Assessment Inventory, affective instability

PAI-BOR-A, affective
instability

Strengths and Difficulties Questionnaire, emotional prob-
lems

SDQ, emotional prob-
lems

Zanarini Rating Scale for Borderline Personality Disor-
der, affective instability

ZAN-BPD, affective in-
stability

SR

SR

CR

3. Chronic feeling of emptiness

Cochrane Database of Systematic Reviews

Main 2017; Morton
2012

Morey 2010

Salzer 2014

Blum 2008; Reneses
2013; Zanarini 2018

Name of scale/means of assessment

Abbreviation

Clinician-rated
(CR)/self-rated
(SR)

Study

Borderline Personality Disorder Severity Index - 4th Edition,
emptiness

BPDSI-IV, empti-
ness

CR

Clinical Global Impression scale for Borderline Personality Dis-
order patients, emptiness

CGI-BPD, emptiness

CR

Zanarini Rating Scale for Borderline Personality Disorder, feel-
ing of emptiness

Zan-BPDf, feeling of
emptiness

CR

Bellino 2010; Ka-
malabadi 2012;
Leppänen 2016

Amianto 2011; Soler
2009

Reneses 2013

4. Impulsivity

Name of scale/means of assessment

Abbreviation

Clinician-rated
(CR)/self-rated
(SR)

Study

Barrett Impulsiveness Scale

BIS

Barrett Impulsiveness Scale - 11, non-planning

BIS-11, non-plan-
ning

Borderline Personality Disorder Severity Index - 4th
Edition, impulsivity

BPDSI-IV, impulsiv-
ity

Clinical Global Impression scale for Borderline Person-
ality Disorder patients, impulsivity

CGI-BPD, impulsivi-
ty

SR

SR

CR

CR

Bianchini 2019, McMain
2017; Pascual 2015

Carmona í Farrés 2019;
Elices 2016

Bellino 2010; Kamalabadi
2012; Leppänen 2016; Van
den Bosch 2005

Amianto 2011; Soler 2009

Diagnostic Interview for Borderline Personality Disor-
der - Revised, impulsive

DIB-R, impulsive

CR

Farrell 2009

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

494

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

  (Continued)

Cochrane Database of Systematic Reviews

Difficulties in Emotion Regulation Scale, impulsive
dyscontrol

DERS, impulse
dyscontrol

Eysenck Impulsivity Venturesomeness Empathy Ques-
tionnaire, impulsivity

IVE, impulsivity

SR

SR

Gratz 2006; Gratz 2014

Cottraux 2009

Target Behaviour Rating, impulsiveness

TBR, impulsiveness

CR

Turner 2000

Zanarini Rating Scale for Borderline Personality Disor-
der, impulsivity

ZAN-BPD, impulsiv-
ity

CR, SR

Blum 2008; Reneses 2013;
Robinson 2016; Zanarini
2018

5. Interpersonal problems

Name of scale/means of assessment

Abbreviation

Clinician-rated
(CR)/self-rated
(SR)

Study

Borderline Personality Disorder Severity Index - 4th Edition,
interpersonal relationships

BPDSI-IV, interper-
sonal relationships

Borderline Personality Disorder Severity Index - 4th Edition,
unstable relationships

BPDSI-IV, unstable
relationships

Clinical Global Impression scale for Borderline Personality
Disorder patients, unstable relations

CGI-BPD, unstable
relations

Circumplex of Interpersonal Problems

CIP

Revised Diagnostic Interview for Borderlines, Interpersonal
subscale

DIB-R, Interpersonal
subscale

EQ-5D Health-Related Quality of Life
Questionnaire, social relationships

EQ-5D, social rela-
tionships

Inventory of Interpersonal Problems - Borderline Personality
Disorder, Related composite

IIP-BPD, Related
composite

Inventory of Interpersonal Problems - Circumflex ver-
sion/64-item version

IIP-C/IIP-64

Inventory of Interpersonal Problems - 25-item version

IIP-25

Inventory of Interpersonal Problems Short Circumplex - 32-
item version

IIP-SC/IIP-32

Outcome Questionnaire 45, interpersonal relations

OQ45, interpersonal
relations

CR

CR

CR

SR

CR

SR

SR

SR

SR

SR

SR

Bellino 2010; Kamal-
abadi 2012

Leppänen 2016

Amianto 2011; Soler
2009

Antonsen 2017

Farrell 2009

Robinson 2016

Gratz 2014

Bateman 1999; Bate-
man 2009; Jørgensen
2013; Laurenssen
2018; Leichsenring
2016; McMain 2009;
Philips 2018

Harned 2014

Davidson 2006

Haeyen 2018; Kramer
2011; Kramer 2014;
Kramer 2016

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

495

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

  (Continued)

Personality Assessment Inventory - Borderline Features
Scale - negative relationships

PAI-BOR-N

Strengths and Difficulties Questionnaire, problems in rela-
tionships

SDQ, problems in re-
lationships

Abbreviated World Health Organization Quality of Life Ques-
tionnaire, Social relationships score

WHOQOL-Bref, Social
relationships score

Zanarini Rating Scale for Borderline Personality Disor-
der, disturbed relationships

ZAN-BPD, disturbed
relationships

SR

SR

SR

CR

Morey 2010

Salzer 2014

Bos 2010; Carter
2010

Blum 2008; Reneses
2013; Zanarini 2018

6. Abandonment

Name of scale/means of assessment

Abbreviation

Borderline Personality Disorder Severity Index - 4th Edition,
abandonment

BPDSI-IV, abandon-
ment

Clinical Global Impression scale for Borderline Personality Dis-
order patients, fear of abandonment

CGI-BPD, fear of
abandonment

Clinician-rated
(CR)/self-rated
(SR)

Study

CR

CR

Bellino 2010; Ka-
malabadi 2012;
Leppänen 2016

Amianto 2011

7. Identity disturbance

Name of scale/means of assessment

Abbreviation

Clinician-rated
(CR)/self-rated
(SR)

Study

Borderline Personality Disorder Severity Index - 4th Edition,
identity disturbance

BPDSI-IV, identity
disturbance

Borderline Personality Inventory, identity diffusion

BPI, identity diffu-
sion

Clinical Global Impression scale for Borderline Personality Dis-
order patients, identity distortion 

CGI-BPD, identity
distortion

Personality Assessment Inventory - Borderline Features Scale -
identity disturbance

PAI-BOR-I

Severity Indices of Personality Problems

SIPP

Zanarini Rating Scale for Borderline Personality Disorder, Iden-
tity subscale

Zan-BPD, Identity
subscale

CR

SR

CR

SR

SR

CR

Bellino 2010; Ka-
malabadi 2012;
Leppänen 2016

Leichsenring 2016

Amianto 2011

Morey 2010

Antonsen 2017

Reneses 2013

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

496

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

8. Dissociation and psychotic-like symptoms

Cochrane Database of Systematic Reviews

Name of scale/means of assessment

Abbreviation

Clinician-rated
(CR)/self-rated
(SR)

Study

Borderline Personality Disorder Severity Index - 4th Edition,
paranoid ideation

BPDSI-IV, paranoid
ideation

Borderline Personality Disorder Severity Index - 4th Edition,
dissociation

BPDSI-IV, dissocia-
tion

Brief Psychiatric Rating Scale

BPRS

Clinical Global Impression scale for Borderline Personality
Disorder patients, dissociative symptoms

CGI-BPD, dissocia-
tive symptoms

Revised Diagnostic Interview for Borderlines, Cognitive
subscale

DIB-R, Cognitive
subscale

Dissociative Experiences Scale

DES

Dissociative Experiences Scale - Taxon

DES-T

CR

CR

CR

CR

CR

SR

SR

Bellino 2010; Leppänen
2016

Kamalabadi 2012

Gleeson 2012; Kredlow
2017a; Soler 2009; Turn-
er 2000

Amianto 2011

Farrell 2009

Bohus 2013; Feigen-
baum 2012;  Gregory
2008b; Koons 2001a 

Harned 2014

Zanarini Rating Scale for Borderline Personality Disor-
der, cognitive

Zan-BPD, cognitive

CR

Blum 2008

9. Depression

Name of scale/means of assessment

Abbreviation

Clinician-rated
(CR)/self-rated
(SR)

Study

Beck Depression Inventory

BDI

Beck Depression Inventory-II

BDI-II

Depression Anxiety Stress Scales

DASS

Depression Anxiety Stress Scale - 21

DASS-21

SR

SR

SR

SR

Antonsen 2017; Bateman 1999; Bateman
2009; Blum 2008; Cottraux 2009; Doering
2010; Gregory 2008b; Koons 2001a; Lau-
renssen 2018; Leichsenring 2016; McMain
2009; Schilling 2018; Turner 2000

Bohus 2013; Davidson 2006; Feigen-
baum 2012; Jørgensen 2013; Kredlow
2017a; Kredlow 2017b; McMain 2017; Mo-
hamadizadeh 2017

Gratz 2006; Gratz 2014; Morton 2012

Robinson 2016

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

497

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

  (Continued)

Diagnostic Interview Schedule for Chil-
dren – Predictive Scales

DISC - PS

General Health Questionnaire, Depres-
sion subscale

GHQ, Depression
subscale

Hamilton Depression Inventory

Ham-D

SR

SR

CR

Santisteban 2015

Kamalabadi 2012

Bellino 2006; Bellino 2007; Bellino 2010;
Smith 2012

Hamilton Depression Inventory  - 17-
item

Ham-D-17

SR, CR

Linehan 2006; Soler 2009

Hamilton Depression Rating Scale

HDRS

Hamilton Depression and Anxiety Scale

HADS

None

MADRS

Ko’s Depression Inventory

Montgomery Åsberg Depression Rating
Scale

Mood and Feelings Questionnaire - par-
ticipants scoring higher than cut-off for
depression

Clinically Useful Depression Outcome
Scale, total score

10. Adverse effects

SR

SR

SR

CR

Andreoli 2016; Harned 2014; Jahangard
2012; Linehan 2015a

Borschmann 2013; Davidson 2014; McMur-
ran 2016

Lin 2019

Gleeson 2012; Mehlum 2014; Pascual 2015;
Reneses 2013

MFQ - above cut-off

SR

Rossouw 2012b

None

SR

Zanarini 2018

Name of scale/means
of assessment

Abbreviation

Spontaneous report-
ing

-

Clinician-rated
(CR)/self-rated
(SR)

-

 Study

Andreoli 2016; Davidson 2014; Haeyen 2018; Leichsenring
2016; McMurran 2016; Pascual 2015; Robinson 2016; Stanley
2017

The remaining trials did not report adverse effects

Appendix 5. 'Risk of bias' components and criteria for assigning judgements

Selection bias

Random sequence generation

1. Low risk of bias: The method used was adequate (e.g. computer-generated random numbers, table of random numbers) or was unlikely

to introduce selection bias.

2. Unclear risk of bias: The information was insufficient for the assessment of whether the method used could introduce selection bias.
3. High risk of bias: The method used was likely to introduce bias.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

498

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Allocation concealment

Cochrane Database of Systematic Reviews

1. Low risk of bias: The method used (e.g. central allocation) was unlikely to bias allocation to groups.
2. Unclear risk of bias: The information was insufficient for assessment of whether the method used could bias allocation to groups.
3. High risk of bias: The method used (e.g. open random allocation schedule) could bias allocation to groups.

Detection bias: blinding of outcome assessment

1. Low risk of bias: The method of blinding was described and blinding was conducted in a satisfactory way.
2. Unclear risk of bias: The information was insufficient for assessment of whether the type of blinding used was likely to bias the estimate

of effect.

3. High risk of bias: There was no blinding or incomplete blinding.

Attrition bias: incomplete outcome data

1. Low risk of bias: The underlying reasons for missing data probably would not affect outcome measurement, as all missing data can be

considered as missing at random or all data were reported.

2. Unclear risk of bias: The information was insufficient for the assessment of whether the missing data or the method used to handle

missing data was likely to bias the estimate of effect.

3. High risk of bias: The crude estimate of effects could be biased given the reasons for the missing data, or the methods used to handle

missing data are unsatisfactory.

Reporting bias: selective outcome reporting

1. Low risk of bias: The trial protocol was available and all prespecified outcomes of interest were reported.
2. Unclear risk of bias: The information was insufficient for the assessment of whether selective outcome reporting could have occurred.
3. High  risk  of  bias:  Not  all  of  the  primary  outcomes  specified  beforehand  were  reported  or  participants  were  excluded  after

randomisation.

Other potential sources of bias

Treatment adherence bias

1. Low risk of bias: Measures were undertaken to assure adequate treatment adherence; for example, by regular supervision or use of

adherence ratings of videotaped or audio-taped therapy sessions.

2. Unclear risk of bias: There was insufficient information to assess the extent of adequate treatment adherence.
3. High  risk  of  bias:  There  was  inadequate  treatment  adherence.  Steps/measures  were  undertaken  to  assure  adequate  treatment

adherence.

Attention bias

1. Low risk of bias: The treatment conditions were sufficiently similar in duration and intensity.
2. Unclear risk of bias: There was insufficient information in regards to treatment duration and intensity.
3. High risk of bias: One treatment condition was markedly more intense or was of longer duration than (a)nother condition(s).

Affiliation bias

1. Low  risk  of  bias:  The  principal  investigator  was  not  the  developer  of  the  treatment  under  investigation  (if  compared  to  a  control

condition), or both treatment developers were involved if two treatments were directly compared.

2. Unclear risk of bias: There was insufficient information to assess affiliation bias.
3. High risk of bias: The principal investigator was the developer of the treatment under investigation (if compared to a control condition),

or only one of the treatment developers was involved if two treatments were directly compared.

Other sources of bias

1. Low risk of bias: The trial appeared to be free of other sources of bias.
2. Unclear risk of bias: The information was inadequate for the assessment of other possible sources of bias.
3. High risk of bias: Other sources of bias were identified.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

499

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Appendix 6. Trial Sequential Analysis (TSA) and funnel plots figures

Psychotherapy versus TAU

Primary outcomes

BPD symptom severity

We performed a TSA on the primary outcome of borderline symptom severity at end of treatment. The analysis shows that the required
information size was reached. See Figure 4 below.

Figure 4.   Trial Sequential Analysis on primary outcome: Psychotherapy - borderline symptom severity at end of
treatment

We drew a funnel plot for the comparison between psychotherapy and TAU for the primary outcome of BPD symptom severity. The funnel
plot shows a small asymmetry. See Figure 5 below.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

500

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 5.   Funnel plot of comparison 1: Psychotherapy versus TAU, outcome: 1.1 Primary outcome: BPD symptom
severity.

0

SE(SMD)

0.2

0.4

0.6

0.8

1

-2

-1

0

1

2

Subgroups
End of treatment
0-6 months follow-up

6-12 months follow-up
12 months and over follow-up

SMD

Self-harm

We performed a TSA on the primary outcome of self-harm at end of treatment. The analysis shows that the required information size was
reached. See Figure 6 below.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

501

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 6.   Trial Sequential Analysis on primary outcome: Psychotherapy - self-harm at end of treatment

We drew a funnel plot for the comparison between psychotherapy and TAU for the outcome of self-harm. The funnel plot shows symmetry.
See Figure 7 below.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

502

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 7.   Funnel plot of comparison: 1 Psychotherapy versus TAU, outcome: 1.3 Primary outcome: self-harm.

0

SE(SMD)

0.1

0.2

0.3

0.4

0.5

-2

-1

0

1

2

Subgroups
End of treatment

0-6 months follow-up

6-12 months follow-up

SMD

Suicide-related outcomes

We  performed  a  TSA  on  the  primary  outcome  of  suicide-related  outcomes  at  end  of  treatment.  The  analysis  shows  that  the  required
information size was reached. See Figure 8 below.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

503

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 8.   Trial Sequential Analysis on primary outcome: Psychotherapy - suicide-related outcomes at end of
treatment

We drew a funnel plot for the comparison between psychotherapy and TAU for suicide-related outcomes. The funnel plot shows symmetry.
See Figure 9 below.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

504

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 9.   Funnel plot of comparison: 1 Psychotherapy compared with TAU, outcome: 1.5 Primary outcome: suicide-
related outcomes.

0

SE(SMD)

0.2

0.4

0.6

0.8

1

-2

-1

0

1

2

Subgroups
End of treatment
0-6 months follow-up

6-12 months follow-up
Above 12 months follow-up

SMD

Psychosocial functioning

We  performed  a  TSA  on  the  primary  outcome  of  psychosocial  functioning  at  end  of  treatment.  The  analysis  shows  that  the  required
information size was reached. See Figure 10 below.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

505

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 10.   Trial Sequential Analysis on primary outcome: Psychotherapy - psychosocial functioning at end of
treatment

We drew a funnel plot for the comparison between psychotherapy and TAU for the outcome of psychosocial functioning. The funnel plot
shows symmetry. See Figure 11 below.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

506

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 11.   Funnel plot of comparison: 1 Psychotherapy compared with TAU, outcome: 1.7 Primary outcome:
psychosocial functioning.

0

SE(SMD)

0.2

0.4

0.6

0.8

1

-4
Subgroups
End of treatment
0-6 months follow-up

-2

0

2

4

SMD

6-12 months follow-up
Above 12 months follow-up

Secondary outcome: depression

We performed a TSA on the secondary outcome of depression at end of treatment. The analysis shows that the required information size
was not reached. See Figure 12 below.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

507

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 12.   Trial Sequential Analysis on secondary outcome: Psychotherapy - depression at end of treatment

F E E D B A C K

Feedback, 8 October 2020

Summary

The study ‘Democratic therapeutic community treatment for personality disorder: randomised controlled trial.’ published in the British
Journal of Psychiatry in 2017, seems not to have been included in the review, either in the included or excluded studies. Given that it meets
the criteria for inclusion, this looks like an oversight. In particular, the study included over 90% of participants suffering from Borderline
Personality Disorder; it is an RCT; and it was published in one of the journals which was hand searched. It falls within the time limits of
the searches carried out for the review. Authors were not approached to supply data on the subsample of participants with a Borderline
Personality Disorder diagnosis. Grateful for your comments on this. Sincerely Dr S Pearce Reference: Pearce S, Scott L, Attwood G, Saunders
K, Dean M, De Ridder R, Galea D, Konstandinidou H, Crawford M. Democratic therapeutic community treatment for personality disorder:
randomised controlled trial. Br J Psychiatry (2017), Vol. 210, 149-156. (doi.org/10.1192/bjp.bp.116.184366).

Reply

Thank you for the comment augmenting that we should have included the trial in our Cochrane systematic review: 'Psychological therapies
for people with borderline personality disorder'.

We did identify your trial (available at doi.org/10.1192/bjp.bp.116.184366) of democratic therapeutic community (DTC) in our searches,
but we excluded it at the title and abstract screening stage, because the intervention is not eligible for our review. In light of your comment,
we have discussed this further and have reached the same decision: that it is not eligible for the following reasons.

The  intervention  that  you  tested  is  a  socioenvironmental  therapy,  because  it  consists  of  being  part  of  a  therapeutic  community  that
is  built  on  democratic  principles  (consisting  of  shared  decision-making  around  group  matters,  discussion  of  behavior,  feedback  on
behavior, shared living, creating a community and activities, etc.). Therefore, we regard it as a socioenvironmental intervention rather than
psychotherapy.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

508

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

In our Methods section, we wrote the following about the types of interventions to be included: "Any defined psychological intervention
regardless of theoretical orientation (e.g. psychodynamic therapy, CBT, systemic therapy or eclectic therapies designed for BPD treatment),
in any kind of treatment setting (e.g. inpatient, outpatient or day clinic)".

Furthermore, in our Background section (Description of the intervention), we noted that although therapeutic community can be used
as  an  add-on  therapy  to  psychotherapy,  we  would  not  regard  it  as  the  core  therapy  in  itself  and  we  have  excluded  trials  with  similar
interventions (e.g. the Carta 2014 trial: 'Sailing can improve quality of life of people with severe mental disorders: results of a cross over
randomized controlled trial').

Contributors

Dr S Pearce, Honorary Senior Clinical Lecturer, University of Oxford; Dr Ole Jakob Storebø, Psychiatry of Region Zealand, Denmark; Prof
Mike Clarke, DPLP Feedback Editor.

W H A T ' S   N E W

Date

Event

Description

2 November 2020

Feedback has been incorporated

Feedback from Dr Pearce submitted via Cochrane Library on 8
October (supplied to DPLP by EMD). No change made.

H I S T O R Y

Protocol first published: Issue 2, 2018
Review first published: Issue 5, 2020

Date

Event

Description

5 May 2020

Amended

Adding acknowledgement for peer reviewers.

C O N T R I B U T I O N S   O F   A U T H O R S

Ole Jakob Storebø: protocol development; study selection; data extraction; data entry; assessment of risk of bias and GRADE; data analysis;
and writing of final report

Jutta M Stoffers-Winterling: protocol development; study selection; data extraction; data entry; assessment of risk of bias and GRADE; data
analysis; and writing of final report

Birgit A Völlm: protocol development; study selection; data extraction; and writing of final report

Mickey T Kongerslev: protocol development; study selection; data extraction; assessment of risk of bias; and writing of final report

Jessica T Mattivi: protocol development; study selection; data extraction; and writing of final report

Mie Sedoc Jørgensen: study selection; data extraction; assessment of risk of bias; and writing of final report

Erlend Faltinsen: study selection; data extraction; data entry; assessment of risk of bias; data analysis; and writing of final report

Adnan Todorovac: study selection; data extraction; data entry; assessment of risk of bias; data analysis; and writing of final report

Christian Paul Sales: study selection; data extraction; and writing of final report

Henriette E Callesen: study selection, data extraction; assessment of risk of bias and GRADE; data analysis; and writing of final report

Klaus Lieb: protocol development; data extraction; and writing of final report

Erik Simonsen: protocol development; data extraction; and writing of final report

All authors contributed to writing the review. Ole Jakob Storebø is the guarantor for the review.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

509

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

D E C L A R A T I O N S   O F   I N T E R E S T

Cochrane Database of Systematic Reviews

Jutta M Stoffers-Winterling is a board-certified psychologist, who has worked on a dialectical behaviour therapy (DBT) ward, and attended
courses on DBT and schema-focused therapy (SFT).

Ole Jakob Storebø (OJS) is an Editor with Cochrane Developmental, Psychosocial and Learning Problems (CDPLP). He is involved in a trial
investigating group mentalisation-based treatment (MBT) for adolescents with borderline personality disorder (BPD). This trial is included
in the review as an ongoing study. OJS was not involved in the evaluation of this trial. The assessment of eligibility of the trial was done
by Erlend Faltinsen and Adnan Todorovac.

Jessica  T  Mattivi's  institution  received  a  grant  from  the  German  Federal  Ministry  of  Education  and  Research  for  a  systematic  review
on  psychosocial  interventions  for  self-harm  in  adolescents  and  a  systematic  review  on  pharmacological  and  non-pharmacological
interventions for post-operative delirium in older patients.

Birgit A Völlm ‒ none known.

Mickey Kongerslev is a certified specialist in psychotherapy from the Danish Psychological Association. He has received training in group
analysis, cognitive behavioural therapy, and MBT. He received money, from private and public agencies, for teaching MBT for BPD, including
supervising psychologists under training to becoming licenced 'special psykolog' certified by the Danish National Health Authorities, and
has published scientific articles together with the developers of this treatment. He also receives money for teaching and supervision in
assessment and management of personality disorder.

Mie Poulsgaard Jørgensen (MPJ) is a trained DBT therapist and currently conducting a trial on group MBT for adolescents with BPD. This
trial is included in the review as an ongoing study. MPJ was not involved in the evaluation of this trial. The assessment of eligibility of the
trial was done by Erlend Faltinsen and Adnan Todorovac.

Henriette Edemann Callesen - none known.

Adnan Todorovac - none known.

Christian Sales - none known.

Erlend Faltinsen ‒ none known.

Klaus Lieb (KL) is an Editor with CDPLP. He is a board-certified cognitive behaviour therapist with a special interest in schema therapy. KL
has been involved in trials investigating inpatient DBT (Bohus 2004); and inpatient SFT (Reiss 2014). He was not involved in the evaluation
of these trials (Bohus 2004: Jutta M Stoffers-Winterling and Birgit A Völlm did eligibility assessments for the previous version of this review;
Reiss 2014: Signe Sofie Nielsen and Mickey Kongerslev did the eligibility assessment for this study for the current review).

Erik Simonsen is a board-certified therapist in group analysis.

S O U R C E S   O F   S U P P O R T

Internal sources

• Psychiatric Research Unit, Region Zealand Psychiatry, Roskilde, Denmark

Ole Jakob Storebø, Mickey Kongerslev, Mie Poulsgaard Jørgensen, Henriette Edeman Callesen, Adnan Todorovac, Erlend Faltinsen, and
Erik Simonsen worked on the review during office hours.

• University Medical Center Mainz, Department of Psychiatry and Psychotherapy, Germany

Jutta Stoffers-Winterling, Jessica Mattivi and Klaus Lieb worked on the review during office hours.

External sources

• None, Other

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

Authorship

The previous version of this review had the following authors.

1. Jutta M Stoffers
2. Birgit A Völlm
3. Gerta Rücker

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

510

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

4. Antje Timmer
5. Nick Huband
6. Klaus Lieb

Gerta Rücker and Antje Timmer were not involved in either preparing the protocol or the updated current version of the review.

The protocol of the current version of the review had the following authors.

1. Ole Jakob Storebø
2. Jutta M Stoffers-Winterling
3. Birgit A Völlm
4. Mickey T Kongerslev
5. Jessica T Mattivi
6. Maja Lærke Kielsholm
7. Signe Sofie Nielsen
8. Mie Sedoc Jørgensen
9. Erlend Faltinsen
10.Klaus Lieb
11.Erik Simonsen

These following authors worked on the final review but not on the protocol stage and received authorship.

1. Adnan Todorovac
2. Christian Paul Sales
3. Henriette E. Callesen

The following authors did not contribute sufficiently to the final review after the protocol stage and did not receive authorship on the
current version of the review.

1. Maja Lærke Kielsholm
2. Signe Sofie Nielsen

Methods

We were not able to use all of our methods as planned (Storebø 2018). We report the unused methods in Table 1.

Search methods for identification of studies: searching other resources

Whilst not specified in the protocol (Storebø 2018), we intend to handsearch the following journals in future updates of this review, in
addition to those already listed under Searching other resources:

1. Borderline Personality Disorder and Emotion Dysregulation; and
2. Personality and Mental Health.

Furthermore, we will handsearch any other journal wherein a substantial number of primary trials included in this version of the review
have been published, and which may not be included in the list of journals to be handsearched.

Data collection and analysis

Selection of studies

The protocol specified that six review authors (OJS, JMSW, BAV, JTM, MTK, SSN) would work in pairs and independently screen titles and
abstracts of all records retrieved by the searches. However, the following additional review authors also selected trials: AT; EF; MSJ and HEC.

The following authors, who worked on the protocol for the review, selected some trials but left the author group early in the development
of the review as they no longer wished to be authors: SSN and MTK.

The protocol moreover specified that KL and ES would act as arbiters. However, in the review, OJS and JMSW also functioned as arbiters.

Assessment of risk of bias in included studies

We intend to assess the risk of bias due to unequal rates of medication use in the respective treatment groups in future updates of this
review.

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

511

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Measures of treatment effects: continuous data

Cochrane Database of Systematic Reviews

For outcomes for which we did not compute an MIREDIF, we specified that we would provide an interpretation of the effect size using
Cohen's D (Cohen 1988), considering 0.2 as a small effect, 0.5 as a medium effect size, and 0.8 as a large effect size, in order to help the
reader to understand the results.

Unit of analysis issues: adjustment for multiplicity

We  planned  to  adjust  the  P  values  and  CIs  for  multiplicity  due  to  the  many  secondary  outcome  comparisons  following  the  method
described  by  Jakobsen  2014.  However,  we  only  adjusted  the  primary  outcomes  and  one  secondary  outcome  for  multiplicity.  We  did
this because we only wanted to adjust the outcomes presented in the 'Summary of findings' table and felt that adjusting all secondary
outcomes was not necessary.

Subgroup analysis and investigation of heterogeneity

Due to a lack of study samples with mean ages above 50 years, we only performed subgroup analyses for the age groups of 15 to under
18 years of age and above 18 years of age.

Moreover, we added the following four, post hoc subgroup analyses.

1. Types of raters
2. Types of TAU
3. Trials comparing psychotherapy with TAU compared with trials comparing psychotherapy with waiting list or no treatment
4. Types of scales

TSA

When performing the TSA analyses, we did not use a standard deviation (SD) for the primary outcome of 1.0, and we did not always use
an anticipated intervention effect of Hedge´s g of 0.5 ( ½ SD) as described in the protocol (Storebø 2018). Instead, we used the SD from
the trial as a basis for the transformation of SMD values to MD values. Also, we preferred to use the MIREDIF reported in articles, and only
if we could not find it did we use the ½ SD.

Sensitivity analysis

We added one analysis post hoc: imprecision as assessed by GRADE, by conducting TSA analyses on all primary outcomes and the three
secondary outcomes (for the main comparison versus TAU) not closely connected to the BPD core symptoms (depression, attrition and
adverse effects) with significant findings.

N O T E S

This  is  a  new  review,  which  replaces  the  following,  published  review:  Stoffers  JM,  Völlm  BA,  Rücker  G,  Timmer  A,  Huband  N,  Lieb  K.
Psychological therapies for people with borderline personality disorder. Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.:
CD005652. DOI: 10.1002/14651858.CD005652.pub2.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Borderline Personality Disorder  [*therapy];  Depression  [therapy];  Dialectical Behavior Therapy  [statistics & numerical data]; 
Mentalization;  Patient Dropouts  [statistics & numerical data];  Psychotherapy  [*methods]  [statistics & numerical data];  Randomized
Controlled Trials as Topic;  Self-Injurious Behavior  [therapy];  Suicide Prevention;  Treatment Outcome;  Waiting Lists

MeSH check words

Adolescent; Adult; Female; Humans; Male; Middle Aged; Young Adult

Psychological therapies for people with borderline personality disorder (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

512
